<SEC-DOCUMENT>0000950123-22-003270.txt : 20220517
<SEC-HEADER>0000950123-22-003270.hdr.sgml : 20220517
<ACCEPTANCE-DATETIME>20220228171327
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-22-003270
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		36
FILED AS OF DATE:		20220228
<PUBLIC-REL-DATE>20220517
DATE AS OF CHANGE:		20220301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Heart Test Laboratories, Inc.
		CENTRAL INDEX KEY:			0001468492
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				261344466
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-06055
		FILM NUMBER:		22691364

	BUSINESS ADDRESS:	
		STREET 1:		550 RESERVE ST, SUITE 360
		CITY:			SOUTHLAKE
		STATE:			TX
		ZIP:			76092
		BUSINESS PHONE:		214-763-8480

	MAIL ADDRESS:	
		STREET 1:		550 RESERVE ST, SUITE 360
		CITY:			SOUTHLAKE
		STATE:			TX
		ZIP:			76092
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED BY HEART TEST LABORATORIES, INC. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">PURSUANT TO 17 C.F.R. SECTION 200.83 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Confidential&nbsp;draft submitted to the Securities and Exchange Commission on&nbsp;<U></U>February&nbsp;28, 2022.&nbsp;This draft registration statement has
not been filed publicly with the Securities and Exchange Commission and all information contained herein remains confidential. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-</FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Under The Securities Act of 1933 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Heart Test
Laboratories, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Texas</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>334510</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">26-1344466</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of<BR>incorporation or organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Primary Standard Industrial<BR>Classification Code Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer</B><I><BR></I><B>Identification Number)</B></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>550 Reserve St, Suite 360</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Southlake, Texas 76092</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">682-237-7781</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Mark Hilz</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>550 Reserve St, Suite 360</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Southlake, Texas 76092</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">682-237-7781</FONT></FONT></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service)</B></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Richard F. Dahlson</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Jackson Walker L.L.P.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>2323
Ross Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Suite 600</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Dallas, Texas 75201-2725</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">214-953-6000</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Steven R. Jacobs</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Erin Camp</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Jackson Walker
L.L.P.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>112 East Pecan Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Suite 2400</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>San Antonio,
Texas</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>78205</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">210-978-7700</FONT></FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Andrea Cataneo</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Mitchell Silberberg&nbsp;&amp; Knupp LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>437 Madison Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>25<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>New York, New York 10022</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-509-3900</FONT></FONT></B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public:&nbsp;As soon as practicable after the effective date of this
Registration Statement. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this form is filed to register additional securities for an offering pursuant to
Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT>
filer, a smaller reporting company or an emerging growth company. See the definitions of&nbsp; &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>The Registrant hereby amends
this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in
accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#eb0029"><B>The information in this preliminary prospectus is not complete and may be changed. We
may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these
securities in any state where the offer or sale is not permitted </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#eb0029"><B>SUBJECT TO COMPLETION, DATED
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2022 </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#eb0029"><B>PRELIMINARY PROSPECTUS </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]
Shares of Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Heart Test Laboratories, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is the initial public offering of Heart Test Laboratories, Inc. We are offering
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of common stock, par value $0.001 per share, or Common Stock. We anticipate that the initial public offering price will be between
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] and $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]. We are offering all of the Common Stock offered by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to apply to list our Common Stock on the Nasdaq Capital Market, or Nasdaq, under the symbol
&#147;[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>].&#148; No assurance can be given that our application will be approved or that a trading market will develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company,&#148; as defined under the U.S. federal securities laws, and, as such,
have elected to comply with certain reduced public company reporting requirements. See &#147;Prospectus Summary&#151;Implications of Being an &#145;Emerging Growth Company&#146; and a &#145;Smaller Reporting Company&#146;.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See &#147;<A HREF="#rom271308_5">Risk Factors</A>&#148; beginning on page&nbsp;17. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to us (before expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We have agreed to reimburse the underwriters for certain expenses and the underwriters will receive
compensation in addition to underwriting discounts and commissions. See the section titled &#147;Underwriting&#148; beginning on page 133 of this prospectus for additional disclosure regarding underwriter compensation and offering expenses.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the representative of the underwriters an option to purchase from us, at the public offering price, up to additional
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock, less the underwriting discounts and commissions, within 30 days from the date of this prospectus to cover over-allotments, if any. If the
representative of the underwriters exercises the option in full, the total underwriting discounts and commissions and management fees payable will be $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] and the total
proceeds to us, before expenses, will be $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities
and Exchange Commission, or the SEC, nor any state or other foreign securities commission has approved nor disapproved these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal
offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the Common Stock on or about
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Book Running Manager </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>The Benchmark Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The
date of this prospectus is [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], 2022 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_4">SUMMARY FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_8">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_9">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_10">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_11">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_12">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_13">BENEFICIAL OWNERSHIP OF PRINCIPAL SHAREHOLDERS AND
MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_14">RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_15">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_16">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_17">U.S. FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_18">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_19">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_20">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom271308_21">INDEX TO FINANCIAL STATEMENTS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to
which we have referred you. We have not authorized anyone to provide you with information that is different. We are offering to sell the Common Stock, and seeking offers to buy the Common Stock, only in jurisdictions where offers and sales are
permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of the Common Stock. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and
the distribution of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus, &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; the &#147;Company&#148; and
&#147;HeartSciences&#148; refer to Heart Test Laboratories, Inc. References to &#147;Fiscal 2022&#148; refer to the <FONT STYLE="white-space:nowrap">12-months</FONT> ended April&nbsp;30, 2022, references to &#147;Fiscal 2021&#148; refer to the <FONT
STYLE="white-space:nowrap">12-months</FONT> ended April&nbsp;30, 2021 and references to &#147;Fiscal 2020&#148; refer to the <FONT STYLE="white-space:nowrap">12-months</FONT> ended April&nbsp;30, 2020. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRADEMARKS AND TRADE NAMES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our trademarks are the subject of trademark registrations in the United States as well as various other countries. Other brand names, names
and trademarks contained in this prospectus are the property of their respective owners. Solely for convenience, trademarks, service marks and tradenames are referred to in this prospectus without the
<SUP STYLE="font-size:85%; vertical-align:top">SM</SUP>, <SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and/or <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> symbols or any typographical emphasis (such as italicized or
underlined text), but such references are not intended to indicate, in any way, that the owner thereof will not assert, to the fullest extent under applicable law, such owner&#146;s rights to their service marks, trade names and trademarks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, <I>wav</I>ECG<SUP
STYLE="font-size:85%; vertical-align:top"> TM</SUP>, HEARTSCIENCES, and Heart Test Laboratories are trademarks and/or service marks of the Company registered with the United States Patent and Trademark Office, or USPTO. Other trademarks, service
marks and trade names in this prospectus are the property of their respective owners. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDUSTRY AND MARKET DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus includes statistical, market and industry data and forecasts which we obtained from publicly available information and
independent industry publications and reports that we believe to be reliable sources. These publicly available industry publications and reports generally state that they obtain their information from sources that they believe to be reliable, but
they do not guarantee the accuracy or completeness of the information. Although we believe that these sources are reliable, we have not independently verified the information contained in such publications. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REVERSE STOCK SPLIT AND CONVERTIBLE BRIDGE NOTE PRIVATE PLACEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;31, 2022, our shareholders granted our Board of Directors the discretion to effect a consolidation, which we refer to as the
reverse stock split, of our Common Stock at a rate to be determined by our Board of Directors at a later date. The Board of Directors approved a one-for-[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] reverse stock split
on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2022. In addition, since October 2021, we have sold an aggregate of
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] million of senior subordinated convertible notes, which we refer to as the Bridge Notes, and warrants, which we refer to as the Bridge Warrants, to purchase a total
of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock in a private placement, which we refer to as the 2021 Bridge Financing. Upon consummation of this offering, the Bridge Notes will convert
into a total of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock, assuming each holder converts its Bridge Notes up to the Maximum Percentage, as defined in the Glossary of Terms. Unless the
context otherwise expressly dictates or as otherwise set forth in this prospectus, all references to share and per share amounts referred to herein reflect the reverse stock split, the conversion of the Bridge Notes up to the Maximum Percentage by
each holder of Bridge Notes and the conversion of all of the $1.5M Notes, as defined in the Glossary of Terms. For more information, please refer to the &#147;Summary&#151;Recent Developments.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_1"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the statements made under &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Use of Proceeds,&#148;
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; &#147;Business&#148; and elsewhere in this prospectus constitute forward-looking statements. In some cases, you can identify forward-looking
statements by terminology such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148;
&#147;intends,&#148; or &#147;continue,&#148; or the negative of these terms or other comparable terminology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking
statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements
relating to the research, development, completion and use of our device, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or
may occur in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties.
We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they
believe to be appropriate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Important factors that could cause actual results, developments and business decisions to
differ materially from those anticipated in these forward-looking statements include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectation regarding the sufficiency of our existing cash and cash equivalents to fund our current
operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance the development of the MyoVista wavECG, or MyoVista, our full function conventional <FONT
STYLE="white-space:nowrap">12-lead</FONT> electrocardiograph, or ECG, device that incorporates an additional proprietary artificial intelligence-based algorithm that detects cardiac dysfunction caused by heart disease or <FONT
STYLE="white-space:nowrap">age-related</FONT> cardiac dysfunction and future potential products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize the MyoVista and any future potential products including sales of the MyoVista and
any future products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our assessment of the potential of the MyoVista and future potential products to diagnose certain indications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our planned level of capital expenditures and liquidity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to continue to invest in research and development to develop technology for new products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">anticipated actions of the U.S. Food and Drug Administration, or FDA, state regulators, if any, or other similar
foreign regulatory agencies, including approval to conduct clinical trials, the timing and scope of those trials and the prospects for regulatory approval or clearance of, or other regulatory action with respect to the MyoVista;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the regulatory environment and changes in the health policies and regimes in the countries in which we intend to
operate, including the impact of any changes in regulation and legislation that could affect the medical device industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to meet our expectations regarding the commercial supply of the MyoVista and any future products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to retain key executives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to internally develop new inventions and intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the overall global economic environment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and resulting government actions on us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of competition and new technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general market, political and economic conditions in the countries in which we operate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to internally develop new devices and intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the use of proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in our strategy; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">litigation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our
or our industry&#146;s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in this prospectus in greater detail under the
heading &#147;Risk Factors&#148; and elsewhere in this prospectus. You should not rely upon forward-looking statements as predictions of future events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this
prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GLOSSARY OF TERMS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following definitions shall apply to the terms used in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Terms Used by and for United States Federal Regulators and Regulations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;510(k)&#148; means a premarket notification submission to the FDA for determination that a medical device is substantially equivalent to
another legally U.S. marketed medical device prior to such device being distributed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;510(k) Clearance&#148; means a determination
from FDA that a device is substantially equivalent to another legally U.S. marketed medical device thereby authorizing the device to be marketed in the U.S. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;ACA&#148; means the Patient Protection and Affordable Care Act, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;CARES Act&#148; means the Coronavirus Aid, Relief and Economic Security Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;CDC&#148; means the U.S. Centers for Disease Control and Prevention. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Class&nbsp;I&#148; means a classification of medical devices with the lowest risk to the patient for which safety and effectiveness can
be assured by adherence to the FDA&#146;s General Controls for medical devices, which include compliance with the applicable portions of the QSR facility registration and product listing, reporting of adverse medical events, and truthful and <FONT
STYLE="white-space:nowrap">non-misleading</FONT> labeling, advertising and promotional materials </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Class&nbsp;II&#148; means a
classification of medical devices that are subject to the FDA&#146;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include submission of a
510(k), performance standards, post-market surveillance, patient registries and FDA guidance documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Class&nbsp;III&#148; means a
classification of medical devices that pose the greatest risks, such as life sustaining, life supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of
a legally marketed device. Class&nbsp;III devices generally require approval of a PMA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entities&#148; means, collectively,
health plans, health care clearinghouses and certain health care providers as provided for under HIPAA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;CMS&#148; means U.S. Centers
for Medicare &amp; Medicaid Services. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;De Novo&#148; means the process for obtaining authorization from the FDA of a novel medical
device that is low to moderate risk for which general controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness for the intended use, but for which there is no legally marketed predicate device.
Devices that are classified (or <FONT STYLE="white-space:nowrap">re-classified)</FONT> into Class&nbsp;I or Class&nbsp;II through a De Novo classification request may be marketed and used as predicates for future premarket notification 510(k)
submissions, when applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;DOJ&#148; means the U.S. Department of Justice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;FCA&#148; means the False Claims Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;FDA&#148; means the U.S. Food and Drug Administration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;FDASIA&#148; means the Food and Drug Administration Safety and Innovation Act of 2012, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;FDCA&#148; means the Federal Food, Drug and Cosmetic Act, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;FINRA&#148; means the Financial Industry Regulatory Authority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;GUDID&#148; means the FDA&#146;s Global Unique Device Identification Database. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;HCPCS&#148; means Healthcare Common Procedure Coding System. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;HHS&#148; means the U.S. Health and Human Services&#151;Office of the Inspector
General. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;HIPAA&#148; means the Health Insurance Portability and Accountability Act of 1996, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;HITECH&#148; means the Health Information Technology for Economic and Clinical Health Care Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;IDE&#148; means the FDA&#146;s investigational device exemption regulations which govern medical device clinical trials. The IDE
regulations exempt investigational devices from many regulations, but otherwise govern investigational device labeling, prohibit promotion of the investigational device, and specify an array of submission, recordkeeping, reporting and monitoring
responsibilities of study sponsors and study investigators intended to encourage public health and safety and with ethical standards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;IRB&#148; means the Institutional Review Board formally designated by the FDA regulations, which has oversite of a study being conducted
at a clinical site. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;JOBS Act&#148; means the Jumpstart our Business Startups Act of 2012. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;NAMCS&#148; means the 2018 National Ambulatory Medical Care Survey. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;PMA&#148; means a premarket approval application requesting the determination of the safety and effectiveness of Class&nbsp;III medical
devices pursuant to a scientific and regulatory review by the FDA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;QSR&#148; means the FDA&#146;s Quality System Regulation, which
is the current good manufacturing practice requirements for medical devices. The requirements govern the methods used in, and the facilities and controls used for, the design, manufacture, packaging, labeling, storage, installation, and servicing of
all finished devices intended for human use. The requirements are intended to ensure that finished devices will be safe and effective and otherwise in compliance with the Federal Food, Drug, and Cosmetic Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;SEC&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Trade Laws&#148; means, collectively, U.S. and foreign anticorruption, anti-money laundering, export control, sanctions and other trade
laws and regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;UDI&#148; means Unique Device Identifiers as required by U.S. federal laws and regulations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;USPSTF&#148; means the U.S. Preventive Services Task Force. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;VA&#148; means the U.S. Department of Veterans Affairs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Terms Used for Other Regulators and Regulations within the U.S. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;CCPA&#148; means the California Consumer Privacy Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;CPRA&#148; means the California Privacy Rights Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Terms Used in Jurisdictions Other Than the U.S. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;CE&#148; means Conformit&#233; Europ&#233;ene. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;CJUE&#148; means the Court of Justice of the European Union. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;EC&#148; means European Community. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;EEA&#148; means the European Economic Area. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;EU&#148; means the European Union. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;EU MDR&#148; means the EU Medical Device Regulation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Financial Promotion Order&#148; means the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;FinSA&#148; means the Swiss Financial Services Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;FSMA&#148; means the UK&#146;s Financial Services and Markets Act 2000, as amended.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;GDPR&#148; means the EU&#146;s General Data Protection Regulation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;MDD&#148; means the EU Medical Devices Directive. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Notified Body&#148; means an organization accredited by a Relevant State to conduct conformity assessments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Privacy Shield&#148; means the transfer framework, agreed to by the U.S. and the EU, for transferring data from the EU to the U.S., but
which was invalidated in July 2020 by the CJUE. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;relevant persons&#148; means, collectively, persons outside the UK and those persons in the UK who (i) who have professional experience
in matters relating to investments and who fall within the definition of investment professionals (as defined in Article 19(5) of the Financial Promotion Order), (ii) fall within Article 49(2)(a) to (d) of the Financial Promotion Order, or (iii) are
any other persons to whomit may otherwise lawfully be made under the Financial Promotion Order. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Relevant State&#148; means a member
state of the EEA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;UK&#148; means the United Kingdom. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Terms Used for Medical and Medical Device Related Purposes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;ACC&#148; means the American College of Cardiology. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Afib&#148; means atrial fibrillation or an irregular and often very rapid heart rhythm (or arrhythmia). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;AI&#148; means artificial intelligence. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;AMA&#148; means the American Medical Association. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;APC&#148; means ambulatory payment classification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;ARIC score&#148; means the Atherosclerosis Risk in Communities studies score. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;AUC&#148; means area under the curve. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;BNP testing&#148; means the <FONT STYLE="white-space:nowrap">B-type</FONT> natriuretic peptide testing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;CAD&#148; means coronary artery disease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;CPT&#148; means Current Procedural Terminology. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;CROs&#148; means contract research organizations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;CT&#148; means computerized tomography. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;CCTAs&#148; means coronary CT angiograms </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;CVD&#148; means cardiovascular disease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;diastolic phase&#148; means the period of relaxation or filling phase (as opposed to the period of contraction or pumping phase called
&#147;systolic&#148;) of a heartbeat. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;diastolic dysfunction&#148; means impaired left ventricular relaxation and elevated filling
pressures during the diastolic phase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;ECG&#148; means electrocardiogram or electrocardiograph as appropriate, which is also known by
the acronym &#147;EKG.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;echo&#148; means an echocardiogram. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;elderly&#148; means an individual that is 65 years old or older. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vi </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#147;e-prime&#148;</FONT> or &#147; e&#146; &#148; means a
key echocardiographic measurement of left ventricular diastolic function during the early diastolic phase, more specifically, this is a measurement of the speed of mitral annular motion at early diastole. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;GCP&#148; means good clinical practice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;HFpEF&#148; means heart failure with preserved ejection fraction or where a patient is not yet classified as having systolic dysfunction,
or, also known as severe diastolic dysfunction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;HFrEF&#148; means heart failure with reduced ejection fraction, or heart failure is
classified with systolic dysfunction, also known as severe diastolic dysfunction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;KOLs&#148; means key opinion leaders, such as
leading cardiologists. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;LV&#148; means left ventricular. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;LVD&#148; means left ventricular dysfunction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;LVDD&#148; means left ventricular diastolic dysfunction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;myocardial infarction&#148; is another term for a heart attack. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> means the use of products for a purpose other than as approved by the FDA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;sensitivity&#148; means the true positive rate or the percentage probability of a positive test result identifying patient with a
condition as compared to the gold standard test which in our case is an echo. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;specificity&#148; means the true negative rate or the
percentage probability of a negative test result identifying a patient without a condition as compared to the gold standard test, which in our case is an echo. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Terms Used in Connection with Our Company and Products </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;$1.5M Notes&#148; means our 12% secured convertible promissory notes in the aggregate principal amount of $1.5 million issued to
accredited investors in December 2020. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;$1M Lender Warrants&#148; means the warrants issued to holders of the $1M Notes as
consideration for the extension of the maturity of the $1M Notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;$1.5M Lender Warrants&#148; means the warrants issued to holders
of the $1.5M Notes as consideration for the extension of the maturity of the $1.5M Notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;$1M Loan and Security Agreement&#148;
means Loan and Security Agreement by and among the Company, FRV and John Q. Adams Sr. in April 2020 in connection with the $1M Notes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;$130K Note&#148; means our private placement on August 12, 2019 with FRV, an accredited investor, of an unsecured drawdown convertible
promissory note for an aggregate amount not to exceed $130,000. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;$1M Notes&#148; means our 12% secured, non-convertible promissory
notes payable to FRV and John Q. Adams Sr. in the aggregate principal amount of $1 million. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;IT&#148; means our information
technology. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;ewECG&#148; means energy waveform ECG, an alternative description of the MyoVista wavECG device used in the clinical
study titled [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Investor Warrants&#148; means
warrants to purchase [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Common Stock issued from 2015 to 2019 in connection with funding or as consideration for services rendered. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;MyoVista&#148; means the MyoVista wavECG device. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;MyoVista Algorithm&#148; means our wavECG proprietary algorithm. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Series A Preferred Stock&#148; means our Series A preferred stock, par value $0.001 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Series B Preferred Stock&#148; means our Series B preferred stock, par value $0.001
per share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Series C Preferred Stock&#148; means our Series C preferred stock, par value $0.001 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Terms Used in Connection with Our 2021 Bridge Financing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;2021 Bridge Financing&#148; means our private placement to accredited investors of the Bridge Notes and Bridge Warrants beginning in
October 2021. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Attribution Parties&#148; are any Purchaser, together with its affiliates and any other person acting as a group as
defined under Section 13(d) of the Exchange Act with regard to determining Maximum Percentage. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Bridge Notes&#148; means the 8%
subordinated convertible notes we sold to Purchasers pursuant to the Securities Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Bridge Warrants&#148; means
warrants to purchase our Common Stock issued pursuant to the Securities Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Conversion Price&#148; means the initial
conversion price of the Bridge Notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Exercise Price&#148; means the exercise price of the Bridge Warrants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Maximum Percentage&#148; means the beneficial ownership in excess of 4.99% of the number of shares of the Common Stock outstanding
immediately prior to, and immediately after giving effect to, the conversion of all or any portion of the Bridge Notes as applied to Attribution Parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;OID&#148; means the 10% original issue discount given upon issuance of our 2021 Bridge Notes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Pre-Funded Warrants&#148; means the warrants issued in the event the number of shares of Common Stock to be issued to a Purchaser upon
conversion of in the Bridge Notes would be in excess of the Maximum Percentage. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Purchasers&#148; means the accredited investors who
purchased our Securities pursuant to the Securities Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Registration Rights Agreement&#148; means the registration
rights agreement we entered into with the Purchasers in conjunction with the Securities Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Securities&#148; means,
collectively, all of the Bridge Notes, Bridge Warrants and Pre-Funded Warrants sold pursuant to the Securities Purchase Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Securities Purchase Agreement&#148; means the Securities Purchase Agreement we entered into with the Purchasers in connection with the
2021 Bridge Financing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Terms Used in Connection with this Offering Not Otherwise Listed </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;ASC&#148; means the Accounting Standards Codification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;FRV&#148; means Front Range Ventures, LLC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;FRV Side Letter&#148; means the letter agreement entered into by and between the Company and FRV on April&nbsp;10, 2019. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;GE&#148; means the General Electric Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Hill-Rom&#148; means Hill-Rom Holdings, Inc. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;MD&amp;A&#148; means Management&#146;s Discussion &amp; Analysis of Financial Condition and Results of Operations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Nasdaq&#148; means the Nasdaq Capital Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Philips&#148; means Koninklijke Philips N.V. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">viii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;PPP&#148; means the Paycheck Protection Program established pursuant to the CARES Act.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY OF RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to numerous risks, as more fully described in the section entitled &#147;Risk Factors&#148; immediately following the
prospectus summary. The following is a summary of the most significant risks and uncertainties that we believe could adversely affect our business, financial condition, and results of operations. In addition to the following summary, you should read
the other information set forth in &#147;Risk Factors&#148; before you invest in the Common Stock. In particular, our risks include, but are not limited to, the following: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Condition and Capital Requirements: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history and we have incurred significant operating losses since our inception, and
anticipate that we will incur continued losses for the foreseeable future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our financial condition is dependent on regulatory approval for, and the successful development, marketing and
sale of, the MyoVista, which we have not received as of the date of this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if this offering is successful, we will need to raise substantial additional funding, which may not be
available on acceptable terms, or at all. Failure to obtain funding on acceptable terms and on a timely basis may require us to curtail, delay or discontinue our development efforts and other operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All of our assets are subject to security interests; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our independent registered public accounting firm has expressed substantial doubt about our ability to continue
as a going concern, which could prevent us from obtaining new financing either on reasonable terms or at all. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to Our Business and Industry: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our future success depends on our ability to develop, receive regulatory clearance or approval for, and introduce
the MyoVista to the market in a timely manner. If we do not obtain and maintain the regulatory registrations and clearances for our device, we will be unable to market and sell the MyoVista in the United States, Europe or other regions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our success will be dependent upon physician acceptance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If third-party payors do not provide adequate coverage and reimbursement for the use of the MyoVista, our revenue
will be negatively impacted; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our success is partly dependent on the use of our specialized electrodes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We manage our business through a small number of employees and key consultants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Medical device development is costly and involves continual technological change in order to remain competitive
which may render the MyoVista obsolete; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face intense competition in the market and, as a result, we may be unable to effectively compete in our
industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are not able to attract and retain highly skilled managerial, scientific, technical and marketing
personnel, we may not be able to implement our business model successfully; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may need to expand our organization and we may experience difficulties in recruiting additional employees and
consultants, which could disrupt our operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our management team has limited experience managing a public company; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ix </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We expect to conduct business outside of the U.S. and doing so exposes us to additional business, regulatory,
political, operational, financial and economic risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are subject to certain U.S. and foreign anticorruption, anti-money laundering, export control, sanctions and
other trade laws and regulations. We could face serious consequences for any violations of such laws and regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will be dependent upon third-party manufacturers and suppliers, making us vulnerable to supply shortages and
problems, increased costs and quality or compliance issues, any of which could harm our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We could become subject to product liability, warranty or similar claims and product recalls that could be
expensive, divert management&#146;s attention and harm our business reputation and financial results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business and operations would suffer in the event of computer system failures, cyber-attacks or a deficiency
in our cybersecurity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business may be impacted by changes in general economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face business disruption and related risks resulting from the outbreak of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which could have a material adverse effect on our business and results of operations. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Product Development and Regulatory Approval: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our device and operations are subject to extensive government regulation and oversight both in the U.S. and
abroad, and our failure to comply with applicable requirements could harm our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Once commercialized, modifications to our marketed products may require new 510(k) clearances, or may require us
to cease marketing or recall the modified products until clearances or approvals are obtained; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical studies may be necessary to support future product submissions to the FDA. The clinical trial process is
lengthy and expensive with uncertain outcomes, and often requires the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical studies will prevent us from
commercializing any modified or new products and will adversely affect our business, operating results and prospects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Medical device development involves a lengthy and expensive process with an uncertain outcome, and results of
earlier studies may not be predictive of future study results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the third parties on which we rely to conduct our clinical studies and to assist us with <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development do not perform as required or expected, we may be delayed or unable to obtain regulatory clearance or approval for or commercialize our device; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may encounter substantial delays in our clinical studies, or we may fail to demonstrate specificity and
sensitivity to the satisfaction of applicable regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The results of future clinical studies may not support additional or new claims for future products or may result
in the discovery of adverse side effects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including
substantial penalties, and might require us to recall or withdraw a product from the market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The MyoVista must be manufactured in accordance with federal, state and foreign regulations, and we could be
forced to recall our devices or terminate production if we fail to comply with these regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The misuse or <FONT STYLE="white-space:nowrap">off-label</FONT> use of our device may harm our reputation in the
marketplace, could potentially cause harm to the patient and that lead to product liability suits or result in costly </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">x </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our device may cause or contribute to adverse medical events or be subject to failures or malfunctions that we
are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our device, or a recall
of our device either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The MyoVista may in the future be subject to product recalls that could harm our reputation, business and
financial results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims
laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Legislative or regulatory reforms in the United States or the European Union may make it more difficult and
costly for us to obtain regulatory clearances or approvals for our device or to manufacture, market or distribute our device after clearance or approval is obtained; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Healthcare legislative and regulatory reform measures may have a material adverse effect on our business and
results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could
hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or approved or commercialized in a timely manner or at all, or otherwise prevent those
agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in laws or regulations relating to data protection, or any actual or perceived failure by us to comply
with such laws and regulations or our privacy policies, could materially and adversely affect our business or could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain effective patent rights for our device, we may not be able to compete
effectively in our markets. If we are unable to protect the confidentiality of our trade secrets or <FONT STYLE="white-space:nowrap">know-how,</FONT> such proprietary information may be used by others to compete against us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Intellectual property rights of third parties could adversely affect our ability to commercialize our device, and
we might be required to litigate or obtain licenses from third parties in order to develop or market our device. Such litigation or licenses could be costly or not available on commercially reasonable terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be subject to claims challenging the inventorship of our intellectual property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time
consuming, and unsuccessful; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Third-party claims of intellectual property infringement may prevent or delay our development and
commercialization efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patent policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our
patent applications and the enforcement or defense of any issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be able to protect our intellectual property rights throughout the world. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">xi </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering and the Ownership of the Common Stock: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not know whether a market for the Common Stock will be sustained, what the trading price of the Common
Stock will be, or whether there will be an active, liquid, trading market for our Common Stock, which may trade at a discount from the initial public offering price and make it difficult for you to sell the Common Stock you purchase;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The market price of our Common Stock may be highly volatile, and you could lose all or part of your investment;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Future sales of a substantial number of shares of our Common Stock by our existing shareholders could cause our
stock price to decline; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If securities or industry analysts do not publish or cease publishing research or reports about us, our business
or our market, or if they publish negative reports regarding our business or the Common Stock, our share price and trading volume could decline; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Management will have broad discretion as to the use of the proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need additional capital, and the sale of additional shares of the Common Stock or equity or debt
securities could result in additional dilution to our shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have identified weaknesses in our internal controls, and we cannot provide assurances that these weaknesses
will be effectively remediated or that additional material weaknesses will not occur in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Board of Directors is authorized to issue and designate shares of our preferred stock in additional series
without shareholder approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our principal shareholders, officers and directors currently beneficially own approximately
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]% of our Common Stock. They will therefore be able to exert significant control over matters submitted to our shareholders for approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If you purchase the Common Stock in this offering, you will incur immediate and substantial dilution in the book
value of your shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will incur significant increased costs as a result of the listing of our securities for trading on Nasdaq. By
becoming a public company in the U.S., our management will be required to devote substantial time to new compliance initiatives as well as compliance with ongoing U.S. requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may be subject to securities litigation, which is expensive and could divert management attention;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have never paid cash dividends on our Common Stock, and we do not anticipate paying any cash dividends in the
foreseeable future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are an &#147;emerging growth company,&#148; and any decision on our part to comply with certain reduced
disclosure requirements applicable to emerging growth companies could make the Common Stock less attractive to investors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anti-takeover provisions could make a third party acquisition of us difficult; and/or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If our shares become subject to the penny stock rules, it would become more difficult to trade our shares.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">xii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our securities. Before you decide to invest in our securities, you should read the entire prospectus carefully, including the &#147;Risk Factors&#148; section and the financial statements and related notes appearing at
the end of this prospectus. In this prospectus, &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; the &#147;Company&#148; and &#147;HeartSciences&#148; refer to Heart Test Laboratories, Inc. Unless the context otherwise expressly dictates or as
otherwise set forth in this prospectus, all references to share and per share amounts referred to herein reflect the reverse stock split, the conversion of the Maximum Percentage of the Bridge Notes by each holder and the conversion of all of the
$1.5M Notes. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a medical technology company focused on applying innovative <FONT STYLE="white-space:nowrap">AI-based</FONT> technology to an ECG (also
known as an EKG) to expand and improve an ECG&#146;s clinical usefulness. Our objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-care</FONT></FONT> clinical settings. HeartSciences&#146; first product candidate, the MyoVista <I>wav</I>ECG, or MyoVista, is a resting
<FONT STYLE="white-space:nowrap">12-lead</FONT> ECG which provides diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG
information in the same test. Our business model, which involves the use of the MyoVista device and consumables for each test, is <FONT STYLE="white-space:nowrap">&#147;razor-razorblade&#148;</FONT> as the electrodes used with the MyoVista are
proprietary to HeartSciences, and new electrodes are required for every test performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is currently no <FONT
STYLE="white-space:nowrap">low-cost,</FONT> front-line, medical device that is effective at screening for heart disease. As a result, frontline physicians face a significant challenge in determining if a patient has heart disease. In 2012, the
United States Preventive Services Task Force, or USPSTF, conducted an evaluation of conventional ECG testing and stated: &#147;There is no good evidence that an ECG helps physicians predict heart risks in people with no symptoms any better than
traditional considerations such as current or former smoking, blood pressure and cholesterol levels.&#148; We believe the MyoVista will benefit patients, healthcare providers, healthcare payors and the like by providing improved frontline testing
and referral processes for cardiac dysfunction caused by heart disease in patients of all ages or <FONT STYLE="white-space:nowrap">age-related</FONT> cardiac dysfunction in elderly patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ECG devices record the electrical signals of a patient&#146;s heart. There are three basic categories of heart disease: electrical (such as an
arrhythmia), structural (such as valvular disease) and ischemic (such as coronary artery disease, or CAD). Conventional resting ECGs have limited sensitivity in detecting structural and ischemic disease and are typically used for diagnosing cardiac
rhythm abnormalities, such as atrial fibrillation, also known as Afib, or acute coronary syndrome, such as a myocardial infarction, which is also known as a heart attack. However, traditional ECGs have a limited role in identifying cardiac
dysfunction associated with structural and ischemic disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AI and machine learning provide the ability to create much more complex
algorithms using much larger data sets which we believe can be applied to the electrical signals of a patient&#146;s heart and to expand the capability of an ECG to be able to detect cardiac dysfunction. The MyoVista is a full function conventional
resting <FONT STYLE="white-space:nowrap">12-lead</FONT> ECG device that also incorporates our proprietary, <FONT STYLE="white-space:nowrap">AI-based</FONT> algorithm that detects cardiac dysfunction caused by heart disease and/or <FONT
STYLE="white-space:nowrap">age-related</FONT> cardiac dysfunction. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The editorial comment associated with the study titled &#147;Prediction of Abnormal
Myocardial Relaxation from Signal Processed Surface ECG&#148; presented below discusses recent applications of machine learning to data derived from surface <FONT STYLE="white-space:nowrap">12-lead</FONT> ECGs in relation to cardiac dysfunction:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;These are some of the most significant advances in electrocardiography since its inception, which has historically had a limited,
if any, role in the evaluation of cardiac dysfunction. In the past, our cardiovascular community was resigned to the fact that surface ECGs are poor indicators for cardiac dysfunction.&#148; </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Khurram Nasir, MD, MPH, MSC, Department of Cardiology, Houston Methodist DeBakey Heart&nbsp;&amp; Vascular Center, Houston, Texas, et. al.,<I>
Journal of American College of Cardiology Editorial Comment Volume 76 Number 8 2020.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Almost all forms of heart disease affect heart
muscle, or cardiac, function including the early stages of heart disease prior to symptoms. Impaired cardiac function is first observed as impaired cardiac relaxation which is an early indicator of diastolic dysfunction and continues to increase in
severity as heart disease progresses. The diastolic phase of the cardiac cycle occurs when the heart muscle relaxes (following contraction). Diastolic dysfunction may also be related to <FONT STYLE="white-space:nowrap">age-related</FONT> cardiac
dysfunction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients that are diagnosed with cardiac dysfunction are typically evaluated by a cardiologist to determine the severity of
their condition, its cause(s) and recommended treatment. Additional testing upon referral is often performed through an imaging diagnostic test called an echocardiogram, or echo, which is similar to an ultrasound. Further cardiac testing may also be
required. Cardiology-based testing generally involves expensive imaging equipment, is performed by a specialist and involves expert interpretation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The significant challenge in frontline healthcare environments, such as primary care, is the lack of a readily available test to screen for
heart disease or related cardiac dysfunction caused by heart disease. As a result, cardiology referral decisions are often based on a patient&#146;s risk factors and/or a conventional ECG test. Accordingly, many patients with heart disease are left
undetected while many other patients that are referred for subsequent testing receive a negative test, finding no heart disease, leading physicians and healthcare practitioners to conclude that no treatment or intervention is required. We believe
that adding the capability to detect cardiac dysfunction to a standard <FONT STYLE="white-space:nowrap">12-lead</FONT> resting ECG will be valuable for patients, physicians, health systems and third-party payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ECG is a ubiquitous, relatively <FONT STYLE="white-space:nowrap">low-cost,</FONT> simple and quick test; it is portable and can be
performed in a wide range of clinical settings by a <FONT STYLE="white-space:nowrap">non-specialist</FONT> clinician or clinical aide. For patients, early intervention often creates the best chance of a successful outcome by addressing a problem
before symptoms develop. Preventative care can help patients avoid the long-term health implications and costs of acute care associated with heart attacks, heart failure and chronic disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New Class&nbsp;II devices or existing devices with new capabilities require De Novo premarket review. The MyoVista along with its proprietary
software and hardware is classified as a Class&nbsp;II medical device by the FDA. Premarket review and clearance by the FDA for these devices is generally accomplished through the 510(k) premarket notification process or De Novo classification
request, or petition process. The Company previously submitted a De Novo classification request in late 2019 that included clinical performance data. Based on feedback we received from our 2019 De Novo submission and further communications with the
FDA during 2020, we concluded that we would need to undertake a new validation clinical study at institutions independent of those involved in collecting patient data used in the algorithm development process. The study protocol of this new
validation clinical study was submitted to the FDA for review and, in May 2021, the FDA agreed that the study design should be acceptable and would be expected to provide statistical information on which the FDA can effectively evaluate the
performance results of the MyoVista. The new validation study is currently underway and, once it is completed, we expect to incorporate the data we receive into a new De Novo </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
submission. Additionally, EMC testing is required for all FDA electronic medical devices to ensure that electrical noise does not interfere with producing accurate results. The FDA also required
additional testing related to electromagnetic compatibility due to testing guideline changes. Additional EMC testing is expected to be complete for the next FDA submission and we will include the results of such testing in the new De Novo submission
mentioned above. The FDA&#146;s De Novo classification authorization process generally takes from five to twelve months from the date the application is submitted but can take significantly longer. We expect to submit this new De Novo request later
this year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information regarding the FDA regulatory process, see &#147;Business&#151;Government Regulation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Heart Disease Facts and Current ECG Testing Limitations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heart disease refers to a variety of conditions that affect the heart&#151;including heart rhythm problems, heart valve problems, genetic
defects and blood-vessel diseases such as coronary artery disease. It is often referred to as the &#147;silent killer&#148; and, according to the American Heart Association, one in three patients are not properly diagnosed until after a heart attack
occurs and 50% of men and 64% of women who died suddenly of coronary heart disease had no previous symptoms. Statistics published by the U.S. Centers for Disease Control and Prevention, or CDC, show that in the United States heart disease is the
leading cause of death for men, women, and people of most racial and ethnic groups. According to the CDC, one person dies from cardiovascular disease every 36 seconds and heart disease accounts for approximately one in four deaths. In 2018,
30.3&nbsp;million U.S. adults were diagnosed with heart disease including 18.2&nbsp;million adults with CAD. Approximately 605,000 patients in the U.S. have a heart attack each year with approximately 20% of deaths from CAD occurring in adults less
than 65 years old. The scale of the problem is similar worldwide. In 2020, the World Health Organization confirmed that heart disease has remained the leading cause of death at the global level for the last 20 years. Ischemic heart disease now
represents 16% of global deaths and an estimated 17.9&nbsp;million people died from cardiovascular diseases in 2019, representing 32% of all global deaths. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As heart disease progresses to more acute stages, the cost to treat patients increases significantly. Cardiovascular disease is the leading
cost to the healthcare system and is estimated to be responsible for one in every six healthcare dollars spent in the United States. Heart disease costs in the United States were approximately $363&nbsp;billion in each of 2016 and 2017, including
the cost of health care services, medicines, and lost productivity due to death. Governments, healthcare providers and payors are motivated to shift the diagnosis and management of these conditions to earlier stages where better patient outcomes can
be delivered at lower costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is currently no <FONT STYLE="white-space:nowrap">low-cost,</FONT> front-line, medical device that is
effective for screening for heart disease. As a result, frontline physicians face a significant challenge in determining if a patient has heart disease. The conventional ECG is thought of by many to be the front-line tool in cardiac testing, but it
has poor sensitivity in detecting CAD or structural heart disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overuse of Expensive Cardiology-Based Diagnostic Testing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The absence of effective front-line or primary-care-based testing has resulted in the <FONT STYLE="white-space:nowrap">over-use</FONT> of
costly cardiology-based diagnostic tests. Noninvasive cardiac tests are significant contributors to healthcare costs, accounting for greater than 40% of Medicare Part B spending on medical imaging, or over $17&nbsp;billion annually according to the
U.S. Centers for Medicare &amp; Medicaid Services, or CMS. There are a variety of effective, though expensive, diagnostic tests for patients used to detect heart disease. These are typically performed in a specialist cardiology or hospital setting
and include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stress ECG testing</I>, a <FONT STYLE="white-space:nowrap">non-invasive</FONT> diagnostic test with a cost of
approximately $200 with, according to the American College of Cardiology, or ACC, a sensitivity of 68% in the detection of CAD. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Echocardiogram</I>, a <FONT STYLE="white-space:nowrap">non-invasive</FONT> diagnostic imaging test, similar to
an ultrasound, that is effective in the detection of heart disease; however, the Medicare cost of an echo in a hospital is approximately $600 and can be as much as $3,000 if performed privately. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Cardiac imaging tests</I>, such as nuclear stress tests and coronary CT angiograms, or CCTA, alternatively can
be conducted noninvasively, but typically cost $1,000 or more. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Coronary angiogram</I>, an invasive test in which dye that is visible by
<FONT STYLE="white-space:nowrap">X-ray</FONT> is injected into the blood vessels of the heart. A coronary angiogram can cost in excess of $5,000. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information see &#147;Business&#151;Heart Disease Facts and Current ECG Testing Limitations.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Diastolic Dysfunction, an Early Indicator of Heart Disease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The symptoms and causes of cardiac dysfunction have been researched for many years. The causes of cardiac dysfunction during the contraction
(systolic) phase, also called left <U>ventricular</U> reduced ejection fraction, have been well understood for many years. However, according to the American Heart Association Statistics Committee report in 2013, approximately 50% of patients with
heart failure symptoms have ejection fraction measures that are not markedly abnormal. In addition, multiple articles published by the NIH state that approximately 50% of HF cases are due to severe diastolic dysfunction, also called heart failure
with preserved ejection fraction or HFpEF. As a result, understanding the causes and progression of diastolic dysfunction has become a key area of scientific and clinical interest. This research has led to the understanding that almost all patients
with systolic dysfunction also have diastolic dysfunction and almost all types of heart disease including CAD, valvular disease, cardiomyopathy, hypertension, congenital heart disease, and pericardial disease induce diastolic dysfunction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to an article by Dr.&nbsp;Dalane&nbsp;W. Kitzman, MD and Dr.&nbsp;William&nbsp;C. Little, MD published in the February&nbsp;14, 2012
issue of the <I>Journal of the American Heart Association</I>, diastolic dysfunction is not only an indicator of systolic dysfunction, it is a sensitive indicator of cardiovascular dysfunction. According to this research, since left ventricular
diastolic function is impaired by all of the common pathological processes that affect LV function or produce LV hypertrophy or fibrosis, including hypertension, diabetes, ischemia, myocarditis, toxins, and infiltrative cardiomyopathies, LV
diastolic dysfunction, or LVDD, begins early in the heart disease process and continues to increase in severity as heart disease progresses. LVDD is now recognized as one of the earliest signs of heart disease and typical onset occurs when a patient
is still asymptomatic. We believe that the early detection of diastolic dysfunction can be a valuable marker for almost all forms of heart disease and age-related cardiac abnormalities that may otherwise be missed by current conventional ECG
devices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information see &#147;Business&#151;Diastolic Dysfunction, an Early Indicator of Heart Disease.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Product and Technology </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MyoVista
device has been developed in response to the recent understanding that most forms of heart disease are associated with left ventricular, or LV, relaxation abnormalities and diastolic dysfunction. MyoVista is a
<FONT STYLE="white-space:nowrap">12-lead</FONT> resting ECG device that features a proprietary algorithm developed to detect cardiac dysfunction in the diastolic phase, specifically slower than normal left ventricular relaxation rates as defined by
the American Society of Echocardiology Guidelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MyoVista also includes the capabilities of a full-featured conventional <FONT
STYLE="white-space:nowrap">12-lead</FONT> resting ECG including analysis using the Glasgow Algorithm, also known as the Glasgow ECG Interpretation Algorithm. Developed by the University of Glasgow in the UK, the
<FONT STYLE="white-space:nowrap">12-lead</FONT> ECG Analysis Algorithm has been relied upon for more than 35 years and is a widely respected resting ECG interpretive algorithms. The Glasgow Algorithm was developed and has been continuously improved
over the years by a team of world-renowned ECG researchers. The Glasgow Algorithm is licensed to the Company pursuant to the Glasgow License Agreement. For additional information regarding the Glasgow Algorithm and our license, see
&#147;&#151;Intellectual Property&#151;Glasgow License Agreement.&#148; </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the MyoVista, the conventional ECG (including the Glasgow Algorithm) and our proprietary
algorithm for detection of diastolic abnormalities are combined as a single test with results presented separately. The MyoVista has a high-resolution touchscreen display and incorporates many easy and intuitive to use features commonly associated
with a tablet device. For additional information see &#147;Business&#151;Product and Technology.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>MyoVista device with 1 lead view
of signal processed waveform</I><B> </B><I> </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308g01a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Opportunity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Diagnostic Gap </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The significant diagnostic
gap in heart disease is early identification. Heart disease often remains asymptomatic for many years as disease progresses until it reaches an acute stage, at which point many patients have a heart attack or die without prior diagnosis of disease.
For this reason, heart disease is often referred to as the &#147;silent killer.&#148; In 2012, the United States Preventative Services Task Force stated that there is no good evidence that an ECG helps physicians predict heart risks in people with
no symptoms any better than traditional considerations such as smoking, blood pressure and cholesterol levels, acknowledging the diagnostic gap that currently exists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the CDC, cardiovascular disease remains the biggest cost for the US healthcare system at approximately $216&nbsp;billion per
year. The cost of treating acute cardiac events and heart failure is especially high in comparison to preventative treatment. Governments, healthcare providers and third-party payors are focused on shifting the diagnosis and management of heart
disease to earlier stages where better patient outcomes can be delivered at lower cost; however, to make substantial progress the existing diagnostic gap needs to be closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that this scale of cardiac disease as well as changing demographics, growing ECG market, impetus to identify risks earlier for more
effective <FONT STYLE="white-space:nowrap">low-cost</FONT> testing, along with the increasing number and type of health care settings creates a significant opportunity for a device such as the MyoVista. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changing Demographics </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heart disease is
most commonly found in individuals age 65 and older with incidences of heart disease increasing at 65 years for men and 71.8 years for women. According to the Organization for Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and
Development, advances in the field of medicine have led to an increase in life expectancy which, as of 2019, was estimated to average 78.9 years for a person in the U.S., up from 75.4 years in 1990. As life expectancy increases, the average age of
the population is expected to increase. According to the HHS, the </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
population age 65 and older increased from 38.8&nbsp;million in 2008 to 52.4&nbsp;million in 2018 (a 35% increase) and is projected to reach 94.7&nbsp;million in 2060. By 2030, more than
20&nbsp;percent of U.S. residents are projected to be age 65 and over. Since heart disease is most commonly found in individuals age 65 years and older, and that population pool is increasing, we believe there is a significant opportunity for a
device such as MyoVista. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Growing ECG Market </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The demand for electrocardiograph devices and related supplies known as electrodes is on the rise worldwide. Despite the limitations of the
conventional ECG and healthcare guidance around the world that recommends against its use for screening, in the absence of a better alternative, the ECG remains a ubiquitous and widely-used test throughout healthcare including <FONT
STYLE="white-space:nowrap">non-cardiology</FONT> settings. It is estimated that 1.5&nbsp;million to 3&nbsp;million ECGs are performed worldwide every day, making it one of the most commonly used cardiovascular diagnostic tests in healthcare and a
fundamental tool in clinical practice. It is estimated that more than 100&nbsp;million ECGs are performed each year in the United States. The 2018 National Ambulatory Medical Care Survey <U>indicated</U> that office-based patient care physicians,
excluding anesthesiologists and federal facilities such as VA clinics, ordered or provided 27&nbsp;million ECG tests and four million stress ECGs during office visits and the 2017 National Hospital Ambulatory Medical Care Survey showed that during
ambulatory care visits to hospital emergency departments, an additional 28&nbsp;million ECG tests were ordered or performed by hospital emergency departments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Impetus to Identify Risks Earlier for More Effective <FONT STYLE="white-space:nowrap">Low-Cost</FONT> Testing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key goal of the HHS is reducing healthcare costs. This places pressure on physicians and healthcare institutions to contain healthcare costs.
Additionally, one of the key objectives of HHS&#146;s <I>Healthy People 2030</I>, is to increase preventive care for people of all ages. We believe that efforts towards preventive care and maintenance will lead to more testing for high-risk
individuals and patients that have existing cardiac conditions. This trend, we believe, in tandem with the push to shorten hospital stays, has created an impetus to identify <FONT STYLE="white-space:nowrap">pre-symptomatic</FONT> patients at risk
more effectively at the front-line physician or clinic level and to treat recovering cardiac patients through outpatient care and rehabilitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is our belief that the MyoVista is positioned to respond to the global need for more effective,
<FONT STYLE="white-space:nowrap">low-cost</FONT> ECG testing alternative for heart disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changing Nature of Healthcare Providers </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The delivery of healthcare in the U.S. is evolving. Alternative treatment sites, such as retail clinics, concierge medicine, urgent care
clinics and ambulatory surgical centers, deliver care from qualified providers in settings outside of emergency departments, hospitals or traditional physician offices. We expect this trend to accelerate the drive to provide more effective
preventative care and represents a significant opportunity for the introduction of MyoVista as a new medical device that offers an enhanced ability to screen for heart disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Capitation Provides an Incentive to Identify Medicare Advantage Patients </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers are paid either through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-service</FONT></FONT> or
capitation. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fee-for-service</FONT></FONT> is a payment model where services are unbundled and paid for separately. In health care, the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">fee-for-service</FONT></FONT> payment model incentivizes physicians to provide more treatments because payment is dependent on the quantity, rather than quality of care. Capitation is a payment arrangement that pays a
physician or group of physicians a set amount for each enrolled person assigned to them, per period of time, whether or not that person seeks care. Under capitation, the amount of remuneration is based on the average expected healthcare utilization
of that patient, with greater payment for patients with significant history of medical problems. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approximately 42% (approximately 26&nbsp;million people) of those covered by Medicare
according to CMS are enrolled in a Medicare Advantage plan. With respect to these patients, CMS pays capitation to healthcare providers. CMS uses risk adjustment to adjust capitation payments to health plans, either higher or lower, to account for
the differences in the health costs of individuals with ailments such as heart failure, CAD, angina and valvular heart disease. Accordingly, under CMS guidelines, risk factor adjustments per patient will provide payment that is higher for sicker
patients who have conditions where diagnosis codes are documented in the medical record as a result of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">face-to-face</FONT></FONT> visit. Therefore, there is a financial incentive to
identify those Medicare Advantage patients that are sicker, including those that have undiagnosed ailments such as heart disease. We believe that undiagnosed heart disease represents a significant problem, and we believe insurance plans that have a
high number of Medicare Advantage patients could be a target market for MyoVista. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our objective is to make the
MyoVista wavECG a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care,</FONT></FONT> as an affordable and valuable medical test. Our business model, which involves the capital sale of the MyoVista device and the use of
proprietary supplies (electrodes) for each test, is <FONT STYLE="white-space:nowrap">&#147;razor-razorblade.&#148;</FONT> The electrode connection system is patented, and the electrodes are superior quality to facilitate high quality, stable ECG
signal capture. This is important, as the MyoVista also analyzes frequency data along with conventional ECG information. The proprietary electrodes would provide recurring <FONT STYLE="white-space:nowrap">per-test</FONT> revenue for each MyoVista
device sold. Unlike many new healthcare products, we do not expect to rely on high charges because of our recurring revenue business model </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Territories
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our initial sales focus will primarily be within the U.S. We intend to market the MyoVista in the U.S. using a direct sales force
following FDA clearance. Outside of the U.S., for markets such as Europe and Latin America, we will utilize medical device distributors that have existing healthcare provider relationships and experience selling ECG devices, that will be supported
by a small number of local field personnel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential Markets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that there is a large variety of potential markets for the MyoVista. Conventional ECGs are used throughout healthcare in almost
every clinical setting including clinics, doctor&#146;s offices, urgent care centers, and hospitals. In many of those settings, the additional information on cardiac dysfunction provided by the MyoVista in addition to the conventional ECG
information it provides could be extremely valuable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MyoVista&#146;s range of applications and potential uses are vast, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Primary care</U>&#151;providing front-line cardiac testing/referral tool, heart disease screening.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Retail Healthcare</U>&#151;such as CVS, Walmart and Walgreens. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Emergency Departments</U>&#151;providing enhanced ECG testing for emergency room patients.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Cardiologists</U>&#151;providing prescreening cardiology patients </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Hospitals</U>&#151;providing <FONT STYLE="white-space:nowrap">in-patient</FONT> testing or testing prior to
discharge, particularly cardiac wards. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Surgery</U>&#151;providing <FONT STYLE="white-space:nowrap">pre-anesthesia</FONT> testing, pre/post
intervention </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Life Insurance testing</U>&#151;providing ECGs are sometimes required in connection with the issuance of life
insurance policies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Specialty Environments</U>&#151;such as cardiomyopathy, cardiac oncology, drug trials, heart failure, and
diabetes. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Athlete testing</U>&#151;providing cardiac screening programs for athletes. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Early Target Markets </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, our
focus markets will be: cardiology; primary care providers that serve upper to middle income regions including concierge medicine providers; retail clinics; and insurers with high levels of Medicare Advantage patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Competitive Advantages </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The MyoVista provides several
competitive advantages compared to traditional ECG devices. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Price comparability</U>. A major brand, full-feature, resting <FONT STYLE="white-space:nowrap">12-lead</FONT>
ECG typically costs between $5,000 and $10,000 and we anticipate pricing our device competitively by setting the price for the MyoVista at, or lower than, a good-quality conventional ECG from a mainstream manufacturer<I>.</I> We believe that
competitive pricing will help us to increase adoption of the MyoVista. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Familiarity of use and protocol</U>. The conventional ECG is the most common cardiac test and is used in
almost all areas of healthcare and is often performed by a physician assistant or a nurse, rather than a physician. The MyoVista provides both conventional ECG information and proprietary cardiac dysfunction information in a single test, using
standard <FONT STYLE="white-space:nowrap">12-lead</FONT> ECG testing protocols with standard lead placement. This makes the MyoVista easy to use and, consequently, easy to train people to use. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Positioned at the forefront of electrocardiography</U>. There have been very few significant changes in the
efficacy of electrocardiography testing for many decades. We believe that positioning the MyoVista at the forefront of science will attract healthcare providers. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Health system savings</U>. We believe that the MyoVista has the opportunity to generate significant cost
savings to healthcare systems by improving earlier diagnosis and reducing unnecessary referrals to cardiology that lead to unnecessary testing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Physician Profitability</U>. We believe that the MyoVista will offer primary care physicians a significant
advance in their ability to assess patient heart health. Several primary care physicians have informed us that they would expect to be able to charge additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> patient fees of $25 to $100 for the additional diagnostic information provided by a MyoVista test until reimbursement for this portion of MyoVista testing
is available. Even based on low usage and competitive pricing, the payback on the capital cost of the MyoVista (approximately $5,000) would be realized quickly. We also expect lease or debt financing to be available (through third parties) which
would permit the doctor to avoid the need for an upfront capital cost to acquire the device. In high use environments such as a cardiac screening clinic, hospital or family practice office, we expect the financial returns to be significant
especially as available reimbursement increases. We intend to develop financial models demonstrating the potential profitability and establish reference sites that are using the MyoVista. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Razor-Razorblade Business Model</U>. Sales of the MyoVista will be accompanied by our proprietary electrodes,
which are recurring consumable supplies and therefore generate revenue from every test. Beyond the revenue from the MyoVista unit sale itself, revenue will also be earned every time the MyoVista device is used for a patient test. The MyoVista is
extremely sensitive and requires the use of our proprietary electrodes to ensure clinical efficacy. To aid in accomplishing clinical efficiency, we will sell proprietary electrodes incorporating a patented security system unique to us. These
electrodes are a onetime use item thereby providing revenue for each test. We believe that the sale of our proprietary electrodes could also provide us with the ability to maximize revenue and profitability through pricing structures focused on
adoption strategies rather than price maximization. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information see &#147;Business&#151;Market
Opportunity&#151;Competitive Advantages.&#148; </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Reimbursement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to penetrating the health care settings described above, a key element of our strategy is to qualify for third-party payor
reimbursement. This strategy has two stages. During the first stage, we intend to seek the support of the American College of Cardiology, or ACC, to use existing Current Procedural Terminology, or CPT, codes for the standard ECG functionality of
MyoVista. CPT codes are numbers assigned to each task or service provided by a healthcare provider including medical, surgical and diagnostic services. Insurers use the numbers to determine the amount to pay a provider. Once approved by ACC, this
will provide physicians with the ability to use existing <FONT STYLE="white-space:nowrap">12-lead</FONT> ECG reimbursement codes. Reimbursement for existing ECG testing procedures with interpretation and report ranges from approximately $17 to $55
depending on the type of healthcare facility. These charges will go directly to the healthcare facility/physician. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After this initial
stage, our longer-term reimbursement strategy is to obtain additional reimbursement for the MyoVista capabilities related to detecting cardiac dysfunction. If we are successful, this would provide total potential reimbursement that is larger than
reimbursement for conventional ECG devices, thus placing the MyoVista at a competitive advantage as compared to conventional ECG devices. Any additional CPTs that are issued and recognized by payors for the MyoVista related to our longer-term
reimbursement strategy will provide a revenue advantage as compared to CPTs for conventional ECG devices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The medical device industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary
products. There are many medical device companies, biotechnology companies, public and private universities and research organizations actively engaged in the research and development of products that may be similar to the MyoVista. Competitors
could include traditional ECG manufacturers such as General Electric Company, or GE, Koninklijke Philips N.V., or Philips, and Nihon Kohden Corporation that may seek to innovate due to competition from HeartSciences, and new competitors that also
see the opportunity to finally innovate in a market that has significant need for improved products and technology change. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our technology is protected by a patent portfolio as well as trade secrets, which together comprise an important part of technology
protection for our existing and future proprietary algorithms (rather than, especially when developing proprietary algorithms). We believe that the combination of patents and trade secrets create valuable competitive barriers for HeartSciences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The USPTO has issued five utility patents and one design patent to us and we have two utility patent applications under the USPTO&#146;s
review. We also have seven utility patents and fourteen design registrations granted by international jurisdictions such as China, Japan, the European Union, France, Germany and Australia as well as several pending patent applications in several
international jurisdictions including <U></U>Brazil, Canada, India, Israel, Mexico and the United Emirates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have entered
into two agreements that are material to our rights to the intellectual property utilized in the MyoVista: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In January 2014, we entered into an invention assignment agreement, which we refer to as the 2013 Technology
Agreement, under which certain specified MyoVista technology and proprietary and intellectual property rights thereto (including patents, copyright, trademarks, trade secrets and <FONT STYLE="white-space:nowrap">know-how)</FONT> were transferred and
assigned to us by the inventor; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In December 2015, we entered into a licensing agreement, which we refer to as the, Glasgow Licensing Agreement,
with The University Court of the University of Glasgow, under which we obtained a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide perpetual license, renewing every five years, to software modules for an
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Android platform for analysis of resting 12-lead electrocardiograms and all intellectual property rights (including patents, copyright, trademarks, trade secrets and <FONT
STYLE="white-space:nowrap">know-how)</FONT> relating to the software modules to be used in the MyoVista. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information,
including a listing of the patents and trademarks that have been registered with the USPTO, see &#147;Business&#151;Intellectual Property.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s R&amp;D staff designs the hardware, software and <FONT STYLE="white-space:nowrap">AI-based</FONT> algorithms. Hardware development assistance is provided by outside consulting firms. The Company internally develops the signal
processing software elements along with outside assistance. The user interface elements of the software are designed by the Company along with the assistance of outside consultants. The data science work necessary to build the <FONT
STYLE="white-space:nowrap">AI-based</FONT> algorithms is performed both internally and externally using outside consultants. Incorporation of all software elements into the MyoVista hardware is performed internally. We currently employ five
full-time R&amp;D staff. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Recent Developments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2021 Bridge Financing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning in
October 2021, we initiated a private placement with accredited investors of Bridge Notes and Bridge Warrants, which we refer to as our 2021 Bridge Financing. We had an initial closing of $712,222 in principal amount of the Bridge Notes and Bridge
Warrants to purchase a total of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of the Common Stock. At the time of this initial closing, we informed the investors that we were negotiating terms of a possible
investment by a lead investor and that in the event the terms of the Bridge Notes and Bridge Warrants changed, these initial investors would be given the opportunity to exchange their initial Bridge Notes and Bridge Warrants for Bridge Notes and
Bridge Warrants on the same terms as those received by the lead investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2021, we entered into a Securities Purchase
Agreement, which we refer to as the Securities Purchase Agreement, with the lead investor and additional accredited investors, or the Purchasers, pursuant to which we issued and sold (i)&nbsp;Bridge Notes in an aggregate principal amount of
$2.22&nbsp;million, referred to herein as the Bridge Notes, and (ii)&nbsp;warrants to purchase [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] million shares of Common Stock or, the Bridge Warrants, and together with the
Bridge Notes, the Bridge Securities, in the 2021 Bridge Financing. Subsequent to December 2021 and through February&nbsp;25, 2022, we sold an aggregate total principal of $1.04&nbsp;million of Bridge Notes and Bridge Warrants to purchase
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] million shares of Common Stock. Through February&nbsp;25, 2022, the Company received net proceeds (after the OID) of $3.58 million in connection with the 2021 Bridge
Financing. The 2021 Bridge Financing concluded on February&nbsp;28, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Bridge Note was issued with 10% original issue discount
and is convertible into a number of shares of Common Stock equal to the principal amount of the Bridge Note divided by an initial conversion price of the lower of (i) $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]
per share or (ii)&nbsp;a 30% discount to the original issue price in a qualified offering (as defined below), which is referred to as the Conversion Price. For two years after the issuance date of the Bridge Notes, the Conversion Price of the Bridge
Notes is subject to adjustment for certain events such as stock dividends and splits and issuances of shares of Common Stock or securities convertible into or exercisable for shares of Common Stock at a price less than the Conversion Price in which
event the Conversion Price will be subject to a full ratchet downward to the price at which such newly-issued shares of Common Stock or securities convertible into or exercisable for shares of Common Stock were issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bridge Notes bear interest at 8% per annum payable, have a maturity date of December&nbsp;22, 2024 and are secured by a subordinated
security interest in substantially all of the assets, including patents and other intellectual property, of the Company. From and after the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the issuance of the Bridge
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Notes, the Company may prepay the principal of the Bridge Notes and all accrued and unpaid interest thereon at a price of 115% of the principal amount to be prepaid (plus accrued and unpaid
interest). In addition, upon the occurrence of an event of default or a change of control of the Company (as defined in the Bridge Notes), the holders of the Bridge Notes may redeem their Bridge Notes in an amount equal to 125% of the principal
amount (plus accrued and unpaid interest). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bridge Notes are expected to convert into shares of Common Stock at the Conversion Price
automatically upon the consummation of this offering, which we anticipate will satisfy the definition of a qualified offering set forth in the Bridge Notes. A qualified offering is defined as a public offering in the U.S. pursuant to a registration
statement declared effective by the SEC, pursuant to which the Common Stock is listed for trading on a securities exchange, such as the Nasdaq, with (i)&nbsp;minimum gross proceeds of $6.0&nbsp;million, and (ii)&nbsp;minimum net proceeds of
$5.0&nbsp;million after deducting all fees and expenses in connection with such offering. With respect to the conversion of the Bridge Notes, in the event any Purchaser, together with its affiliates and any other person acting as a group as defined
under Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended, whom we refer to as the Attribution Parties, would beneficially own in excess of 4.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to, the conversion of all or any portion of the Bridge Notes, or the Maximum Percentage, shall receive Pre-Funded Warrants in lieu of shares of Common Stock. Any such Purchaser may adjust the Maximum Percentage at any time, upon 61 days&#146;
notice, provided that the Maximum Percentage may not be adjusted above 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the conversion of all or any portion of the Bridge Notes. The exercise of the
Pre-Funded Warrants is also subject to the Maximum Percentage, except that any exercise of the Pre-Funded Warrants resulting in a number of shares in excess of the Maximum Percentage shall be deemed null and void and shall be cancelled <I>ab
initi</I><I>o</I>. A description of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants is set forth in &#147;Description of Capital Stock&#151;Warrants.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the 2021 Bridge Financing, we also issued warrants to purchase
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] million shares of Common Stock, which we refer to as the Bridge Warrants. The Bridge Warrants expire in five years from the date of issuance, beginning on
December&nbsp;22, 2026, and have an initial Exercise Price of $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share, subject to certain adjustments. No holder of a Bridge Warrant may exercise any portion of a
Bridge Warrant if after giving effect to such exercise such holder (together with its Attribution Parties) would beneficially own in excess of the Maximum Percentage of 4.99% of the number of shares of the Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock but not including shares of Common Stock issuable upon exercise of such holder&#146;s Bridge Warrants or Pre-Funded Warrants. This limitation may be waived by a holder, at its election, upon
not less than 61 days&#146; prior notice to the Company, to change the limitation to 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of such
holder&#146;s warrant. Any exercise of the Bridge Warrants resulting in a number of shares in excess of 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the exercise shall be deemed null and void and
shall be cancelled <I>ab initio</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price of the Bridge Warrants is subject to adjustment for certain events such as stock
dividends and splits and, if and whenever on or prior to the later of (i)&nbsp;the second anniversary of December&nbsp;22, 2021 or (ii)&nbsp;the <FONT STYLE="white-space:nowrap">18-month</FONT> anniversary of the effective date of this offering,
there are issuances of shares of Common Stock or securities convertible into or exercisable for shares of Common Stock at a price less than the exercise price of the Bridge Warrants, in which event the Exercise Price will be reduced to the price at
which such newly issued shares of Common Stock or securities convertible into or exercisable for shares of Common Stock were issued. In addition, if the per share price in this offering is less than 125% of the Exercise Price, then the Exercise
Price would be decreased to the issuance price of the shares of Common Stock sold in this offering. Upon a decrease in the Exercise Price, the number of shares of Common Stock to be received shall be adjusted such that the total consideration to be
received by the Company upon exercise in full of the Bridge Warrants would equal 150% of the principal amount of the Bridge Note purchased by such holder in the 2021 Bridge Financing. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the 2021 Bridge Financing, we also entered into a registration rights
agreement, or the Registration Rights Agreement, with the Purchasers pursuant to which we agreed to file a resale registration statement no later than 90 days after the date of this prospectus with respect to the shares of Common Stock issuable upon
conversion of the Bridge Notes, exercise of the Bridge Warrants or resulting from anti-dilution provisions in the Bridge Notes, the Bridge Warrants and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants (if any) or any securities issued
or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event. In the event that the registration statement relating to the resale of the Registrable Securities is not declared effective by the SEC on or
prior to 150 days after the date of this Prospectus, we are required to pay to each holder of Registrable Securities an amount in cash equal to two percent of the principal amount of such holder&#146;s Bridge Notes. For additional information with
respect to the Registration Rights Agreement, see &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Implications of
Being an &#147;Emerging Growth Company&#148; and a &#147;Smaller Reporting Company&#148; </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth
company&#148; under the Jumpstart our Business Startups Act of 2012, or the JOBS Act. For so long as we remain an emerging growth company, we may take advantage of relief from certain reporting requirements and other burdens generally applicable to
public companies. In particular, as an emerging growth company we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not required to obtain an attestation and report from our auditors on our management&#146;s assessment of our
internal control over financial reporting pursuant to the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not required to provide a detailed narrative disclosure discussing our compensation principles, objectives
and elements and analyzing how those elements fit with our principles and objectives (commonly referred to as &#147;compensation discussion and analysis&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not required to obtain a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote from our
shareholders on executive compensation or golden parachute arrangements (commonly referred to as the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay,&#148;</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;say-on-frequency&#148;</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-golden-parachute&#148;</FONT></FONT> votes); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are exempt from certain executive compensation disclosure provisions requiring a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> graph and CEO pay ratio disclosure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may present only two years of audited financial statements and only two years of related Management&#146;s
Discussion&nbsp;&amp; Analysis of Financial Condition and Results of Operations, or MD&amp;A; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are eligible to claim longer <FONT STYLE="white-space:nowrap">phase-in</FONT> periods for the adoption of new or
revised financial accounting standards under &#167;107 of the JOBS Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to take advantage of these reduced
reporting requirements and exemptions, including the longer <FONT STYLE="white-space:nowrap">phase-in</FONT> periods for the adoption of new or revised financial accounting standards under &#167;107 of the JOBS Act. Our election to use the <FONT
STYLE="white-space:nowrap">phase-in</FONT> periods may make it difficult to compare our financial statements to those of <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies and other emerging growth companies that have opted out of
the <FONT STYLE="white-space:nowrap">phase-in</FONT> periods under &#167;107 of the JOBS Act. Please see &#147;Risk Factors&#151;We are an &#145;emerging growth company.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, we may take advantage of the above-described reduced reporting requirements and exemptions for up to five years after our
initial sale of common equity pursuant to a registration statement declared effective under the Securities Act of 1933, as amended, or such earlier time that we no longer meet the definition of an emerging growth company. In this regard, the JOBS
Act provides that we would cease to be an &#147;emerging growth company&#148; if we have more than $1.07&nbsp;billion in annual revenue, have more than $700&nbsp;million in market value of our Common Stock held by
<FONT STYLE="white-space:nowrap">non-affiliates,</FONT> or issue more than $1&nbsp;billion in principal amount of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. Further, under current SEC rules we will
continue to qualify as a </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;smaller reporting company&#148; for so long as we have a public float (i.e., the market value of common equity held by <FONT STYLE="white-space:nowrap">non-affiliates)</FONT> of less than
$250&nbsp;million as of the last business day of our most recently completed second fiscal quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the reduced reporting
requirements and exemptions available to us as an &#147;emerging growth company&#148; are also available to us due to the fact that we also qualify as a &#147;smaller reporting company&#148; under the Securities and Exchange Commission, or the SEC
rules, which means that the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&nbsp;million and our
annual revenue was less than $100&nbsp;million during the most recently completed fiscal year For instance, smaller reporting companies are not required to obtain an auditor attestation and report regarding internal control over financial reporting;
are not required to provide a compensation discussion and analysis; are not required to provide a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> graph or CEO pay ratio disclosure; and may present
only two years of audited financial statements and related MD&amp;A disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a smaller reporting company at the time we
cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies and, we may continue to be a smaller reporting company after this offering if either
(i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million as of the last business day of the second fiscal quarter or (ii)&nbsp;our annual revenue was less than
$100&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million as of the last business day of the second fiscal
quarter. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging
growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate
Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a Texas corporation based in Southlake, Texas and were incorporated in Texas in August 2007. Our principal
executive offices are located at 550 Reserve Street, Suite 360, Southlake TX 76092. Our telephone number is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">682-237-7781.</FONT></FONT> We are doing business under an assumed name,
HeartSciences. Our website address is <I>www.heartsciences.com</I>. The information contained on, or that can be accessed through, our website is not part of this prospectus. We have included our website address in this prospectus solely as an
inactive textual reference. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_3"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common Stock currently issued and outstanding </B></P></TD>
<TD>[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common Stock offered by us </B></P></TD>
<TD>[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common Stock to be outstanding after this offering </B></P></TD>
<TD>[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]shares or [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares if the underwriters exercise in full the over-allotment option to
purchase additional shares of Common Stock, subject to the assumptions set forth below. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Over-allotment option </B></P></TD>
<TD>We have granted the underwriters an option for a period of up to 30 days to purchase, at the public offering price, up to [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of additional Common Stock, less
underwriting discounts and commissions, to cover over-allotments, if any. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Representative&#146;s Warrants </B></P></TD>
<TD>We will issue to The Benchmark Company LLC, the representative of the underwriters, or its permitted designees, warrants to purchase up to [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock
(or [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock if the underwriters exercise their over-allotment option in full). The representative&#146;s warrants will have an exercise price of 100% of
the per share public offering price, will be exercisable on the date of issuance and will expire five years from the effective date of the registration statement of which this prospectus forms a part. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of proceeds </B></P></TD>
<TD>We expect to receive net proceeds from this offering of approximately $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], after deducting underwriting discounts and commissions and estimated offering expenses, or
approximately $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] if the underwriter exercises the over-allotment option in full. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend the net proceeds from this offering to repay the $1M Loan and Security Agreement and the remainder, if any, for working capital and general corporate purposes, which may include the hiring of additional
personnel, capital expenditures and the costs of operating as a public company. The $1M Loan and Security Agreement, as amended, matures on September&nbsp;30, 2022. At January&nbsp;31, 2022, the principal balance outstanding under the $1M Loan and
Security Agreement was $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] and the interest rate was 12% per annum. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk factors </B></P></TD>
<TD>Investing in our securities involves a high degree of risk. You should read the &#147;Risk Factors&#148; section starting on page&nbsp;[20] of this prospectus for a discussion of factors to consider carefully before deciding to invest in our
Common Stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Proposed Listing: </B></P></TD>
<TD>We intend to apply to list our Common Stock to be issued in this offering on the Nasdaq Capital Market under the symbol &#147;[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>].&#148; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The number of shares of Common Stock to be outstanding immediately after this offering as shown above assumes that all of the shares of Common Stock offered hereby are sold, and is based on
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock outstanding as of January&nbsp;31, 2022, plus [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common
Stock to be issued upon the conversion of up to the Maximum Percentage by each holder of the Bridge Notes, plus [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock to be issued upon conversion of
the $1.5M Notes. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">This number of shares of the Common Stock excludes: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock issuable
upon conversion of Preferred Stock (including conversion of the shares of Series C Preferred Stock issuable upon conversion of the $130K Note). See &#147;Description of Capital Stock&#151;Preferred Stock&#148; for additional information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock issuable
upon the exercise of stock options issued to directors, employees and consultants of the Company, of which [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] were vested as of such date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock to be
issued upon exercise of the Investor Warrants, the $1M Lender Warrants, the $1.5M Lender Warrants, the Bridge Warrants, and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. See &#147;Description of Capital Stock&#151;Warrants&#148;
for more information; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock to be
issued upon exercise of the representative&#146;s warrants. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">This number of shares of Common Stock also excludes shares issuable pursuant to antidilution provisions set forth in the Bridge Warrants, $1M Lender Warrants and $1.5M Lender Warrants and the Series C Preferred Stock as
well as shares of Common Stock issuable upon conversion of the Series A Preferred Stock or the Series B Preferred Stock, which are each dependent on the market price of our Common Stock at the time of conversion. For additional information, see
&#147;Description of Capital Stock&#151;Antidilution Provisions.&#148; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_4"></A>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our financial data. We have derived the following statements of operations data for Fiscal 2021 and Fiscal 2020
from our audited financial statements included elsewhere in this prospectus. We have derived the following statements of operations data for the nine&nbsp;months ended January&nbsp;31, 2022 and 2021, and the balance sheet data as of January&nbsp;31,
2022, from our unaudited interim condensed financial statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in the future. The following summary financial data
should be read in conjunction with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and with our financial statements and related notes included elsewhere in this prospectus. Share numbers are
based on the number of shares outstanding prior to the reverse stock split. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended January 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended April 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,182</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,460</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,722</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,708,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,040,227</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">874,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,795,679</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,016</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,581,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,845,922</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,566,465</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,828,200</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(132,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,811</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on settlement of payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,790</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,897</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,082</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,452,170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,811,118</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,356,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,355,498</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>January&nbsp;31,</B><br><B>2022</B><br><B>(unaudited)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">723,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">496,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">392,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">396,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,927,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,955,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,880,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">650,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,836,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,640,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,574,648</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,122,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Stockholders&#146; (Deficit) Equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,909,590</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. See our audited financial statements and
the related notes include elsewhere in this prospectus for further details regarding our assets and liabilities as of April&nbsp;30, 2021 and 2020. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. You should consider carefully the risks and uncertainties described below,
together with all of the other information in this prospectus, including the financial statements and related notes, before deciding whether to purchase our securities. If any of the following risks are realized, our business, operating results,
financial condition and prospects could be materially and adversely affected. In that event, the price of our Common Stock could decline, and you could lose part or all of your investment. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Our Financial Condition and Capital Requirements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating history and we have incurred significant operating losses since our inception, and anticipate that we will
incur continued losses for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a development-stage medical device company with a limited operating
history. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the
medical device industry. To date, we have generated limited revenue from the sale of the MyoVista during its development stage. We have incurred losses in each year since our inception, including net losses of approximately $2.4&nbsp;million and
$3.8&nbsp;million for Fiscal 2021 and Fiscal 2020, respectively, and approximately $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] million and
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] million for the nine months ended January&nbsp;31, 2021 and January&nbsp;31, 2022, respectively. As of January&nbsp;31, 2022, we had an accumulated deficit of
approximately $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] million. See &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Results of Operations&#148; for
additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approval to market the MyoVista, our future revenue will depend upon the size of the
market in which the device or any future product receives approval as well as our ability to achieve sufficient market acceptance, pricing, and reimbursement from third-party payors, which we may never achieve. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also anticipate that our expenses will increase substantially if and as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue research and development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are granted regulatory and marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing, and distribution infrastructure; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify, assess, acquire, license, and/or develop subsequent generations of the MyoVista and any new
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to maintain, protect, and expand our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to attract and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create additional infrastructure to support our operations as a public company as well as our device development
and planned future commercialization efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience any delays or encounter issues with respect to any of the above, including, but not limited to, failed
studies, complex results, safety issues or other regulatory challenges that require longer <FONT STYLE="white-space:nowrap">follow-up</FONT> of existing studies or additional supportive studies in order to pursue marketing approval.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant operating losses for the foreseeable future. As a result of the numerous
risks and uncertainties associated with developing a medical device, we are unable to predict the extent of any future losses or whether we will ever achieve and maintain profitability. Further, the operating losses that we incur may fluctuate
significantly from quarter to quarter and year to year, such that a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a good indication of our future
performance. Other unanticipated costs may also arise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Our financial condition is dependent on regulatory approval for, and the
successful development, marketing and sale of, the MyoVista, which we have not received as of the date of this prospectus</I></B><B>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MyoVista is our only current product candidate. As a result, the success of our business plan is entirely dependent on our ability to
obtain regulatory approval and to subsequently develop, manufacture and commercialize the MyoVista. Our failure to do so would likely cause our business to fail. Successful commercialization of medical devices is a complex, lengthy, costly and
uncertain process, dependent on the efforts of management, manufacturers, local operators, integrators, medical professionals, third-party payors, as well as general economic conditions, among other factors. For more information, see
&#147;&#151;Risks Related to Our Business and Industry&#151;Our future success depends on our ability to develop, receive regulatory clearance or approval for, and introduce the MyoVista to the market in a timely manner&#133;&#148; Any factor that
adversely impacts the approval, development and commercialization of the MyoVista will have a negative impact on our business, financial condition and results of operations. We may face several challenges with respect to our commercialization
efforts including, among others, that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may fail to obtain regulatory clearance or approvals or, even if regulatory approval is obtained, we may face
adverse regulatory and/or legal actions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not have adequate financial or other resources to properly commercialize the MyoVista or sell it in
economically viable quantities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to manufacture in commercial quantities, at an adequate quality or at an acceptable cost;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to establish adequate sales, marketing and distribution channels; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">healthcare professionals and patients may not accept the MyoVista; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to compete with existing solutions for cardiac screening; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technological breakthroughs in heart disease screening solutions may reduce the potential demand for the
MyoVista; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party payors may not agree to reimburse patients for any or all of the charges related to testing the
MyoVista, which may adversely affect physicians&#146; adoption and use of the device; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may face third-party claims of intellectual property infringement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain regulatory approval and accomplish any one or more of the challenges listed above, our ability to effectively
commercialize the MyoVista could be limited, which in turn could have a material adverse effect on our business, financial condition and results of operations. For additional information regarding risks related to our ability to successfully
develop, market and sell the MyoVista, see &#147;&#151;Risks Related to Our Business and Industry&#151;Our future success depends on our ability to develop, receive regulatory clearance or approval for, and introduce the MyoVista to the market in a
timely manner. If we do not obtain and maintain the regulatory registrations and clearances for our device, we will be unable to market and sell the MyoVista in the United States, Europe or other regions&#148; and &#147;&#151;Risks Related to Our
Business and Industry&#151;Our success will be dependent upon physician acceptance.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Even if this offering is successful, we
will need to raise substantial additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding on acceptable terms and on a timely basis may require us to curtail, delay or discontinue our development efforts
and other operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain funding on a timely basis, we may (i)&nbsp;need to significantly curtail, delay
or discontinue our development and/or commercialization efforts, or (ii)&nbsp;be unable to continue operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and
results of operations. Even if this offering is completed, we expect that we will require substantial additional capital to commercialize the MyoVista. In addition, our planned expenses and operations
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may change as a result of many factors that could be currently unknown to us and we may need to seek additional funds sooner than planned. Our future funding requirements will depend on many
factors including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress, results and costs of our ongoing and planned studies and, if applicable, clinical trials of the
MyoVista as well as any future products and services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost, timing and outcomes of regulatory review of current and any future products and services;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of product development, testing, manufacturing, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> development and, if applicable, clinical trials for any other product that we may develop or otherwise obtain in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of our future activities, including establishing sales, marketing and distribution capabilities for the
MyoVista, in any particular geography, where we receive marketing and/or regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of any collaborative, licensing, payment plan and/or other arrangements that we may
establish; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual
property rights and defending any intellectual property-related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of revenue, if any, received from commercial sales of the MyoVista if we receive marketing approval.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also be required to seek additional funds at an earlier stage than would otherwise be desirable and, as a
result, we may be required to relinquish rights to some of our intellectual property, our device, or otherwise agree to terms unfavorable to us or our shareholders, any of which may have a material adverse effect on our business. Even if we believe
that we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic objectives such as, acquiring IP, partnering with a vendor or other
worthwhile business endeavors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize the MyoVista and any future product. In addition, we cannot guarantee that future financing will be available in
sufficient amounts or on terms acceptable to us, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>All of our assets are subject to security interests. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At January&nbsp;31, 2022, we had a total of $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]&nbsp;million of
indebtedness. For more information, see &#147;Capitalization&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Description of Indebtedness.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to service our indebtedness will depend upon, among other things, the receipt of regulatory approvals for the MyoVista and
thereafter our future financial and operating performance, which will be affected by prevailing economic conditions and financial, business, regulatory and other factors, some of which are beyond our control. If our operating results are not
sufficient to service our current or future indebtedness, we will be forced to take actions such as reducing or delaying the development and sales and marketing of the MyoVista, restructuring or refinancing our indebtedness or seeking additional
debt or equity capital or bankruptcy protection. We may not be able to affect any of these remedies on satisfactory terms or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
breach of the terms and conditions of our indebtedness would likely result in an event of default. If an event of default occurs (after any applicable notice and cure periods), the lenders would be entitled to accelerate the repayment of amounts
outstanding (including accrued and unpaid interest and fees).&nbsp;Upon such a default, the lenders could also foreclose against any collateral securing such obligations, which consists of all of our assets.&nbsp;In addition to the assets securing
our indebtedness, our obligation to pay certain royalties to the inventor of certain specified MyoVista technology and proprietary and intellectual property rights thereto (including patents, copyright, trademarks, trade secrets and <FONT
STYLE="white-space:nowrap">know-how)</FONT> is secured by a first lien security interest. If we fail to pay those royalties, the inventor could foreclose on the technology. For more information, please see
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;Business&#151;Intellectual Property.&#148; If any such foreclosure occurred, we would likely not be able to continue to operate as a going concern. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern,
which could prevent us from obtaining new financing either on reasonable terms or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our auditors&#146; report on our audited
financial statements for Fiscal 2021 contains an explanatory paragraph regarding substantial doubts about our ability to continue as a going concern because we have experienced recurring losses, negative cash flows from operations, limited capital
resources, a net shareholders&#146; deficit, as well as significant debt obligations. These events and conditions, along with other matters, indicate that a material uncertainty exists that may cast significant doubt on our ability to continue as a
going concern. The perception that we may not be able to continue as a going concern may have a material adverse effect on our share price and our ability to raise new capital (whether it is through the issuance of equity or debt securities or
otherwise), enter into critical contractual relations with third parties and otherwise execute our business objectives. Until we can generate significant recurring revenues, we expect to satisfy our future cash needs through debt or equity
financing. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to continue as a going concern, we may have to liquidate our assets, and the values we receive for our assets in liquidation
or dissolution could be significantly lower than the values reflected in our financial statements. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Our Business and
Industry </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to develop, receive regulatory clearance or approval for, and introduce the
MyoVista to the market in a timely manner. If we do not obtain and maintain the regulatory registrations and clearances for our device, we will be unable to market and sell the MyoVista in the United States, Europe or other regions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, before we can market a new medical device, or a new use of, new claim for or significant modification to, an existing
product, we must first receive either approval of a Premarket Approval Application, or PMA, clearance under Section&nbsp;510(k), or be granted a De Novo classification, in accordance with the Federal Food, Drug, and Cosmetic Act, or the FDCA. For
additional information on the PMA or the De Novo classification processes, see &#147;Business&#151;FDA and Other Government Regulation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA can delay, limit or deny clearance or approval of a medical device for many reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to demonstrate to the FDA&#146;s satisfaction that the MyoVista is safe and effective for its
intended use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data from our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials may be
insufficient to support clearance or approval, where required; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturing process or facilities we use or contract to use may not meet applicable requirements; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions at the FDA caused by funding shortages or global health concerns, including the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We previously submitted a De Novo application in late 2019. The
FDA determined that the Company would need to undertake a new algorithm validation clinical study using patients gathered from institutions that were not part of the studies used for algorithm development. Due to the time of completion of the study,
submission of the new validation study results requires a new De Novo submission. The new validation study is currently underway and we intend to submit a new De Novo application for the MyoVista later this year.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Additional clinical studies are being conducted as part of the outcome of the previous application process. The De Novo process can be expensive, lengthy and unpredictable. De Novo classification
requests require the performance of at least one clinical trial. Despite the time, effort and cost, we may not ultimately be successful in completing the review process and our De Novo application may not be granted by the FDA in a timely manner or
at all. Any delay or failure to obtain necessary regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for
the MyoVista, which may limit the market for the device in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to sell the device in member countries of the
European Economic Area, or EEA, our device must comply with the essential requirements of the EU Medical Device Regulation (EU) 2017/745, or EU MDR. Compliance with these requirements is a prerequisite to be able to affix the Conformit&eacute;
Europ&eacute;ene, or CE, mark to our device, without which it cannot be sold or marketed in the EEA. For additional information on the PMA or the De Novo classification processes, see &#147;Business&#151;FDA and Other Government Regulation.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has previously achieved a CE Mark under the EU Medical Devices Directive or MDD in February 2017. The Medical Device
Directive was established on June&nbsp;14, 1993 but the EU Medical Devices Directive, or MDD regulatory framework, has since been replaced by EU MDR. In order to sell in member countries of the European Economic Area, or EEA, our device must now
comply with the essential requirements of the newer, updated regulatory framework or EU MDR. In October 2021, the Company submitted the documentation required to establish compliance with EU MDR. The submission of the technical file is currently
under review and our CE Mark issued under MDD lapsed in February 2022. If the technical file submission is found to comply with the new requirements, a certificate of conformity will be issued to verify the Company&#146;s compliance with EU MDR. An
updated CE mark certificate under EU MDR will entitle the Company to market the MyoVista in the European Economic Area as well as other countries for which CE Mark represents an appropriate regulatory standard. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our device outside of the United States and the EEA are also subject to foreign regulatory requirements that vary widely from country
to country. Approval procedures vary among countries and can involve additional testing. Complying with foreign regulatory requirements, including obtaining registrations, clearances or approvals, can be expensive and time-consuming, and we may not
receive regulatory clearances or approvals in each country in which we plan to market our device or we may be unable to do so on a timely basis. If we modify our device, we may need to apply for additional regulatory clearances or approvals before
we are permitted to sell the modified device. In addition, we may not continue to meet the quality and safety standards required to maintain the authorizations that we have received. If we are unable to maintain our authorizations in a particular
country, we will no longer be able to sell the applicable device in that country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory clearance or approval by the FDA does not
ensure registration, clearance or approval by regulatory authorities in other countries, and registration, clearance or approval by one or more foreign regulatory authorities does not ensure registration, clearance or approval by regulatory
authorities in other foreign countries or by the FDA. However, a failure or delay in obtaining registration or regulatory clearance or approval in one country may have a negative effect on the regulatory process in others. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our success will be dependent upon physician acceptance. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future growth and profitability largely depend on our ability to increase physician awareness of the MyoVista and on the willingness of
hospitals, physicians, patients and/or third-party payors to use it. These parties may not use our device unless they are able to determine, based on experience, clinical data, medical society recommendations and other analyses, that our device is
safe, effective and cost-effective, on a stand-alone basis and relative to our competitors&#146; products. If we fail to deliver a device that physicians want to use, our revenue potential, financial results and business may be significantly harmed.
Even if we are able to deliver a superior device and are able to raise physician awareness of our device through effective marketing, physicians tend to be slow in making changes to their medical treatment practices and may be hesitant to select our
device as their preferred diagnostic device for a variety of reasons, including: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">long-standing relationships with competing companies and distributors that sell competing devices;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of experience with the MyoVista and concerns that we are new to market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack or perceived lack of sufficient clinical evidence, including long-term data, supporting safety or clinical
benefits; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">time commitment and skill development that may be required to gain familiarity and proficiency with the MyoVista.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Physicians play a significant role in determining the course of a patient&#146;s treatment and, as a result, the type
of treatment that will be utilized and provided to a patient. We intend to focus our sales, marketing and education efforts on educating cardiologists and any other potential referring physicians. However, if physicians do not perceive the MyoVista
to be useful and reliable, we may not be able to attract or retain customers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If third-party payors do not provide adequate
coverage and reimbursement for the use of the MyoVista, our revenue will be negatively impacted. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MyoVista does not currently
have coverage and reimbursement approved for third-party payor coverage or reimbursement. Such reimbursement, if and when approved, will vary based on the identity of the third-party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In both U.S. <FONT STYLE="white-space:nowrap">and&nbsp;non-U.S.&nbsp;markets,</FONT> our ability to successfully commercialize and achieve
market acceptance of the MyoVista depends, in significant part, on the availability of adequate financial coverage and reimbursement from third-party payors, including governmental payors (such as the Medicare and Medicaid programs in the U.S.),
managed care organizations and private health insurers. Third-party payors decide which treatments they will cover and then establish reimbursement rates for those treatments. If approved and successfully commercialized, we expect that the MyoVista
may be purchased by hospitals and other providers who will then seek reimbursement from third-party payors for the use of the MyoVista and, in many cases, the decision whether or not to purchase the MyoVista will be dependent upon whether or not
such purchaser will be able to seek reimbursement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increasingly, third-party payors are also examining the cost effectiveness of
products, in addition to their safety and efficacy, when making coverage and payment decisions. Third-party payors have also instituted initiatives to limit the growth of healthcare costs using, for example, price regulation or controls and
competitive pricing programs. Some third-party payors also require demonstrated superiority, on the basis of randomized clinical trials, <FONT STYLE="white-space:nowrap">or&nbsp;pre-approval&nbsp;of</FONT> coverage, for new or innovative devices
before they will reimburse healthcare providers who use such devices. Additionally, there is no uniform policy for coverage and reimbursement in the U.S., and coverage and reimbursement can differ significantly from payor to payor. Third-party
payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from the Medicare coverage determination process. It is uncertain whether
the MyoVista will be viewed as sufficiently cost effective to warrant coverage and adequate reimbursement levels for use in any given jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to engage with the American Medical Association, or AMA, and American College of Cardiology to gain approval for use of the standard
ECG reimbursement coding for the conventional ECG functions of the MyoVista. We will also seek to have private third-party payors provide reimbursement for the wavECG proprietary algorithm, or the MyoVista Algorithm. We cannot assure you that these
efforts will be successful to our obtaining third-party payor reimbursement. The lack of reimbursement from third-party payors would have an adverse effect on our revenues, which could have an adverse effect on our business, financial condition and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reimbursement systems in international markets vary significantly by country and, within some countries, by region
and reimbursement approvals must be obtained on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;country-by-country&nbsp;or</FONT></FONT> a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">region-by-region</FONT></FONT> basis. In certain international markets, a product must be approved for reimbursement before it can be approved for sale in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that country. Furthermore, many international markets have government-managed healthcare systems that control reimbursement for new devices. In most markets, there are private insurance systems
as well as government-managed systems. For more information regarding the process of receiving reimbursement approval, please see &#147;Business&#151;Market Strategy&#151;Reimbursement.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our success is partly dependent on the use of our specialized electrodes. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business model involves both the sale of the MyoVista device and the use of our proprietary, specialized electrodes. These proprietary
electrodes are required for every test performed. Less expensive electrodes for use with ECG devices are widely available. If customers bypass our security system to ensure use of our electrodes with the MyoVista and then use less expensive,
third-party electrodes, it may have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Medical device development is costly and involves continual technological change in order to remain competitive which may render the
MyoVista obsolete. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are successful in obtaining regulatory clearance or approval for the MyoVista and are able to
commercialize the MyoVista, our future success will depend on our ability to enhance the MyoVista as well as develop or acquire new technologies to keep pace with technological developments, evolving industry standards, as well as responses to
changes in customer needs and expectations. The market for medical devices is unique due to factors such as: rapid technological change, medical advances, short device lifecycles, changing regulatory requirements and evolving industry standards.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any one of these factors could either reduce potential demand for the MyoVista or require substantial resources and expenditures for,
among other things, research, design and development, to avoid technological or market obsolescence. A failure to adequately develop enhancements and improvements to the MyoVista or acquire new devices that will address changing technologies and
customer requirements adequately, or to introduce such devices on a timely basis, may have a material adverse effect on our business, financial condition and results of operations. We might have insufficient financial resources to improve the
MyoVista at a competitive rate, if at all. Technological advances by one or more competitors or future entrants into the field may result in the MyoVista becoming <FONT STYLE="white-space:nowrap">non-competitive</FONT> or obsolete, which may
adversely affect our business and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We face intense competition in the market and, as a result, we may be
unable to effectively compete in our industry. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors, such as General Electric Company, or GE, Koninklijke
Philips N.V., or Philips, and <FONT STYLE="white-space:nowrap">Hill-Rom</FONT> Holdings, Inc., or <FONT STYLE="white-space:nowrap">Hill-Rom,</FONT> have long histories and strong reputations within the industry. These competitors have significantly
greater brand recognition, and financial and human resources than we do. They also have more experience and capabilities in researching and developing diagnostic devices, obtaining and maintaining regulatory clearances and other requirements,
manufacturing and marketing those products than we do. There is a significant risk that we may be unable to overcome the advantages held by our competition, and our inability to do so could lead to the failure of our business and the loss of your
investment. In addition, we may be unable to develop additional products in the future or to keep pace with developments and innovations in the market and lose market share to our competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medical device markets, and more specifically ECG technologies and solutions markets, are competitive, which can lead to, among other things,
price reductions, longer selling cycles, lower product margins, loss of market share and additional working capital requirements. To succeed, we must, among other critical matters, gain consumer acceptance for our device as compared to other
solutions currently available in the cardiac screening market or advanced cardiac screening offering. For more information regarding risks related to our dependence on physician acceptance, see &#147;&#151;Our success will be dependent upon
physician acceptance.&#148; </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our competitors offer significant discounts on certain products and solutions, we may
need to lower our prices or offer other favorable terms in order to compete successfully. Any broad-based changes to our prices and pricing policies could make it difficult to generate revenues or cause our revenues to decline. Moreover, if our
competitors develop and commercialize products and solutions that are more effective or desirable than products and solutions than we may develop, we may not convince our customers to use our products and solutions. Any such changes would likely
reduce our commercial opportunity and revenue potential and could materially adversely impact our operating results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are not
able to attract and retain highly skilled managerial, scientific, technical and marketing personnel, we may not be able to implement our business model successfully. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management as well as clinical and
scientific personnel to implement our business strategy. We are highly dependent upon our senior management, our employees, consultants and scientific and medical collaborators. Our management team must be able to act decisively to apply and adapt
our business model in the rapidly changing markets in which we will compete. In addition, we rely upon technical and scientific employees or third-party contractors to effectively establish, manage and grow our business. In order to attract and
retain highly skilled managerial, sales, scientific and technical personnel, we may need to pay them higher compensation or fees than currently expected and such higher compensation may have a negative effect on our operating results. Competition
for experienced, high-quality personnel in the medical device field is intense. Our failure to hire and retain quality personnel on acceptable terms could impair our ability to develop new products and services and manage our business effectively.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may need to expand our organization and we may experience difficulties in recruiting additional employees and consultants, which
could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As our development and commercialization plans and strategies develop, we will likely need
additional managerial, operational, sales, marketing, financial, legal and other resources. The competition for qualified personnel in the medical device industry is intense. Due to this intense competition, we may be unable to attract and retain
qualified personnel necessary for the development of our business or to recruit suitable replacement personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management may need
to divert its attention away from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and devote a substantial amount of time to managing these growth activities. We may not be able to
effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth
could require capital expenditures and may divert financial resources from other projects, such as the development of additional medical device products. If our management is unable to effectively manage our growth, our expenses may increase more
than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize medical device products and compete effectively
will depend, in part, on our ability to effectively manage any future growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our management team has limited experience managing a
public company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some members of our management team have limited experience managing a publicly traded company, interacting with
public company investors and complying with the increasingly complex laws pertaining to public companies in the United States. Our management team may not successfully or efficiently manage our transition to being a public company due to significant
regulatory oversight and reporting obligations under the U.S. federal securities laws and the continuous scrutiny of securities analysts and investors. These new obligations and constituents will require significant attention from our senior
management and could divert their attention away from the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of our business, which could make it more difficult for us to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attract and retain qualified persons to serve on our Board of Directors, any committees of our Board of Directors, or as executive officers and/or adversely affect our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We manage our business through a small number of employees and key consultants.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], 2022, we had twelve full-time employees and six independent consultants. Our future growth and success depend, to a
large extent, on the continued service of members of our current management. Any of our employees and contractors may leave our Company or discontinue services at any time. Our operational success will substantially depend on the continued
employment of our management, including our executive officers,, technical staff and other key personnel. We do not currently maintain key person life insurance policies on any of our employees. The loss of key personnel may have an adverse effect
on our operations and financial performance and adversely affect our ability to execute our business plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We expect to conduct
business outside of the U.S. and doing so exposes us to additional business, regulatory, political, operational, financial and economic risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to conduct business outside of the U.S. which will therefore subject us to a number of risks, including, but not limited to,
conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since we anticipate conducting business outside of the U.S., we anticipate that we will be subject to rules and regulations in <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> jurisdictions. In some countries, pricing may be subject to governmental control under certain circumstances. In these countries, pricing negotiations with governmental agencies can take considerable time
after the receipt of marketing approval for a medical device. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of MyoVista to other available products.
If reimbursement of our device is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to certain U.S. and foreign anticorruption, anti-money laundering, export control, sanctions and other trade laws and
regulations. We could face serious consequences for any violations of such laws and regulations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among other matters, U.S. and
foreign anticorruption, anti-money laundering, export control, sanctions and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal
counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the
public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm,
and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> activities to increase over time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals, and we can be
held liable for the corrupt or other illegal activities of our personnel, agents or partners, even if we do not explicitly authorize or have prior knowledge of such activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will be dependent upon third-party manufacturers and suppliers, making us
vulnerable to supply shortages and problems, increased costs and quality or compliance issues, any of which could harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MyoVista consists mostly of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> components and
once we are able to sell the MyoVista, we will need to rely on third parties to supply components and assemble the components into a completed device. Any third-party supplier that we work with and may eventually depend on could encounter problems
during sourcing and manufacturing which could delay or impede such supplier&#146;s ability to meet our requirements. Any reliance on these third-party suppliers will also subjects us to other risks that could harm our business, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are not currently a major customer of any of our suppliers, and these suppliers may therefore give other
customers&#146; needs higher priority than ours; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to obtain an adequate supply in a timely manner or on commercially reasonable terms;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our suppliers may make errors in manufacturing that could negatively affect the efficacy or safety of our device
or cause delays in shipment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may have difficulty locating and qualifying alternative suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">switching components or suppliers may require product redesign and possibly additional future submission(s) to
the FDA or other similar foreign regulatory agencies, which could impede or delay our commercial activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">one or more of our suppliers may be unwilling or unable to supply components of our device;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the occurrence of a fire, natural disaster or other catastrophe impacting one or more of our suppliers may affect
their ability to deliver products to us in a timely manner; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our suppliers may encounter financial or other business hardships unrelated to our demand, which could inhibit
their ability to fulfill our orders and meet our requirements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to quickly establish additional or
alternative suppliers if necessary, in part because we may need to undertake additional activities and incur additional expenses to establish such suppliers as required by the regulatory approval process. Any interruption or delay in obtaining
products from our third-party suppliers, or our inability to obtain products from qualified alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers and cause them to switch to competing
products. Given our reliance on certain suppliers, we may be susceptible to supply shortages while looking for alternate suppliers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We could become subject to product liability, warranty or similar claims and product recalls that could be expensive, divert
management&#146;s attention and harm our business reputation and financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business exposes us to an inherent risk of
potential product liability, warranty or similar claims and product recalls. The medical device industry has historically been litigious, and we face financial exposure to product liability, warranty or similar claims if the use of the MyoVista were
to cause or contribute to injury or death. There is also the possibility that defects in the design or manufacture of the MyoVista may necessitate a product recall. Although we plan to maintain product liability insurance, the coverage limits of
these policies may not be adequate to cover future claims. In the future, we may be unable to maintain product liability insurance on acceptable terms or at reasonable costs and such insurance may not provide us with adequate coverage against
potential liabilities. A product liability claim, regardless of merit or ultimate outcome, or any product recall could result in substantial costs to us, damage to our reputation, customer dissatisfaction and frustration and a substantial diversion
of management attention. A successful claim brought against us in excess of, or outside of, our insurance coverage could have a material adverse effect on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our business and operations would suffer in the event of computer system failures,
cyber-attacks or a deficiency in our cybersecurity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures and safeguards intended to
secure our data against impermissible access and to preserve the integrity and confidentiality of our data, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural
disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of
a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted
attacks and intrusions from around the world have increased. To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur material legal claims and liability, including under data privacy and protection laws, damage to our reputation, disruption to our operations, and the further development of the MyoVista. Although we take measures to
protect sensitive information from unauthorized access or disclosure, our information technology, or IT, and infrastructure, we may be vulnerable to cyber-attacks by hackers or viruses or breached due to employee error, malfeasance or other
disruptions. We rely extensively on IT systems, networks and services, including internet sites, data hosting and processing facilities and tools, physical security systems and other hardware, software and technical applications and platforms, some
of which are managed, hosted, provided and/or used by third parties or their vendors, to assist in conducting our business. A significant breakdown, invasion, corruption, destruction or interruption of critical information technology systems or
infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities
for the unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers&#146; systems, portable media or storage devices. We could also experience a business interruption, theft of
confidential information or reputational damage from industrial espionage attacks, malware or other cyber-attacks, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. Although
the aggregate impact on our operations and financial condition has not been material to date, we may become the target of events of this nature and expect them to continue as cybersecurity threats have been rapidly evolving in sophistication and
becoming more prevalent in the industry. There can be no assurance, however, that our efforts will prevent breakdowns or breaches to our or our third-party providers&#146; databases or systems that could materially and adversely affect our business,
financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our business may be impacted by changes in general economic conditions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to risks arising from changes in domestic and global economic conditions, including adverse economic conditions in
markets in which we operate, which may harm our business. If our future customers significantly reduce spending in areas in which our technology and products are utilized, or prioritize other expenditures over our technology and products, our
business, financial condition, results of operations and prospects would be materially adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruption to the global
economy could also result in a number of <FONT STYLE="white-space:nowrap">follow-on</FONT> effects on our business, including a possible slow-down resulting from lower customer expenditures; inability of customers to pay for products on time, if at
all; more restrictive export regulations which could limit our potential customer base; negative impact on our liquidity, financial condition and share price, which may impact our ability to raise capital in the market, obtain financing and secure
other sources of funding in the future on terms favorable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the occurrence of catastrophic events, such as hurricanes,
storms, earthquakes, tsunamis, floods, medical epidemics and other catastrophes that adversely affect the business climate in any of our markets could have a material adverse effect on our business, financial condition and results of operations.
Some of our operations are located in areas that may be in the future, susceptible to such occurrences. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We face business disruption and related risks resulting from the outbreak of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which could have a material adverse effect on our business and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">COVID-19</FONT> continues to mutate which may reduce the efficacy of treatments currently available and the
final implications of the pandemic are difficult to estimate at this stage; however, it is clear that it has affected the lives of a large portion of the global population. At this time, the pandemic has caused states of emergency to be declared in
various countries, travel restrictions to be imposed globally and quarantines established in certain jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">COVID-19</FONT> infection of our workforce could result in a temporary disruption in our business activities. The spread of an infectious disease, including <FONT STYLE="white-space:nowrap">COVID-19,</FONT> may also result
in the inability of our manufacturers to deliver components or finished products on a timely basis and may also result in the inability of our suppliers to deliver the parts required by our manufacturers to complete manufacturing of components or
finished products. In addition, governments may divert spending from other budgeted resources as they seek to reduce and/or stop the spread of <FONT STYLE="white-space:nowrap">COVID-19.</FONT> Such events may result in a period of business and
manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations. The extent to which <FONT STYLE="white-space:nowrap">COVID-19</FONT> impacts our business will
depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and the actions to contain <FONT
STYLE="white-space:nowrap">COVID-19</FONT> or treat its impact, among others. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Product Development and Regulatory
Approval </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our device and operations are subject to extensive government regulation and oversight both in the U.S. and abroad,
and our failure to comply with applicable requirements could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MyoVista is subject to extensive regulation in
the U.S. and elsewhere, including by the FDA and its foreign counterparts, the U.S. Department of Justice, or the DOJ, and the U.S. Health and Human Services&#151;Office of the Inspector General, or the HHS. The FDA and foreign regulatory agencies
regulate, among other things, with respect to our device: design, development and manufacturing; <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical testing, safety, efficacy, labeling, content and language of instructions for use and
storage; clinical trials; product safety; establishment registration and device listing; marketing, sales and distribution; <FONT STYLE="white-space:nowrap">pre-market</FONT> clearance and approval; conformity assessment procedures; record keeping
procedures; advertising and promotion; recalls and field safety corrective actions; post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to occur, could lead to death or serious injury;
post-market approval studies; and product import and export. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulations our product is subject to are complex and have tended to
become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales for any approved, cleared or authorized product. FDA
enforces these regulatory requirements through, among other means, periodic unannounced inspections. We do not know whether we will be found compliant in connection with any future regulatory inspections. Moreover, the FDA and state authorities have
broad enforcement powers. Failure to comply with applicable regulations could jeopardize our ability to sell our future products, if cleared or approved, and result in enforcement actions such as: adverse publicity; warning, untitled letters, or it
has come to our attention letters; fines; injunctions; consent decrees; civil penalties; customer notifications; repair, replacement, or refunds; termination of distribution; recalls or seizures of products; administrative detention of medical
devices believed to be adulterated or misbranded; delays in the introduction of products into the market; operating restrictions; total or partial suspension of production; refusal to grant future clearances or approvals for new products, new
intended uses or modifications to our device; withdrawals or suspensions of regulatory clearances or approvals in place, resulting in prohibitions on sales of our device; and in the most serious cases, criminal prosecution or penalties. The
occurrence of any of these events would have a material adverse effect on our business, financial condition and results of operations and could result in shareholders losing their entire investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Once commercialized, modifications to our marketed products may require new 510(k)
clearances, or may require us to cease marketing or recall the modified products until clearances or approvals are obtained. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a
De Novo classification is granted, any future modifications to the device may require us to submit a 510(k) premarket notification or obtain FDA approval prior to implementing the change. The FDA requires every manufacturer to initially make and
document a determination of whether or not a modification requires a new approval, supplement or clearance. A manufacturer may determine that a modification could not significantly affect safety or efficacy and does not represent a major change in
its intended use, so that no new clearance or approval is necessary. The FDA may review any manufacturer&#146;s decision. The FDA may not agree with our decisions regarding whether new clearances or approvals are necessary. We may make modifications
or add additional features in the future that we believe, based on FDA&#146;s regulatory framework, do not require a new 510(k) clearance or PMA. If the FDA disagrees with our determination and requires us to submit new 510(k) notifications or even
a PMA for modifications to our previously cleared products for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval,
and we may be subject to significant enforcement actions. If the FDA requires us to go through a lengthier, more rigorous examination for future products or modifications to existing products than we had expected, product introductions or
modifications could be delayed or canceled, which could adversely affect our ability to grow our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical studies may be
necessary to support future product submissions to the FDA. The clinical trial process is lengthy and expensive with uncertain outcomes, and often requires the enrollment of large numbers of patients, and suitable patients may be difficult to
identify and recruit. Delays or failures in our clinical studies will prevent us from commercializing any modified or new products and will adversely affect our business, operating results and prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initiating and completing clinical studies necessary to support any future PMA or De Novo applications, and additional safety and efficacy data
beyond that typically required for a 510(k) clearance, for our possible future product candidates, will be time-consuming and expensive and the outcome uncertain. Moreover, the results of early clinical studies are not necessarily predictive of
future results, and any product we advance into clinical studies may not have favorable results in later clinical studies. The results of preclinical studies and clinical studies of our device conducted to date and ongoing or future studies and
studies of our current, planned or future products may not be predictive of the results of later clinical studies, and interim results of a clinical trial do not necessarily predict final results. Our interpretation of data and results from our
clinical studies do not ensure that we will achieve similar results in future clinical studies. In addition, preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their
products performed satisfactorily in preclinical studies and earlier clinical studies have nonetheless failed to replicate results in later clinical studies. Products in later stages of clinical studies may fail to show the desired safety and
efficacy despite having progressed through nonclinical studies and earlier clinical studies. Failure can occur at any stage of clinical testing. Our clinical studies may produce negative or inconclusive results, and we may decide, or regulators may
require us, to conduct additional clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> testing in addition to those we have planned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initiation and completion of any of clinical studies may be prevented, delayed, or halted for numerous reasons. We may experience delays
in our ongoing clinical studies for a number of reasons, which could adversely affect the costs, timing or successful completion of our clinical studies, including related to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to submit an IDE application to the FDA, which must become effective prior to commencing
certain human clinical studies of medical devices, and the FDA may reject our IDE application and notify us that we may not begin clinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators and other comparable foreign regulatory authorities may disagree as to the design or implementation of
our clinical studies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators and/or an Institutional Review Board, or IRB, or other reviewing bodies may not authorize us or our
investigators to commence a clinical trial, or to conduct or continue a clinical trial at a prospective or specific trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and
clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical studies may produce negative or inconclusive results, and we may decide, or regulators may require us,
to conduct additional clinical studies or abandon product development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of subjects or patients required for clinical studies may be larger than we anticipate, enrollment in
these clinical studies may be insufficient or slower than we anticipate, and the number of clinical studies being conducted at any given time may be high and result in fewer available patients for any given clinical trial, or patients may drop out
of these clinical studies at a higher rate than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors, including those manufacturing products or conducting clinical studies on our behalf,
may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we might have to suspend or terminate clinical studies for various reasons, including a finding that the subjects
are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may have to amend clinical trial protocols or conduct additional studies to reflect changes in regulatory
requirements or guidance, which we may be required to submit to an IRB and/or regulatory authorities for <FONT STYLE="white-space:nowrap">re-examination;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, IRBs, or other parties may require or recommend that we or our investigators suspend or terminate
clinical research for various reasons, including safety signals or noncompliance with regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical studies may be greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites may not adhere to the clinical protocol or may drop out of a clinical trial;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to recruit a sufficient number of clinical trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators, IRBs, or other reviewing bodies may fail to approve or subsequently find fault with our manufacturing
processes or facilities of third-party manufacturers with which we enter into agreement for clinical and commercial supplies, the supply of devices or other materials necessary to conduct clinical studies may be insufficient, inadequate or not
available at an acceptable cost, or we may experience interruptions in supply; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval policies or regulations of the FDA or applicable foreign regulatory agencies may change in a manner
rendering our clinical data insufficient for approval; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our current or future products may have undesirable side effects or other unexpected characteristics.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of
the factors that cause, or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical studies must be conducted in accordance with the laws and regulations of the FDA and other applicable regulatory authorities&#146;
legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and IRBs at the medical institutions where the clinical studies are conducted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Conducting successful clinical studies will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical
studies and completion of patient participation and <FONT STYLE="white-space:nowrap">follow-up</FONT> depends on many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts
and risks associated with, the treatments received by enrolled subjects, the availability of appropriate clinical trial investigators, support staff, and proximity of patients to clinical sites and able to comply with the eligibility and exclusion
criteria for participation in the clinical trial and patient compliance. For example, patients may be discouraged from enrolling in our clinical studies if the trial protocol requires them to undergo extensive post-treatment procedures or <FONT
STYLE="white-space:nowrap">follow-up</FONT> to assess the safety and effectiveness of our device or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We depend on our collaborators and on medical institutions and CROs to conduct our clinical studies in compliance with good clinical practice,
or GCP, requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical studies, fail to conduct the study to GCP standards or are delayed for a significant time in the execution of studies, including achieving
full enrollment, we may be affected by increased costs, program delays or both. In addition, clinical studies that are conducted in countries outside the United States may subject us to further delays and expenses as a result of increased shipment
costs, additional regulatory requirements and the engagement of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA, and different standards of
diagnosis, screening and medical care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy
are required and we may not adequately develop such protocols to support clearance and approval. Further, the FDA may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer <FONT
STYLE="white-space:nowrap">follow-up</FONT> period or change the data collection requirements or data analysis applicable to our clinical studies. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may
cause an increase in costs and delays in the approval and attempted commercialization of our device or result in the failure of the clinical trial. In addition, despite considerable time and expense invested in our clinical studies, the FDA may not
consider our data adequate to demonstrate safety and efficacy. Such increased costs and delays or failures could adversely affect our business, operating results and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Medical device development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be
predictive of future study results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its outcome is
inherently uncertain. Failure can occur at any time during the clinical study process. The results of preclinical studies and early clinical studies of our product candidates may not be predictive of the results of later-stage clinical studies.
Product candidates that have shown promising results in early-stage clinical studies may still suffer significant setbacks in subsequent advanced clinical studies. There is a high failure rate for medical devices proceeding through clinical studies,
and product candidates in later stages of clinical studies may fail to show the desired sensitivity and specificity parameters despite having progressed satisfactorily through preclinical studies and initial clinical studies. A number of companies
in the medical device industry have suffered significant setbacks in advanced clinical studies due to insufficient sensitivity and specificity or adverse safety profiles, notwithstanding promising results in earlier studies. Moreover, preclinical
and clinical data are often susceptible to varying interpretations and analyses. We do not know whether any pivotal studies we may conduct will demonstrate consistent or adequate sensitivity and specificity sufficient to obtain regulatory approval
to market our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If the third parties on which we rely to conduct our clinical studies and to assist us
with <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development do not perform as required or expected, we may be delayed or unable to obtain regulatory clearance or approval for or commercialize our device. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not have the ability to independently conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical studies for our
future products and we may need to rely on third parties, such as CROs, medical institutions, clinical investigators and contract laboratories to conduct such studies. We would depend on our collaborators and on medical institutions and CROs to
conduct our clinical studies in compliance with GCP requirements and other regulatory requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical studies, fail to conduct the study to GCP standards or are
delayed for a significant time in the execution of studies, including achieving full enrollment, including on account of the outbreak of infectious disease, such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, or otherwise, we may
be affected by increased costs, program delays or both, any resulting data may be unreliable or unusable for regulatory purposes, and we may be subject to enforcement action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these
third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> development activities or clinical studies may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our device on
a timely basis, if at all, and our business, operating results and prospects may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter
substantial delays in our clinical studies, or we may fail to demonstrate specificity and sensitivity to the satisfaction of applicable regulatory authorities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval from regulatory authorities for the sale of the MyoVista, we must conduct extensive clinical studies to
demonstrate its specificity and sensitivity. Clinical testing is expensive, time consuming and uncertain as to outcome. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. Our clinical
studies involve adults and, before we are permitted to enroll them in clinical studies, we must demonstrate that although the research may pose a risk to the subjects, there is a prospect of direct benefit to each patient. We must do so to the
satisfaction of each research site&#146;s IRB. If we fail to adequately demonstrate this to the satisfaction of the relevant IRB, it will decline to approve the research, which could have significant adverse consequences for us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful. Events
that may prevent successful or timely completion of clinical development include but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching a consensus with regulatory agencies on study design; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and
clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining required IRB approval at each clinical study site; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a clinical hold by regulatory agencies, after review of an IDE application, or equivalent
application, or an inspection of our clinical study operations or study sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in recruiting suitable patients to participate in our clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty collaborating with patient groups and investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by our CROs, other third parties or us to adhere to clinical study requirements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to perform in accordance with the FDA&#146;s GCP requirements, or applicable regulatory guidelines in
other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in having patients complete participation in a study; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients dropping out of a study; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its
potential benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical studies of our product candidates being greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical studies of our product candidates producing negative or inconclusive results, which may result in us
deciding, or regulators requiring us, to conduct additional clinical studies or abandon product development programs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of
our product for use in clinical studies or the inability to do any of the foregoing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any inability to successfully
complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. We may also be required to conduct additional safety, efficacy and comparability studies before we will be allowed to
start clinical studies. Clinical study delays could also shorten any periods during which our device have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully
commercialize our product candidates and may harm our business and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The results of future clinical studies
may not support additional or new claims for future products or may result in the discovery of adverse side effects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be
certain that the results of our future clinical studies will support our claims for the MyoVista or any future product claims or that the FDA will agree with our conclusions regarding them. Success in
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and early clinical studies does not ensure that later clinical studies will be successful, and we cannot be sure that the later studies will replicate the results of prior studies and <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the proposed indicated uses, which could cause us to abandon a product candidate and
may delay development of others. Any delay or termination of our clinical studies will delay the filing of our product submissions and, ultimately, our ability to commercialize our product candidates and generate revenues. It is also possible that
patients enrolled in clinical studies will experience adverse side effects that are not currently part of the future product&#146;s profile. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties,
and might require us to recall or withdraw a product from the market. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we receive regulatory clearance or approval of
our product, we will remain subject to ongoing and pervasive regulatory requirements governing, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacture&#151;as set forth in the QSR requirements, which require manufacturers, including third-party
manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">labeling and marketing regulations, which require that promotion is truthful, not misleading, fairly balanced and
provides adequate directions for use and that all claims are substantiated, and also </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top">prohibit the promotion of products for unapproved or <FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses and impose other restrictions on labeling; FDA guidance on <FONT STYLE="white-space:nowrap">off-label</FONT>
dissemination of information and responding to unsolicited requests for information;; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical device reporting, sale, promotion, import, export, registration, and listing of devices.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety
or effectiveness or that would constitute a major change in intended use of one of our cleared devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets
may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field
corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with the new federal law and regulations requiring Unique Device Identifiers, or UDI, on devices and
also requiring the submission of certain information about each device to the FDA&#146;s Global Unique Device Identification Database, or GUDID; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA&#146;s recall authority, whereby the agency can order device manufacturers to recall from the market a
product that is in violation of governing laws and regulations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to
protect the public health or to provide additional safety and effectiveness data for the device. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulations to
which we are subject are complex and have become more stringent over time. Regulatory changes could result in restrictions on our ability to continue or expand our operations, higher than anticipated costs, or lower than anticipated sales. Even
after we have obtained the proper regulatory clearance or approval to market a device, we have ongoing responsibilities under FDA regulations and applicable foreign laws and regulations. The FDA, state and foreign regulatory authorities have broad
enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA, state or foreign regulatory authorities, which may include any of the following sanctions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse publicity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;it has come to our attention&#148; letters, untitled letters or warning letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, injunctions, consent decrees and civil penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recalls, termination of distribution, administrative detention, or seizure of our device; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">customer notifications or repair, replacement or refunds; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating restrictions or partial suspension or total shutdown of production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or refusal to grant our requests for future clearances or approvals or foreign marketing authorizations
of new products, new intended uses, or modifications to existing products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawals or suspensions of product clearances or approvals, resulting in prohibitions on sales of our device;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">criminal prosecution. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these sanctions could result in higher than anticipated costs or lower than
anticipated sales and have a material adverse effect on our reputation, business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, the FDA or state or foreign authorities may change their clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may require, prevent or delay clearance or approval of our
future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain new clearances or approvals, increase the costs of compliance or restrict our
ability to maintain any approvals we are able to obtain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The MyoVista must be manufactured in accordance with federal, state and
foreign regulations, and we could be forced to recall our devices or terminate production if we fail to comply with these regulations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The methods used in, and the facilities used for, the manufacture of our device must comply with the FDA&#146;s Quality System Regulation, or
QSR, which is a complex regulatory scheme that covers the procedures and documentation of the design, testing, production, process controls, quality assurance, labeling, packaging, handling, storage, distribution, installation, servicing and
shipping of medical devices. As manufacturers of electron radiation-emitting products, we are also responsible for compliance with the radiological health regulations and certain radiation safety performance standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we are required to verify that our suppliers maintain facilities, procedures and operations that comply with our quality
standards and applicable regulatory requirements. The FDA enforces the QSR through periodic announced or unannounced inspections of medical device manufacturing facilities, which include the facilities of subcontractors. Our device is also subject
to similar state regulations and various laws and regulations of foreign countries governing manufacturing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our third-party manufacturers
may not take the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our device. In addition, failure to comply with applicable FDA or state or foreign requirements or later discovery of previously
unknown problems with our device or manufacturing processes could result in, among other things: warning letters or untitled letters; fines, injunctions or civil penalties; suspension or withdrawal of approvals; seizures or recalls of our device;
total or partial suspension of production or distribution; administrative or judicially imposed sanctions; the FDA&#146;s refusal to grant pending or future clearances or approvals for our device; clinical holds; refusal to permit the import or
export of our device; and criminal prosecution of us, our suppliers or our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these actions could significantly and
negatively affect supply of our device. If any of these events occurs, our reputation could be harmed, we could be exposed to product liability claims and we could lose customers and experience reduced sales and increased costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The misuse or <FONT STYLE="white-space:nowrap">off-label</FONT> use of our device may harm our reputation in the marketplace, could
potentially cause harm to the patient and that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly
to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advertising and promotion of our future products that obtains approval in the United States may be heavily
scrutinized by the FDA, the DOJ, HHS, state attorneys general, members of Congress, and the public. In addition, advertising and promotion of any future product that obtains approval outside of the United States will be heavily scrutinized by
comparable foreign regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that, if cleared or approved, the MyoVista will also be cleared by the requisite
regulatory authorities for specific indications. We expect to train our marketing personnel and direct sales force to not promote our devices for uses outside of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> indications for use, known as <FONT
STYLE="white-space:nowrap">&#147;off-label</FONT> uses.&#148; Physicians may use our devices <FONT STYLE="white-space:nowrap">off-label,</FONT> when in the physician&#146;s independent professional medical judgment, he
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or she deems it appropriate as the FDA does not restrict or regulate a physician&#146;s choice of treatment within the practice of medicine. There may be increased risk of injury to patients if
physicians attempt to use our devices <FONT STYLE="white-space:nowrap">off-label.</FONT> Furthermore, the use of our devices for indications other than those approved by the FDA or approved by any foreign regulatory body may not effectively treat
such conditions, which could harm our reputation in the marketplace among healthcare providers and patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA or any state or
foreign regulatory body determines that our promotional materials or training constitute promotion of an <FONT STYLE="white-space:nowrap">off-label</FONT> use, it could request that we modify our training or promotional materials or subject us to
regulatory or enforcement actions, including the issuance or imposition of a warning letter, an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine or criminal penalties, which could
have an adverse impact on our reputation and financial results. It is also possible that other federal, state or foreign enforcement authorities might take action under other regulatory authority, such as false claims laws, if they consider our
business activities to constitute promotion of an <FONT STYLE="white-space:nowrap">off-label</FONT> use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines,
disgorgement, exclusion from participation in government healthcare programs and the curtailment or restructuring of our operations. We may become subject to such actions and, if we are not successful in defending against such actions, those actions
may have a material adverse effect on our business, financial condition and results of operations. Equivalent laws and potential consequences exist in foreign jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if our device is cleared or approved, healthcare providers may misuse our device or use improper techniques if they are not
adequately trained, potentially leading to injury and an increased risk of product liability. If our devices are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients. Product
liability claims could divert management&#146;s attention from our core business, be expensive to defend and result in sizeable damage awards against us that may not be covered by insurance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our device may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to
the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our device, or a recall of our device either
voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the MyoVista
receives clearance, authorization, or approval, we will be subject to the FDA&#146;s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA when we receive or become aware of information that
reasonably suggests that one or more of our device may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, could cause or contribute to a death or serious injury. The timing of
our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize
that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our
reporting obligations, the FDA or other regulatory bodies could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance or
approval, seizure of our device or delay in clearance or approval of future products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and foreign regulatory bodies have the
authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. The FDA&#146;s authority to
require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or
voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
defects, labeling or design deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors may occur in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the corrective action we take to redress a product&#146;s deficiencies or defects, the FDA may require, or we may decide, that we
will need to obtain new clearances or approvals for the device before we may market or distribute the corrected device. Seeking such clearances or approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do
not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate
voluntary withdrawals or corrections for our device in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it could require us to report those actions as recalls and we may be subject to
enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action, whether voluntary or involuntary, as well as
defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The MyoVista may in the future be subject to product recalls that could harm our reputation, business and financial results.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medical devices can experience performance problems in the field that require review and possible corrective action. The
occurrence of component failures, manufacturing errors, software errors, design defects or labeling inadequacies affecting a medical device could lead to a government-mandated or voluntary recall by the device manufacturer, in particular when such
deficiencies may endanger health. The FDA requires that certain classifications of recalls be reported to the FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are
not reportable to the FDA. We may initiate voluntary recalls involving our device in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as
recalls. Product recalls may divert management attention and financial resources, expose us to product liability or other claims, harm our reputation with customers and adversely impact our business, financial condition and results of operations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health
information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many federal, state and foreign healthcare laws and regulations apply to medical devices. We may be subject to certain federal and state
regulations, including the federal healthcare programs&#146; Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving, or paying any remuneration, directly or indirectly, in cash or in kind,
to induce or reward purchasing, ordering or arranging for or recommending the purchase or order of any item or service for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid; the federal
Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and
willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or services; the federal Civil Monetary Penalties Law, which
authorizes the imposition of substantial civil monetary penalties against an entity that engages in activities including, among others (1)&nbsp;knowingly presenting, or causing to be presented, a claim for services not provided as claimed or that is
otherwise false or fraudulent in any way; (2)&nbsp;arranging for or contracting with an individual or entity that is excluded from participation in federal healthcare programs to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide items or services reimbursable by a federal healthcare program; (3)&nbsp;violations of the federal Anti-Kickback Statute; or (4)&nbsp;failing to report and return a known overpayment; the
federal False Statements Statute, which prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false
writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry, in connection with the delivery of or payment for healthcare benefits, items, or services; the federal civil False Claims Act, or the
FCA, which prohibits, among other things, knowingly presenting, or causing to be presented claims for payment of government funds that are false or fraudulent, or knowingly making, using or causing to be made or used a false record or statement
material to such a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government; and other federal and state false claims laws. The FCA
prohibits anyone from knowingly presenting, conspiring to present, making a false statement in order to present, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services that are
false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. This law also prohibits anyone from knowingly underpaying an obligation owed to a federal program. Increasingly, U.S.
federal agencies are requiring nonmonetary remedial measures, such as corporate integrity agreements in FCA settlements. The DOJ announced in 2016 its intent to follow the &#147;Yates Memo,&#148; taking a far more aggressive approach in pursuing
individuals as FCA defendants in addition to corporations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of states also have statutes similar to the federal Anti-Kickback
Statute and false claims laws that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, that apply regardless of whether the payor is a government entity or a private commercial entity. The Federal
Open Payments, or Physician Payments Sunshine Act, program requires manufacturers of drugs, medical devices, and biologics for which payment is available under Medicare, Medicaid or the State Children&#146;s Health Insurance Program, to track and
report annually to the federal government (for disclosure to the public) certain payments and other transfers of value made to physicians and teaching hospitals as well as disclosure of payments and other transfers of value provided to physicians
and teaching hospitals, and ownership and investment interests in the manufacturer held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations. Our failure to appropriately track
and report Sunshine Act covered payments to the government could result in civil fines and penalties, which could adversely affect the results of our operations. In addition, several U.S. states and localities have enacted legislation requiring
medical device companies to establish marketing compliance programs, file periodic reports with the state, and/or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Other state laws prohibit certain
marketing-related activities including the provision of gifts, meals or other items to certain healthcare providers. Many of these laws and regulations contain ambiguous requirements that government officials have not yet clarified. Given the lack
of clarity in the laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The medical device industry has been under heightened scrutiny as the subject of government investigations and enforcement actions involving
manufacturers who allegedly offered unlawful inducements to potential or existing customers in an attempt to procure their business, including arrangements with physician consultants. If our operations or arrangements are found to be in violation of
such governmental regulations, we may be subject to civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs and the curtailment of our operations. All of these penalties could adversely affect our ability to
operate our business and our financial results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Legislative or regulatory reforms in the United States or the European Union may
make it more difficult and costly for us to obtain regulatory clearances or approvals for our device or to manufacture, market or distribute our device after clearance or approval is obtained. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the
regulation of medical devices. In addition, the FDA may change its clearance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our future products under
development or impact our ability to modify our currently cleared products on a timely basis. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of planned or future
products. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our device.
Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance for or approval of, manufacture, market
or distribute our device. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things,
require: additional testing prior to obtaining clearance or approval; changes to manufacturing methods; recall, replacement or discontinuance of our device; or additional record keeping. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s and other regulatory authorities&#146; policies may change and additional government regulations may be promulgated that could
prevent, limit or delay regulatory clearance or approval of our future products. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States
or abroad. For example, certain forthcoming policies of the Biden administration could impact our business and industry. It is difficult to predict what policies may be implemented or how any such executive actions will be implemented, and the
extent to which they will impact the FDA&#146;s ability to exercise its regulatory authority. If executive actions or new policies impose restrictions on the FDA&#146;s ability to engage in oversight and implementation activities in the normal
course, our business may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any
marketing approval or clearance that we may have obtained and we may not achieve or sustain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The European Parliament passed
the Medical Devices Regulation (Regulation 2017/745), which repeals and replaces the EU Medical Devices Directive. The Medical Devices Regulation, among other things, is intended to establish a uniform, transparent, predictable and sustainable
regulatory framework across the EEA for medical devices and ensure a high level of safety and health while supporting innovation. Among other things, the Medical Devices Regulation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strengthen the rules on placing devices on the market and reinforce surveillance once they are available;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish explicit provisions on manufacturers&#146; responsibilities for
<FONT STYLE="white-space:nowrap">follow-up</FONT> regarding the quality, performance and safety of devices placed on the market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">improve the traceability of medical devices throughout the supply chain to the
<FONT STYLE="white-space:nowrap">end-user</FONT> or patient through a unique identification number; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">set up a central database to provide patients, healthcare professionals and the public with comprehensive
information on products available in the EU; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strengthened rules for the assessment of certain high-risk devices, which may have to undergo an additional check
by experts before they are placed on the market. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These modifications may have an effect on the way we conduct our
business in the EEA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare legislative and regulatory reform measures may have a material adverse effect on our business and
results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry is highly regulated and changes in law may adversely impact our business, operations or
financial results. In the United States and some foreign jurisdictions, there have been, and continue to be, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
legislative and regulatory changes and proposed changes regarding the healthcare system and how its costs should be controlled or managed. Certain of these proposals could limit the prices we are
able to charge for our device or the coverage and reimbursement available for our device and could limit the acceptance and availability of our device. In particular, there have been and continue to be a number of initiatives at the U.S. federal and
state levels that are directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future or their full impact. Additionally, it remains unclear how any new legislation or regulation might
affect the prices we may obtain for any of our product for which regulatory approval is obtained. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The
implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our device. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently, there has been heightened governmental scrutiny over the manner in which companies set prices for their marketed products, which has
resulted in several U.S. Congressional inquiries and proposed and enacted federal legislation designed to bring transparency to product pricing and reduce the cost of products and services under government healthcare programs. Additionally,
individual states in the United States have also increasingly passed legislation and implemented regulations designed to control product pricing, including price or reimbursement constraints, discounts, restrictions on certain product access and
marketing cost disclosure and transparency measures. Moreover, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what products to purchase and which suppliers will be included in their
healthcare programs. Adoption of price controls and other measures designed to restrict spending or purchasing power may prevent or limit our ability to generate revenue and attain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the delivery of healthcare in the European Union, including the establishment and operation of health services, is almost
exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that
context. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval, restrict or regulate post-approval activities and affect our ability to
commercialize any products for which we obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently unable to predict what additional legislation or
regulation, if any, relating to the health care industry may be enacted in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our business. The pendency or approval of such
proposals or reforms could result in a decrease in the price of our Common Stock or limit our ability to raise capital or to enter into collaboration agreements for the further development and potential commercialization of our device. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to
hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing
normal business functions on which the operation of our business may rely, which could negatively impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability
of the FDA to review and clear or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#146;s ability to hire and retain key personnel and
accept the payment of user fees, and other events that may otherwise affect the FDA&#146;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other
government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies may also slow the time necessary for new medical devices or modifications to cleared or approved
medical devices to be reviewed and/or approved by necessary government </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agencies, which would adversely affect our business. For example, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, in March of 2020 the FDA postponed most inspections
of foreign manufacturing and domestic facilities. Although limited inspections were again initiated in 2021, FDA also utilized alternative methods for inspections and could continue to exercise discretion on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis to approve products based on a desk review, particularly for foreign inspections. If a prolonged government shutdown occurs, or if global health concerns continue to prevent or temporarily
restrict the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which
could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory authorities outside the United States may adopt similar restrictions or
other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting
their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse
effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Changes in laws or regulations relating to data protection, or any actual or perceived failure by us to
comply with such laws and regulations or our privacy policies, could materially and adversely affect our business or could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of business, we will receive health information and other highly sensitive or confidential information and
data of patients and other third parties, which we compile and analyze. Our collection and use of this data, including that of our vendors, might raise privacy and data protection concerns, which could negatively impact our business. There are
numerous federal, state and international laws and regulations regarding privacy, data protection, information security, and the collection, storing, sharing, use, processing, transfer, disclosure, and protection of personal information and other
data, and the scope of such laws and regulations may change, be subject to differing interpretations, and may be inconsistent among countries and regions we intend to operate in (e.g., the United States and the European Union), or conflict with
other laws and regulations. The regulatory framework for privacy and data protection worldwide is, and is likely to remain for the foreseeable future, uncertain and complex, and this or other actual or alleged obligations may be interpreted and
applied in a manner that we may not anticipate or that is inconsistent from one jurisdiction to another. Further, any significant change to applicable laws, regulations, or industry practices regarding the collection, use, retention, security, or
disclosure of data, or any changes regarding the manner in which the consent of relevant users for the collection, use, retention, or disclosure of such data must be obtained, could increase our costs and require us to modify our services and
products, possibly in a material manner, which we may be unable to complete, and may limit our ability to store and process patients&#146; data or develop new services and features. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, we are subject to U.S. data protection laws and regulations (i.e., laws and regulations that address privacy and data security
of personal information) at both the federal and state levels. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on privacy and data security issues. Numerous
federal and state laws, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, and disclosure of health-related and other personal
information. Failure to comply with such laws and regulations could result in government enforcement actions and create liability for us (including the imposition of significant civil or criminal penalties), private litigation and/or adverse
publicity that could negatively affect our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we expect to obtain health information that is subject to privacy and
security requirements under HIPAA and its implementing regulations. The Privacy Standards and Security Standards under HIPAA establish a set of standards for the protection of individually identifiable health information by health plans, health care
clearinghouses and certain health care providers, referred to as Covered Entities, and the business associates with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whom Covered Entities enter into service relationships pursuant to which individually identifiable health information may be exchanged. Notably, whereas HIPAA previously directly regulated only
Covered Entities, HITECH makes certain of HIPAA&#146;s privacy and security standards also directly applicable to Covered Entities&#146; business associates. As a result, both Covered Entities and business associates are now subject to significant
civil and criminal penalties for failure to comply with Privacy Standards and Security Standards. As part of our normal operations, we expect to collect, process and retain personal identifying information regarding patients, including as a business
associate of Covered Entities, so we expect to be subject to HIPAA, including changes implemented through HITECH, and we could be subject to criminal penalties if we improperly handle or knowingly obtain or disclose individually identifiable health
information in a manner that is not authorized or permitted by HIPAA. A data breach affecting sensitive personal information, including health information, also could result in significant legal and financial exposure and reputational damages that
could potentially have an adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA requires Covered Entities (like many of our potential customers) and
business associates (like us) to develop and maintain policies and procedures with respect to protected health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such
information. HITECH expands the notification requirement for breaches of patient-identifiable health information, restricts certain disclosures and sales of patient-identifiable health information, and provides for civil monetary penalties for HIPAA
violations. HITECH also increased the civil and criminal penalties that may be imposed against Covered Entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts
to enforce HIPAA and its implementing regulations and seek attorney&#146;s fees and costs associated with pursuing federal civil actions. Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which
may be more stringent than HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, certain state laws govern the privacy and security of health-related and other personal
information in certain circumstances, some of which may be more stringent, broader in scope or offer greater individual rights with respect to protected health information than HIPAA, many of which may differ from each other, thus, complicating
compliance efforts. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. Failure
to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, California enacted the California Consumer Privacy Act, or CCPA, which creates individual
privacy rights for California consumers (as defined in the law), including the right to opt out of certain disclosures of their information, and places increased privacy and security obligations on entities handling certain personal data of
consumers or households and may apply to us in the future. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Further, the California
Privacy Rights Act, or CPRA, was recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for
sensitive data such as health information, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information
security enforcement. The majority of the provisions will go into effect on January&nbsp;1, 2023, and additional compliance investment and potential business process changes may be required. The CCPA and CPRA are reflective of a trend toward more
stringent privacy legislation in the United States, as other states or the federal government have followed or may follow California&#146;s lead and increase protections for U.S. residents. For example, on March&nbsp;2, 2021, the Virginia Consumer
Data Protection Act, which will take effect on January&nbsp;1, 2023, was signed into law, and the on July&nbsp;8, 2021 the Colorado Privacy Act, which will take effect on July&nbsp;1, 2023, was also signed into law. The CCPA has already prompted a
number of proposals for new federal and state privacy legislation that, if passed, could increase our potential liability, add layers of complexity to compliance in the U.S. market, increase our compliance costs and adversely affect our business.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internationally, many jurisdictions have or are considering enacting privacy or data
protection laws or regulations relating to the collection, use, storage, transfer, disclosure and/or other processing of personal data, as well as certification requirements for the hosting of health data specifically. Such laws and regulations may
include data hosting, data residency or data localization requirements (which generally require that certain types of data collected within a certain country be stored and processed within that country), data export restrictions, international
transfer laws (which prohibit or impose conditions upon the transfer of such data from one country to another), or may require companies to implement privacy or data protection and security policies, enable users to access, correct and delete
personal data stored or maintained by such companies, inform individuals of security breaches that affect their personal data or obtain individuals&#146; consent to use their personal data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The General Data Protection Regulation, or GDPR, which went into effect in May 2018, imposes stringent requirements for controllers and
processors of personal data of individuals within the European Economic Area, or EEA. As Switzerland and the United Kingdom are not part of the European Union they enforce separate laws governing personal data, which are derived from or directly
based on the GDPR. The GDPR applies to any company established in the EEA as well as to those outside the EEA if they collect, process, and use personal data in connection with the offering of goods or services to individuals in the EEA or the
monitoring of their behavior. The GDPR, together with national legislation, regulations and guidelines of the EEA countries governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze and
transfer personal data, including health data from clinical trials and adverse event reporting. In particular, these obligations and restrictions involve the consent of the individuals to whom the personal data relates, the information provided to
the individuals, the transfer of personal data out of the EEA to jurisdictions deemed to have inadequate data protection laws, security breach notifications, security and confidentiality of the personal data and imposition of substantial potential
fines for breaches of the data protection obligations. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for
noncompliance of up to &#128;20&nbsp;million or 4% of the annual global revenues of the noncompliant company, whichever is greater. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among
other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of
current transfer mechanisms between the European Union, or EU, and the United States remains uncertain. In 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy
Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union, or CJUE. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European
Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses
must now be assessed on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and
rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. The CJEU went on to state that if a competent supervisory authority
believes that the standard contractual clauses cannot be complied with in the destination country and the required level of protection cannot be secured by other means, such supervisory authority is under an obligation to suspend or prohibit that
transfer. The European Commission has published revised standard contractual clauses for data transfers from the EEA: the revised clauses must be used for relevant new data transfers from September&nbsp;27, 2021; existing standard contractual
clauses arrangements must be migrated to the revised clauses by December&nbsp;27, 2022. If applicable, we would be required to implement the revised standard contractual clauses, in relation to relevant existing contracts and certain additional
contracts and arrangements, within the relevant time frames. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to <FONT
STYLE="white-space:nowrap">non-EEA</FONT> entities subject to the GDPR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we implement various measures intended to enable us to
comply with applicable privacy or data protection laws, regulations and contractual obligations, these measures may not always be effective and do not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
guarantee compliance. Any failure or perceived failure by us to comply with our contractual or legal obligations or regulatory requirements relating to privacy, data protection, or information
security may result in governmental investigations or enforcement actions, litigation, claims, or public statements against us by consumer advocacy groups or others and could result in significant liability, cause our customers, partners or patients
to lose trust in us, and otherwise materially and adversely affect our reputation and business. Furthermore, the costs of compliance with, and other burdens imposed by, the laws, regulations, and policies that are applicable to the businesses of our
customers or partners may limit the adoption and use of, and reduce the overall demand for, our device. Additionally, if third parties we work with violate applicable laws, regulations, or agreements or suffer data breaches such violations or data
breaches may put the data we have received at risk, could result in governmental investigations or enforcement actions, fines, litigation, claims, or public statements against us by consumer advocacy groups or others and could result in significant
liability, cause our customers, partners or patients to lose trust in us, and otherwise materially and adversely affect our reputation and business. Further, public scrutiny of, or complaints about, technology companies or their data handling or
data protection practices, even if unrelated to our business, industry or operations, may lead to increased scrutiny of technology companies, including us, and may cause government agencies to enact additional regulatory requirements, or to modify
their enforcement or investigation activities, which may increase our costs and risks. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to Our Intellectual Property
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and maintain effective patent rights for our device, we may not be able to compete effectively in
our markets. If we are unable to protect the confidentiality of our trade secrets or <FONT STYLE="white-space:nowrap">know-how,</FONT> such proprietary information may be used by others to compete against us. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success and future revenue growth will depend, in part, on our ability to protect our patent rights. In addition to the protection afforded
by any patents that may be granted, historically, we have relied on trade secret protection and confidentiality agreements with our employees, consultants, and contractors to protect proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> that
is not patentable or that we elect not to patent, processes that are not easily known, knowable, or easily ascertainable, and for which patent infringement is difficult to monitor and enforce and any other elements of our product discovery and
development processes that involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information or technology that is not covered by patents. However, agreements may be breached, trade secrets may be difficult to protect, and we may not
receive adequate remedies for any breach. In addition, our trade secrets and intellectual property may otherwise become known or be independently discovered by competitors or other unauthorized third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no guarantee that the patent applications that we submitted with regards to our technologies will result in patent grants. In the
event of failure to obtain patent registration, our developments will not be proprietary, which might allow other entities to manufacture our device and compete with them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, there is no assurance that all potentially relevant prior art relating to our patent applications has been found, which can
invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our device, third parties may challenge their validity, enforceability, or scope, which may
result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patent applications and any future patents may not adequately protect our intellectual property, products and provide
exclusivity for our new products or future services or prevent others from designing around our claims. Furthermore, there is no guarantee that third parties will not infringe or misappropriate our patents or similar proprietary rights. In addition,
there can be no assurance that we will not have to pursue litigation against other parties to assert its rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these outcomes
could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cannot obtain
and maintain effective patent rights for our device, we may not be able to compete effectively, and our business and results of operations would be harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot provide any assurances that our trade secrets and other confidential proprietary
information will not be disclosed in violation of our confidentiality agreements or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Also,
misappropriation or unauthorized and unavoidable disclosure of our trade secrets and intellectual property could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our
trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse against third parties for misappropriating any trade secret. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of medical device companies generally is highly uncertain and involves complex legal and factual questions for which many
legal principles remain unresolved. In recent years, patent rights have been the subject of significant litigation within our industry. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly
uncertain. Further, the issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and in-licensed patents may be challenged, invalidated or legally circumvented by third parties, or may expire. We cannot be
certain that our patents will be upheld as valid and enforceable or will prevent the development of competitive products by third parties. For example, we may become involved in opposition, interference, derivation, <I>inter partes</I> review or
other proceedings challenging our patent rights, and the outcome of any proceedings are highly uncertain. Such challenges may result in the patent claims of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents being narrowed,
invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our products
and technology. Consequently, competitors could develop, manufacture and sell products that directly compete with our products, which could decrease our sales and affect our ability to compete. In addition, competitors could attempt to reverse
engineer our device to replicate some or all of the competitive advantages we derive from our development efforts, design around our protected technology, or develop their own competitive technologies that fall outside the scope of our patents. If
our intellectual property does not adequately protect us from our competitors&#146; products and methods, our business and competitive position could be adversely affected. We may in the future become involved in litigation to protect the patents
associated with our products, which could result in substantial costs and distraction to management and other employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights of third-parties could adversely affect our ability to commercialize our device, and we might be required
to litigate or obtain licenses from third parties in order to develop or market our device. Such litigation or licenses could be costly or not available on commercially reasonable terms. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is inherently difficult to conclusively assess our freedom to operate without infringing on third-party rights. Our competitive position may
be adversely affected if existing patents or patents resulting from patent applications issued to third parties in the future or other third-party intellectual property rights are held to cover our device or elements thereof, or our manufacturing or
uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize products or services unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right
concerned or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may also be pending patent applications that if they result in issued patents, could be alleged to be
infringed by our new products or services. If such an infringement claim should be brought and be successful, we may be required to pay substantial damages, be forced to abandon our new products or services or seek a license from any patent holders.
No assurances can be given that a license will be available on commercially reasonable terms, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also possible that we have
failed to identify relevant third-party patents or applications. For example, U.S. patent applications filed before November&nbsp;29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the United States
remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18&nbsp;months after the earliest filing for which priority is claimed, with such earliest filing date being commonly
referred to as the priority date. Therefore, patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applications covering our new products could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain
limitations, be later amended in a manner that could cover our services, our new products or the use of our new products. Third-party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee
that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and
time-consuming litigation and may be prevented from or experience substantial delays in pursuing the development of and/or marketing our new products or services. If we fail in any such dispute, in addition to being forced to pay damages, we may be
temporarily or permanently prohibited from commercializing our new products or services that are held to be infringing. We might, if possible, also be forced to redesign our new products so that we no longer infringe the third-party intellectual
property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship of our intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees, collaborators or other third parties have an interest in, or right to compensation, with
respect to our current patent and patent applications, future patents or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> For example, we may have inventorship disputes arise from conflicting
obligations of consultants or others who are involved in developing our device. Litigation may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation. If we fail in defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business.
Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Such litigation or proceedings could increase our operating losses and reduce the
resources available for development activities or any future sales, marketing or distribution activities. Some of our competitors may be able to devote significantly more resources to intellectual property proceedings, and may have significantly
broader intellectual property portfolios to assert against us if we assert our rights against them. Further, because of the substantial discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be disclosed or otherwise compromised leading to others making, using, importing or selling products that are the same or substantially the same as ours, which could adversely affect our ability to compete in the
market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming,
and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our intellectual property. If we were to initiate legal proceedings against a
third-party to enforce a patent covering one of our new products or services, the defendant could counterclaim that the patent covering our product is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims
alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or
<FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the United States Patent and Trademark
Office, or USPTO, or made a misleading statement, during prosecution. Under the Leahy-Smith Act, the validity of U.S. patents may also be challenged in post-grant proceedings before the USPTO. The outcome following legal assertions of invalidity and
unenforceability is unpredictable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Derivation proceedings initiated by third parties or brought by us may be necessary to determine the
priority of inventions and/or their scope with respect to our patent or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the
prevailing party. Our business could be harmed if the prevailing party does not offer us a license on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other
employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from
third parties, or enter into development partnerships that would help us bring our new products or services to market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could
also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our
Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement may prevent or delay our development and commercialization
efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third
parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing new products and services. As our industries expand and more patents are issued, the
risk increases that our device may be subject to claims of infringement of the patent rights of third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert
that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, designs or methods of manufacture related to the use or manufacture of our device. There may
be currently pending patent applications or continued patent applications that may later result in issued patents that our device may infringe. In addition, third parties may obtain patents or services in the future and claim that use of our
technologies infringes upon these patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any third-party patents were held by a court of competent jurisdiction to cover aspects of
our processes for designs, or methods of use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product unless we obtain a license or until such patent expires or is finally determined to be
invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making
claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our device. Defense of these claims, regardless of their merit, would involve substantial litigation
expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for
willful infringement, pay royalties, redesign our infringing products or services, or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patent policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of any issued patents. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United
States and other countries may diminish the value of any patents that may issue from our patent applications or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the
United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&nbsp;months after filing, or
in some cases not at all. We therefore cannot be certain that we were the first to file the invention claimed in our owned and licensed patent or pending applications, or that we or our licensor were the first to file for patent protection of such
inventions. Assuming all other requirements for patentability are met, in the United </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
States prior to March&nbsp;15, 2013, the first to make the claimed invention without undue delay in filing, is entitled to the patent, while generally outside the United States, the first to file
a patent application is entitled to the patent. After March&nbsp;15, 2013, under the Leahy-Smith America Invents Act (the &#147;Leahy-Smith Act&#148;), enacted on September&nbsp;16, 2011, the United States has moved to a first to file system. The
Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. In general, the Leahy-Smith Act and its implementation could increase the uncertainties
and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents, all of which could have a material adverse effect on our business and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The America Invents Act also includes a number of significant changes that affect the way patent applications are prosecuted, redefine prior
art and provide more efficient and cost-effective avenues for competitors to challenge the validity of the patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack
the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Further, because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary
standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to
invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a
defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents,
all of which could have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the U.S.
Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the
U.S. Congress, the U.S. courts, the USPTO and the relevant <FONT STYLE="white-space:nowrap">law-making</FONT> bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to
obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect
our intellectual property rights throughout the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, and defending patents on products and services, as
well as monitoring their infringement in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries can be less extensive than those in the United States. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may use our technologies develop their own products or services in jurisdictions where we have not obtained patent protection to
and may export infringing products or services to territories where we have patent protection, but where patents are not enforced as strictly as they are in the United States. These products or services may compete with our device or services.
Future patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies
have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents,
trade secrets, and other intellectual property protection, which could make it difficult for us to stop the marketing of competing products or services in violation of our proprietary rights generally. Proceedings to enforce our patent rights in
foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our future patents at risk of being invalidated or interpreted narrowly, put the
issuance of our patent applications at risk, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and any damages or other remedies that we may be awarded, may not be commercially
meaningful. Accordingly, our efforts to monitor and enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Related to this Offering and the Ownership of the Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We do not know whether a market for the Common Stock will be sustained, what the trading price of the Common Stock will be, or whether
there will be an active, liquid, trading market for our Common Stock, which may trade at a discount from the initial public offering price and make it difficult for you to sell the Common Stock you purchase. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we intend to apply to list the Common Stock on Nasdaq, an active trading market for the Common Stock may not be achieved or sustained.
It may be difficult for you to sell your Common Stock without depressing the market price for the Common Stock or at all. Consequently, you may not be able to sell your Common Stock at or above the offering price or at all. Further, an inactive
market may also impair our ability to raise capital by selling additional shares of Common Stock and it also may impair our ability to enter into strategic partnerships or acquire companies, products, or services by using our equity securities as
consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has not been a public trading market for shares of our Common Stock. We cannot predict the
extent to which investor interest in us will lead to the development of a trading market or how active and liquid that market may become. If an active and liquid trading market does not develop or continue, you may have difficulty selling your
Common Stock at an attractive price or at all. The initial public offering price per share of Common Stock will be determined by agreement between us and the representatives of the underwriters, and may not be indicative of the price at which shares
of our Common Stock will trade in the public market after this offering. The market price of our Common Stock may decline below the initial offering price and you may not be able to sell your Common Stock at or above the price you paid in this
offering, or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our Common Stock may be highly volatile, and you could lose all or part of your
investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of our Common Stock is likely to be volatile, which may prevent you from being able to sell your
Common Stock at or above the price you paid for your securities. This volatility could be the result of\ a variety of factors, which include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we achieve our anticipated corporate objectives; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated fluctuations in our quarterly or annual operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in our financial or operational estimates or projections; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to implement our operational plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement or other restrictions on the ability
of our shareholders to sell shares after this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the economic performance or market valuations of companies similar to ours; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic or political conditions in the U.S. or elsewhere; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, including those resulting from war, incidents of terrorism or responses to these events.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general, and the stock of publicly-traded medical device companies in particular, have
experienced extreme price and volume fluctuations that have often been unrelated or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disproportionate to the operating performance of such companies. Broad market and industry factors may negatively affect the market price of our Common Stock, regardless of our actual operating
performance, and we have little or no control over these factors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of a substantial number of shares of our Common
Stock by our existing shareholders could cause our stock price to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a significant number of shares of restricted
Common Stock that will become eligible for sale after this offering. Prior to the consummation of this offering, on a pro forma basis, we had [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Common
Stock outstanding, $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] in convertible notes outstanding that are convertible into [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares
of our Common Stock (based on interest calculated through [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], 2022),
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Preferred Stock outstanding that, as of the date of this prospectus, are convertible into
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock, warrants exercisable for [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Common Stock and, upon
consummation of this offering, we have agreed to issue [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Common Stock based on an assumed initial public offering price of
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share of Common Stock. All of the shares sold in this offering will be eligible for sale immediately upon effectiveness of this registration statement. All of the
remaining shares will be eligible for sale in the public market upon the effectiveness of a registration statement we are required to file relating to the shares of our Common Stock issued upon conversion of the Bridge Notes, the exercise of the
Bridge Warrants and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the conversion of the Series C Preferred Stock and expiration of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements five months after the date of
this registration statement. In addition, under Rule&nbsp;144 under the Securities Act as in effect on the date hereof, beginning 90&nbsp;days after the date hereof, a person who holds restricted shares of Common Stock (assuming there are any
restricted shares) and is not one of our affiliates at any time during the three months preceding a sale, and who has beneficially owned these restricted shares for at least six months, would be entitled to sell an unlimited number of shares of our
Common Stock, provided current public information about us is available. In addition, under Rule&nbsp;144, a person who holds restricted shares in us and is not one of our affiliates at any time during the three months preceding a sale, and who has
beneficially owned these restricted shares for at least one year, would be entitled to sell an unlimited number of shares immediately upon the closing of this offering without regard to whether current public information about us is available. It is
conceivable that following the holding period, many shareholders may wish to sell some or all of their shares. If our shareholders sell substantial amounts of our Common Stock in the public market at the same time, the market price of our Common
Stock could decrease significantly due to an imbalance in the supply and demand of our Common Stock. Even if they do not actually sell the Common Stock, the perception in the public market that our shareholders might sell significant Common Stock
could also depress the market price of our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish or cease publishing
research or reports about us, our business or our market, or if they publish negative reports regarding our business or the Common Stock, our share price and trading volume could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for the Common Stock will be influenced by the research and reports that industry or securities analysts may publish about
us, our business, our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover us or provide favorable coverage. If any of the analysts who may cover us adversely change
their recommendation regarding the Common Stock, or provide more favorable relative recommendations about our competitors, the price of our Common Stock would likely decline. If any analyst who may cover us were to cease coverage of our Company or
fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the price of our Common Stock or trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Management will have broad discretion as to the use of the proceeds from this offering. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the allocation of the net proceeds and could use them for purposes other than those contemplated
at the time of this offering. Our shareholders may not agree with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manner in which our management chooses to allocate and spend the net proceeds. For additional information regarding our anticipated uses of proceeds, see &#147;Use of Proceeds.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will need additional capital, and the sale of additional shares of the Common Stock or equity or debt securities could result in
additional dilution to our shareholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will need to raise additional capital through a combination of private and public
equity offerings, debt financings and collaborations, and strategic and licensing arrangements. To the extent that we raise additional capital through the issuance of equity (such as this offering) or convertible debt securities, your ownership
interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a holder of our Common Stock. Debt financing, if available, may involve agreements that include covenants limiting or
restricting our ability to take certain actions, such as incurring debt, without prior approval, making capital expenditures or declaring dividends. If we raise additional funds through strategic partnerships and alliances and licensing arrangements
with third parties, we may have to relinquish valuable rights to our technologies or product or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be
required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have identified weaknesses in our internal controls, and we cannot provide assurances that these weaknesses will be effectively
remediated or that additional material weaknesses will not occur in the future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the completion of this offering, we have
been a private company with limited accounting personnel to adequately execute our accounting processes and limited supervisory resources with which to address our internal control over financial reporting. As a private company, we have not designed
or maintained an effective control environment as required of public companies under the rules and regulations of the SEC. Although we are not yet subject to the certification or attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act, management and our independent registered public accounting firm, Haskell&nbsp;&amp; White LLP, identified several material weaknesses in our internal control over financial reporting in connection with our preparation and the audits of our
financial statements for Fiscal 2021 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A material weakness is a deficiency, or combination of deficiencies, in internal control
over financing reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses we and our independent
registered public accounting firms identified are listed below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we did not maintain sufficient GAAP and SEC accounting resources commensurate with those required of a public
company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial reporting closing process did not effectively determine all
<FONT STYLE="white-space:nowrap">period-end</FONT> adjustments with a sufficient level of precision; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we did not employ a sufficient number of staff to maintain optimal segregation of duties and to provide optimal
levels of oversight; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we did not employ <FONT STYLE="white-space:nowrap">month-end</FONT> financial reporting controls that prevented
timely production of accurate monthly financial reports; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we did not employ proper independent review of monthly financial reports to verify that such reports are accurate
and reconciled properly to the supporting documentation schedules; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we did not have strong accounting consideration and analysis over equity accounts, accrurals, and inventory
valuation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These material weaknesses resulted in adjustments to our current and prior year financial statements
primarily related to equity accounts, accruals, and inventory and could result in a misstatement of any account </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
balances or disclosures that would result in a material misstatement to the annual or interim financial statements that would not be prevented or detected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have begun implementation of a plan to remediate these material weaknesses. These remediation measures are ongoing and include hiring
additional accounting and financial reporting personnel and implementing additional policies, procedures and controls. We cannot assure you that these measures will significantly improve or remediate the material weaknesses described above. The
implementation of these remediation measures is in the early stages and will require validation and testing of the design and operating effectiveness of internal controls over a sustained period of financial reporting cycles. As a result, the timing
of when we will be able to fully remediate the material weaknesses is uncertain, and we may not fully remediate these material weaknesses during Fiscal 2022. If the steps we take do not remediate the material weaknesses in a timely manner, there
could continue to be a reasonable possibility that these control deficiencies or others would result in a material misstatement of our annual or interim consolidated financial statements that would not be prevented or detected on a timely basis.
This, in turn, could jeopardize our ability to comply with our reporting obligations, limit our ability to access the capital markets and adversely impact our stock price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our independent registered public accounting firms were not required to perform an evaluation of our internal control over financial
reporting as of either April&nbsp;30, 2021 or April&nbsp;30, 2020 in accordance with the provisions of the Sarbanes-Oxley Act. Accordingly, we cannot assure you that we have identified all, or that we will not in the future have additional, material
weaknesses. Material weaknesses may still exist when we report on the effectiveness of our internal control over financial reporting as required by reporting requirements under Section&nbsp;404 after the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to successfully remediate the existing material weakness in our internal control over financial reporting, the accuracy and
timing of our financial reporting, and our stock price, may be adversely affected and we may be unable to maintain compliance with the applicable stock exchange listing requirements. Implementing any appropriate changes to our internal controls may
divert the attention of our officers and employees, entail substantial costs to modify our existing processes and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls,
and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. In addition, investors&#146; perceptions that our internal
controls are adequate or that we are unable to produce accurate financial statements on a timely basis may harm our stock price and make it more difficult for us to effectively market and sell our services to new and existing customers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Board of Directors will be authorized to issue and designate shares of our preferred stock in additional series without shareholder
approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will authorize our Board of Directors, without the approval of our
shareholders, to issue shares of our preferred stock, subject to limitations prescribed by applicable law, rules and regulations and the provisions of our amended and restated certificate of incorporation, as shares of preferred stock in series, to
establish from time to time the number of shares to be included in each such series and to fix the designation, powers, preferences, privileges and rights of the shares of each such series and the qualifications, limitations or restrictions thereof.
The powers, preferences and rights of these additional series of preferred stock may be senior to or on parity with our common stock, which may reduce its value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our principal shareholders, officers and directors currently beneficially own approximately
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]% of our Common Stock. They will therefore be able to exert significant control over matters submitted to our shareholders for approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our principal shareholders, officers and directors beneficially own approximately
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]% of the outstanding shares of our Common Stock. This significant concentration of share ownership may adversely affect the trading price for our Common Stock because investors often perceive
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disadvantages in owning shares in companies with controlling shareholders. As a result, these shareholders, if they acted together, could significantly influence or even unilaterally approve
matters requiring approval by our shareholders, including the election of directors and the approval of mergers or other business combination transactions. The interests of these shareholders may not always coincide with our interests or the
interests of other shareholders. For more information regarding the beneficial ownership of such principal shareholders, officers and directors, see &#147;Beneficial Ownership of Principal Shareholders and Management.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase Common Stock in this offering, you will incur immediate and substantial dilution in the book value of your shares.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering price of the Common Stock is substantially higher than the net tangible book value per share of our Common Stock.
Therefore, if you purchase Common Stock in this offering, you will pay a price per share that substantially exceeds our net tangible book value per share after this offering. To the extent outstanding options or warrants are exercised, you will
incur further dilution. Based on an assumed offering price of $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share, which is the midpoint of the price range set forth on the cover page of this prospectus, you
will experience immediate dilution of $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share, representing the difference between our pro forma net tangible book value per share of Common Stock after giving
effect to this offering and the offering price. See &#147;Dilution&#148; for further information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We will incur significant
increased costs as a result of the listing of our securities for trading on Nasdaq. By becoming a public company in the U.S., our management will be required to devote substantial time to new compliance initiatives as well as compliance with ongoing
U.S. requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the listing of securities on Nasdaq, we will become a publicly traded company in the United States and as
such, we will incur additional significant accounting, legal and other expenses that we did not incur before the offering. We also anticipate that we will incur costs associated with corporate governance requirements of the SEC, as well as
requirements under Section&nbsp;404 and other provisions of the Sarbanes-Oxley Act. We expect these rules and regulations to increase our legal and financial compliance costs, introduce new costs such as investor relations, stock exchange listing
fees and shareholder reporting, and to make some activities more time consuming and costly. The implementation and testing of such processes and systems may require us to hire outside consultants and incur other significant costs. Any future changes
in the laws and regulations affecting public companies in the United States, including Section&nbsp;404 and other provisions of the Sarbanes-Oxley Act, and the rules and regulations adopted by the SEC, for so long as they apply to us, will result in
increased costs to us as we respond to such changes. These laws, rules and regulations could make it more difficult or more costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced
to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on
our Board of Directors, any committees of our Board of Directors, or as executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to securities
litigation, which is expensive and could divert management attention. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, companies that have experienced volatility in
the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management&#146;s
attention and resources, which could seriously hurt our business. Any adverse determination in litigation could also subject us to significant liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We have never paid cash dividends on our Common Stock, and we do not anticipate paying any cash dividends in the foreseeable future.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have neither declared nor paid cash dividends, and we do not anticipate paying cash dividends in the foreseeable future.
Therefore, you should not rely on an investment in Common Stock as a source for any future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dividend income. Our Board of Directors has complete discretion as to when or whether to distribute dividends. Even if our Board of Directors decides to declare and pay dividends, the timing,
amount and form of future dividends, if any, will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiaries, our financial condition,
contractual restrictions and other factors deemed relevant by our Board of Directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth
company,&#148; and any decision on our part to comply with certain reduced disclosure requirements applicable to emerging growth companies could make the Common Stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the JOBS Act, and, for as long as we continue to be an emerging growth company, we
may choose to take advantage of exemptions from various reporting requirements applicable to other public companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act, not being required to comply with any new requirements adopted by the Public Company Accounting Oversight Board, or the PCAOB, requiring mandatory audit firm rotation or a supplement to the auditor&#146;s report in which the
auditor would be required to provide additional information about the audit and the financial statements of the issuer, not being required to comply with any new audit rules adopted by the PCAOB after April&nbsp;5, 2012 unless the SEC determines
otherwise, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of
any golden parachute payments not previously approved. We could remain an emerging growth company until the earlier of: (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more;
(ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of our first sale of common equity securities pursuant to an effective registration statement; (iii)&nbsp;the date on which we have issued more than
$1.0&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer. We cannot predict if investors will find our Units less attractive if we choose to rely on these
exemptions. If some investors find our Units less attractive as a result of any choices to reduce future disclosure, there may be a less active trading market for our Units and our stock price may be more volatile. Further, as a result of these
scaled regulatory requirements, our disclosure may be more limited than that of other public companies and you may not have the same protections afforded to shareholders of such companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided
in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), for complying with new or revised accounting standards. We have opted for taking advantage of the extended transition period for complying with
new or revised accounting standards pursuant to Section&nbsp;107(b) of the Jobs Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions could make a third
party acquisition of us difficult. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of formation and amended and restated bylaws eliminate the
ability of shareholders to call special meetings or take action by less than unanimous written consent. These provisions could make it more difficult for a third party to acquire us without the approval of our board. In addition, the TBOC also
contains certain provisions that could make an acquisition by a third party more difficult. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>If our shares become subject to the
penny stock rules, it would become more difficult to trade our shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC has adopted rules that regulate broker-dealer
practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain
automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. If we do not retain a listing on Nasdaq and if the price of our Common Stock is
less than $5.00, our Common Stock will be deemed a penny stock. The penny stock rules require a broker-dealer, before a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules require
that before effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive (i)&nbsp;the
purchaser&#146;s written acknowledgment of the receipt of a risk disclosure statement; (ii)&nbsp;a written agreement to transactions involving penny stocks; and (iii)&nbsp;a signed and dated copy of a written suitability statement. These disclosure
requirements may have the effect of reducing the trading activity in the secondary market for our Common Stock, and therefore shareholders may have difficulty selling their shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to receive net proceeds from this offering of approximately
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], after deducting underwriting discounts and commissions and estimated offering expenses, or approximately
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] if the underwriter exercises the over-allotment option in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $1.00 increase or decrease in the assumed public offering price of
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share would increase or decrease the proceeds from this offering by approximately
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] million, assuming that the number of shares of Common Stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the
estimated underwriting discounts and commissions. Similarly, each increase or decrease of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock offered would increase or decrease our proceeds by
approximately $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] million, assuming the assumed public offering price remains the same, and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. This information is illustrative only and will depend on the actual initial public offering price and other terms of this offering determined at pricing. We do not expect that a change in the initial public offering
price or the numbers of shares by these amounts would have a material effect on our intended uses of the net proceeds from this offering, although a decrease in the initial offering price without a corresponding increase in the number of shares
offered may accelerate the time at which we will need to seek additional capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend the net proceeds from this offering to repay
the $1M Loan and Security Agreement and the remainder for working capital and general corporate purposes, which may include the hiring of additional personnel, capital expenditures and the costs of operating as a public company. The $1M Loan and
Security Agreement, as amended, matures on September&nbsp;30, 2022. At January&nbsp;31, 2022, the principal balance outstanding under the $1M Loan and Security Agreement was
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] and the interest rate was 12% per annum. It is payable to FRV and John&nbsp;Q. Adams, Sr., both of whom are beneficial owners of more than five percent (5%)
of&nbsp;our Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changing circumstances may cause us to consume capital significantly faster than we currently anticipate. The
amounts and timing of our actual expenditures will depend upon numerous factors, including the progress of our global marketing and sales efforts, the development efforts and the overall economic environment. Therefore, our management will retain
broad discretion over the use of the proceeds from this offering. We may ultimately use the proceeds for different purposes than what we currently intend. Pending any ultimate use of any portion of the proceeds from this offering, if the anticipated
proceeds will not be sufficient to fund all the proposed purposes, our management will determine the order of priority for using the proceeds, as well as the amount and sources of other funds needed. We believe that the funds raised in this offering
will be sufficient to finance the purposes described above, and we do not think that material amounts of other funds will be necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending our use of the net proceeds from this offering, we may invest the net proceeds in a variety of capital preservation investments,
including short-term, investment grade, interest bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our Common Stock and do not anticipate paying any cash dividends in the foreseeable
future. Payment of cash dividends, if any, in the future will be at the discretion of our Board of Directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital
requirements, business prospects and other factors our Board of Directors may deem relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and our capitalization as of January&nbsp;31, 2022: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to give effect to: (i)&nbsp;the reverse stock split; (ii)&nbsp;the conversion of up to the
Maximum Percentage of the Bridge Notes by each holder thereof; and (iii)&nbsp;the conversion of all of the $1.5M Notes; and on a pro forma as adjusted basis to give effect to the issuance of shares of Common Stock in this offering, at an assumed
public offering price of $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting underwriting
discounts and commissions and estimated offering expenses, as if the sale of the Common Stock had occurred on January&nbsp;31, 2022. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma as adjusted information set forth in the table below is illustrative only and will be adjusted based on the actual public
offering price and other terms of this offering determined at pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this table in conjunction with the sections titled
&#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and related notes included elsewhere in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of January&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B><br><B>as Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(U.S. dollars in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Indebtedness</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bridge Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$130K Note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$1.5M Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan and Security Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Indebtedness</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity (deficit):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A Preferred Stock, $0.001 par value per share,
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock, $0.001 par value per share,
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Stock, $0.001 par value per share,
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Stock, $0.001 par value per share,
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accumulated deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total capitalization</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock owned by existing shareholders is based on
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock issued and outstanding as of January&nbsp;31, 2022 and excludes the following as of such date: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock issuable
upon conversion of Preferred Stock (including conversion of the shares of Series C Preferred Stock issuable upon conversion of the $130K Note). See &#147;Description of Capital Stock&#151;Preferred Stock&#148; for additional information;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock issuable
upon the exercise of stock options issued to directors, employees and consultants of the Company, of which [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] were vested as of such date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock to be
issued upon exercise of the Investor Warrants, the $1M Lender Warrants, the $1.5M Lender Warrants, the Bridge Warrants, and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. See &#147;Description of Capital Stock&#151;Warrants&#148;
for more information; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock to be
issued upon exercise of the representative&#146;s warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This number of shares of Common Stock also excludes shares
issuable pursuant to antidilution provisions set forth in the Bridge Warrants, $1M Lender Warrants and $1.5M Lender Warrants and the Series C Preferred Stock as well as shares of Common Stock issuable upon conversion of the Series A Preferred Stock
or the Series B Preferred Stock, which are each dependent on the market price of our Common Stock at the time of conversion. For additional information, see &#147;Description of Capital Stock&#151;Antidilution Provisions.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our Common Stock, your interest will be diluted immediately to the extent of the difference between the public offering price
per share of Common Stock you will pay in this offering and the pro forma net tangible book value per share after this offering. On January&nbsp;31, 2022, we had a negative net tangible book value of
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], corresponding to a negative net tangible book value of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share. Net tangible book
value per share represents the amount of our total tangible assets less our total liabilities, divided by [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], the total number of shares of Common Stock issued and
outstanding on January&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of January&nbsp;31, 2022 was
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], representing approximately $([<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]) per share. Pro forma net tangible book value per
share represents the amount of our total tangible assets less our total liabilities, divided by the total number of shares of Common Stock outstanding at January&nbsp;31, 2022, after giving effect (i)&nbsp;to the reverse stock split; (ii)&nbsp;the
issuance of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares in this offering; (iii)&nbsp;the conversion of the Bridge Notes into
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock; and (iv)&nbsp;the conversion of the $1.5M Notes into [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares
of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of the shares of Common Stock offered by us in this offering, assuming no exercise of
the underwriter&#146;s option to purchase additional shares of Common Stock and after deducting the estimated underwriting discounts and commissions and management fees and estimated offering expenses payable by us, our pro forma net tangible book
value estimated at January&nbsp;31, 2022 would have been approximately $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] million, representing
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share. At the assumed public offering price for this offering of $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share,
which is the midpoint of the price range set forth on the cover page of this prospectus, this represents an immediate increase in historical net tangible book value of
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share to existing shareholders and an immediate dilution in net tangible book value of
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share to purchasers of Common Stock in this offering. Dilution for this purpose represents the difference between the price per share paid by these purchasers and
pro forma net tangible book value per share of Common Stock immediately after the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table
illustrates this dilution on a per share basis to purchasers of Common Stock in this offering: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro Forma net tangible book value per share as of January&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per Share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Percentage of dilution in net tangible book value per share for new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dilution information set forth in the table above is illustrative only and will be adjusted based on the
actual public offering price and other terms of this offering determined at pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $1.00 increase or decrease in the assumed initial
public offering price of $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share would increase or decrease our pro forma net tangible book value per share after this offering by
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] and the dilution per share to new investors by $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], assuming the number of shares of
Common Stock offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the
number of shares of Common Stock we are offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An increase or decrease of 1&nbsp;million shares of Common Stock in the number of
shares of Common Stock offered by us would increase or decrease our pro forma net tangible book value after this offering by approximately $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] million and the increase or
decrease pro forma net tangible book value per share after this offering by $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share and would increase or decrease the dilution per share to new investors by
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], after deducting estimated underwriting discounts and estimated offering expenses payable by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes, on a pro forma basis as of January&nbsp;31, 2022, the
differences between the number of shares of Common Stock acquired from us, the total amount paid and the average price per share paid by the existing holders of our Common Stock and by investors in this offering and based upon an assumed public
offering price of $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share, which is the midpoint of the price range set forth on the cover page of this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Price Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock owned by existing shareholders is based on
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock issued and outstanding as of January&nbsp;31, 2022, plus [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]
shares of Common Stock to be issued upon the conversion of up to the Maximum Percentage by each purchaser of the Bridge Notes, plus [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock to be issued
upon conversion of the $1.5M Notes. This number of shares of the Common Stock excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock issuable
upon conversion of Preferred Stock (including conversion of the shares of Series C Preferred Stock issuable upon conversion of the $130K Note). See &#147;Description of Capital Stock&#151;Preferred Stock&#148; for additional information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock issuable
upon the exercise of stock options issued to directors, employees and consultants of the Company, of which [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] were vested as of such date; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock to be
issued upon exercise of the Investor Warrants, the $1M Lender Warrants, the $1.5M Lender Warrants, the Bridge Warrants, and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. See &#147;Description of Capital Stock&#151;Warrants&#148;
for more information; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock to be
issued upon exercise of the representative&#146;s warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This number of shares of Common Stock also excludes shares
issuable pursuant to antidilution provisions set forth in the Bridge Warrants, $1M Lender Warrants and $1.5M Lender Warrants and the Series C Preferred Stock as well as shares of Common Stock issuable upon conversion of the Series A Preferred Stock
or the Series B Preferred Stock, which are each dependent on the market price of our Common Stock at the time of conversion. For additional information, see &#147;Description of Capital Stock&#151;Antidilution Provisions.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If all of our issued and outstanding options, convertible securities and warrants had been exercised as of January&nbsp;31, 2022, the number
of shares of Common Stock held by existing shareholders would increase to [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], or [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]% of the
total number of shares of Common Stock outstanding after this offering, and the average price per share paid by the existing shareholders would be $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares of Common Stock in full in this offering, the number of shares of
Common Stock held by new investors will increase to [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], or [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]% of the total number of
shares of Common Stock issued and outstanding after this offering and the percentage of shares of Common Stock held by existing shareholders will decrease to [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]% of the
total number of shares of Common Stock issued and outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis of our financial condition and results of operations should be
read in conjunction with our financial statements and the related notes included elsewhere in this prospectus. The discussion below contains forward-looking statements that are based upon our current expectations and are subject to uncertainty and
changes in circumstances. Actual results may differ materially from these expectations due to inaccurate assumptions and known or unknown risks and uncertainties, including those identified in &#147;Cautionary Note Regarding Forward-Looking
Statements&#148; and under &#147;Risk Factors&#148; elsewhere in this prospectus. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a medical technology company focused on applying innovative <FONT STYLE="white-space:nowrap">AI-based</FONT> technology to an ECG (also
known as an EKG) to expand and improve an ECG&#146;s clinical usefulness. Our objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-care</FONT></FONT> clinical settings. HeartSciences&#146; first product candidate, the MyoVista is a resting <FONT STYLE="white-space:nowrap">12-lead</FONT> ECG which
provides diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. Our business model, which
involves the use of the MyoVista device and consumables for each test, is <FONT STYLE="white-space:nowrap">&#147;razor-razorblade&#148;</FONT> as the electrodes used with the MyoVista are proprietary to HeartSciences, and new electrodes are required
for every test performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is currently no <FONT STYLE="white-space:nowrap">low-cost,</FONT> front-line, medical device that is
effective at screening for heart disease. As a result, frontline physicians face a significant challenge in determining if a patient has heart disease. In 2012, the United States Preventive Services Task Force, or USPSTF, conducted an evaluation of
conventional ECG testing and stated: &#147;There is no good evidence that an ECG helps physicians predict heart risks in people with no symptoms any better than traditional considerations such as current or former smoking, blood pressure and
cholesterol levels.&#148; We believe the MyoVista will benefit patients, healthcare providers, healthcare payors and the like by providing improved frontline testing and referral processes for cardiac dysfunction caused by heart disease in patients
of all ages or <FONT STYLE="white-space:nowrap">age-related</FONT> cardiac dysfunction in elderly patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ECG devices record the
electrical signals of a patient&#146;s heart. There are three basic categories of heart disease: electrical (such as an arrhythmia), structural (such as valvular disease) and ischemic (such as coronary artery disease, or CAD). Conventional resting
ECGs have limited sensitivity in detecting structural and ischemic disease and are typically used for diagnosing cardiac rhythm abnormalities, such as atrial fibrillation, also known as Afib, or acute coronary syndrome, such as a myocardial
infarction, which is also known as a heart attack. However, traditional ECGs have a limited role in identifying cardiac dysfunction associated with structural and ischemic disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AI and machine learning provide the ability to create much more complex algorithms using much larger data sets which we believe can be applied
to the electrical signals of a patient&#146;s heart and to expand the capability of an ECG to be able to detect cardiac dysfunction. The MyoVista is a full function conventional resting <FONT STYLE="white-space:nowrap">12-lead</FONT> ECG device that
also incorporates our proprietary, <FONT STYLE="white-space:nowrap">AI-based</FONT> algorithm that detects cardiac dysfunction caused by heart disease and/or <FONT STYLE="white-space:nowrap">age-related</FONT> cardiac dysfunction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The editorial comment associated with the study titled &#147;Prediction of Abnormal Myocardial Relaxation from Signal Processed Surface
ECG&#148; presented below discusses recent applications of machine learning to data derived from surface <FONT STYLE="white-space:nowrap">12-lead</FONT> ECGs in relation to cardiac dysfunction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;These are some of the most significant advances in electrocardiography since its inception, which has historically had a limited, if
any, role in the evaluation of cardiac dysfunction. In the past, our cardiovascular community was resigned to the fact that surface ECGs are poor indicators for cardiac dysfunction.&#148; </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Khurram Nasir, MD, MPH, MSC, Department of Cardiology, Houston Methodist DeBakey
Heart&nbsp;&amp; Vascular Center, Houston, Texas, et. al.,<I> Journal of American College of Cardiology Editorial Comment Volume 76 Number 8 2020.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Almost all forms of heart disease affect heart muscle, or cardiac, function including the early stages of heart disease prior to symptoms.
Impaired cardiac function is first observed as impaired cardiac relaxation which is an early indicator of diastolic dysfunction and continues to increase in severity as heart disease progresses. The diastolic phase of the cardiac cycle occurs when
the heart muscle relaxes (following contraction). Diastolic dysfunction may also be related to <FONT STYLE="white-space:nowrap">age-related</FONT> cardiac dysfunction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients that are diagnosed with cardiac dysfunction are typically evaluated by a cardiologist to determine the severity of their condition,
its cause(s) and recommended treatment. Additional testing upon referral is often performed through an imaging diagnostic test called an echocardiogram, or echo, similar to an ultrasound. Further cardiac testing may also be required.
Cardiology-based testing generally involves expensive imaging equipment, is performed by a specialist and involves expert interpretation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The significant challenge in frontline healthcare environments, such as primary care, is the lack of a readily available test to screen for
heart disease or related cardiac dysfunction caused by heart disease. As a result, cardiology referral decisions are often based on a patient&#146;s risk factors and/or a conventional ECG test. Accordingly, many patients with heart disease are left
undetected while many patients that are referred for subsequent testing receive a negative test, finding no heart disease and concluding that no treatment or intervention is required. We believe that adding the capability to detect cardiac
dysfunction to a standard <FONT STYLE="white-space:nowrap">12-lead</FONT> resting ECG will be valuable for patients, physicians, health systems and third-party payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ECG is a ubiquitous, relatively <FONT STYLE="white-space:nowrap">low-cost,</FONT> simple and quick test, it is portable and can be
performed in a wide range of clinical settings by a <FONT STYLE="white-space:nowrap">non-specialist</FONT> clinician or clinical aide. For patients, early intervention often creates the best chance of a successful outcome by addressing a problem
before symptoms develop. Preventative care can help patients avoid the long-term health implications and costs of acute care associated with heart attacks, heart failure and chronic disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New Class&nbsp;II devices or existing devices with new capabilities require De Novo premarket review. The MyoVista along with its proprietary
software and hardware is classified as a Class&nbsp;II medical device by the FDA. Premarket review and clearance by the FDA for these devices is generally accomplished through the 510(k) premarket notification process or De Novo classification
request, or petition process. The Company previously submitted a De Novo classification request in late 2019 that included clinical performance data. Based on feedback we received from our 2019 De Novo submission and further communications with the
FDA during 2020, we concluded that we would need to undertake a new validation clinical study at institutions independent of those involved in collecting patient data used in the algorithm development process. The study protocol of this new
validation clinical study was submitted to the FDA for review and, in May 2021, the FDA agreed that the study design should be acceptable and would be expected to provide statistical information on which the FDA can effectively evaluate the
performance results of the MyoVista. The new validation study is currently underway and, once it is completed, we expect to incorporate the data we receive into a new De Novo submission. Additionally, EMC testing is required for all FDA electronic
medical devices to ensure that electrical noise does not interfere with producing accurate results. The FDA also required additional testing related to electromagnetic compatibility due to testing guideline changes. Additional EMC testing is
expected to be complete for the next FDA submission and we will include the results of such testing in the new De Novo submission mentioned above. The FDA&#146;s De Novo classification authorization process generally takes from five to twelve months
from the date the application is submitted but can take significantly longer. We expect to submit this new De Novo request later this year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information regarding the FDA regulatory process, see &#147;Business&#151;Government Regulation.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenues </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues, which have been
minimal to date, consist mainly of sales of devices, electrodes and other supplies in the establishment of distributor relationships outside the U.S. during the approval, development and improvement of the MyoVista. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cost of Sales </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of sales consists
primarily of costs related to materials, components and subassemblies. Cost of sales also includes certain direct costs such as those incurred for shipping and freight. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operating Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operating
expenses have consisted solely of research and development expenses and selling, general and administrative expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development
Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development activities primarily consist of engineering and research programs associated with our MyoVista
device. Research and development expenses include payroll and personnel-related costs for our research and development, clinical and regulatory personnel, including expenses related to stock-based compensation for such employees , consulting
services, clinical trial expenses, regulatory expenses, prototyping and testing. Research and development expenses also include costs attributable to clinical trial expenses including clinical trial design, site development and study costs, data,
related travel expenses, the cost of products used for clinical activities, and internal and external costs associated with regulatory compliance. We expense research and development costs as they are incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Selling, General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our selling, general and administrative expenses consist of payroll and personnel-related costs for field support personnel, business
development, consulting, stock-based compensation, and for administrative personnel that support our general operations such as executive management and financial accounting. Selling, general and administrative expenses also include costs
attributable to professional fees for legal and accounting services, premises costs, IT, insurance, consulting, recruiting fees, travel expenses and depreciation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Expense </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense
relates to our loan facilities and convertible notes. For more information, see &#147;&#151;Description of Indebtedness.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Income (Expense),
Net </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income (expense), net primarily consists of forgiveness of loans issued under the CARES Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the periods presented and as a
percentage of our total revenue for those periods based on our statement of operations data. The year over year comparison of results of operations is not necessarily indicative of results of operations for future periods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary of Statements of Operations for the nine months ended January&nbsp;31, 2022 compared with the nine months ended January&nbsp;31, 2021: </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Nine Months Ended</B><br><B>January&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$ Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands, unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on settlement of payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Summary of Statements of Operations for Fiscal 2021 compared with Fiscal 2020: </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$ Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-59</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-76</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(921</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-51</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-120</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,265</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,566</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,828</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(129</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4612</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on settlement of payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">569</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-36</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues declined from $64,000 to $26,000 in 2021 when compared to 2020, a decrease of approximately 59%. Our
revenues to date have been in relation to establishing distributor relationships outside the United States during product development and improvement. The decrease in revenue is due to the timing of engaging new distributors and declines resulting
from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic which impacted engagement with medical institutions and distributors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of sales decreased $35,000 or 76% to $11,000 during Fiscal 2021 compared to $46,000 as of Fiscal 2020 and the decline is consistent
with the decrease noted in revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During Fiscal 2021, research and development expenses decreased $332,000 when compared to Fiscal
2020, a decrease of 16%, primarily resulting from a decreases of $35,000 in premises costs, $133,000 in software consulting and $81,000 in payroll expenditures which is consistent with work associated with the first De Novo submission which took
place during Fiscal 2020 and cost reduction measures implemented by management at the outset of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During Fiscal 2021, selling, general, and administrative expenses decreased $921,000 or 51% when compared to Fiscal 2020. The primary
decreases were in payroll related expenditures and reductions in consulting and travel expenditures which is consistent with cost reduction measures implemented by management at the outset of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our interest expense increased $129,000 during Fiscal 2021 when compared to Fiscal 2020, primarily due to interest from the $1M
Loan and Security Agreement entered into in April 2020. For more information, see &#147;&#151;Description of Indebtedness.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our cash requirements are, and will, continue to be, dependent upon a variety of factors. We expect to continue devoting significant capital
resources to R&amp;D, clinical studies and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">go-to-market</FONT></FONT> strategies. Our principal sources of capital are cash on hand and the proceeds of future offerings of equity and
debt securities. We cannot assure you that we will be able to consummate the sale of any such securities on terms acceptable to us, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;31, 2022, we had approximately $[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] of cash, an
increase of $[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] from $[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] as of April&nbsp;31, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended January&nbsp;31, 2022, we raised an additional
$[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] in connection with the 2021 Bridge Financing to support our <FONT STYLE="white-space:nowrap">on-going</FONT> business plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception through January&nbsp;31, 2022, we have funded our operations principally from sales of equity and debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The auditors&#146; report on our financial statements for Fiscal 2021 contains an explanatory paragraph regarding substantial doubt about our
ability to continue as a going concern. These events and conditions, along with other matters, indicate that a material uncertainty exists that may cast significant doubt on our ability to continue as a going concern. Additionally, financial
statements for future fiscal years may continue to include this explanatory paragraph with respect to our ability to continue as a going concern. Our financial statements do not include any adjustments that may result from the outcome of this
uncertainty. This going concern opinion could materially limit our ability to raise additional funds through the issuance of equity or debt securities or otherwise. Until we can generate significant recurring revenues, we expect to satisfy our
future cash needs through debt or equity financing. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate
research or development plans for, or commercialization efforts with respect to our device. If we are unable to continue as a going concern, we may have to liquidate our assets, and the values we receive for our assets in liquidation or dissolution
could be significantly lower than the values reflected in our financial statements. Our lack of cash resources and our potential inability to continue as a going concern may materially adversely affect our share price and our ability to raise new
capital, enter into critical contractual relations with third parties and otherwise execute our business objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below
presents our cash flows for the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Nine Months</B><br><B>Ended&nbsp;January&nbsp;31,&nbsp;2022<BR>(Unaudited)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended</B><br><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>U.S. dollars in thousands</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,452</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,022</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used by our operating activities of $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] during the nine
months ended January&nbsp;31, 2022, is primarily due to [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used by our operating activities of $2.5&nbsp;million during Fiscal 2021, was primarily due to our net loss of $2.5&nbsp;million. Net
cash used by our operating activities of $3.8&nbsp;million during Fiscal 2020, was primarily due to our net loss of $3.8&nbsp;million plus net <FONT STYLE="white-space:nowrap">non-cash</FONT> items of $167,000, offset by $196,000 of net changes in
operating assets and liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our primary sources of capital will be the proceeds of this offering and the
net proceeds of the 2021 Bridge Financing, cash and cash equivalents and, if an opportunity presents itself, the sale of debt or equity securities, although we may not be able to complete financing on terms acceptable to us, if at all. The
accompanying financial statements have been prepared assuming that the Company will continue as a &#147;going concern.&#148; For more information, please refer to &#147;Risk Factors&#151; Our independent registered public accounting firm has
expressed substantial doubt about our ability to continue as a going concern.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities in the nine months ended January&nbsp;31, 2022 of
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] primarily relates to [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During Fiscal 2021, net cash provided from financing activities was $2.68&nbsp;million and was primarily from the issuance of convertible
promissory notes, Series C Preferred Stock, and shareholder notes. During Fiscal 2020, net cash provided from financing activities was $1.81&nbsp;million and was primarily from the issuance of convertible promissory notes, Series C Preferred Stock,
and shareholder notes. For additional information, please refer to &#147;Management&#146;s Discussion&nbsp;&amp; Analysis&#151;Description of Indebtedness.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of Indebtedness </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;31, 2022,
we had a total of $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] million of indebtedness outstanding as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>January&nbsp;31,<BR>2022</B><br><B>(unaudited)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(U.S. dollars in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bridge Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$130K Note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$1.5M Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$1M Loan and Security Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PPP Loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bridge Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the 2021 Bridge Financing, as of February&nbsp;25, 2021, the Company had issued the Bridge Notes in an aggregate principal amount
of $3.98 million. The Bridge Notes bear interest at 8% per annum payable, have a maturity date of December&nbsp;22, 2024 and are secured by a subordinated security interest in substantially all of the assets, including patents and other intellectual
property, of the Company. From and after the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the issuance of the Bridge Notes, the Company may prepay the principal of the Bridge Notes and all accrued and unpaid interest thereon at a
price of 115% of the principal amount to be prepaid (plus accrued and unpaid interest). In addition, upon the occurrence of an event of default or a change of control of the Company (as defined in the Bridge Notes), the holders of the Bridge Notes
may redeem their Bridge Notes in an amount equal to 125% of the principal amount (plus accrued and unpaid interest). Through February&nbsp;25, 2022, the Company received net proceeds (after the OID) of $3.58 million in connection with the 2021
Bridge Financing. For more information regarding the 2021 Bridge Financing, see &#147;Summary&#151;Recent Developments&#151;2021 Bridge Financing.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Bridge Note was issued with an original issue discount of 10% and is convertible into a number of shares of Common Stock equal to an
initial conversion price of the lower of (i) $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share or (ii)&nbsp;a 30% discount of the original issue price in this offering, or
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share. The Bridge Notes will convert into shares of Common Stock at the Conversion Price automatically upon the consummation of this offering. Any holder
(including its Attribution Parties) who would beneficially own in excess of the Maximum Percentage of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the conversion of all or any portion of the Bridge Notes, may elect to receive a <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant for all shares in excess of the Maximum Percentage. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have substantially the same terms as the Bridge Warrants issued in the 2021
Bridge Financing. See, &#147;Description of Capital Stock&#151;Warrants&#148; for more information. The exercise price of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants is $0.0001 per share. Any such Purchaser may adjust the Maximum
Percentage at any time, upon 61 days&#146; notice, provided that the Maximum Percentage may not be adjusted above 9.99% of the number of shares of Common Stock outstanding immediately prior to, and immediately after giving effect to, the conversion
of all or any portion of the Bridge Notes. The exercise of the Pre-Funded Warrants is also subject to the Maximum Percentage except that any exercise of the Pre-Funded Warrants resulting in a number of shares in excess of the Maximum Percentage
shall be deemed null and void and shall be cancelled <I>ab initio</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For two years after the issuance date of the Bridge Notes, the
Conversion Price of the Bridge Notes is subject to adjustment for certain events such as stock dividends and splits and issuances of shares of Common Stock or securities convertible into or exercisable for shares of Common Stock at a price less than
the Conversion Price in which event the Conversion Price will be subject to a full ratchet downward to the price at which such newly issued shares of Common Stock or securities convertible into or exercisable for shares of Common Stock were issued.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bridge Notes contain covenants that, among other things, restrict our ability to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur or guarantee additional indebtedness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grant certain liens; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redeem or repay certain other indebtedness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfer or sell assets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">repurchase any equity securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay dividends or make other distributions on capital stock or make other restricted payments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">engage in transactions with affiliates other than on an &#147;arm&#146;s length&#148; basis; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change in the principal nature of our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bridge Notes contain numerous events of default, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure to file a registration statement relating to the shares of Common Stock to be received upon
conversion of the Bridge Notes as required by the Registration Rights Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure to keep any such registration statement in effect as required under the Registration Rights
Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the suspension of our Common Stock from trading; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure to keep 200% of the number of shares of Common Stock as shall be necessary to effect a conversion of
the Bridge Notes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">nonpayment of principal or interest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">violations of covenants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the breach of any representation or warranty set forth in any of the documents and instruments executed and
delivered in connection with the 2021 Bridge Financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cross default and cross acceleration to certain other indebtedness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">bankruptcy and judgments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure to pay any indebtedness greater than $250,000 when due. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>$130K Note </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;12, 2019, the Company entered into an unsecured drawdown convertible promissory note with Front Range Ventures, LLC, or FRV, for
an aggregate amount not to exceed $130,000, which we refer to as the $130K Note. FRV is the beneficial owner of more than five percent (5%) of our Common Stock. The $130K Note may be repaid at any time upon 20 days&#146; notice to the holder. The
$130K Note is convertible into Series C Preferred Stock at any time, upon written notice by either the holder or the Company or at maturity, at the lowest price paid for the Series C Preferred Stock prior to conversion, which is currently
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share. The $130K Note matures 20 days following FDA clearance of the MyoVista. Under the terms of the agreement, the note is
<FONT STYLE="white-space:nowrap">non-interest</FONT> bearing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $130K Note does not contain any covenants that restrict our ability to
conduct business. The $130K Note does not contain specific events of default but any breach of its terms by the Company would entitle FRV to all available rights and remedies, at law or in equity, available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>$1.5M Notes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2020, the Board
of Directors approved the private offering to accredited investors of a series of secured convertible promissory notes in the amount of $1.5&nbsp;million, which we refer to as the $1.5M Notes. The $1.5M Notes had an original maturity of
July&nbsp;31, 2022 and were subsequently amended on November&nbsp;2, 2021, extending maturity to October&nbsp;31, 2022. As consideration for the extension, we issued the $1.5M Lender Warrants to the noteholders. For more information, see
&#147;Description of Capital Stock&#151;Warrants&#151;$1.5M Lender Warrants.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event the $1.5M Notes are converted into Common
Stock on or prior to the maturity date, no interest shall accrue or be payable. Interest is only payable if the notes are not converted on or prior to the maturity date, in which event interest shall accrue and be payable on the outstanding
principal balance of the notes at a simple interest rate of 12% per annum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $1.5M Notes are secured by substantially all of the
Company&#146;s assets and intellectual property. This security interest is subordinate to the security interests granted pursuant to the 2013 Technology Agreement and the Loan and Security Agreement described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is entitled to either repay the principal and all accrued but unpaid interest on the $1.5M Notes upon giving 10 days written
notice to the holders at any time; or the outstanding principal amount, and accrued but unpaid interest, is convertible into Common Stock at an exercise price equal to the lower of
(i)&nbsp;$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share and (ii)&nbsp;a 30% discount to the offering price for the sale of Common Stock in a public offering, adjusted for any splits, recapitalizations,
combinations or other similar transactions affecting the Company&#146;s Common Stock upon or after any of the following events: (i) 30 days following FDA clearance of the MyoVista; (ii)&nbsp;the closing of further funding of $5&nbsp;million or more
which values entire equity capital of the Company at $50&nbsp;million or more; (iii)&nbsp;a public offering Common Stock which values the entire equity capital of the Company at $50&nbsp;million or more; or (iv)&nbsp;the sale or merger of a majority
of the voting stock of the Company. Each holder of a note may elect for conversion at any time upon written notice to the Company. As of January&nbsp;31, 2022, accrued and unpaid interest was approximately
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $1.5M Notes contain numerous events of default, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">nonpayment of principal or interest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">violations or nonperformance of covenants </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commencement of liquidation, reorganization, or dissolution; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">bankruptcy and judgments. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $1.5M Notes do not contain any covenants, other than those that are defined as events of default listed above, that restrict our ability
to conduct business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assumed that all of the $1.5M Notes will convert into shares of Common Stock upon
the consummation of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>$1M Loan and Security Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2020, the Company entered into a loan and security agreement, which we refer to as the $1M Loan and Security Agreement, with FRV and
John Q. Adams Sr. who are beneficial owners of more than five percent (5%) of our Common Stock of the Company. Each of FRV and John Q. Adams Sr. committed to lend a principal amount of $500,000, totaling $1&nbsp;million and evidenced by secured, <FONT
STYLE="white-space:nowrap">non-convertible</FONT> promissory notes that we refer to as the $1M Notes. The loan was drawn in three installments of $300,000 upon execution of the $1M Loan and Security Agreement, $350,000 in July 2020 and $350,000 in
September 2020. The loan accrues interest at a rate of 12% per annum, compounded annually, which is payable at maturity. The Company is also required to pay default interest at a rate of 18% per annum, compounded annually, on any unpaid amounts due
at maturity until the loan amounts are fully <FONT STYLE="white-space:nowrap">re-paid.</FONT> The loan is secured by substantially all of the Company&#146;s assets and intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loan had an original maturity date of September&nbsp;30, 2021 which was amended on September&nbsp;30, 2021 making the note repayable on
demand. The loan was amended again on November&nbsp;3, 2021, extending the maturity to September&nbsp;30, 2022. As consideration for the extension, we issued the $1M Lender Warrants to FRV and John Q. Adams Sr. For more information, see
&#147;Description of Capital Stock&#151;Warrants&#151;$1M Lender Warrants.&#148; As of January&nbsp;31, 2022, accrued and unpaid interest totaled $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $1M Notes contain numerous events of default, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">nonpayment of principal or interest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the breach of any representation or warranty set forth in any of the documents and instruments executed and
delivered in connection with the $1M Loan and Security Agreement, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cross default and cross acceleration to certain other indebtedness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">bankruptcy and judgments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a final judgment or order for payment of money in excess of $10,000 rendered against the Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cessation of our operations; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sale, conveyance or disposition of all or substantially all of the Company&#146;s assets or the effectuation of a
transaction or series of related transactions in which more than 50% of the voting power of the Company is transferred. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $1M Notes do not contain any covenants, other than those that are defined as events of default and therefore listed above, that restrict
our ability to conduct business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering to repay this loan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Paycheck Protection Program Loans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
April&nbsp;20, 2020, the Company received loan proceeds in the amount of $250,200 under the Paycheck Protection Program, or the PPP, which was established as part of the Coronavirus Aid, Relief and Economic Security Act. Following the PPP
guidelines, the loan was forgiven in November 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;25, 2021, the Company received a second PPP loan in the amount of
$250,200. Following the PPP guidelines, the loan was forgiven in June 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current Outlook </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have financed our operations to date primarily through the issuance of Common Stock, Preferred Stock and debt securities. We have incurred
losses and generated negative cash flows from operations since inception. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Since inception, we have generated limited revenues from the sale of products through establishment of distributor relationships outside the U.S. during the development of the MyoVista. We
require FDA clearance to market the MyoVista in the U.S. and do not expect to generate significant revenues from the sale of our device in the near future or prior to FDA clearance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;31, 2022, our cash and cash equivalents were
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]. We expect that our existing cash and cash equivalents as of the date of this prospectus will be sufficient to fund our current operations until
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], without using the net proceeds from this offering and/or the net proceeds from exercise of existing warrants. In addition, our operating plans may change as a result
of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress and costs of our research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of manufacturing our device; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential costs of contracting with third parties to provide marketing and distribution services for us or
for building such capacities internally; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the magnitude of our general and administrative expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we can generate significant recurring revenues and profit, we expect to satisfy our future cash needs through equity financings. We
cannot be certain that additional funding will be available to us when needed, on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or
commercialization efforts with respect to our device. This may raise substantial doubts about our ability to continue as a going concern. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical
Accounting Policies and Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion and analysis of our financial condition and results of operations are based on our
financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of these financial statements in accordance with U.S. GAAP requires us to make estimates,
assumptions and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Our estimates are based on our knowledge of current events and actions we may
undertake in the future and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results may materially differ from these estimates under different assumptions or conditions. We believe the accounting policies discussed below are critical to understanding our historical and future performance, as these
policies relate to the more significant areas involving management&#146;s judgements and estimates. For additional details regarding our critical accounting policies, see the &#147;Financial Statements&#151;Notes to the Financial Statements, Note
3.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Determination of Fair Value of Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the absence of a public trading market of our Common Stock, and in accordance with the guidance as outlined in the American Institute of
Certified Public Accountants&#146; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, our Board of Directors exercised reasonable judgment and considered numerous objective and subjective
factors to determine the best estimate of the fair value of our Common Stock including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external market conditions affecting the medical devices industry and trends within the industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual operating and financial performance; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">current business conditions and projections; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights, preferences and privileges of our preferred stock relative to those of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial condition and operating results, including our levels of available capital resources;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">equity market conditions affecting comparable public companies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general U.S. market conditions and the lack of marketability of our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock-Based Compensation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
accounts for employee and <FONT STYLE="white-space:nowrap">non-employee</FONT> share-based compensation in accordance with the provisions of ASC 718, <I>Compensation&#151;Stock Compensation</I>. Under ASC 718, share-based compensation cost is
measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair value of common stock option awards is calculated using the Black-Scholes option pricing model, based on key assumptions
such as fair value of common stock, expected volatility, and expected term. These estimates require the input of subjective assumptions, including (i)&nbsp;the expected stock price volatility, (ii)&nbsp;the calculation of the expected term of the
award, (iii)&nbsp;the risk-free rate and (iv)&nbsp;expected dividend yields. These assumptions are primarily based on third-party valuations, historical data, and judgement of management regarding future trends and other factors. The Company has
estimated the expected term of its common stock options using the &#147;simplified&#148; method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of
sufficient historical data. The expected volatility is based on third-party valuations. The risk-free interest rates for periods within the expected term of the option are based on the US Treasury securities with a maturity date that commensurate
with the expected term of the associated award. There is no expected dividend yield since the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For stock options issued to employees and <FONT STYLE="white-space:nowrap">non-employees,</FONT> the fair value of stock-based awards is
recognized as compensation expense over the requisite service period, which is defined as the period during which an employee is required to provide service in exchange for an award. The Company uses a straight-line attribution method for all grants
that include only a service condition.<B><I> </I></B>The Company accounts for forfeitures when they occur. Stock-based compensation expense recognized in the financial statements is reduced by actual awards forfeited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Debt </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information
regarding our indebtedness, see &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Description of Indebtedness.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pricing and Valuation of Inventories </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory consists of finished goods, work in progress, <FONT STYLE="white-space:nowrap">sub-assemblies</FONT> and raw materials and is stated
at the lower of cost or net realizable value using the <FONT STYLE="white-space:nowrap">first-in,</FONT> <FONT STYLE="white-space:nowrap">first-out,</FONT> referred to as the FIFO method. Reserves for slow-moving, excess, or obsolete inventories are
recorded when required to reduce inventory values to their estimated net realizable values based on product life cycle, development plans, production expiration or quality issues. Inventory that is used for research and development are expensed as
consumed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory is consumed for research and development purposes and product sales. The Company has not received FDA clearance to
sell its MyoVista<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>device in the United States and until FDA clearance occurs, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
MyoVista<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>is subject to changes through research and development. While the majority of the Company&#146;s inventory is intended for use in
finished products to be sold post FDA clearance, management&#146;s reserve methodology is to record a charge for inventory obsolescence and/or device development changes on an annual basis. The Company records any reserve charges in research and
development expenses on the statements of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Going Concern </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Accounting Standards Codification, or ASC, <FONT STYLE="white-space:nowrap">205-40,</FONT> <I>Going Concern</I>, management
has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#146;s ability to continue as a going concern within one year after the date that these financial statements are
issued. As of the end of Fiscal 2021, the Company had an accumulated retained deficit of $1.9&nbsp;million. In addition, the Company has generated recurring losses and negative cash flows from operations since its inception. Based on its current
business plan assumptions and expected cash burn rate, management believes that it has insufficient cash to fund its current operations without additional financing for the next 12 months. These factors raise substantial doubt regarding the
Company&#146;s ability to continue as a going concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management evaluated the significance of these conditions in relation to its
ability to meet its obligations. The Company&#146;s continued operations will depend on its ability to raise additional capital through various potential sources such as an IPO, equity and/or debt financings, or strategic relationships. The Company
has implemented cost reduction measures and has continued its fundraising efforts as discussed in Note 12 of the financial statements. If the Company does not complete an IPO, the Company plans to continue to fund its operations and capital funding
needs through a combination of private equity offerings, debt financings, and other sources. While a number of the Company&#146;s investors have participated in multiple rounds of funding, management can provide no assurance that such financing or
strategic relationships will be available which would likely have a material adverse effect on the Company and its financial statements. Additionally, the Company&#146;s ability to continue as a going concern is dependent upon receiving FDA
clearance and achieving profitable operations by commercializing its medical devices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore, there is substantial doubt about the
Company&#146;s ability to continue as a going concern within one year after the date that the financial statements are issued. These financial statements do not include any adjustments relating to the recoverability and classification of recorded
asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern for a reasonable period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The JOBS Act and Smaller Reporting Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; or EGC, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay
adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective
dates for public and private companies until the earlier of the date we (i)&nbsp;are no longer an EGC or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial
statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private
companies. We have irrevocably elected not to avail ourselves of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other
public companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an EGC until the earliest of (i)&nbsp;the last day of our fiscal year
(a)&nbsp;following the fifth anniversary of the completing of this offering, (b)&nbsp;in which we have total annual gross revenues of at least $1.07&nbsp;billion or (ii)&nbsp;in which we are deemed to be a large accelerated filer, which means the
market value of our Common Stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million as of the prior December 31st and (ii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt securities over a three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even after we no longer qualify as an
emerging growth company, we may still qualify as a &#147;smaller reporting company,&#148; which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the
auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a medical
technology company focused on applying innovative <FONT STYLE="white-space:nowrap">AI-based</FONT> technology to an ECG (also known as an EKG) to expand and improve an ECG&#146;s clinical usefulness. Our objective is to make an ECG a far more
valuable cardiac screening tool, particularly in frontline or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-care</FONT></FONT> clinical settings. HeartSciences&#146; first product candidate, the MyoVista, is a resting <FONT
STYLE="white-space:nowrap">12-lead</FONT> ECG which provides diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG
information in the same test. Our business model, which involves the use of the MyoVista device and consumables for each test, is &#147;razorblade&#148; as the electrodes used with the MyoVista are proprietary to HeartSciences, and new electrodes
are required for every test performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is currently no <FONT STYLE="white-space:nowrap">low-cost,</FONT> front-line, medical device
that is effective at screening for heart disease. As a result, frontline physicians face a significant challenge in determining if a patient has heart disease. In 2012, the USPSTF conducted an evaluation of conventional ECG testing and stated:
&#147;There is no good evidence that an ECG helps physicians predict heart risks in people with no symptoms any better than traditional considerations such as current or former smoking, blood pressure and cholesterol levels.&#148; We believe the
MyoVista will benefit patients, healthcare providers, healthcare payors and the like by providing improved frontline testing and referral processes for cardiac dysfunction caused by heart disease in patients of all ages or <FONT
STYLE="white-space:nowrap">age-related</FONT> cardiac dysfunction in elderly patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ECG devices record the electrical signals of a
patient&#146;s heart. There are three basic categories of heart disease: electrical (such as an arrhythmia), structural (such as valvular disease) and ischemic (such as coronary artery disease, or CAD). Conventional resting ECGs have limited
sensitivity in detecting structural and ischemic disease and are typically used for diagnosing cardiac rhythm abnormalities, such as atrial fibrillation, also known as Afib, or acute coronary syndrome, such as a myocardial infarction, which is also
known as a heart attack. However, traditional ECGs have a limited role in identifying cardiac dysfunction associated with structural and ischemic disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AI and machine learning provide the ability to create much more complex algorithms using much larger data sets which we believe can be applied
to the electrical signals of a patient&#146;s heart and to expand the capability of an ECG to be able to detect cardiac dysfunction. The MyoVista is a full function conventional resting <FONT STYLE="white-space:nowrap">12-lead</FONT> ECG device that
also incorporates our proprietary, <FONT STYLE="white-space:nowrap">AI-based</FONT> algorithm that detects cardiac dysfunction caused by heart disease and/or <FONT STYLE="white-space:nowrap">age-related</FONT> cardiac dysfunction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The editorial comment associated with the study titled &#147;Prediction of Abnormal Myocardial Relaxation from Signal Processed Surface
ECG&#148; presented below discusses recent applications of machine learning to data derived from surface <FONT STYLE="white-space:nowrap">12-lead</FONT> ECGs in relation to cardiac dysfunction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;These are some of the most significant advances in electrocardiography since its inception, which has historically had a limited, if
any, role in the evaluation of cardiac dysfunction. In the past, our cardiovascular community was resigned to the fact that surface ECGs are poor indicators for cardiac dysfunction.&#148; </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Khurram Nasir, MD, MPH, MSC, Department of Cardiology, Houston Methodist DeBakey Heart&nbsp;&amp; Vascular Center, Houston, Texas, et. al.,<I>
Journal of American College of Cardiology Editorial Comment Volume 76 Number 8 2020.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Almost all forms of heart disease affect heart
muscle, or cardiac, function including the early stages of heart disease prior to symptoms. Impaired cardiac function is first observed as impaired cardiac relaxation which is an early indicator of diastolic dysfunction and continues to increase in
severity as heart disease progresses. The diastolic phase of the cardiac cycle occurs when the heart muscle relaxes (following contraction). Diastolic dysfunction may also be related to <FONT STYLE="white-space:nowrap">age-related</FONT> cardiac
dysfunction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients that are diagnosed with cardiac dysfunction are typically evaluated by a
cardiologist to determine the severity of their condition, its cause(s) and recommended treatment. Additional testing upon referral is often performed through an imaging diagnostic test called an echocardiogram, or echo, similar to an ultrasound.
Further cardiac testing may also be required. Cardiology-based testing generally involves expensive imaging equipment, is performed by a specialist and involves expert interpretation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The significant challenge in frontline healthcare environments, such as primary care, is the lack of a readily available test to screen for
heart disease or related cardiac dysfunction caused by heart disease. As a result, cardiology referral decisions are often based on a patient&#146;s risk factors and/or a conventional ECG test. Accordingly, many patients with heart disease are left
undetected while many patients that are referred for subsequent testing receive a negative test, finding no heart disease and concluding that no treatment or intervention is required. We believe that adding the capability to detect cardiac
dysfunction to a standard <FONT STYLE="white-space:nowrap">12-lead</FONT> resting ECG will be valuable for patients, physicians, health systems and third-party payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ECG is a ubiquitous, relatively <FONT STYLE="white-space:nowrap">low-cost,</FONT> simple and quick test, it is portable and can be
performed in a wide range of clinical settings by a <FONT STYLE="white-space:nowrap">non-specialist</FONT> clinician or clinical aide. For patients, early intervention often creates the best chance of a successful outcome by addressing a problem
before symptoms develop. Preventative care can help patients avoid the long-term health implications and costs of acute care associated with heart attacks, heart failure and chronic disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New Class&nbsp;II devices or existing devices with new capabilities require De Novo premarket review. The MyoVista along with its proprietary
software and hardware is classified as a Class&nbsp;II medical device by the FDA. Premarket review and clearance by the FDA for these devices is generally accomplished through the 510(k) premarket notification process or De Novo classification
request, or petition process. The Company previously submitted a De Novo classification request in late 2019 that included clinical performance data. Based on feedback we received from our 2019 De Novo submission and further communications with the
FDA during 2020, we concluded that we would need to undertake a new validation clinical study at institutions independent of those involved in collecting patient data used in the algorithm development process. The study protocol of this new
validation clinical study was submitted to the FDA for review and, in May 2021, the FDA agreed that the study design should be acceptable and would be expected to provide statistical information on which the FDA can effectively evaluate the
performance results of the MyoVista. The new validation study is currently underway and, once it is completed, we expect to incorporate the data we receive into a new De Novo submission. Additionally, EMC testing is required for all FDA electronic
medical devices to ensure that electrical noise does not interfere with producing accurate results. The FDA also required additional testing related to electromagnetic compatibility due to testing guideline changes. Additional EMC testing is
expected to be complete for the next FDA submission and we will include the results of such testing in the new De Novo submission mentioned above. The FDA&#146;s De Novo classification authorization process generally takes from five to twelve months
from the date the application is submitted but can take significantly longer. We expect to submit this new De Novo request later this year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information regarding the FDA regulatory process, see &#147;Business&#151;Government Regulation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Heart Disease Facts and Current ECG Testing Limitations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heart disease refers to a variety of conditions that affect the heart&#151;including heart rhythm problems, heart valve problems, genetic
defects and blood-vessel diseases such as coronary artery disease. It is often referred to as the &#147;silent killer&#148; and, according to the American Heart Association, one in three patients are not properly diagnosed until after a heart attack
occurs and 50% of men and 64% of women who died suddenly of coronary heart disease had no previous symptoms. Statistics published by the CDC show that in the United States heart disease is the leading cause of death for men, women, and people of
most racial and ethnic groups. According to the CDC, one person dies from cardiovascular disease every 36 seconds and heart disease accounts for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approximately one in four deaths. In 2018, 30.3&nbsp;million U.S. adults were diagnosed with heart disease including 18.2&nbsp;million adults with CAD. Approximately 605,000 patients in the U.S.
have a heart attack each year with approximately 20% of deaths from CAD occurring in adults less than 65 years old. The scale of the problem is similar worldwide. In 2020, the World Health Organization confirmed that heart disease has remained the
leading cause of death at the global level for the last 20 years. Ischemic heart disease now represents 16% of global deaths and an estimated 17.9&nbsp;million people died from cardiovascular diseases in 2019, representing 32% of all global deaths.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As heart disease progresses to more acute stages, the cost to treat patients increases significantly. Cardiovascular disease is the
leading cost to the healthcare system and is estimated to be responsible for one in every six healthcare dollars spent in the United States. Heart disease costs in the United States were approximately $363&nbsp;billion in each of 2016 and 2017,
including the cost of health care services, medicines, and lost productivity due to death. Governments, healthcare providers and payors are motivated to shift the diagnosis and management of these conditions to earlier stages where better patient
outcomes can be delivered at lower costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is currently no <FONT STYLE="white-space:nowrap">low-cost,</FONT> front-line, medical
device that is effective at screening for heart disease. As a result, frontline physicians face a significant challenge in determining if a patient has heart disease. The conventional ECG is thought of by many to be the front-line tool in cardiac
testing, but it has poor sensitivity in detecting CAD or structural heart disease. According to <I>Appropriate Use of <FONT STYLE="white-space:nowrap">Non-Invasive</FONT> Testing for Diagnosis of Stable Coronary Artery Disease</I>, an article
published in the April 2014 issue of the <I>Journal of European Society of Cardiology</I>, current, conventional, resting <FONT STYLE="white-space:nowrap">12-lead</FONT> ECG devices have a 50% or less sensitivity in identifying CAD. In 2012, the
USPSTF conducted an evaluation of conventional ECG testing and stated: &#147;There is no good evidence that an ECG helps physicians predict heart risks in people with no symptoms any better than traditional considerations such as current or former
smoking, blood pressure and cholesterol levels.&#148; In 2018, the USPSTF reconfirmed (i)&nbsp;its recommendation not to screen with resting or exercise ECG testing for adults at low risk of CVD events and (ii)&nbsp;that it had found that there is
also insufficient evidence to recommend screening with resting or exercise ECG tests for adults at intermediate or even high risk of CVD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the limitations of the conventional ECG and healthcare guidance around the world that recommends against its use for heart disease
screening, in the absence of a better alternative, the ECG remains a ubiquitous and widely-used test throughout healthcare including <FONT STYLE="white-space:nowrap">non-cardiology</FONT> settings. It is estimated that 1.5 to 3&nbsp;million ECGs are
performed worldwide every day, making it one of the most commonly used cardiac diagnostic tests and a fundamental tool in clinical practice. It is estimated that more than 100&nbsp;million ECGs are performed each year in the United States. The 2018
National Ambulatory Medical Care Survey indicated that patient care physicians, excluding anesthesiologists and federal facilities such as VA clinics, ordered or provided 27&nbsp;million ECG tests and 4&nbsp;million stress ECGs at office visits, and
the 2017 National Hospital Ambulatory Medical Care Survey showed that on ambulatory care visits to hospital emergency departments, an additional 28&nbsp;million ECG tests were ordered or performed by hospital emergency departments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overuse of Expensive Cardiology-Based Diagnostic Testing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The absence of effective front-line or primary-care-based testing has resulted in the <FONT STYLE="white-space:nowrap">over-use</FONT> of
costly cardiology-based diagnostic tests. Noninvasive cardiac tests are significant contributors to healthcare costs, accounting for greater than 40% of Medicare Part B spending on medical imaging, or over $17&nbsp;billion annually according to the
CMS. There are a variety of effective, though expensive, diagnostic tests for patients used to detect heart disease. These are typically performed in a specialist cardiology or hospital setting and include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stress ECG testing</I>, a <FONT STYLE="white-space:nowrap">non-invasive</FONT> diagnostic test with a cost of
approximately $200 with, according to the American College of Cardiology, a sensitivity of 68% in the detection of CAD; typically performed in a cardiologist setting and requires the patient to run on a treadmill, which can be difficult for many
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
patients. A study published in March 2018 by the American Heart Association, or AHA, demonstrated that among 553,027 patients that were younger than 65 that underwent stress testing, only 5.1%
were hospitalized for a heart attack, required a stent, revascularization procedure or were referred for a coronary angiogram. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Echocardiogram</I>, a <FONT STYLE="white-space:nowrap">non-invasive</FONT> diagnostic imaging test, similar to
an ultrasound, that is effective in the detection of heart disease; however, the Medicare cost of an echo in a hospital is approximately $600 and can be as much as $3,000 if performed privately. The echo is frequently ordered by primary care
physicians and is the most common cardiac imaging test upon referral. According to the 2018 National Ambulatory Medical Care Survey, office-based patient care physicians, excluding anesthesiologists and federal facilities such as VA clinics, ordered
or provided 10&nbsp;million echos. However, according to a December 2017 study in Clinical Cardiology that examined the appropriateness versus the value of echocardiograms ordered by primary care physicians, only 22% of patients had abnormalities
and only 2.5% experienced a change in patient management that corresponded with the initial suspected diagnosis and echocardiographic findings. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Cardiac imaging tests</I>, such as nuclear stress tests and coronary CT angiograms, or CCTAs, alternatively
can be conducted noninvasively, but typically cost $1,000 or more. There are more than 10&nbsp;million cardiac imaging tests conducted in the United States each year. According to a study published by the AHA in September 2020 that reviewed previous
CT test results of nearly 40,00 patients who underwent coronary CCTAs from January 2007 to December 2013, only 15.3% of patients had obstructive CAD. Despite the high negative outcome rates, exorbitant costs and high patient exposure to radiation,
these tests remain commonplace. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Coronary angiogram</I>, an invasive test in which dye that is visible by
<FONT STYLE="white-space:nowrap">X-ray</FONT> is injected into the blood vessels of the heart. The <FONT STYLE="white-space:nowrap">X-ray</FONT> machine rapidly takes a series of images (angiograms), offering a look at the patient&#146;s blood
vessels. Coronary angiogram is considered the &#147;gold standard&#148; for diagnosing coronary arterial disease and can cost in excess of $5,000. According to an article in the <I>New England Journal of Medicine</I>, in a large 2010 study which
reviewed angiogram results of 400,000 patients, only 38% of patients (without known CAD) actually had obstructive CAD. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the referral process for cardiology testing is ineffective and costly for health systems due to the absence of an effective
gateway test, particularly for primary care. Not only are many patients with heart disease missed, but most cardiology testing has a negative test result that requires no further treatment or testing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Diastolic Dysfunction, an Early Indicator of Heart Disease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The symptoms and causes of cardiac dysfunction have been researched for many years. The causes of cardiac dysfunction during the contraction
(systolic) phase, also called left ventricular reduced ejection fraction, have been well understood for many years. However, according to the American Heart Association Statistics Committee report in 2013, approximately 50% of patients with heart
failure symptoms have ejection fraction measures that are not markedly abnormal. In addition, multiple articles published by the NIH state that approximately 50% of HF cases are due to severe diastolic dysfunction, also called heart failure with
preserved ejection fraction or HFpEF. As a result, understanding the causes and progression of diastolic dysfunction has become a key area of scientific and clinical interest. This research has led to the understanding that almost all patients with
systolic dysfunction also have diastolic dysfunction and almost all types of heart disease including CAD, valvular disease, cardiomyopathy, hypertension, congenital heart disease, and pericardial disease induce diastolic dysfunction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to an article by Dr.&nbsp;Dalane&nbsp;W. Kitzman, MD and Dr.&nbsp;William&nbsp;C. Little, MD published in the February&nbsp;14, 2012
issue of the <I>Journal of the American Heart Association</I>, diastolic dysfunction is not only an indicator of systolic dysfunction, it is a sensitive indicator of cardiovascular dysfunction. According to this research, since left ventricular
diastolic function is impaired by all of the common pathological processes that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affect LV function or produce LV hypertrophy or fibrosis, including hypertension, diabetes, ischemia, myocarditis, toxins, and infiltrative cardiomyopathies, LV diastolic dysfunction, or LVDD,
begins early in the heart disease process and continues to increase in severity as heart disease progresses. LVDD is now recognized as one of the earliest signs of heart disease and typical onset occurs when a patient is still asymptomatic. We
believe that the early detection of diastolic dysfunction can be a valuable marker for almost all forms of heart disease and <FONT STYLE="white-space:nowrap">age-related</FONT> cardiac abnormalities that may otherwise be missed by current
conventional ECG devices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The myocardial ischemic cascade diagram below is a standard diagram in cardiology that illustrates the sequence
of events that take place as ischemia (lack of blood supply to the heart) increases in severity. As noted below, the first detectable changes during the early stages of heart disease are in the diastolic phase. Conventional ECG changes, if seen at
all, occur much later in the disease process. However, diastolic dysfunction continues to act as a reliable marker as heart disease progresses as the severity of dysfunction increases. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g271308g01a02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proprietary MyoVista <I>wav</I>ECG algorithm, or the MyoVista Algorithm, is designed to detect
abnormally slow relaxation rates during the early diastolic phase of the cardiac cycle, an early indicator for diastolic dysfunction. The algorithm was designed based on an echocardiogram measure known as
<FONT STYLE="white-space:nowrap">e-prime</FONT> which is a key echocardiographic measure of left ventricular diastolic function. The e-prime measurement calculates the maximum left ventricle longitudinal tissue velocities during the early diastolic
phase. The echo measurement is taken from two different points, the septal and lateral side of the mitral valve annulus. Abnormal left ventricular relaxation rates as defined by the 2016 guidelines from the American Society of Echocardiography are
septal &lt;7cm/sec and lateral &lt;10 cm/sec. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Product and Technology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MyoVista device has been developed in response to the recent understanding that most forms of heart disease are associated with left
ventricular, or LV, relaxation abnormalities and diastolic dysfunction. MyoVista is a <FONT STYLE="white-space:nowrap">12-lead</FONT> resting ECG device that features a proprietary algorithm developed to detect cardiac dysfunction in the diastolic
phase, specifically slower than normal left ventricular relaxation rates as defined by the American Society of Echocardiology Guidelines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MyoVista also includes the capabilities of a full-featured conventional <FONT STYLE="white-space:nowrap">12-lead</FONT> resting ECG
including analysis using the Glasgow Algorithm, also known as the Glasgow ECG Interpretation Algorithm. Developed by </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the University of Glasgow in the UK,
the <FONT STYLE="white-space:nowrap">12-lead</FONT> ECG Analysis Algorithm has been relied upon for more than 35 years and is a widely respected resting ECG interpretive algorithms. The Glasgow Algorithm was developed
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and has been continuously improved over the years by a team of world-renowned ECG researchers. The Glasgow Algorithm is licensed to the Company pursuant to the Glasgow License Agreement. For
additional information regarding the Glasgow Algorithm and our license, see &#147;&#151;Intellectual Property&#151;Glasgow License Agreement.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the MyoVista, the conventional ECG (including the Glasgow Algorithm) and our proprietary algorithm for detection of diastolic abnormalities
are combined as a single test with results presented separately. The MyoVista has a high-resolution touchscreen display and incorporates many easy and intuitive to use features commonly associated with a tablet device. The MyoVista&#146;s design
focuses on ease of use and features include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Wall mount and cart mount capabilities as well as tabletop. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Locking capability to a cart or table to prevent theft. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A backup <FONT STYLE="white-space:nowrap">lithium-ion</FONT> battery to provide power if moving from location to
location within an environment or if power has been lost. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A large 15.6&#148; touch screen with very high resolution and contrast providing a quality color image on which
to view a patient&#146;s results, which is easily wiped clean for infection control purposes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gesture feature capabilities have been added for ease of use. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A touch screen that is designed to function even when the clinician is wearing latex gloves.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A touchscreen keyboard as well as the ability to connect a traditional keyboard. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An available HDMI display port to provide an oversized screen as a viewing option. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Electronic medical records integration capabilities that is critical for large hospitals. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interpretive analysis software of the Glasgow Algorithm. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>MyoVista device with 1 lead view of signal processed waveform </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308g01a07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MyoVista is intended for use in a clinical setting, by a clinician or other trained personnel who are
acting on the orders of a licensed physician. It is not intended for use as a sole means of diagnosis and the information provided is only significant when used in conjunction with a physician review and consideration of all other relevant patient
data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MyoVista uses electrical information from the heart captured during a standard resting
<FONT STYLE="white-space:nowrap">12-lead</FONT> ECG test as inputs to a proprietary <FONT STYLE="white-space:nowrap">AI-based</FONT> algorithm. The device then extracts additional frequency content from the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
electrical signal once captured using wavelet transform based signal processing to provide additional valuable inputs to the <FONT STYLE="white-space:nowrap">AI-based</FONT> algorithm. A wavelet
is a mathematical function used to divide a continuous-time signal into its different frequency components. A wavelet transform is the representation of the converted signal by wavelets. Wavelet transform mathematics has emerged over recent years as
a valuable time&#150;frequency analysis tool. It has been particularly useful in applications related to <FONT STYLE="white-space:nowrap">bio-signal</FONT> processing such as ECG electrical signals. Our signal processing patents relate to the
extraction and use of certain frequency related data from the signal processed ECG which are used to produce more accurate and effective algorithms. For more information about our patents, please refer to &#147;&#151;Intellectual Property.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have conducted multiple comparisons related to the additional algorithm performance benefits using the frequency information gathered
through signal processing by comparing the number of frequency variables used in any given algorithm as compared to conventional ECG inputs and their related statistical significance. The frequency variables generated by the MyoVista consistently
rank in the <FONT STYLE="white-space:nowrap">top-tier</FONT> of statistically significant input variables to our AI algorithm and make up a significant overall percentage of the selected input variables as compared to the conventional ECG variables.
During a <FONT STYLE="white-space:nowrap">20-second</FONT> test, more than 1,000 pieces of extracted data points may be obtained. The software on the device preselects which of the data variables represent the most valuable inputs for the cardiac
dysfunction algorithm and uses those to perform an assessment. The output results of the test are provided as indicators and associated statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>MyoVista Proprietary Algorithm Indications and Statements </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308g01a03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MyoVista Algorithm is designed to detect whether a patient is negative or positive for abnormally slow
left ventricular diastolic relaxation rates as defined by the American Society of Echocardiography. For patients whose results are highly positive or highly negative, the probability that the test is accurate is especially high. For patients that
are borderline, the results mean that it is likely that the patient is close to the guideline thresholds and therefore the test produces borderline results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MyoVista has multiple reporting options which can be configured in the settings menu and includes an option for a clinical interpretation
report. The clinical interpretation report includes clinical performance information observed in a reference clinical study population to provide context to a patient&#146;s wavECG test results and assists interpretation by a physician. The device
also performs all conventional ECG assessments including software-based automated ECG interpretation through incorporation of the Glasgow Algorithm. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>MyoVista Device screen image with descriptions </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308g01a04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>MyoVista Patented Center Post Electrode Systems </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Electrodes are the sticky patches that are applied to the skin to capture the ECG signal. The MyoVista Center Post Electrodes pictured below
are high quality, <FONT STYLE="white-space:nowrap">single-use</FONT> disposable ECG electrodes that are designed to be used exclusively with the MyoVista. A new set of electrodes is required for each test. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unlike a conventional ECG, the MyoVista analyzes frequency content from the heart&#146;s electrical signal. The MyoVista requires
high-quality, low impedance signal capture to ensure clinical efficacy. Accordingly, we have developed a patented cable connection and high-quality electrode system that is unique to us. The design of the electrodes includes a hollow center post
connector (pictured below) that aligns firmly to the complementing post design on the cable grabber, allowing for a secure connection to help overcome the challenges of stable signal capture and induced signal noise that are common in other style
electrodes. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308g01a05.jpg" ALT="LOGO">



<IMG SRC="g271308g01a06.jpg" ALT="LOGO">



<IMG SRC="g271308g01a08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary electrodes are applied to the skin using high-quality electrode hydrogel. The hydrogel is
designed to provide improved conductivity of electrical signals and optimize consistent high-quality signal capture. Electrical tests per the Association for the Advancement of Medical Instrumentation, or AAMI,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
standards were performed and demonstrated improved performance over multiple major brands of electrodes. The hydrogel adhesive, while easily repositionable, provides a comfortable and firm
adhesion that provides positive contact with the skin surface and ensures optimal signal transmission and minimal signal noise. The electrodes also provide optimal skin contact while accommodating easy, painless removal after single use. The
electrodes have passed the International Organization for Standardization, standard ISO 10993-1for biocompatibility testing for skin sensitivity and irritations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Previous FDA De Novo Submission </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company previously submitted a De Novo classification request in late 2019 that included clinical performance data obtained using a clinical validation dataset made up of patient&#146;s ECGs collected during clinical studies. The data set used for
performance validation was not used during construction of the algorithm and was held out separately for performance testing purposes only. Based on feedback we received from our 2019 De Novo submission as well as additional communications with the
FDA during 2020, we concluded that we would need to undertake a new validation clinical study at institutions that are independent of those involved in the collection of patient data used in the algorithm development process. The study protocol of
this new validation clinical study was submitted to the FDA for review and in May 2021, the FDA agreed that the study appeared to provide a sufficient amount of statistical information such that the FDA could effectively evaluate the MyoVista&#146;s
diagnostic performance results. The new validation study is currently underway and, once it is completed, we will incorporate the data we receive into a new De Novo Submission. We anticipate that we will submit this new De Novo request later this
year. Additionally, EMC testing is required for all FDA electronic medical devices to ensure that electrical noise does not interfere with producing accurate results. The FDA also required additional testing related to electromagnetic compatibility
due to testing guideline changes. Additional EMC testing is expected to be complete for the next FDA submission and we will include the results of such testing in the new De Novo submission mentioned above. The FDA&#146;s De Novo classification
authorization process generally takes from five to twelve months from the date the application is submitted but can take significantly longer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on feedback from the 2019 De Novo submission and subsequent interaction with the FDA, multiple other changes have already been
incorporated into the device and associated documentation, including software, user interface changes, documentation, and test report information, layout, style and language. For additional information regarding the FDA regulatory process, see
&#147;Business&#151;Government Regulation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The previous algorithm validation dataset that was submitted as part of the previous De
Novo submission included 343 patients. The <FONT STYLE="white-space:nowrap">343-patient</FONT> dataset was captured as part of a data collection effort with multiple institutions to build and validate the performance of the diastolic relaxation
abnormalities algorithm. The previous validation dataset was kept separate from the algorithm development dataset and was not used during algorithm development. The results of the <FONT STYLE="white-space:nowrap">343-patient</FONT> validation that
formed part of the prior De Novo submission are provided below. The device output indicates a patient as either Highly Negative, Negative, Borderline, Positive and Highly Positive for left ventricular relaxation abnormalities. Because the
proprietary algorithm contains a borderline result (which is the same for a conventional ECG interpretive analysis), overall algorithm performance results are measured twice; once with borderline patients classified as negative, and once with
borderline patients classified as positive. The <FONT STYLE="white-space:nowrap">343-patient</FONT> dataset had 16.9% of patients indicated as borderline. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">SENSITIVITY</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">SPECIFICITY</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">ACCURACY</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borderline Positive</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borderline Negative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information regarding government regulations and the regulatory authorization process,
including the FDA&#146;s authorization or clearance, see &#147;&#151;Government Regulations.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Opportunity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Diagnostic Gap </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The significant diagnostic
gap in heart disease is early identification. Heart disease often remains asymptomatic for many years as disease progresses until it reaches an acute stage, at which point many patients have a heart attack or die without prior diagnosis of disease.
For this reason, heart disease is often referred to as the &#147;silent killer.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Frontline physicians face a significant challenge
in identifying cardiac disease early. There is currently no <FONT STYLE="white-space:nowrap">low-cost,</FONT> front-line, medical device which is effective at screening for heart disease. According to the 2018 National Ambulatory Medical Care
Survey, 72% of office visits involved patients having one or more of the main cardiac risk factors of hypertension, hyperlipidemia, diabetes, or obesity. In the absence of a <FONT STYLE="white-space:nowrap">low-cost,</FONT> front-line, medical
device which is effective at screening for heart disease, frontline healthcare providers rely predominantly on a patient&#146;s risk factors. Despite its poor sensitivity and limited ability to identify cardiac dysfunction associated with structural
and ischemic disease, the conventional ECG test still remains widely used by frontline physicians. As a result of its current limitations, many patients with heart disease go undiagnosed, and many patients referred to cardiology for subsequent
testing do not have heart disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2012, the USPSTF stated that there is no good evidence that an ECG helps physicians predict heart
risks in people with no symptoms any better than traditional considerations such as smoking, blood pressure and cholesterol levels, acknowledging the diagnostic gap that currently exists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, according to the CDC, cardiovascular disease remains the biggest cost for the US healthcare system at approximately
$216&nbsp;billion per year. The cost of treating acute cardiac events and heart failure is especially high in comparison to preventative treatment. Governments, healthcare providers and third-party payors are focused on shifting the diagnosis and
management of heart disease to earlier stages where better patient outcomes can be delivered at lower cost; however, to make substantial progress in improving patient outcomes at lower costs, the existing diagnostic gap needs to be closed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changing Demographics </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heart disease is
most commonly found in individuals age 65 and older with incidences of heart disease increasing at 65 years for men and 71.8 years for women. According to the Organization for Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and
Development, advances in the field of medicine have led to an increase in life expectancy which, as of 2019, was estimated to average 78.9 years for a person in the U.S., up from 75.4 years in 1990. As life expectancy increases, the average age of
the population is expected to increase. According to the HHS, the population age 65 and older increased from 38.8&nbsp;million in 2008 to 52.4&nbsp;million in 2018 (a 35% increase) and is projected to reach 94.7&nbsp;million in 2060. By 2030, more
than 20&nbsp;percent of U.S. residents are projected to be age 65 and over. Since heart disease is most common in elderly individuals, and that population pool is increasing, we believe there is a significant opportunity for a device such as the
MyoVista. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Growing ECG Market </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
demand for electrocardiograph devices and related supplies known as electrodes is on the rise worldwide. Despite the limitations of the conventional ECG and healthcare guidance around the world that recommends against its use for screening, in the
absence of a better alternative, the ECG remains a ubiquitous and widely-used test throughout healthcare including <FONT STYLE="white-space:nowrap">non-cardiology</FONT> settings. It is estimated that 1.5&nbsp;million to 3.0&nbsp;million ECGs are
performed worldwide every day, making it one of the most commonly used diagnostic tests in healthcare and a fundamental tool in clinical practice. It is estimated that more than 100&nbsp;million ECGs are performed each year in the United States. The
2018 National Ambulatory Medical Care Survey reflected that office-based patient care physicians, excluding anesthesiologists and federal facilities such as VA clinics, ordered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or provided 27&nbsp;million ECG tests and four million stress ECGs during office visits and the 2017 National Hospital Ambulatory Medical Care Survey showed that during ambulatory care visits to
hospital emergency departments an additional 28&nbsp;million ECG tests were ordered or performed by hospital emergency departments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to <I>Markets and Markets Global Diagnostic ECG</I>, approximately 770,000 ECG devices were estimated to have been sold worldwide in
2015. We expect changing demographics, such as the aging population and increasing rates of obesity, to contribute to even greater numbers of cardio-related testing, and therefore ECG devices and supply usage, over the coming years. According to
<I>Markets and Markets Diagnostic ECG Market (2019-2024</I>), the global diagnostic ECG device market excluding supplies is approximately $7.5&nbsp;billion per year and projected to be valued at $10.3&nbsp;billion in 2024 with an expected 6.4%
compounded annual growth rate, or CAGR. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Impetus to Identify Risks Earlier for More Effective <FONT STYLE="white-space:nowrap">Low-Cost</FONT> Testing
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key goal of the HHS is reducing healthcare costs. This places pressure on physicians and healthcare institutions to contain
healthcare costs. Additionally, one of the key objectives of HHS&#146;s <I>Healthy People 2030</I>, is to increase preventive care for people of all ages. We believe that efforts towards preventive care and maintenance will lead to more testing for
high-risk individuals and patients that have existing cardiac conditions. This trend, we believe, in tandem with the push to shorten hospital stays, has created an impetus to identify <FONT STYLE="white-space:nowrap">pre-symptomatic</FONT> patients
at risk more effectively at the front-line physician or clinic level and to treat recovering cardiac patients through outpatient care and rehabilitation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changing Nature of Healthcare Providers </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The delivery of healthcare in the U.S. is evolving. Alternative treatment sites, such as retail clinics, concierge medicine, urgent care
clinics and ambulatory surgical centers deliver care from qualified providers in settings outside of emergency departments, hospitals or traditional physician offices. We expect this trend to accelerate the drive to provide more effective
preventative care and represents a significant opportunity for the introduction of MyoVista as a new medical device that offers an enhanced ability to screen for heart disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Retail Clinics</U>. Retail clinics have seen significant growth and, according to a report by The Insight Partners titled, &#147;<I>Retail
Clinics Market to 2027</I>,&#148; the global retail clinics market is expected to reach $8.1&nbsp;billion in 2027 and increase from $3.4&nbsp;billion in 2018. In the U.S., major players operating retail clinics include The Kroger Co., CVS Health,
Rite Aid Corp, Walmart Inc., and Walgreens Co. Walmart alone has announced that it intends to have 4,000 primary care &#147;supercenters&#148; in stores by 2029 having opened its first one in 2019. Walmart and other retail clinic providers are
seeking to radically change frontline health delivery by offering access to convenient, <FONT STYLE="white-space:nowrap">low-cost</FONT> medical testing and treatment either with or without traditional insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Concierge Medicine</U>. Concierge medicine is increasing rapidly in the U.S. According to a 2021 report by Research and Markets, the U.S.
concierge medicine market is expected to reach $10.0&nbsp;billion by 2028 and is expected to expand at a CAGR of 9.39% from 2021 to 2028. Increased waiting time for physician appointments, shortage of physicians and rising prevalence of chronic
diseases are driving patients from conventional settings to <FONT STYLE="white-space:nowrap">non-traditional</FONT> care settings. This, along with increased face time with physicians and a focus on preventive care, is driving the growth of the
market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Urgent Care Clinics</U>. Urgent Care Clinics market sector has exhibited strong growth. According to IBIS World market
research, shifting consumer preference to the convenience and timesaving of urgent care, coupled with rising hospital emergency care costs and a shortage of primary care physicians, has stimulated demand for industry services. In response, industry
revenue is anticipated to grow at an annualized rate of 4.6% to $40.3&nbsp;billion during 2022. An increase in the number of insured Americans has benefited industry operators due to the Affordable Care Act, or ACA. There are currently over 9,500
urgent care centers in the U.S. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Ambulatory Surgical Centers</U>. According to a 2018 Research and Markets report on
ambulatory surgical centers, the number of freestanding surgical centers has been expanding over the last decade, experiencing strong growth. As a result of this growth, the number of outpatient surgical procedures performed in ambulatory surgery
centers increased by 32% from 2005 to 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that this scale of cardiac disease as well as changing demographics, growing ECG
market, impetus to identify risks earlier for more effective low-cost testing, along with the increasing number and type of health care settings creates a significant opportunity for a device such as the MyoVista. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Capitation Provides an Incentive to Identify Medicare Advantage Patients </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers are paid either through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-service</FONT></FONT> or
capitation. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fee-for-service</FONT></FONT> is a payment model where services are unbundled and paid for separately. In health care, the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">fee-for-service</FONT></FONT> payment model incentivizes physicians to provide more treatments because payment is dependent on the quantity, rather than quality of care. Capitation is a payment arrangement that pays a
physician or group of physicians a set amount for each enrolled person assigned to them, per period of time, whether or not that person seeks care. Under capitation, the amount of remuneration is based on the average expected healthcare utilization
of that patient, with greater payment for patients with significant history of medical problems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approximately 42% (approximately
26&nbsp;million people) of those covered by Medicare, according to CMS, are enrolled in a Medicare Advantage plan. With respect to these patients, CMS pays capitation to healthcare providers. CMS uses risk adjustment to adjust capitation payments to
health plans, either higher or lower, to account for the differences in health costs of individuals such as heart failure, CAD, angina and valvular heart disease. Accordingly, under CMS guidelines, risk factor adjustments per patient will provide
payment that is higher for sicker patients who have conditions where diagnosis codes are documented in the medical record as a result of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">face-to-face</FONT></FONT> visit. Therefore,
there is a financial incentive to identify those Medicare Advantage patients that are sicker, including those that have undiagnosed ailments such as heart disease. We believe that undiagnosed heart disease represents a significant problem, and we
believe insurance plans that have a high number of Medicare Advantage patients could be a target market for MyoVista testing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our objective is to make the
MyoVista wavECG a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care,</FONT></FONT> as an affordable, and valuable medical test. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business model, which involves the capital sale of the MyoVista device and the use of proprietary supplies (electrodes) for each test, is <FONT
STYLE="white-space:nowrap">&#147;razor-razorblade&#148;.</FONT> The electrode connection system is patented, and the electrodes are superior quality to facilitate high quality, stable ECG signal capture. This is an important aspect of the MyoVista,
as the MyoVista also analyses frequency data along with conventional ECG information. The proprietary electrodes would provide recurring <FONT STYLE="white-space:nowrap">per-test</FONT> revenue for each MyoVista device sold. Unlike many new
healthcare products, we do not expect or need to rely on high charges because of our recurring revenue business model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our go-to market
strategy focuses on device adoption rather than price maximization and we aim to ensure that the purchase price of the MyoVista is affordable. A major brand full-featured, resting <FONT STYLE="white-space:nowrap">12-lead</FONT> ECG, such as GE and
Phillips, typically costs between $5,000 to $10,000 and we anticipate pricing our device competitively by setting the price for the MyoVista at the lower end of that range. As conventional ECGs are typically used multiple times per day (in a high
use environment this could be as much as thirty times per day), the annual revenue from electrodes per <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">device-in-use</FONT></FONT> could exceed that of the upfront sale of the unit.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to develop a direct sales force and to target hospitals, physicians&#146; offices as well as large retail healthcare
organizations. We intend to use technical presentations, peer reviewed clinical data, and reference </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sites to achieve penetration of these markets. We also expect to expand our medical advisory board, conduct clinical trials with KOLs to generate the necessary clinical evidence in various
healthcare settings, as well as establish reference sites among these customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Communicating the benefits and value to the medical
community, while at the same time creating brand awareness, is fundamental to our marketing strategy. We anticipate that we will participate in a number of healthcare industry tradeshow events such as the American Heart Association and regional
primary care events. Participating in these events will be in addition to limited advertising in key medical publications and targeted social media campaigns to increase awareness of MyoVista and its benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also consider offering potential purchasers different financing options or models to assist them with certain costs related to the
MyoVista such as, <FONT STYLE="white-space:nowrap">up-front</FONT> costs related to purchasing the device or a licensing model charging a monthly fee, a is fairly common practice in healthcare. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Territories </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our initial sales focus will
primarily be within the U.S. We intend to market the MyoVista in the U.S. using a direct sales force following FDA clearance. Outside of the U.S., for markets such as Europe and Latin America, we will utilize medical device distributors that have
existing healthcare provider relationships and experience selling ECG devices, that will be supported by a small number of local field personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company previously achieved regulatory compliance in Europe under the EU Medical Devices Directive or MDD in February 2017. With EU
compliance, the Company is permitted to affix a certificate of conformity called a CE Mark denoting that the device is allowed to be marketed, This provided the Company with a limited number of distributor relationships in Europe including
Neovitalis Aps, whose territory covers Denmark, Sweden, Norway and Finland, and also a relationship with Heart Medical Europe BV, whose territory covers Belgium, Netherlands and Luxembourg. These prior relationships aided the Company in development
of the final version of the MyoVista device and its related proprietary software by eliciting feedback from KOLs in Europe. The MDD regulatory framework was established on June&nbsp;14, 1993 but has since been replaced by EU MDR which became
effective in May 2021. In order to sell medical devices in member countries of the European Economic Area, or EEA, our device must now comply with the requirements of the newer, updated regulatory framework or EU MDR. In October 2021, the Company
submitted the documentation required to establish compliance with EU MDR. The submission of the technical file is currently under review. If the submission is found to comply with the new requirements, a new certificate of conformity will be issued
to verify the Company&#146;s compliance with EU MDR. An updated CE mark certificate under EU MDR will entitle the Company to market the MyoVista in the European Economic Area. The Company intends to pursue limited efforts in Europe though these
distributor relationships as well as a limited number of additional distributor relationships outside the U.S. See &#147;&#151;FDA and other Government Regulation&#148; for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential Markets </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that there
is a large variety of potential markets for the MyoVista. Conventional ECGs are used throughout healthcare in almost every clinical setting including clinics, doctor&#146;s offices, urgent care centers, and hospitals. In many of those settings, the
additional information on cardiac dysfunction provided by the MyoVista in addition to the conventional ECG information it provides could be extremely valuable. MyoVista&#146;s range of applications and potential uses are vast, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Primary care</U>&#151;providing front-line cardiac testing/referral tool, heart disease screening.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Retail Healthcare</U>&#151;such as CVS, Walmart and Walgreens. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Emergency Departments</U>&#151;providing enhanced ECG testing for emergency room patients.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Cardiologists</U>&#151;providing prescreening cardiology patients </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Hospitals</U> &#151;providing <FONT STYLE="white-space:nowrap">in-patient</FONT> testing or testing prior to
discharge, particularly cardiac wards. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Surgery</U>&#151;providing <FONT STYLE="white-space:nowrap">pre-anesthesia</FONT> testing, pre/post
intervention </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Life Insurance testing</U>&#151;providing ECGs are sometimes required in connection with the issuance of life
insurance policies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Specialty Environments</U>&#151;such as cardiomyopathy, cardiac oncology, drug trials, heart failure, and
diabetes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Athlete testing</U>&#151;providing cardiac screening programs for athletes. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Early Target Markets </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, our
focus markets will be: (i)&nbsp;cardiology; (ii) primary care providers that serve upper to middle income regions including concierge medicine providers; (iii)&nbsp;retail clinics and cardiac screening providers; and (iv)&nbsp;insurers with
significant numbers of Medicare Advantage patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Cardiology.</U> According to the American College of Cardiology, there are
approximately 23,000 cardiologists in the U.S. We do not believe that cardiology will be the principal market for MyoVista as cardiologists diagnose specific heart disease conditions rather than screen for heart disease. Nonetheless, we intend to
have an early focus on leading cardiologists or key opinion leaders, known as KOLs. We have experience internationally with KOL engagement and believe that building advocacy through KOLs and other respected cardiologists will be important as we seek
to establish our new technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company intends to hire sales representatives that have experience presenting new medical devices to
cardiologists. The initial focus will be on cardiology centers of excellence and working to generate sales and daily use at these institutions. The field team will also act as a liaison with HeartSciences clinical staff as clinical study
opportunities present themselves. We believe that building clinical evidence, particularly for specific clinical indications for use, such as hypertensive patients, will be a key pillar not only in our discussions with payors, but also as a driver
for competitive differentiation and adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Primary Care and Concierge Medicine</U><I>. </I>According to the HHS, there are
approximately 209,000 primary care physicians in the U.S., not including pediatricians. The 2018 National Ambulatory Medical Care Survey showed that there were 860&nbsp;million visits to nonfederal office-based patient care physicians of which
approximately 50% were to primary care physicians. According to a 2021 report by Research and Markets, the U.S. concierge medicine market size is expected to reach $10.0 billion by 2028 and is expected to expand at a CAGR of 9.39% from 2021 to 2028.
In 2016, there were approximately 12,000 physicians that provide some level of concierge services with over half being either family medicine 32% or internal medicine 23%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Informal feedback to date from concierge physicians and primary care physicians that serve upper to middle income regions indicates that a
patient pay charge for utilizing the MyoVista would be generally accepted which creates revenue potential and value for the physician. This would be in addition to reimbursement for the conventional ECG test provided by the MyoVista. The Company
intends to initially hire sales representatives that will focus on these physicians in densely populated middle income to affluent regions of the U.S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, primary care and concierge medicine clinics that are not hospital based usually have flexible procurement processes and
physicians have greater autonomy related to purchasing decisions for lower cost capital equipment. Concierge medicine is increasing rapidly in the U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to take advantage of the market opportunity of selling to primary care physicians and concierge
physicians: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We intend to create specialized marketing, sales, education and training materials focused on the primary care
market. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The sales team will focus on demonstrating ease of use and clinical advantages as well as present the financial
advantages of using the MyoVista device. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will focus on practices in higher income areas initially. We believe that these practices tend to have more
financial flexibility to purchase new devices. There are approximately 209,000 primary care physicians excluding pediatricians as well as 24,000 cardiologists. Sales efforts on specialized clinical areas will increase over time as the salesforce
expands. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With initial reimbursement codes being the same as a conventional resting 12-lead ECG, a MyoVista test is
profitable in cardiology and hospital environments as well as primary care providers whose patient populations are not fundamentally reliant on Medicare. Moreover, the Company believes there is a significant opportunity in additional specialty areas
but the sales process will take longer since there would need to be a body of clinical evidence that the MyoVista is effective in these additional clinical use areas. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Competitive Advantages </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The MyoVista provides several
competitive advantages compared to traditional ECG devices: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Price comparability</U>. A major brand, full-feature, resting <FONT STYLE="white-space:nowrap">12-lead</FONT>
ECG typically costs between $5,000 to $10,000. We anticipate pricing our device competitively by setting the price for the MyoVista at the lower end of the range for a good-quality conventional ECG from a mainstream manufacturer<I>.</I> We believe
that competitive pricing will help us to increase adoption of the MyoVista. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Familiarity of use and protocol</U>. The conventional ECG is the most common cardiac test and is used in
almost all areas of healthcare and is often performed by a physician assistant or a nurse, rather than a physician. The MyoVista provides both conventional ECG information and proprietary cardiac dysfunction information in a single test, using
standard <FONT STYLE="white-space:nowrap">12-lead</FONT> ECG testing protocols with standard lead placement. This makes the MyoVista easy to use and, consequently, easy to train people to use. The complexities that come with training a person to use
new technology in medicine often prevents the adoption of new technologies and devices in medicine. We believe that by being easy to use with minimal training requirements, the MyoVista has a competitive advantage over other, more complicated
devices. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Positioned at the forefront of electrocardiography</U>. There have been very few significant changes in the
efficacy of electrocardiography for many decades. We believe that positioning MyoVista at the forefront of science will attract healthcare providers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Health system savings</U>. We believe that the MyoVista has the opportunity to generate significant cost
savings to healthcare systems by improving earlier diagnosis and reducing unnecessary referrals to cardiology that lead to unnecessary testing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Physician Profitability</U>. We believe that MyoVista will offer primary care physicians a significant advance
in their ability to assess patient heart health. Multiple primary care physicians have informally advised HeartSciences that they would expect to charge additional
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> patient fees of $25 to $100 for the additional cardiac dysfunction diagnostic element of the MyoVista testing until available reimbursement for this
portion of MyoVista testing is available. Even based on low usage and competitive pricing, the payback on the capital cost of the MyoVista (for example $5,000) would be realized quickly. We also expect lease or debt financing to be available
(through third parties) which would permit the doctor to avoid the need for an upfront capital cost to acquire the device. In high use environments such as a cardiac screening clinic, hospital or family practice office, we expect the
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
financial returns to be significant especially as available reimbursement increases. We intend to develop financial models demonstrating the potential profitability and establish reference sites
that are using the MyoVista. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Razor/Razorblade Business Model</U>. Sales of the MyoVista will be accompanied by our specialized electrodes,
which are recurring consumable supplies, generating revenue from every test. The MyoVista is extremely sensitive and requires the use of high-quality electrodes to ensure clinical efficacy. To aid in accomplishing clinical efficiency, we will sell
our proprietary electrodes incorporating a patented security system unique to us. These electrodes are a onetime use item thereby providing revenue for each test. We believe that the sale of our proprietary electrodes could also provide us with the
ability to maximize revenue and profitability through pricing structures focused on adoption strategies rather than price maximization. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Reimbursement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to penetrating
the health care settings described above, a key element of our strategy is to qualify for third-party payor reimbursement. This strategy has two stages. During the first stage, upon FDA approval, we intend to seek the support of the American College
of Cardiology, or ACC, to use existing Current Procedural Terminology, or CPT, codes for the standard ECG functionality of MyoVista. CPT codes are numbers assigned to each task or service provided by a healthcare provider including medical, surgical
and diagnostic services. Insurers use the numbers to determine the amount to pay a provider. Once approved by ACC, this will provide physicians with the ability to use existing <FONT STYLE="white-space:nowrap">12-lead</FONT> ECG reimbursement codes.
Reimbursement for existing ECG testing procedures with interpretation and report ranges from approximately $17 to $55 depending on the type of healthcare facility. These charges will go directly to the healthcare facility/physician. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The existing procedure codes are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CPT 93799: Unlisted cardiovascular procedure (not otherwise classified) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CPT 93000: Electrocardiogram, routine ECG with at least 12 leads; includes running test, interpretation and
report </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CPT 93005: Electrocardiogram, routine ECG with at least 12 leads; testing only, without interpretation and report
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CPT 93010: Electrocardiogram, routine ECG with at least 12 leads, interpretation and report only
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After this initial stage, our longer-term strategy is to obtain additional reimbursement for the MyoVista capabilities
related to detecting cardiac dysfunction. If we are successful, this would provide total potential reimbursement that is greater than reimbursement for conventional ECG devices, placing the MyoVista at a competitive advantage. Any additional CPTs or
modifiers that are issued and recognized for the MyoVista related to our longer-term reimbursement strategy will provide a revenue advantage as compared to reimbursement for conventional ECG devices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Category III code</U><I>.</I> New technologies must meet AMA&#146;s Level of Evidence and the Use Requirement, so a Category III code will
be issued as a precursor to a final Category I code. Category III codes are generally temporary codes requiring additional studies and individual payor efforts to obtain coverage from each payor. Individual payors do not initially provide
reimbursement for Category III codes so each payor will need clinical evidence that demonstrates the benefits of the MyoVista based cardiac dysfunction testing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Category I code</U><I>.</I> Category I codes are long term codes that are expected to be in use for many years. Generally, to obtain this
code, five peer-reviewed publications from at least two different patient populations are required. All third-party payors typically pay CAT I coded diagnostic testing procedures. Approval by the AMA CPT Editorial Panel of new or expanded CPT codes
for the MyoVista ultimately could provide a revenue advantage as compared to reimbursement for conventional ECG devices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>New Tech Ambulatory Payment Classification (or APC) code</U>. The new tech APC code is
utilized for new and significant technologies which warrant having a unique code under the Healthcare Common Procedure Coding System, or HCPCS. An HCPCS is a payment code issued by the Centers for Medicare and Medicaid Services, or CMS, for use in
ambulatory outpatient hospital environments and certain integrated practices. Once the device receives FDA clearance, the Company intends to quickly file an application for a cardiac dysfunction APC code for the MyoVista. If the application is
successful, it would provide enhanced revenue over existing conventional ECG devices in a hospital integrated practice such as a cardiology practice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The medical device industry
is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. There are many medical device companies, biotechnology companies, public and private universities and research organizations
actively engaged in the research and development of products that may be similar to the MyoVista. Competitors could include traditional ECG manufacturers such as GE, Philips, and Nihon Kohden Corporation that may seek to innovate due to competition
from HeartSciences, and new competitors that also see the opportunity to finally innovate in a market that has significant need for improved products and technology change. The current ECG device manufacturers with the greatest market share are GE,
Philips, and <FONT STYLE="white-space:nowrap">Hill-Rom</FONT> Holdings, Inc., or <FONT STYLE="white-space:nowrap">Hill-Rom.</FONT> The leading competitors in the ECG market have substantially greater name recognition and financial, technical,
manufacturing, marketing, research and development resources, and experience obtaining the FDA and other regulatory clearances of those devices and commercializing those devices around the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are additional competitors that are using AI to innovate in electrocardiography including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AliveCor Inc., a commercial stage developer of cardiac monitoring devices and applications for heart health
monitoring. AliveCor&#146;s ECG recorder has received FDA clearance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Heart Output Input, Inc., or Heartio, a development stage, digital diagnostic utilizing AI in a cloud-based
software tool used in conjunction with electrocardiograms to help emergency providers more effectively stratify patient risk and make admit/discharge decisions. Heartio currently does not have any FDA clearance or authorization.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Corvista Health Inc., a development stage ECG device company with a proprietary platform focused on diagnosing
heart failure, coronary artery disease, and pulmonary hypertension. Corvista currently does not have any FDA clearance or authorization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Anumana Inc., a development stage company funded by the MayoClinic focused on developing <FONT
STYLE="white-space:nowrap">AI-enabled</FONT> ECG algorithms for physician use, integrating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-care</FONT></FONT> applications into existing workflows. Anumana currently does not
have any FDA clearance or authorization. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Studies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have participated in and/or conducted multiple studies at various sites including at Mount Sinai Health System, West Virginia University,
University of California, Los Angeles, and The Baker Heart and Diabetes Institute in Australia. The purpose of conducting the studies was threefold: (i): to collect patient data using the MyoVista to build an effective algorithm to detect cardiac
dysfunction for the early detection of heart disease, (ii)&nbsp;to create <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> algorithms for determination by HeartSciences of the viability of an FDA
version of the algorithm, and (iii)&nbsp;to use the collected data to conduct research for potential development of additional future algorithms. The peer review article summaries highlighted below used the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> algorithms developed by the institutions from the MyoVista data collected. MyoVista devices were used in each study for the collection of patient ECG information. Data was extracted from
these ECG readings to develop separate <FONT STYLE="white-space:nowrap">AI-based</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> algorithms in each individual study. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following are summaries of the peer- reviewed articles: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Journal of the American College of Cardiology</I> (JACC) April 2018, Volume 71 Number 15 (2018) Partho P. Sengupta, MD DM,
Hemant Kulkarni, MD, Jagat Narula, MD PHD, et al. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The study was conducted at Mount Sinai NY. The article is titled, &#147;Prediction of
Abnormal Myocardial Relaxation from Signal Processed Surface ECG&#148; and presents the results from the investigator-initiated clinical study that focused on evaluating the feasibility of MyoVista as a diagnostic tool for predicting myocardial
relaxation abnormalities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Results from the feasibility study demonstrated that the MyoVista patented technology can detect myocardial
relaxation abnormalities associated with Left Ventricular Diastolic Dysfunction, or LVDD. The study results demonstrated 80% sensitivity and 84% specificity with an area under the curve of 91% for the prediction of low (e&#146;), an
echocardiographic parameter widely used in determination of LVDD. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Comment from the associated editorial Jeroen J. Bax, MD, PHD, former
President of the European Society of Cardiology, et al.: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><I>&#147;Sengupta et al. have successfully applied advanced signal processing
and machine learning to the diagnosis of early diastolic dysfunction from a standard, <FONT STYLE="white-space:nowrap">12-lead</FONT> surface ECG. The amount of information gleaned from an ECG in this way far surpasses any visual interpretation and
expands the diagnostic potential of the <FONT STYLE="white-space:nowrap">12-lead</FONT> ECG.&#148; </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Journal of the
American College of Cardiology</I> (JACC) August 2020, Volume 76 Number 8 (2020) Nobuyuki Kagiyama, MD, PHD, Marco Piccirilli, PHD, Naveena Yanamala, PHD et al. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The participating centers were The Icahn School of Medicine, Mount Sinai Hospital, New York, The West Virginia University Heart and Vascular
Institute, The Windsor Cardiac Centre, Windsor, Ontario, Canada and the David Geffen School of Medicine at UCLA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The article titled
&#147;Machine Learning Assessment of Left Ventricular Diastolic Function Based on Electrocardiographic Features&#148; presents the results from evaluating the feasibility of MyoVista <I>wav</I>ECG<SUP STYLE="font-size:85%; vertical-align:top">
</SUP>technology to provide actual quantitative estimates related to myocardial relaxation that can be used to identify LVDD. Diastolic dysfunction is recognized as playing a major role in the pathophysiology of heart failure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The study results demonstrated that the estimated <FONT STYLE="white-space:nowrap">e-prime</FONT> values provided by the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> algorithm discriminated the guideline-recommended thresholds for abnormal myocardial relaxation, LVDD and systolic dysfunction (LV ejection fraction) with an
AUC of 0.84, 0.80, and 0.81 respectively in the external test set. Moreover, the estimated <FONT STYLE="white-space:nowrap">e-prime</FONT> values allowed prediction of LV diastolic dysfunction based on multiple age and
<FONT STYLE="white-space:nowrap">sex-adjusted</FONT> reference limits with an AUC of 0.94 in the external test set. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Comment from the
associated editorial by Khurram Nasir, MD, MPH, MSC Department of Cardiology, Houston Methodist DeBakey Heart&nbsp;&amp; Vascular Center,Houston, Texas, et al.: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><I>&#147;These represent some of the most significant advances in electrocardiography since its inception, which has historically had a
limited, if any, role in the evaluation of cardiac dysfunction. In the past, our cardiovascular community was resigned to the fact that surface ECGs are poor indicators for cardiac dysfunction&#148; </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>JACC Cardiovascular Imaging</I> Oct 2021, Volume 14 Number 10 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Elizabeth L. Potter, MBBS, Thomas H. Marwick, MBBS, PHD, MPH et al. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The participating centers were Baker Heart and Diabetes Institute, Melbourne, Australia, Baker Heart and Diabetes Institute, Monash University,
Melbourne, Australia, Melbourne University, Melbourne, Australian National University, Canberra, and the West Virginia University Heart and Vascular Institute. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The article titled &#147;Machine Learning of ECG Waveforms to Improve Selection for Testing
for Asymptomatic Left Ventricular Dysfunction Prompt&#148; focused on developing a screening algorithm using the MyoVista for detection of Left Ventricular Dysfunction, or LVD. References to ewECG mean energy waveform ECG and are an alternative name
for the MyoVista device and the included wavelet transform signal processing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The study results in an external test set demonstrated 85%
sensitivity and 72% specificity AUC 0.83. Conventional methods for Left Ventricular Dysfunction, or LVD, screening (ARIC score, BNP testing, and standard ECG analysis) had inferior screening capabilities. Integration of ewECG (a MyoVista based
algorithm with the level of performance in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept)</FONT></FONT> in screening of people at risk of heart failure would reduce need for echocardiography by 45% while
missing 12% of LVD cases. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Study Conclusion: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><I>&#147;Machine-learning applied to ewECG is a sensitive screening test for LVD and its integration into screening of patients at risk of HF
would reduce the number of echocardiograms by almost one half.&#148; </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The study below demonstrated, through a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> algorithm developed using the data gathered from studies in which MyoVista ECGs were collected from study subjects, the opportunity to create future
algorithms for detection of additional heart disease conditions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>European Heart Journal</I>&#151;<I>Digital Health</I>
November 2020, Volume 1 Issue 1 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Peter D. Farjo MD, Naveena Yanamala PHD et al. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The participating centers were West Virginia University Heart and Vascular Institute, Carnegie Mellon University, Juntendo University, Japan
and Harbor-UCLA Medical Center. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The study article titled &#147;Prediction of coronary artery calcium scoring from surface
electrocardiogram in atherosclerotic cardiovascular disease: a pilot study&#148; aimed to determine whether machine learning (ML)&nbsp;approaches can aid cardiovascular risk stratification by predicting guideline recommended Coronary Artery Calcium,
or CAC, score categories from clinical features and surface electrocardiograms using the MyoVista. CAC scoring is an established tool for cardiovascular risk stratification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The study results included two machine learning models that were developed for prediction of CAC scores equal to 0 and CAC &gt;_400. The
performance was evaluated using an independent data set, the CAC= 0 algorithm performance provided sensitivity 92%, specificity 70%, AUC 84%, and the CAC &gt;_400 algorithm provided sensitivity 91%, specificity 75% and AUC 87% . The CAC &gt;_400
model was further tested to risk stratify a cohort of 87 subjects referred for invasive coronary angiography. Using an intermediate or higher pretest probability (&gt;_15%) to predict CAC &gt;_400, the model predicted the presence of significant
coronary artery stenosis, the need for revascularization, notably bypass surgery, and major adverse cardiovascular events during a median <FONT STYLE="white-space:nowrap">follow-up</FONT> period of two years. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Study Conclusion: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><I>&#147;ML
techniques can extract information from electrocardiographic data and clinical variables to predict CAC score categories and similarly risk-stratify patients with suspected coronary artery disease.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FDA and Other Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proposed products are subject to regulation by the FDA and various other federal and state agencies, as well as by foreign governmental
agencies. These agencies enforce laws and regulations that govern the development, testing, manufacturing, labeling, advertising, marketing and distribution, and market surveillance of our medical device products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to those indicated below, the only other regulations we encounter are
regulations that are common to all businesses, such as employment legislation, implied warranty laws, and environmental, health and safety standards, to the extent applicable. We will also encounter in the future industry-specific government
regulations that would govern our device, if and when developed for commercial use. It may become the case that other regulatory approvals will be required for the design and manufacture of our device. In previous communications with the FDA, the
Company determined that the a submission would need to use the De Novo classification process for the MyoVista device. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>FDA Requirements and Other
Regulatory Approval Requirements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our device and our operations are subject to regulation by numerous worldwide regulatory bodies
including the FDA and comparable international regulatory agencies. In previous communications with the FDA, the Company determined that the submission would need to use the De Novo classification process for the MyoVista device. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our device is subject to regulation as a medical device under the Federal Food, Drug, and Cosmetic Act, or FDCA, as implemented and enforced
by the FDA. The FDA regulates the development, design, <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage, installation, servicing, recordkeeping, premarket
clearance or approval, import, export, adverse event reporting, advertising, promotion, marketing and distribution of medical devices to ensure that medical devices distributed domestically are safe and effective for their intended uses and
otherwise meet the requirements of the FDCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to U.S. regulations, we are subject to a variety of regulations in the European
Economic Area, or the EEA, governing clinical trials and the commercial sales and distribution of our device. Whether or not we have or are required to obtain FDA clearance or approval for a product, we will be required to obtain authorization
before commencing clinical trials and to obtain marketing authorization or approval of our device under the comparable regulatory authorities of countries outside of the United States before we can commence clinical trials or commercialize our
device in those countries. The approval process varies from country to country and the time may be longer or shorter than that required for FDA clearance or approval. Medical devices are generally subject to varying levels of regulatory control
based on risk level of the device. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A clearance or authorization letter from the FDA authorizes commercial marketing of the device for one
or more specific indications of use. After clearance or authorization, the Company will be required to comply with a number of post-clearance requirements, including, but not limited to, Medical Device Reporting and complaint handling, and, if
applicable, reporting of corrective actions. Also, quality control and manufacturing procedures must continue to conform to the QSR. The FDA periodically inspects manufacturing facilities to assess compliance with QSRs, which impose extensive
procedural, substantive, and record keeping requirements on medical device manufacturers. In addition, changes to the manufacturing process are strictly regulated, and, depending on the change, validation activities may need to be performed.
Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with the QSR and other types of regulatory controls. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and the Federal Trade Commission, or FTC, will also regulate the advertising claims of the Company&#146;s products to ensure that the
claims it makes are consistent with its regulatory clearances, that there is scientific data to substantiate the claims and that product advertising is neither false nor misleading. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>FDA Clearance Process and FDA Validation Clinical Study </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless an exemption applies, each medical device commercially distributed in the United States requires FDA clearance of a 510(k) premarket
notification, granting of a de novo request, or approval of an application for premarket approval, or PMA. Under the FDCA, medical devices are classified into one of three classes&#151;Class&nbsp;I, Class&nbsp;II or Class&nbsp;III&#151;depending on
the degree of risk associated with each medical device and the extent of regulatory controls needed to ensure its safety and effectiveness. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&nbsp;I includes devices with the lowest risk to the patient and are those for which
safety and effectiveness can be assured by adherence to the FDA&#146;s General Controls for medical devices, which include compliance with the applicable portions of the Quality System Regulation, or QSR, facility registration and product listing,
reporting of adverse medical events, and truthful and <FONT STYLE="white-space:nowrap">non-misleading</FONT> labeling, advertising and promotional materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&nbsp;II devices are subject to the FDA&#146;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety
and effectiveness of the device. These special controls can include performance standards, post-market surveillance, patient registries and FDA guidance documents. While most Class&nbsp;I devices are exempt from the 510(k) premarket notification
requirement, manufacturers of most Class&nbsp;II devices are required to submit to the FDA a premarket notification under Section&nbsp;510(k) of the FDCA requesting permission to commercially distribute the device. The FDA&#146;s permission to
commercially distribute a device subject to class II controls is generally described as 510(k) clearance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Devices deemed by the FDA to
pose the greatest risks, such as life sustaining, life supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed
in Class&nbsp;III, requiring approval of a PMA. Some <FONT STYLE="white-space:nowrap">pre-amendment</FONT> devices are unclassified but are subject to FDA&#146;s premarket notification and clearance process in order to be commercially distributed.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>510(k) Clearance Marketing Pathway </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain 510(k) clearance, we must submit to the FDA a premarket notification submission demonstrating that the proposed device is
&#147;substantially equivalent&#148; to a predicate device already on the market. A predicate device is a legally marketed device that is not subject to PMA, i.e., a device that was legally marketed prior to May&nbsp;28, 1976 <FONT
STYLE="white-space:nowrap">(pre-amendments</FONT> device) and for which a PMA is not required, a device that has been reclassified from Class&nbsp;III to Class&nbsp;II or I, or a device that was found substantially equivalent through the 510(k)
process. The FDA&#146;s 510(k) clearance process usually takes from three to twelve months, but often takes longer. The FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence. In
addition, the FDA collects user fees for certain medical device submissions and annual fees for medical device establishments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA
agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. If the FDA determines that the device is &#147;not substantially equivalent&#148; to
a previously cleared device, the device is automatically designated as a Class&nbsp;III device. The device sponsor must then fulfill more rigorous PMA requirements or can request a risk-based classification determination for the device in accordance
with the &#147;De Novo&#148; process, which is a route to market novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would
constitute a major change in its intended use, will require a new 510(k) or possibly a PMA. The FDA requires each manufacturer to make this determination initially, but the FDA can review any such decision and can disagree with a manufacturer&#146;s
determination. If the FDA disagrees with our determination not to seek a new 510(k) clearance, the FDA may retroactively require us to seek 510(k) clearance or possibly a PMA. The FDA could also require us to cease marketing and distribution and/or
recall the modified device until 510(k) clearance or a PMA is obtained. Also, in these circumstances, we may be subject to significant regulatory fines and penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PMA Approval Pathway </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&nbsp;III
devices require approval of a PMA before they can be marketed, although some <FONT STYLE="white-space:nowrap">pre-amendment</FONT> Class&nbsp;III devices for which the FDA has not yet required a PMA are cleared through the 510(k) process. The
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
PMA process is more demanding than the 510(k) premarket notification process. In a PMA application, the manufacturer must demonstrate that the device is safe and effective, and the PMA
application must be supported by extensive data, including data from preclinical studies and human clinical trials. The PMA application must also contain a full description of the device and its components, a full description of the methods,
facilities, and controls used for manufacturing, and proposed labeling. Following receipt of a PMA application, the FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the application
for review, it has 180 days under the FFDCA to complete its review of a PMA application, although in practice, the FDA&#146;s review often takes significantly longer, and can take up to several years. An advisory panel of experts from outside the
FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel&#146;s recommendation. In addition, the FDA will generally conduct a <FONT
STYLE="white-space:nowrap">pre-approval</FONT> inspection of the applicant or its third-party manufacturers&#146; or suppliers&#146; manufacturing facility or facilities to ensure compliance with the QSR. PMA devices are also subject to the payment
of user fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA
application constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). A PMA may include post-approval conditions intended to ensure the safety and effectiveness of the
device, including, among other things, restrictions on labeling, promotion, sale and distribution, and collection of long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> data from patients in the clinical study that supported the PMA or
requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form of post-market surveillance when deemed necessary to protect the public health or to provide additional safety and efficacy data for
the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number of years and to make periodic reports to the FDA on the clinical status of those
patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain changes to an approved device, such as changes in manufacturing facilities, methods, or quality control procedures, or changes in the
design performance specifications, which affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is
limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel. Certain other changes to an approved device require the submission
of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that
were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness. None of our currently developed products require a PMA to be commercialized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>De Novo Classification </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medical device
types that the FDA has not previously classified as Class&nbsp;I, II or III are automatically classified into Class&nbsp;III regardless of the level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a new
route to market for low to moderate risk medical devices that are automatically placed into Class&nbsp;III due to the absence of a predicate device, called the &#147;Request for Evaluation of Automatic Class&nbsp;III Designation,&#148; or the De
Novo classification procedure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This procedure allows a manufacturer whose novel device is automatically classified into Class&nbsp;III to
request down-classification of its medical device into Class&nbsp;I or Class&nbsp;II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. Prior to the enactment of the
Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA, a medical device could only be eligible for De Novo classification if the manufacturer first submitted a 510(k) <FONT STYLE="white-space:nowrap">pre-market</FONT>
notification and received a determination from the FDA that the device was not substantially equivalent. FDASIA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
streamlined the De Novo classification pathway by permitting manufacturers to request De Novo classification directly without first submitting a 510(k)
<FONT STYLE="white-space:nowrap">pre-market</FONT> notification to the FDA and receiving a not substantially equivalent determination. Under FDASIA, the FDA is required to classify the device within 120 days following receipt of the De Novo
application. If the manufacturer seeks reclassification into Class&nbsp;II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical
device. In addition, the FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk or that general controls
would be inadequate to control the risks and special controls cannot be developed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Devices such as ECG devices are generally considered
to have moderate risk and are generally classified as Class&nbsp;II devices. Applicants must submit a notification to the FDA demonstrating that its proposed device is either substantially equivalent to a predicate (existing) device that is a
Class&nbsp;II, or for devices with no existing predicate they will seek to be designated with a De Novo classification. Through previous interactions and correspondence with the FDA, the Company determined there was not an existing predicate to the
MyoVista AI algorithm and therefore was not eligible to submit an application via the more common 510(k) clearance process. The Company also previously received formal notification from the FDA that the regulatory pathway for MyoVista was determined
to be with a De Novo classification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After initial authorization, any modification that could significantly affect its safety or
effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, another De Novo classification request, or PMA approval. The FDA requires each
manufacturer to determine whether the proposed change requires submission of a 510(k) or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#146;s determination. If the FDA disagrees with a
manufacturer&#146;s determination, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified device until 510(k) marketing clearance or PMA approval is obtained. Also, in these circumstances, the manufacturer
may be subject to significant regulatory fines or penalties. We have previously submitted and intend to seek authorization to market the device through submission of a new De Novo request for the MyoVista device. Delays in receipt or failure to
receive the necessary clearances, or the failure to comply with existing or future regulatory requirements, could reduce the Company&#146;s business prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trials </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials are
almost always required to support a De Novo request and are sometimes required to support a 510(k) submission. All clinical investigations of investigational devices to determine safety and effectiveness must be conducted in accordance with the
FDA&#146;s investigational device exemption, or IDE, regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of
study sponsors and study investigators. If the device presents a &#147;significant risk&#148; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to
commencing human clinical trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important
in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and
laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30&nbsp;days after receipt by the FDA unless the FDA notifies the
Company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the study must be approved by, and conducted under the oversight of, an Institutional Review Board, or IRB, for each clinical
site. The IRB is responsible for the initial and continuing review of the IDE, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs, human clinical trials may begin at a specific number of
investigational sites with a specific number of patients, as approved by the FDA. If the device presents a <FONT STYLE="white-space:nowrap">non-significant</FONT> risk to the patient, a sponsor may begin the clinical trial after obtaining approval
for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and
record-keeping requirements. Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials
support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator may make a change to the investigational plan that
may affect its scientific soundness, study plan or the rights, safety or welfare of human subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During a study, the sponsor is
required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and
prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the clinical study are also subject to FDA regulations and must obtain patient informed consent, rigorously
follow the investigational plan and study protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or
terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-market Regulation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a device is
cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment registration and device listing with the FDA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">QSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design,
testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">labeling and marketing regulations, which require that promotion is truthful, not misleading, fairly balanced and
provide adequate directions for use and that all claims are substantiated, and also prohibit the promotion of products for unapproved or <FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses and impose other restrictions on labeling;
FDA guidance on <FONT STYLE="white-space:nowrap">off-label</FONT> dissemination of information and responding to unsolicited requests for information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clearance or approval of product modifications to 510(k)-cleared devices, or those
<FONT STYLE="white-space:nowrap">re-classified</FONT> to 510(k) cleared devices, that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices, or approval of a
supplement for certain modifications to PMA devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets
may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field
corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with the new federal law and regulations requiring Unique Device Identifiers (UDI) on devices and also
requiring the submission of certain information about each device to the FDA&#146;s Global Unique Device Identification Database (GUDID); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA&#146;s recall authority, whereby the agency can order device manufacturers to recall from the market a
product that is in violation of governing laws and regulations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to
protect the public health or to provide additional safety and effectiveness data for the device. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacturing
processes for medical devices are required to comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling,
packaging, distribution, installation and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, device history file, and complaint files. These requirements impose
certain procedural and documentation requirements upon us and our third-party manufacturers related to the methods used in and the facilities and controls used for designing, manufacturing, packaging, labeling, storing, medical devices. As a
manufacturer, we will be subject to periodic scheduled or unscheduled inspections by the FDA. Following these inspections, the FDA may assert noncompliance with QSR requirements on a Form 483, which is a report of observations from an inspection, or
by way of &#147;untitled letters&#148; or &#147;warning letters&#148; that could cause us or any third-party manufacturers to modify certain activities. A Form 483 notice, if issued at the conclusion of an FDA inspection, can list conditions the FDA
investigators believe may have violated QSR or other FDA requirements. We cannot be certain that we or our present or any future third-party manufacturers or suppliers will be able to comply with QSR or other FDA regulatory requirements to the
agency&#146;s satisfaction. Failure to comply with these obligations may lead to possible legal or regulatory enforcement action by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory
requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recalls, withdrawals, or administrative detention or seizure of our device; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating restrictions or partial suspension or total shutdown of production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawing 510(k) clearances or PMA approvals that have already been granted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to grant export or import approvals for our device; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">or criminal prosecution. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advertising and Promotion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and
other regulatory agencies closely regulate the post-approval marketing and promotion of medical devices, including standards and regulations for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT>
advertising, communications about unapproved uses, industry- sponsored scientific and educational activities and promotional activities involving the internet. Devices may be marketed only for the approved or cleared indications and in accordance
with the provisions of the approved or cleared label. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign Regulation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we plan to market our device in the EU and other foreign markets, in addition to regulations in the United States, we will be subject to a
variety of foreign regulations governing clinical trials and commercial sales and distribution of our device in foreign countries. Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory
authorities of foreign countries before we can </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commence clinical trials or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA
approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement also vary greatly from country to country and such regulatory requirements have been changing and increasing in some countries. We may
be unable to maintain regulatory qualifications, clearances, approvals or CE Certificates of Conformity in these countries or to obtain clearances or approvals in other countries. We may incur significant costs in attempting to obtain, renew, or
modify foreign regulatory clearances or approvals, qualifications or CE Certificates of Conformity. If we experience difficulties in receiving, maintaining, renewing or modifying necessary qualifications, clearances, approvals or CE Certificates of
Conformity to market our products outside the United States, or if we fail to receive, renew, modify or maintain those qualifications, clearances, approvals or CE Certificates of Conformity, we may be unable to market our products or enhancements in
certain international markets effectively, or at all. We previously received CE clearance for marketing the MyoVista in Europe and will continue efforts to maintain regulatory approval in Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2017, a new regulation on medical devices was adopted to establish a modernized and more robust European Union legislative
framework, with the aim of ensuring better protection of public health and patient safety: Regulation (EU) 2017/745 of the European Parliament and of the Council of 5&nbsp;April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC)
No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC, which became applicable from May&nbsp;26, 2021, or the EU MDR. The EU MDR repeals and replaces the EU Medical Devices Directive and unlike
directives, which must be given effect through transposition into the national domestic laws of the Relevant States, regulations are directly applicable (i.e., without the need for transposition into national laws implementing them) in all Relevant
States. The EU MDR is also applicable in the EEA. Regulations (as EU law instruments) must be applied in their entirety across the EU so that legal acts are automatically and uniformly applied to all EU countries as soon as they enter into force to
minimize variations that may arise in transposition of EU law into national law. These modifications may have an effect on the way we design and manufacture products and conduct our business in the EU and EEA. For example, as a result of the
transition towards the new regime, Notified Bodies have lengthened their review times, and product introductions or modifications could be delayed or canceled or otherwise rejected, which could adversely affect our ability to grow our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has previously achieved a CE Mark under the EU Medical Devices Directive or MDD in February 2017. The Medical Device Directive was
established on June&nbsp;14, 1993 but EU Medical Devices Directive or MDD regulatory framework has since been replaced by EU MDR. In order to sell in member countries of the European Economic Area, or EEA, our device must now comply with the
essential requirements of the newer, updated regulatory framework or EU MDR. In October 2021, the Company submitted the documentation required to establish compliance with EU MDR. The submission of the technical file is currently under review and
our CE Mark issued under MDD lapsed in February 2022. If the technical file submission is found to comply with the new requirements, a certificate of conformity will be issued to verify the Company&#146;s compliance with EU MDR. An updated CE mark
certificate under EU MDR will entitle the Company to market the MyoVista in the European Economic Area as well as other countries for which CE Mark represents an appropriate regulatory standard. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current FDA Validation Study </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
previously submitted the design of the <FONT STYLE="white-space:nowrap">575-patient</FONT> validation study to the FDA for review prior to initiating the study and the FDA agreed that the study design should be acceptable and would be expected to
provide statistical information on which the FDA can effectively evaluate the performance results of the MyoVista. HeartSciences is in the process of conducting the new validation study that is expected to be used as part of a FDA De Novo
submission. The study is currently taking place at the following institutions: Rutgers University (New Jersey), Beth Israel Hospital (Massachusetts), Scripps Health (California), Einstein Health (Pennsylvania), Montefiore Medical Center (New York)
and UT Southwestern (Texas). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A minimum of 575 patients are expected to be recruited. The patients undergo an
echocardiogram and a MyoVista test as part of the study. Once all of the patient data is collected and the data is checked for accuracy then the MyoVista diastolic relaxation abnormalities algorithm will be checked against the echocardiogram results
of each patient for determination of normal or abnormal LV cardiac relaxation abnormalities as determined by the ASE guidelines. These results will then be summarized into various statistical performance measures such as overall sensitivity,
specificity, and various subgroup analyses statistics. HeartSciences is currently conducting the study and is expecting to submit the algorithm performance results to the FDA as part of a new De Novo request which is expected to take place during
calendar 2022, which the FDA will then review. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our technology is protected by a patent portfolio as well as trade secrets, which together comprise an important part of technology protection
especially when developing proprietary algorithms. We believe that the combination of patents and trade secrets create valuable competitive barriers for HeartSciences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States Patent and Trademark Office, or the USPTO, has issued five utility patents and one design patent to us and we have two
utility patent applications under the USPTO&#146;s review. We also have seven utility patents and fourteen design registrations granted by international jurisdictions such as China, Japan, the European Union, France, Germany and Australia as well as
several pending patent applications in several international jurisdictions including Brazil, Canada, India, Israel, Mexico and the United Emirates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following chart includes a list of the five utility patents that have been granted to us by the USPTO: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="41%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Patent No.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Patent Title</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Description of General Subject Matter</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">US 8219186</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">System and method for scanning the heart</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Medical apparatus for scanning the heart to locate and detect heart malfunctions, vascular and nonvascular plaque and ischemia.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">US 9700226</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Quantitative Heart Testing</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Heart condition and function can be quantified using repolarization measures and/or repolarization indices derived from a time-frequency transform of an electrocardiogram</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">US 10561327</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">US 10170846</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Electrode and Cable Connectors in Electrocardiography</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Patient cable connecting one or more electrodes to a processing device for processing ECG signals may include one or more electrode connectors mechanically keyed to respective electrodes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">US 10856756</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Time-Frequency Analysis of Electrocardiograms</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Electrocardiograms can be analyzed in the time-frequency domain, following conversion into time-frequency maps, to determine characteristics or features of various waveforms, such as waveform morphology and/or the amplitude(s) and
location(s) (in time and/or frequency) of one or more extrema of the waveform</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following chart includes a list of the trademarks that we have registered with the USPTO: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Application No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Trademark</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Type of Trademark</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">87/073,995</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">HEART TEST LABORATORIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Design</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">87/073,975</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">MYOVISTA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Design</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">87/460,853</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">HEARTSCIENCES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Word</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">87/460,859</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Heart Logo</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Design</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">87/888,945</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">wavECG</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Word</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2013 Technology Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2014, the Company entered into a technology agreement, which we refer to as the 2013 Technology Agreement, with the inventor of certain
specified MyoVista technology and proprietary and intellectual property rights thereto (including patents, copyright, trademarks, trade secrets and <FONT STYLE="white-space:nowrap">know-how).</FONT> In the 2013 Technology Agreement, the inventor
conveyed ownership of all his rights in the MyoVista to us. In exchange, we entered into a security agreement with the inventor that requires us to pay the inventor royalties on any sales of the MyoVista. Royalty payments are $500 per device for the
first 2,400 devices sold and then $200 per device thereafter until the aggregate amount of royalties paid to the inventor equals $3.5&nbsp;million which, in any event, is the maximum amount we are required to pay in royalties under the 2013
Technology Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Glasgow Licensing Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2015, we entered into an licensing agreement, which we refer to as the Glasgow Licensing Agreement, with The University Court of
the University of Glasgow, wherein we obtained a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide perpetual license, renewing every five years, to software modules for an Android platform for analysis of resting 12-lead
electrocardiograms and all intellectual property rights (including patents, copyright, trademarks, trade secrets and <FONT STYLE="white-space:nowrap">know-how)</FONT> relating to the software modules, which are collectively referred to in only this
section as the Glasgow Technology, to be used in the MyoVista. The Glasgow Licensing Agreement also granted the Company the right to <FONT STYLE="white-space:nowrap">sub-license</FONT> all of the Company&#146;s rights under the Glasgow Licensing
Agreement to any third party to, among other things, manufacture, assemble, market, distribute and sell the MyoVista product containing the Glasgow Technology. Under the Glasgow Licensing Agreement, we are obliged to pay, per <FONT
STYLE="white-space:nowrap">12-month</FONT> period, the greater of (i) $40,000 or (ii)&nbsp;the aggregate amount of royalties owed per MyoVista sold, which is $50 per unit for the first 2,000 sold, $40 per unit for the next 3,000 sold and $35 per
unit thereafter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preparations for Manufacturing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At this time, we have fully functional hardware versions of the MyoVista, which have also been used in most of our medical clinical studies. We
have a scalable manufacturing strategy and have engaged Benchmark Electronics, a firm with deep experience in manufacturing medical devices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Benchmark Electronics is an NYSE listed <FONT STYLE="white-space:nowrap">US-based</FONT> medical device manufacturing organization that is FDA
Registered and ISO 13485 Certified and has over 30 years of product manufacturing experience. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s R&amp;D staff designs the hardware, software and <FONT STYLE="white-space:nowrap">AI-based</FONT> algorithms. Hardware
development assistance is provided by outside consulting firms. The Company internally develops the signal processing software elements along with outside assistance. The user interface elements of the software are designed by the Company along with
the assistance of outside consultants. The data science work necessary to build the <FONT STYLE="white-space:nowrap">AI-based</FONT> algorithms is performed both internally and externally using outside consultants. Incorporation of all software
elements into the MyoVista hardware is performed internally. We currently employ five full-time R&amp;D staff. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our research demonstrates the feasibility of developing further algorithms for a
range of additional or alternative clinical indications. Studies involving use of the MyoVista have already been published as an example of alternative clinical indications. We believe that, in the future, the ECG will have significantly greater
clinical value and will facilitate far more effective heart disease screening and referral. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Future Products </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future plans include the development of additional algorithms for different clinical indications, additional hardware platforms and
cloud-based services that allow other ECG devices to send standard ECG recordings and have them evaluated using our algorithms. Additional development opportunities could include development of a version of the algorithm to run on smartphones or
tablets or a lower cost version of the MyoVista. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has already cooperated with cardiology researchers to assist them in the
development of three <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> algorithms in key specific areas of heart disease beyond cardiac dysfunction. For example, a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> algorithm was developed to detect abnormally high coronary artery calcium scores; the results were published in the European Heart Journal in November 2020. Two additional <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> algorithms were developed by researchers and results presented as abstracts. A
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> algorithm was developed to predict which heart disease patients were at a higher risk for having a major adverse cardiac event, or MACE, within three
years, results were presented at the annual ACC conference in April 2021. In addition, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> algorithm has also been developed to detect patients that have
valvular heart disease; results will be presented at the ACC conference in March 2022. Some additional opportunities for new algorithms include reduced ejection fraction and CAD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Property and Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
leases a 4,634 square foot suite located at 550 Reserve Street, Suite 360, Southlake, Texas 76092, pursuant to an Office Lease, dated May 2, 2017, by and between the Company and GPI-MT, LP. The lease is a 64 month lease and expires in September
2022. We consider our current office space sufficient to meet our anticipated needs for the foreseeable future and believe it is suitable for the conduct of our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees and Independent Contractors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2022, we had 12 employees (including our Chief Executive Officer), all of which are full-time employees, and 6 independent contractors. All of our
employment and consulting agreements include employees&#146; and consultants&#146; undertakings with respect to <FONT STYLE="white-space:nowrap">non-competition</FONT> and assignment to us of intellectual property rights developed in the course of
employment and confidentiality. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not
currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement
costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
business and affairs are managed under the direction of our Board of Directors, which currently consists of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] members. The number of directors is determined by our Board
of Directors, subject to the terms of our amended and restated certificate of incorporation and amended and restated bylaws. Upon the completion of this offering, our Board of Directors will consist of five members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors will be divided into three classes as nearly equal in size as is practicable. The composition of the Board of Directors
immediately following the offering will be as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;I, which will initially consist of Brian Szymczak and Bruce Bent, whose terms will expire at our
annual meeting of shareholders to be held in 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;II, which will initially consist of Mark Hilz and Patrick Kanouff, whose terms will expire at our
annual meeting of shareholders to be held in 2023; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;III, which will initially consist of Andrew Simpson, whose term will expire at our annual meeting of
shareholders to be held in 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the expiration of the initial term of office for each class of directors, each
director in such class shall be elected for a term of three years and serve until a successor is duly elected and qualified or until his or her earlier death, resignation or removal. Vacancies occurring on the Board of Directors, whether due to
death, resignation, removal, retirement, disqualification or for any other reason, and newly created directorships resulting from an increase in the authorized number of directors, may be filled by a majority of the remaining members of the Board of
Directors. Directors may be removed, but only for cause, with the affirmative vote of the holders of a majority of the voting power of our Common Stock and Preferred Stock voting together as a single class. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the
completion of this offering, our Common Stock will be listed on The Nasdaq Capital Market. Under Nasdaq rules, independent directors must comprise a majority of a listed company&#146;s Board of Directors within a specified period after completion of
this offering. In addition, Nasdaq rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and governance committees must be independent. Under Nasdaq rules, a director will only
qualify as an &#147;independent director&#148; if, in the opinion of that Company&#146;s Board of Directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities
of a director. Ownership of a significant amount of our stock, by itself, does not constitute a material relationship. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Audit committee
members of a listed company must also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. In order to be considered independent for purposes of Rule
<FONT STYLE="white-space:nowrap">10A-3,</FONT> a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the Board of Directors, or any other board committee: (i)&nbsp;accept,
directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries; or (ii)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors undertook a review of its composition, the composition of its committees and the independence of each director. Based
upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our Board of Directors has determined that that Bruce Bent, Patrick Kanouff and Brian
Szymczak, representing a majority of our directors, do not have any relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is
&#147;independent&#148; as that term is defined under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Nasdaq rules and Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. In making these determinations, our Board of Directors considered the relationships that each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director has with our Company and all other facts and circumstances our Board of Directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by
each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Background and Experience of Directors and Executive Officers </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When considering whether directors and nominees have the experience, qualifications, attributes or skills, taken as a whole, to enable our
Board of Directors to satisfy its oversight responsibilities effectively in light of our business and structure, the Board of Directors focused primarily on each person&#146;s background and experience as reflected in the information discussed in
each of the directors&#146; individual biographies set forth below. We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding our executive officers and directors as of the date of this prospectus: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Board of Directors and Executive Officers </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Simpson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chairman of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Hilz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer, Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Barber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Interim Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bruce Bent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Kanouff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Szymczak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Andrew Simpson&#151;</B><I>Chairman of the Board of Directors</I><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since July 2012, Andrew Simpson, 53, has served as a director of the Company and, since June 2013, as the Chairman of the Board of Directors.
Mr.&nbsp;Simpson has over 30 years&#146; experience across a wide variety of business sectors and sizes. He was Group CEO of The Peel Group from 2006 to 2010. The Peel Group is a large private company in the UK which, at the time, had approximately
$8&nbsp;billion of business assets across the real estate, ports, airports, energy, media, telecoms and environmental sectors. He was a main board director of Speedy Hire plc from 2003 to 2006 (during which time it became a FTSE 250 company) and
during his tenure was Managing Director of its Equipment Rental division which had revenues of approximately $200&nbsp;million and was responsible for its development and expansion which included seventeen acquisitions and several <FONT
STYLE="white-space:nowrap">non-core</FONT> divestments. Andrew qualified as a Chartered Accountant with Price Waterhouse Coopers and spent eight years working in investment banking at Rothschild, advising on a wide variety of merger and acquisition
transactions, debt and equity fundraisings, IPOs and other advisor assignments. Andrew graduated from [&nbsp;&nbsp;&nbsp;&nbsp;] first-class honors B.A. (Hons) in Accounting and Management in 1991. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mark Hilz&#151;</B><I>Chief Executive Officer and Director</I><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since June 2013, Mark Hilz, 63, has served as a director and the Chief Executive Officer of the Company. Mr.&nbsp;Hilz has over 30 years of
experience as a President and/or CEO of multiple startup companies. He was previously CEO of INX Inc., a technology infrastructure consulting company. INX Inc. started in 2000 and grew to $400&nbsp;million in revenue with 15 offices, 2,000
customers, and 500 employees. INX Inc. was traded on the NASDAQ, completed multiple offerings and was successfully sold to private equity in December 2011. Prior to that, Mr.&nbsp;Hilz founded and was CEO of a technology logistics outsourcing firm,
PC Service Source Inc., that grew to over $160&nbsp;million in revenue with 1,100 employees in an eight year span. Mr.&nbsp;Hilz raised the startup </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital from traditional venture capital sources and after four years of operations took PC Service Source Inc. public in an IPO as a NASDAQ global listed company. Mr.&nbsp;Hilz&#146;s experience
includes raising venture capital as well as multiple successful public offerings and numerous merger and acquisition transactions as both a buyer and a seller. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Richard Barber&#151;</B><I>Interim Chief Financial Officer</I><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since February 2022, Richard Barber, 62, has served as Interim Chief Financial Officer of the Company. Mr.&nbsp;Barber has been Managing
Partner of L.H. Frishkoff&nbsp;&amp; Company, a public accounting firm, since 2016. Mr.&nbsp;Barber holds a CPA license in New York and is a member of the AICPA and New York State Board of Accountancy. Rick is the lead partner for tax and accounting
services, working with clients in a variety of industries, including manufacturing, entertainment, real estate and import/export. He also works with private equity firms where he performs due diligence and advisory on merger and acquisition
transactions as well as sophisticated tax strategies. He specializes in purchase/sale transactions providing advice on both the buy and sell side in tax and structure advisory capacity, including due diligence. He received his Bachelor of Arts
Degree in Business Studies from England&#146;s Sheffield Hallam University in 1980. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bruce Bent&#151;</B><I>Director </I><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since May 2020, Bruce Bent, 66, has served as a director of the Company. Mr. Bent brings more than 35&nbsp;years of experience in financial
management. He is CFO of The Matthews Group, referred to in this section as Matthews, and president of various Canadian subsidiaries of Matthews. Matthews is a $500M real estate development company with offices in Dallas, Texas, Vancouver and
Mississauga, Canada and Dubai. Mr. Bent was integral in the completion of a major real estate project, a $1.7&nbsp;billion dollar corporate headquarters building for Encana (now Ovintiv Inv., NYSE: OVV). Prior than his time as CFO of The Matthews
Group, Mr.&nbsp;Bent was president of MSW Investments Limited, a family office providing early stage financing. Mr.&nbsp;Bent is also Chairman of Enerdynamic Hybrid Technologies Corp. a TSXV listed public company. In addition, Mr. Bent serves in the
same capacity for Astro Aerospace Ltd, an OTC listed public company. Mr.&nbsp;Bent graduated from the University of Manitoba with a Bachelor of Commerce (honors) and obtained his Chartered Professional Accounting designation from the Province of
Ontario. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Brian Szymczak&#151;</B><I>Director</I><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since 2014, Brian Szymczak, 49, has served as a director of the Company. Mr.&nbsp;Szymczak, 49, is the lead attorney for Apollo Endosurgery,
Inc. in Austin, Texas where he serves as Vice President of Legal and Compliance. In this role, Mr.&nbsp;Szymczak manages legal disputes and litigation matters and provides general legal counsel to the company&#146;s leadership, sales, operations,
research and development, and human resources groups. Prior to working at Apollo, Mr.&nbsp;Szymczak served as Associate General Counsel and Director of Legal Affairs for a large surgical device manufacturer and previously worked as an associate at
the law firm of Baker Botts, LLP where he counseled clients on patent and other intellectual property matters in a variety of industries. Mr.&nbsp;Szymczak is a 1999 graduate of Duke University School of Law and holds a Bachelor of Science in
Mechanical Engineering from Texas A&amp;M University. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patrick Kanouff&#151;</B><I>Director</I><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since April 2019, Patrick Kanouff, 52, has served as a director of the Company. Mr.&nbsp;Kanouff has served as Chief Operating Officer of
Bohemian Companies since 2020. Bohemian Companies is a private family financial office and includes Bohemian Asset Management, an investment company with private equity, fixed income securities, and private equity holdings. Prior to Bohemian
Companies, Mr. Knouff was the managing partner of Davis&nbsp;&amp; Ceriani, P.C., a law firm located in Denver, CO, where Mr.&nbsp;Kanouff&#146;s practice was comprised of a combination of complex commercial litigation and business counseling.
Mr.&nbsp;Kanouff is a 1995 graduate of the University of Denver School of Law and holds a Bachelor of Arts from Creighton University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, our Board of Directors will have three standing committees: an audit committee, a compensation committee and
a nominating and corporate governance committee. Under Nasdaq rules and Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, the membership of the audit committee is required to consist entirely of independent directors,
subject to applicable <FONT STYLE="white-space:nowrap">phase-in</FONT> periods. The following is a brief description of our committees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Audit
committee</I><B><I></I></B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B>In accordance with our audit committee charter, after this offering, our audit committee
will: oversee our corporate accounting and financial reporting processes and our internal controls over financial reporting; evaluate our independent registered public accounting firm&#146;s qualifications, independence and performance; engage and
provide for the compensation of our independent registered public accounting firm; approve the retention of our independent registered public accounting firm to perform any proposed permissible <FONT STYLE="white-space:nowrap">non-audit</FONT>
services; review our financial statements; review our critical accounting policies and estimates and internal controls over financial reporting; and discuss with management and our independent registered public accounting firm the results of the
annual audit and the reviews of our quarterly financial statements. We believe that our audit committee members meet the requirements for financial literacy under the current requirements of the Sarbanes-Oxley Act, Nasdaq and SEC rules and
regulations. The audit committee will be composed of Bruce Bent, Patrick Kanouff and Brian Szymczak. Nasdaq rules require that all of the members of the audit committee meet the independence standards set forth above, subject to the applicable <FONT
STYLE="white-space:nowrap">phase-in</FONT> periods of Nasdaq. Our Board of Directors has determined that Bruce Bent, Patrick Kanouff and Brian Szymczak meet the independence requirements of the Sarbanes-Oxley Act, Rule
<FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act and the applicable listing standards of Nasdaq. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation committee </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with our compensation committee charter, after this offering, our compensation committee will review and recommend policies
relating to compensation and benefits of our officers and employees, including reviewing and approving corporate goals and objectives relevant to compensation of the Chief Executive Officer and other senior officers, evaluating the performance of
these officers in light of those goals and objectives and setting compensation of these officers based on such evaluations. The compensation committee will also administer the issuance of stock options and other awards under our equity-based
incentive plans. We believe that the composition of our compensation committee meets the requirements for independence under, and the functioning of our compensation committee complies with, any applicable requirements of the Sarbanes-Oxley Act,
Nasdaq and SEC rules and regulations. We intend to comply with future requirements to the extent they become applicable to us. The compensation committee will be composed of Bruce Bent, Patrick Kanouff and Brian Szymczak. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nominating and governance committee </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
accordance with our nominating and governance committee charter, after this offering, our nominating and governance committee will recommend to the Board of Directors nominees for election as directors, and meet as necessary to review director and
nominees for election as directors; recommend members for each committee of the Board of Directors; oversee corporate governance standards and compliance with applicable listing and regulatory requirements; develop and recommend to the Board of
Directors governance principles applicable to the company; and oversee the evaluation of the Board of Directors and its committees. We believe that the composition of our nominating and governance committee meets the requirements for independence
under, and the functioning of our nominating and governance committee complies with, any applicable requirements of the Sarbanes-Oxley Act, Nasdaq and SEC rules and regulations. We intend to comply with future requirements to the extent they become
applicable to us. The nominating and governance committee will be composed of Bruce Bent, Patrick Kanouff and Brian Szymczak. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will adopt a new code of business conduct and ethics that applies to all of our officers, directors and employees, including our principal
executive officer, principal financial officer, principal accounting officer and controller, or persons performing similar functions, which will be posted on our website. Our code of business conduct and ethics is a &#147;code of ethics,&#148; as
defined in Item 406(b) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> The information contained on, or accessible from, our website is not part of this prospectus by reference or otherwise. We will make any legally required disclosures
regarding amendments to, or waivers of, provisions of our code of business conduct and ethics on our website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and
Insider Participation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee is an executive officer or employee of our Company. None of
our executive officers serves as a member of the Board of Directors or compensation committee of any entity that has one or more executive officers serving on our Board of Directors or compensation committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth summary compensation information for our Chief Executive Officer and our Chairman of the Board of Directors. We refer to these persons as our &#147;named executive officers&#148; in this prospectus. The Company had no other
executive officers during Fiscal 2021 and Fiscal 2020. The following table includes all compensation earned by the named executive officers for the respective period, regardless of whether such amounts were actually paid during the period </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Position(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Hilz</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">104,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">269,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Simpson</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Chairman of the Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U></U>43,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><U></U>50,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">During Fiscal 2020 and Fiscal 2021, the Company did not employ a chief financial officer.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the full grant date value of the stock award or option grant, as applicable, calculated in
accordance with FASB ASC Topic 718, <I>Compensation&#151;Stock Compensation</I>. Our policy and assumptions made in the valuation of share-based payments are contained in Note 7 of our Fiscal 2021 financial statements. The value of option awards
presented in the Summary Compensation Table reflects the grant date fair value of the awards and does not correspond to the actual value that will be recognized by the named executive officers. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Does not include $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] and
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] paid to Kyngstone Limited in which Mr.&nbsp;Simpson is a director and controlling shareholder in Fiscal 2020 and Fiscal 2021, respectively. For additional information
regarding this agreement, see &#147;Related Party Transactions.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has an employment agreement with its Chief Executive Officer, Mark Hilz. On March&nbsp;7, 2017, Mr.&nbsp;Hilz entered into an
employment agreement with the Company, which provides for Mr.&nbsp;Hilz&#146;s terms of employment, duties and responsibilities, base salary, bonus and stock option opportunities at the discretion of the Board of Directors, and eligibility to
participate in our employee benefit plans generally. Mr.&nbsp;Hilz&#146;s employment agreement also contains certain restrictive covenants that restrict Mr.&nbsp;Hilz&#146;s ability to take certain actions, such as a
<FONT STYLE="white-space:nowrap">non-compete,</FONT> a <FONT STYLE="white-space:nowrap">non-solicitation</FONT> covenant restricting Mr.&nbsp;Hilz&#146;s ability to solicit employees of the Company, and the requirement that Mr.&nbsp;Hilz devote his
full time and attention to the business of the Company. Mr.&nbsp;Hilz&#146;s employment agreement automatically renews until otherwise terminated in accordance with its terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at January&nbsp;31, 2022 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows outstanding option awards held by the named executive officers as of January&nbsp;31, 2022: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vested&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unvested&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Hilz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">625,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Simpson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">625,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Hilz has been awarded 5,750,000 shares of which 500,000 are time-based awards and have all vested. The
remaining 5,250,000 shares are based on Company performance metrics. As of April&nbsp;30, 2021, 125,000 of these shares have vested. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Simpson has been awarded 5,750,000 shares of which 500,000 are time-based awards and have all vested.
The remaining 5,250,000 shares are based on Company performance metrics. As of April&nbsp;30, 2021, 125,000 of these shares had vested. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compensate our directors with equity awards. There were no equity awards granted in Fiscal 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_13"></A>BENEFICIAL OWNERSHIP OF PRINCIPAL SHAREHOLDERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding beneficial ownership of our Common Stock and Preferred Stock as of
January&nbsp;31, 2022 by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known to us to be the beneficial owner of more than 5% of our
outstanding Common Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors and executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC, and includes voting or investment power with respect to the Common
Stock. The Common Stock issuable upon (i)&nbsp;conversion of notes or preferred stock or (ii)&nbsp;exercise of options or warrants that are exercisable within 60 days after
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] , 2022, are deemed outstanding for the purpose of computing the percentage ownership of the person holding such notes, preferred stock, options or warrants but are not
deemed outstanding for the purpose of computing the percentage ownership of any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not controlled by another
corporation, by any foreign government or by any natural or legal persons except as set forth herein, and there are no arrangements known to us which would result in a change in control of our Company at a subsequent date. Except as indicated in
footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with respect to all shares shown to be beneficially owned by them, based on information provided to us by such shareholders. Unless
otherwise noted below, each beneficial owner&#146;s address is c/o Heart Test Laboratories, Inc., 2550 Reserve Street, Suite 360, Southlake, Texas 76092. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage of beneficial ownership prior to this offering in the table below is based on
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Common Stock deemed to be outstanding as of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] 2022, assuming the
conversion of the $1.5M Notes into a total of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of the Common Stock and, the conversion of the Maximum Percentage of Bridge Notes into the number of shares of
Common Stock. The percentage of beneficial ownership in the table below is based on [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Common Stock assumed to be outstanding after the closing of the
offering. The information in the table below assumes no exercise of the underwriter&#146;s option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial Ownership</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of Shares(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Prior to<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Combined<BR>Voting<BR>Power<BR>Prior to<BR>Offering(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Combined<BR>Voting<BR>Power<BR>After<BR>Offering(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Holders of 5% or more of our voting securities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Guangren &#147;Gary&#148; Chen(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Front Range Ventures LLC(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John H. Matthews(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Albert Paul Knuckley(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Q. Adams Sr.(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lary Snodgrass(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and executive officers who are not 5% holders of our voting securities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Simpson(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Hilz*(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Szymczak*(12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick Kanouff*(13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bruce Bent*(14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Barber*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers as a group (6 persons):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For each person named in the table, the number of shares of Preferred Stock listed opposite of such
person&#146;s name as being beneficially owned by such person represents the total number of all Series A Preferred Shares, Series B Preferred Shares and Series C Preferred Shares owned by such person. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For each person named in the table, the Preferred Stock voting percentage listed opposite of such person&#146;s
name represents the combined voting percentage of all Series A Preferred Shares, Series B Preferred Shares and Series C Preferred Shares owned by such person. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For each person named in the table, the voting percentages listed opposite of such person&#146;s name under the
columns &#147;Combined Voting Power Prior to Offering&#148; and &#147;Combined Voting Power After Offering&#148; represent the combined voting percentage of all shares of the Common Stock and all Series A Preferred Shares, Series B Preferred Shares
and Series C Preferred Shares on an as converted basis owned by such person prior to and immediately after the offering, respectively. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Common
Stock and [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Preferred Stock beneficially owned by Dr.&nbsp;Chen&#146;s spouse. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">FRV&#146;s sole member is the L. Lee Stryker Irrevocable Trust U/A/D 09/10/1974. Bohemian Asset Management,
Inc. has voting and dispositive power with respect to the shares of our Common Stock on behalf of the L. Lee Stryker Irrevocable Trust U/A/D 09/10/1974. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of the Common
Stock and [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Preferred Stock beneficially owned by Matthews Holdings Southwest, Inc. Mr.&nbsp;Matthews is the controlling shareholder of Matthews Holdings
Southwest, Inc. and has voting and dispositive power over all of the shares set forth opposite his name. Also includes warrants and options to purchase a total of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]
shares of the Common Stock beneficially owned by Mr.&nbsp;Matthews and Matthews Holdings Southwest, Inc., collectively, that are exercisable for shares of the Common Stock within 60 days of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All of the shares are owned by PSKS Investments, L.P. and Mr.&nbsp;Knuckley, as general partner of PSKS
Investments, L.P., has voting and dispositive power over all such shares. Includes all warrants and options beneficially owned by PSKS Investments, L.P. that are exercisable for our Common Stock within 60 days of this offering.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes warrants and options to purchase a total of
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of the Common Stock beneficially owned by Mr.&nbsp;Adams that are exercisable for our Common Stock within 60 days of this offering.. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes, in aggregate, [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]
shares of our Common Stock and [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Preferred Stock beneficially owned by Lary Snodgrass Family Limited and Snodgrass Children&#146;s Limited as to each of
which Mr.&nbsp;Snodgrass is the sole managing member of each of their general partners. Also includes warrants and options to purchase a total of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of the Common
Stock beneficially owned by Mr.&nbsp;Snodgrass, Lary Snodgrass Family Limited and Snodgrass Children&#146;s Limited, collectively, that are exercisable for our Common Stock within 60 days of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Does not include [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of
the Common Stock and [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Preferred Stock owned by Simpson Family Benefit Trust.. The trustee,
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], has voting and dispositive power over all such shares. [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] disclaims beneficial
ownership of such shares. Also includes warrants and options to purchase a total of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of the Common Stock beneficially owned by Mr.&nbsp;Simpson that are
exercisable for our Common Stock within 60 days of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes warrants and options to purchase a total of
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of the Common Stock beneficially owned by Mr.&nbsp;Hilz, which are exercisable for our Common Stock within 60 days of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Szymczak holds Bridge Notes jointly with his spouse. The number of shares of our Common Stock includes
(i)&nbsp;all shares into which such Bridge Notes may be converted up to the Maximum Percentage and (ii)&nbsp;warrants and options to purchase a total of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of the
Common Stock beneficially owned by Mr.&nbsp;Szymczak that are exercisable for our Common Stock within 60 days of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes options to purchase [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares
of Common Stock that are exercisable within 60 days of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes all shares and warrants and options to purchase a total of
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of the Common Stock beneficially owned by Mr.&nbsp;Bent and his spouse, jointly; all such warrants and options are exercisable for our Common Stock within 60
days of this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_14"></A>RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of transactions or series of transactions since the beginning of Fiscal 2021 to which we were or will be a
party, in which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The amount involved in the transaction exceeds, or will exceed, the lesser of $120,000 or one percent of the
average of our total assets for the last two completed fiscal years; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in which any of our executive officers, directors or holders of five percent or more of any class of our capital
stock, including their immediate family members or affiliated entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
additional information regarding compensation arrangements for our named executive officers and directors, see &#147;Executive Compensation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with Related Parties: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>$130K Note </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;12, 2019, the Company entered into an unsecured drawdown convertible promissory note, which is referred to as the $130K Note,
with Front Range Ventures, LLC, or FRV, for an aggregate amount not to exceed $130,000. FRV is a beneficial owner or more than five percent (5%) of our Common Stock and is entitled to appoint a member of the Company&#146;s Board of Directors. The
Company drew down on the $130K Note in Fiscal 2021. For more information regarding the $130K Note and other indebtedness of the Company, see &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#151;Description of Indebtedness&#151;$130K Note.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>$1.5M Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2020, we issued a series of secured convertible promissory notes, which we refer to as the $1.5M Notes, in the amount of
$1.5&nbsp;million. These accrue at a simple interest rate of 12% per annum. The $1.5M Notes were sold as a series to a number of investors and $1,490,000 of the $1.5M Notes were sold to certain shareholders of the Company and certain members of the
Board of Directors of the Company. For more information regarding the $1.5M Notes and other indebtedness of the Company, see &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Description of
Indebtedness&#151;$1.5M Notes.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2021, in consideration for the extension of the maturity date of the $1.5M Notes from
July&nbsp;31, 2022 to October&nbsp;31, 2022, we issued warrants, that we refer to as the $1.5M Lender Warrants, to purchase an aggregate of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock. For
more information regarding the $1.5M Lender Warrants, see &#147;Description of Capital Stock&#151;Warrants&#151;$1.5M Lender Warrants.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes purchases of the $1.5M Notes and $1.5M Lender Warrants by beneficial owners of more than five percent (5%) of
our Common Stock: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Shareholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal&nbsp;Amount&nbsp;of<BR>$1.5M Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$1.5M&nbsp;Lender<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John H. Matthews(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">515,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Szymczak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Hilz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lary Snodgrass(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Albert Paul Knuckley(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes principal amount of $1.5M Notes held by Matthews Holdings Southwest, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes principal amount of $1.5M Notes held by Lary Snodgrass Family Limited and Snodgrass Children&#146;s
Limited. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes principal amount of $1.5M Notes held by PSKS Investments LP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>$1M Loan and Security Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2020, the Company entered into a loan and security agreement that we refer to as the $1M Loan and Security Agreement, with FRV and
John Q. Adams who are both beneficial owners of more than five percent (5%) of our Common Stock. For more information regarding the $1M Loan and Security Agreement and other indebtedness of the Company, see &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#151;Description of Indebtedness&#151;$1M Loan and Security Agreement.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
November 2021, in consideration for an extension of the maturity date of the $1M Loan and Security Agreement from September&nbsp;30, 2021 to September&nbsp;30, 2022, we issued warrants, that we refer to as the $1M Lender Warrants, to purchase an
aggregate of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock to FRV and Mr.&nbsp;Adams. For more information regarding $1M Lender Warrants, see &#147;Description of Capital
Stock&#151;Warrants&#151;$1M Lender Warrants.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2021 Bridge Financing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the 2021 Bridge Financing, certain beneficial ownership of more than five percent (5%) of our Common Stock purchased Bridge
Notes and Bridge Warrants. For more information in regards to the 2021 Bridge Financing, see &#147;Summary&#151;Recent Developments&#151;2021 Bridge Financing.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the names of such shareholders and amount of the Bridge Notes and Bridge Warrants purchased through
February&nbsp;25, 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Shareholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal&nbsp;Amount&nbsp;of&nbsp;Bridge<BR>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants&nbsp;to&nbsp;Purchase&nbsp;the<BR>Following&nbsp;Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Albert Paul Knuckley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,111.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lary Snodgrass</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,222.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John H. Matthews(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,111.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes Bridge Notes and Bridge Warrants held by Matthews Holdings Southwest, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration Rights Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with the 2021 Bridge Financing, we entered into the Registration Rights Agreement with the purchasers of the Bridge Notes pursuant to which we agreed to file a resale registration statement no later than 90 days after the date of this
prospectus with respect to the shares of Common Stock issuable upon conversion of the Bridge Notes, exercise of the Bridge Warrants or resulting from anti-dilution provisions in the Bridge Notes or the Bridge Warrants or any securities issued or the
issuable upon any stock split, dividend or other distribution, recapitalization or similar event, collectively referred to as the Registrable Securities. For more information regarding the Registration Rights Agreement, see &#147;Description of
Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Short-term $500K Unsecured Note </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;12, 2021, we issued a note for the amount of $500,000 to Matthews Southwest Holdings, Inc., a beneficial owner owning more than
5% of our Common Stock. The maturity date of this note, as amended, was December&nbsp;31, 2021. This note has been repaid and there are no further obligations owed by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Kyngstone Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Andrew Simpson, the Chairman of the Board of Directors of the Company, is a member of the board of directors and is the controlling shareholder
of Kyngstone Limited, or Kyngstone, a company incorporated in the United Kingdom. Kyngstone provides advisory services to the Company pursuant to a Consulting Agreement dated June&nbsp;25, 2013 between the Company and Kyngstone. For the Fiscal 2021
and Fiscal 2020, the Company recorded expenditures of $100,000 and $191,667, respectively with Kyngstone. As of Fiscal 2021 and Fiscal 2020, the Company had balances outstanding to Kyngstone in the amounts of $88,444 and $97,177, respectively. As of
January&nbsp;31, 2022, the Company has a balance outstanding to Kyngstone in the amount of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_15"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description summarizes the terms of our capital stock, our amended and restated certificate of formation and our amended and
restated bylaws. As it is only a summary, it does not contain all the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of formation and amended and restated bylaws, each
of which will be in effect upon the consummation of this offering, the forms of which are filed as exhibits to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our purpose is to engage in any lawful act or activity for which corporations may now or hereafter be organized under the Texas Business
Organizations Code, or the TBOC. Our authorized capital stock consists of 500,000,000 shares of Common Stock, par value $0.001 per share, and twenty million (20,000,000) shares of preferred stock, or Preferred Stock, par value $0.001 per share of
which, as of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], 2022, there were [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock outstanding and held of record
by [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shareholders and shares of Preferred Stock outstanding and was of record by [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]
shareholders of which, (i)&nbsp;ten thousand&nbsp;(10,000) shares have been designated as Series&nbsp;A Convertible Preferred Stock, or the&nbsp;Series A Preferred Stock, having a par value of $0.001 per share, (ii)&nbsp;ten thousand&nbsp;(10,000)
shares have been designated as Series&nbsp;B Convertible Preferred Stock, or the&nbsp;Series B Preferred Stock, having a par value of $0.001 per share, and (iii)&nbsp;six hundred thousand&nbsp;(600,000) shares have been designated as Series&nbsp;C
Convertible Preferred Stock, or the&nbsp;Series C Preferred Stock, having a par value of $0.001 per share. Unless our Board of Directors determines otherwise, we will issue all shares of our capital stock in uncertificated form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our executive officers, directors and certain of our significant shareholders, will sign <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements with the underwriters that will, subject to certain customary exceptions, restrict the sale of the shares of our Common Stock and certain other securities held by them for 180 days following the date of this prospectus. See
&#147;Underwriting&#148; for a description of <FONT STYLE="white-space:nowrap">these&nbsp;lock-up&nbsp;agreements.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our Common Stock are entitled to one vote for each share held of record on all matters on which shareholders are entitled to vote
generally, including the election or removal of directors, subject to certain limitations. The holders of our Common Stock do not have cumulative voting rights in the election of directors. Upon our liquidation, dissolution or winding up and after
payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of our Common Stock will be entitled to receive pro rata our remaining assets available for
distribution on a pro rata basis. Holders of our Common Stock do not have preemptive, subscription, redemption or conversion rights. The Common Stock will not be subject to further calls or assessment by us. There will be no redemption or sinking
fund provisions applicable to the Common Stock. All shares of our Common Stock that will be outstanding at the time of the completion of the offering will be fully paid <FONT STYLE="white-space:nowrap">and&nbsp;non-assessable.</FONT> The rights,
powers, preferences and privileges of holders of our Common Stock will be subject to those of the holders of any shares of our preferred stock we may authorize and issue in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a Texas corporation, we are subject to certain restrictions on dividends under the TBOC. Generally, a Texas corporation may pay dividends
to its shareholders out of its surplus (the excess of its assets over its liabilities and stated capital) unless the dividend would render the corporation insolvent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The declaration, amount and payment of any future dividends will be at the sole discretion of our Board of Directors. Our Board of Directors
may take into account general and economic conditions, our financial condition and results of operations, our available cash and current and anticipated cash needs, capital requirements, contractual, legal, tax and regulatory restrictions and
implications on the payment of dividends by us to our shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently expect to retain all future earnings for use in the operation and expansion of
our business and have no current plans to pay dividends. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of formation authorizes our Board of Directors to establish one or more series of preferred stock
(including convertible preferred stock). Unless required by law or by the TBOC, the authorized shares of preferred stock will be available for issuance without further action by our shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors will be able to determine, with respect to any series of preferred stock, the powers including preferences and relative
participations, optional or other special rights, and the qualifications, limitations or restrictions thereof, of that series, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of the series, which our Board of Directors may, except where otherwise provided in the
preferred stock designation, increase (but not above the total number of authorized shares of the class) or decrease (but not below the number of shares then outstanding); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends, if any, will be cumulative
<FONT STYLE="white-space:nowrap">or&nbsp;non-cumulative&nbsp;and</FONT> the dividend rate of the series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates at which dividends, if any, will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the redemption rights and price or prices, if any, for shares of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and amounts of any sinking fund provided for the purchase or redemption of shares of the series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts payable on shares of the series in the event of any voluntary or involuntary liquidation, dissolution
<FONT STYLE="white-space:nowrap">or&nbsp;winding-up&nbsp;of</FONT> the affairs of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the shares of the series will be convertible into shares of any other class or series, or any other
security, of the Company or any other corporation and, if so, the specification of the other class or series or other security, the conversion price or prices or rate or rates, any rate adjustments, the date or dates as of which the shares will be
convertible and all other terms and conditions upon which the conversion may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the issuance of shares of the same series or of any other class or series; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the voting rights, if any, of the holders of the series. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be able to issue a series of preferred stock that could, depending on the terms of the series, impede or discourage an acquisition
attempt or other transaction that some, or a majority, of the holders of our Common Stock might believe to be in their best interests or in which the holders of our Common Stock might receive a premium for their Common Stock over the market price of
the Common Stock. In addition, the issuance of Preferred Stock may adversely affect the rights of holders of our Common Stock by restricting dividends on the Common Stock, diluting the voting power of the Common Stock or subordinating the
liquidation rights of the Common Stock. As a result of these or other factors, the issuance of Preferred Stock may have an adverse impact on the market price of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;31, 2022, there were 10,000 shares of the Series A Preferred Stock, 10,000 shares of the Series B Preferred Stock and
600,000 shares of Series C Preferred Stock outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock was issued to employees and directors of the Company
in 2014 and is subordinate to the Common Stock upon a liquidation. As of January&nbsp;31, 2022, the Common Stock had a liquidation preference of $4.5&nbsp;million to the Series A Preferred Stock. The Series A Preferred Stock was issued subject to
certain repurchase rights in favor of the Company. An amendment to, or waiver of rights of, the Series A convertible preferred stock requires the approval of holders of a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the outstanding
shares of Series A convertible preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series B Preferred Stock was issued to employees and directors in 2015 and is
subordinate to the Common Stock upon a liquidation. As of January&nbsp;31, 2022, the Common Stock had a liquidation preference of $35&nbsp;million to the Series B Preferred Stock. The Series B Preferred Stock was issued subject to certain repurchase
rights in favor of the Company. An amendment to, or waiver of rights of, the Series B Preferred Stock requires the approval of holders of a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the outstanding shares of the Series B
Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series C Preferred Stock was issued to
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] accredited investors and has a liquidation preference to the Common Stock. As of January&nbsp;31, 2022, the liquidation preference was equal to
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]. An amendment to, or waiver of rights of the Series C Preferred Stock requires the approval of holders of a majority of the outstanding shares of the Series C
Preferred Stock. Additionally, pursuant to the agreement that the Company entered into with FRV on April&nbsp;10, 2019, FRV is entitled to appoint a member of the Board of Directors as well as a board observer, for so long as FRV holds at least
71,000 shares of Series C Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting and Dividends </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the shares of the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred have voting rights equal to
an equivalent number of shares of the Common Stock into which it is convertible and vote together as one class with the Common Stock. The holders of the Series A Preferred Stock are not entitled to receive any dividends until the holders of common
stock have received $4.5&nbsp;million in payments (in dividends, the proceeds of a sales transaction, or otherwise) (the &#147;Series A Threshold&#148;). Thereafter, the Series A Preferred Stock participates in any dividend declared on the shares of
the Common Stock by the Company&#146;s Board out of funds legally available on and as converted basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Series B Preferred
Stock are not entitled to receive any dividends until the holders of Common Stock have received $35&nbsp;million in payments (in dividends, the proceeds of a sales transaction, or otherwise), or the Series B Threshold. Thereafter, the Series B
Preferred Stock participates in any dividend on the shares of the Common Stock by the Company&#146;s Board of Directors out of funds legally available on and as converted basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Series C Preferred Stock are entitled to receive dividends at an annual rate of $[____] per share (adjusted to reflect
recapitalizations). Such dividends shall accrue and are payable out of funds legally available, are payable only when and if declared by the Board, and are noncumulative. The Company is not permitted to declare, pay or set aside any dividends on
shares of any other class or series of capital stock of the Company (other than dividends on shares of the Common Stock payable in shares of Common Stock) unless the holders of the shares of the Series C Preferred Stock then outstanding first
receive, or simultaneously receive, a dividend on each outstanding share of the Series C Preferred Stock in an amount at least equal to the greater of (i)&nbsp;the amount of the aggregate dividends then accrued on such share of the Series C
Preferred Stock and not previously paid and (ii)&nbsp;in the case of a dividend on the Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Series C Preferred Stock as would equal the product of
(1)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into common stock and (2)&nbsp;the number of shares of common stock issuable upon conversion
of a share of the Series C Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No dividends have been declared to date on any shares of Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any
liquidation, dissolution or winding up of the Company, either voluntarily or involuntarily, the holders of the Series C Preferred Stock are entitled to receive, prior and in preference to the holders of the Series A Preferred Stock, the Series B
Preferred Stock, and the Common Stock, a per share amount equal to 1.0 times the original issue price ($25.00 per share) plus any accrued but unpaid dividends thereon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If upon the liquidation, dissolution or winding up of the Company, the assets of the Company
that are legally available for distribution to the holders of the Series C Preferred Stock are insufficient to permit the payment to such holders of the full amounts above, then the entire assets of the Company that are legally available for
distribution shall be distributed with equal priority and <FONT STYLE="white-space:nowrap">pro-rata</FONT> among the holders of the Series C Preferred Stock in proportion to what they would otherwise be entitled to receive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the payment of the full Series C Preferred Stock liquidation preference and unpaid accrued dividends, the holders of the Series C
Preferred Stock shall participate in the distribution of the entire remaining assets of the Company legally available for distributions <FONT STYLE="white-space:nowrap">pro-rata</FONT> to holders of the Common Stock on an as converted basis. The
sale of a majority of the capital stock of the Company or the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Company or any subsidiary of the Company of all or
substantially all the assets of the Company and its subsidiaries taken as a whole shall be a deemed liquidation for the purpose of the Series C Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any liquidation, dissolution or winding up of the Company, either voluntarily or involuntarily, the holders of the Series A
Preferred Stock shall only participate in the distribution of the entire remaining assets of the Company legally available for distributions after the holders of the Common Stock have received $4.5&nbsp;million in payments (in dividends, the
proceeds of a sales transaction, or otherwise). Thereafter, the holders of the Series A Preferred Stock shall participate on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis with holders of the Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any liquidation, dissolution or winding up of the Company, either voluntarily or involuntarily, the holders of the Series B
Preferred Stock shall only participate in the distribution of the entire remaining assets of the Company legally available for distributions after the holders of the Common Stock have received $35&nbsp;million in payments (in dividends, the proceeds
of a sales transaction, or otherwise). Thereafter, the Series B Preferred Stock shall participate on a <FONT STYLE="white-space:nowrap">pro-rata</FONT> basis with holders of the Common Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of the Series A
Preferred Stock is convertible, at the option of the holder thereof, into fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock at any time prior to May&nbsp;1, 2024. Additionally, if the holders of the Series
A Preferred Stock are entitled to make, but have not made, an election to convert the Series A Preferred Stock by May&nbsp;1, 2024, then such shares will automatically be converted into Common Stock. The number of shares of Common Stock into which
the Series A Preferred Stock may be converted is based on a formula set forth in the Company&#146;s certificate of formation, as amended. It varies according to the fair market value of the Common Stock at the time of conversion and is subject to a
$4.5&nbsp;million minimum value threshold of the Common Stock, (less any payments previously made to holders of the Common Stock). Unless the $4.5&nbsp;million minimum value threshold is met, no shares of the Series A Preferred Stock would convert
into shares of the Common Stock. Each share of the Series B Preferred Stock is convertible, at the option of the holder thereof, into fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock at any time prior to
July&nbsp;7, 2025. Additionally, if the holders of the Series B Preferred Stock are entitled to make, but have not made, an election to convert their shares by July&nbsp;7, 2025, then such shares will automatically be converted into Common Stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No conversion of the Series B Preferred Stock may take place if a repurchase right exists. The holders of the Series B Preferred Stock
each entered into a restricted stock agreement in July 2015 whereby the Company was granted the right to repurchase up to all of such holders&#146; Series B Preferred Stock at a price of $0.001 per share under certain conditions. The repurchase
rights over 80% of the Series B Preferred Stock have now expired with the remaining right over 20% expiring upon the Company&#146;s receiving FDA clearance for the MyoVista. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the restricted shareholder is terminated as an employee of the Company for just cause (as defined in the restricted stock
agreement) or resigns other than for a constructive termination (as defined in the restricted stock agreement), or (ii)&nbsp;if such holder is a director of HeartSciences, such holder resigns as a director of HeartSciences prior to the
Company&#146;s receiving FDA clearance for the MyoVista, the remaining 20% may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
repurchased by the Company. The Series B Preferred Stock repurchase rights automatically terminate (i)&nbsp;upon the closing of a sales transaction (as defined below), or (ii)&nbsp;at such time
as the holders of common stock have received $35&nbsp;million in proceeds from the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock into
which shares of the Series B Preferred Stock may be converted is based on a formula set forth in the Company&#146;s certificate of formation, as amended. It varies according to the fair market value of the Company&#146;s Common Stock at the time of
conversion and is subject to a $35&nbsp;million minimum value threshold (less any payments previously made to holders of Common Stock). In the event that the $35&nbsp;million minimum threshold value is not met, none of the shares of Series B
Preferred Stock would convert into shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purpose of the conversion formulas of the Series A Preferred Stock and
the Series B Preferred, the fair market value of the Company&#146;s Common Stock is determined as: (i)&nbsp;if the Common Stock is publicly-traded, the value will be determined by using a <FONT STYLE="white-space:nowrap">30-day</FONT> weighted
average closing prices of the Common Stock; (ii)&nbsp;if the Common Stock is not publicly-traded, it shall be the value determined in good faith by the Board, which determination may, but is not required to, include a third-party valuation or
(iii)&nbsp;in the event of a sales of the Company, the value determined by reference to that sales transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Series C
Preferred Stock is convertible, at the option of the holder, at any time after the date of issuance of such share, into such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock determined by
dividing the original issue price by the conversion price for such series in effect at the time of conversion for the Series C Preferred Stock. The conversion price for the Series C Preferred Stock is subject to adjustment in accordance with
conversion provisions contained in the Company&#146;s certificate of formation, as amended. As of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], 2022, the conversion price of the Series C Preferred Stock was
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Series C Preferred Stock
automatically converts into shares of Common Stock at the conversion price at the time in effect immediately upon the Company&#146;s sale of its Common Stock in a public offering provided that the offering price is not less than
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share (as adjusted for recapitalizations, stock combinations, stock dividends, stock splits and the like) and which results in aggregate cash proceeds of not less
than $20.0&nbsp;million before underwriting discounts, commissions, and fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investor Warrants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From 2015 to 2019, the
Company issued warrants, or the Investor Warrants, in connection with funding or as consideration for services rendered. The Investor Warrants have a term of five years from the date of issuance. At January&nbsp;31, 2022, there were Investor
Warrants to purchase [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock at an exercise price of $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share
outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrants issued in connection with the 2021 Bridge Financing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We issued the Bridge Warrants to purchase [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common
Stock in connection with the 2021 Bridge Financing. The Bridge Warrants expire in five years after the date of issuance, beginning on December&nbsp;22, 2026, and have an initial Exercise Price of
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share, subject to certain adjustments. No holder of a Bridge Warrant may exercise any portion of a Bridge Warrant if after giving effect to such exercise such
holder (together with its Attribution Parties) would beneficially own in excess of the Maximum Percentage of 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of such holder&#146;s Bridge Warrant. This limitation may be waived by a holder, at its election, upon not less than 61 days&#146; prior notice to the Company, to change the limitation to 9.99% of the number of shares of the
Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of such holder&#146;s warrant. Any exercise of the Bridge Warrants resulting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in a number of shares in excess of 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the exercise shall be deemed null and void and shall be
cancelled <I>ab initio</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price of the Bridge Warrants is subject to adjustment for certain events such as stock dividends
and splits and, if and whenever on or prior to the later of (i)&nbsp;the second anniversary of the issuance date or (ii)&nbsp;the <FONT STYLE="white-space:nowrap">18-month</FONT> anniversary of the effective date of this offering, there are
issuances of shares of Common Stock or securities convertible into or exercisable for shares of Common Stock at a price less than the exercise price of the Bridge Warrants in which event the exercise price will be reduced to the price at which such
newly issued shares of Common Stock or securities convertible into or exercisable for shares of Common Stock were issued. In addition, if the per share issuance price in this offering is less than 125% of the Exercise Price then in effect, the
Exercise Price would be decreased to the issuance price of the Common Stock being issued in this offering. Upon a decrease of the Exercise Price, the number of shares of Common Stock to be received shall be adjusted such that the total consideration
to be received by the Company upon exercise in full of the Bridge Warrants would equal 150% of the principal amount of the Bridge Note purchased by the holder in the 2021 Bridge Financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the Bridge Warrants, in the event any holder (including its Attribution Parties) of the Bridge Notes who would beneficially own
in excess of the Maximum Percentage of 4.99% of the number of shares of the Common Stock outstanding immediately prior to, and immediately after giving effect to, the conversion of all or any portion of the Bridge Notes, may elect to receive a <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant, or the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, for all shares in excess of the Maximum Percentage. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have
substantially the same terms as the Bridge Warrants except that the exercise price is $0.0001 per share. For more information regarding the Bridge Notes, please see &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results
of Operations-Description of Indebtedness.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>$1M Lender Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2021, the Company issued warrants to purchase [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares of
our Common Stock, which we refer to as the $1M Lender Warrants, to the lenders of the $1M Notes as consideration for the extension of the maturity of the $1M Loan and Security Agreement to September&nbsp;30, 2022. The $1M Lender Warrants expire on
September&nbsp;30, 2026. The $1M Lender Warrants are exercisable for Common Stock at an exercise price equal to the lower of (i)&nbsp;$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share and (ii)&nbsp;a 30%
discount to the offering price for the sale of Common Stock in an initial public offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>$1.5M Lender Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2021, the Company also issued warrants to purchase [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
shares of our Common Stock, which we refer to as the $1.5M Lender Warrants, to noteholders of the $1.5M Notes as consideration for the extension of the maturity of the $1.5M Notes to October&nbsp;31, 2022. The $1.5M Lender Warrants expire on
October&nbsp;12, 2026. The $1M Lender Warrants <U></U>are exercisable for Common Stock at an exercise price equal to the lower of (i)&nbsp;$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share and (ii)&nbsp;a
30% discount to the offering price for the sale of Common Stock in an initial public offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company grants certain employees and board members stock option awards where vesting is contingent upon a service period, as it believes
that such awards better align the interests of its employees with those of its shareholders. Stock option awards are granted with an exercise price equal to or above the market price of the Company&#146;s stock at the date of grant. Certain stock
option awards provide for accelerated vesting if there is a change in control, as defined in the option agreement. Unvested stock options are forfeited when an employee leaves the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where option awards are granted based on service periods, they generally vest quarterly based on three years of continuous service for
executive directors and employees, or 12 months continuous service for directors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and have <FONT STYLE="white-space:nowrap">10-year</FONT> contractual terms. At [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], 2022, there were time-based
options to purchase a total of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock at an average exercise price of
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also grants stock option awards
where vesting is contingent upon meeting various departmental and company-wide performance goals, including FDA and CE Mark regulatory approval and certain EBITDA and funding thresholds. Such performance-based stock options are expected to vest when
the performance criteria and metrics have been met. These stock options have a term of ten years. At [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>], 2022, there were performance-based options to purchase a total of
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock at an average exercise price of $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Antidilution Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approximately
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock issuable upon exercise of the Bridge Notes, [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common
Stock issuable upon exercise of outstanding warrants and the Series C Preferred Stock are subject to a form of antidilution protection provisions that may be triggered by the issuance of Common Stock at a price below the purchase price of the Common
Stock or the exercise price of the warrants in effect, or the issuance of warrants, options, rights or convertible securities that have an exercise price or conversion price less than the purchase price or exercise price, as applicable, other than
for certain previously outstanding securities and certain exempt issuances or securities (as described in the relevant agreement). These investors are to receive additional shares of Common Stock and, with respect to the Bridge Notes and the Bridge
Warrants, an adjustment to the Conversion Price or Exercise Price, as applicable. In addition, the number of shares issuable upon conversion of the Series A Preferred Stock and Series B Preferred Stock will vary depending on the market price of our
Common Stock at the time of conversion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the 2021 Bridge Financing, we entered into the Registration Rights Agreement (with the Purchasers pursuant to which we
agreed to file a resale registration statement no later than 90 days after the date of this prospectus with respect to the shares of Common Stock issuable upon conversion of the Bridge Notes, exercise of the Bridge Warrants or resulting from
anti-dilution provisions in the Bridge Notes or the Bridge Warrants or any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event, collectively referred to as the Registrable
Securities. In the event that the Registration Statement relating to the resale of the Registrable Securities is not declared effective by the SEC on or prior to 150 days after the date of this Prospectus, we are required to pay to each holder of
Registrable Securities an amount in cash equal to two percent of the principal amount of such holder&#146;s bridge notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also
previously granted certain registration rights to the holders of the Series C Preferred Stock. Under the terms of this registration rights agreement, which we refer to as the Series C Registration Rights Agreement, the holders of the Series C
Preferred Stock owning not less than 30% of (i)&nbsp;the Common Stock issuable or issued upon conversion of the Series C Preferred Stock; and (ii)&nbsp;any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or
other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clause (i)&nbsp;above, referred to herein as the Series C Registrable Securities, and the
anticipated aggregate offering price, net of certain expenses, would exceed $10&nbsp;million, may demand at any time after the completion of this offering may demand that the Company file a registration statement relating to the Series C Registrable
Securities owned by the holders who have demanded such registration. In addition, if at any time when it is eligible to use a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement, the Company receives a request from holders of at
least twenty-five percent (25%) of the Series C Registrable Securities then outstanding that the Company file a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement with respect to outstanding Series C Registrable Securities of
such holders having an anticipated aggregate offering price, net of certain expenses, of at least $3&nbsp;million, then the Company will be required to file a registration statement relating to the resale of the Series C Registrable Securities owned
by such holders. Finally, if the Company proposes to register (including, for this purpose, a registration effected by the Company for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shareholders other than the holders of the Series C Preferred Stock) any of the Common Stock under the Securities Act in connection with the public offering of such securities solely for cash,
the Company is required to give each holder of Series C Registrable Securities notice of such registration and such holders may include their Series C Registrable Securities in such registration statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annual Shareholder Meetings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended
and restated bylaws provide that annual shareholder meetings will be held at a date, time and place, if any, as exclusively selected by our Board of Directors. To the extent permitted under applicable law, we may conduct meetings by remote
communications, including by webcast. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover Effects of Certain Provisions of Our Amended and Restated Certificate of Formation, Amended and
Restated Bylaws and Texas Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of formation and amended and restated bylaws and the TBOC contains
provisions, which are summarized in the following paragraphs, that are intended to enhance the likelihood of continuity and stability in the composition of our Board of Directors. These provisions are intended to avoid costly takeover battles,
reduce our vulnerability to a hostile change of control and enhance the ability of our Board of Directors to maximize shareholder value in connection with any unsolicited offer to acquire us. However, these provisions may have an anti-takeover
effect and may delay, deter or prevent a merger or acquisition of the Company by means of a tender offer, a proxy contest or other takeover attempt that a shareholder might consider in its best interest, including those attempts that might result in
a premium over the prevailing market price for the shares of Common Stock held by shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized but unissued capital stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Texas law does not require shareholder approval for any issuance of authorized shares. However, the listing requirements of the Nasdaq, which
would apply if and so long as our Common Stock remains listed on the Nasdaq, require shareholder approval of certain issuances equal to or exceeding 20% of the then outstanding voting power or then outstanding number of shares of Common Stock.
Additional shares that may be issued in the future may be used for a variety of corporate purposes, including future public offerings, to raise additional capital or to facilitate acquisitions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors may generally issue preferred shares on terms calculated to discourage, delay or prevent a change of control of the
Company or the removal of our management. Moreover, our authorized but unissued shares of preferred stock will be available for future issuances without shareholder approval and could be utilized for a variety of corporate purposes, including future
offerings to raise additional capital, to facilitate acquisitions and employee benefit plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the effects of the existence of
unissued and unreserved shares of Common Stock or preferred stock may be to enable our Board of Directors to issue shares to persons friendly to current management, which issuance could render more difficult or discourage an attempt to obtain
control of the Company by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of our management and possibly deprive our shareholders of opportunities to sell their shares of Common Stock at prices higher
than prevailing market prices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Classified Board of Directors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of formation provides that our Board of Directors be divided into three classes of directors, with the
classes to be as nearly equal in number as possible, and with the directors serving three-year terms. As a result, <FONT STYLE="white-space:nowrap">approximately&nbsp;one-third&nbsp;of</FONT> our Board of Directors will be elected each year. The
classification of directors will have the effect of making it more difficult for shareholders to change the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
composition of our Board of Directors. Our amended and restated certificate of formation and amended and restated bylaws will provide that, subject to any rights of holders of preferred stock to
elect additional directors under specified circumstances, the number of directors will be fixed from time to time exclusively pursuant to a resolution adopted by the Board of Directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Removal of directors; vacancies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under
the TBOC, unless otherwise provided in our certificate of formation, directors serving on a classified board may be removed by the shareholders only for cause. Our amended and restated certificate of formation provides that directors may be removed
only with cause. In addition, our amended and restated certificate of formation also provides that, subject to the rights granted to one or more series of preferred stock then outstanding, any vacancies on our Board of Directors will be filled by a
majority of the directors then in office. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No cumulative voting </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Texas law, the right to vote cumulatively does not exist unless the certificate of formation specifically authorizes cumulative voting.
Our amended and restated certificate of formation does not authorize cumulative voting. Therefore, shareholders holding a majority in voting power of the shares of our stock entitled to vote generally in the election of directors will be able to
elect all our directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special shareholder meetings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of formation provides that special meetings of our shareholders may be called at any time only by or at
the direction of the Board of Directors, the chairman of the Board of Directors or the chief executive officer of the Company is entitled to be voted at the special meeting. Our amended and restated bylaws prohibit the conduct of any business at a
special meeting other than as specified in the notice for such meeting. These provisions may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in control or management of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Requirements for advance notification of director nominations and shareholder proposals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws establish advance notice procedures with respect to shareholder proposals and the nomination of for election as
directors, other than nominations made by or at the direction of the Board of Directors or a committee of the Board of Directors. In order for any matter to be &#147;properly brought&#148; before a meeting, a shareholder will have to comply with
advance notice requirements and provide us with certain information. Generally, to be timely, a shareholder&#146;s notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary
date of the immediately preceding annual meeting of shareholders. Our amended and restated bylaws will also specify requirements as to the form and content of a shareholder&#146;s notice. Our amended and restated bylaws will allow the chairman of
the meeting at a meeting of the shareholders to adopt rules and regulations for the conduct of meetings which may have the effect of precluding the conduct of certain business at a meeting if the rules and regulations are not followed. These
provisions will not apply to our Sponsors and their affiliates so long as the shareholders agreement remains in effect. These provisions may also defer, delay or discourage a potential acquiror from conducting a solicitation of proxies to elect the
acquiror&#146;s own slate of directors or otherwise attempting to influence or obtain control of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shareholder action by written consent
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of formation will provide that any action required or permitted to be taken at an annual or
special meeting of shareholders may be taken by written consent in lieu of a meeting of shareholders only with the unanimous written consent of our shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment and restatement of bylaws </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws provide that the Board of Directors is expressly authorized to make, alter, amend, change, add to, rescind or
repeal, in whole or in part, our amended and restated bylaws without a shareholder vote in any matter not inconsistent with the laws of the State of Texas and our amended and restated certificate of formation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combination of the classification of our Board of Directors and the lack of cumulative voting will make it more difficult for shareholders
to replace our Board of Directors as well as for another party to obtain control of us by replacing our Board of Directors. Because our Board of Directors has the power to retain and discharge our officers, these provisions could also make it more
difficult for existing shareholders or another party to effect a change in management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may have the effect of deterring
hostile takeovers or delaying or preventing changes in control of our management or the Company, such as a merger, reorganization or tender offer. These provisions are intended to enhance the likelihood of continued stability in the composition of
our Board of Directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of the Company. These provisions are designed to reduce our vulnerability to an unsolicited acquisition
proposal. The provisions are also intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they
also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. Such provisions may also have the effect of preventing changes in management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dissenters&#146; rights of appraisal and payment </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the TBOC, with certain exceptions, our shareholders will have appraisal rights in connection with a merger, a sale of all or
substantially all of our assets, an interest exchange or a conversion. Pursuant to the TBOC, shareholders who properly request and perfect appraisal rights in connection with such merger, sale of all or substantially all of our assets, interest
exchange or conversion will have the right to receive payment of the fair value of their shares as agreed to between the shareholder and the Company or, if they are unable to reach agreement, as determined by the State District Court in Tarrant
County, Texas. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shareholders&#146; derivative actions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the TBOC, any of our shareholders may bring an action in our name to procure a judgment in our favor, also known as a derivative action,
provided that the shareholder bringing the action (i)&nbsp;is a holder of our shares at the time of the transaction to which the action relates or such shareholder became a shareholder by operation of law from a person that was a shareholder at the
time of the transaction to which the action relates and (ii)&nbsp;fairly and adequately represents the interests of the Company in enforcing the right of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conflicts of interest </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Texas law permits
corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors or shareholders. Our amended and restated certificate of formation will, to the maximum
extent permitted from time to time by Texas law, renounce any interest or expectancy that we have in, or right to be offered an opportunity to participate in, specified business opportunities that are from time to time presented to our officers,
directors or shareholders or their respective affiliates, other than those officers, directors, shareholders or affiliates who are our or our subsidiaries&#146; employees. Our amended and restated certificate of formation will provide that, to the
fullest extent permitted by law, none of our affiliates or any director who is not employed by us (including <FONT STYLE="white-space:nowrap">any&nbsp;non-employee&nbsp;director</FONT> who serves as one of our officers in both his director and
officer capacities) or his or her affiliates will have any duty to refrain from (1)&nbsp;engaging in a corporate opportunity in the same or similar lines of business in which we or our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affiliates now engage or propose to engage or (2)&nbsp;otherwise competing with us or our affiliates. In addition, to the fullest extent permitted by law, in the event that a <FONT
STYLE="white-space:nowrap">non-employee&nbsp;director</FONT> acquires knowledge of a potential transaction or other business opportunity which may be a corporate opportunity for itself or himself or its or his affiliates or for us or our affiliates,
such person will have no duty to communicate or offer such transaction or business opportunity to us or any of our affiliates and they may take any such opportunity for themselves or offer it to another person or entity. Our amended and restated
certificate of formation will not renounce our interest in any business opportunity that is expressly offered to <FONT STYLE="white-space:nowrap">a&nbsp;non-employee&nbsp;director</FONT> solely in his or her capacity as a director or officer of the
Company. To the fullest extent permitted by law, no business opportunity will be deemed to be a potential corporate opportunity for us unless we would be permitted, to undertake the opportunity under our amended and restated certificate of
formation, we have sufficient financial resources to undertake the opportunity and the opportunity would be in line with our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitations on
liability and indemnification of officers and directors </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The TBOC authorizes corporations to limit or eliminate the personal liability
of directors to corporations and their shareholders for monetary damages for breaches of directors&#146; fiduciary duties (other than breaches of the directors&#146; duty of loyalty to corporations or their shareholders), subject to certain
exceptions. Our amended and restated certificate of formation includes a provision that eliminates the personal liability of directors for monetary damages for any breach of fiduciary duty as a director, except to the extent such exemption from
liability or limitation thereof is not permitted under the TBOC. The effect of these provisions will be to eliminate the rights of us and our shareholders, through shareholders&#146; derivative suits on our behalf, to recover monetary damages from a
director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior. However, exculpation will not apply to any director if the director has acted in bad faith, engaged in intentional misconduct,
knowingly violated the law, authorized illegal dividends or redemptions, derived an improper benefit from his or her actions as a director or engaged in an act or omission for which the liability of the director is expressly provided by an
applicable statute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws provide that we must indemnify and advance expenses to our directors and officers to
the fullest extent authorized by the TBOC. We also expressly authorized to carry directors&#146; and officers&#146; liability insurance providing indemnification for our directors, officers and certain employees for some liabilities. We believe that
these indemnification and advancement provisions and insurance will be useful to attract and retain qualified directors and officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
limitation of liability, indemnification and advancement provisions in our amended and restated certificate of formation and amended and restated bylaws may discourage shareholders from bringing a lawsuit against directors for breach of their
fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our shareholders. In addition,
your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is currently no pending material litigation or proceeding involving any of our directors, officers or employees for which
indemnification is sought. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Business combinations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Title 2, Chapter 21, Subchapter M of the TBOC, we may not engage in certain &#147;business combinations&#148; with any &#147;affiliated
shareholder,&#148; or any affiliate or associate of the affiliated shareholder for a three-year period following the tie that the shareholder became an affiliated shareholder, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to such time, our Board of Directors approved either the business combination of the transaction which
resulted in the shareholder becoming an affiliated shareholder; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not less than six months after the affiliated shareholders&#146; share acquisition date, the business combination
is approved by the affirmative vote at a meeting, and not by written consent, of holders of at least 66<SUP STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of our outstanding voting shares that are not owned by
the affiliated shareholder or an affiliate or associate of the affiliated shareholder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a &#147;business
combination&#148; includes a merger, asset or stock sale or other similar transaction. Subject to certain exceptions, an &#147;affiliated shareholder&#148; is a person who beneficially owns (as determined pursuant to Title 2, Chapter 21, Subchapter
M of the TBOC), or within the previous three years beneficially owned, 20% or more of our outstanding voting shares. For purposes of this section only, &#147;voting share&#148; has the meaning given to it in Title 2, Chapter 21, Subchapter M of the
TBOC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under certain circumstances, this provision will make it more difficult for a person who would be an &#147;affiliated
shareholder&#148; to effect various business combinations with the Company for a three-year period. This provision may encourage companies interested in acquiring the Company to negotiate in advance with our Board of Directors because the
shareholder approval requirement would be avoided if our Board of Directors approves either the business combination or the transaction that results in such shareholder becoming an affiliated shareholder. These provisions also may have the effect of
preventing changes in our Board of Directors and may make it more difficult to accomplish transactions which shareholders may otherwise deem to be in their best interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to apply to have our
Common Stock listed on the Nasdaq Capital market under the symbol &#147;[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>].&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer agent and registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our Common Stock is American Stock Transfer and Trust Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_16"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we intend to apply to list our Common Stock on Nasdaq, under the symbol
&#147;[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>].&#148; No assurance can be given that our application will be approved. Sales of substantial amounts of shares of our Common Stock in the public market, or the
perception that such sales could occur, could adversely affect prevailing market prices of our Common Stock. Upon completion of this offering, we will have [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] outstanding
shares of Common Stock, assuming the underwriters do not exercise their over-allotment option. All of the shares of Common Stock sold in this offering will be freely transferable without restriction or further registration under the Securities Act
by persons other than by our affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our executive officers, directors, and certain shareholders have agreed not to offer, sell, agree to sell, directly or indirectly, or
otherwise dispose of any shares of Common Stock or any other securities convertible into or exchangeable for Common Stock except for the Common Stock offered in this offering without the prior written consent of the representative for a period of
180 days after the consummation of this offering. After the expiration of such day period, the shares of Common Stock held by our directors, executive officers or certain of our other existing shareholders may be sold subject to the restrictions
under applicable securities laws or by means of registered public offerings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144 under the Securities Act as in effect on the date hereof, beginning 90 days after the date hereof, a person who
holds restricted shares of Common Stock (assuming there are any restricted shares) and is not one of our affiliates at any time during the three months preceding a sale, and who has beneficially owned these restricted shares for at least six months,
would be entitled to sell an unlimited number of shares of our Common Stock, provided current public information about us is available. In addition, under Rule 144, a person who holds restricted shares in us and is not one of our affiliates at any
time during the three months preceding a sale, and who has beneficially owned these restricted shares for at least one year, would be entitled to sell an unlimited number of shares immediately upon the closing of this offering without regard to
whether current public information about us is available. Beginning 90 days after the date hereof, our affiliates who have beneficially owned shares of our Common Stock for at least six months will be entitled to sell within any three-month period a
number of shares that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of Common Stock then outstanding; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of shares of our Common Stock on Nasdaq during the four calendar weeks
preceding the filing of a notice on Form 144 with respect to the sale; provided that current public information about us is available and the affiliate complies with the manner of sale requirements imposed by Rule 144. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Affiliates are also subject to additional restrictions on the manner of sales under Rule 144 and notice filing requirements. We cannot
estimate the number of our Common Stock that our existing shareholders will elect to sell. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulation S </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation S under the Securities Act provides that securities owned by any person may be sold without registration in the United States,
provided that the sale is effected in an offshore transaction and no directed selling efforts are made in the United States (as these terms are defined in Regulation S), subject to certain other conditions. In general, this means that our Common
Stock may be sold in some manner outside the United States without requiring registration in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 701 of the Securities Act as currently in effect, each of our employees, consultants or advisors who purchases shares of
our Common Stock from us in connection with a compensatory share plan or other written agreement executed prior to the completion of this offering is eligible to resell such shares of our Common Stock in reliance on Rule 144, but without compliance
with some of the restrictions, including the holding period, contained in Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES
NOT COVER ALL SHARE TRANSFER RESTRICTION MATTERS THAT MAY BE OF IMPORTANCE TO A PROSPECTIVE INVESTOR. EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN LEGAL ADVISOR REGARDING THE PARTICULAR SECURITIES LAWS AND TRANSFER RESTRICTION CONSEQUENCES OF
PURCHASING, HOLDING, AND DISPOSING OF THE COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_17"></A>U.S. FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THE FOLLOWING SUMMARY IS INCLUDED HEREIN FOR GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR TAX
ADVICE. EACH U.S. HOLDER SHOULD CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND SALE OF COMMON STOCK AND AMERICAN DEPOSITARY SHARES, INCLUDING THE EFFECTS OF APPLICABLE
STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND POSSIBLE CHANGES IN THE TAX LAWS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the limitations described in the next two
paragraphs, the following discussion summarizes the material U.S. federal income tax consequences to a &#147;U.S. Holder&#148; arising from the purchase, ownership and sale of the Common Stock. For this purpose, a &#147;U.S. Holder&#148; is a holder
of Common Stock that is: (1)&nbsp;an individual citizen or resident of the United States, including an alien individual who is a lawful permanent resident of the United States or meets the substantial presence residency test under U.S. federal
income tax laws; (2)&nbsp;a corporation (or entity treated as a corporation for U.S. federal income tax purposes) or a partnership (other than a partnership that is not treated as a U.S. person under any applicable U.S. Treasury regulations) created
or organized under the laws of the United States or the District of Columbia or any political subdivision thereof; (3)&nbsp;an estate, the income of which is includable in gross income for U.S. federal income tax purposes regardless of source;
(4)&nbsp;a trust if a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust; or (5)&nbsp;a trust that
has a valid election in effect to be treated as a U.S. person to the extent provided in U.S. Treasury regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is for
general information purposes only and does not purport to be a comprehensive description of all of the U.S. federal income tax considerations that may be relevant to a decision to purchase our Common Stock. This summary generally considers only U.S.
Holders that will own our Common Stock as capital assets. Except to the limited extent discussed below, this summary does not consider the U.S. federal tax consequences to a person that is not a U.S. Holder, nor does it describe the rules applicable
to determine a taxpayer&#146;s status as a U.S. Holder. This summary is based on the provisions of the Internal Revenue Code of 1986, as amended, or the Code, final, temporary and proposed U.S. Treasury regulations promulgated thereunder,
administrative and judicial interpretations thereof, all as in effect as of the date hereof and all of which are subject to change, possibly on a retroactive basis, and all of which are open to differing interpretations. We will not seek a ruling
from the IRS with regard to the U.S. federal income tax treatment of an investment in our Common Stock by U.S. Holders and, therefore, can provide no assurances that the IRS will agree with the conclusions set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not address all of the aspects of U.S. federal income taxation that may be relevant to a particular U.S. holder based on
such holder&#146;s particular circumstances and in particular does not discuss any estate, gift, generation-skipping transfer, state, local, excise or foreign tax considerations. In addition, this discussion does not address the U.S. federal income
tax treatment of a U.S. Holder who is: (1)&nbsp;a bank, life insurance company, regulated investment company, or other financial institution or &#147;financial services entity;&#148; (2)&nbsp;a broker or dealer in securities or foreign currency;
(3)&nbsp;a person who acquired our Common Stock in connection with employment or other performance of services; (4)&nbsp;a U.S. Holder that is subject to the U.S. alternative minimum tax; (5)&nbsp;a U.S. Holder that holds our Common Stock as a hedge
or as part of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction transaction for U.S. federal income tax purposes; (6)&nbsp;a <FONT STYLE="white-space:nowrap">tax-exempt</FONT> entity; (7)&nbsp;real estate
investment trusts or grantor trusts; (8)&nbsp;a U.S. Holder that expatriates out of the United States or a former long-term resident of the United States; or (9)&nbsp;a person having a functional currency other than the U.S. dollar. This discussion
does not address the U.S. federal income tax treatment of a U.S. Holder that owns, directly or constructively, at any time, Common Stock representing 10% or more of our voting power. Additionally, the U.S. federal income tax treatment of
partnerships (or other pass-through entities) or persons who hold Common Stock through a partnership or other pass-through entity are not addressed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each prospective investor is advised to consult his or her own tax adviser for the specific
tax consequences to that investor of purchasing, holding or disposing of our Common Stock, including the effects of applicable state, local, foreign or other tax laws and possible changes in the tax laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxation of Dividends Paid on Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not intend to pay dividends in the foreseeable future. In the event that we do pay dividends, and subject to the discussion of
&#147;qualified dividend income&#148; below, a U.S. Holder, other than certain U.S. Holders that are U.S. corporations, will be required to include in gross income as ordinary income the amount of any distribution paid on Common Stock to the extent
that such distribution does not exceed our current and accumulated earnings and profits, as determined for U.S. federal income tax purposes. The amount of a distribution which exceeds our earnings and profits will be treated first as a <FONT
STYLE="white-space:nowrap">non-taxable</FONT> return of capital, reducing the U.S. Holder&#146;s tax basis for the Common Stock to the extent thereof, and then capital gain. We do not expect to maintain calculations of our earnings and profits under
U.S. federal income tax principles and, therefore, U.S. Holders should expect that the entire amount of any distribution generally will be reported as dividend income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, preferential tax rates for &#147;qualified dividend income&#148; and long-term capital gains are applicable for U.S. Holders that
are individuals, estates or trusts. &#147;Qualified dividend income&#148; means, inter alia, dividends received from a U.S. Corporation. A U.S. Holder will not be entitled to the preferential rate: (1)&nbsp;if the U.S. Holder has not held our Common
Stock for at least 61 days of the 121 day period beginning on the date which is 60 days before the <FONT STYLE="white-space:nowrap">ex-dividend</FONT> date, or (2)&nbsp;to the extent the U.S. Holder is under an obligation to make related payments on
substantially similar property. Any days during which the U.S. Holder has diminished its risk of loss on our Common Stock are not counted towards meeting the <FONT STYLE="white-space:nowrap">61-day</FONT> holding period. Finally, U.S. Holders who
elect to treat the dividend income as &#147;investment income&#148; pursuant to Code section 163(d)(4) will not be eligible for the preferential rate of taxation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of a distribution of property other than cash with respect to our Common Stock will be measured by the amount of the fair market
value of any property distributed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxation of the Disposition of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the sale, exchange or other disposition of our Common Stock, a U.S. Holder will recognize capital gain or loss in an amount equal to the
difference between such U.S. Holder&#146;s tax basis for the Common Stock in U.S. dollars and the amount realized on the disposition. The gain or loss realized on the sale, exchange or other disposition of Common Stock will be long-term capital gain
or loss if the U.S. Holder has a holding period of more than one year at the time of the disposition. Individuals who recognize long-term capital gains may be taxed on such gains at reduced rates of tax. The deduction of capital losses is subject to
various limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax on Net Investment Income </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders who are individuals, estates or trusts will be required to pay a 3.8% Medicare tax on their net investment income
(including dividends on and gains from the sale or other disposition of our Common Stock), or in the case of estates and trusts on their net investment income that is not distributed to beneficiaries of the estate or trust. In each case, the 3.8%
Medicare tax applies only to the extent the U.S. Holder&#146;s total adjusted income exceeds applicable thresholds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Consequences for <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided below, an individual, corporation, estate or
trust that is not a U.S. Holder, referred to below as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder, generally will not be subject to U.S. federal income or withholding tax on the payment of dividends on, and the proceeds from the
disposition of, our Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder may be subject to U.S. federal
income tax on a dividend paid on our Common Stock or gain from the disposition of our Common Stock if: (1)&nbsp;such item is effectively connected with the conduct by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder of a trade or business
in the United States and, if required by an applicable income tax treaty is attributable to a permanent establishment or fixed place of business in the United States; or (2)&nbsp;in the case of a disposition of our Common Stock, the individual <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> Holder is present in the United States for 183 days or more in the taxable year of the disposition and other specified conditions are met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holders will not be subject to backup withholding with respect to the payment of
dividends on our Common Stock if payment is made through a paying agent, or office of a foreign broker outside the United States. However, if payment is made in the United States or by a U.S. related person,
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holders may be subject to backup withholding, unless the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder provides an applicable IRS Form <FONT STYLE="white-space:nowrap">W-8</FONT> (or a
substantially similar form) certifying its foreign status, or otherwise establishes an exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of any backup withholding
from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder will be allowed as a credit against such holder&#146;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is
timely furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder may be subject to backup withholding at a rate of 24% with respect to cash dividends and proceeds from a disposition of Common
Stock. In general, backup withholding will apply only if a U.S. Holder fails to comply with specified identification procedures. Backup withholding will not apply with respect to payments made to designated exempt recipients, such as corporations
and <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations. Backup withholding is not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a U.S. Holder, provided that the required information
is timely furnished to the IRS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_18"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriter named below have entered into an underwriting agreement with respect to the shares of Common Stock being offered.
Subject to certain conditions, the underwriter has agreed to purchase the number of units indicated in the following table. The Benchmark Company, LLC is acting as the representatives of the underwriter. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Benchmark Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter is committed to take and pay for all of the shares of Common Stock being offered, if any are
taken, other than the Common Stock covered by the option described below unless and until this option is exercised. The underwriting agreement also provides that if underwriter defaults, the offering may be terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter has an option to buy up to [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] additional shares
of Common Stock included in the shares of Common Stock and/or additional warrants to purchase [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of Common Stock from us [in any combination thereof] to cover
sales of shares by the underwriter which exceed the number of shares specified in the table above. The underwriter has [30] days from the date of this prospectus to exercise this over-allotment option. If any shares and/or additional warrants are
purchased with this over-allotment option, the underwriter will purchase shares and/or additional warrants in approximately the same proportion as shown in the table above. If any additional shares of common stock and/or additional warrants are
purchased, the underwriters will offer the additional shares and additional warrants, respectively. on the same terms as those on which the shares and warrants are being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriter by us assuming both no
exercise and full exercise of the underwriter&#146;s over-allotment option. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Without<br><FONT STYLE="white-space:nowrap">Over-Allotment</FONT><br>Exercise</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">With Full<br><FONT STYLE="white-space:nowrap">Over-Allotment</FONT><br>Exercise</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per share of Common Stock(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$<U></U></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><U></U>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD NOWRAP VALIGN="bottom">]&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The underwriter will receive a discount of
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]% of the public offering price. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Common
Stock sold by the underwriter to the public will initially be offered at the initial public offering price set forth on the cover of this prospectus. [Any units sold by the underwriter to securities dealers may be sold at a discount of up to
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per unit from the initial public offering price.] After the initial offering of the units, the representatives may change the offering price and the other selling
terms. The offering of the shares of Common Stock by the underwriter is subject to receipt and acceptance and subject to the underwriter&#146;s right to reject any order in whole or in part. Sales of shares made outside of the United States may be
made by affiliates of the underwriter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expense Reimbursement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to pay or reimburse the underwriter for certain of their actual
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses, including &#147;road show,&#148; diligence, filing fees and communication expenses associated with the review </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of this offering by the Financial Industry Regulatory Authority, Inc., and legal fees up to a maximum of
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]. We have also agreed to pay the costs of background checks on our senior management in an amount of up to
$[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-accountable</FONT> Expense Allowance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with and upon closing of this offering, the Company shall pay to the underwriter a
<FONT STYLE="white-space:nowrap">non-accountable</FONT> expense allowance equal to one percent (1%) of the gross proceeds received by the Company from the sale of the units. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Purchase Option </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing
of this offering, we have agreed to sell to the underwriter a share purchase option to purchase [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]% of the total number of shares sold in this offering (including shares
sold upon the underwriter&#146;s exercise of the over-allotment option). The share purchase option will have an exercise price equal to [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]% of the public offering price
set forth on the cover page of this prospectus (or $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share), subject to standard anti-dilution adjustments for share splits and similar transactions. The share
purchase option will be exercisable at any time, and from time to time, in whole or in part, during the period commencing 180 days from the commencement of sales in this offering, and expiring
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] years from the commencement of sales in this offering. The share purchase option is also exercisable on a cashless basis. The share purchase option has been deemed
compensation by FINRA and is therefore subject to a <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> pursuant to FINRA Rule 5110(e)(1). Except as permitted by Rule 5110(e)(1), the underwriter (or
permitted assignees under the Rule) will not sell, transfer, assign, pledge, or hypothecate the share purchase option or the securities underlying the share purchase option, nor will any, of them engage in any hedging, short sale, derivative, put,
or call transaction that would result in the effective economic disposition of the option or the underlying securities for a period of 180 days from the commencement of sales under this prospectus. Although the share purchase option and the
underlying securities have been registered in the registration statement of which this prospectus forms a part, we have also agreed to provide holders of the share purchase option one demand registration right and unlimited &#147;piggy-back&#148;
registration rights with respect to the securities underlying the share purchase option on only one occasion to register all of such securities at such time as we become eligible to file a resale registration statement on Form <FONT
STYLE="white-space:nowrap">S-3.</FONT> These registration rights apply to all of the securities directly and indirectly issuable upon exercise of the share purchase option, and shall expire on the fourth anniversary of the commencement of sales in
this offering. We will bear all fees and expenses attendant to registering the securities issuable on exercise of the share purchase option, other than underwriting commissions incurred and payable by the holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed with the underwriter that we will not, without the prior consent of the representatives, directly or indirectly sell, offer,
contract or grant any option to sell, pledge, transfer, or otherwise dispose of or enter into any transaction which may result in the disposition of any common stock or securities convertible into, exchangeable or exercisable for any common stock
for a period of [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] months after the effectiveness of this registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, each of our executive officers and directors and our primary shareholders have agreed with the underwriter not to directly or
indirectly sell, offer, contract or grant any option to sell, pledge, transfer (excluding intra-family transfers, transfers to a trust for estate planning purposes or to beneficiaries of officers, directors and shareholders upon their death), or
otherwise dispose of or enter into any transaction which may result in the disposition of any common stock or securities convertible into, exchangeable or exercisable for any common stock, without the prior written consent of the representative,
until after (i)&nbsp;the three month anniversary of the effective date of this offering with respect to <FONT STYLE="white-space:nowrap">one-third</FONT> of such shareholder&#146;s shares of Common Stock, (ii)&nbsp;the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">four month anniversary of the effective date of this offering with respect to <FONT STYLE="white-space:nowrap">one-third</FONT> of such shareholder&#146;s
shares of Common Stock, and (iii)&nbsp;the five month anniversary of the effective date of this offering with respect to the remaining shares of Common Stock held by such shareholder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stabilization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this
offering, the underwriter may engage in transactions that stabilize, maintain or otherwise affect the price of our Common Stock. Specifically, the underwriter may over-allot in connection with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this offering by selling more shares than they are obligated to purchase under the underwriting agreement, creating a short position in our securities. The short position may be either a covered
short position or a naked short position. In a covered short position, the number of securities over-allotted by the underwriters is not greater than the number of securities that they may purchase in the over-allotment option. In a naked short
position, the number of securities involved is greater than the number of securities in the over-allotment option. To close out a short position or to stabilize the price per security the underwriters may bid for, and purchase, securities in the
open market. The underwriters may also elect to reduce any short position by exercising all or part of the over-allotment option. In determining the source of securities to close out the short position, the underwriters will consider, among other
things, the price of the security available for purchase in the open market as compared to the price at which it may purchase the security through the over-allotment option. If the underwriters sell more than could be covered by the over-allotment
option, a naked short position, the position can only be closed out by buying securities in the open market. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of
the securities in the open market after pricing that could adversely affect investors who purchase in the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, the
underwriter may bid for, and purchase, securities in market making transactions, including &#147;passive&#148; market making transactions as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing transactions may stabilize or maintain the market price of our securities at a price that is higher than the price that might
otherwise exist in the absence of these activities. The underwriter is not required to engage in these activities, and may discontinue any of these activities at any time without notice. These transactions may be effected on a national securities
exchange or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriter and selling group, if any, or their affiliates may engage in
passive market making transactions in common stock on a national securities exchange immediately prior to the commencement of sales in this offering, in accordance with Rule 103 of Regulation M under the Exchange Act. Rule 103 generally provides
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a passive market maker may not effect transactions or display bids for our Common Stock in excess of the highest
independent bid price by persons who are not passive market makers; net purchases by a passive market maker on each day are generally limited to 30% of the passive market maker&#146;s average daily trading volume in our common share during a
specified <FONT STYLE="white-space:nowrap">two-month</FONT> prior period or 200 shares, whichever is greater, and must be discontinued when that limit is reached; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">passive market making bids must be identified as such. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such passive market transactions may stabilize or maintain the market price of our common stock at a level above that which might otherwise prevail and, if
commenced, may be discontinued at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriter against certain liabilities, including liabilities under the Securities Act and liabilities arising
from breaches of representations and warranties contained in the underwriting agreement, or to contribute to payments that the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participation in Future Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until
twelve months from the closing of the offering, the underwriter shall have a right of first refusal to act on our behalf as exclusive placement agent or sole book-running manager and sole lead managing underwriter, as applicable, for any offering of
securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Determination of Public Offering Price </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has not been a public market for our shares and warrants. The public offering price of the shares offered by this
prospectus has been determined by negotiation between us and the underwriter. Among the factors considered in determining the public offering price of the shares were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our history and our prospects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial information and historical performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the industry in which we operate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the status and development prospects for our device; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the experience and skills of our executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the general condition of the securities market at the time of this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering price stated on the cover page of this prospectus should not be considered an indication of the actual value of the securities.
That price is subject to change as a result of market conditions and other factors, and we cannot assure you that the securities can be resold at or above the public offering price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our
common stock and the warrants included in the units on the Nasdaq Capital Market under the symbols &#147;[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]&#148; and
&#147;[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>],&#148; respectively, upon our satisfaction of the exchange&#146;s initial listing criteria, including the completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in
electronic format may be made available on websites or through other online services maintained by the underwriter of this offering, or by its affiliates. Other than the prospectus in electronic format, the information on the underwriter&#146;s
website and any information contained in any other website maintained by the underwriter is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or the
underwriters in their capacity as underwriters, and should not be relied upon by investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter has informed us that they do not expect to confirm sales of our shares offered by this prospectus to any accounts over which
they exercise discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter and its affiliates may in the future engage in investment banking and other
commercial dealings in the ordinary course of business with us or our affiliates. They may in the future receive customary fees and commissions for these transactions. In addition, in the ordinary course of their business activities, the underwriter
and its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their
customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research
views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter and its respective affiliates is a full service financial institution engaged in various activities, which may include sales
and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and <FONT STYLE="white-space:nowrap">non-financial</FONT> activities and services. The underwriter and its respective affiliates have provided, and may in the future provide, a variety of these
services to the issuer and to persons and entities with relationships with the issuer, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of their various business activities, the underwriter and its respective affiliates, officers, directors and employees
may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their customers,
and such investment and trading activities may involve or relate to assets, securities or instruments of the issuer (directly, as collateral securing other obligations or otherwise) or persons and entities with relationships with the issuer. The
underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas or publish or express independent research views in respect of such assets, securities or instruments and may at
any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling
Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute an offer to sell to, or a solicitation of an offer to buy from, anyone in any country
or jurisdiction (i)&nbsp;in which such an offer or solicitation is not authorized, (ii)&nbsp;in which any person making such offer or solicitation is not qualified to do so or (iii)&nbsp;in which any such offer or solicitation would otherwise be
unlawful. No action has been taken that would, or is intended to, permit a public offer of the units or possession or distribution of this prospectus or any other offering or publicity material relating to the units in any country or jurisdiction
(other than the U.S.) where any such action for that purpose is required. Accordingly, each underwriter has undertaken that it will not, directly or indirectly, offer or sell any units or have in its possession, distribute or publish any prospectus,
form of application, advertisement or other document or information in any country or jurisdiction except under circumstances that will, to the best of its knowledge and belief, result in compliance with any applicable laws and regulations and all
offers and sales of units by it will be made on the same terms.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Switzerland </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is not intended to constitute an offer or solicitation to purchase or invest in the securities described herein. The securities
may not be publicly offered, directly or indirectly, in Switzerland within the meaning of the Swiss Financial Services Act, or FinSA, and will not be listed on the SIX Swiss Exchange or on any other exchange or regulated trading facility in
Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities constitutes a prospectus as such term is understood pursuant to the FinSA, and neither this prospectus nor any other offering or marketing
material relating to the securities may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>European Economic Area </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Relevant State, no securities have been offered or will be offered pursuant to this offering to the public in any Relevant
State prior to the publication of a prospectus in relation to the securities which have been approved by the competent authority in such Relevant State or, where appropriate, approved in another Relevant State with notification provided to the
competent authority in such Relevant State, all in accordance with the Prospectus Regulation, except that the securities may be offered to the public in any Relevant State at any time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity that is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the
Prospectus Regulation), subject to obtaining the prior consent of the representative for any such offer; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This all applies so long as no such offer of the securities requires the Company or any underwriter to publish a prospectus pursuant to
Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes
of this provision, (i)&nbsp;the expression an &#147;offer to the public&#148; in relation to securities in the UK means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be
offered so as to enable an investor to decide to purchase or subscribe for any securities and (ii)&nbsp;the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>United Kingdom </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No securities have been
offered or will be offered pursuant to this offering to the public in the UK prior to the publication of a prospectus in relation to the securities which have been approved by the Financial Conduct Authority of the UK, except that the shares may be
offered to the public in the UK at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the
Prospectus Regulation), subject to obtaining the prior consent of the representative for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Section&nbsp;86 of the UK&#146;s Financial Services and Markets Act
2000, as amended, or FSMA. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This all applies so long as no such offer of the shares requires the Company or any
underwriter to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, (i)&nbsp;the expression an &#147;offer to the public&#148; in relation to securities in the UK means the
communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase or subscribe for any securities and (ii)&nbsp;the expression
&#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The communication of this prospectus and any other document or
materials relating to the issue of the securities offered hereby is not being made, and such documents and/or materials have not been approved, by an authorized person for the purposes of Section&nbsp;21 of the FSMA. Accordingly, such documents
and/or materials are not being distributed to, and must not be passed on to, the general public in the UK. The communication of such documents and/or materials as a financial promotion is only being made to and directed at persons outside the UK and
those persons in the UK who have professional experience in matters relating to investments and who fall within the definition of investment professionals (as defined in Article 19(5) of the FSMA), or who fall within Article 49(2)(a) to (d)&nbsp;of
the Financial Promotion Order, or who are any other persons to whom it may otherwise lawfully be made under the Financial Promotion Order (all such persons together being referred to as &#147;relevant persons&#148;). In the UK, the securities
offered hereby are only available to, and any investment or investment activity to which this prospectus relates will be engaged only with, relevant persons. Any person in the UK that is not a relevant person should not act or rely on this
prospectus or any of its contents. Each underwriter has represented, warranted and agreed that it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in
investment activity (within the meaning of Section&nbsp;21 of the FSMA) received by it in connection with the issue or sale of the securities in circumstances in which Section&nbsp;21(1) of the FSMA does not apply to the Company; and it has complied
with and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the securities in, from or otherwise involving the UK. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Conflict of Interest </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Benchmark Company, LLC is acting as the representative for the underwriter in connection with this offering. An affiliate and a principal
of The Benchmark Company, LLC holds a position as a member of the Board of Directors of our company, as well as a member of the supervisory board of our parent, Biofrontera, AG. While those positions do not constitute a &#147;conflict of
interest&#148; for purposes of Rule 5121(f)(5) of FINRA, they represent a potential conflict of interest that may impact The Benchmark Company, LLC&#146;s independence in its execution of its diligence and pricing obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_19"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal matters concerning this offering will be passed upon for us by Jackson Walker L.L.P., Dallas, Texas. Certain legal matters with
respect to the legality of the issuance of the securities offered by this prospectus. Certain legal matters related to the offering will be passed upon for the underwriters by Mitchell Silberberg Knupp LLP, New York, New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial
statements for Fiscal 2021 and Fiscal 2020 that are included in this prospectus have been so included in reliance upon the report of Haskell&nbsp;&amp; White LLP, an independent registered public accounting firm, given on the authority of said firm
as experts in auditing and accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_20"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> which includes exhibits, schedules
and amendments, under the Securities Act with respect to the shares of our Common Stock we are offering pursuant to this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information set
forth in the registration statement, some of which is contained in exhibits to the registration statement, as permitted by the rules and regulations of the SEC. For further information with respect to us and our Common Stock, we refer you to the
registration statement, including the exhibits filed as a part of the registration statement. Statements made in this prospectus concerning the contents of any contract, agreement or other document are summaries of all material information about the
contract, agreement or other document summarized, but are not complete descriptions of all terms of those contracts, agreements or other documents. If we filed any of those contracts, agreements or other documents as an exhibit to the registration
statement, you may read the contract, agreement or other document itself for a complete description of its terms. Each statement in this prospectus relating to a contract, agreement or other document filed as an exhibit is qualified in all respects
by the filed exhibit. When we complete this offering, we will become subject to the information and reporting requirements of the Exchange Act and, in accordance with law, we will be required to file annual, quarterly and special reports, proxy
statements and other information with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You can read our SEC filings, including the registration statement, over the Internet at
the SEC&#146;s website at<I>&nbsp;www.secgov</I>. We also maintain a website at<I>&nbsp;www.heartsciences.com</I>, at which, following the completion of this offering, you may access our annual, quarterly and special reports, proxy statements and
other information free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on, or that can be accessed through, our website does not constitute part of this
prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. Investors should not rely on any such information in deciding whether to purchase shares of our Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308g69l36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATRIES, INC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_21"></A>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO FINANCIAL STATEMNTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin271308_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin271308_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin271308_3">Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin271308_4">Statements of Stockholders&#146; (Deficit) Equity</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin271308_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin271308_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to the
financial statements</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin271308_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and the Board of Directors of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Heart Test
Laboratories, Inc. dba HeartSciences </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Southlake, Texas </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on the Financial Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
audited the accompanying balance sheets of Heart Test Laboratories, Inc. dba HeartSciences (the &#147;Company&#148;) as of April&nbsp;30, 2021 and 2020, the related statements of operations, stockholders&#146; (deficit) equity, and cash flows for
each of the two years in the period ended April&nbsp;30, 2021, and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of April&nbsp;30, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended April&nbsp;30, 2021, in conformity with U.S. generally accepted accounting principles.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has experienced recurring losses, negative cash flows from operations, limited capital
resources, a net stockholders&#146; deficit, and significant debt obligations. These matters raise substantial doubt about the Company&#146;s ability to continue as a going concern. Management&#146;s plans in regard to these matters are also
described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for
Opinion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the
Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to
error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial
reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">/s/ Haskell&nbsp;&amp; White LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HASKELL&nbsp;&amp; WHITE LLP</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Irvine, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 25, 2022 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin271308_2"></A>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Balance Sheets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CURRENT ASSETS:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 723,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">496,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">750,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">857,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,638,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,537,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">289,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL ASSETS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,927,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,955,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES AND STOCKHOLDERS&#146; (DEFICIT) EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CURRENT LIABILITIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 335,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">358,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">421,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">337,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PPP loans payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,245,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,141,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LONG-TERM LIABILITIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,590,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">498,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL LIABILITIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,836,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,640,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COMMITMENTS AND CONTINGENCIES (NOTE 2, 5, and 10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">STOCKHOLDERS (DEFICIT) EQUITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A, B, and C convertible preferred stock, $0.0001 par value, 20,000,000 shares authorized as
of April&nbsp;30, 2021 and 2020; 483,261 and 475,261 shares as of April&nbsp;30, 2021 and 2020 issued and outstanding, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 300,000,000 shares authorized as of April&nbsp;30, 2021 and 2020;
109,356,748 shares issued and outstanding as of April&nbsp;30, 2021 and 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,555,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,328,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,574,648</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,122,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL STOCKHOLDERS (DEFICIT) EQUITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,909,590</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL LIABILITIES AND STOCKHOLDERS (DEFICIT) EQUITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,927,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,955,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to the
financial statements</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin271308_3"></A>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Operations </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>For the Years ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross margin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,708,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,040,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">874,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,795,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,581,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,845,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,566,465</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,828,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(132,454</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,811</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on settlement of payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,897</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,452,170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,811,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.02</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,356,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,355,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to the
financial statements</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin271308_4"></A>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Stockholders&#146; (Deficit) Equity </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Series&nbsp;A&nbsp;Convertible<BR>Preferred Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Series&nbsp;B&nbsp;Convertible<BR>Preferred Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Series&nbsp;C&nbsp;Convertible<BR>Preferred Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total&nbsp;Convertible<BR>Preferred Stock</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Additional<br><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Accumulated<br>Deficit</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<br>Stockholder&#146;s<BR>(Deficit)<BR>Equity</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amount</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amount</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amount</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amount</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>BALANCES AT APRIL&nbsp;30, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">408,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,341,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,016,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(43,311,360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,815,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common stock issued to nonemployees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock based compensation - management&nbsp;&amp; other employees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock based compensation - <FONT STYLE="white-space:nowrap">non-employee</FONT> advisers</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock based compensation - board of directors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series C convertible preferred stock issued to investors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,175,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,175,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,811,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,811,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>BALANCES AT APRIL&nbsp;30, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">455,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,356,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,328,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47,122,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">315,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock based compensation - management&nbsp;&amp; other employees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock based compensation - <FONT STYLE="white-space:nowrap">non-employee</FONT> advisers</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Warrants issued to nonemployees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series C convertible preferred stock issued to investors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,452,170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,452,170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>BALANCES AT APRIL&nbsp;30, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">463,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,356,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,555,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49,574,648</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,909,590</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to the financial statements</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin271308_5"></A>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Cash Flows </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>For the Years ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM OPERATING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,452,170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,811,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on extinguishment of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(250,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on settlement of payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in current assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(20,651</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(305,936</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(42,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(221</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,452,294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,839,995</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM INVESTING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(712</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposition of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(712</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM FINANCING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of series c preferred convertible stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,175,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from shareholder note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from convertible promissory note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,529,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from PPP loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of financing lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,679,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,810,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,021,639</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">496,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,518,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 723,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">496,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">NON-CASH</FONT> FINANCING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock warrants in connection with payable settlements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes to the
financial statements</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin271308_6"></A>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1
</B>&#150; <B>Organization and Operations</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heart Test Laboratories, Inc. d/b/a HeartSciences (&#147;HeartSciences&#148; or the &#147;Company&#148;) is
a medical technology company specializing in cardiovascular diagnostic technology. The Company is a Texas <FONT STYLE="white-space:nowrap">C-Corporation</FONT> and is headquartered in Southlake, Texas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HeartSciences&#146; initial focus is on applying novel technology to extend the clinical indications for use of an electrocardiograph (&#147;ECG&#148;)
device. Its first device, the MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is an ECG which can be used in a wide range of clinical settings and provides diagnostic information to a qualified healthcare professional on cardiac
dysfunction which has traditionally only been provided using cardiac imaging. In addition, the MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> provides conventional ECG information. The Company plans to market its device both
domestically and internationally to various hospitals, clinics, and medical centers and manufacture the devices using outsourced production facilities. To date the Company has had small amounts of revenue from key opinion leader engagement and
establishment of distributor relationships outside the United States during the development and product improvement phase of the MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. There have been a number of published clinical
studies that have validated the MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>technology and the Company is preparing to seek U.S. Food and Drug Administration
(&#147;FDA&#148;) clearance of the MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> during 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2 </B>&#150; <B>Liquidity,
Going Concern, and other Uncertainties</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Accounting Standards Codification (&#147;ASC&#148;)
<FONT STYLE="white-space:nowrap">205-40,</FONT> <I>Going Concern</I>, management has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#146;s ability to continue as a going
concern within one year after the date that these financial statements are issued. At April&nbsp;30, 2021, the Company had an accumulated retained deficit of $1,909,590. In addition, the Company has generated recurring losses and negative cash flows
from operations since its inception. Based on its current business plan assumptions and expected cash burn rate, management believes that it has insufficient cash to fund its current operations without additional financing for the next 12 months.
These factors raise substantial doubt regarding the Company&#146;s ability to continue as a going concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management evaluated the significance of these
conditions in relation to its ability to meet its obligations. The Company&#146;s continued operations will depend on its ability to raise additional capital through various potential sources such as an IPO, equity and/or debt financings, or
strategic relationships. The Company has implemented cost reduction measures and has continued its fundraising efforts as discussed in Note 12. If the Company does not complete an IPO, the Company plans to continue to fund its operations and capital
funding needs through a combination of private equity offerings, debt financings, and other sources. While a number of the Company&#146;s investors have participated in multiple rounds of funding, management can provide no assurance that such
financing or strategic relationships will be available which would likely have a material adverse effect on the Company and its financial statements. Additionally, the Company&#146;s ability to continue as a going concern is dependent upon receiving
FDA clearance and achieving profitable operations by commercializing its medical devices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Therefore, there is substantial doubt about the Company&#146;s
ability to continue as a going concern within one year after the date that the financial statements are issued. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or
the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern for a reasonable period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;30, 2020, the World Health Organization (&#147;WHO&#148;) announced a global health emergency, a result of the new strain of coronavirus <FONT
STYLE="white-space:nowrap">(&#147;COVID-19&#148;)</FONT> and the risks to the international community as the virus spreads </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
globally beyond its point of origin. In March 2020, the WHO classified the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak as a pandemic, based on the rapid increase in exposure
globally. In response to the pandemic, numerous states and local jurisdictions imposed social distancing and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> orders, quarantines, and other restrictions
which impacted the Company&#146;s operations due to changes in working practices and disruption in accessing clinical institutions and physicians for research. While the extent of these disruptions are reducing, they may continue to negatively
impact the company&#146;s results of operations and liquidity beyond 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3 &#150; Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of Presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial
statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#147;US GAAP&#148;) and have been prepared on a basis which assumes that the Company will continue as a going concern, which
contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with US&nbsp;GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities, and the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those
estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and Cash Equivalents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The fair value of cash and cash equivalents approximates carrying value. At times, the Company&#146;s cash balances may exceed the
current insured amounts under the Federal Deposit Insurance Corporation (&#147;FDIC&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inventory </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory consists of finished goods, work in progress, <FONT STYLE="white-space:nowrap">sub-assemblies</FONT> and raw materials and is stated at the lower of
cost or net realizable value using the <FONT STYLE="white-space:nowrap">first-in,</FONT> <FONT STYLE="white-space:nowrap">first-out</FONT> (&#147;FIFO&#148;) method. Reserves for slow-moving, excess, or obsolete inventories are recorded when
required to reduce inventory values to their estimated net realizable values based on product life cycle, development plans, production expiration or quality issues. Inventory that is used for research and development are expensed as consumed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory consists of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raw materials</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">384,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Sub-assemblies</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">414,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">415,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Work in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finished goods</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">296,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">314,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserve for obsolescence</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(370,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(285,946</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">750,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">857,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory is consumed for research and development purposes and product sales. The Company has not received
FDA clearance to sell its MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>product in the United States and until FDA clearance occurs, the MyoVista<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>device is subject to changes through research and development. While the majority of the Company&#146;s inventory is intended for use in
finished products to be sold post FDA clearance, management&#146;s reserve methodology is to record a charge for inventory obsolescence and/or device development changes on an annual basis. The Company records any reserve charges in research and
development expenses on the statements of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with ASC Topic 730, <I>Accounting for Research and Development Costs, </I>the Company accounts for research and development expenditures,
including payments to collaborative research partners and regulatory filing costs, as research and development expenses. Accordingly, all research and development costs are charged to expense as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Property and Equipment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are
recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives. The range of estimated useful lives used to calculate depreciation is generally 3 to 5 years. Ordinary
maintenance and repairs are charged to expense as incurred, and replacements and betterments are capitalized. When items are retired or otherwise disposed, the related cost and accumulated depreciation are removed from the accounts and any resulting
gain or loss is reflected in other income (expense). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">377,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">379,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture&nbsp;&amp; fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">513,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">515,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(418,386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(386,573</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense for the years ended April&nbsp;30, 2021 and 2020 was $32,967 and $45,712, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accounting guidance
establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would
be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset transaction between market participants on the measurement date. Where available, fair value is based on observable market prices or
is derived from such prices. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value
hierarchy, which prioritizes the inputs used in measuring fair value as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1 &#150; Observable inputs such as quoted prices in active markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2 &#150; Inputs, other than the quoted prices in active markets, that are observable either directly
or indirectly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3 &#150; Unobservable inputs in which there is little or no market data, which require the reporting
entity to develop its own assumptions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In certain cases, the inputs used to measure fair value may fall into different levels of the
fair value hierarchy. In such cases, the assignment of an asset or liability within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgement and considers factors
specific to the asset or liability. The carrying amounts of the Company&#146;s financial instruments, which primarily include cash and cash equivalents, accounts payable and accrued expenses, approximate their fair values due to their short-term
nature. The carrying amounts of the Company&#146;s existing notes payable approximate their fair values at the stated interest rates and are reflective of the prevailing market rates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the Financial Accounting
Standards Codification Board issued ASU <FONT STYLE="white-space:nowrap">2016-2,</FONT> <I>Leases</I> (&#147;ASC 842&#148;) to increase transparency and comparability among organizations by requiring the recognition of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) assets and corresponding lease liabilities on the balance sheet for all leases with a term of longer than 12 months. Leases with an
initial term of 12 months or less are not recorded on the balance sheet but are recognized as lease expense on a straight-line basis over the applicable lease terms. The Company adopted ASC 842 on May&nbsp;1, 2019 using the modified retrospective
method, which was applied to all leases existing at the date of initial application of the ASU. As permitted under the transaction guidance, the Company elected the hindsight practical expedient with respect to determining the lease terms and
assessing impairment of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets. No impairment is expected at this time. The adoption of Topic 842 did not materially impact the Company&#146;s net
income or cash flows and did not result in a cumulative-effect adjustment to the opening balance of retained earnings. For additional details, see Note 9. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for
employee and <FONT STYLE="white-space:nowrap">non-employee</FONT> share-based compensation in accordance with the provisions of ASC 718, <I>Compensation &#150; Stock Compensation</I>. Under ASC 718, share-based compensation cost is measured at the
grant date, based on the calculated fair value of the award, and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated fair value of common stock option awards is calculated using the Black-Scholes option pricing model, based on key assumptions such as fair value
of common stock, expected volatility, and expected term. These estimates require the input of subjective assumptions, including (i)&nbsp;the expected stock price volatility, (ii)&nbsp;the calculation of the expected term of the award, (iii)&nbsp;the
risk-free rate and (iv)&nbsp;expected dividend yields. These assumptions are primarily based on third-party valuations, historical data, and judgement of management regarding future trends and other factors. The Company has estimated the expected
term of its common stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
options using the &#147;simplified&#148; method, whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of
sufficient historical data. The expected volatility is based on third-party valuations. The risk-free interest rates for periods within the expected term of the option are based on the US Treasury securities with a maturity date that commensurate
with the expected term of the associated award. There is no expected dividend yield since the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For stock options issued to employees and <FONT STYLE="white-space:nowrap">non-employees,</FONT> the fair value of stock-based awards is recognized as
compensation expense over the requisite service period, which is defined as the period during which an employee is required to provide service in exchange for an award. The Company uses a straight-line attribution method for all grants that include
only a service condition.<B><I> </I></B>The Company accounts for forfeitures when they occur. Stock-based compensation expense recognized in the financial statements is reduced by actual awards forfeited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net Loss Per Common Share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share
excludes the effect of dilution and is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common
stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock, stock options, common stock subject to repurchase related to early exercise of stock
options, convertible stock warrants and convertible notes are considered to be potentially dilutive securities. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per
common share for those periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company grants warrants to purchase common stock in connection with financing transactions. Warrants are valued based on Black-Scholes models and the fair
value is recorded to additional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital.</FONT></FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company adopted ASC 606, <I>Revenue from Contracts with Customers</I>, effective May&nbsp;1, 2019 using the modified retrospective method. The
adoption of this standard did not have a cumulative effect on opening accumulated deficit as of May&nbsp;1, 2019, as the timing and measurement of revenue recognition is materially the same for the Company under ASC 606 as it was under the prior
guidance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or
services. The guidance focuses on the core principle for revenue recognition, which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which
the entity expects to be entitled in exchange for those goods or services. The Company recognizes revenue in accordance with ASC 606, which provides a five-step model for recognizing revenue from contracts with customers as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Step 1: Identify the contract(s) with a customer </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Step 2: Identify the performance obligations in the contract </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Step 3: Determine the transaction price </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Step 4: Allocate the transaction price to the performance obligations in the contract </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A contract with a customer exists when (i)&nbsp;the Company enters into a legally enforceable contract with a customer, through a purchase order, that defines
each party&#146;s rights regarding the products to be transferred and identifies the payment terms related to these products, (ii)&nbsp;the contract has commercial substance and, (iii)&nbsp;the Company determines that collection of substantially all
consideration for products that are transferred is probable based on the customer&#146;s intent and ability to pay the promised consideration. The only performance obligation is to create and ship the product and each product has separate, distinct
pricing. Performance obligations are met and revenue is recognized at a point in time when the order for its goods are shipped FOB manufacturer and control is transferred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction price is determined based on the amount expected to be entitled to in exchange for transferring the product to the customer net of any
transaction price adjustments. The Company&#146;s payment terms to customers generally range from 30 to 60 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment terms fall within the <FONT
STYLE="white-space:nowrap">one-year</FONT> guidance for the practical expedient which allows the Company to forgo adjustment of the promised amount of consideration for the effects of a significant financing component. The Company accepts product
returns at its discretion or if the product is defective as manufactured. Historically, the actual product returns have been immaterial to the Company&#146;s financial statements. The Company elected to treat shipping and handling costs as a
fulfillment cost and included them in the cost of goods sold as incurred. Costs associated with product sales include commissions. The Company applies the practical expedient and recognizes commissions as expense when incurred because the expense is
incurred at a point in time and the amortization period is less than one year. Commissions are recorded as selling expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2021 and
2020, the Company did not have any contract assets or liabilities from contracts with customers and there were no remaining performance obligations that the Company had not satisfied. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes under
the asset and liability method, which requires recognition of deferred tax assets, subject to valuation allowances, and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax
returns. Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting and income tax purposes. Management considers many factors when assessing the
likelihood of future realization of deferred tax assets, including recent cumulative experience by taxing jurisdiction, expectations of future taxable income or loss, the carry-forward periods available to the Company for tax reporting purposes, and
other relevant factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A valuation allowance is established if it is more likely than not that all or a portion of the net deferred
tax assets will not be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accruals for uncertain tax positions are provided for in accordance with applicable accounting standards. The Company
may recognize the tax benefits from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits
recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Judgement is required in assessing the future tax consequences
of events that have been recognized in the financial statements or tax returns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on its analysis, the Company has determined that it has not
incurred any liability for unrecognized tax benefits as of April&nbsp;30, 2021 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may be subject to potential examination by U.S.
federal, U.S. states or foreign jurisdiction authorities in the areas of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with
U.S. federal, U.S. state and foreign tax laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to income taxes in the U.S. federal jurisdiction and franchise taxes in the State
of Texas. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. Generally, the Company is no longer subject to income tax examinations by major
taxing authorities for years before 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Standards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;)
<FONT STYLE="white-space:nowrap">No.&nbsp;2020-06,</FONT> <I>Debt&#151;Debt with Conversion and Other Options</I> (Subtopic <FONT STYLE="white-space:nowrap">470-20)</FONT> and <I>Derivatives and Hedging&#151; Contracts in Entity&#146;s Own Equity
</I>(Subtopic <FONT STYLE="white-space:nowrap">815-40):</FONT> <I>Accounting for Convertible Instruments and Contracts in an Entity&#146;s Own Equity</I>. For convertible instruments, the FASB decided to reduce the number of accounting models for
convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Convertible instruments that continue to be subject to separation models are (1)&nbsp;those with embedded conversion features that are not clearly and closely
related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2)&nbsp;convertible debt instruments issued with substantial premiums for which the premiums are
recorded as <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. The FASB decided to amend the guidance for the derivatives scope exception for contracts in an entity&#146;s own equity to reduce form-over-substance-based accounting conclusions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FASB observed that the application of the derivatives scope exception guidance results in accounting for some contracts as derivatives while
accounting for economically similar contracts as equity. The FASB also decided to improve and amend the related EPS guidance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendments in this ASU
are effective for fiscal years beginning after December&nbsp;15, 2021, including interim periods within those fiscal years. Management is currently evaluating the effect on the Company&#146;s financial statements if and when future convertible
securities are issued. The adoption of this ASU is not expected to have a material impact on the Company&#146;s financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2020, the FASB issued ASU <FONT STYLE="white-space:nowrap">2020-10,</FONT> <I>Codification
Improvements,</I> which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#146;s regulations. The Company will adopt ASU <FONT STYLE="white-space:nowrap">2020-10</FONT> as of the reporting
period beginning May&nbsp;1, 2021. The adoption of this update is not expected to have a material effect on the Company&#146;s financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concentration of Credit Risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments which
potentially subject the Company to concentrations of credit risk consist primarily of cash. The Company maintains its cash with high-credit quality financial institutions. At April&nbsp;30, 2021 and 2020, the Company did have a cash balance that was
$473,481 and $246,853 in excess of federally insured limits. The Company does not anticipate <FONT STYLE="white-space:nowrap">non-performance</FONT> by its financial institution. The Company has certain debt holders that account for 54% of the
Company&#146;s debt instruments which are fully convertible. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4 &#150; Debt </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Debt consists of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$130K Unsecured drawdown convertible promissory note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$1.5M Secured convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$1M Loan and security agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment Protection Program loans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,880,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">650,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: current maturities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(380,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(350,766</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notes payable, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>$130K Unsecured Drawdown Convertible Promissory Note </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;12, 2019, the Company entered into an unsecured drawdown convertible promissory note with Front Range Ventures, LLC (&#147;FRV&#148;) for an
aggregate amount not to exceed $130,000 (&#147;$130K Note&#148;). FRV is a shareholder of the Company and the Company entered into an agreement with FRV where FRV is entitled to appoint a member of the Board of Directors and a board observer so long
as it holds at least 71,000 shares of Series C convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $130K Note may be repaid at any time upon 20 days&#146; notice to the
holder. The $130k Note is convertible into Series C convertible Preferred Stock at any time, upon written notice by either the holder or the Company or at maturity, at the lowest price paid for the Series C convertible preferred C stock prior to
conversion, which is currently $25.00 per share. The $130k Note matures 20 days following FDA clearance of the Company&#146;s MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> medical device. Under the terms of the agreement, the
note is <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>$1.5M Secured Convertible Promissory Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2020, the Board of Directors approved the offering of a series of secured convertible promissory notes in the amount of $1,500,000 (&#147;$1.5M
Notes&#148;). The notes had an original maturity of July&nbsp;31, 2022 and were subsequently amended on November&nbsp;2, 2021, extending maturity to October&nbsp;31, 2022. The $1.5M Notes were sold as a series to a number of different investors with
$1,490,000 of the notes being sold to shareholders of the Company of which members of the Board of Directors of the Company subscribed for $30,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event the $1.5M Notes are converted into common stock on or prior to the maturity date, no interest
shall accrue or be payable. Interest is only payable if the notes are not converted on or prior to the maturity date, in which event interest shall accrue and be payable on the outstanding principal balance of the notes at a simple interest rate of
12% per annum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $1.5M Notes are collateralized by substantially all of the Company&#146;s assets and intellectual property and such security interest
is subordinate to the secured interests discussed in Note 10 and the $1M Loan and Security Agreement below.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is
entitled to either repay the principal and all accrued but unpaid interest on the $1.5M Notes upon giving 10 days written notice to the Holder at any time; or the outstanding principal amount, and accrued but unpaid interest, is convertible into
common stock at $0.05 per share, adjusted for any splits, recapitalizations, combinations or other similar transactions affecting the Company&#146;s common stock upon or after any of the following events: (i) 30 days following FDA clearance of the
Company&#146;s MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> medical device; (ii)&nbsp;the closing of further funding of $5&nbsp;million or more which values entire share capital of the Company at $50&nbsp;million or more;
(iii)&nbsp;a public offering of common stock which values the entire share capital of the Company at $50&nbsp;million or more; or (iv)&nbsp;the sale or merger of a majority of the voting stock of the Company. The Holder of a note may elect for
conversion at any time upon written notice to the Company. As of April&nbsp;30, 2021, accrued interest was approximately $34,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>$1M Loan and
Security Agreement&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2020, the Company entered into a loan and security agreement with FRV and John Q. Adams who are
both shareholders of the Company. John Q. Adams is also a Director of the Company. Each party committed to lend a principal amount of $500,000, totaling $1,000,000 and the loan was drawn in three installments of $300,000 upon execution of the loan
agreement, $350,000 on or about July&nbsp;2, 2020 and $350,000 on or about September&nbsp;4, 2020. The loan accrues interest at a rate of 12% per annum, compounded annually, which is payable at maturity. The Company is also required to pay default
interest at a rate of 18% per annum, compounded annually, on any unpaid amounts due at maturity until the loan amounts are fully <FONT STYLE="white-space:nowrap">re-paid.</FONT> The loan is collateralized by substantially all of the Company&#146;s
assets and intellectual property, except for the secured interest on the covered technology as discussed in Note 10.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The loan had
an original maturity date of September&nbsp;30, 2021 which was amended on September&nbsp;30, 2021 making the note repayable on demand. The loan was amended again on November&nbsp;3, 2021, extending the maturity to September&nbsp;30, 2022. As of
April&nbsp;30, 2021 and 2020, accrued interest totaled $98,082 and $447 respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s long-term notes payable all mature in 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment Protection Program Loans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;20, 2020,
the Company received loan proceeds in the amount of $250,200 under the Paycheck Protection Program (&#147;PPP&#148;) which was established as part of the Coronavirus Aid, Relief and Economic Security Act (&#147;CARES Act&#148;), provided for loans
to qualifying businesses for amounts up to 2.5 times the average monthly payroll expenses of the qualifying business. Following the PPP guidelines, the Company filed for loan forgiveness in October 2020 and in November 2020, the Small Business
Administration approved the filing and forgave the loan. The forgiveness of the PPP loan is recorded in gain on extinguishment of debt in the statement of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;25, 2021, the Company received a second PPP loan in the amount of $250,200. Following the PPP
guidelines, the Company filed for loan forgiveness in May 2021 and in June 2021, the Small Business Administration approved the filing and forgave the loan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With these events, the Company has presented the PPP loans as current liabilities on the balance sheet as of April&nbsp;30, 2021 and 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5 &#150; Convertible Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s Certificate of Formation, as amended, has authorized 20,000,000 shares of preferred stock with a par value of $0.001 per share of which 620,000 has been designated in series A through C as described below. In the years ended
April&nbsp;30, 2021 and 2020, the Company issued 8,000 and 46,890 shares of Series C convertible preferred stock at a price per share of $25.00 for approximately $200,000 and $1,180,000 respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Convertible preferred stock consists of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Series A convertible preferred stock (&#147;Series A&#148;) was issued to employees and directors in 2014 and
is subordinate to the common stock. As of April&nbsp;30, 2021 and 2020, the common stock has a liquidation preference of $4,500,000 to the Series A. The Series A convertible preferred stock was issued subject to certain repurchase rights in favor of
the Company. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Series A</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Original<BR>Issue&nbsp;Price</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares<BR>Authorized</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares&nbsp;Issued<BR>and&nbsp;Outstanding</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Net&nbsp;Carrying<BR>Value</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Liquidation&nbsp;Preference<BR>of the Common Stock<BR>to Series A</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An amendment to, or waiver of rights of, the Series A convertible preferred stock requires the approval of holders of a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority of the outstanding shares of Series A convertible preferred stock. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Series B convertible preferred stock (&#147;Series B&#148;) was issued to employees and directors in 2015 and
is subordinate to the common stock. As of April&nbsp;30, 2021 and 2020, the common stock had a liquidation preference of $35,000,000 to the Series B. The Series B convertible preferred stock was issued subject to certain repurchase rights in favor
of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Series B</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Original<BR>Issue&nbsp;Price</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares<BR>Authorized</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares&nbsp;Issued<BR>and&nbsp;Outstanding</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Net&nbsp;Carrying<BR>Value</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Liquidation&nbsp;Preference<BR>of the Common Stock<BR>to Series B</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An amendment to, or waiver of rights of, the Series B convertible preferred stock requires the approval of holders of a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority of the outstanding shares of Series B convertible preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Series C convertible preferred stock (&#147;Series C&#148;) which was issued to investors and has a liquidation
preference to the common stock. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Series C</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Original<BR>Issue&nbsp;Price</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares<BR>Authorized</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares Issued<BR>and&nbsp;Outstanding</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Net&nbsp;Carrying<BR>Value</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Liquidation&nbsp;Preference<BR>of the Series C to<BR>Common Stock</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">455,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,381,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">463,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,581,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An amendment to, or waiver of rights in the Series C certificate of designation requires the approval of holders of a majority
of the outstanding shares of Series C convertible preferred stock and Front Range Ventures LLC (&#147;FRV&#148;) (so long as FRV owns any at least 71,000 shares of Series C convertible preferred stock) (the &#147;Requisite Holders&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the convertible preferred stock have the following rights, privileges, and preferences. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of Series A, Series B and Series C has
voting rights equal to an equivalent number of shares of common stock into which it is convertible and vote together as one class with the common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Series A are not entitled to
receive any dividends until the holders of common stock have received $4,500,000 in payments (in dividends, the proceeds of a sales transaction, or otherwise) (the &#147;Series A Threshold&#148;). Thereafter, the Series A shall participate in any
dividend declared to common stockholders by the Company&#146;s Board out of funds legally available on and as converted to common stock basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
holders of Series B are not entitled to receive any dividends until the holders of common stock have received $35,000,000 in payments (in dividends, the proceeds of a sales transaction, or otherwise) (the &#147;Series B Threshold&#148;). Thereafter,
the Series B shall participate in any dividend declared to common stockholders by the Company&#146;s Board out of funds legally available on an as converted to common stock basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Series C are entitled to receive dividends at an annual rate of $1.50 per share of Series C (adjusted to reflect recapitalizations). Such dividends
shall accrue and are payable out of funds legally available, are payable only when and if declared by the Board, and are noncumulative. The Company shall not declare, pay or set aside any dividends on shares of any other class or series of capital
stock of the Company (other than dividends on shares of common stock payable in shares of common stock) unless the holders of Series C then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Series C in an
amount at least equal to the greater of (i)&nbsp;the amount of the aggregate dividends then accrued on such share of Series C and not previously paid and (ii)&nbsp;in the case of a dividend on common stock or any class or series that is convertible
into common stock, that dividend per share of Series C Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been
converted into common stock and (2)&nbsp;the number of shares of common stock issuable upon conversion of a share of Series C convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No dividends have been declared to date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any liquidation, dissolution or winding up of the Company, either voluntarily or involuntarily, the holders of Series C are entitled to
receive, prior and in preference to the holders of Series A, Series B, and common stock, a per share amount equal to 1.0 times the original issue price plus any accrued but unpaid dividends thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If upon the liquidation, dissolution or winding up of the Company, the assets of the Company that are legally available for distribution to the holders of
Series C are insufficient to permit the payment to such holders of the full amounts above, then the entire assets of the Company that are legally available for distribution shall be distributed with equal priority and
<FONT STYLE="white-space:nowrap">pro-rata</FONT> among the holders of the Series C in proportion to what they would otherwise be entitled to receive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the payment of the full Series C liquidation preference and unpaid accrued dividends, the Series C stockholders shall participate in the distribution of
the entire remaining assets of the Company legally available for distributions <FONT STYLE="white-space:nowrap">pro-rata</FONT> to holders of common stock on an as converted to common stock basis. The sale of a majority of the capital stock of the
Company or the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the
Corporation and its subsidiaries taken as a whole shall be a deemed liquidation for the purpose of the Series C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any liquidation,
dissolution or winding up of the Company, either voluntarily or involuntarily, the holders of Series A shall only participate in the distribution of the entire remaining assets of the Company legally available for distributions after the holders of
common stock have received $4,500,000 in payments (in dividends, the proceeds of a sales transaction, or otherwise). Thereafter, the Series A shall participate <FONT STYLE="white-space:nowrap">pro-rata</FONT> to the common stockholders on an as
converted to common stock basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any liquidation, dissolution or winding up of the Company, either voluntarily or involuntarily, the
holders of Series B shall only participate in the distribution of the entire remaining assets of the Company legally available for distributions after the holders of common stock have received $35,000,000 in payments (in dividends, the proceeds of a
sales transaction, or otherwise). Thereafter, the Series B shall participate <FONT STYLE="white-space:nowrap">pro-rata</FONT> to the common stockholders on an as converted to common stock basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of Series A convertible preferred
stock is convertible, at the option of the holder thereof, into fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock at any time prior to </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;1, 2024. Additionally, if the holders of Series A convertible preferred stock are entitled to make, but have not made, an election to convert Series A
convertible preferred stock by May&nbsp;1, 2024, then such shares will automatically be converted into common stock and canceled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of
common stock into which Series A convertible preferred stock may be converted is based on a formula set forth in the Company&#146;s certificate of formation, as amended. It varies according to the fair market value of the Company&#146;s common stock
at the time of conversion and is subject to a $4,500,000 minimum value threshold of the common stock, (less any payments previously made to common stockholders). Unless the $4,500,000 minimum value threshold is met, each share of Series A
convertible preferred stock would convert into nil shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of Series B convertible preferred stock is convertible, at the
option of the holder thereof, into fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock at any time prior to July&nbsp;7, 2025. Additionally, if the holders of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Series B convertible preferred stock are entitled to make, but have not made, an election to convert Series B convertible preferred stock by July&nbsp;7, 2025, then such shares will automatically
be converted into common stock and canceled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No conversion of the Series B convertible preferred stock may take place if a repurchase right exists. The
holders of the Series B convertible preferred stock each entered into a restricted stock agreement in July 2015 whereby the Company was granted the right to repurchase up to all of such stockholders&#146; Series B convertible preferred stock at a
price of $0.001 per share under certain conditions. The repurchase rights over 80% of the Series B convertible preferred stock have now expired with the remaining right over 20% expiring upon the Company receiving FDA clearance for its MyoVista<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> medical device. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the restricted stockholder is terminated as an employee of the
Company for just cause (as defined in the restrictive stock agreement or resigns other than for a constructive termination (as defined in the restrictive stock agreement), or (ii)&nbsp;if such holder is a director of HeartSciences, such holder
resigns as a director of HeartSciences prior to the Company receiving FDA clearance for its MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> medical device the remaining 20% may be repurchased by the Company. The Series B
convertible preferred stock repurchase rights automatically terminate (i)&nbsp;upon the closing of a sales transaction (as defined below), or (ii)&nbsp;at such time as the holders of common stock have received $35,000,000 in proceeds from the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock into which Series B convertible preferred stock may be converted is based on a formula set forth in the
Company&#146;s certificate of formation, as amended. It varies according to the fair market value of the Company&#146;s common stock at the time of conversion and is subject to a $35,000,000 minimum value threshold (less any payments previously made
to common stockholders). Unless the $35,000,000 minimum threshold value is met each share of Series B convertible preferred stock would convert into nil shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of the Series A and Series B conversion formula the fair market value of the Company&#146;s common stock is determined as: (i)&nbsp;if the
common stock is publicly-traded the value will be determined by using a <FONT STYLE="white-space:nowrap">30-day</FONT> weighted average closing prices of the common stock; (ii)&nbsp;if the common stock is not publicly-traded, it shall be the value
determined in good faith by the Board, which determination may, but is not required to, include a third-party valuation or (iii)&nbsp;in the event of a sales of the Company, the value determined by reference to that sales transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of Series C preferred stock is convertible, at the option of the holder at any time after the date of issuance of such share, into such number of
fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock determined by dividing the original issue price by the conversion price for such series in effect at the time of conversion for the Series C. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conversion price on the issuance of the Series C convertible preferred stock was $0.25 per share (being convertible into common stock on a one <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">hundred-for-one</FONT></FONT> basis) subject to adjustment in accordance with conversion provisions contained in the Company&#146;s certificate of formation, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each share of Series C is automatically converted into shares of common stock at the conversion price at the time in effect immediately upon the
Company&#146;s sale of its common stock in a public offering provided that the offering price is not less than $0.50 per share (as adjusted for recapitalizations, stock combinations, stock dividends, stock splits and the like) and which results in
aggregate cash proceeds of not less than $20.0&nbsp;million before underwriting discounts, commissions, and fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6 &#150; Stockholders&#146; (Deficit) Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Certificate of Formation,
as amended, has authorized 300,000,000 shares of common stock with a par value of $0.001 per share. As of April&nbsp;30, 2021 and 2020, the Company had issued 109,356,748 shares of common stock. The holders of common stock are entitled to receive
dividends whenever funds and assets are legally available and when declared by the board of directors, subject to the rights of holders of series of convertible preferred stock outstanding. No dividends were declared as of or through April&nbsp;30,
2021. In the year ended April&nbsp;30, 2020, the Company issued 15,000 shares of common stock for approximately $585. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of warrant activity as of April&nbsp;30, 2021 and 2020 is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants<BR>Outstading&nbsp;and<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise Price</B><br><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Strike&nbsp;Price<BR>per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, May&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,940,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.105&nbsp;-&nbsp;$2.00</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(82,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, April&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,857,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.105&nbsp;-&nbsp;$2.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">461,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(284,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance April&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,035,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.105&nbsp;-&nbsp;$2.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From 2015 to 2019, the Company issued warrants to investors in connection with funding or for services rendered. The warrants
are convertible into a fixed number of shares of the Company&#146;s common stock for a period of 5 years from the date of issuance. There were no warrants issued in 2020 and there were 461,720 warrants issued in 2021 for consulting services
rendered. Approximately 20,498,000 warrants have expired subsequent to year end. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine interest expense related to the Company&#146;s outstanding
warrants issued in conjunction with debt offerings, the fair value of each award grant is estimated on the date of grant using the Black-Scholes option pricing model and the fair values are amortized over the life of the warrant. The principal
assumptions we used in applying this model were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life in years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The risk-free interest rate is based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are derived
from third party valuations. The expected life in years is based on the contract term of the warrant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7 &#150; Stock-based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company grants certain employees and board members stock option awards where vesting is contingent upon a service period, as it believes that such awards
better align the interests of its employees with those of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shareholders. Stock option awards are granted with an exercise price equal to above the market price of the Company&#146;s stock at the date of grant. Certain stock option awards provide for
accelerated vesting if there is a change in control, as defined in the Nonstatutory Stock Option Agreement. Unvested stock options forfeit when an employee leaves the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where option awards are granted based on service periods, they generally vest quarterly based on 3 years continuous service for executive directors and
employees, or 12 months continuous service for directors and have <FONT STYLE="white-space:nowrap">10-year</FONT> contractual terms. During the years ended April&nbsp;30, 2021 and 2020, the Company granted 50,000 and 420,000 shares of common stock
awards to employees based on service periods, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also grants stock option awards where vesting is contingent upon meeting various
departmental and company-wide performance goals, including FDA and CE Mark regulatory approval and certain EBITDA and funding thresholds. Such performance-based stock options are expected to vest when the performance criteria and metrics have been
met. These stock options have contractual lives of ten years. During the years ended April&nbsp;30, 2021 and 2020, the Company granted 4,810,000 and 4,525,000 performance-based stock option awards, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not have an ERISA stock awards plan. So, all stock options issued are <FONT STYLE="white-space:nowrap">Non-ERISA</FONT> Plan options and do
not have any of the tax and other benefits afforded to ERISA stock option awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of service-based stock options for the
periods ended April&nbsp;30, 2021 and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Options<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average&nbsp;Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Remaining<BR>Contractual&nbsp;Life<BR>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;April 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,062,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">420,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(92,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;April 30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,389,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;April 30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,439,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested at April&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,298,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates fair values of stock options using the Black-Scholes option-pricing model on grant date. For years ended
April&nbsp;30, 2021 and 2020, the assumptions used in the Black-Scholes option pricing model were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.08%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.15%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">53.0%&nbsp;-&nbsp;66.2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">53.0%&nbsp;-&nbsp;66.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of performance-based stock option awards for the periods ended April&nbsp;30, 2021
and 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Options<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average&nbsp;Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Remaining<BR>Contractual&nbsp;Life<BR>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;April 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,110,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,525,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(227,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;April 30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,408,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,810,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(125,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;April 30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,093,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,316,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested at April&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">776,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates fair values of performance-based stock options using the Black-Scholes option-pricing model on grant
date. For years ended April&nbsp;30, 2021 and 2020, the assumptions used in the Black-Scholes option pricing model were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>April&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.08%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.15%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">53.0%&nbsp;-&nbsp;66.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">53.0%&nbsp;-&nbsp;66.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2021, there was approximately $1,560,000 of unrecognized compensation costs related to <FONT
STYLE="white-space:nowrap">non-vested</FONT> performance-based common stock options and approximately $1,800 of unrecognized compensation costs related to <FONT STYLE="white-space:nowrap">non-vested</FONT> service-based common stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of stock-based compensation expense: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;years&nbsp;ended&nbsp;April&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, General and Administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">135,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8 &#150; Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax effects of temporary differences and carry-forwards that give rise to significant portions of the deferred tax assets and liabilities are presented
below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of April&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets (liabilities):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,215,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,659,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Start-up</FONT> costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,137,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,238,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option and warrant payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">396,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">390,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,212</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">255,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">255,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,024,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,562,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation Allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(9,024,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,562,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Deferred Tax Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2021 and 2020, the Company&#146;s cumulative net operating loss for federal income tax purposes was
approximately $34&nbsp;million<B> </B>and $32&nbsp;million, respectively. The net operating loss, subject to limitations, may be available in future tax years to offset taxable income. The net operating loss carry-forward will begin to expire in
year 2028. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the
deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based upon the projections
for future taxable income over the periods in which the deferred tax assets are deductible, management believes it is more likely than not that the Company will not realize the benefits of these deductible differences, and therefore, a full
valuation allowance has been recorded at April&nbsp;30, 2021 and 2020, resulting in an increase in the valuation allowance by $461,457 and $183,973, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9 &#150; Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;1, 2019, the Company
adopted ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases</I>, using the modified retrospective method. The new lease standard amended the previous guidance for lease accounting and related disclosure requirements. The new guidance
requires the recognition of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and liabilities on the balance sheet for leases with terms greater than twelve months or leases that contain a purchase
option that is reasonably certain to be exercised. The Company has elected not to recognize leases with original lease terms of 12 months or less (short-term leases) on the Company&#146;s balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has a long-term operating lease for office, industrial, and laboratory space that expires in 2023. The lease has an option to extend for five
years however given the future anticipated expansion of the Company, it is more likely than not that the option will not be exercised. Rent expense for operating leases for the years ended April&nbsp;30, 2021 and 2020 was $173,405 and $208,360,
respectively. The Company records <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and liabilities at the present value of the fixed lease payments over the term at the commencement date. The
Company uses its incremental borrowing rate of 12% to determine the present value of the lease as the rate implicit in the lease is typically not readily available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information related to the Company&#146;s
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities as of April&nbsp;30, 2021 and 2020 was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">289,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">291,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of April&nbsp;30, 2021, future maturities of lease liabilities due under lease agreements was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">221,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10 &#150; Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Litigation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the Company may be subject
to legal proceedings and claims that arise in the ordinary course of business. The Company does not believe that the outcome of those matters will have a material adverse effect to the financial position, operating results or cash flows. However,
there can be no assurance such legal proceedings will not have a material impact. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is not aware of any material claims outstanding or pending
against the Company as of April&nbsp;30, 2021 and 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Royalty Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2013, the Company entered into an agreement (&#147;Technology Agreement&#148;) with its founder, conveying ownership of all intellectual property and rights
to the Company. As part of that agreement, the Company will make royalty payments, based upon paid MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> device unit sales, as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">$500 on each of the first 2,400 MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> devices
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">$200 on each MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> device thereafter until
royalties total $3,500,000. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The royalty obligation has a first secured interest and pledge on the covered technology (as defined in the
Technology Agreement but essentially the intellectual property of the MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> device) over the debt holders of the $1.5M Secured Convertible Promissory Notes and $1M Loan and Security
Agreement as discussed further in Note 4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon either (i)&nbsp;the aggregate payment of $3,000,000 of royalties; (ii)&nbsp;if the common stock is
publicly listed and the closing quoted share price is $2.08333 per share or more; or (iii)&nbsp;a bona fide offer valuing the common stock at $2.08333 is received, then the secured interest and pledge shall be released. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a bankruptcy of the Company, any balance of the $3,500,000 royalty not paid at that point
would accelerate and become an immediately due debt obligation of the Company with the benefit of the secured interest and pledge (if it remained at such time). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended April&nbsp;30, 2021 and 2020, the sales royalties expensed to cost of goods sold were $1,500 and $7,000 respectively. As of April&nbsp;30,
2021 the aggregate sales royalties expensed under this agreement was $51,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has an agreement with The University Court of The University of
Glasgow for the license of the Glasgow algorithm interpretive analysis for the conventional ECG trace. As part of that agreement the Company is obliged to make royalty payments, based upon
MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> device unit sales at the rate of $35&#150;$50 per unit depending on sale volumes per year. The agreement is subject to an annual minimum fee and should the sale volume royalties be
below this level then the minimum will apply. To date, MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> device unit sales have such that the minimum payments have applied. Prior to FDA clearance, the Company does not expect to
achieve device unit sales volumes which would exceed the minimum. The minimum fee has been expensed to research and development as the Glasgow algorithm is an essential part of the device development as part of the submission for FDA clearance of
the MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> device. For the years ended April&nbsp;30, 2021 and 2020, the minimum payments were $20,000 respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11 &#150; Related Parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kyngstone Limited
(&#147;Kyngstone&#148;), a company incorporated in the United Kingdom in which the Chairman of the Board is a director and controlling shareholder, has provided advisory services to the Company during the course of business. For the years ended
April&nbsp;30, 2021 and 2020 the Company recorded expenditures of $100,000 and $191,667, respectively with Kyngstone. As of April&nbsp;30, 2021 and 2020, the Company had balances outstanding to Kyngstone in the amounts of $88,444 and $97,177,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 4 for details regarding related party debt held with shareholders, board members, and Company directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 12 &#150; Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has
evaluated subsequent events through February 25, 2022, the date these financial statements were available for issuance, and has concluded that no events or transactions have occurred that require disclosure in the accompanying financial statements,
except as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June and July 2021,
the Company issued 365,760 warrants to <FONT STYLE="white-space:nowrap">non-employees</FONT> in exchange for settlement of payables fair valued at approximately $1,609. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2021, the Company issued an aggregate of 500,000 warrants for shares of common stock to the lenders as consideration for the extension of the
maturity of the $1M Loan and Security Agreement, as discussed in Note 4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2021, the Company issued an aggregate of 150,000 warrants for shares
of common stock to note holders as consideration for the extension of the maturity of the $1.5M Notes, as discussed in Note 4. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2021 and February 2022, the Company granted options for 75,000 and 150,000 shares of common stock, subject to service-based vesting conditions, with a
weighted-average exercise price of $0.04 and $0.11 per share to certain employees of the Company. In February 2022, the Board of Directors approved an additional 5,357,500 options for shares of common stock to be granted to employees, with a
weighted-average exercise price of $0.11 and subject to service and performance-based conditions.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unsecured promissory draw
down note </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2021, the Company issued an Unsecured Promissory Draw Down Note with Matthews Holdings Southwest, Inc. for a maximum amount of
$500,000 as a short-term loan repayable upon closing a subsequent offering. Per the terms of the note, $250,000 was drawn by the Company in August 2021 and an additional $250,000 was drawn in September 2021. The Company issued 333,333 shares of
common stock as a facility fee for the note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No interest is payable on the note other than upon the occurrence of an event of default, as defined in the
agreement, at which that time the borrower will pay interest to the holder, payable on demand, on the outstanding principal balance of the note from the date of the event of default until payment in full at the rate of 12% per annum. The note
originally matured on October&nbsp;11, 2021 and was amended on October&nbsp;11, 2021 and again on November&nbsp;29, 2021, extending maturity to November&nbsp;30, 2021 and December&nbsp;31, 2021, respectively. The note was fully repaid on
December&nbsp;27, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bridge offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December
2021 the Board approved the sale of up to $5,555,555.56 principal amount of the Senior Subordinated Convertible Loan Notes (the &#147;2021 Bridge Notes&#148;) and up to 30,275,507 associated warrants (the &#147;2021 Bridge Warrants&#148;), together
the &#147;2021 Bridge Securities.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 Bridge Notes were issued with a 10% original issue discount (OID), accrue interest at 8% per annum and
have a maturity date of December&nbsp;22, 2024. The notes convert into common stock of the Company, or in the event that such conversion would result in a note holder receiving more than 4.99% of the outstanding common stock then such note holder
shall receive <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. The conversion price is the lower of $0.1835 per share or a 30% discount to the new issue price in a qualified offering. For two years post issuance, the conversion price is
subject to full ratchet downward adjustment in the event of an issuance of common stock prior to conversion at a lower price per share than the then conversion price (or issuance of convertible securities or options at a lower price conversion/
strike price than the then conversion price). The notes are convertible by the holder at any time and automatic conversion (of principal and accrued but unpaid interest) shall occur upon a qualified offering, which means a public offering in the
United States pursuant to a registration statement declared effective by the Securities and Exchange Commission pursuant to the Securities Act, pursuant to which the Common Stock is listed for trading on The New York Stock Exchange, the NYSE
American, the Nasdaq Capital Market, the Nasdaq Global Select Market, or the Nasdaq Global Market, each an Eligible Market, with (i)&nbsp;minimum gross proceeds of $6,000,000, and (ii)&nbsp;minimum net proceeds of $5,000,000 after deducting all fees
and expenses in connection with such qualified offering. After <FONT STYLE="white-space:nowrap">one-year</FONT> the Company may <FONT STYLE="white-space:nowrap">pre-pay</FONT> the notes in an amount of 115% of the principal amount (plus accrued and
unpaid interest) or in the event of a change of control or event of default each note holder shall have the right to have its notes redeemed in the amount of 125% of the principal amount (plus accrued but unpaid interest). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors in the 2021 Bridge Notes have also received warrants to purchase one share of Common Stock for each $0.1835 purchased in the 2021 Bridge Note
(inclusive of OID). The 2021 Bridge Warrants have a <FONT STYLE="white-space:nowrap">5-year</FONT> term </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D/B/A HEARTSCIENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from their date of issuance and an initial exercise price of $0.27525 per share (being 150% of the conversion price of the note). The exercise price of the warrants is subject to full ratchet
downward adjustment in the event of an issuance of common stock prior to conversion at a lower price per share than the then conversion price (or issuance of convertible securities or options at a lower price conversion/ strike price than the then
conversion price). In addition if the new issue price on a qualified offering is less than 125% of the then exercise price in effect the exercise price of the warrants will be lowered to the new issue price. Upon a lowering of the exercise price the
holder will be entitled to excise such number of warrants such that the then exercise price multiplied by the number of warrants is 150% of the principal amount of their 2021 Bridge Notes purchased. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2021 the Company issued and sold an aggregate principal amount of $2,222,222 of the 2021 Bridge Securities with various purchasers with
Cavalry Investment Fund L.P. acting as lead investor. Subsequent to December 2021 through February&nbsp;25, 2022, the Company sold further 2021 Bridge Securities in the aggregate principal amount of $1,044,444, including the exchange of $712,222 of
convertible loan notes and warrants which had been issued in October 2021, representing the entire amount of such 2021 Bridge Securities issued and sold in October 2021. The convertible loan notes and warrants issued in October 2021 were originally
issued on similar terms to the 2021 Bridge Securities and they were all voided as part of the exchange. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Common Stock </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Book
Running Manager </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>The Benchmark Company </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom271308_22"></A>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. Other expenses of issuance and distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the expenses payable by the Registrant expected to be incurred in connection with the issuance and distribution
of Common Stock being registered hereby (other than the underwriting discounts and commissions). All of such expenses are estimates, except for the Securities and Exchange Commission, or the SEC, registration fee, the Financial Industry Regulatory
Authority Inc., or FINRA, filing fee and the filing fee and listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(dollars in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NASDAQ listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue Sky fees and expenses (including legal fees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be completed by amendment. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of directors and officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heart Test Laboratories, Inc. was incorporated under the laws of Texas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Texas Business Organizations Code, or the TBOC, permits a corporation to indemnify a director who was, is or is threatened to be a named
defendant or respondent in a proceeding as a result of the performance of his duties if such person acted in good faith and, in the case of conduct in the person&#146;s official capacity as a director, in a manner he reasonably believed to be in the
best interests of the corporation and, in all other cases, that the person reasonably believed his conduct was not opposed to the best interests of the corporation and with respect to any criminal action or proceeding, that such person had no
reasonable cause to believe his conduct was unlawful. Subject to certain exceptions, the TBOC further permits a corporation to eliminate in its charter all monetary liability of the corporation&#146;s directors to the corporation or its shareholders
for conduct in performance of such director&#146;s duties. Our amended and restated certificate of formation will provide that a director of the corporation will not be liable to the corporation or its shareholders for monetary damages for any act
or omission by the director in the performance of his duties, except that there will be no limitation of liability to the extent the director has been found liable under applicable law for: (i)&nbsp;breach of the director&#146;s duty of loyalty owed
to the corporation or its shareholders; (ii)&nbsp;an act or omission not in good faith that constitutes a breach of duty of the director to the corporation or that involves intentional misconduct or a knowing violation of the law; (iii)&nbsp;a
transaction from which the director received an improper benefit, regardless of whether the benefit resulted from an action taken within the scope of the director&#146;s duties; or (iv)&nbsp;an act or omission for which the liability of the director
is expressly provided for by an applicable statute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sections 8.101 and 8.103 of the TBOC provide that a corporation may indemnify a
person who was, is or is threatened to be a named defendant or respondent in a proceeding because the person is or was a director only if a determination is made that such indemnification is permissible under the TBOC: (i)&nbsp;by a majority vote of
the directors who at the time of the vote are disinterested and independent, regardless of whether such directors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
constitute a quorum; (ii)&nbsp;by a majority vote of a board committee designated by a majority of disinterested and independent directors and consisting solely of disinterested and independent
directors; (iii)&nbsp;by special legal counsel selected by the Board of Directors or a committee of the Board of Directors as set forth in (i)&nbsp;or (ii); (iv) by the shareholders in a vote that excludes the shares held by directors who are not
disinterested and independent; or (v)&nbsp;by a unanimous vote of the shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.104 of the TBOC provides that the
corporation may pay or reimburse, in advance of the final disposition of the proceeding, reasonable expenses incurred by a present director who was, is or is threatened to be made a named defendant or respondent in a proceeding after the corporation
receives a written affirmation by the director of his good faith belief that he has met the standard of conduct necessary for indemnification under Section&nbsp;8.101 and a written undertaking by or on behalf of the director to repay the amount paid
or reimbursed if it is ultimately determined that he has not met that standard or if it is ultimately determined that indemnification of the director is not otherwise permitted under the TBOC. Section&nbsp;8.105 also provides that reasonable
expenses incurred by a former director, or a present or former employee, agent or officer of the corporation, who was, is or is threatened to be made a named defendant or respondent in a proceeding may be paid or reimbursed by the corporation, in
advance of the final disposition of the action, as the corporation considers appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.105 of the TBOC provides that,
subject to restrictions in its certificate of formation and to the extent consistent with other law, a corporation may indemnify and advance expenses to a person who is not a director, including an officer, employee or agent of the corporation as
provided by: (i)&nbsp;the corporation&#146;s governing documents; (ii)&nbsp;an action by the corporation&#146;s governing authority; (iii)&nbsp;resolution by the shareholders; (iv)&nbsp;contract; or (v)&nbsp;common law. As consistent with
Section&nbsp;8.105, persons who are not directors may seek indemnification and advancement of expenses from a corporation to the same extent that directors may seek indemnification and advancement of expenses from a corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our amended and restated certificate of formation and amended and restated bylaws will provide that we must indemnify our directors
and officers to the fullest extent authorized by law. We are also expressly required to advance certain expenses to our directors and officers and carry directors&#146; and officers&#146; insurance providing indemnification for our directors and
officers for some liabilities. We believe that these indemnification provisions and the directors&#146; and officers&#146; insurance are useful to attract and retain qualified directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also entered into, or will enter into prior to the completion of this offering, indemnification agreements with each of our directors
and certain of our officers. The indemnification agreements provide, or will provide, among other things, for indemnification to the fullest extent permitted by the TBOC and our amended and restated certificate of formation and amended and restated
bylaws against (i)&nbsp;any and all direct and indirect liabilities and reasonable expenses, including judgments, fines, penalties, interest and amounts paid in settlement of any claim with our approval and reasonable counsel fees and disbursements
and (ii)&nbsp;any liabilities incurred as a result of serving as a director, officer, employee or agent (including as a trustee, fiduciary, partner or manager or in a similar capacity) of another enterprise or an employee benefit plan at our
request. The indemnification agreements also provide for, or will provide for, the advancement or payment of expenses to the indemnitee and for reimbursement to us if it is found that such indemnitee is not entitled to such indemnification under
applicable law and our amended and restated certificate of formation and amended and restated bylaws or the terms of the indemnification agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to maintain standard policies of insurance that provide coverage (1)&nbsp;to our directors and officers against loss rising from
claims made by reason of breach of duty or other wrongful act and (2)&nbsp;to us with respect to indemnification payments that we may make to such directors and officers. The underwriting agreement provides for indemnification by the underwriters of
us and our officers and directors, and by us of the underwriters, for certain liabilities arising under the Securities Act or otherwise in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted
to directors, officers or persons controlling us under any of the foregoing provisions, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Recent sales of Unregistered Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the three years preceding the filing of this registration statement, we have issued the securities described in this section, which were not
registered under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Issuance of Capital Stock </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From April to May 2019, we issued and sold 246,685 shares of our Series C Preferred Stock at a purchase price of
$25.00 per share for $6,167,125 in cash consideration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In August 2019, we issued and sold an unsecured drawdown convertible promissory note, or the $130K Note, in the
aggregate principal amount of $130,000. The $130K Note does not accrue interest. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In October 2019, we issued and sold 11,600 shares of our Series C Preferred Stock at a purchase price of $25.00
per share for $290,000 in cash consideration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In April 2020, we issued and sold 28,990 shares of our Series C Preferred Stock at a purchase price of $25.00 per
share for $724,750 in cash consideration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In June 2020, we issued warrants to purchase an aggregate amount of
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Common Stock at an exercise price of $0.25 per share to settle approximately $114,750 worth of services rendered by a third-party contractor of the
Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In October 2020, we issued and sold 8,000 shares of our Series C Preferred Stock at a purchase price of $25.00
per share for $200,000 in cash consideration. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From December 2020 to April 2021, we issued and sold secured convertible promissory notes, or the $1.5M Notes, in
the aggregate principal amount of $1.5&nbsp;million. The $1.5M Notes accrued interest at a rate of 12% per annum. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From June to July 2021, we issued warrants to purchase an aggregate amount of
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our common stock at an exercise price of $0.25 per share to settle approximately $129,730 worth of services rendered by a third-party contractor of the
Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In November 2021, we issued warrants to purchase
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Common Stock at an exercise price equal to the lower of (i) $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share
and (ii) 30% discount to the offering price for the sale of Common Stock in a public offering, as consideration for the extension of the maturity of the $1.5M Notes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In November 2021, we issued warrants to purchase
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Common Stock at an exercise price equal to the lower of (i) $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share
and (ii) 30% discount to the offering price for the sale of Common Stock in a public offering, as consideration for the extension of the maturity of the $1M Loan and Security Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From October 2021 to February 25, 2022, in connection with our 2021 Bridge Financing, we issued and sold senior
subordinated convertible notes, or the Bridge Notes, in the aggregate principal amount of $3.98&nbsp;million. The Bridge Notes accrue interest at a rate of 8% per annum. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">From October 2021 to February 25, 2022, in connection with our 2021 Bridge Financing, we issued warrants to
purchase [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Common Stock at an initial exercise price of $[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] per share
subject to certain round down provisions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No underwriters were involved in the foregoing sales of securities described
above in this Item 15(a). Unless otherwise stated, the sales of securities described above were deemed to be exempt from registration pursuant to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section&nbsp;4(a)(2) of the Securities Act, including Rule 506(b) of Regulation D promulgated thereunder, as transactions by an issuer not involving a public offering. All of the purchasers in
these transactions represented to us in connection with their purchase that they were accredited investors, acquiring the securities for investment and not distribution, that they could bear the risks of the investment and could hold the securities
for an indefinite period of time. Such purchasers received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration or an available exemption from such
registration. All of the foregoing securities are deemed restricted securities for the purposes of the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Grants and Exercises of Stock
Options </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In September 2019, we granted stock options to purchase an aggregate amount of 4.6&nbsp;million shares of our
Common Stock at an exercise price of $0.039 per share, of which 370,000 shares vest over a period of time and 4.23&nbsp;million shares vest upon specific Company performance metrics. As of January&nbsp;31, 2022, 352,925 shares of time-based awards
have vested and 17,075 shares were unvested. All of the performance-based awards were unvested. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In November 2020, we granted stock options to purchase an aggregate amount of
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Common Stock at an exercise price of $0.035 per share, of which [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares
vest over a period of time and [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares vest upon specific Company performance metrics. As of [January&nbsp;31], 2022,
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of time-based awards have vested and [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares were unvested. All of the
performance-based awards were unvested. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In May 2021, we granted stock options to purchase an aggregate amount of
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Common Stock at an exercise price of $0.035 per share, vesting over a period of time. As of [January&nbsp;31], 2022,
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares have vested and [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares were unvested. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In [February] 2022, we granted stock options to purchase an aggregate amount of
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] shares of our Common Stock at an exercise price of $0.11 per share, vesting over a period of time. These shares have not vested. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuances of the securities described above in this Item 15(b) were deemed to be exempt from registration pursuant to Section&nbsp;4(a)(2)
of the Securities Act. The shares of Common Stock to be issued upon the exercise of options are deemed to be restricted securities for purposes of the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exhibits. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibits: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Amended and Restated Certificate of Formation of Heart Test Laboratories, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Amended and Restated Bylaws of Heart Test Laboratories, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Common Stock Certificate of the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Registration Rights Agreement by and between Heart Test Laboratories, Inc. and Buyers listed as signatories thereto, dated December&nbsp;22, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Registration Rights Agreement by and among Heart Test Laboratories, Inc. and the parties listed as signatories thereto related to the Series C Preferred Stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Bridge Warrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of $1M Lender Warrant and $1.5M Lender Warrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.7*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Investor Warrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Jackson Walker L.L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2013 Technology Agreement, by and between Heart Test Laboratories, Inc. and Guangren &#147;Gary&#148; Chen, dated December&nbsp;31, 2013</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment of 2013 Technology Agreement by and between Heart Test Laboratories, Inc. and Guangren &#147;Gary&#148; Chen, dated March&nbsp;13, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Master Assignment by and between Heart Test Laboratories, Inc. and Guangren &#147;Gary&#148; Chen, dated January&nbsp;1, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Security Agreement and Pledge by and between Heart Test Laboratories, Inc. and Guangren &#147;Gary&#148; Chen, dated March&nbsp;14, 2014</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Evaluation, Option and License Agreement by and between Heart Test Laboratories, Inc. and The University Court of The University of Glasgow, dated June&nbsp;2, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exercise of Option Agreement by and between Heart Test Laboratories, Inc. and The University Court of The University of Glasgow, dated December&nbsp;23, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$130K Note by and between Heart Test Laboratories, Inc. and Front Range Ventures LLC, dated August&nbsp;12, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$1M Loan and Security Agreement by and among Heart Test Laboratories, Inc., Front Range Ventures LLC and John. Q. Adams, dated April&nbsp;24, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No.&nbsp;1 to the $1M Loan and Security Agreement, dated September&nbsp;30, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No.&nbsp;2 to the $1M Loan and Security Agreement, dated November&nbsp;3, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of $1.5M Note</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amendment No.&nbsp;1 to the Form of $1.5M Note by and among Heart Test Laboratories, Inc. and the Requisite Noteholders, dated November&nbsp;2, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Securities Purchase Agreement by and between Heart Test Laboratories, Inc. and Purchasers listed as signatories thereto, dated December&nbsp;22, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Bridge Note</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consulting Agreement by and between Heart Test Laboratories, Inc. and Kyngstone Limited, Inc., dated June&nbsp;25, 2013</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16*&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement by and between Heart Test Laboratories, Inc. and Mark Hilz, dated March&nbsp;7, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Series C Side Letter by and between Heart Test Laboratories, Inc. and Front Range Ventures LLC, dated August 10, 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Haskell&nbsp;&amp; White LLP, independent registered public accounting firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Jackson Walker L.L.P. (included in Exhibit 5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature pages)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Filing Fee Table</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Management contract or compensatory plan or arrangement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(b) Financial Statement Schedules </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All financial statement schedules are omitted because the information called for is not required or is shown either in the financial statements
or in the notes thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement
certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Insofar as indemnification by the Registrant for liabilities arising under the Securities Act may be permitted to directors, officers and
controlling persons of the Registrant pursuant to the provisions described in Item 14 or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and
is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The undersigned Registrant hereby undertakes that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus
filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(l) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this
registration statement as of the time it was declared effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) For the purpose of determining any liability under
the Securities Act, each post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-1</FONT> and has duly caused this registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly
authorized, in <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 2022. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Heart Test Laboratories, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned officers and directors of Heart Test Laboratories, Inc. hereby constitute and appoint each of
[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] and [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>] with full power of substitution, each of them singly our true and lawful <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents to take any actions to enable the Company to comply with the Securities Act, and any rules, regulations and requirements of the SEC, in connection
with this registration statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> including the power and authority to sign for us in our names in the capacities indicated below any and all further amendments to this registration statement and
any other registration statement filed pursuant to the provisions of Rule 462 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of
the Securities Act of 1933, this amendment to the registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> has been signed by the following persons in the capacities and on the dates indicated. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer, Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal Executive Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,&nbsp;2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interm Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Principal Financial and Accounting Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,&nbsp;2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director, Chairman of the Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,&nbsp;2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,&nbsp;2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,&nbsp;2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,&nbsp;2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,&nbsp;2022</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 4.2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This<B> REGISTRATION RIGHTS AGREEMENT</B> (this &#147;<B>Agreement</B>&#148;), dated as of December&nbsp;22, 2021, is by and among Heart Test
Laboratories, Inc. (d/b/a HeartSciences), a Texas corporation with offices located at 550 Reserve Street, Suite 360, Southlake, TX 76092 (the &#147;<B>Company</B>&#148;), and the undersigned buyers (each, a &#147;<B>Buyer</B>,&#148; and
collectively, the &#147;<B>Buyers</B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RECITALS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. In connection with the Securities Purchase Agreement by and among the parties hereto, dated as of December&nbsp;22, 2021 (the
&#147;<B>Securities Purchase Agreement</B>&#148;), the Company has agreed, upon the terms and subject to the conditions of the Securities Purchase Agreement, to issue and sell to each Buyer (i)&nbsp;the Notes (as defined in the Securities Purchase
Agreement) which will be convertible into Conversion Shares (as defined in the Securities Purchase Agreement) in accordance with the terms of the Notes and (ii)&nbsp;the Warrants (as defined in the Securities Purchase Agreement) which will be
exercisable to purchase Warrant Shares (as defined in the Securities Purchase Agreement) in accordance with the terms of the Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.
To induce the Buyers to consummate the transactions contemplated by the Securities Purchase Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations
thereunder, or any similar successor statute (collectively, the &#147;<B>1933 Act</B>&#148;), and applicable state securities laws. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AGREEMENT </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW,
THEREFORE,</B> in consideration of the premises and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and each of the Buyers hereby agree as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>Definitions.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized
terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Business Day</B>&#148; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York
are authorized or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#147;stay at home&#148;, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;shelter-in-place&#148;,</FONT></FONT> <FONT STYLE="white-space:nowrap">&#147;non-essential</FONT> employee&#148;&nbsp;or any other similar orders or restrictions or the closure of any
physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Closing Date</B>&#148; shall have the meaning set forth in the Securities Purchase Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Effective Date</B>&#148; means the date that the applicable Registration
Statement has been declared effective by the SEC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Effectiveness Deadline</B>&#148; means (i)&nbsp;with respect to the initial
Registration Statement required to be filed pursuant to Section&nbsp;2(a), the earlier of the (A) 150<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> calendar day after the Public Company Date (as defined in the Securities Purchase Agreement)
and (B) 2nd Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that such Registration Statement will not be reviewed or will not be subject to further review and (ii)&nbsp;with respect to any
additional Registration Statements that may be required to be filed by the Company pursuant to this Agreement, the earlier of the (A) 90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> calendar day following the date on which the Company was
required to file such additional Registration Statement and (B) 2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP> Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that such
Registration Statement will not be reviewed or will not be subject to further review. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Filing Deadline</B>&#148; means
(i)&nbsp;with respect to the initial Registration Statement required to be filed pursuant to Section&nbsp;2(a), the 90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> calendar day after the Public Company Date and (ii)&nbsp;with respect to
any additional Registration Statements that may be required to be filed by the Company pursuant to this Agreement, the date on which the Company was required to file such additional Registration Statement pursuant to the terms of this Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Investor</B>&#148; means a Buyer or any transferee or assignee of any Registrable Securities, Notes or Warrants, as
applicable, to whom a Buyer assigns its rights under this Agreement and who agrees to become bound by the provisions of this Agreement in accordance with Section&nbsp;9 and any transferee or assignee thereof to whom a transferee or assignee of any
Registrable Securities, Notes or Warrants, as applicable, assigns its rights under this Agreement and who agrees to become bound by the provisions of this Agreement in accordance with Section&nbsp;9. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Person</B>&#148; means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an
unincorporated organization or a government or any department or agency thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>register</B>,&#148;
&#147;<B>registered</B>,&#148; and &#147;<B>registration</B>&#148; refer to a registration effected by preparing and filing one or more Registration Statements in compliance with the 1933 Act and pursuant to Rule 415 and the declaration of
effectiveness of such Registration Statement(s) by the SEC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Registrable Securities</B>&#148; means (i)&nbsp;the Conversion
Shares, (ii)&nbsp;the Warrant Shares and (iii)&nbsp;any capital stock of the Company issued or issuable with respect to the Conversion Shares, the Warrant Shares, the Notes or the Warrants, including, without limitation, (1)&nbsp;as a result of any
stock split, stock dividend, recapitalization, exchange or similar event or otherwise and (2)&nbsp;shares of capital stock of the Company into which the shares of Common Stock (as defined in the Notes) are converted or exchanged and shares of
capital stock of a Successor Entity (as defined in the Warrants) into which the shares of Common Stock are converted or exchanged, in each case, without regard to any limitations on conversion of the Notes or exercise of the Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) &#147;<B>Registration Statement</B>&#148; means a registration statement or registration
statements of the Company filed under the 1933 Act covering Registrable Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) &#147;<B>Required Holders</B>&#148; shall have the
meaning as set forth in the Securities Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B>Required Registration Amount</B>&#148; means 200% of the sum of
(i)&nbsp;the maximum number of Conversion Shares issuable upon conversion of the Notes (assuming for purposes hereof that (x)&nbsp;the Notes are convertible at the Alternate Conversion Price (as defined in the Notes) assuming an Alternate Conversion
Date (as defined in the Notes) as of such date of determination, (y)&nbsp;interest on the Notes shall accrue through the third anniversary of the Closing Date and will be converted in shares of Common Stock at the Alternate Conversion Price assuming
an Alternate Conversion Date as of such date of determination and (z)&nbsp;any such conversion shall not take into account any limitations on the conversion of the Notes set forth in the Notes) and (ii)&nbsp;the maximum number of Warrant Shares
issuable upon exercise of the Warrants (without taking into account any limitations on the exercise of the Warrants set forth therein), all subject to adjustment as provided in Section&nbsp;2(d) and/or Section&nbsp;2(f). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) &#147;<B>Rule 144</B>&#148; means Rule 144 promulgated by the SEC under the 1933 Act, as such rule may be amended from time to time, or any
other similar or successor rule or regulation of the SEC that may at any time permit the Investors to sell securities of the Company to the public without registration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) &#147;<B>Rule 415</B>&#148; means Rule 415 promulgated by the SEC under the 1933 Act, as such rule may be amended from time to time, or any
other similar or successor rule or regulation of the SEC providing for offering securities on a continuous or delayed basis. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)
&#147;<B>SEC</B>&#148; means the United States Securities and Exchange Commission or any successor thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Registration.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Mandatory Registration</U>. The Company shall prepare and, as soon as practicable after the Public Company Date, but in no event later
than the Filing Deadline, file with the SEC an initial Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> covering the resale of all of the Registrable Securities, provided that such initial Registration Statement shall
register for resale at least the number of shares of Common Stock equal to the Required Registration Amount as of the date such Registration Statement is initially filed with the SEC. Such initial Registration Statement, and each other Registration
Statement required to be filed pursuant to the terms of this Agreement, shall contain (except if otherwise directed by the Required Holders) the &#147;<U>Selling Stockholders</U>&#148; and &#147;<U>Plan of Distribution</U>&#148; sections in
substantially the form attached hereto as <B>Exhibit B</B>. The Company shall use its reasonable best efforts to have such initial Registration Statement, and each other Registration Statement required to be filed pursuant to the terms of this
Agreement, declared effective by the SEC as soon as practicable, but in no event later than the applicable Effectiveness Deadline for such Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Legal Counsel</U>. Subject to Section&nbsp;5 hereof, Kelley Drye&nbsp;&amp; Warren
LLP, counsel solely to the lead investor (&#147;<B>Legal Counsel</B>&#148;) shall review and oversee any registration, solely on behalf of the lead investor, pursuant to this Section&nbsp;2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Ineligibility to Use Form <FONT STYLE="white-space:nowrap">S-3</FONT></U>. In the event that Form
<FONT STYLE="white-space:nowrap">S-3</FONT> is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i)&nbsp;register the resale of the Registrable Securities on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> or another appropriate form reasonably acceptable to the Required Holders and (ii)&nbsp;undertake to register the resale of the Registrable Securities on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> as soon as such form is available, provided that the Company shall maintain the effectiveness of all Registration Statements then in effect until such time as a Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> covering the resale of all the Registrable Securities has been declared effective by the SEC and the prospectus contained therein is available for use. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Sufficient Number of Shares Registered</U>. In the event the number of shares available under any Registration Statement is insufficient
to cover all of the Registrable Securities required to be covered by such Registration Statement or an Investor&#146;s allocated portion of the Registrable Securities pursuant to Section&nbsp;2(h), the Company shall amend such Registration Statement
(if permissible), or file with the SEC a new Registration Statement (on the short form available therefor, if applicable), or both, so as to cover at least the Required Registration Amount as of the Trading Day immediately preceding the date of the
filing of such amendment or new Registration Statement, in each case, as soon as practicable, but in any event not later than fifteen (15)&nbsp;days after the necessity therefor arises (but taking account of any Staff position with respect to the
date on which the Staff will permit such amendment to the Registration Statement and/or such new Registration Statement (as the case may be) to be filed with the SEC). The Company shall use its reasonable best efforts to cause such amendment to such
Registration Statement and/or such new Registration Statement (as the case may be) to become effective as soon as practicable following the filing thereof with the SEC, but in no event later than the applicable Effectiveness Deadline for such
Registration Statement. For purposes of the foregoing provision, the number of shares available under a Registration Statement shall be deemed &#147;insufficient to cover all of the Registrable Securities&#148; if at any time the number of shares of
Common Stock available for resale under the applicable Registration Statement is less than the product determined by multiplying (i)&nbsp;the Required Registration Amount as of such time by (ii) 0.90. The calculation set forth in the foregoing
sentence shall be made without regard to any limitations on conversion, amortization and/or redemption of the Notes or exercise of the Warrants (and such calculation shall assume (A)&nbsp;that the Notes are then convertible in full into shares of
Common Stock at the then prevailing Conversion Rate (as defined in the Notes), (B) the initial outstanding principal amount of the Notes remains outstanding through the scheduled Maturity Date (as defined in the Notes) and no redemptions of the
Notes occur prior to the scheduled Maturity Date and (C)&nbsp;the Warrants are then exercisable in full into shares of Common Stock at the then prevailing Exercise Price (as defined in the Warrants)). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Effect of Failure to File and Obtain and Maintain Effectiveness of any Registration Statement</U>. If (i)&nbsp;a Registration Statement
covering the resale of all of the Registrable Securities required to be covered thereby (disregarding any reduction pursuant to Section&nbsp;2(f)) and required to be filed by the Company pursuant to this Agreement is (A)&nbsp;not filed with the SEC
on or before the Filing Deadline for such Registration Statement (a &#147;<B>Filing Failure</B>&#148;) (it being understood that if the Company files a Registration Statement without affording each Investor who holds at least
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$500,000 of Notes (each, a &#147;<B>Threshold Investor</B>&#148;) and Legal Counsel the reasonable opportunity to review and comment on the same as required by Section&nbsp;3(c) hereof, the
Company shall be deemed to not have satisfied this clause&nbsp;(i)(A) and such event shall be deemed to be a Filing Failure) or (B)&nbsp;not declared effective by the SEC on or before the Effectiveness Deadline for such Registration Statement (an
&#147;<B>Effectiveness Failure</B>&#148;) (it being understood that if on the Business Day immediately following the Effective Date for such Registration Statement the Company shall not have filed a &#147;final&#148; prospectus for such Registration
Statement with the SEC under Rule 424(b) in accordance with Section&nbsp;3(b) (whether or not such a prospectus is technically required by such rule), the Company shall be deemed to not have satisfied this clause (i)(B) and such event shall be
deemed to be an Effectiveness Failure), (ii) other than during an Allowable Grace Period (as defined below), on any day after the Effective Date of a Registration Statement sales of all of the Registrable Securities required to be included on such
Registration Statement (disregarding any reduction pursuant to Section&nbsp;2(f)) cannot be made pursuant to such Registration Statement (including, without limitation, because of a failure to keep such Registration Statement effective, a failure to
disclose such information as is necessary for sales to be made pursuant to such Registration Statement, a suspension or delisting of (or a failure to timely list) the shares of Common Stock on the Principal Market (as defined in the Securities
Purchase Agreement) or any other limitations imposed by the Principal Market, or a failure to register a sufficient number of shares of Common Stock or by reason of a stop order) or the prospectus contained therein is not available for use for any
reason (a &#147;<B>Maintenance Failure</B>&#148;), or (iii)&nbsp;if a Registration Statement is not effective for any reason or the prospectus contained therein is not available for use for any reason, and either (x)&nbsp;after the Public Company
Date, the Company fails for any reason to satisfy the requirements of Rule 144(c)(1), including, without limitation, the failure to satisfy the current public information requirement under Rule 144(c) or (y)&nbsp;the Company has ever been an issuer
described in Rule 144(i)(1)(i) or becomes such an issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a &#147;<B>Current Public Information Failure</B>&#148;) as a result of which any of the
Investors are unable to sell Registrable Securities without restriction under Rule&nbsp;144 (including, without limitation, volume restrictions), then, as partial relief for the damages to any holder by reason of any such delay in, or reduction of,
its ability to sell the underlying shares of Common Stock (which remedy shall not be exclusive of any other remedies available at law or in equity, including, without limitation, specific performance), the Company shall pay to each holder of
Registrable Securities relating to such Registration Statement an amount in cash equal to two percent (2%) of such Investor&#146;s original principal amount stated in such Investor&#146;s Note on the Closing Date (1)&nbsp;on the date of such Filing
Failure, Effectiveness Failure, Maintenance Failure or Current Public Information Failure, as applicable, and (2)&nbsp;on every thirty (30)&nbsp;day anniversary of (I)&nbsp;a Filing Failure until such Filing Failure is cured; (II)&nbsp;an
Effectiveness Failure until such Effectiveness Failure is cured; (III)&nbsp;a Maintenance Failure until such Maintenance Failure is cured; and (IV)&nbsp;a Current Public Information Failure until the earlier of (i)&nbsp;the date such Current Public
Information Failure is cured and (ii)&nbsp;such time that such public information is no longer required pursuant to Rule&nbsp;144 (in each case, pro rated for periods totaling less than thirty (30)&nbsp;days). The payments to which a holder of
Registrable Securities shall be entitled pursuant to this Section&nbsp;2(e) are referred to herein as &#147;<B>Registration Delay Payments</B>.&#148; Following the initial Registration Delay Payment for any particular event or failure (which shall
be paid on the date of such event or failure, as set forth above), without limiting the foregoing, if an event or failure giving rise to the Registration Delay Payments is cured prior to any thirty (30)&nbsp;day anniversary of such event or failure,
then such Registration Delay Payment shall be made on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the third (3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP>) Business Day after such cure. In the event the Company fails to make Registration Delay Payments in a timely manner in
accordance with the foregoing, such Registration Delay Payments shall bear interest at the rate of two percent (2%) per month (prorated for partial months) until paid in full. Notwithstanding the foregoing, no Registration Delay Payments shall be
owed to an Investor (other than with respect to a Maintenance Failure resulting from a suspension or delisting of (or a failure to timely list) the shares of Common Stock on the Principal Market) with respect to any period during which all of such
Investor&#146;s Registrable Securities may be sold by such Investor without restriction under Rule 144 (including, without limitation, volume restrictions) and without the need for current public information required by Rule 144(c)(1) (or Rule
144(i)(2), if applicable). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Offering</U>. Notwithstanding anything to the contrary contained in this Agreement, but subject to the
payment of the Registration Delay Payments pursuant to Section&nbsp;2(e), in the event the staff of the SEC (the &#147;<B>Staff</B>&#148;) or the SEC seeks to characterize any&nbsp;offering pursuant to a Registration Statement filed pursuant to this
Agreement as constituting an&nbsp;offering of securities by, or on behalf of, the Company, or in any other manner, such that&nbsp;the Staff or&nbsp;the SEC do not&nbsp;permit such Registration Statement to become effective and used for resales in a
manner that does not constitute such an offering and that permits the continuous resale at the market by the Investors participating&nbsp;therein&nbsp;(or as otherwise may be acceptable to each Investor) without being named therein as an
&#147;underwriter,&#148; then the Company shall reduce the number of shares to be included in such Registration Statement by all Investors until such time as the Staff&nbsp;and the SEC shall so permit such Registration Statement to become effective
as aforesaid. In making such reduction, the Company shall reduce the number of shares to be included by all Investors on a pro rata basis (based upon the number of Registrable Securities otherwise required to be included for each Investor) unless
the inclusion of shares by a particular Investor or a particular set of Investors are resulting in the Staff or the SEC&#146;s &#147;by or on behalf of the Company&#148; offering position, in which event the shares held by such Investor or set of
Investors shall be the only shares subject to reduction (and if by a set of Investors on a pro rata basis by such Investors or on such other basis as would result in the exclusion of the least number of shares by all such Investors); provided, that,
with respect to such pro rata portion allocated to any Investor, such Investor may elect the allocation of such pro rata portion among the Registrable Securities of such Investor. In addition, in the event that the Staff or the SEC requires any
Investor seeking to&nbsp;sell securities under a Registration Statement filed pursuant to this Agreement&nbsp;to be specifically identified as an &#147;underwriter&#148; in order to permit such Registration Statement to become effective, and such
Investor does not consent to being so named as an underwriter in such Registration Statement,&nbsp;then, in each such case, the Company&nbsp;shall reduce the total number of Registrable Securities to be registered on behalf
of&nbsp;such&nbsp;Investor,&nbsp;until such time as the Staff or the SEC does not require such identification or until such Investor accepts such identification and the manner thereof. Any reduction pursuant to this paragraph will&nbsp;first reduce
all Registrable Securities other than those issued pursuant to the Securities Purchase Agreement.&nbsp;In the event of any&nbsp;reduction in Registrable Securities pursuant to this paragraph,&nbsp;an affected Investor shall have the right to
require, upon delivery of a written request to the Company signed by such Investor, the Company to file a registration statement within twenty (20)&nbsp;days of such request (subject to any restrictions imposed by Rule 415 or required&nbsp;by
the&nbsp;Staff or the SEC) for resale by such Investor in a manner reasonably acceptable to such Investor, and the Company shall, following such request, cause to be and keep effective such registration statement in the same manner as otherwise
contemplated&nbsp;in this Agreement for registration statements hereunder, in each case until such time as: (i)&nbsp;all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Registrable Securities held by such Investor&nbsp;have been registered and sold pursuant to an effective Registration Statement in a manner acceptable to such Investor&nbsp;or (ii)&nbsp;all
Registrable Securities may be resold by such Investor&nbsp;without restriction (including, without limitation, volume limitations) pursuant to Rule 144 (taking account of any Staff position with respect to &#147;affiliate&#148; status) and without
the need for current public information required by Rule 144(c)(1) (or Rule 144(i)(2), if applicable) or (iii)&nbsp;such Investor agrees to be named as an underwriter in any such Registration Statement in a manner acceptable to such Investor as to
all Registrable Securities held by such Investor and that have not theretofore been included in a Registration Statement under this Agreement (it being understood that the special demand right under this sentence may be exercised by an Investor
multiple times and with respect to limited amounts of Registrable Securities in order to permit the resale thereof by such Investor as contemplated above). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Piggyback Registrations</U>. Without limiting any obligation of the Company hereunder or under the Securities Purchase Agreement, after
the initial Filing Deadline, if there is not an effective Registration Statement covering all of the Registrable Securities or the prospectus contained therein is not available for use and the Company shall determine to prepare and file with the SEC
a registration statement or offering statement relating to an offering for its own account or the account of others under the 1933 Act of any of its equity securities (other than on Form <FONT STYLE="white-space:nowrap">S-4</FONT> or Form <FONT
STYLE="white-space:nowrap">S-8</FONT> (each as promulgated under the 1933 Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in
connection with the Company&#146;s stock option or other employee benefit plans), then the Company shall deliver to each Investor a written notice of such determination and, if within fifteen&nbsp;(15) days after the date of the delivery of such
notice, any such Investor shall so request in writing, the Company shall include in such registration statement or offering statement all or any part of such Registrable Securities such Investor requests to be registered; provided, however, the
Company shall not be required to register any Registrable Securities pursuant to this Section&nbsp;2(g) that are eligible for resale pursuant to Rule 144 without restriction (including, without limitation, volume restrictions) and without the need
for current public information required by Rule 144(c)(1) (or Rule&nbsp;144(i)(2), if applicable) or that are the subject of a then-effective Registration Statement. The Company shall have the right to terminate or withdraw any registration
initiated by it pursuant to this Section&nbsp;2(g) before the effective date of such registration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Allocation of Registrable
Securities</U>. The initial number of Registrable Securities included in any Registration Statement and any increase in the number of Registrable Securities included therein shall be allocated pro rata among the Investors based on the number of
Registrable Securities held by each Investor at the time such Registration Statement covering such initial number of Registrable Securities or increase thereof is declared effective by the SEC. In the event that an Investor sells or otherwise
transfers any of such Investor&#146;s Registrable Securities, each transferee or assignee (as the case may be) that becomes an Investor shall be allocated a pro rata portion of the then-remaining number of Registrable Securities included in such
Registration Statement for such transferor or assignee (as the case may be). Any shares of Common Stock included in a Registration Statement and which remain allocated to any Person which ceases to hold any Registrable Securities covered by such
Registration Statement shall be allocated to the remaining Investors, pro rata based on the number of Registrable Securities then held by such Investors which are covered by such Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>No Inclusion of Other Securities</U>. The Company shall in no event include any
securities other than Registrable Securities on any Registration Statement filed in accordance herewith without the prior written consent of the Required Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Related Obligations.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
shall use its reasonable best efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition thereof, and, pursuant thereto, the Company shall have the following obligations: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) After the Public Company Date, the Company shall promptly prepare and file with the SEC a Registration Statement with respect to all the
Registrable Securities (but in no event later than the applicable Filing Deadline) and use its reasonable best efforts to cause such Registration Statement to become effective as soon as practicable after such filing (but in no event later than the
Effectiveness Deadline). Subject to Allowable Grace Periods, the Company shall keep each Registration Statement effective (and the prospectus contained therein available for use) pursuant to Rule 415 for resales by the Investors on a delayed or
continuous basis at then-prevailing market prices (and not fixed prices) at all times until the earlier of (i)&nbsp;the date as of which all of the Investors may sell all of the Registrable Securities required to be covered by such Registration
Statement (disregarding any reduction pursuant to Section&nbsp;2(f)) without restriction pursuant to Rule 144 (including, without limitation, volume restrictions) and without the need for current public information required by Rule 144(c)(1) (or
Rule 144(i)(2), if applicable) or (ii)&nbsp;the date on which the Investors shall have sold all of the Registrable Securities covered by such Registration Statement (the &#147;<B>Registration Period</B>&#148;). Notwithstanding anything to the
contrary contained in this Agreement, the Company shall ensure that, when filed and at all times while effective, each Registration Statement (including, without limitation, all amendments and supplements thereto) and the prospectus (including,
without limitation, all amendments and supplements thereto) used in connection with such Registration Statement (1)&nbsp;shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or
necessary to make the statements therein (in the case of prospectuses, in the light of the circumstances in which they were made) not misleading and (2)&nbsp;will disclose (whether directly or through incorporation by reference to other SEC filings
to the extent permitted) all material information regarding the Company and its securities. The Company shall submit to the SEC, within two (2)&nbsp;Business Days after the later of the date that (i)&nbsp;the Company learns that no review of a
particular Registration Statement will be made by the Staff or that the Staff has no further comments on a particular Registration Statement (as the case may be) and (ii)&nbsp;the consent of Legal Counsel is obtained pursuant to Section&nbsp;3(c)
(which consent shall be promptly sought), a request for acceleration of effectiveness of such Registration Statement to a time and date not later than twenty-four&nbsp;(24) hours after the submission of such request. The Company shall respond in
writing to comments made by the SEC in respect of a Registration Statement as soon as practicable, but in no event later than fifteen (15)&nbsp;days after the receipt of comments by or notice from the SEC that an amendment is required in order for a
Registration Statement to be declared effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Subject to Section&nbsp;3(r) of this Agreement, the Company shall prepare and file
with the SEC such amendments (including, without limitation, post-effective amendments) and supplements to each Registration Statement and the prospectus used in connection with each such Registration Statement, which prospectus is to be filed
pursuant to Rule 424 promulgated under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the 1933 Act, as may be necessary to keep each such Registration Statement effective at all times during the Registration Period for such Registration Statement, and, during such period, comply
with the provisions of the 1933 Act with respect to the disposition of all Registrable Securities of the Company required to be covered by such Registration Statement until such time as all of such Registrable Securities shall have been disposed of
in accordance with the intended methods of disposition by the seller or sellers thereof as set forth in such Registration Statement; provided, however, by 9:00 a.m. (New York time) on the Business Day immediately following each Effective Date, the
Company shall file with the SEC in accordance with Rule 424(b) under the 1933 Act the final prospectus to be used in connection with sales pursuant to the applicable Registration Statement (whether or not such a prospectus is technically required by
such rule). In the case of amendments and supplements to any Registration Statement which are required to be filed pursuant to this Agreement (including, without limitation, pursuant to this Section&nbsp;3(b)) by reason of the Company filing a
report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT STYLE="white-space:nowrap">10-K</FONT> or any analogous report under the Securities Exchange Act of 1934, as amended (the
&#147;<B>1934 Act</B>&#148;), the Company shall, if permitted under the applicable rules and regulations of the SEC, have incorporated such report by reference into such Registration Statement, if applicable, or shall file such amendments or
supplements with the SEC on the same day on which the 1934 Act report is filed which created the requirement for the Company to amend or supplement such Registration Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company shall (A)&nbsp;permit Legal Counsel and legal counsel for each other Threshold Investor to review and comment upon
(i)&nbsp;each Registration Statement at least five (5)&nbsp;Business Days prior to its filing with the SEC and (ii)&nbsp;all amendments and supplements to each Registration Statement (including, without limitation, the prospectus contained therein)
(except for Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and any similar or
successor reports) within a reasonable number of days prior to their filing with the SEC, and (B)&nbsp;not file any Registration Statement or amendment or supplement thereto in a form to which Legal Counsel or any legal counsel for any Threshold
Investor reasonably objects. The Company shall not submit a request for acceleration of the effectiveness of a Registration Statement or any amendment or supplement thereto or to any prospectus contained therein without the prior consent of Legal
Counsel, which consent shall not be unreasonably withheld. The Company shall promptly furnish to Legal Counsel and legal counsel for each other Investor, without charge, (i)&nbsp;copies of any correspondence from the SEC or the Staff to the Company
or its representatives relating to each Registration Statement, provided that such correspondence shall not contain any material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any of its Subsidiaries (as
defined in the Securities Purchase Agreement), (ii)&nbsp;after the same is prepared and filed with the SEC, one (1)&nbsp;copy of each Registration Statement and any amendment(s) and supplement(s) thereto, including, without limitation, financial
statements and schedules, all documents incorporated therein by reference, if requested by an Investor, and all exhibits and (iii)&nbsp;upon the effectiveness of each Registration Statement, one (1)&nbsp;copy of the prospectus included in such
Registration Statement and all amendments and supplements thereto. The Company shall reasonably cooperate with Legal Counsel and legal counsel for each other Investor in performing the Company&#146;s obligations pursuant to this Section&nbsp;3. Such
copies shall be deemed provided if such documents are publicly available via EDGAR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company shall promptly furnish to each Investor whose Registrable Securities are
included in any Registration Statement, without charge, (i)&nbsp;after the same is prepared and filed with the SEC, at least one (1)&nbsp;copy of each Registration Statement and any amendment(s) and supplement(s) thereto, including, without
limitation, financial statements and schedules, all documents incorporated therein by reference, if requested by an Investor, all exhibits and each preliminary prospectus, (ii)&nbsp;upon the effectiveness of each Registration Statement, one&nbsp;(1)
copy of the prospectus included in such Registration Statement and all amendments and supplements thereto (or such other number of copies as such Investor may reasonably request from time to time) and (iii)&nbsp;such other documents, including,
without limitation, copies of any preliminary or final prospectus, as such Investor may reasonably request from time to time in order to facilitate the disposition of the Registrable Securities owned by such Investor. Such copies shall be deemed
provided if they are publicly available on the the SEC&#146;s Electronic Data Gathering, Analysis, and Retrieval system. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company
shall use its reasonable best efforts to (i)&nbsp;register and qualify, unless an exemption from registration and qualification applies, the resale by Investors of the Registrable Securities covered by a Registration Statement under such other
securities or &#147;blue sky&#148; laws of all applicable jurisdictions in the United States, (ii)&nbsp;prepare and file in those jurisdictions, such amendments (including, without limitation, post-effective amendments) and supplements to such
registrations and qualifications as may be reasonably necessary to maintain the effectiveness thereof during the Registration Period, (iii)&nbsp;take such other actions as may be necessary to maintain such registrations and qualifications in effect
at all times during the Registration Period, and (iv)&nbsp;take all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however, the Company shall not be required in
connection therewith or as a condition thereto to (x)&nbsp;qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section&nbsp;3(e), (y) subject itself to general taxation in any such
jurisdiction, or (z)&nbsp;file a general consent to service of process in any such jurisdiction. The Company shall promptly notify Legal Counsel, legal counsel for each Threshold Investor and each Investor who holds Registrable Securities of the
receipt by the Company of any notification with respect to the suspension of the registration or qualification of any of the Registrable Securities for sale under the securities or &#147;blue sky&#148; laws of any jurisdiction in the United States
or its receipt of actual notice of the initiation or threatening of any proceeding for such purpose. Such copies shall be deemed provided if such documents are publicly available via EDGAR. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company shall notify Legal Counsel, legal counsel for each Threshold Investor and each Investor in writing of the happening of any
event, as promptly as practicable after becoming aware of such event, as a result of which the prospectus included in a Registration Statement, as then in effect, may include an untrue statement of a material fact or omission to state a material
fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading (provided that in no event shall such notice contain any material, <FONT
STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any of its Subsidiaries), and, subject to Section&nbsp;3(r), promptly prepare a supplement or amendment to such Registration Statement and such prospectus contained
therein to correct such untrue statement or omission and deliver one (1)&nbsp;copy of such supplement or amendment to Legal Counsel, legal counsel for each Threshold Investor and each Investor (or such other number of copies as Legal Counsel, legal
counsel for each Threshold Investor or such Investor may reasonably request). Such copies shall be deemed provided if such documents are publicly available via EDGAR. The Company shall also promptly notify Legal Counsel, legal counsel for each
Threshold Investor and each Investor in writing (i)&nbsp;when a prospectus or any prospectus supplement or post-effective amendment has been filed, when a Registration Statement or any post-effective amendment has
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
become effective (notification of such effectiveness shall be delivered to Legal Counsel, legal counsel for each Threshold Investor and each Investor by
<FONT STYLE="white-space:nowrap">e-mail</FONT> on the same day of such effectiveness), and when the Company receives written notice from the SEC that a Registration Statement or any post-effective amendment will be reviewed by the SEC, (ii)&nbsp;of
any request by the SEC for amendments or supplements to a Registration Statement or related prospectus or related information, (iii)&nbsp;of the Company&#146;s reasonable determination that a post-effective amendment to a Registration Statement
would be appropriate; and (iv)&nbsp;of the receipt of any request by the SEC or any other federal or state governmental authority for any additional information relating to the Registration Statement or any amendment or supplement thereto or any
related prospectus. The Company shall respond as promptly as practicable to any comments received from the SEC with respect to each Registration Statement or any amendment thereto (it being understood and agreed that the Company&#146;s response to
any such comments shall be delivered to the SEC no later than fifteen&nbsp;(15) Business Days after the receipt thereof). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Company
shall (i)&nbsp;use its reasonable best efforts to prevent the issuance of any stop order or other suspension of effectiveness of each Registration Statement or the use of any prospectus contained therein, or the suspension of the qualification, or
the loss of an exemption from qualification, of any of the Registrable Securities for sale in any jurisdiction and, if such an order or suspension is issued, to obtain the withdrawal of such order or suspension at the earliest practicable moment and
(ii)&nbsp;notify Legal Counsel, legal counsel for each Threshold Investor and each Investor who holds Registrable Securities of the issuance of such order and the resolution thereof or its receipt of actual notice of the initiation or threat of any
proceeding for such purpose. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) If any Investor may be required under applicable securities law to be described in any Registration
Statement as an underwriter and such Investor consents to so being named an underwriter, at the request of any Investor, the Company shall furnish to such Investor, on the date of the effectiveness of such Registration Statement and thereafter from
time to time on such dates as an Investor may reasonably request (i)&nbsp;a letter, dated such date, from the Company&#146;s independent certified public accountants in form and substance as is customarily given by independent certified public
accountants to underwriters in an underwritten public offering, addressed to the Investors, and (ii)&nbsp;an opinion, dated as of such date, of counsel representing the Company for purposes of such Registration Statement, in form, scope and
substance as is customarily given in an underwritten public offering, addressed to the Investors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) If any Investor may be required
under applicable securities law to be described in any Registration Statement as an underwriter and such Investor consents to so being named an underwriter, upon the written request of such Investor, the Company shall make available for inspection
by (i)&nbsp;such Investor, (ii)&nbsp;legal counsel for such Investor and (iii)&nbsp;one (1) firm of accountants or other agents retained by such Investor (collectively, the &#147;<B>Inspectors</B>&#148;), at such Investor&#146;s cost and expense,
all pertinent financial and other records, and pertinent corporate documents and properties of the Company (collectively, the &#147;<B>Records</B>&#148;), as shall be reasonably deemed necessary by each Inspector, and cause the Company&#146;s
officers, directors and employees to supply all information which any Inspector may reasonably request; provided, however, each Inspector shall agree in writing to hold in strict confidence and not to make any disclosure (except to such Investor) or
use of any Record or other information which the Company&#146;s board of directors determines in good faith to be confidential, and of which determination the Inspectors are so notified, unless (1)&nbsp;the disclosure of such Records is necessary to
avoid or correct a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
misstatement or omission in any Registration Statement or is otherwise required under the 1933 Act, (2)&nbsp;the release of such Records is ordered pursuant to a final, <FONT
STYLE="white-space:nowrap">non-appealable</FONT> subpoena or order from a court or government body of competent jurisdiction, or (3)&nbsp;the information in such Records has been made generally available to the public other than by disclosure in
violation of this Agreement or any other Transaction Document (as defined in the Securities Purchase Agreement). Such Investor agrees that it shall, upon learning that disclosure of such Records is sought in or by a court or governmental body of
competent jurisdiction or through other means, give prompt notice to the Company and allow the Company, at its expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, the Records deemed confidential.
Nothing herein (or in any other confidentiality agreement between the Company and such Investor, if any) shall be deemed to limit any Investor&#146;s ability to sell Registrable Securities in a manner which is otherwise consistent with applicable
laws and regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Company shall hold in confidence and not make any disclosure of information concerning an Investor provided
to the Company unless (i)&nbsp;disclosure of such information is necessary to comply with federal or state securities laws, (ii)&nbsp;the disclosure of such information is necessary to avoid or correct a misstatement or omission in any Registration
Statement or is otherwise required to be disclosed in such Registration Statement pursuant to the 1933 Act, (iii)&nbsp;the release of such information is ordered pursuant to a subpoena or other final,
<FONT STYLE="white-space:nowrap">non-appealable</FONT> order from a court or governmental body of competent jurisdiction, or (iv)&nbsp;such information has been made generally available to the public other than by disclosure in violation of this
Agreement or any other Transaction Document. The Company agrees that it shall, upon learning that disclosure of such information concerning an Investor is sought in or by a court or governmental body of competent jurisdiction or through other means,
give prompt written notice to such Investor and allow such Investor, at such Investor&#146;s expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Without limiting any obligation of the Company under the Securities Purchase Agreement, the Company shall use its best efforts either to
(i)&nbsp;cause all of the Registrable Securities covered by each Registration Statement to be listed on each securities exchange on which securities of the same class or series issued by the Company are then listed, if any, if the listing of such
Registrable Securities is then permitted under the rules of such exchange, (ii)&nbsp;secure designation and quotation of all of the Registrable Securities covered by each Registration Statement on an Eligible Market (as defined in the Securities
Purchase Agreement), or (iii)&nbsp;if, despite the Company&#146;s reasonable best efforts to satisfy the preceding clauses&nbsp;(i) or (ii)&nbsp;the Company is unsuccessful in satisfying the preceding clauses (i)&nbsp;or (ii), without limiting the
generality of the foregoing, to use its reasonable best efforts to arrange for at least two market makers to register with the Financial Industry Regulatory Authority (&#147;<B>FINRA</B>&#148;) as such with respect to such Registrable Securities. In
addition, the Company shall reasonably cooperate with each Investor and any broker or dealer through which any such Investor proposes to sell its Registrable Securities in effecting a filing with FINRA pursuant to FINRA Rule 5110 as requested by
such Investor. The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section&nbsp;3(k). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) The Company shall reasonably cooperate with the Investors who hold Registrable
Securities being offered and, to the extent applicable and in accordance with applicable federal and state securities laws, facilitate the timely preparation and delivery of certificates (not bearing any restrictive legend) representing the
Registrable Securities to be offered pursuant to a Registration Statement and enable such certificates to be in such denominations or amounts (as the case may be) as the Investors may reasonably request from time to time and registered in such names
as the Investors may reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) If requested by an Investor, the Company shall as soon as practicable after receipt of notice
from such Investor and subject to Section&nbsp;3(r) hereof, (i)&nbsp;incorporate in a prospectus supplement or post-effective amendment such information as an Investor reasonably requests to be included therein relating to the sale and distribution
of Registrable Securities, including, without limitation, information with respect to the number of Registrable Securities being offered or sold, the purchase price being paid therefor and any other terms of the offering of the Registrable
Securities to be sold in such offering; (ii)&nbsp;make all required filings of such prospectus supplement or post-effective amendment after being notified of the matters to be incorporated in such prospectus supplement or post-effective amendment;
and (iii)&nbsp;supplement or make amendments to any Registration Statement or prospectus contained therein if reasonably requested by an Investor holding any Registrable Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) The Company shall use its reasonable best efforts to cause the Registrable Securities covered by a Registration Statement to be registered
with or approved by such other governmental agencies or authorities as may be necessary to consummate the disposition of such Registrable Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) The Company shall make generally available to its security holders as soon as practical, but not later than ninety (90)&nbsp;days after the
close of the period covered thereby, an earnings statement (in form complying with, and in the manner provided by, the provisions of Rule&nbsp;158 under the 1933 Act) covering a twelve-month period beginning not later than the first day of the
Company&#146;s fiscal quarter next following the applicable Effective Date of each Registration Statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) The Company shall otherwise
use its reasonable best efforts to comply with all applicable rules and regulations of the SEC in connection with any registration hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) Within one (1)&nbsp;Business Day after a Registration Statement which covers Registrable Securities is declared effective by the SEC, if
required by the transfer agent for such Registrable Securities, the Company shall deliver, and shall cause legal counsel for the Company to deliver, to such transfer agent (with copies to the Investors whose Registrable Securities are included in
such Registration Statement) confirmation that such Registration Statement has been declared effective by the SEC in the form attached hereto as <B>Exhibit A</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) Notwithstanding anything to the contrary herein (but subject to the last sentence of this Section&nbsp;3(r)), at any time after the
Effective Date of a particular Registration Statement, the Company may delay the disclosure of material, <FONT STYLE="white-space:nowrap">non-public</FONT> information concerning the Company or any of its Subsidiaries the disclosure of which at the
time is not, in the good faith opinion of the board of directors of the Company, in the best interest of the Company and, in the opinion of counsel to the Company, otherwise required (a &#147;<B>Grace Period</B>&#148;), provided that the Company
shall promptly notify the Investors in writing of the (i)&nbsp;existence of material, <FONT STYLE="white-space:nowrap">non-public</FONT> information giving rise to a Grace Period (provided that in each such notice the Company shall not disclose the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
content of such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information to any of the Investors) and the date on which such Grace Period will begin and (ii)&nbsp;date on which
such Grace Period ends, provided further that (I)&nbsp;no Grace Period shall exceed fourteen (14)&nbsp;consecutive days and during any three hundred sixty five (365)&nbsp;day period all such Grace Periods shall not exceed an aggregate of sixty
(60)&nbsp;days, (II) the first day of any Grace Period must be at least five&nbsp;(5) Trading Days after the last day of any prior Grace Period and (III)&nbsp;no Grace Period may exist during the sixty (60)&nbsp;Trading Day period immediately
following the Effective Date of such Registration Statement (provided that such sixty (60)&nbsp;Trading Day period shall be extended by the number of Trading Days during such period and any extension thereof contemplated by this proviso during which
such Registration Statement is not effective or the prospectus contained therein is not available for use) (each, an &#147;<B>Allowable Grace Period</B>&#148;). For purposes of determining the length of a Grace Period above, such Grace Period shall
begin on and include the date the Investors receive the notice referred to in clause (i)&nbsp;above and shall end on and include the later of the date the Investors receive the notice referred to in clause (ii)&nbsp;above and the date referred to in
such notice. The provisions of Section&nbsp;3(g) hereof shall not be applicable during the period of any Allowable Grace Period. Upon expiration of each Grace Period, the Company shall again be bound by the first sentence of Section&nbsp;3(f) with
respect to the information giving rise thereto unless such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information is no longer applicable. Notwithstanding anything to the contrary contained in this Section&nbsp;3(r), the Company
shall cause its transfer agent to deliver unlegended shares of Common Stock to a transferee of an Investor in accordance with the terms of the Securities Purchase Agreement in connection with any sale of Registrable Securities with respect to which
such Investor has entered into a contract for sale, and delivered a copy of the prospectus included as part of the particular Registration Statement to the extent applicable, prior to such Investor&#146;s receipt of the notice of a Grace Period and
for which the Investor has not yet settled. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) The Company shall take all other reasonable actions necessary to expedite and facilitate
disposition by each Investors of its Registrable Securities pursuant to each Registration Statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) Neither the Company nor any
Subsidiary or affiliate thereof shall identify any Investor as an underwriter in any public disclosure or filing with the SEC without the written consent of such Investor, the Principal Market or any Eligible Market and any Buyer being deemed an
underwriter by the SEC shall not relieve the Company of any obligations it has under this Agreement or any other Transaction Document (as defined in the Securities Purchase Agreement); provided, however, that the foregoing shall not prohibit the
Company from including the disclosure found in the &#147;Plan of Distribution&#148; section attached hereto as Exhibit B in the Registration Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company or any of its Subsidiaries, on or
after the date of this Agreement, enter into any agreement with respect to its securities, that would have the effect of impairing the rights granted to the Buyers in this Agreement or otherwise conflicts with the provisions hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>Obligations of the Investors.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) At least five (5)&nbsp;Business Days prior to the first anticipated filing date of each Registration Statement, the Company shall notify
each Investor in writing of the information the Company requires from each such Investor with respect to such Registration Statement. It shall be a condition precedent to the obligations of the Company to complete the registration pursuant to this
Agreement with respect to the Registrable Securities of a particular Investor that such Investor shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the
Registrable Securities held by it, as shall be reasonably required to effect and maintain the effectiveness of the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company may
reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Investor, by such Investor&#146;s acceptance of the Registrable Securities, agrees to cooperate with the
Company as reasonably requested by the Company in connection with the preparation and filing of each Registration Statement hereunder, unless such Investor has notified the Company in writing of such Investor&#146;s election to exclude all of such
Investor&#146;s Registrable Securities from such Registration Statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Each Investor agrees that, upon receipt of any notice from
the Company of the happening of any event of the kind described in Section&nbsp;3(g) or the first sentence of 3(f), such Investor will immediately discontinue disposition of Registrable Securities pursuant to any Registration Statement(s) covering
such Registrable Securities until such Investor&#146;s receipt of the copies of the supplemented or amended prospectus contemplated by Section&nbsp;3(g) or the first sentence of Section&nbsp;3(f) or receipt of notice that no supplement or amendment
is required. Notwithstanding anything to the contrary in this Section&nbsp;4(c), the Company shall cause its transfer agent to deliver unlegended shares of Common Stock to a transferee of an Investor in accordance with the terms of the Securities
Purchase Agreement in connection with any sale of Registrable Securities with respect to which such Investor has entered into a contract for sale, and deliver a copy of the prospectus as part of the particular Registration Statement to the extent
applicable, prior to the Investor&#146;s receipt of a notice from the Company of the happening of any event of the kind described in Section&nbsp;3(g) or the first sentence of Section&nbsp;3(f) and for which such Investor has not yet settled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Expenses of Registration.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
reasonable expenses, other than underwriting discounts and commissions incurred in connection with registrations, filings or qualifications pursuant to Sections&nbsp;2 and 3, including, without limitation, all registration, listing and
qualifications fees, printers and accounting fees, FINRA filing fees (if any) and fees and disbursements of counsel for the Company shall be paid by the Company. The Company shall reimburse Legal Counsel for its fees and disbursements in connection
with registration, filing or qualification pursuant to Sections&nbsp;2 and 3 of this Agreement which amount shall be limited to $10,000 for each such registration, filing or qualification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>Indemnification.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) To the fullest
extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend each Investor and each of its directors, officers, shareholders, members, partners, employees, agents, advisors, representatives (and any other Persons
with a functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or any other title) and each Person, if any, who controls such Investor within the meaning of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
1933 Act or the 1934 Act and each of the directors, officers, shareholders, members, partners, employees, agents, advisors, representatives (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding the lack of such title or any other title) of such controlling Persons (each, an &#147;<B>Indemnified Person</B>&#148;), against any losses, obligations, claims, damages, liabilities,
contingencies, judgments, fines, penalties, charges, costs (including, without limitation, court costs, reasonable attorneys&#146; fees and costs of defense and investigation), amounts paid in settlement or expenses, joint or several, (collectively,
&#147;<B>Claims</B>&#148;) incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory
agency, body or the SEC, whether pending or threatened, whether or not an Indemnified Person is or may be a party thereto (&#147;<B>Indemnified Damages</B>&#148;), to which any of them may become subject insofar as such Claims (or actions or
proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i)&nbsp;any untrue statement or alleged untrue statement of a material fact in a Registration Statement or any post-effective amendment thereto or in
any filing made in connection with the qualification of the offering under the securities or other &#147;blue sky&#148; laws of any jurisdiction in which Registrable Securities are offered (&#147;<B>Blue Sky Filing</B>&#148;), or the omission or
alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any preliminary prospectus
if used prior to the effective date of such Registration Statement, or contained in the final prospectus (as amended or supplemented, if the Company files any amendment thereof or supplement thereto with the SEC) or the omission or alleged omission
to state therein any material fact necessary to make the statements made therein, in light of the circumstances under which the statements therein were made, not misleading or (iii)&nbsp;any violation or alleged violation by the Company of the 1933
Act, the 1934 Act, any other law, including, without limitation, any state securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities pursuant to a Registration Statement or (iv)&nbsp;any
violation of this Agreement (the matters in the foregoing clauses (i)&nbsp;through (iv) being, collectively, &#147;<B>Violations</B>&#148;). Subject to Section&nbsp;6(c), the Company shall reimburse the Indemnified Persons, promptly as such expenses
are incurred and are due and payable, for any legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification
agreement contained in this Section&nbsp;6(a): (i) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Company by
such Indemnified Person for such Indemnified Person expressly for use in connection with the preparation of such Registration Statement or any such amendment thereof or supplement thereto, if such prospectus was timely made available by the Company
pursuant to Section&nbsp;3(d); and (ii)&nbsp;shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld or delayed.
Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of any of the Registrable Securities by any of the Investors pursuant to
Section&nbsp;9. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In connection with any Registration Statement in which an Investor is participating, such Investor agrees to severally
and not jointly indemnify, hold harmless and defend, to the same extent and in the same manner as is set forth in Section&nbsp;6(a), the Company, each of its directors, each of its officers who signs the Registration Statement and each Person, if
any, who controls the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company within the meaning of the 1933 Act or the 1934 Act (each, an &#147;<B>Indemnified Party</B>&#148;), against any Claim or Indemnified Damages to which any of them may become subject, under
the 1933 Act, the 1934 Act or otherwise, insofar as such Claim or Indemnified Damages arise out of or are based upon any Violation, in each case, to the extent, and only to the extent, that such Violation occurs in reliance upon and in conformity
with written information furnished to the Company by such Investor expressly for use in connection with such Registration Statement; and, subject to Section&nbsp;6(c) and the below provisos in this Section&nbsp;6(b), such Investor will reimburse an
Indemnified Party any legal or other expenses reasonably incurred by such Indemnified Party in connection with investigating or defending any such Claim; provided, however, the indemnity agreement contained in this Section&nbsp;6(b) and the
agreement with respect to contribution contained in Section&nbsp;7 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of such Investor, which consent shall not be unreasonably
withheld or delayed, provided further that such Investor shall be liable under this Section&nbsp;6(b) for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds to such Investor as a result of the applicable sale of
Registrable Securities pursuant to such Registration Statement. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer of any of the
Registrable Securities by any of the Investors pursuant to Section&nbsp;9. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an Indemnified Person or
Indemnified Party (as the case may be) under this Section&nbsp;6 of notice of the commencement of any action or proceeding (including, without limitation, any governmental action or proceeding) involving a Claim, such Indemnified Person or
Indemnified Party (as the case may be) shall, if a Claim in respect thereof is to be made against any indemnifying party under this Section&nbsp;6, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying
party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the
indemnifying party and the Indemnified Person or the Indemnified Party (as the case may be); provided, however, an Indemnified Person or Indemnified Party (as the case may be) shall have the right to retain its own counsel with the fees and expenses
of such counsel to be paid by the indemnifying party if: (i)&nbsp;the indemnifying party has agreed in writing to pay such fees and expenses; (ii)&nbsp;the indemnifying party shall have failed promptly to assume the defense of such Claim and to
employ counsel reasonably satisfactory to such Indemnified Person or Indemnified Party (as the case may be) in any such Claim; or (iii)&nbsp;the named parties to any such Claim (including, without limitation, any impleaded parties) include both such
Indemnified Person or Indemnified Party (as the case may be) and the indemnifying party, and such Indemnified Person or such Indemnified Party (as the case may be) shall have been advised by outside counsel that a conflict of interest is likely to
exist if the same counsel were to represent such Indemnified Person or such Indemnified Party and the indemnifying party (in which case, if such Indemnified Person or such Indemnified Party (as the case may be) notifies the indemnifying party in
writing that it elects to employ separate counsel at the expense of the indemnifying party, then the indemnifying party shall not have the right to assume the defense thereof and such counsel shall be at the expense of the indemnifying party,
provided further that in the case of clause (iii)&nbsp;above the indemnifying party shall not be responsible for the reasonable fees and expenses of more than one (1)&nbsp;separate legal counsel for such Indemnified Person or Indemnified Party (as
the case may be). The Indemnified Party or Indemnified Person (as the case may be) shall reasonably cooperate with the indemnifying party in connection with any negotiation or defense of any such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action or Claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified Party or Indemnified Person (as the case may be)
which relates to such action or Claim. The indemnifying party shall keep the Indemnified Party or Indemnified Person (as the case may be) reasonably apprised at all times as to the status of the defense or any settlement negotiations with respect
thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its prior written consent; provided, however, the indemnifying party shall not unreasonably withhold, delay or condition its
consent. No indemnifying party shall, without the prior written consent of the Indemnified Party or Indemnified Person (as the case may be), consent to entry of any judgment or enter into any settlement or other compromise which does not include as
an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party or Indemnified Person (as the case may be) of a release from all liability in respect to such Claim or litigation, and such settlement shall not include
any admission as to fault on the part of the Indemnified Party. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person (as the case may be) with
respect to all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall
not relieve such indemnifying party of any liability to the Indemnified Person or Indemnified Party (as the case may be) under this Section&nbsp;6, except to the extent that the indemnifying party is materially and adversely prejudiced in its
ability to defend such action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The indemnification required by this Section&nbsp;6 shall be made by periodic payments of the amount
thereof during the course of the investigation or defense, as and when bills are received or Indemnified Damages are incurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The
indemnity and contribution agreements contained herein shall be in addition to (i)&nbsp;any cause of action or similar right of the Indemnified Party or Indemnified Person against the indemnifying party or others, and (ii)&nbsp;any liabilities the
indemnifying party may be subject to pursuant to the law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>Contribution.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum
contribution with respect to any amounts for which it would otherwise be liable under Section&nbsp;6 to the fullest extent permitted by law; provided, however: (i)&nbsp;no contribution shall be made under circumstances where the maker would not have
been liable for indemnification under the fault standards set forth in Section&nbsp;6 of this Agreement, (ii)&nbsp;no Person involved in the sale of Registrable Securities which Person is guilty of fraudulent misrepresentation (within the meaning of
Section&nbsp;11(f) of the 1933 Act) in connection with such sale shall be entitled to contribution from any Person involved in such sale of Registrable Securities who was not guilty of fraudulent misrepresentation; and (iii)&nbsp;contribution by any
seller of Registrable Securities shall be limited in amount to the amount of net proceeds received by such seller from the applicable sale of such Registrable Securities pursuant to such Registration Statement. Notwithstanding the provisions of this
Section&nbsp;7, no Investor shall be required to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds actually received by such Investor from the applicable sale of the Registrable Securities subject to the
Claim exceeds the amount of any damages that such Investor has otherwise been required to pay, or would otherwise be required to pay under Section&nbsp;6(b), by reason of such untrue or alleged untrue statement or omission or alleged omission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>Reports Under the 1934 Act.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a view to making available to the Investors the benefits of Rule 144, the Company agrees from and after the Public Company Date to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) make and keep public information available, as those terms are understood and defined in Rule 144; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) file with the SEC in a timely manner all reports and other documents required of the Company under the 1933 Act and the 1934 Act so long as
the Company remains subject to such requirements (it being understood and agreed that nothing herein shall limit any obligations of the Company under the Securities Purchase Agreement) and the filing of such reports and other documents is required
for the applicable provisions of Rule 144; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) furnish to each Investor so long as such Investor owns Registrable Securities, promptly
upon request, (i)&nbsp;a written statement by the Company, if true, that it has complied with the reporting, submission and posting requirements of Rule 144, the 1933 Act and the 1934 Act, (ii)&nbsp;a copy of the most recent annual or quarterly
report of the Company and such other reports and documents so filed by the Company with the SEC if such reports are not publicly available via EDGAR, and (iii)&nbsp;such other information as may be reasonably requested to permit the Investors to
sell such securities pursuant to Rule 144 without registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <U>Assignment of Registration Rights</U><U>.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All or any portion of the rights under this Agreement shall be automatically assignable by each Investor to any transferee or assignee (as the
case may be) of all or any portion of such Investor&#146;s Registrable Securities, Notes or Warrants if: (i)&nbsp;such Investor agrees in writing with such transferee or assignee (as the case may be) to assign all or any portion of such rights, and
a copy of such agreement is furnished to the Company within a reasonable time after such transfer or assignment (as the case may be); (ii) the Company is, within a reasonable time after such transfer or assignment (as the case may be), furnished
with written notice of (a)&nbsp;the name and address of such transferee or assignee (as the case may be), and (b)&nbsp;the securities with respect to which such registration rights are being transferred or assigned (as the case may be);
(iii)&nbsp;immediately following such transfer or assignment (as the case may be) the further disposition of such securities by such transferee or assignee (as the case may be) is restricted under the 1933 Act or applicable state securities laws if
so required; (iv)&nbsp;at or before the time the Company receives the written notice contemplated by clause (ii)&nbsp;of this sentence such transferee or assignee (as the case may be) agrees in writing with the Company to be bound by all of the
provisions contained herein; (v)&nbsp;such transfer or assignment (as the case may be) shall have been made in accordance with the applicable requirements of the Securities Purchase Agreement, the Notes and the Warrants (as the case may be); and
(vi)&nbsp;such transfer or assignment (as the case may be and applicable federal and state securities laws, rules, and regulations) shall have been conducted in accordance with all applicable federal and state securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <U>Amendment of Registration Rights.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either
retroactively or prospectively), only with the written consent of the Company and the Required Holders; provided that any such amendment or waiver that complies with the foregoing, but that disproportionately, materially and adversely affects the
rights and obligations of any Investor relative to the comparable rights and obligations of the other Investors shall require the prior written consent of such adversely affected Investor. Any amendment or waiver effected in accordance with this
Section&nbsp;10 shall be binding upon each Investor and the Company, provided that no such amendment shall be effective to the extent that it (1)&nbsp;applies to less than all of the holders of Registrable Securities or (2)&nbsp;imposes any
obligation or liability on any Investor without such Investor&#146;s prior written consent (which may be granted or withheld in such Investor&#146;s sole discretion). No waiver shall be effective unless it is in writing and signed by an authorized
representative of the waiving party. No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration (other than the reimbursement of legal
fees) also is offered to all of the parties to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <U>Miscellaneous.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Solely for purposes of this Agreement, a Person is deemed to be a holder of Registrable Securities whenever such Person owns, or is deemed
to own, of record such Registrable Securities. If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable Securities, the Company shall act upon the basis of instructions,
notice or election received from such record owner of such Registrable Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any notices, consents, waivers or other
communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i)&nbsp;upon receipt, when delivered personally; (ii)&nbsp;upon receipt, when sent by electronic mail
(provided that such sent email is kept on file (whether electronically or otherwise) by the sending party and the sending party does not receive an automatically generated message from the recipient&#146;s email server that such <FONT
STYLE="white-space:nowrap">e-mail</FONT> could not be delivered to such recipient); or (iii)&nbsp;one (1) Business Day after deposit with a nationally recognized overnight delivery service with next day delivery specified, in each case, properly
addressed to the party to receive the same. The addresses and email addresses for such communications shall be: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Heart Test Laboratories, Inc. (d/b/a HeartSciences). </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">550 Reserve Street, Suite 360 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Southlake, TX 76092 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Telephone:
(___) ___-____ </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">With a copy (for informational purposes only) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Jackson Walker, L.L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">2323
Ross Ave., Suite 600 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Dallas, Texas 75201 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Telephone: (214) <FONT STYLE="white-space:nowrap">953-5896</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Richard A. Dahlson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: rdahlson@jw.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to
Legal Counsel: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Kelley Drye&nbsp;&amp; Warren LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">3 World Trade Center </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">175
Greenwich Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">New York, NY 10007 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Telephone: (212) <FONT STYLE="white-space:nowrap">808-7540</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: Michael A. Adelstein, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> madelstein@kelleydrye.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to a Buyer, to its address and/or email address set forth on the Schedule of Buyers attached to the Securities Purchase Agreement, with copies to such
Buyer&#146;s representatives as set forth on the Schedule of Buyers, or to such other address, and/or email address and/or to the attention of such other Person as the recipient party has specified by written notice given to each other party five
(5)&nbsp;days prior to the effectiveness of such change, provided that Kelley Drye&nbsp;&amp; Warren LLP shall only be provided notices sent to the lead investor. Written confirmation of receipt (A)&nbsp;given by the recipient of such notice,
consent, waiver or other communication, (B)&nbsp;mechanically or electronically generated by the sender&#146;s email containing the time, date, recipient email address or (C)&nbsp;provided by a courier or overnight courier service shall be
rebuttable evidence of personal service, receipt by <FONT STYLE="white-space:nowrap">e-mail</FONT> or receipt from a nationally recognized overnight delivery service in accordance with clause&nbsp;(i), (ii) or (iii)&nbsp;above, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or
remedy, shall not operate as a waiver thereof. The Company and each Investor acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific
terms or were otherwise breached. It is accordingly agreed that each party hereto shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement by any other party hereto and to enforce specifically
the terms and provisions hereof (without the necessity of showing economic loss and without any bond or other security being required), this being in addition to any other remedy to which any party may be entitled by law or equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal
laws of the State of Illinois, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Illinois or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than
the State of Illinois. Each party hereby irrevocably submits to the exclusive jurisdiction of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
state and federal courts sitting in The City of Chicago, County of Cook, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or
discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an
inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy
thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way
any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT
OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If any provision of this Agreement is prohibited by law or otherwise
determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and
enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change, the original
intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or
the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect
of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) This Agreement, the other
Transaction Documents, the schedules and exhibits attached hereto and thereto and the instruments referenced herein and therein constitute the entire agreement among the parties hereto and thereto solely with respect to the subject matter hereof and
thereof. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein and therein. This Agreement, the other Transaction Documents, the schedules and exhibits attached hereto and thereto and the
instruments referenced herein and therein supersede all prior agreements and understandings among the parties hereto solely with respect to the subject matter hereof and thereof; provided, however, nothing contained in this Agreement or any other
Transaction Document shall (or shall be deemed to)&nbsp;(i) have any effect on any agreements any Investor has entered into with the Company or any of its Subsidiaries prior to the date hereof with respect to any prior investment made by such
Investor in the Company, (ii)&nbsp;waive, alter, modify or amend in any respect any obligations of the Company or any of its Subsidiaries or any rights of or benefits to any Investor or any other Person in any agreement entered into prior to the
date hereof between or among the Company and/or any of its Subsidiaries and any Investor and all such agreements shall continue in full force and effect or (iii)&nbsp;limit any obligations of the Company under any of the other Transaction Documents.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Subject to compliance with Section&nbsp;9 (if applicable), this Agreement shall inure to
the benefit of and be binding upon the permitted successors and assigns of each of the parties hereto. This Agreement is not for the benefit of, nor may any provision hereof be enforced by, any Person, other than the parties hereto, their respective
permitted successors and assigns and the Persons referred to in Sections&nbsp;6 and 7 hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) The headings in this Agreement are for
convenience of reference only and shall not limit or otherwise affect the meaning hereof. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms
thereof. The terms &#147;including,&#148; &#147;includes,&#148; &#147;include&#148; and words of like import shall be construed broadly as if followed by the words &#147;without limitation.&#148; The terms &#147;herein,&#148; &#147;hereunder,&#148;
&#147;hereof&#148; and words of like import refer to this entire Agreement instead of just the provision in which they are found. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) This
Agreement may be executed in two or more identical counterparts, each of which shall be deemed an original, but all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party
and delivered to the other party. In the event that any signature is delivered by an email which contains a portable document format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all
such other agreements, certificates, instruments and documents as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent and no
rules of strict construction will be applied against any party. Notwithstanding anything to the contrary set forth in Section&nbsp;10, terms used in this Agreement but defined in the other Transaction Documents shall have the meanings ascribed to
such terms on the Closing Date in such other Transaction Documents unless otherwise consented to in writing by each Investor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) All
consents and other determinations required to be made by the Investors pursuant to this Agreement shall be made, unless otherwise specified in this Agreement, by the Required Holders, determined as if all of the outstanding Notes then held by the
Investors have been converted for Registrable Securities without regard to any limitations on redemption, amortization and/or conversion of the Notes and the outstanding Warrants then held by Investors have been exercised for Registrable Securities
without regard to any limitations on exercise of the Warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) This Agreement is intended for the benefit of the parties hereto and
their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) The obligations of each Investor under this Agreement and the other Transaction
Documents are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor under this Agreement or any other Transaction Document.
Nothing contained herein or in any other Transaction Document, and no action taken by any Investor pursuant hereto or thereto, shall be deemed to constitute the Investors as, and the Company acknowledges that the Investors do not so constitute, a
partnership, an association, a joint venture or any other kind of group or entity, or create a presumption that the Investors are in any way acting in concert or as a group or entity with respect to such obligations or the transactions contemplated
by the Transaction Documents or any matters, and the Company acknowledges that the Investors are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or the transactions contemplated
by this Agreement or any of the other the Transaction Documents. Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of any other Transaction
Documents, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The use of a single agreement with respect to the obligations of the Company contained herein was solely in the
control of the Company, not the action or decision of any Investor, and was done solely for the convenience of the Company and not because it was required or requested to do so by any Investor. It is expressly understood and agreed that each
provision contained in this Agreement and in each other Transaction Document is between the Company and an Investor, solely, and not between the Company and the Investors collectively and not between and among Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each Buyer and the Company have caused their respective signature
page to this Registration Rights Agreement to be duly executed as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HEART TEST LABORATORIES, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D/B/A HEARTSCIENCES)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each Buyer and the Company have caused their respective signature
page to this Registration Rights Agreement to be duly executed as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BUYER::</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CAVALRY INVESTMENT FUND, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, each Buyer and the Company have caused their respective signature
page to this Registration Rights Agreement to be duly executed as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BUYERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Lary Conel
Snodgrass</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Albert Paul
Knuckley</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Daniel Simpson</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Raymond Pettitt</B></P></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>John J. Bussa</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Marilyn L.
Bussa</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MATTHEWS HOLDINGS SOUTHWEST, INC</B>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Scott Sullivan</B></P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 4.4 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEITHER THE ISSUANCE AND SALE
OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE
OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I)&nbsp;IN THE ABSENCE OF (A)&nbsp;AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B)&nbsp;AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY
THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II)&nbsp;UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE
SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET
FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(a) OF THIS WARRANT. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>H<SMALL>EART</SMALL> T<SMALL>EST</SMALL>
L<SMALL>ABORATORIES</SMALL>, I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(<SMALL>D</SMALL>/<SMALL>B</SMALL>/<SMALL>A</SMALL>
H<SMALL>EART</SMALL>S<SMALL>CIENCES</SMALL>) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>W<SMALL>ARRANT</SMALL> T<SMALL>O</SMALL> P<SMALL>URCHASE</SMALL> C<SMALL>OMMON</SMALL>
S<SMALL>TOCK</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant No.: 2021- </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date of
Issuance: January ___, 2022 (&#147;<B>Issuance Date</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heart Test Laboratories, Inc. (d/b/a HeartSciences), a Texas corporation
(the &#147;<B>Company</B>&#148;), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ______________________, the registered holder hereof or its permitted assigns (the
&#147;<B>Holder</B>&#148;), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant to Purchase Common Stock (including any Warrants to
Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#147;<B>Warrant</B>&#148;), at any time or times on or after the Issuance Date, but not after 11:59 p.m., New York time, on the Expiration Date (as defined below),
___________ (subject to adjustment as provided herein) fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock (as defined below)<B> </B>(the &#147;<B>Warrant Shares</B>&#148;). Except as otherwise defined
herein, capitalized terms in this Warrant shall have the meanings set forth in Section&nbsp;19. This Warrant is one of the Warrants to Purchase Common Stock (the &#147;<B>SPA Warrants</B>&#148;) issued pursuant to Section&nbsp;1 of that certain
Securities Purchase Agreement, dated as of December 22, 2021 (the &#147;<B>Subscription Date</B>&#148;), by and among the Company and the investors (the &#147;<B>Buyers</B>&#148;) referred to therein, as amended from time to time (the
&#147;<B>Securities Purchase Agreement</B>&#148;). </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>EXERCISE OF WARRANT.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Mechanics of Exercise</U>. Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in
Section&nbsp;1(f)), this Warrant may be exercised by the Holder on any day on or after the Issuance Date (an &#147;<B>Exercise Date</B>&#148;), in whole or in part, by delivery (whether via <FONT STYLE="white-space:nowrap">e-mail</FONT> or
otherwise) of a written notice, in the form attached hereto as <B><U>Exhibit A</U></B> (the &#147;<B>Exercise Notice</B>&#148;), of the Holder&#146;s election to exercise this Warrant. Within one (1)&nbsp;Trading Day following an exercise of this
Warrant as aforesaid, the Holder shall deliver payment to the Company of an amount equal to the Exercise Price in effect on the date of such exercise multiplied by the number of Warrant Shares as to which this Warrant was so exercised (the
&#147;<B>Aggregate Exercise Price</B>&#148;) in cash or via wire transfer of immediately available funds if the Holder did not notify the Company in such Exercise Notice that such exercise was made pursuant to a Cashless Exercise (as defined in
Section&nbsp;1(d)). The Holder shall not be required to deliver the original of this Warrant in order to effect an exercise hereunder. Execution and delivery of an Exercise Notice with respect to less than all of the Warrant Shares shall have the
same effect as cancellation of the original of this Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares. Execution and delivery of an Exercise Notice for all of the then-remaining Warrant
Shares shall have the same effect as cancellation of the original of this Warrant after delivery of the Warrant Shares in accordance with the terms hereof. On or before the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) Trading Day
following the date on which the Company has received an Exercise Notice, the Company shall transmit by electronic mail an acknowledgment of confirmation of receipt of such Exercise Notice, in the form attached hereto as
<B><U>Exhibit</U></B><B><U></U></B><B><U>&nbsp;B</U></B>, to the Holder and, if after the Public Company Date, the Company&#146;s transfer agent (the &#147;<B>Transfer Agent</B>&#148;), which confirmation shall, if after the Public Company Date,
constitute an instruction to the Transfer Agent to process such Exercise Notice in accordance with the terms herein. On or before the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) Trading Day following the date on which the
Company has received such Exercise Notice (or such earlier date as required pursuant to the 1934 Act or other applicable law, rule or regulation for the settlement of a trade of such Warrant Shares initiated on the applicable Exercise Date), the
Company shall (X)&nbsp;if on or after the Public Company Date, provided that the Transfer Agent is participating in The Depository Trust Company (&#147;<B>DTC</B>&#148;) Fast Automated Securities Transfer Program (&#147;<B>FAST</B>&#148;), upon the
request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&#146;s or its authorized designee&#146;s balance account with DTC through its Deposit/Withdrawal at
Custodian system, or (Y)&nbsp;if either (x)&nbsp;prior to the Public Company Date or (y)&nbsp;on or after the Public Company Date if the Transfer Agent is not participating in FAST, upon the request of the Holder, issue and deliver (via reputable
overnight courier) to the address as specified in the Exercise Notice, a certificate, registered in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder shall be entitled pursuant to such exercise.
Upon delivery of an Exercise Notice, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date such Warrant Shares
are credited to the Holder&#146;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares (as the case may be). If this Warrant is submitted in connection with any exercise pursuant to this Section&nbsp;1(a) and the
number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise and upon surrender of this Warrant to the Company by the Holder, then, at the request of the
Holder, the Company shall as soon as practicable and in no event later than two (2)&nbsp;Business Days after any exercise and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
at its own expense, issue and deliver to the Holder (or its designee) a new Warrant (in accordance with Section&nbsp;7(d)) representing the right to purchase the number of Warrant Shares
purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised. No fractional shares of Common Stock are to be issued upon the exercise of this Warrant, but rather
the number of shares of Common Stock to be issued shall be rounded up to the nearest whole number. The Company shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses (including, without limitation, fees and expenses of
the Transfer Agent) that may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant. Notwithstanding the foregoing, except in the case where an exercise of this Warrant is validly made pursuant to a
Cashless Exercise, the Company&#146;s failure to deliver Warrant Shares to the Holder on or prior to the later of (i)&nbsp;two (2) Trading Days after receipt of the applicable Exercise Notice (or, after the Public Company Date, such earlier date as
required pursuant to the 1934 Act or other applicable law, rule or regulation for the settlement of a trade of such Warrant Shares initiated on the applicable Exercise Date) and (ii)&nbsp;one (1) Trading Day after the Company&#146;s receipt of the
Aggregate Exercise Price (or valid notice of a Cashless Exercise) (such later date, the &#147;<B>Share Delivery Deadline</B>&#148;) shall not be deemed to be a breach of this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Price</U>. For purposes of this Warrant, &#147;<B>Exercise Price</B>&#148; means $0.27525, subject to adjustment as provided
herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Company</U><U>&#146;</U><U>s Failure to Timely Deliver Securities</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>General</U>. The Company shall in all cases use its reasonable best efforts to comply with the delivery requirements set
forth herein and shall do all things and take all actions reasonably requested by the Holder in furtherance thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)
<U>Exercise Failures On or After the Public Company Date</U>. If on or after the Public Company Date, the Company shall fail, for any reason or for no reason, on or prior to the Share Delivery Deadline, if the Transfer Agent is not participating in
FAST, to issue and deliver to the Holder (or its designee) a certificate for the number of Warrant Shares to which the Holder is entitled and register such Warrant Shares on the Company&#146;s share register or, if the Transfer Agent is
participating in FAST, to credit the balance account of the Holder or the Holder&#146;s designee with DTC for such number of Warrant Shares to which the Holder is entitled upon the Holder&#146;s exercise of this Warrant (as the case may be) (a
&#147;<B>Delivery Failure</B>&#148;), then, in addition to all other remedies available to the Holder, (X)&nbsp;the Company shall pay in cash to the Holder on each day after the Share Delivery Date and during such Delivery Failure an amount equal to
2% of the product of (A)&nbsp;the sum of the number of shares of Common Stock not issued to the Holder on or prior to the Share Delivery Deadline and to which the Holder is entitled, multiplied by (B)&nbsp;any trading price of the Common Stock
selected by the Holder in writing as in effect at any time during the period beginning on the applicable Exercise Date and ending on the applicable Share Delivery Date, and (Y)&nbsp;the Holder, upon written notice to the Company, may void its
Exercise Notice with respect to, and retain or have returned, as the case may be, any portion of this Warrant that has not been exercised pursuant to such Exercise Notice; provided that the voiding of an Exercise Notice shall not affect the
Company&#146;s obligations to make any payments which have accrued prior to the date of such notice pursuant to this Section&nbsp;1(c) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or otherwise. In addition to the foregoing, if on or after the Public Company Date and on or prior to the Share Delivery Deadline the Transfer Agent is not participating in the DTC Fast Automated
Securities Transfer Program, the Company shall fail to issue and deliver to the Holder (or its designee) a certificate and register such shares of Common Stock on the Company&#146;s share register or, if the Transfer Agent is participating in the
DTC Fast Automated Securities Transfer Program, the Transfer Agent shall fail to credit the balance account of the Holder or the Holder&#146;s designee with DTC for the number of shares of Common Stock to which the Holder is entitled upon the
Holder&#146;s exercise hereunder or pursuant to the Company&#146;s obligation pursuant to clause (ii)&nbsp;below, and if on or after such Share Delivery Deadline the Holder acquires (in an open market transaction, stock loan or otherwise) shares of
Common Stock to deliver in satisfaction of a sale by the Holder of all or any portion of the number of shares of Common Stock issuable upon such exercise that the Holder anticipated receiving from the Company (a &#147;<B><FONT
STYLE="white-space:nowrap">Buy-In</FONT></B>&#148;), then, in addition to all other remedies available to the Holder, the Company shall, within two (2)&nbsp;Business Days after the Holder&#146;s request and in the Holder&#146;s discretion, either
(i)&nbsp;pay cash to the Holder in an amount equal to the Holder&#146;s total purchase price (including brokerage commissions, stock loan costs and other reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, if any) for the shares of Common Stock so acquired (including, without limitation, by any other Person in respect, or on behalf, of the Holder)
(the &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT> Price</B>&#148;), at which point the Company&#146;s obligation to so issue and deliver such certificate (and to issue such shares of Common Stock) or credit the balance account of such
Holder or such Holder&#146;s designee, as applicable, with DTC for the number of Warrant Shares to which the Holder is entitled upon the Holder&#146;s exercise hereunder (as the case may be) (and to issue such Warrant Shares) shall terminate, or
(ii)&nbsp;promptly honor its obligation to so issue and deliver to the Holder a certificate or certificates representing such Warrant Shares or credit the balance account of such Holder or such Holder&#146;s designee, as applicable, with DTC for the
number of Warrant Shares to which the Holder is entitled upon the Holder&#146;s exercise hereunder (as the case may be) and pay cash to the Holder in an amount equal to the excess (if any) of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> Price
over the product of (A)&nbsp;such number of Warrant Shares multiplied by (B)&nbsp;the lowest Closing Sale Price of the Common Stock on any Trading Day during the period commencing on the date of the applicable Exercise Notice and ending on the date
of such issuance and payment under this clause (ii) (the &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT> Payment Amount</B>&#148;). Nothing shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or
in equity, including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver certificates representing shares of Common Stock (or to electronically deliver such
shares of Common Stock) upon the exercise of this Warrant as required pursuant to the terms hereof. In addition to the foregoing rights, if after the Public Company Date, (i)&nbsp;if the Company fails to deliver the applicable number of Warrant
Shares upon an exercise pursuant to Section&nbsp;1 by the applicable Share Delivery Deadline, then the Holder shall have the right to rescind such exercise in whole or in part and retain and/or have the Company return, as the case may be, any
portion of this Warrant that has not been exercised pursuant to such Exercise Notice; provided that the rescission of an exercise shall not affect the Company&#146;s obligation to make any payments that have accrued prior to the date of such notice
pursuant to this Section&nbsp;1(c) or otherwise, and (ii)&nbsp;if a registration statement covering the issuance or resale of the Warrant Shares that are subject to an Exercise Notice is not available for the issuance
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or resale, as applicable, of such Warrant Shares and the Holder has submitted an Exercise Notice prior to receiving notice of the <FONT STYLE="white-space:nowrap">non-availability</FONT> of such
registration statement and the Company has not already delivered the Warrant Shares underlying such Exercise Notice electronically without any restrictive legend by crediting such aggregate number of Warrant Shares to which the Holder is entitled
pursuant to such exercise to the Holder&#146;s or its designee&#146;s balance account with DTC through its Deposit / Withdrawal At Custodian system, the Holder shall have the option, by delivery of notice to the Company, to (x)&nbsp;rescind such
Exercise Notice in whole or in part and retain or have returned, as the case may be, any portion of this Warrant that has not been exercised pursuant to such Exercise Notice; provided that the rescission of an Exercise Notice shall not affect the
Company&#146;s obligation to make any payments that have accrued prior to the date of such notice pursuant to this Section&nbsp;1(c) or otherwise, and/or (y)&nbsp;switch some or all of such Exercise Notice from a cash exercise to a Cashless
Exercise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Cashless Exercise</U>. Notwithstanding anything contained herein to the contrary (other than Section&nbsp;1(f) below),
commencing on the six (6)&nbsp;month anniversary of the Closing (as defined in the Securities Purchase Agreement), in the event that the issuance of the Warrant Shares is not registered under the 1933 Act pursuant to an effective registration
statement or no current prospectus is available for resale of the Warrant Shares by the Holder in accordance with the 1933 Act and other applicable securities laws, the Holder may, in its sole discretion, exercise this Warrant in whole or in part
and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the &#147;Net Number&#148; of Warrant Shares
determined according to the following formula (a &#147;<B>Cashless Exercise</B>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">Net Number = <U>(A x B) - (A x C)</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:26%; font-size:10pt; font-family:Times New Roman">B </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:11%; font-size:10pt; font-family:Times New Roman">For purposes of the
foregoing formula: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">A= the total number of shares with respect to which this Warrant is then being exercised. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">B = (i) prior to the Public Company Date, the greatest of (A)&nbsp;the last purchase price at which the Company issued or sold Common Stock
preceding the date of the Exercise Notice, (B)&nbsp;the initial conversion price of the last Convertible Securities issued or sold by the Company preceding the date of the Exercise Notice, (C)&nbsp;the initial exercise price of the last Options
issued or sold by the Company preceding the date of the Exercise Notice and (D)&nbsp;the fair market value of the Common Stock as mutually determined by the Company and the Required Holders and (ii)&nbsp;on or after the Public Company Date, as
elected by the Holder, (A)&nbsp;the VWAP of the shares of Common Stock on the Trading Day immediately preceding the date of the applicable Exercise Notice if such Exercise Notice is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;1(a)
hereof on a day that is not a Trading Day or (2)&nbsp;both executed and delivered pursuant to Section&nbsp;1(a) hereof on a Trading Day prior to the opening of &#147;regular trading hours&#148; (as defined in Rule 600(b)(64) of Regulation NMS
promulgated under the federal securities laws) on such Trading </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Day, (B)&nbsp;either (x) the VWAP on the Trading Day immediately preceding the date of the applicable Exercise Notice or (y)&nbsp;the Bid Price of the shares of Common Stock as of the time of the
Holder&#146;s execution of the applicable Exercise Notice if such Exercise Notice is executed during &#147;regular trading hours&#148; on a Trading Day and is delivered within two (2)&nbsp;hours thereafter pursuant to Section&nbsp;1(a) hereof, or
(C)&nbsp;the Closing Sale Price of the Common Stock on the date of the applicable Exercise Notice if the date of such Exercise Notice is a Trading Day and such Exercise Notice is both executed and delivered pursuant to Section&nbsp;1(a) hereof after
the close of &#147;regular trading hours&#148; on such Trading Day. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">C = the Exercise Price then in effect for the applicable Warrant
Shares at the time of such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144(d) promulgated under the 1933 Act, as in effect on the Subscription Date,
it is intended that the Warrant Shares issued in a Cashless Exercise shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued
pursuant to the Securities Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In the event of termination or expiration of this Warrant (including upon the Expiration
Date), to the extent that this Warrant is then exercisable and such exercise would result in the issuance of Warrant Shares to the Holder, this Warrant shall be deemed to have been automatically exercised pursuant to a Cashless Exercise immediately
prior to the time at which it would otherwise terminate or expire. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Disputes</U>. In the case of a dispute as to the determination
of the Exercise Price or the arithmetic calculation of the number of Warrant Shares to be issued pursuant to the terms hereof, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute
in accordance with Section&nbsp;13. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Limitations on Exercises</U>. From and after the Public Company Date, the Company shall not
effect the exercise of any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant to the terms and conditions of this Warrant and any such exercise shall be null and void and treated as if
never made, to the extent that after giving effect to such exercise, the Holder together with the other Attribution Parties collectively would beneficially own in excess of 4.99% (the &#147;<B>Maximum Percentage</B>&#148;) of the shares of Common
Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of
shares of Common Stock held by the Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude
shares of Common Stock which would be issuable upon (A)&nbsp;exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of the other Attribution Parties and (B)&nbsp;exercise or conversion of the
unexercised or unconverted portion of any other securities of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including other SPA Warrants) beneficially owned by the Holder or any other
Attribution Party subject to a limitation on conversion or exercise analogous </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the limitation contained in this Section&nbsp;1(f). For purposes of this Section&nbsp;1(f), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the 1934 Act. For
purposes of determining the number of outstanding shares of Common Stock the Holder may acquire upon the exercise of this Warrant without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as
reflected in (x)&nbsp;the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> or other public filing with the SEC, as the case may be, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other written notice by the Company or the Transfer Agent, if any, setting
forth the number of shares of Common Stock outstanding (the &#147;<B>Reported Outstanding Share Number</B>&#148;). From and after the Public Company Date, if the Company receives an Exercise Notice from the Holder at a time when the actual number of
outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i)&nbsp;notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Exercise Notice
would otherwise cause the Holder&#146;s beneficial ownership, as determined pursuant to this Section&nbsp;1(f)(i), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of Warrant Shares to be acquired pursuant to
such Exercise Notice (the number of shares by which such purchase is reduced, the &#147;<B>Reduction Shares</B>&#148;) and (ii)&nbsp;as soon as reasonably practicable, the Company shall return to the Holder any exercise price paid by the Holder for
the Reduction Shares. For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1)&nbsp;Business Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common
Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and any other Attribution
Party since the date as of which the Reported Outstanding Share Number was reported. From and after the Public Company Date, in the event that the issuance of shares of Common Stock to the Holder upon exercise of this Warrant results in the Holder
and the other Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section&nbsp;13(d) of the 1934 Act), the number of shares
so issued by which the Holder&#146;s and the other Attribution Parties&#146; aggregate beneficial ownership exceeds the Maximum Percentage (the &#147;<B>Excess Shares</B>&#148;) shall be deemed null and void and shall be cancelled ab initio, and the
Holder shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the exercise price paid by the
Holder for the Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase (with such increase not effective until the sixty-first (61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after
delivery of such notice) or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified in such notice; provided that (i)&nbsp;any such increase in the Maximum Percentage will not be effective until the sixty-first
(61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after such notice is delivered to the Company and (ii)&nbsp;any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to any other holder of
SPA Warrants that is not an Attribution Party of the Holder. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the
Holder for any purpose including for purposes of Section&nbsp;13(d) or Rule <FONT STYLE="white-space:nowrap">16a-1(a)(1)</FONT> of the 1934 Act. No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the
applicability of the provisions of this paragraph with respect to any subsequent determination of exercisability. The provisions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;1(f) to the extent necessary to correct this paragraph or
any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section&nbsp;1(f) or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)
<U>Reservation</U><U> of Shares</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Required Reserve Amount</U>. As of the Closing Date, the Company shall have
reserved from its duly authorized capital stock not less than 60,000,000 shares of Common Stock for issuance upon conversion of the Notes and exercise of the SPA Warrants. From and after January&nbsp;31, 2022, so long as any of the SPA Warrants
remain outstanding, the Company shall take all action necessary to at all times have authorized, and reserved for the purpose of issuance, no less than 200% of the sum of (i)&nbsp;the maximum number of Conversion Shares issuable upon conversion of
the Notes, and (ii)&nbsp;the maximum number of Warrant Shares issuable upon exercise of all the SPA Warrants then outstanding (without regard to any limitations on the exercise of the Warrants set forth therein) (collectively, the &#147;<B>Required
Reserve Amount</B>&#148;); provided that at no time shall the number of shares of Common Stock reserved pursuant to this Section&nbsp;1(g) be reduced other than proportionally in connection with any exercise or redemption of SPA Warrants or such
other event covered by Section&nbsp;2(a) below. The Required Reserve Amount (including, without limitation, each increase in the number of shares so reserved) shall be allocated pro rata among the holders of the SPA Warrants based on the number of
shares of Common Stock issuable upon exercise of SPA Warrants held by each holder on the Closing Date (without regard to any limitations on exercise) or increase in the number of reserved shares, as the case may be (the &#147;<B>Authorized Share
Allocation</B>&#148;). In the event that a holder shall sell or otherwise transfer any of such holder&#146;s SPA Warrants, each transferee shall be allocated a pro rata portion of such holder&#146;s Authorized Share Allocation. Any shares of Common
Stock reserved and allocated to any Person which ceases to hold any SPA Warrants shall be allocated to the remaining holders of SPA Warrants, pro rata based on the number of shares of Common Stock issuable upon exercise of the SPA Warrants then held
by such holders (without regard to any limitations on exercise). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Insufficient Authorized Shares</U>. If at any
time after January&nbsp;31, 2022, the number of shares of Common Stock authorized and reserved for issuance is not sufficient to meet the Required Reserve Amount (an &#147;<B>Authorized Share Failure</B>&#148;), the Company will promptly take all
corporate action necessary to authorize and reserve a sufficient number of shares, including, without limitation, calling a special meeting of stockholders to authorize additional shares to meet the Company&#146;s obligations pursuant to the
Transaction Documents, in the case of an insufficient number of authorized shares, obtain stockholder approval of an increase in such authorized number of shares, and voting the management shares of the Company in favor of an increase in the
authorized shares of the Company to ensure that the number of authorized shares is sufficient to meet the Required Reserve Amount. On or prior to January&nbsp;31, 2022 (the &#147;<B>Consent Deadline</B>&#148;), holders of a majority of the issued
and outstanding shares of Common Stock and the Preferred Stock shall have voted by written consent (the <B>&#147;</B><B>Stockholder Resolutions</B><B>&#148;</B>) approving an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
amendment to the Certificate of Incorporation to, among other items, approve a reverse stock split and, on an advisory basis, approve the transactions contemplated by this Agreement (the
&#147;<B>Stockholder Approval</B>&#148;, and the date the Stockholder Approval is obtained, the &#147;<B>Stockholder Approval Date</B>&#148;). Thereafter, the Company shall provide each stockholder entitled to vote at a meeting of stockholders of
the Company notice of the Consent Action (the &#147;<B>Consent Notice</B>&#148;). The Stockholder Resolutions and the Consent Notice shall be in a form reasonably acceptable to the Buyers and Kelley Drye&nbsp;&amp; Warren LLP, at the expense of the
Company, with the Company obligated to reimburse the expenses of Kelley Drye&nbsp;&amp; Warren LLP incurred in connection therewith in an amount not exceed $3,000, The Company shall be obligated to seek to obtain the Stockholder Approval by the
Consent Deadline.&nbsp;If, despite the Company&#146;s reasonable best efforts the Stockholder Approval is not obtained on or prior to the Consent Deadline, the Company shall cause either an additional consent action or a stockholder meeting to be
held on or prior to March&nbsp;31, 2021.&nbsp;If, despite the Company&#146;s reasonable best efforts the Stockholder Approval is not obtained after such subsequent consent action or stockholder meeting, the Company shall cause an additional consent
action or stockholder meeting to be held semi-annually thereafter until such Stockholder Approval is obtained. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>ADJUSTMENT OF EXERCISE PRICE AND
NUMBER OF WARRANT SHARES</U>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section&nbsp;2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and Splits</U>. Without limiting any provision of Section&nbsp;2(b) or Section&nbsp;4, if the Company, at any time on or
after the Subscription Date, (i)&nbsp;pays a stock dividend on one or more classes of its then outstanding shares of Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock,
(ii)&nbsp;subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its then outstanding shares of Common Stock into a larger number of shares or (iii)&nbsp;combines (by combination, reverse stock split or
otherwise) one or more classes of its then outstanding shares of Common Stock into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common
Stock outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, and any adjustment pursuant to clause (ii)&nbsp;or (iii) of this paragraph shall become effective immediately after
the effective date of such subdivision or combination. If any event requiring an adjustment under this paragraph occurs during the period that an Exercise Price is calculated hereunder, then the calculation of such Exercise Price shall be adjusted
appropriately to reflect such event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Adjustment Upon Issuance of Shares of Common Stock</U>. If and whenever on or after the
Subscription Date and on or prior to the later of (x)&nbsp;the second anniversary of the Closing, and (y)&nbsp;the eighteen (18)&nbsp;month anniversary of the occurrence of a Qualified Offering, the Company grants, issues or sells (or enters into
any agreement to grant, issue or sell), or in accordance with this Section&nbsp;2 is deemed to have granted, issued or sold, any shares of Common Stock (including the issuance or sale of shares of Common Stock owned or held by or for the account of
the Company, but excluding any Excluded Securities granted issued or sold or deemed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to have been granted issued or sold) for a consideration per share (the &#147;<B>New Issuance Price</B>&#148;) less than a price equal to the Exercise Price in effect immediately prior to such
granting, issuance or sale or deemed granting issuance or sale (such Exercise Price then in effect is referred to herein as the &#147;<B>Applicable Price</B>&#148;) (the foregoing a &#147;<B>Dilutive Issuance</B>&#148;), then immediately after such
Dilutive Issuance, the Exercise Price then in effect shall be reduced to an amount equal to the New Issuance Price. For all purposes of the foregoing (including, without limitation, determining the adjusted Exercise Price and the New Issuance Price
under this Section&nbsp;2(b)), the following shall be applicable: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Issuance of Options</U>. If the Company in any
manner grants, issues or sells (or enters into any agreement to grant, issue or sell) any Options and the lowest price per share for which one share of Common Stock is at any time issuable upon the exercise of any such Option or upon conversion,
exercise or exchange of any Convertible Securities issuable upon exercise of any such Option or otherwise pursuant to the terms thereof is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have
been issued and sold by the Company at the time of the granting or sale of such Option for such price per share. For purposes of this Section&nbsp;2(b)(i), the &#147;lowest price per share for which one share of Common Stock is at any time issuable
upon the exercise of any such Options or upon conversion, exercise or exchange of any Convertible Securities issuable upon exercise of any such Option or otherwise pursuant to the terms thereof&#148; shall be equal to (1)&nbsp;the lower of
(x)&nbsp;the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to any one share of Common Stock upon the granting, issuance or sale of such Option, upon exercise of such Option and upon
conversion, exercise or exchange of any Convertible Security issuable upon exercise of such Option or otherwise pursuant to the terms thereof and (y)&nbsp;the lowest exercise price set forth in such Option for which one share of Common Stock is
issuable (or may become issuable assuming all possible market conditions) upon the exercise of any such Options or upon conversion, exercise or exchange of any Convertible Securities issuable upon exercise of any such Option or otherwise pursuant to
the terms thereof minus (2)&nbsp;the sum of all amounts paid or payable to the holder of such Option (or any other Person) upon the granting, issuance or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of
any Convertible Security issuable upon exercise of such Option or otherwise pursuant to the terms thereof plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Option (or any other Person).
Except as contemplated below in Section&nbsp;2(b)(iii), no further adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common Stock or of such Convertible Securities upon the exercise of such Options or
otherwise pursuant to the terms of or upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Convertible Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Issuance of Convertible Securities</U>. If the Company in any manner issues or sells (or enters into any agreement to
issue or sell) any Convertible Securities and the lowest price per share for which one share of Common Stock is at any time issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof is less than the
Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the issuance or sale (or the time of execution of such agreement to issue or sell, as applicable) of
such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Convertible Securities for such price per share. For the purposes of this Section&nbsp;2(b)(ii), the &#147;lowest price per share for which one share of Common Stock is at any time issuable upon
the conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof&#148; shall be equal to (1)&nbsp;the lower of (x)&nbsp;the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect
to one share of Common Stock upon the issuance or sale (or pursuant to the agreement to issue or sell, as applicable) of the Convertible Security and upon conversion, exercise or exchange of such Convertible Security or otherwise pursuant to the
terms thereof and (y)&nbsp;the lowest conversion price set forth in such Convertible Security for which one share of Common Stock is issuable (or may become issuable assuming all possible market conditions) upon conversion, exercise or exchange
thereof or otherwise pursuant to the terms thereof minus (2)&nbsp;the sum of all amounts paid or payable to the holder of such Convertible Security (or any other Person) upon the issuance or sale (or the agreement to issue or sell, as applicable) of
such Convertible Security plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Convertible Security (or any other Person). Except as contemplated below in Section&nbsp;2(b)(iii), no further
adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Convertible Securities or otherwise pursuant to the terms thereof, and if any such issuance or sale
of such Convertible Securities is made upon exercise of any Options for which adjustment of this Warrant has been or is to be made pursuant to other provisions of this Section&nbsp;2(b), except as contemplated below, no further adjustment of the
Exercise Price shall be made by reason of such issuance or sale. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Change in Option Price or Rate of
Conversion</U>. If the purchase or exercise price provided for in any Options, the additional consideration, if any, payable upon the issue, conversion, exercise or exchange of any Convertible Securities, or the rate at which any Convertible
Securities are convertible into or exercisable or exchangeable for shares of Common Stock increases or decreases at any time (other than proportional changes in conversion or exercise prices, as applicable, in connection with an event referred to in
Section&nbsp;2(a)), the Exercise Price in effect at the time of such increase or decrease shall be adjusted to the Exercise Price which would have been in effect at such time had such Options or Convertible Securities provided for such increased or
decreased purchase price, additional consideration or increased or decreased conversion rate, as the case may be, at the time initially granted, issued or sold . For purposes of this Section&nbsp;2(b)(iii), if the terms of any Option or Convertible
Security (including, without limitation, any Option or Convertible Security that was outstanding as of the Subscription Date) are increased or decreased in the manner described in the immediately preceding sentence, then such Option or Convertible
Security and the shares of Common Stock deemed issuable upon exercise, conversion or exchange thereof shall be deemed to have been issued as of the date of such increase or decrease. No adjustment pursuant to this Section&nbsp;2(b) shall be made if
such adjustment would result in an increase of the Exercise Price then in effect. If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to
the Company upon such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option or Convertible Security is issued or amended, any adjustment to the Exercise Price that would result under the terms of this
Section&nbsp;2(b) at the time of such issuance or amendment shall instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of
calculating such adjustment to the Exercise Price that such issuance or amendment took place at the time such calculation can first be made. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U>Calculation of Consideration Received</U>. If any Option and/or
Convertible Security and/or Adjustment Right is issued in connection with the issuance or sale or deemed issuance or sale of any other securities of the Company (as determined by the Holder, the &#147;<B>Primary Security</B>&#148;, and such Option
and/or Convertible Security and/or Adjustment Right, the &#147;<B>Secondary Securities</B>&#148;), together comprising one integrated transaction, (or one or more transactions if such issuances or sales or deemed issuances or sales of securities of
the Company either (A)&nbsp;have at least one investor or purchaser in common, (B)&nbsp;are consummated in reasonable proximity to each other and/or (C)&nbsp;are consummated under the same plan of financing) the aggregate consideration per share of
Common Stock with respect to such Primary Security shall be deemed to be equal to the difference of (x)&nbsp;the lowest price per share for which one share of Common Stock was issued (or was deemed to be issued pursuant to Section&nbsp;2(b)(i) or
2(b)(ii) above, as applicable) in such integrated transaction solely with respect to such Primary Security, minus (y)&nbsp;with respect to such Secondary Securities, the sum of (I)&nbsp;the Black Scholes Consideration Value of each such Option, if
any, (II)&nbsp;the fair market value (as determined by the Holder in good faith) or the Black Scholes Consideration Value, as applicable, of such Adjustment Right, if any, and (III)&nbsp;the fair market value (as determined by the Holder) of such
Convertible Security, if any, in each case, as determined on a per share basis in accordance with this Section&nbsp;2(b)(iv). If any shares of Common Stock, Options or Convertible Securities are issued or sold or deemed to have been issued or sold
for cash, the consideration received therefor (for the purpose of determining the consideration paid for such Common Stock, Option or Convertible Security, but not for the purpose of the calculation of the Black Scholes Consideration Value) will be
deemed to be the net amount of consideration received by the Company therefor. If any shares of Common Stock, Options or Convertible Securities are issued or sold for a consideration other than cash, the amount of such consideration received by the
Company (for the purpose of determining the consideration paid for such Common Stock, Option or Convertible Security, but not for the purpose of the calculation of the Black Scholes Consideration Value) will be the fair value of such consideration,
except where such consideration consists of publicly traded securities, in which case the amount of consideration received by the Company for such securities will be the arithmetic average of the VWAPs of such security for each of the five
(5)&nbsp;Trading Days immediately preceding the date of receipt. If any shares of Common Stock, Options or Convertible Securities are issued to the owners of the <FONT STYLE="white-space:nowrap">non-surviving</FONT> entity in connection with any
merger in which the Company is the surviving entity, the amount of consideration therefor (for the purpose of determining the consideration paid for such Common Stock, Option or Convertible Security, but not for the purpose of the calculation of the
Black Scholes Consideration Value) will be deemed to be the fair value of such portion of the net assets and business of the <FONT STYLE="white-space:nowrap">non-surviving</FONT> entity as is attributable to such shares of Common Stock, Options or
Convertible Securities (as the case may be). The fair value of any consideration other than cash or publicly traded securities will be determined jointly by the Company and the Required Holders (as defined in the Securities Purchase Agreement). If
such parties are unable to reach agreement within ten (10)&nbsp;days </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
after the occurrence of an event requiring valuation (the &#147;<B>Valuation Event</B>&#148;), the fair value of such consideration will be determined within five (5)&nbsp;Trading Days after the
tenth (10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day following such Valuation Event by an independent, reputable appraiser jointly selected by the Company and the Required Holders. The determination of such appraiser shall be final
and binding upon all parties absent manifest error and the fees and expenses of such appraiser shall be borne by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Record Date</U>. If the Company takes a record of the holders of shares of Common Stock for the purpose of entitling
them (A)&nbsp;to receive a dividend or other distribution payable in shares of Common Stock, Options or in Convertible Securities or (B)&nbsp;to subscribe for or purchase shares of Common Stock, Options or Convertible Securities, then such record
date will be deemed to be the date of the issuance or sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other distribution or the date of the granting of such right of
subscription or purchase (as the case may be). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Number of Warrant Shares</U>. Simultaneously with any adjustment to the Exercise
Price pursuant to this Section&nbsp;2, the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for
the adjusted number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment (without regard to any limitations on exercise contained herein). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Holder&#146;s Right of Alternative Exercise Price Following Issuance of Certain Options or Convertible Securities</U>. In addition to
and not in limitation of the other provisions of this Section&nbsp;2, if the Company in any manner issues or sells or enters into any agreement to issue or sell, any Common Stock, Options or Convertible Securities (any such securities,
&#147;<B>Variable Price Securities</B>&#148;) after the Subscription Date that are issuable pursuant to such agreement or convertible into or exchangeable or exercisable for shares of Common Stock at a price which varies or may vary with the market
price of the shares of Common Stock, including by way of one or more reset(s) to a fixed price, but exclusive of such formulations reflecting customary anti-dilution provisions (such as share splits, share combinations, share dividends and similar
transactions) (each of the formulations for such variable price being herein referred to as, the &#147;<B>Variable Price</B>&#148;), the Company shall provide written notice thereof via <FONT STYLE="white-space:nowrap">e-mail</FONT> and overnight
courier to the Holder on the date of such agreement and the issuance of such Convertible Securities or Options. From and after the date the Company enters into such agreement or issues any such Variable Price Securities, the Holder shall have the
right, but not the obligation, in its sole discretion to substitute the Variable Price for the Exercise Price upon exercise of this Warrant by designating in the Exercise Notice delivered upon any exercise of this Warrant that solely for purposes of
such exercise the Holder is relying on the Variable Price rather than the Exercise Price then in effect. The Holder&#146;s election to rely on a Variable Price for a particular exercise of this Warrant shall not obligate the Holder to rely on a
Variable Price for any future exercises of this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Stock Combination Event Adjustment</U>.<B> </B>If at any time and from time to time
on or after the Issuance Date there occurs any stock split, stock dividend, stock combination recapitalization or other similar transaction involving the Common Stock (each, a &#147;<B>Stock Combination Event</B>&#148;, and such date thereof, the
&#147;<B>Stock Combination Event Date</B>&#148;) and the Event Market Price is less than the Exercise Price then in effect (after giving effect to the adjustment in clause 2(a) above), then on the sixteenth (16th) Trading Day immediately following
such Stock Combination Event, the Exercise Price then in effect on such sixteenth (16th) Trading Day (after giving effect to the adjustment in clause 2(a) above) shall be reduced (but in no event increased) to the Event Market Price. For the
avoidance of doubt, if the adjustment in the immediately preceding sentence would otherwise result in an increase in the Exercise Price hereunder, no adjustment shall be made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Other Events</U>. In the event that the Company (or any Subsidiary (as defined in the Securities Purchase Agreement)) shall take any
action to which the provisions hereof are not strictly applicable, or, if applicable, would not operate to protect the Holder from dilution or if any event occurs of the type contemplated by the provisions of this Section&nbsp;2 but not expressly
provided for by such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights with equity features), then the Company&#146;s board of directors shall in good faith determine and
implement an appropriate adjustment in the Exercise Price and the number of Warrant Shares (if applicable) so as to protect the rights of the Holder, provided that no such adjustment pursuant to this Section&nbsp;2(e) will increase the Exercise
Price or decrease the number of Warrant Shares as otherwise determined pursuant to this Section&nbsp;2, provided further that if the Required Holders do not accept such adjustments as appropriately protecting its interests hereunder against such
dilution, then the Company&#146;s board of directors and the Required Holders shall agree, in good faith, upon an independent investment bank of nationally recognized standing to make such appropriate adjustments, whose determination shall be final
and binding absent manifest error and whose fees and expenses shall be borne by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Calculations</U>. All calculations
under this Section&nbsp;2 shall be made by rounding to the nearest cent or the nearest 1/100<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of a share, as applicable. The number of shares of Common Stock outstanding at any given time shall
not include shares owned or held by or for the account of the Company, and the disposition of any such shares shall be considered an issuance or sale of Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Voluntary Adjustment By Company</U>. The Company may at any time during the term of this Warrant, with the prior written consent of the
Required Holders (as defined in the Securities Purchase Agreement), reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company; provided, that as of the Public Company
Date, the foregoing shall be subject to the rules and regulations of the Principal Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Adjustment Upon Public Company Date and
Qualified Offering</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) If a Public Company Date occurs without the occurrence of a Qualified Offering with respect
thereto and, if on the Public Company Date, 125% of the Closing Bid Price of the Common Stock on the Public Company Date is less than the Exercise Price then in effect (the &#147;<B>No QO Measuring Price</B>&#148;), immediately following the Public
Company Date, the Exercise Price shall automatically lower to the No QO Measuring Price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Upon the occurrence of a Qualified Offering, if 125% of the New
Issuance Price of such Qualified Offering is less than the Exercise Price then in effect (the &#147;<B>QO Measuring Price</B>&#148;), immediately following the time of consummation of such Qualified Offering, the Exercise Price shall automatically
lower to the QO Measuring Price. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>RIGHTS UPON DISTRIBUTION OF ASSETS</U>. In addition to any adjustments pursuant to Section&nbsp;2 above or
Section&nbsp;4 below, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without
limitation, any distribution of cash, stock or other securities, property, options, evidence of indebtedness or any other assets by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar
transaction) (a &#147;<B>Distribution</B>&#148;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated
therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum
Percentage) immediately before the date on which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such
Distribution (provided, however, that, on or after the Public Company Date, to the extent that the Holder&#146;s right to participate in any such Distribution would result in the Holder and the other Attribution Parties exceeding the Maximum
Percentage, then the Holder shall not be entitled to participate in such Distribution to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and
beneficial ownership) to the extent of any such excess) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other
Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution or on any subsequent Distribution held similarly in
abeyance) to the same extent as if there had been no such limitation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Purchase Rights</U>. In addition to any adjustments pursuant to Sections&nbsp;2 or 3 above, if at any time the Company grants, issues or
sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the &#147;<B>Purchase Rights</B>&#148;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no
such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issuance or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, on or after the Public Company Date, to the
extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right
to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of Common Stock as a result of such Purchase Right (and beneficial ownership) to the extent of any such excess) and such Purchase Right to such extent shall be held in abeyance for the
benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such right (and any
Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right held similarly in abeyance) to the same extent as if there had been no such limitation). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Fundamental Transactions</U>. The Company shall not enter into or be party to a Fundamental Transaction unless the Successor Entity
assumes in writing all of the obligations of the Company under this Warrant and the other Transaction Documents (as defined in the Securities Purchase Agreement) in accordance with the provisions of this Section&nbsp;4(b) pursuant to written
agreements in form and substance reasonably satisfactory to the Required Holders and approved by the Required Holders prior to such Fundamental Transaction, including agreements to deliver to each Holder in exchange for this Warrant a security of
the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant, including, without limitation, which is exercisable for a corresponding number of shares of capital stock equivalent to the shares of
Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to
such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such adjustments to the number of shares of capital stock
and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction). Upon the consummation of each Fundamental Transaction, the Successor Entity shall
succeed to, and be substituted for (so that from and after the date of the applicable Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#147;Company&#148; shall refer instead to the
Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as
the Company herein. Upon consummation of each Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the applicable
Fundamental Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other property (except such items still issuable under Sections&nbsp;3 and 4(a) above, which shall continue to be receivable thereafter)) issuable
upon the exercise of this Warrant prior to the applicable Fundamental Transaction, such shares of publicly traded common stock (or its equivalent) of the Successor Entity (including its Parent Entity) which the Holder would have been entitled to
receive upon the happening of the applicable Fundamental Transaction had this Warrant been exercised immediately prior to the applicable Fundamental Transaction (without regard to any limitations on the exercise of this Warrant), as adjusted in
accordance with the provisions of this Warrant. Notwithstanding the foregoing, and without limiting Section&nbsp;1(f) hereof, the Holder may elect, at its sole option, by delivery of written notice to the Company to waive this Section&nbsp;4(b) to
permit the Fundamental Transaction without the assumption of this Warrant. In addition to and not in substitution for any other rights hereunder, prior to the consummation of each Fundamental Transaction pursuant to which holders of shares of Common
Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a &#147;<B>Corporate Event</B>&#148;), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company shall make appropriate provision to insure that the Holder will thereafter have the right to receive upon an exercise of this Warrant at any time after the consummation of the
applicable Fundamental Transaction but prior to the Expiration Date, in lieu of the shares of the Common Stock (or other securities, cash, assets or other property (except such items still issuable under Sections&nbsp;3 and 4(a) above, which shall
continue to be receivable thereafter)) issuable upon the exercise of the Warrant prior to such Fundamental Transaction, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or
subscription rights) which the Holder would have been entitled to receive upon the happening of the applicable Fundamental Transaction had this Warrant been exercised immediately prior to the applicable Fundamental Transaction (without regard to any
limitations on the exercise of this Warrant). The provision made pursuant to the preceding sentence shall be in a form and substance reasonably satisfactory to the Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Black Scholes Value</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Fundamental Transaction Redemption</U>. Notwithstanding the foregoing and the provisions of Section&nbsp;4(b) above, at
the written request of the Holder delivered at any time commencing on the earliest to occur of (x)&nbsp;the public disclosure of any Fundamental Transaction, (y)&nbsp;the consummation of any Fundamental Transaction and (z)&nbsp;the Holder first
becoming aware of any Fundamental Transaction through the date that is ninety (90)&nbsp;days after the public disclosure of the consummation of such Fundamental Transaction by the Company pursuant to a press release or Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> filed with the SEC, the Company or the Successor Entity (as the case may be) shall purchase this Warrant from the Holder on the date of such request by paying to the Holder cash in an amount equal to the Black
Scholes Value. Payment of such amounts shall be made by the Company (or at the Company&#146;s direction) to the Holder on or prior to the later of (x)&nbsp;the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) Trading Day after the
date of such written request and (y)&nbsp;the date of consummation of such Fundamental Transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Event of
Default Redemption</U>. Notwithstanding the foregoing and the provisions of Section&nbsp;4(b) above, at the request of the Holder delivered at any time after the occurrence of an Event of Default (as defined in the Notes)(assuming for such purpose
that the Notes remain outstanding), the Company or the Successor Entity (as the case may be) shall purchase this Warrant from the Holder on the date of such request by paying to the Holder cash in an amount equal to the Event of Default Black
Scholes Value. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Application</U>. The provisions of this Section&nbsp;4 shall apply similarly and equally to successive Fundamental
Transactions and Corporate Events and shall be applied as if this Warrant (and any such subsequent warrants) were fully exercisable and without regard to any limitations on the exercise of this Warrant (provided that the Holder shall continue to be
entitled to the benefit of the Maximum Percentage, applied however with respect to shares of capital stock registered under the 1934 Act and thereafter receivable upon exercise of this Warrant (or any such other warrant)). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>NONCIRCUMVENTION</U>. The Company hereby covenants and agrees that the Company will not, by amendment
of its Certificate of Incorporation (as defined in the Securities Purchase Agreement), Bylaws (as defined in the Securities Purchase Agreement) or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement,
dissolution, issuance or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant
and take all reasonable action as may be reasonably required to protect the rights of the Holder. Without limiting the generality of the foregoing, the Company (a)&nbsp;shall not increase the par value of any shares of Common Stock receivable upon
the exercise of this Warrant above the Exercise Price then in effect, and (b)&nbsp;shall take all such actions as may be reasonably necessary or appropriate in order that the Company may validly and legally issue fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock upon the exercise of this Warrant. Notwithstanding anything herein to the contrary, if after the sixty (60)&nbsp;calendar day anniversary of the Issuance Date, the Holder is not
permitted to exercise this Warrant in full for any reason (other than pursuant to restrictions set forth in Section&nbsp;1(f) hereof), the Company shall use its reasonable best efforts to promptly remedy such failure, including, without limitation,
obtaining such consents or approvals as necessary to permit such exercise into shares of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>WARRANT HOLDER NOT DEEMED A STOCKHOLDER</U>.
Except as otherwise specifically provided herein, the Holder, solely in its capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall
anything contained in this Warrant be construed to confer upon the Holder, solely in its capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action
(whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the
Warrant Shares which it is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this
Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this Section&nbsp;6, the Company shall provide the Holder with copies of the same notices
and other information given to the stockholders of the Company generally, contemporaneously with the giving thereof to the stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>REISSUANCE
OF WARRANTS.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Transfer of Warrant</U>. Subject to Section&nbsp;2(g) of the Securities Purchase Agreement, if this Warrant is to
be transferred, the Holder shall surrender this Warrant to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section&nbsp;7(d)), registered as the Holder may request,
representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with
Section&nbsp;7(d)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Lost,
Stolen or Mutilated Warrant</U>. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant (as to which a written certification and the indemnification contemplated
below shall suffice as such evidence), and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary and reasonable form and, in the case of mutilation, upon surrender and cancellation
of this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section&nbsp;7(d)) representing the right to purchase the Warrant Shares then underlying this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Exchangeable for Multiple Warrants</U>. This Warrant is exchangeable, upon the
surrender hereof by the Holder at the principal office of the Company, for a new Warrant or Warrants (in accordance with Section&nbsp;7(d)) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this
Warrant, and each such new Warrant will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, no warrants for fractional shares of Common Stock shall be
given. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Issuance of New Warrants</U>. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant,
such new Warrant (i)&nbsp;shall be of like tenor with this Warrant, (ii)&nbsp;shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being
issued pursuant to Section&nbsp;7(a) or Section&nbsp;7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrants issued in connection with such issuance, does not
exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv)&nbsp;shall have the same rights and conditions as
this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>NOTICES</U>. Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given
in accordance with Section&nbsp;9(f) of the Securities Purchase Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant (other than the issuance of shares of Common Stock upon exercise
in accordance with the terms hereof), including in reasonable detail a description of such action and the reason therefor. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i)&nbsp;promptly upon
each adjustment of the Exercise Price and the number of Warrant Shares, setting forth in reasonable detail, and certifying, the calculation of such adjustment(s), (ii) at least fifteen (15)&nbsp;days prior to the date on which the Company closes its
books or takes a record (A)&nbsp;with respect to any dividend or distribution upon the shares of Common Stock, (B)&nbsp;with respect to any grants, issuances or sales of any Options, Convertible Securities or rights to purchase stock, warrants,
securities or other property to holders of shares of Common Stock or (C)&nbsp;for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to
the public prior to or in conjunction with such notice being provided to the Holder, (iii)&nbsp;at least ten (10)&nbsp;Trading Days prior to the consummation of any Fundamental Transaction and (iv)&nbsp;within two (2)&nbsp;Business Day of the
occurrence of an Event of Default (as defined in the Notes), setting forth in reasonable detail any material events with respect to such Event of Default and any efforts by the Company to cure such Event of Default. From and after the Public Company
Date, to the extent that any notice provided hereunder constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any of its Subsidiaries (as defined in the Securities Purchase
Agreement), the Company shall simultaneously file such notice with the SEC (as defined in the Securities Purchase Agreement) pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> From and after the Public Company Date, if
the Company or any of its Subsidiaries provides material <FONT STYLE="white-space:nowrap">non-public</FONT> information to the Holder that is not simultaneously filed in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holder has not agreed to receive such material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company hereby covenants and agrees that the Holder shall not have any duty of
confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents with respect to, or a duty to any of the foregoing not to trade on the basis of, such material <FONT
STYLE="white-space:nowrap">non-public</FONT> information. . It is expressly understood and agreed that the time of execution specified by the Holder in each Exercise Notice shall be definitive and may not be disputed or challenged by the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <U>AMENDMENT AND WAIVER</U>. Except as otherwise provided herein, the provisions of this Warrant (other than Section&nbsp;1(f)) may be amended and the
Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Required Holders. No waiver shall be effective unless it is in writing and
signed by an authorized representative of the waiving party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <U>SEVERABILITY</U>. If any provision of this Warrant is prohibited by law or otherwise
determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and
enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues to express, without material change, the original
intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or
the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect
of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <U>GOVERNING LAW</U>. This Warrant shall be
governed by and construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of Illinois, without giving
effect to any choice of law or conflict of law provision or rule (whether of the State of Illinois or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Illinois. The Company hereby
irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to the Company at the address set forth in Section&nbsp;9(f) of the Securities Purchase Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Subject to Section&nbsp;13, the Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The
City of Chicago, County of Cook, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or
proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Holder from bringing suit or taking other legal action against the
Company in any other jurisdiction to collect on the Company&#146;s obligations to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Holder, to realize on any collateral or any other security for such obligations, or to enforce a judgment or other court ruling in favor of the Holder. <B>THE COMPANY HEREBY IRREVOCABLY
WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED HEREBY.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <U>CONSTRUCTION; HEADINGS</U>. This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against any
Person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant. Terms used in this Warrant but defined in the other Transaction Documents shall
have the meanings ascribed to such terms on the Closing Date (as defined in the Securities Purchase Agreement) in such other Transaction Documents unless otherwise consented to in writing by the Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <U>DISPUTE RESOLUTION</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Submission
to Dispute Resolution</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the case of a dispute relating to the Exercise Price, the Closing Sale Price, the Bid
Price, Black Scholes Consideration Value, Event of Default Black Scholes Value, Black Scholes Value or fair market value or the arithmetic calculation of the number of Warrant Shares (as the case may be) (including, without limitation, a dispute
relating to the determination of any of the foregoing), the Company or the Holder (as the case may be) shall submit the dispute to the other party via email (A)&nbsp;if by the Company, within five (5)&nbsp;Business Days after the occurrence of the
circumstances giving rise to such dispute or (B)&nbsp;if by the Holder, at any time after the Holder learned of the circumstances giving rise to such dispute. If the Holder and the Company are unable to promptly resolve such dispute relating to such
Exercise Price, such Closing Sale Price, such Bid Price, such Black Scholes Consideration Value, Event of Default Black Scholes Value, Black Scholes Value or such fair market value or such arithmetic calculation of the number of Warrant Shares (as
the case may be), at any time after the fifth (5<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) Business Day following such initial notice by the Company or the Holder (as the case may be) of such dispute to the Company or the Holder (as
the case may be), then the Holder may, at its sole option, select an independent, reputable investment bank to resolve such dispute. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Holder and the Company shall each deliver to such investment bank (A)&nbsp;a copy of the initial dispute submission so
delivered in accordance with the first sentence of this Section&nbsp;13 and (B)&nbsp;written documentation supporting its position with respect to such dispute, in each case, no later than 5:00 p.m. (New York time) by the fifth (5<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) Business Day immediately following the date on which the Holder selected such investment bank (the &#147;<B>Dispute</B> <B>Submission Deadline</B>&#148;) (the documents referred to in the
immediately preceding clauses (A)&nbsp;and (B) are collectively referred to herein as the &#147;<B>Required</B> <B>Dispute Documentation</B>&#148;) (it being understood and agreed that if either the Holder or the Company fails to so deliver all of
the Required Dispute Documentation by the Dispute Submission Deadline, then the party who fails to so submit all of the Required Dispute Documentation shall no longer be entitled to (and hereby waives its right to)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
deliver or submit any written documentation or other support to such investment bank with respect to such dispute and such investment bank shall resolve such dispute based solely on the Required
Dispute Documentation that was delivered to such investment bank prior to the Dispute Submission Deadline). Unless otherwise agreed to in writing by both the Company and the Holder or otherwise requested by such investment bank, neither the Company
nor the Holder shall be entitled to deliver or submit any written documentation or other support to such investment bank in connection with such dispute (other than the Required Dispute Documentation). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Company and the Holder shall cause such investment bank to determine the resolution of such dispute and notify the
Company and the Holder of such resolution no later than ten (10)&nbsp;Business Days immediately following the Dispute Submission Deadline. The fees and expenses of such investment bank shall be borne solely by the Company, and such investment
bank&#146;s resolution of such dispute shall be final and binding upon all parties absent manifest error. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Miscellaneous</U>. The
Company expressly acknowledges and agrees that (i)&nbsp;this Section&nbsp;13 constitutes an agreement to arbitrate between the Company and the Holder (and constitutes an arbitration agreement) under the Illinois Uniform Arbitration Act, as amended,
(ii)&nbsp;a dispute relating to the Exercise Price includes, without limitation, disputes as to (A)&nbsp;whether an issuance or sale or deemed issuance or sale of Common Stock occurred under Section&nbsp;2(b), (B) the consideration per share at
which an issuance or deemed issuance of Common Stock occurred, (C)&nbsp;whether any issuance or sale or deemed issuance or sale of Common Stock was an issuance or sale or deemed issuance or sale of Excluded Securities, (D)&nbsp;whether an agreement,
instrument, security or the like constitutes and Option or Convertible Security and (E)&nbsp;whether a Dilutive Issuance occurred, (iii)&nbsp;the terms of this Warrant and each other applicable Transaction Document shall serve as the basis for the
selected investment bank&#146;s resolution of the applicable dispute, such investment bank shall be entitled (and is hereby expressly authorized) to make all findings, determinations and the like that such investment bank determines are required to
be made by such investment bank in connection with its resolution of such dispute (including, without limitation, determining (A)&nbsp;whether an issuance or sale or deemed issuance or sale of Common Stock occurred under Section&nbsp;2(b), (B) the
consideration per share at which an issuance or deemed issuance of Common Stock occurred, (C)&nbsp;whether any issuance or sale or deemed issuance or sale of Common Stock was an issuance or sale or deemed issuance or sale of Excluded Securities,
(D)&nbsp;whether an agreement, instrument, security or the like constitutes and Option or Convertible Security and (E)&nbsp;whether a Dilutive Issuance occurred) and in resolving such dispute such investment bank shall apply such findings,
determinations and the like to the terms of this Warrant and any other applicable Transaction Documents, (iv)&nbsp;the Holder (and only the Holder), in its sole discretion, shall have the right to submit any dispute described in this Section&nbsp;13
to any state or federal court sitting in The City of Chicago, County of Cook in lieu of utilizing the procedures set forth in this Section&nbsp;13 and (v)&nbsp;nothing in this Section&nbsp;13 shall limit the Holder from obtaining any injunctive
relief or other equitable remedies (including, without limitation, with respect to any matters described in this Section&nbsp;13). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <U>REMEDIES, CHARACTERIZATION, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF</U>. The remedies
provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant and the other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief), and
nothing herein shall limit the right of the Holder to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Warrant. The Company covenants to the Holder that there shall be no characterization
concerning this instrument other than as expressly provided herein. Amounts set forth or provided for herein with respect to payments, exercises and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall
not, except as expressly provided herein, be subject to any other obligation of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that
the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this Warrant shall be entitled, in addition to all other available remedies, to an
injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required. The Company shall provide all information and documentation to the Holder that is reasonably requested by the
Holder to enable the Holder to confirm the Company&#146;s compliance with the terms and conditions of this Warrant (including, without limitation, compliance with Section&nbsp;2 hereof). The issuance of shares and certificates for shares as
contemplated hereby upon the exercise of this Warrant shall be made without charge to the Holder or such shares for any issuance tax or other costs in respect thereof, provided that the Company shall not be required to pay any tax which may be
payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than the Holder or its agent on its behalf. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <U>P</U><U>AYMENT OF COLLECTION, ENFORCEMENT AND OTHER COSTS</U>. If (a)&nbsp;this Warrant is placed in the hands of an attorney for collection or
enforcement or is collected or enforced through any legal proceeding or the holder otherwise takes action to collect amounts due under this Warrant or to enforce the provisions of this Warrant or (b)&nbsp;there occurs any bankruptcy, reorganization,
receivership of the company or other proceedings affecting company creditors&#146; rights and involving a claim under this Warrant, then the Company shall pay the costs incurred by the Holder for such collection, enforcement or action or in
connection with such bankruptcy, reorganization, receivership or other proceeding, including, without limitation, attorneys&#146; fees and disbursements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16. <U>TRANSFER</U>. This Warrant may be offered for sale, sold, transferred or assigned without the consent of the Company, except as may otherwise be
required by Section&nbsp;2(g) of the Securities Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17. <U>DISCLOSURE</U>18. . From and after the Public Company Date, upon delivery by
the Company to the Holder (or receipt by the Company from the Holder) of any notice in accordance with the terms of this Warrant, unless the Company has in good faith determined that the matters relating to such notice do not constitute material, <FONT
STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries, the Company shall on or prior to 9:00 am, New York city time on the Business Day immediately following such notice delivery date, publicly
disclose such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information on a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or otherwise. From and after the Public Company Date, in the event that the Company
believes that a notice contains material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries, the Company so shall indicate to the Holder explicitly in writing in such notice (or
immediately upon receipt of notice from the Holder, as applicable), and in the absence of any such written indication in such notice (or notification from the Company immediately upon receipt of notice from the Holder), the Holder shall be entitled
to presume that information contained in the notice does not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18. <U>ABSENCE OF TRADING AND DISCLOSURE RESTRICTIONS</U>. The Company acknowledges and agrees that the
Holder is not a fiduciary or agent of the Company and that the Holder shall have no obligation to (a)&nbsp;maintain the confidentiality of any information provided by the Company or (b)&nbsp;refrain from trading any securities while in possession of
such information in the absence of a written <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement signed by an officer of the Holder that explicitly provides for such confidentiality and trading restrictions. In the absence of such an
executed, written <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement, the Company acknowledges that the Holder may freely trade in any securities issued by the Company, may possess and use any information provided by the Company in
connection with such trading activity, and may disclose any such information to any third party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19. <U>CERTAIN DEFINITIONS</U>. For purposes of this
Warrant, the following terms shall have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>1933 Act</B>&#148; means the Securities Act of 1933, as
amended, and the rules and regulations thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>1934 Act</B>&#148; means the Securities Exchange Act of 1934, as amended,
and the rules and regulations thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Adjustment Right</B>&#148; means any right granted with respect to any securities
issued in connection with, or with respect to, any issuance or sale (or deemed issuance or sale in accordance with Section&nbsp;2) of shares of Common Stock (other than rights of the type described in Section&nbsp;3 and 4 hereof) that could result
in a decrease in the net consideration received by the Company in connection with, or with respect to, such securities (including, without limitation, any cash settlement rights, cash adjustment or other similar rights). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or
is under common control with, such Person, it being understood for purposes of this definition that &#147;control&#148; of a Person means the power directly or indirectly either to vote 10% or more of the stock having ordinary voting power for the
election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Approved Stock Plan</B>&#148; means any employee benefit plan which has been approved by the board of directors of the Company
prior to or subsequent to the date hereof pursuant to which shares of Common Stock and standard options or other equity-based awards to purchase Common Stock may be issued to any employee, officer or director for services provided to the Company in
their capacity as such. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Attribution Parties</B>&#148; means, collectively, the following Persons and
entities: (i)&nbsp;any investment vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the Issuance Date, directly or indirectly managed or advised by the Holder&#146;s investment manager or any of
its Affiliates or principals, (ii)&nbsp;any direct or indirect Affiliates of the Holder or any of the foregoing, (iii)&nbsp;any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and
(iv)&nbsp;any other Persons whose beneficial ownership of the Company&#146;s Common Stock would or could be aggregated with the Holder&#146;s and the other Attribution Parties for purposes of Section&nbsp;13(d) of the 1934 Act. For clarity, the
purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)
&#147;<B>Bid Price</B>&#148; means, for any security as of the particular time of determination, the bid price for such security on the Principal Market as reported by Bloomberg as of such time of determination, or, if the Principal Market is not
the principal securities exchange or trading market for such security, the bid price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg as of such time of
determination, or if the foregoing does not apply, the bid price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security as
reported by Bloomberg as of such time of determination, or, if no bid price is reported for such security by Bloomberg as of such time of determination, the average of the bid prices of any market makers for such security as reported in The Pink
Open Market (or a similar organization or agency succeeding to its functions of reporting prices) as of such time of determination. If the Bid Price cannot be calculated for a security as of the particular time of determination on any of the
foregoing bases, the Bid Price of such security as of such time of determination shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of
such security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;13. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction
during such period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Black Scholes Consideration Value</B>&#148; means (x)&nbsp;prior to the Public Company Date, the fair
market value of the applicable Option, Convertible Security or Adjustment Right (as the case may be) as determined in good faith by the Required Holders, and (y)&nbsp;on or after the Public Company Date, the value of the applicable Option,
Convertible Security or Adjustment Right (as the case may be) as of the date of issuance thereof calculated using the Black Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg utilizing (i)&nbsp;an underlying price
per share equal to the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the public announcement of the execution of definitive documents with respect to the issuance of such Option or Convertible Security (as the case
may be), (ii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of such Option, Convertible Security or Adjustment Right (as the case may be) as of the date of issuance of such Option,
Convertible Security or Adjustment Right (as the case may be), (iii) a zero cost of borrow and (iv)&nbsp;an expected volatility equal to the greater of 100% and the 30 day volatility obtained from the &#147;HVT&#148; function on Bloomberg
(determined utilizing a 365 day annualization factor) as of&nbsp;the Trading Day immediately following the date of issuance of such Option, Convertible Security or Adjustment Right (as the case may be). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Black Scholes Value</B>&#148; means (x)&nbsp;prior to the Public Company Date,
the fair market value of the unexercised portion of this Warrant as determined in good faith by the Required Holders, and (y)&nbsp;on or after the Public Company Date, the value of the unexercised portion of this Warrant remaining on the date of the
Holder&#146;s request pursuant to Section&nbsp;4(c)(i), which value is calculated using the Black Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg utilizing (i)&nbsp;an underlying price per share equal to the
greater of (1)&nbsp;the highest Closing Sale Price of the Common Stock during the period beginning on the Trading Day immediately preceding the announcement of the applicable Fundamental Transaction (or the consummation of the applicable Fundamental
Transaction, if earlier) and ending on the Trading Day of the Holder&#146;s request pursuant to Section&nbsp;4(c)(i) and (2)&nbsp;the sum of the price per share being offered in cash in the applicable Fundamental Transaction (if any) plus the value
of the <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration being offered in the applicable Fundamental Transaction (if any), (ii) a strike price equal to the Exercise Price in effect on the date of the Holder&#146;s request pursuant to
Section&nbsp;4(c)(i), (iii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the greater of (1)&nbsp;the remaining term of this Warrant as of the date of the Holder&#146;s request pursuant to
Section&nbsp;4(c)(i) and (2)&nbsp;the remaining term of this Warrant as of the date of consummation of the applicable Fundamental Transaction or as of the date of the Holder&#146;s request pursuant to Section&nbsp;4(c)(i) if such request is prior to
the date of the consummation of the applicable Fundamental Transaction, (iv)&nbsp;a zero cost of borrow and (v)&nbsp;an expected volatility equal to the greater of 100% and the 30 day volatility obtained from the &#147;HVT&#148; function on
Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the earliest to occur of (A)&nbsp;the public disclosure of the applicable Fundamental Transaction and (B)&nbsp;the date of the Holder&#146;s
request pursuant to Section&nbsp;4(c)(i). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) &#147;<B>Bloomberg</B>&#148; means Bloomberg, L.P. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) &#147;<B>Business Day</B>&#148; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York
are authorized or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#147;stay at home&#148;, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;shelter-in-place&#148;,</FONT></FONT> <FONT STYLE="white-space:nowrap">&#147;non-essential</FONT> employee&#148;&nbsp;or any other similar orders or restrictions or the closure of any
physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B>Closing Sale Price</B>&#148; means, for any security as of any date, the last closing trade price for such security on the
Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing trade price, then the last trade price of such security prior to 4:00:00 p.m., New York time, as
reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for such security, the last trade price of such security on the principal securities exchange or trading market where such security is
listed or traded as reported by Bloomberg, or if the foregoing does not apply, the last trade price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic
bulletin board for such security as reported by Bloomberg, or, if no last trade price is reported for such security by Bloomberg, the average of the ask prices of any market makers for such security as reported in The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be
the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in
Section&nbsp;13. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during such period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) &#147;<B>Common Stock</B>&#148; means (i)&nbsp;the Company&#146;s shares of common
stock, $0.001 par value per share, and (ii)&nbsp;any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) &#147;<B>Convertible Securities</B>&#148; means any stock or other security (other than Options) that is at any time and under any
circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any shares of Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) &#147;<B>Eligible Market</B>&#148; means The New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the Nasdaq Global
Market, the Nasdaq Capital Market or the Principal Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) &#147;<B>Event Market Price</B>&#148; means, with respect to any Stock
Combination Event Date, the quotient determined by dividing (x)&nbsp;the sum of the VWAP of the Common Stock for each of the five (5)&nbsp;lowest Trading Days during the twenty (20)&nbsp;consecutive Trading Day period ending and including the
Trading Day immediately preceding the sixteenth (16th) Trading Day after such Stock Combination Event Date, divided by (y)&nbsp;five (5). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) &#147;<B>Event of Default</B> <B>Black Scholes Value</B>&#148; means (x)&nbsp;prior to the Public Company Date, the fair market value of
the unexercised portion of this Warrant as determined in good faith by the Required Holders, and (y)&nbsp;on or after the Public Company Date, the value of the unexercised portion of this Warrant remaining on the date of the Holder&#146;s request
pursuant to Section&nbsp;4(c)(ii), which value is calculated using the Black Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg utilizing (i)&nbsp;an underlying price per share equal to the highest Closing Sale Price
of the Common Stock during the period beginning on the date of the occurrence of the Event of Default through the date all Events of Default have been cured (assuming for such purpose that the Notes remain outstanding) or, if earlier, the Trading
Day of the Holder&#146;s request pursuant to Section&nbsp;4(c)(ii), (ii) a strike price equal to the Exercise Price in effect on the date of the Holder&#146;s request pursuant to Section&nbsp;4(c)(ii), (iii) a risk-free interest rate corresponding
to the U.S. Treasury rate for a period equal to the greater of (1)&nbsp;the remaining term of this Warrant as of the date of the Holder&#146;s request pursuant to Section&nbsp;4(c)(ii) and (2)&nbsp;the remaining term of this Warrant as of the date
of the occurrence of such Event of Default, (iv)&nbsp;a zero cost of borrow and (v)&nbsp;an expected volatility equal to the greater of 100% and the 30 day volatility obtained from the &#147;HVT&#148; function on Bloomberg (determined utilizing a
365 day annualization factor) as of the Trading Day immediately following later of (x)&nbsp;the date of the occurrence of such Event of Default and (y)&nbsp;the date of the public announcement of such Event of Default. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) &#147;<B>Excluded Securities</B>&#148; means (i)&nbsp;shares of Common Stock or standard options or other equity-based awards to purchase
Common Stock issued to directors, officers or employees of the Company for services rendered to the Company in their capacity as such pursuant to an Approved Stock Plan (as defined above), provided that (A)&nbsp;all such issuances (taking into
account the shares of Common Stock issuable upon exercise of such options) after the Subscription Date pursuant to this clause (i)&nbsp;do not, in the aggregate, exceed more than 5% of the Common Stock
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issued and outstanding immediately prior to the Subscription Date and (B)&nbsp;the exercise price of any such options is not lowered, none of such options are amended to increase the number of
shares issuable thereunder and none of the terms or conditions of any such options are otherwise materially changed in any manner that materially adversely affects any of the holders of the SPA Warrants; (ii)&nbsp;shares of Common Stock issued upon
the conversion or exercise of Convertible Securities (other than standard options to purchase Common Stock issued pursuant to an Approved Stock Plan that are covered by clause (i)&nbsp;above) issued prior to the Subscription Date, provided that the
conversion price of any such Convertible Securities (other than standard options to purchase Common Stock issued pursuant to an Approved Stock Plan that are covered by clause (i)&nbsp;above) is not lowered, none of such Convertible Securities (other
than standard options to purchase Common Stock issued pursuant to an Approved Stock Plan that are covered by clause (i)&nbsp;above) are amended to increase the number of shares issuable thereunder and none of the terms or conditions of any such
Convertible Securities (other than standard options to purchase Common Stock issued pursuant to an Approved Stock Plan that are covered by clause (i)&nbsp;above) are otherwise materially changed in any manner that adversely affects any of the
Buyers; (iii)&nbsp;the shares of Common Stock issuable upon conversion of the Notes or otherwise pursuant to the terms of the Notes; provided, that the terms of the Notes are not amended, modified or changed on or after the Subscription Date (other
than antidilution adjustments pursuant to the terms thereof in effect as of the Subscription Date) and (iv)&nbsp;the shares of Common Stock issuable upon exercise of the SPA Warrants; provided, that the terms of the SPA Warrant are not amended,
modified or changed on or after the Subscription Date (other than antidilution adjustments pursuant to the terms thereof in effect as of the Subscription Date). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) &#147;<B>Expiration Date</B>&#148; means the date that is the fifth (5<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) anniversary
of the Issuance Date or, if such date falls on a day other than a Trading Day or on which trading does not take place on the Principal Market (a &#147;<B>Holiday</B>&#148;), the next date that is not a Holiday. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) &#147;<B>Fundamental Transaction</B>&#148; means (A)&nbsp;that the Company shall, directly or indirectly, including through subsidiaries,
Affiliates or otherwise, in one or more related transactions, (i)&nbsp;consolidate or merge with or into (whether or not the Company is the surviving corporation) another Subject Entity, or (ii)&nbsp;sell, assign, transfer, convey or otherwise
dispose of all or substantially all of the properties or assets of the Company or any of its &#147;significant subsidiaries&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation
<FONT STYLE="white-space:nowrap">S-X)</FONT> to one or more Subject Entities, or (iii)&nbsp;make, or allow one or more Subject Entities to make, or allow the Company to be subject to or have its Common Stock be subject to or party to one or more
Subject Entities making, a purchase, tender or exchange offer that is accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding shares of Common Stock calculated as if any shares of
Common Stock held by all Subject Entities making or party to, or Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding; or (z)&nbsp;such number of shares of Common Stock such that all
Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under
the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or (iv)&nbsp;consummate a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with one or more Subject Entities whereby all such Subject Entities, individually or in the aggregate, acquire, either (x)&nbsp;at least 50% of the outstanding shares of Common
Stock, (y)&nbsp;at least 50% of the outstanding shares of Common Stock calculated as if any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of Common Stock held by all the Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such stock purchase agreement or other business combination
were not outstanding; or (z)&nbsp;such number of shares of Common Stock such that the Subject Entities become collectively the beneficial owners (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the 1934 Act) of at least 50% of
the outstanding shares of Common Stock, or (v)&nbsp;reorganize, recapitalize or reclassify its Common Stock, (B)&nbsp;that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related
transactions, allow any Subject Entity individually or the Subject Entities in the aggregate to be or become the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the 1934 Act), directly or
indirectly, whether through acquisition, purchase, assignment, conveyance, tender, tender offer, exchange, reduction in outstanding shares of Common Stock, merger, consolidation, business combination, reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> scheme of arrangement, reorganization, recapitalization or reclassification or otherwise in any manner whatsoever, of either (x)&nbsp;at least 50% of the aggregate ordinary voting power represented by
issued and outstanding Common Stock, (y)&nbsp;at least 50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock not held by all such Subject Entities as of the date of this Warrant calculated as if any shares of
Common Stock held by all such Subject Entities were not outstanding, or (z)&nbsp;a percentage of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock or other equity securities of the Company sufficient to
allow such Subject Entities to effect a statutory short form merger or other transaction requiring other shareholders of the Company to surrender their shares of Common Stock without approval of the shareholders of the Company or (C)&nbsp;directly
or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, the issuance of or the entering into any other instrument or transaction structured in a manner to circumvent, or that circumvents, the
intent of this definition in which case this definition shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this definition or any portion of this
definition which may be defective or inconsistent with the intended treatment of such instrument or transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)
&#147;<B>Group</B>&#148; means a &#147;group&#148; as that term is used in Section&nbsp;13(d) of the 1934 Act and as defined in Rule <FONT STYLE="white-space:nowrap">13d-5</FONT> thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) &#147;<B>Notes</B>&#148; has the meaning ascribed to such term in the Securities Purchase Agreement, and shall include all notes issued in
exchange therefor or replacement thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) &#147;<B>Options</B>&#148; means any rights, warrants or options to subscribe for or
purchase shares of Common Stock or Convertible Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) &#147;<B>Parent Entity</B>&#148; of a Person means an entity that, directly
or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest
public market capitalization as of the date of consummation of the Fundamental Transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) &#147;<B>Person</B>&#148; means an
individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity or a government or any department or agency thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) &#147;<B>Public Company Date</B>&#148; means the date on which the shares of Common
Stock of the Company (or its direct or indirect successor, subsidiary or parent company, whose securities are issued or issuable to holders of Common Stock), whether as a result of a public offering, merger, recapitalization, reorganization or
otherwise, are registered under the 1934 Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) &#147;<B>Principal Market</B>&#148; means the Eligible Market that is the principal
securities exchange market for the Common Stock after the Public Company Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) &#147;<B>Qualified Offering</B>&#148; means a public
offering in the United States pursuant to a registration statement declared effective by the Securities and Exchange Commission pursuant to the Securities Act, pursuant to which the Common Stock is listed for trading on an Eligible Market, with
(i)&nbsp;minimum gross proceeds of $6,000,000, and (ii)&nbsp;minimum net proceeds of $5,000,000 after deducting all fees and expenses in connection with such Qualified Offering and any proceeds used to cure an Event of Default as permitted under
part (v)&nbsp;of the definition of &#147;Equity Conditions&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) &#147;<B>Required Holders</B>&#148; shall have the meaning set
forth in the Securities Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) &#147;<B>SEC</B>&#148; means the United States Securities and Exchange Commission or the
successor thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <B>&#147;Subject Entity</B>&#148; means any Person, Persons or Group or any Affiliate or associate of any such
Person, Persons or Group. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) &#147;<B>Successor Entity</B>&#148; means the Person (or, if so elected by the Holder, the Parent Entity)
formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been entered into. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) &#147;<B>Trading Day</B>&#148; means, as applicable, (i)&nbsp;prior to the Public Company Date, any Business Day, and (ii)&nbsp;from and
after the Public Company Date, (x)&nbsp;with respect to all price or trading volume determinations relating to the Common Stock, any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal
trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded, provided that &#147;Trading Day&#148; shall not include any day on which the Common Stock is scheduled to
trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing
time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time) unless such day is otherwise designated as a Trading Day in writing by the Holder or (y)&nbsp;with respect to all determinations other than price
or trading volume determinations relating to the Common Stock, any day on which The New York Stock Exchange (or any successor thereto) is open for trading of securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) &#147;<B>VWAP</B>&#148; means, for any security as of any date, the dollar
volume-weighted average price for such security on the principal trading market for such security, during the period beginning at 9:30 a.m., New York time, and ending at 4:00 p.m., New York time, as reported by Bloomberg through its &#147;VAP&#148;
function (set to 09:30 start time and 16:00 end time) or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security during the period beginning at 9:30 a.m., New York time, and ending at 4:00 p.m., New York
time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for
such security as reported in The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices). If the VWAP cannot be calculated for such security on such date on any of the foregoing bases, the VWAP of such
security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved in
accordance with the procedures in Section&nbsp;13. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination, recapitalization or other similar transaction during such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the Company has caused this Warrant to Purchase Common Stock to
be duly executed as of the Issuance Date set out above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HEART TEST LABORATORIES, INC. </B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>(D/B/A HEARTSCIENCES) </B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 4.5 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[FORM OF <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I)&nbsp;IN THE ABSENCE OF (A)&nbsp;AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B)&nbsp;AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR
(II)&nbsp;UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED
BY THE SECURITIES. THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(a) OF THIS WARRANT. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Heart Test Laboratories, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(d/b/a HeartSciences) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrant To Purchase Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant
No.: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date of Issuance: [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2021 (&#147;<B>Issuance
Date</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heart Test Laboratories, Inc. (d/b/a HeartSciences), a Texas corporation (the &#147;<B>Company</B>&#148;), hereby
certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [BUYER], the registered holder hereof or its permitted assigns (the &#147;<B>Holder</B>&#148;), is entitled, subject to the terms set
forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement
hereof, the &#147;<B>Warrant</B>&#148;), at any time or times on or after the Issuance Date, but not after 11:59 p.m., New York time, on the Expiration Date (as defined below), [____________] (subject to adjustment as provided herein) fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock (as defined below)<B> </B>(the &#147;<B>Warrant Shares</B>&#148;). Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanings set forth
in Section&nbsp;19. This Warrant is one of the Warrants to Purchase Common Stock (the &#147;<B>SPA Warrants</B>&#148;) issued pursuant to Section&nbsp;1 of that certain Securities Purchase Agreement, dated as of December [ ], 2021 (the
&#147;<B>Subscription Date</B>&#148;), by and among the Company and the investors referred to therein, as amended from time to time (the &#147;<B>Securities Purchase Agreement</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything herein to the contrary, the Aggregate Exercise Price (as defined below) of this Warrant, except for a nominal
exercise price of $0.0001 per Warrant Share, was <FONT STYLE="white-space:nowrap">pre-funded</FONT> to the Company on or prior to the initial Issuance Date and, consequently, no additional consideration (other than the nominal exercise price of
$0.0001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>EXERCISE OF WARRANT.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Mechanics of Exercise</U>. Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in
Section&nbsp;1(f)), this Warrant may be exercised by the Holder on any day on or after the Issuance Date (an &#147;<B>Exercise Date</B>&#148;), in whole or in part, by delivery (whether via <FONT STYLE="white-space:nowrap">e-mail</FONT> or
otherwise) of a written notice, in the form attached hereto as <B><U>Exhibit A</U></B> (the &#147;<B>Exercise Notice</B>&#148;), of the Holder&#146;s election to exercise this Warrant. Within one (1)&nbsp;Trading Day following an exercise of this
Warrant as aforesaid, the Holder shall deliver payment to the Company of an amount equal to the Exercise Price in effect on the date of such exercise multiplied by the number of Warrant Shares as to which this Warrant was so exercised (the
&#147;<B>Aggregate Exercise Price</B>&#148;) in cash or via wire transfer of immediately available funds if the Holder did not notify the Company in such Exercise Notice that such exercise was made pursuant to a Cashless Exercise (as defined in
Section&nbsp;1(d)). The Holder shall not be required to deliver the original of this Warrant in order to effect an exercise hereunder. Execution and delivery of an Exercise Notice with respect to less than all of the Warrant Shares shall have the
same effect as cancellation of the original of this Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares. Execution and delivery of an Exercise Notice for all of the then-remaining Warrant
Shares shall have the same effect as cancellation of the original of this Warrant after delivery of the Warrant Shares in accordance with the terms hereof. On or before the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) Trading Day
following the date on which the Company has received an Exercise Notice, the Company shall transmit by electronic mail an acknowledgment of confirmation of receipt of such Exercise Notice, in the form attached hereto as
<B><U>Exhibit</U></B><B><U></U></B><B><U>&nbsp;B</U></B>, to the Holder and, if after the Public Company Date, the Company&#146;s transfer agent (the &#147;<B>Transfer Agent</B>&#148;), which confirmation shall, if after the Public Company Date,
constitute an instruction to the Transfer Agent to process such Exercise Notice in accordance with the terms herein. On or before the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) Trading Day following the date on which the
Company has received such Exercise Notice (or such earlier date as required pursuant to the 1934 Act or other applicable law, rule or regulation for the settlement of a trade of such Warrant Shares initiated on the applicable Exercise Date), the
Company shall (X)&nbsp;if on or after the Public Company Date, provided that the Transfer Agent is participating in The Depository Trust Company (&#147;<B>DTC</B>&#148;) Fast Automated Securities Transfer Program (&#147;<B>FAST</B>&#148;), upon the
request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&#146;s or its authorized designee&#146;s balance account with DTC through its Deposit/Withdrawal at
Custodian system, or (Y)&nbsp;if either (x)&nbsp;prior to the Public Company Date or (y)&nbsp;on or after the Public Company Date if the Transfer Agent is not participating in FAST, upon the request of the Holder, issue and deliver (via reputable
overnight courier) to the address as specified in the Exercise Notice, a certificate, registered in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder shall be entitled pursuant to such exercise.
Upon delivery of an Exercise Notice, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date such Warrant Shares
are credited to the Holder&#146;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares (as the case may be). If this Warrant is submitted in connection with any exercise pursuant to this
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section&nbsp;1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise and upon
surrender of this Warrant to the Company by the Holder, then, at the request of the Holder, the Company shall as soon as practicable and in no event later than two (2)&nbsp;Business Days after any exercise and at its own expense, issue and deliver
to the Holder (or its designee) a new Warrant (in accordance with Section&nbsp;7(d)) representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares
with respect to which this Warrant is exercised. No fractional shares of Common Stock are to be issued upon the exercise of this Warrant, but rather the number of shares of Common Stock to be issued shall be rounded up to the nearest whole number.
The Company shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses (including, without limitation, fees and expenses of the Transfer Agent) that may be payable with respect to the issuance and delivery of Warrant
Shares upon exercise of this Warrant. Notwithstanding the foregoing, except in the case where an exercise of this Warrant is validly made pursuant to a Cashless Exercise, the Company&#146;s failure to deliver Warrant Shares to the Holder on or prior
to the later of (i)&nbsp;two (2) Trading Days after receipt of the applicable Exercise Notice (or, after the Public Company Date, such earlier date as required pursuant to the 1934 Act or other applicable law, rule or regulation for the settlement
of a trade of such Warrant Shares initiated on the applicable Exercise Date) and (ii)&nbsp;one (1) Trading Day after the Company&#146;s receipt of the Aggregate Exercise Price (or valid notice of a Cashless Exercise) (such later date, the
&#147;<B>Share Delivery Deadline</B>&#148;) shall not be deemed to be a breach of this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Price</U>. For purposes of
this Warrant, &#147;<B>Exercise Price</B>&#148; means $[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ]<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>, subject to adjustment as provided herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Company</U><U>&#146;</U><U>s Failure to Timely Deliver Securities</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>General</U>. The Company shall in all cases use its reasonable best efforts to comply with the delivery requirements set
forth herein and shall do all things and take all actions reasonably requested by the Holder in furtherance thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)
<U>Exercise Failures On or After the Public Company Date</U>. If on or after the Public Company Date, the Company shall fail, for any reason or for no reason, on or prior to the Share Delivery Deadline, if the Transfer Agent is not participating in
FAST, to issue and deliver to the Holder (or its designee) a certificate for the number of Warrant Shares to which the Holder is entitled and register such Warrant Shares on the Company&#146;s share register or, if the Transfer Agent is
participating in FAST, to credit the balance account of the Holder or the Holder&#146;s designee with DTC for such number of Warrant Shares to which the Holder is entitled upon the Holder&#146;s exercise of this Warrant (as the case may be) (a
&#147;<B>Delivery Failure</B>&#148;), then, in addition to all other remedies available to the Holder, (X)&nbsp;the Company shall pay in cash to the Holder on each day after the Share Delivery Date and during such Delivery Failure an amount equal to
2% of the product of (A)&nbsp;the sum of the number of shares of Common Stock not issued to the Holder on or prior to the Share Delivery Deadline and to which the Holder is entitled, multiplied by (B)&nbsp;any trading price of the Common Stock
selected by the Holder in writing as in effect at any time during the </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Insert 150% of initial Conversion Price of the Notes
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
period beginning on the applicable Exercise Date and ending on the applicable Share Delivery Date, and (Y)&nbsp;the Holder, upon written notice to the Company, may void its Exercise Notice with
respect to, and retain or have returned, as the case may be, any portion of this Warrant that has not been exercised pursuant to such Exercise Notice; provided that the voiding of an Exercise Notice shall not affect the Company&#146;s obligations to
make any payments which have accrued prior to the date of such notice pursuant to this Section&nbsp;1(c) or otherwise. In addition to the foregoing, if on or after the Public Company Date and on or prior to the Share Delivery Deadline the Transfer
Agent is not participating in the DTC Fast Automated Securities Transfer Program, the Company shall fail to issue and deliver to the Holder (or its designee) a certificate and register such shares of Common Stock on the Company&#146;s share register
or, if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, the Transfer Agent shall fail to credit the balance account of the Holder or the Holder&#146;s designee with DTC for the number of shares of Common
Stock to which the Holder is entitled upon the Holder&#146;s exercise hereunder or pursuant to the Company&#146;s obligation pursuant to clause (ii)&nbsp;below, and if on or after such Share Delivery Deadline the Holder acquires (in an open market
transaction, stock loan or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of all or any portion of the number of shares of Common Stock issuable upon such exercise that the Holder anticipated receiving from the
Company (a &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT></B>&#148;), then, in addition to all other remedies available to the Holder, the Company shall, within two (2)&nbsp;Business Days after the Holder&#146;s request and in the
Holder&#146;s discretion, either (i)&nbsp;pay cash to the Holder in an amount equal to the Holder&#146;s total purchase price (including brokerage commissions, stock loan costs and other reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, if any) for the shares of Common Stock so acquired (including, without limitation, by any other Person in respect, or on behalf, of the Holder) (the &#147;<B><FONT
STYLE="white-space:nowrap">Buy-In</FONT> Price</B>&#148;), at which point the Company&#146;s obligation to so issue and deliver such certificate (and to issue such shares of Common Stock) or credit the balance account of such Holder or such
Holder&#146;s designee, as applicable, with DTC for the number of Warrant Shares to which the Holder is entitled upon the Holder&#146;s exercise hereunder (as the case may be) (and to issue such Warrant Shares) shall terminate, or (ii)&nbsp;promptly
honor its obligation to so issue and deliver to the Holder a certificate or certificates representing such Warrant Shares or credit the balance account of such Holder or such Holder&#146;s designee, as applicable, with DTC for the number of Warrant
Shares to which the Holder is entitled upon the Holder&#146;s exercise hereunder (as the case may be) and pay cash to the Holder in an amount equal to the excess (if any) of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> Price over the product
of (A)&nbsp;such number of Warrant Shares multiplied by (B)&nbsp;the lowest Closing Sale Price of the Common Stock on any Trading Day during the period commencing on the date of the applicable Exercise Notice and ending on the date of such issuance
and payment under this clause (ii) (the &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT> Payment Amount</B>&#148;). Nothing shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity,
including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver certificates representing shares of Common Stock (or to electronically deliver such shares of
Common Stock) upon the exercise of this Warrant as required pursuant to the terms hereof. In addition to the foregoing rights, if after the Public Company Date, (i)&nbsp;if the Company fails to deliver the applicable number of Warrant Shares upon an
exercise pursuant to Section&nbsp;1 by the applicable Share Delivery Deadline, then the Holder shall have the right to rescind such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
exercise in whole or in part and retain and/or have the Company return, as the case may be, any portion of this Warrant that has not been exercised pursuant to such Exercise Notice; provided that
the rescission of an exercise shall not affect the Company&#146;s obligation to make any payments that have accrued prior to the date of such notice pursuant to this Section&nbsp;1(c) or otherwise, and (ii)&nbsp;if a registration statement covering
the issuance or resale of the Warrant Shares that are subject to an Exercise Notice is not available for the issuance or resale, as applicable, of such Warrant Shares and the Holder has submitted an Exercise Notice prior to receiving notice of the <FONT
STYLE="white-space:nowrap">non-availability</FONT> of such registration statement and the Company has not already delivered the Warrant Shares underlying such Exercise Notice electronically without any restrictive legend by crediting such aggregate
number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holder&#146;s or its designee&#146;s balance account with DTC through its Deposit / Withdrawal At Custodian system, the Holder shall have the option, by
delivery of notice to the Company, to (x)&nbsp;rescind such Exercise Notice in whole or in part and retain or have returned, as the case may be, any portion of this Warrant that has not been exercised pursuant to such Exercise Notice; provided that
the rescission of an Exercise Notice shall not affect the Company&#146;s obligation to make any payments that have accrued prior to the date of such notice pursuant to this Section&nbsp;1(c) or otherwise, and/or (y)&nbsp;switch some or all of such
Exercise Notice from a cash exercise to a Cashless Exercise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Cashless Exercise</U>. Notwithstanding anything contained herein to
the contrary (other than Section&nbsp;1(f) below), the Holder may, in its sole discretion, exercise this Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in
payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the &#147;Net Number&#148; of Warrant Shares determined according to the following formula (a &#147;<B>Cashless Exercise</B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">Net Number = <U>(A x B) - (A x C)</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing formula: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">A= the total number of shares with respect to which this Warrant is then being exercised. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">B = (i) prior to the Public Company Date, the greatest of (A)&nbsp;the last purchase price at which the Company issued or sold Common Stock
preceding the date of the Exercise Notice, (B)&nbsp;the initial conversion price of the last Convertible Securities issued or sold by the Company preceding the date of the Exercise Notice, (C)&nbsp;the initial exercise price of the last Options
issued or sold by the Company preceding the date of the Exercise Notice and (D)&nbsp;the fair market value of the Common Stock as mutually determined by the Company and the Required Holders and (ii)&nbsp;on or after the Public Company Date, as
elected by the Holder, (A)&nbsp;the VWAP of the shares of Common Stock on the Trading Day immediately preceding the date of the applicable Exercise Notice if such Exercise Notice is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;1(a)
hereof on a day that is not a Trading Day or (2)&nbsp;both executed and delivered pursuant to Section&nbsp;1(a) hereof on a Trading Day prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
to the opening of &#147;regular trading hours&#148; (as defined in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (B)&nbsp;either (x) the
VWAP on the Trading Day immediately preceding the date of the applicable Exercise Notice or (y)&nbsp;the Bid Price of the shares of Common Stock as of the time of the Holder&#146;s execution of the applicable Exercise Notice if such Exercise Notice
is executed during &#147;regular trading hours&#148; on a Trading Day and is delivered within two (2)&nbsp;hours thereafter pursuant to Section&nbsp;1(a) hereof, or (C)&nbsp;the Closing Sale Price of the Common Stock on the date of the applicable
Exercise Notice if the date of such Exercise Notice is a Trading Day and such Exercise Notice is both executed and delivered pursuant to Section&nbsp;1(a) hereof after the close of &#147;regular trading hours&#148; on such Trading Day. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">C = $0.0001 (as adjusted for share splits, share dividends, share combinations, recapitalizations and similar events). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144(d) promulgated under the 1933 Act, as in effect on the Subscription Date, it is intended that the Warrant Shares
issued in a Cashless Exercise shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued pursuant to the Securities Purchase
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In the event of termination or expiration of this Warrant (including upon the Expiration Date), to the extent that this
Warrant is then exercisable and such exercise would result in the issuance of Warrant Shares to the Holder, this Warrant shall be deemed to have been automatically exercised pursuant to a Cashless Exercise immediately prior to the time at which it
would otherwise terminate or expire. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Disputes</U>. In the case of a dispute as to the determination of the Exercise Price or the
arithmetic calculation of the number of Warrant Shares to be issued pursuant to the terms hereof, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance with
Section&nbsp;13. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Limitations on Exercises</U>. From and after the Public Company Date, the Company shall not effect the exercise of
any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant to the terms and conditions of this Warrant and any such exercise shall be null and void and treated as if never made, to the
extent that after giving effect to such exercise, the Holder together with the other Attribution Parties collectively would beneficially own in excess of 4.99% (the &#147;<B>Maximum Percentage</B>&#148;) of the shares of Common Stock outstanding
immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common
Stock held by the Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common
Stock which would be issuable upon (A)&nbsp;exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of the other Attribution Parties and (B)&nbsp;exercise or conversion of the unexercised or unconverted
portion of any other securities of the Company (including, without limitation, any convertible notes or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convertible preferred stock or warrants, including other SPA Warrants) beneficially owned by the Holder or any other Attribution Party subject to a limitation on conversion or exercise analogous
to the limitation contained in this Section&nbsp;1(f). For purposes of this Section&nbsp;1(f), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the 1934 Act. For purposes of determining the number of outstanding
shares of Common Stock the Holder may acquire upon the exercise of this Warrant without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x)&nbsp;the Company&#146;s most recent
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other public filing with the SEC, as the
case may be, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other written notice by the Company or the Transfer Agent, if any, setting forth the number of shares of Common Stock outstanding (the &#147;<B>Reported
Outstanding Share Number</B>&#148;). From and after the Public Company Date, if the Company receives an Exercise Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding
Share Number, the Company shall (i)&nbsp;notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Exercise Notice would otherwise cause the Holder&#146;s beneficial ownership, as determined
pursuant to this Section&nbsp;1(f)(i), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of Warrant Shares to be acquired pursuant to such Exercise Notice (the number of shares by which such purchase is
reduced, the &#147;<B>Reduction Shares</B>&#148;) and (ii)&nbsp;as soon as reasonably practicable, the Company shall return to the Holder any exercise price paid by the Holder for the Reduction Shares. For any reason at any time, upon the written or
oral request of the Holder, the Company shall within one (1)&nbsp;Business Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of
Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number
was reported. From and after the Public Company Date, in the event that the issuance of shares of Common Stock to the Holder upon exercise of this Warrant results in the Holder and the other Attribution Parties being deemed to beneficially own, in
the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section&nbsp;13(d) of the 1934 Act), the number of shares so issued by which the Holder&#146;s and the other Attribution
Parties&#146; aggregate beneficial ownership exceeds the Maximum Percentage (the &#147;<B>Excess Shares</B>&#148;) shall be deemed null and void and shall be cancelled ab initio, and the Holder shall not have the power to vote or to transfer the
Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares. Upon delivery of a written
notice to the Company, the Holder may from time to time increase (with such increase not effective until the sixty-first (61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after delivery of such notice) or decrease the Maximum
Percentage to any other percentage not in excess of 9.99% as specified in such notice; provided that (i)&nbsp;any such increase in the Maximum Percentage will not be effective until the sixty-first
(61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after such notice is delivered to the Company and (ii)&nbsp;any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to any other holder of
SPA Warrants that is not an Attribution Party of the Holder. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the
Holder for any purpose including for purposes of Section&nbsp;13(d) or Rule <FONT STYLE="white-space:nowrap">16a-1(a)(1)</FONT> of the 1934 Act. No prior inability to exercise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of exercisability. The
provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;1(f) to the extent necessary to correct this paragraph or any portion of this paragraph which may be
defective or inconsistent with the intended beneficial ownership limitation contained in this Section&nbsp;1(f) or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this
paragraph may not be waived and shall apply to a successor holder of this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Reservation</U><U> of Shares</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Required Reserve Amount</U> As of the Closing Date, the Company shall have reserved from its duly authorized capital
stock not less than 60,000,000 shares of Common Stock for issuance upon conversion of the Notes and exercise of the Warrants. From and after January&nbsp;31, 2022, so long as any of the SPA Warrants remain outstanding, the Company shall take all
action necessary to at all times have authorized, and reserved for the purpose of issuance, no less than 200% of the sum of (i)&nbsp;the maximum number of Conversion Shares issuable upon conversion of the Notes, and (ii)&nbsp;the maximum number of
Warrant Shares issuable upon exercise of all the SPA Warrants then outstanding (without regard to any limitations on the exercise of the Warrants set forth therein) (collectively, the &#147;<B>Required Reserve Amount</B>&#148;); provided that at no
time shall the number of shares of Common Stock reserved pursuant to this Section&nbsp;1(g)(i) be reduced other than proportionally in connection with any exercise or redemption of SPA Warrants or such other event covered by Section&nbsp;2(a) below.
The Required Reserve Amount (including, without limitation, each increase in the number of shares so reserved) shall be allocated pro rata among the holders of the SPA Warrants based on the number of shares of Common Stock issuable upon exercise of
SPA Warrants held by each holder on the Closing Date (without regard to any limitations on exercise) or increase in the number of reserved shares, as the case may be (the &#147;<B>Authorized Share Allocation</B>&#148;). In the event that a holder
shall sell or otherwise transfer any of such holder&#146;s SPA Warrants, each transferee shall be allocated a pro rata portion of such holder&#146;s Authorized Share Allocation. Any shares of Common Stock reserved and allocated to any Person which
ceases to hold any SPA Warrants shall be allocated to the remaining holders of SPA Warrants, pro rata based on the number of shares of Common Stock issuable upon exercise of the SPA Warrants then held by such holders (without regard to any
limitations on exercise). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Insufficient Authorized Shares</U>. If at any time after January&nbsp;31, 2022, the
number of shares of Common Stock authorized and reserved for issuance is not sufficient to meet the Required Reserve Amount (an &#147;<B>Authorized Share Failure</B>&#148;), the Company will promptly take all corporate action necessary to authorize
and reserve a sufficient number of shares, including, without limitation, calling a special meeting of stockholders to authorize additional shares to meet the Company&#146;s obligations pursuant to the Transaction Documents, in the case of an
insufficient number of authorized shares, obtain stockholder approval of an increase in such authorized number of shares, and voting the management shares of the Company in favor of an increase in the authorized shares of the Company to ensure that
the number of authorized shares is sufficient to meet the Required Reserve Amount. On or prior to January&nbsp;31, 2022 (the &#147;<B>Consent Deadline</B>&#148;), holders of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
majority of the issued and outstanding shares of Common Stock and the Preferred Stock shall have voted by written consent (the <B>&#147;Stockholder Resolutions&#148;</B>) approving an amendment
to the Certificate of Incorporation to, among other items, approve a reverse stock split and, on an advisory basis, approve the transactions contemplated by this Agreement (the &#147;<B>Stockholder Approval</B>&#148;, and the date the Stockholder
Approval is obtained, the &#147;<B>Stockholder Approval Date</B>&#148;). Thereafter, the Company shall provide each stockholder entitled to vote at a meeting of stockholders of the Company notice of the Consent Action (the &#147;<B>Consent
Notice</B>&#148;). The Stockholder Resolutions and the Consent Notice shall be in a form reasonably acceptable to the Buyers and Kelley Drye&nbsp;&amp; Warren LLP, at the expense of the Company, with the Company obligated to reimburse the expenses
of Kelley Drye&nbsp;&amp; Warren LLP incurred in connection therewith in an amount not exceed $3,000, The Company shall be obligated to seek to obtain the Stockholder Approval by the Consent Deadline.&nbsp;If, despite the Company&#146;s reasonable
best efforts the Stockholder Approval is not obtained on or prior to the Consent Deadline, the Company shall cause either an additional consent action or a stockholder meeting to be held on or prior to March&nbsp;31, 2021.&nbsp;If, despite the
Company&#146;s reasonable best efforts the Stockholder Approval is not obtained after such subsequent consent action or stockholder meeting, the Company shall cause an additional consent action or stockholder meeting to be held semi-annually
thereafter until such Stockholder Approval is obtained. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES</U>. The Exercise Price and number
of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section&nbsp;2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and Splits</U>. Without limiting any provision of Section&nbsp;2(b) or Section&nbsp;4, if the Company, at any time on or
after the Subscription Date, (i)&nbsp;pays a stock dividend on one or more classes of its then outstanding shares of Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock,
(ii)&nbsp;subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its then outstanding shares of Common Stock into a larger number of shares or (iii)&nbsp;combines (by combination, reverse stock split or
otherwise) one or more classes of its then outstanding shares of Common Stock into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common
Stock outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, and any adjustment pursuant to clause (ii)&nbsp;or (iii) of this paragraph shall become effective immediately after
the effective date of such subdivision or combination. If any event requiring an adjustment under this paragraph occurs during the period that an Exercise Price is calculated hereunder, then the calculation of such Exercise Price shall be adjusted
appropriately to reflect such event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Number of Warrant Shares</U>. Simultaneously with any adjustment to the Exercise Price
pursuant to this Section&nbsp;2, the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the
adjusted number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment (without regard to any limitations on exercise contained herein). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Stock Combination Event Adjustment</U>.<B> </B>If at any time and from time to time
on or after the Issuance Date there occurs any stock split, stock dividend, stock combination recapitalization or other similar transaction involving the Common Stock (each, a &#147;<B>Stock Combination Event</B>&#148;, and such date thereof, the
&#147;<B>Stock Combination Event Date</B>&#148;) and the Event Market Price is less than the Exercise Price then in effect (after giving effect to the adjustment in clause 2(a) above), then on the sixteenth (16th) Trading Day immediately following
such Stock Combination Event, the Exercise Price then in effect on such sixteenth (16th) Trading Day (after giving effect to the adjustment in clause 2(a) above) shall be reduced (but in no event increased) to the Event Market Price. For the
avoidance of doubt, if the adjustment in the immediately preceding sentence would otherwise result in an increase in the Exercise Price hereunder, no adjustment shall be made. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Events</U>. In the event that the Company (or any Subsidiary (as defined in the Securities Purchase Agreement)) shall take any
action to which the provisions hereof are not strictly applicable, or, if applicable, would not operate to protect the Holder from dilution or if any event occurs of the type contemplated by the provisions of this Section&nbsp;2 but not expressly
provided for by such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights with equity features), then the Company&#146;s board of directors shall in good faith determine and
implement an appropriate adjustment in the Exercise Price and the number of Warrant Shares (if applicable) so as to protect the rights of the Holder, provided that no such adjustment pursuant to this Section&nbsp;2(e) will increase the Exercise
Price or decrease the number of Warrant Shares as otherwise determined pursuant to this Section&nbsp;2, provided further that if the Required Holders do not accept such adjustments as appropriately protecting its interests hereunder against such
dilution, then the Company&#146;s board of directors and the Required Holders shall agree, in good faith, upon an independent investment bank of nationally recognized standing to make such appropriate adjustments, whose determination shall be final
and binding absent manifest error and whose fees and expenses shall be borne by the Company. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Calculations</U>. All calculations
under this Section&nbsp;2 shall be made by rounding to the nearest cent or the nearest 1/100<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of a share, as applicable. The number of shares of Common Stock outstanding at any given time shall
not include shares owned or held by or for the account of the Company, and the disposition of any such shares shall be considered an issuance or sale of Common Stock. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Voluntary Adjustment By Company</U>. The Company may at any time during the term of this Warrant, with the prior written consent of the
Required Holders (as defined in the Securities Purchase Agreement), reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company; provided, that as of the Public Company
Date, the foregoing shall be subject to the rules and regulations of the Principal Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>RIGHTS UPON DISTRIBUTION OF ASSETS</U>. In addition to any adjustments pursuant to Section&nbsp;2
above or Section&nbsp;4 below, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without
limitation, any distribution of cash, stock or other securities, property, options, evidence of indebtedness or any other assets by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar
transaction) (a &#147;<B>Distribution</B>&#148;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated
therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum
Percentage) immediately before the date on which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such
Distribution (provided, however, that, on or after the Public Company Date, to the extent that the Holder&#146;s right to participate in any such Distribution would result in the Holder and the other Attribution Parties exceeding the Maximum
Percentage, then the Holder shall not be entitled to participate in such Distribution to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and
beneficial ownership) to the extent of any such excess) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other
Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution or on any subsequent Distribution held similarly in
abeyance) to the same extent as if there had been no such limitation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Purchase Rights</U>. In addition to any adjustments pursuant to Sections&nbsp;2 or 3 above, if at any time the Company grants, issues or
sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the &#147;<B>Purchase Rights</B>&#148;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no
such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issuance or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, on or after the Public Company Date, to the
extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right
to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Purchase Right (and beneficial ownership) to the extent of any such excess) and such Purchase Right to such
extent shall be held in abeyance for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the
Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right held similarly in abeyance) to the same extent as if there had been no such limitation). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Fundamental Transactions</U>. The Company shall not enter into or be party to a
Fundamental Transaction unless the Successor Entity assumes in writing all of the obligations of the Company under this Warrant and the other Transaction Documents (as defined in the Securities Purchase Agreement) in accordance with the provisions
of this Section&nbsp;4(b) pursuant to written agreements in form and substance reasonably satisfactory to the Required Holders and approved by the Required Holders prior to such Fundamental Transaction, including agreements to deliver to each Holder
in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant, including, without limitation, which is exercisable for a corresponding number of shares
of capital stock equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price
which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such
adjustments to the number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction). Upon the consummation of each
Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of the applicable Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the
&#147;Company&#148; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same
effect as if such Successor Entity had been named as the Company herein. Upon consummation of each Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon exercise of this Warrant at any
time after the consummation of the applicable Fundamental Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other property (except such items still issuable under Sections&nbsp;3 and 4(a) above, which shall
continue to be receivable thereafter)) issuable upon the exercise of this Warrant prior to the applicable Fundamental Transaction, such shares of publicly traded common stock (or its equivalent) of the Successor Entity (including its Parent Entity)
which the Holder would have been entitled to receive upon the happening of the applicable Fundamental Transaction had this Warrant been exercised immediately prior to the applicable Fundamental Transaction (without regard to any limitations on the
exercise of this Warrant), as adjusted in accordance with the provisions of this Warrant. Notwithstanding the foregoing, and without limiting Section&nbsp;1(f) hereof, the Holder may elect, at its sole option, by delivery of written notice to the
Company to waive this Section&nbsp;4(b) to permit the Fundamental Transaction without the assumption of this Warrant. In addition to and not in substitution for any other rights hereunder, prior to the consummation of each Fundamental Transaction
pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a &#147;<B>Corporate Event</B>&#148;), the Company shall make appropriate provision to
insure that the Holder will thereafter have the right to receive upon an exercise of this Warrant at any time after the consummation of the applicable Fundamental Transaction but prior to the Expiration Date, in lieu of the shares of the Common
Stock (or other securities, cash, assets or other property (except such items still issuable under Sections&nbsp;3 and 4(a) above, which shall continue to be receivable thereafter)) issuable upon the exercise of the Warrant prior to such Fundamental
Transaction, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights) which the Holder would have been entitled to receive upon the happening of the applicable Fundamental Transaction had this Warrant been exercised immediately prior to the applicable
Fundamental Transaction (without regard to any limitations on the exercise of this Warrant). The provision made pursuant to the preceding sentence shall be in a form and substance reasonably satisfactory to the Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Black Scholes Value</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Fundamental Transaction Redemption</U>. Notwithstanding the foregoing and the provisions of Section&nbsp;4(b) above, at
the written request of the Holder delivered at any time commencing on the earliest to occur of (x)&nbsp;the public disclosure of any Fundamental Transaction, (y)&nbsp;the consummation of any Fundamental Transaction and (z)&nbsp;the Holder first
becoming aware of any Fundamental Transaction through the date that is ninety (90)&nbsp;days after the public disclosure of the consummation of such Fundamental Transaction by the Company pursuant to a press release or Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> filed with the SEC, the Company or the Successor Entity (as the case may be) shall purchase this Warrant from the Holder on the date of such request by paying to the Holder cash in an amount equal to the Black
Scholes Value. Payment of such amounts shall be made by the Company (or at the Company&#146;s direction) to the Holder on or prior to the later of (x)&nbsp;the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) Trading Day after the
date of such written request and (y)&nbsp;the date of consummation of such Fundamental Transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Event of
Default Redemption</U>. Notwithstanding the foregoing and the provisions of Section&nbsp;4(b) above, at the request of the Holder delivered at any time after the occurrence of an Event of Default (as defined in the Notes)(assuming for such purpose
that the Notes remain outstanding), the Company or the Successor Entity (as the case may be) shall purchase this Warrant from the Holder on the date of such request by paying to the Holder cash in an amount equal to the Event of Default Black
Scholes Value. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Application</U>. The provisions of this Section&nbsp;4 shall apply similarly and equally to successive Fundamental
Transactions and Corporate Events and shall be applied as if this Warrant (and any such subsequent warrants) were fully exercisable and without regard to any limitations on the exercise of this Warrant (provided that the Holder shall continue to be
entitled to the benefit of the Maximum Percentage, applied however with respect to shares of capital stock registered under the 1934 Act and thereafter receivable upon exercise of this Warrant (or any such other warrant)). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>NONCIRCUMVENTION</U>. The Company hereby covenants and agrees that the Company will not, by amendment of its Certificate of Incorporation (as defined in
the Securities Purchase Agreement), Bylaws (as defined in the Securities Purchase Agreement) or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issuance or sale of securities, or any other
voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all reasonable action as may be reasonably required
to protect the rights of the Holder. Without limiting the generality of the foregoing, the Company (a)&nbsp;shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in
effect, and (b)&nbsp;shall take all such actions as may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonably necessary or appropriate in order that the Company may validly and legally issue fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock upon the
exercise of this Warrant. Notwithstanding anything herein to the contrary, if after the sixty (60)&nbsp;calendar day anniversary of the Issuance Date, the Holder is not permitted to exercise this Warrant in full for any reason (other than pursuant
to restrictions set forth in Section&nbsp;1(f) hereof), the Company shall use its reasonable best efforts to promptly remedy such failure, including, without limitation, obtaining such consents or approvals as necessary to permit such exercise into
shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>WARRANT HOLDER NOT DEEMED A STOCKHOLDER</U>. Except as otherwise specifically provided herein, the Holder, solely in its
capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder,
solely in its capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock,
consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which it is then entitled to receive upon the due exercise
of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such
liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this Section&nbsp;6, the Company shall provide the Holder with copies of the same notices and other information given to the stockholders of the Company
generally, contemporaneously with the giving thereof to the stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>REISSUANCE OF WARRANTS.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Transfer of Warrant</U>. Subject to Section&nbsp;2(g) of the Securities Purchase Agreement, if this Warrant is to be transferred, the
Holder shall surrender this Warrant to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section&nbsp;7(d)), registered as the Holder may request, representing the
right to purchase the number of Warrant Shares being transferred by the Holder and, if less than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section&nbsp;7(d)) to the Holder
representing the right to purchase the number of Warrant Shares not being transferred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Lost, Stolen or Mutilated Warrant</U>. Upon
receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant (as to which a written certification and the indemnification contemplated below shall suffice as such evidence),
and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary and reasonable form and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall
execute and deliver to the Holder a new Warrant (in accordance with Section&nbsp;7(d)) representing the right to purchase the Warrant Shares then underlying this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Exchangeable for Multiple Warrants</U>. This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of
the Company, for a new Warrant or Warrants (in accordance with Section&nbsp;7(d)) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to
purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, no warrants for fractional shares of Common Stock shall be given. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Issuance of New Warrants</U>. Whenever the Company is required to issue a new Warrant
pursuant to the terms of this Warrant, such new Warrant (i)&nbsp;shall be of like tenor with this Warrant, (ii)&nbsp;shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant
(or in the case of a new Warrant being issued pursuant to Section&nbsp;7(a) or Section&nbsp;7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrants issued in
connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv)&nbsp;shall
have the same rights and conditions as this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>NOTICES</U>. Whenever notice is required to be given under this Warrant, unless otherwise
provided herein, such notice shall be given in accordance with Section&nbsp;9(f) of the Securities Purchase Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant (other than the
issuance of shares of Common Stock upon exercise in accordance with the terms hereof), including in reasonable detail a description of such action and the reason therefor. Without limiting the generality of the foregoing, the Company will give
written notice to the Holder (i)&nbsp;promptly upon each adjustment of the Exercise Price and the number of Warrant Shares, setting forth in reasonable detail, and certifying, the calculation of such adjustment(s), (ii) at least fifteen
(15)&nbsp;days prior to the date on which the Company closes its books or takes a record (A)&nbsp;with respect to any dividend or distribution upon the shares of Common Stock, (B)&nbsp;with respect to any grants, issuances or sales of any Options,
Convertible Securities or rights to purchase stock, warrants, securities or other property to holders of shares of Common Stock or (C)&nbsp;for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation,
provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder, (iii)&nbsp;at least ten (10)&nbsp;Trading Days prior to the consummation of any Fundamental
Transaction and (iv)&nbsp;within two (2)&nbsp;Business Day of the occurrence of an Event of Default (as defined in the Notes), setting forth in reasonable detail any material events with respect to such Event of Default and any efforts by the
Company to cure such Event of Default. From and after the Public Company Date, to the extent that any notice provided hereunder constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company
or any of its Subsidiaries (as defined in the Securities Purchase Agreement), the Company shall simultaneously file such notice with the SEC (as defined in the Securities Purchase Agreement) pursuant to a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K.</FONT> From and after the Public Company Date, if the Company or any of its Subsidiaries provides material <FONT STYLE="white-space:nowrap">non-public</FONT> information to the Holder that is not simultaneously filed
in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and the Holder has not agreed to receive such material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company hereby covenants and agrees that the Holder
shall not have any duty of confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents with respect to, or a duty to any of the foregoing not to trade on the basis of, such
material <FONT STYLE="white-space:nowrap">non-public</FONT> information. . It is expressly understood and agreed that the time of execution specified by the Holder in each Exercise Notice shall be definitive and may not be disputed or challenged by
the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <U>AMENDMENT AND WAIVER</U>. Except as otherwise provided herein, the provisions of this Warrant (other
than Section&nbsp;1(f)) may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Required Holders. No waiver
shall be effective unless it is in writing and signed by an authorized representative of the waiving party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <U>SEVERABILITY</U>. If any provision of
this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the
broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues to express,
without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or
reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable
provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <U>GOVERNING LAW</U>. This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of Illinois, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Illinois or any other
jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Illinois. The Company hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or
proceeding by mailing a copy thereof to the Company at the address set forth in Section&nbsp;9(f) of the Securities Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Subject
to Section&nbsp;13, the Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of Chicago, County of Cook, for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.
Nothing contained herein shall be deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Company&#146;s obligations to the Holder, to realize on any
collateral or any other security for such obligations, or to enforce a judgment or other court ruling in favor of the Holder. <B>THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE
ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED HEREBY.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <U>CONSTRUCTION; HEADINGS</U>. This Warrant shall be deemed to be jointly drafted by the Company and the
Holder and shall not be construed against any Person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant. Terms used in this Warrant but
defined in the other Transaction Documents shall have the meanings ascribed to such terms on the Closing Date (as defined in the Securities Purchase Agreement) in such other Transaction Documents unless otherwise consented to in writing by the
Holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <U>DISPUTE RESOLUTION</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<U>Submission to Dispute Resolution</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the case of a dispute relating to the Exercise Price, the Closing Sale
Price, the Bid Price, Black Scholes Consideration Value, Event of Default Black Scholes Value, Black Scholes Value or fair market value or the arithmetic calculation of the number of Warrant Shares (as the case may be) (including, without
limitation, a dispute relating to the determination of any of the foregoing), the Company or the Holder (as the case may be) shall submit the dispute to the other party via email (A)&nbsp;if by the Company, within five (5)&nbsp;Business Days after
the occurrence of the circumstances giving rise to such dispute or (B)&nbsp;if by the Holder, at any time after the Holder learned of the circumstances giving rise to such dispute. If the Holder and the Company are unable to promptly resolve such
dispute relating to such Exercise Price, such Closing Sale Price, such Bid Price, such Black Scholes Consideration Value, Event of Default Black Scholes Value, Black Scholes Value or such fair market value or such arithmetic calculation of the
number of Warrant Shares (as the case may be), at any time after the fifth (5<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) Business Day following such initial notice by the Company or the Holder (as the case may be) of such dispute to the
Company or the Holder (as the case may be), then the Holder may, at its sole option, select an independent, reputable investment bank to resolve such dispute. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Holder and the Company shall each deliver to such investment bank (A)&nbsp;a copy of the initial dispute submission so
delivered in accordance with the first sentence of this Section&nbsp;13 and (B)&nbsp;written documentation supporting its position with respect to such dispute, in each case, no later than 5:00 p.m. (New York time) by the fifth (5<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) Business Day immediately following the date on which the Holder selected such investment bank (the &#147;<B>Dispute</B> <B>Submission Deadline</B>&#148;) (the documents referred to in the
immediately preceding clauses (A)&nbsp;and (B) are collectively referred to herein as the &#147;<B>Required</B> <B>Dispute Documentation</B>&#148;) (it being understood and agreed that if either the Holder or the Company fails to so deliver all of
the Required Dispute Documentation by the Dispute Submission Deadline, then the party who fails to so submit all of the Required Dispute Documentation shall no longer be entitled to (and hereby waives its right to) deliver or submit any written
documentation or other support to such investment bank with respect to such dispute and such investment bank shall resolve such dispute based solely on the Required Dispute Documentation that was delivered to such investment bank prior to the
Dispute Submission Deadline). Unless otherwise agreed to in writing by both the Company and the Holder or otherwise requested by such investment bank, neither the Company nor the Holder shall be entitled to deliver or submit any written
documentation or other support to such investment bank in connection with such dispute (other than the Required Dispute Documentation). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Company and the Holder shall cause such investment bank to
determine the resolution of such dispute and notify the Company and the Holder of such resolution no later than ten (10)&nbsp;Business Days immediately following the Dispute Submission Deadline. The fees and expenses of such investment bank shall be
borne solely by the Company, and such investment bank&#146;s resolution of such dispute shall be final and binding upon all parties absent manifest error. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Miscellaneous</U>. The Company expressly acknowledges and agrees that (i)&nbsp;this Section&nbsp;13 constitutes an agreement to
arbitrate between the Company and the Holder (and constitutes an arbitration agreement) under the Illinois Uniform Arbitration Act, as amended, (ii)&nbsp;a dispute relating to the Exercise Price includes, without limitation, disputes as to
(A)&nbsp;whether an issuance or sale or deemed issuance or sale of Common Stock occurred under Section&nbsp;2(b), (B) the consideration per share at which an issuance or deemed issuance of Common Stock occurred, (C)&nbsp;whether an agreement,
instrument, security or the like constitutes and Option or Convertible Security and (D)&nbsp;whether a Dilutive Issuance occurred, (iii)&nbsp;the terms of this Warrant and each other applicable Transaction Document shall serve as the basis for the
selected investment bank&#146;s resolution of the applicable dispute, such investment bank shall be entitled (and is hereby expressly authorized) to make all findings, determinations and the like that such investment bank determines are required to
be made by such investment bank in connection with its resolution of such dispute (including, without limitation, determining (A)&nbsp;whether an issuance or sale or deemed issuance or sale of Common Stock occurred under Section&nbsp;2(b), (B) the
consideration per share at which an issuance or deemed issuance of Common Stock occurred, (C)&nbsp;whether an agreement, instrument, security or the like constitutes and Option or Convertible Security and (D)&nbsp;whether a Dilutive Issuance
occurred) and in resolving such dispute such investment bank shall apply such findings, determinations and the like to the terms of this Warrant and any other applicable Transaction Documents, (iv)&nbsp;the Holder (and only the Holder), in its sole
discretion, shall have the right to submit any dispute described in this Section&nbsp;13 to any state or federal court sitting in The City of Chicago, County of Cook in lieu of utilizing the procedures set forth in this Section&nbsp;13 and
(v)&nbsp;nothing in this Section&nbsp;13 shall limit the Holder from obtaining any injunctive relief or other equitable remedies (including, without limitation, with respect to any matters described in this Section&nbsp;13). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <U>REMEDIES, CHARACTERIZATION, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF</U>. The remedies provided in this Warrant shall be cumulative and in
addition to all other remedies available under this Warrant and the other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder
to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Warrant. The Company covenants to the Holder that there shall be no characterization concerning this instrument other than as expressly
provided herein. Amounts set forth or provided for herein with respect to payments, exercises and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall not, except as expressly provided herein, be subject
to any other obligation of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this Warrant shall be entitled, in addition to all other
available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required. The Company shall provide all information and documentation to the Holder that is
reasonably requested by the Holder to enable the Holder to confirm the Company&#146;s compliance with the terms and conditions of this Warrant (including, without limitation, compliance with Section&nbsp;2 hereof). The issuance of shares and
certificates for shares as contemplated hereby upon the exercise of this Warrant shall be made without charge to the Holder or such shares for any issuance tax or other costs in respect thereof, provided that the Company shall not be required to pay
any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than the Holder or its agent on its behalf. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <U>P</U><U>AYMENT OF COLLECTION, ENFORCEMENT AND OTHER COSTS</U>. If (a)&nbsp;this Warrant is placed in the hands of an attorney for collection or
enforcement or is collected or enforced through any legal proceeding or the holder otherwise takes action to collect amounts due under this Warrant or to enforce the provisions of this Warrant or (b)&nbsp;there occurs any bankruptcy, reorganization,
receivership of the company or other proceedings affecting company creditors&#146; rights and involving a claim under this Warrant, then the Company shall pay the costs incurred by the Holder for such collection, enforcement or action or in
connection with such bankruptcy, reorganization, receivership or other proceeding, including, without limitation, attorneys&#146; fees and disbursements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16. <U>TRANSFER</U>. This Warrant may be offered for sale, sold, transferred or assigned without the consent of the Company, except as may otherwise be
required by Section&nbsp;2(g) of the Securities Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17. <U>DISCLOSURE</U>18. . from and after the Public Company Date, upon delivery by
the Company to the Holder (or receipt by the Company from the Holder) of any notice in accordance with the terms of this Warrant, unless the Company has in good faith determined that the matters relating to such notice do not constitute material, <FONT
STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries, the Company shall on or prior to 9:00 am, New York city time on the Business Day immediately following such notice delivery date, publicly
disclose such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information on a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or otherwise. From and after the Public Company Date, in the event that the Company
believes that a notice contains material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries, the Company so shall indicate to the Holder explicitly in writing in such notice (or
immediately upon receipt of notice from the Holder, as applicable), and in the absence of any such written indication in such notice (or notification from the Company immediately upon receipt of notice from the Holder), the Holder shall be entitled
to presume that information contained in the notice does not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18. <U>ABSENCE OF TRADING AND DISCLOSURE RESTRICTIONS</U>. The Company acknowledges and agrees that the Holder is not a fiduciary or agent of the Company and
that the Holder shall have no obligation to (a)&nbsp;maintain the confidentiality of any information provided by the Company or (b)&nbsp;refrain from trading any securities while in possession of such information in the absence of a written <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> agreement signed by an officer of the Holder that explicitly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provides for such confidentiality and trading restrictions. In the absence of such an executed, written <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement, the Company acknowledges
that the Holder may freely trade in any securities issued by the Company, may possess and use any information provided by the Company in connection with such trading activity, and may disclose any such information to any third party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19. <U>CERTAIN DEFINITIONS</U>. For purposes of this Warrant, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>1933 Act</B>&#148; means the Securities Act of 1933, as amended, and the rules and regulations thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>1934 Act</B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Adjustment Right</B>&#148; means any right granted with respect to any securities issued in connection with, or with respect to,
any issuance or sale (or deemed issuance or sale in accordance with Section&nbsp;2) of shares of Common Stock (other than rights of the type described in Section&nbsp;3 and 4 hereof) that could result in a decrease in the net consideration received
by the Company in connection with, or with respect to, such securities (including, without limitation, any cash settlement rights, cash adjustment or other similar rights). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or
is under common control with, such Person, it being understood for purposes of this definition that &#147;control&#148; of a Person means the power directly or indirectly either to vote 10% or more of the stock having ordinary voting power for the
election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Attribution Parties</B>&#148; means, collectively, the following Persons and entities: (i)&nbsp;any investment vehicle, including,
any funds, feeder funds or managed accounts, currently, or from time to time after the Issuance Date, directly or indirectly managed or advised by the Holder&#146;s investment manager or any of its Affiliates or principals, (ii)&nbsp;any direct or
indirect Affiliates of the Holder or any of the foregoing, (iii)&nbsp;any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and (iv)&nbsp;any other Persons whose beneficial ownership of the
Company&#146;s Common Stock would or could be aggregated with the Holder&#146;s and the other Attribution Parties for purposes of Section&nbsp;13(d) of the 1934 Act. For clarity, the purpose of the foregoing is to subject collectively the Holder and
all other Attribution Parties to the Maximum Percentage. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Bid Price</B>&#148; means, for any security as of the particular
time of determination, the bid price for such security on the Principal Market as reported by Bloomberg as of such time of determination, or, if the Principal Market is not the principal securities exchange or trading market for such security, the
bid price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg as of such time of determination, or if the foregoing does not apply, the bid price of such security
in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security as reported by Bloomberg as of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such time of determination, or, if no bid price is reported for such security by Bloomberg as of such time of determination, the average of the bid prices of any market makers for such security
as reported in The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices) as of such time of determination. If the Bid Price cannot be calculated for a security as of the particular time of
determination on any of the foregoing bases, the Bid Price of such security as of such time of determination shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon
the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;13. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other
similar transaction during such period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Black Scholes Consideration Value</B>&#148; means (x)&nbsp;prior to the Public
Company Date, the fair market value of the applicable Option, Convertible Security or Adjustment Right (as the case may be) as determined in good faith by the Required Holders, and (y)&nbsp;on or after the Public Company Date, the value of the
applicable Option, Convertible Security or Adjustment Right (as the case may be) as of the date of issuance thereof calculated using the Black Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg utilizing (i)&nbsp;an
underlying price per share equal to the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the public announcement of the execution of definitive documents with respect to the issuance of such Option or Convertible
Security (as the case may be), (ii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of such Option, Convertible Security or Adjustment Right (as the case may be) as of the date of issuance
of such Option, Convertible Security or Adjustment Right (as the case may be), (iii) a zero cost of borrow and (iv)&nbsp;an expected volatility equal to the greater of 100% and the 30 day volatility obtained from the &#147;HVT&#148; function on
Bloomberg (determined utilizing a 365 day annualization factor) as of&nbsp;the Trading Day immediately following the date of issuance of such Option, Convertible Security or Adjustment Right (as the case may be). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Black Scholes Value</B>&#148; means (x)&nbsp;prior to the Public Company Date, the fair market value of the unexercised portion of
this Warrant as determined in good faith by the Required Holders, and (y)&nbsp;on or after the Public Company Date, the value of the unexercised portion of this Warrant remaining on the date of the Holder&#146;s request pursuant to
Section&nbsp;4(c)(i), which value is calculated using the Black Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg utilizing (i)&nbsp;an underlying price per share equal to the greater of (1)&nbsp;the highest Closing
Sale Price of the Common Stock during the period beginning on the Trading Day immediately preceding the announcement of the applicable Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on
the Trading Day of the Holder&#146;s request pursuant to Section&nbsp;4(c)(i) and (2)&nbsp;the sum of the price per share being offered in cash in the applicable Fundamental Transaction (if any) plus the value of the
<FONT STYLE="white-space:nowrap">non-cash</FONT> consideration being offered in the applicable Fundamental Transaction (if any), (ii) a strike price equal to the Exercise Price in effect on the date of the Holder&#146;s request pursuant to
Section&nbsp;4(c)(i), (iii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the greater of (1)&nbsp;the remaining term of this Warrant as of the date of the Holder&#146;s request pursuant to
Section&nbsp;4(c)(i) and (2)&nbsp;the remaining term of this Warrant as of the date of consummation of the applicable Fundamental Transaction or as of the date of the Holder&#146;s request pursuant to Section&nbsp;4(c)(i) if such request is prior to
the date of the consummation of the applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Fundamental Transaction, (iv)&nbsp;a zero cost of borrow and (v)&nbsp;an expected volatility equal to the greater of 100% and the 30 day volatility obtained from the &#147;HVT&#148; function on
Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the earliest to occur of (A)&nbsp;the public disclosure of the applicable Fundamental Transaction and (B)&nbsp;the date of the Holder&#146;s
request pursuant to Section&nbsp;4(c)(i). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Bloomberg</B>&#148; means Bloomberg, L.P. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) &#147;<B>Business Day</B>&#148; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York
are authorized or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#147;stay at home&#148;, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;shelter-in-place&#148;,</FONT></FONT> <FONT STYLE="white-space:nowrap">&#147;non-essential</FONT> employee&#148;&nbsp;or any other similar orders or restrictions or the closure of any
physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) &#147;<B>Closing Sale Price</B>&#148; means, for any security as of any date, the last closing trade price for such security on the
Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing trade price, then the last trade price of such security prior to 4:00:00 p.m., New York time, as
reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for such security, the last trade price of such security on the principal securities exchange or trading market where such security is
listed or traded as reported by Bloomberg, or if the foregoing does not apply, the last trade price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic
bulletin board for such security as reported by Bloomberg, or, if no last trade price is reported for such security by Bloomberg, the average of the ask prices of any market makers for such security as reported in The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be
the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in
Section&nbsp;13. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during such period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B>Common Stock</B>&#148; means (i)&nbsp;the Company&#146;s shares of common stock, $0.001 par value per share, and (ii)&nbsp;any
capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) &#147;<B>Convertible Securities</B>&#148; means any stock or other security (other than Options) that is at any time and under any
circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any shares of Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) &#147;<B>Eligible Market</B>&#148; means The New York Stock Exchange, the NYSE American,
the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or the Principal Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) &#147;<B>Event Market
Price</B>&#148; means, with respect to any Stock Combination Event Date, the quotient determined by dividing (x)&nbsp;the sum of the VWAP of the Common Stock for each of the five (5)&nbsp;lowest Trading Days during the twenty (20)&nbsp;consecutive
Trading Day period ending and including the Trading Day immediately preceding the sixteenth (16th) Trading Day after such Stock Combination Event Date, divided by (y)&nbsp;five (5). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) &#147;<B>Event of Default</B> <B>Black Scholes Value</B>&#148; means (x)&nbsp;prior to the Public Company Date, the fair market value of
the unexercised portion of this Warrant as determined in good faith by the Required Holders, and (y)&nbsp;on or after the Public Company Date, the value of the unexercised portion of this Warrant remaining on the date of the Holder&#146;s request
pursuant to Section&nbsp;4(c)(ii), which value is calculated using the Black Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg utilizing (i)&nbsp;an underlying price per share equal to the highest Closing Sale Price
of the Common Stock during the period beginning on the date of the occurrence of the Event of Default through the date all Events of Default have been cured (assuming for such purpose that the Notes remain outstanding) or, if earlier, the Trading
Day of the Holder&#146;s request pursuant to Section&nbsp;4(c)(ii), (ii) a strike price equal to the Exercise Price in effect on the date of the Holder&#146;s request pursuant to Section&nbsp;4(c)(ii), (iii) a risk-free interest rate corresponding
to the U.S. Treasury rate for a period equal to the greater of (1)&nbsp;the remaining term of this Warrant as of the date of the Holder&#146;s request pursuant to Section&nbsp;4(c)(ii) and (2)&nbsp;the remaining term of this Warrant as of the date
of the occurrence of such Event of Default, (iv)&nbsp;a zero cost of borrow and (v)&nbsp;an expected volatility equal to the greater of 100% and the 30 day volatility obtained from the &#147;HVT&#148; function on Bloomberg (determined utilizing a
365 day annualization factor) as of the Trading Day immediately following later of (x)&nbsp;the date of the occurrence of such Event of Default and (y)&nbsp;the date of the public announcement of such Event of Default. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) &#147;<B>Expiration Date</B>&#148; means the date that is the fifth (5<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) anniversary
of the Issuance Date or, if such date falls on a day other than a Trading Day or on which trading does not take place on the Principal Market (a &#147;<B>Holiday</B>&#148;), the next date that is not a Holiday. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) &#147;<B>Fundamental Transaction</B>&#148; means (A)&nbsp;that the Company shall, directly or indirectly, including through subsidiaries,
Affiliates or otherwise, in one or more related transactions, (i)&nbsp;consolidate or merge with or into (whether or not the Company is the surviving corporation) another Subject Entity, or (ii)&nbsp;sell, assign, transfer, convey or otherwise
dispose of all or substantially all of the properties or assets of the Company or any of its &#147;significant subsidiaries&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation
<FONT STYLE="white-space:nowrap">S-X)</FONT> to one or more Subject Entities, or (iii)&nbsp;make, or allow one or more Subject Entities to make, or allow the Company to be subject to or have its Common Stock be subject to or party to one or more
Subject Entities making, a purchase, tender or exchange offer that is accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding shares of Common Stock calculated as if any shares of
Common Stock held by all Subject Entities making or party to, or Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding; or (z)&nbsp;such number of shares of Common Stock such that all
Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such purchase, tender or exchange offer, become collectively </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the beneficial owners (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or (iv)&nbsp;consummate a
stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with one or more Subject Entities whereby
all such Subject Entities, individually or in the aggregate, acquire, either (x)&nbsp;at least 50% of the outstanding shares of Common Stock, (y)&nbsp;at least 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock
held by all the Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such stock purchase agreement or other business combination were not outstanding; or (z)&nbsp;such number of shares of Common Stock such
that the Subject Entities become collectively the beneficial owners (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the 1934 Act) of at least 50% of the outstanding shares of Common Stock, or (v)&nbsp;reorganize, recapitalize
or reclassify its Common Stock, (B)&nbsp;that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any Subject Entity individually or the Subject Entities in
the aggregate to be or become the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the 1934 Act), directly or indirectly, whether through acquisition, purchase, assignment, conveyance, tender,
tender offer, exchange, reduction in outstanding shares of Common Stock, merger, consolidation, business combination, reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off,</FONT> scheme of arrangement, reorganization,
recapitalization or reclassification or otherwise in any manner whatsoever, of either (x)&nbsp;at least 50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock, (y)&nbsp;at least 50% of the aggregate ordinary
voting power represented by issued and outstanding Common Stock not held by all such Subject Entities as of the date of this Warrant calculated as if any shares of Common Stock held by all such Subject Entities were not outstanding, or (z)&nbsp;a
percentage of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock or other equity securities of the Company sufficient to allow such Subject Entities to effect a statutory short form merger or other
transaction requiring other shareholders of the Company to surrender their shares of Common Stock without approval of the shareholders of the Company or (C)&nbsp;directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one
or more related transactions, the issuance of or the entering into any other instrument or transaction structured in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this definition or any portion of this definition which may be defective or inconsistent with the intended treatment of
such instrument or transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) &#147;<B>Group</B>&#148; means a &#147;group&#148; as that term is used in Section&nbsp;13(d) of the
1934 Act and as defined in Rule <FONT STYLE="white-space:nowrap">13d-5</FONT> thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) &#147;<B>Notes</B>&#148; has the meaning
ascribed to such term in the Securities Purchase Agreement, and shall include all notes issued in exchange therefor or replacement thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) &#147;<B>Options</B>&#148; means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible
Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) &#147;<B>Parent Entity</B>&#148; of a Person means an entity that, directly or indirectly, controls the applicable Person
and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of
consummation of the Fundamental Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) &#147;<B>Person</B>&#148; means an individual, a limited liability company, a
partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity or a government or any department or agency thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) &#147;<B>Public Company Date</B>&#148; means the date on which the shares of Common Stock of the Company (or its direct or indirect
successor, subsidiary or parent company, whose securities are issued or issuable to holders of Common Stock), whether as a result of a public offering, merger, recapitalization, reorganization or otherwise, are registered under the 1934 Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) &#147;<B>Principal Market</B>&#148; means the Eligible Market that is the principal securities exchange market for the Common Stock after
the Public Company Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) &#147;<B>Required Holders</B>&#148; shall have the meaning set forth in the Securities Purchase Agreement.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) &#147;<B>SEC</B>&#148; means the United States Securities and Exchange Commission or the successor thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <B>&#147;Subject Entity</B>&#148; means any Person, Persons or Group or any Affiliate or associate of any such Person, Persons or Group.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) &#147;<B>Successor Entity</B>&#148; means the Person (or, if so elected by the Holder, the Parent Entity) formed by, resulting from
or surviving any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been entered into. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) &#147;<B>Trading Day</B>&#148; means, as applicable, (i)&nbsp;prior to the Public Company Date, any Business Day, and (ii)&nbsp;from and
after the Public Company Date, (x)&nbsp;with respect to all price or trading volume determinations relating to the Common Stock, any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal
trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded, provided that &#147;Trading Day&#148; shall not include any day on which the Common Stock is scheduled to
trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing
time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time) unless such day is otherwise designated as a Trading Day in writing by the Holder or (y)&nbsp;with respect to all determinations other than price
or trading volume determinations relating to the Common Stock, any day on which The New York Stock Exchange (or any successor thereto) is open for trading of securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) &#147;<B>VWAP</B>&#148; means, for any security as of any date, the dollar volume-weighted average price for such security on the
principal trading market for such security, during the period beginning at 9:30 a.m., New York time, and ending at 4:00 p.m., New York time, as reported by Bloomberg through its &#147;VAP&#148; function (set to 09:30 start time and 16:00 end time)
or, if the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
foregoing does not apply, the dollar volume-weighted average price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market
on the electronic bulletin board for such security during the period beginning at 9:30 a.m., New York time, and ending at 4:00 p.m., New York time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such
security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported in The Pink Open Market (or a similar organization or agency succeeding to
its functions of reporting prices). If the VWAP cannot be calculated for such security on such date on any of the foregoing bases, the VWAP of such security on such date shall be the fair market value as mutually determined by the Company and the
Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;13. All such determinations shall be appropriately adjusted
for any stock dividend, stock split, stock combination, recapitalization or other similar transaction during such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature
Page Follows</I>] </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the Company has caused this Warrant to Purchase Common Stock to
be duly executed as of the Issuance Date set out above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HEART TEST LABORATORIES, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>(D/B/A HEARTSCIENCES)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXERCISE NOTICE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE
EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Heart Test Laboratories, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(d/b/a HeartSciences) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
undersigned holder hereby elects to exercise the Warrant to Purchase Common Stock No.&nbsp;[_____] (the &#147;<B>Warrant</B>&#148;) of Heart Test Laboratories, Inc. (d/b/a HeartSciences), a Texas corporation (the &#147;<B>Company</B>&#148;) as
specified below. Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Form of Exercise Price</U>. The Holder intends that payment of the Aggregate Exercise Price shall be made as: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#9744; a &#147;<U>Cash
Exercise</U>&#148; with respect to _________________ Warrant Shares; and/or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#9744; a &#147;<U>Cashless Exercise</U>&#148; with respect
to _______________ Warrant Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Holder has elected a Cashless Exercise with respect to some or all of the Warrant
Shares to be issued pursuant hereto, the Holder hereby represents and warrants that (i)&nbsp;this Exercise Notice was executed by the Holder at [__________] [a.m.][p.m.] on the date set forth below and (ii)&nbsp;if applicable, the Bid Price as of
such time of execution of this Exercise Notice was $[________]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Payment of Exercise Price</U>. In the event that the Holder has
elected a Cash Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the Holder shall pay the Aggregate Exercise Price in the sum of $[_______________] to the Company in accordance with the terms of the Warrant.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Delivery of Warrant Shares</U>. The Company shall deliver to Holder, or its designee or agent as specified below, [__________]
shares of Common Stock in accordance with the terms of the Warrant. Delivery shall be made to Holder, or for its benefit, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Check here if requesting delivery as a certificate to the following name and to the following address:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Issue
to:&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Check here if after the Public Company Date and requesting delivery by Deposit/Withdrawal at Custodian as
follows: </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">DTC
Participant:&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">DTC&nbsp;Number:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Account
Number:&nbsp;&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: _____________
__,<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name of Registered Holder</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax ID:____________________________</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E-mail</FONT>
Address:_____________________</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ACKNOWLEDGMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company hereby acknowledges this Exercise Notice and hereby directs [______________] to issue the above indicated number of shares of Common Stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HEART TEST LABORATORIES, INC. (D/B/A HEARTSCIENCES)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 4.6 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEITHER THIS WARRANT NOR THE SHARES (AS DEFINED BELOW) OF THE COMPANY ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER EITHER THE UNITED STATES
SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION AND MAY NOT BE SOLD, ASSIGNED, PLEDGED, HYPOTHECATED OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT RELATED THERETO, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT TO
PURCHASE SHARES OF COMMON STOCK </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>HEART TEST LABORATORIES, INC. </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Void after September&nbsp;30, 2026 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant No.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Issue Date:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS CERTIFIES THAT</B>, for value received, [Name], or their registered successors or assigns
(hereinafter, the &#147;<B>Holder</B>&#148;), is entitled to purchase, subject to the conditions set forth below, at any time or from time to time during the Exercise Period (as defined in subsection 1.1 below), [Number] (Number in words) fully-paid
and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares (the &#147;<B>Shares</B>&#148;) of the common stock, par value $0.001 per share (the &#147;<B>Common Stock</B>&#148;), of Heart Test Laboratories, Inc., a Texas corporation (the
&#147;<B>Company</B>&#148;), at an exercise price which is the lower of: (i) $0.1833 per share or (ii)&nbsp;a 30% discount to the price at which a closing of an offering for the sale of shares of Common Stock to the public (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock), in an initial public offering pursuant to an effective registration statement under the Securities Act of
1933, subject to adjustment as provided in Section&nbsp;3 below (the &#147;<B>Exercise Price</B>&#148;). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXERCISE OF WARRANT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms and conditions upon which this Warrant may be exercised, and the Shares covered hereby may be purchased, are as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Exercise Period and Vesting</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) This Warrant is fully-vested as of the date of this Warrant. The exercise period of this Warrant is the period beginning on
the date of this Warrant and ending at 5:00 p.m., Dallas, Texas time, on September&nbsp;30, 2026 (the &#147;<B>Exercise Period</B>&#148;). Exercise of the purchase rights represented by this Warrant may be made at any time or times on or during the
Exercise Period by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of such Holder appearing on the books of the Company) of a duly executed
facsimile copy of the Notice of Exercise in the form attached to this Warrant (the &#147;<B>Notice of Exercise</B>&#148;); </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
provided, however, within three (3)&nbsp;Business Days after the date said Notice of Exercise is delivered to the Company, the Holder shall have surrendered this Warrant to the Company, and, if
the Holder has not elected to make a cashless exercise as provided below, the Company shall have received payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier&#146;s check drawn on a United States bank.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that Holder elects to make a cashless exercise as provided above, the Company shall issue to Holder the
number of shares of Common Stock equal to the result obtained by (i)&nbsp;subtracting B from A; (ii)&nbsp;multiplying the difference by C; and (iii)&nbsp;dividing the product by A, as set forth in the following equation: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">X = <U>(A&#151;B) x C</U> where: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">A </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">X = the
number of Shares issuable upon a cashless exercise of the Warrant pursuant to the provisions of this Section&nbsp;1.1. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">A = the Fair Market
Value (as defined below) of one share of Common Stock on the date of the Notice of Exercise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">B = the Exercise Price for one Share under
this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">C = the number of Shares as to which this Warrant is being exercised. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If the foregoing calculation results in a negative number, then no Shares shall be issued upon a cashless exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) For the purpose of the above calculations, the &#147;<B>Fair Market Value</B>&#148; per share of Common Stock shall be,
(i)&nbsp;if the cashless exercise of the Warrant is in connection with a public offering of Common Stock, the public offering price (before deducting commission, discounts or expenses) at which the Common Stock is sold in such offering; (ii)&nbsp;if
a public market for the Common Stock exists at the time of such exercise, the average of the closing bid and asked prices of the Common Stock quoted in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Over-The-Counter</FONT></FONT> Market Summary or the last reported sale price of the Common Stock or closing price quoted on the NASDAQ National Market or on any exchange on which the
Common Stock is listed, whichever is applicable, as published in <I>The Wall Street Journal</I> for the five (5)&nbsp;trading days prior to the date of determination of fair market value; or (iii)&nbsp;if there is no public market for the Common
Stock, determined by the Company&#146;s Board of Directors in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Issuance Of Shares and New Warrant</U>. Certificates for
Shares purchased hereunder shall be delivered by the Company to Holder as soon as possible after delivery by Holder to the Company of the items described in Section&nbsp;1.1 above; provided, however, if the Company has appointed a transfer agent for
the Common Stock, then certificates for Shares shall be transmitted by the transfer agent of the Company to the Holder by crediting the account of the Holder&#146;s prime broker with the Depository Trust Company through its Deposit Withdrawal Agent
Commission (&#147;<B>DWAC</B>&#148;) system if the Company is a participant in such system, and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise within 3 trading days from the delivery to the Company of
the Notice of Exercise form, surrender of this Warrant and payment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the aggregate Exercise Price as set forth above (&#147;<B>Share Delivery Date</B>&#146;). This Warrant shall be deemed to have been exercised on the date the Exercise Price is received by the
Company. The Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such Shares for all purposes, as of the date the Warrant has been
exercised by payment to the Company of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section&nbsp;1.5 below prior to the issuance of such Shares, have been paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the time of
delivery of the certificate or certificates representing Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Shares called for by this Warrant, which new Warrant shall in all other respects be
identical with this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 <U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional Shares shall
be issued upon the exercise of this Warrant. As to any fraction of a Share which Holder would otherwise be entitled to purchase upon such exercise, the Company shall pay a cash adjustment in respect of such final fraction in an amount equal to such
fraction multiplied by the Exercise Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 <U>Charges. Taxes and Expenses</U>. Issuance of certificates for Shares shall be made
without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of
the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event certificates for Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be
accompanied by the Assignment Form attached hereto duly executed by the Holder; and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSFERS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Sections 2.4, 5 and 6.1
below, this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company, together with the appropriate form of Assignment, as attached hereto, duly executed by the
Holder and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or
assignees and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. A
Warrant, if properly assigned, may be exercised by a new holder for the purchase of Shares without having a new Warrant issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon
presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with
Section&nbsp;2.1, as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such
notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the &#147;<B>Warrant Register</B>&#148;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Transfer Restrictions</U>. If,
at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be registered pursuant to an effective registration statement under the Securities Act and under applicable state
securities or blue sky laws, the Company may require, as a condition of allowing such transfer (i)&nbsp;that the Holder or transferee of this Warrant, as the case may be, furnish to the Company a written opinion of counsel (which opinion shall be in
form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that such transfer may be made without registration under the Securities Act and under applicable state securities or blue sky laws, (ii)&nbsp;that
the Holder or transferee execute and deliver to the Company an investment letter in form and substance acceptable to the Company, and (iii)&nbsp;that the transferee be an &#147;accredited investor&#148; as defined in Rule 501(a) of Regulation D
promulgated under the Securities Act or a qualified institutional buyer as defined in Rule 144A(a) under the Securities Act. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ANTIDILUTION PROVISIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of this Section&nbsp;3 shall apply in the event that any of the events described in this Section&nbsp;3 shall occur with respect
to the Shares at any time on or after the original issuance date of this Warrant: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Splits and Combinations</U>. If the Company
shall at any time subdivide or combine its outstanding shares of Common Stock, this Warrant shall, after that subdivision or combination, evidence the right to purchase the number of shares that would have been issuable as a result of that change
with respect to the Shares which were purchasable under this Warrant immediately before that subdivision or combination. If the Company shall at any time subdivide the outstanding shares of Common Stock, the Exercise Price then in effect immediately
before that subdivision shall be proportionately decreased, and, if the Company shall at any time combine the outstanding shares, the Exercise Price then in effect immediately before that combination shall be proportionately increased. Any
adjustment under this Section shall become effective at the time that such subdivision or combination becomes effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2
<U>Reclassification, Exchange and Substitution</U>. If the Shares issuable upon exercise of this Warrant shall be changed into the same or a different number of securities of any other class or classes of stock, whether by capital reorganization,
reclassification, or otherwise (other than a subdivision or combination of shares provided for above), the Holder of this Warrant shall, on its exercise, be entitled to purchase for the same aggregate consideration, in lieu of the Shares which the
Holder would have become entitled to purchase but for such change, the number of securities of such other class or classes of stock equivalent to the number of Shares that would have been subject to purchase by the Holder on exercise of this Warrant
immediately before that change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Reorganizations, Mergers, Consolidations Or Sale Of Assets</U>. If at any time there
shall be a capital reorganization of the shares of Common Stock (other than a combination, reclassification, exchange, or subdivision of shares provided for elsewhere above) then, as a part of such reorganization, lawful provision shall be made so
that the Holder of this Warrant shall thereafter be entitled to receive upon exercise of this Warrant, during the period specified in this Warrant and upon payment of the Exercise Price then in effect, the number of shares or other securities or
property of the Company to which a holder of the Shares deliverable upon exercise of this Warrant would have been entitled in such capital reorganization if this Warrant had been exercised immediately before that capital reorganization. In any such
case, appropriate adjustment (as determined in good faith by the Company&#146;s Board of Directors) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder of this Warrant after the
reorganization to the end that the provisions of this Warrant (including adjustment of the Exercise Price then in effect and number of Shares purchasable upon exercise of this Warrant) shall be applicable after that event, as near as reasonably may
be, in relation to any shares or other property deliverable after that event upon exercise of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 <U>Distributions</U>. In
the event the Company should at any time prior to the expiration of this Warrant fix a record date for the determination of the holders of shares entitled to receive a distribution payable in additional shares of Common Stock or other securities or
rights convertible into or entitling the holder thereof to receive, directly or indirectly, additional shares of Common Stock (hereinafter referred to as the &#147;<B>Share Equivalents</B>&#148;) without payment of any consideration by such holder
for the additional shares (including the additional shares issuable upon conversion or exercise thereof), then, as of such record date (or the date of such distribution, split or subdivision if no record date is fixed), the Exercise Price shall be
appropriately decreased and the number of Shares issuable upon exercise of the Warrant shall be appropriately increased in proportion to such increase of outstanding shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5 <U>Adjustments of Other Distributions</U>. In the event the Company shall declare a distribution payable in securities of other persons,
evidences of indebtedness issued by the Company or other persons, assets (excluding cash dividends) or options or rights not referred to in Section&nbsp;3.4 above, then, in each such case for the purpose of this Section&nbsp;3.5, upon exercise of
this Warrant the Holder hereof shall be entitled to a proportionate share of any such distribution as though such Holder was the holder of the number of Shares into which this Warrant may be exercised as of the record date fixed for the
determination of the holders of shares entitled to receive such distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6 <U>Certificate as to Adjustments</U>. In the case of
each adjustment or readjustment of the Exercise Price pursuant to this Section&nbsp;3, the Company will promptly compute such adjustment or readjustment in accordance with the terms hereof and cause a certificate setting forth such adjustment or
readjustment and showing in detail the facts upon which such adjustment or readjustment is based, to be delivered to the Holder of this Warrant. The Company will, upon the written request at any time of the Holder of this Warrant, furnish or cause
to be furnished to such Holder a certificate setting forth: (a)&nbsp;such adjustments and readjustments; (b)&nbsp;the Exercise Price at the time in effect; and (c)&nbsp;the number of Shares issuable upon exercise of the Warrant and the amount, if
any, of other property at the time receivable upon the exercise of the Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7 <U>Reservation of Shares Issuable Upon Exercise</U>. The Company shall at all times
reserve and keep available out of its authorized but unissued shares of Common Stock solely for the purpose of effecting the exercise of this Warrant such number of shares of Common Stock as shall from time to time be sufficient to effect the
exercise of this Warrant and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the exercise of this Warrant, in addition to such other remedies as shall be available to the Holder of this
Warrant, the Company will use its best efforts to take such action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RIGHTS PRIOR TO EXERCISE OF WARRANT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Warrant does not entitle the Holder to any of the rights of a shareholder of the Company. If, however, at any time prior to the expiration
of this Warrant and prior to its exercise, any of the following events shall occur: (a)&nbsp;the Company shall make any distribution (other than a cash distribution) to the holders of shares of Common Stock; (b)&nbsp;the Company shall offer to all
of the holders of shares of Common Stock any additional shares or Share Equivalents or any right to subscribe for or purchase any thereof; or (c)&nbsp;a dissolution, liquidation or winding up of the Company (other than in connection with a
consolidation, merger, sale, transfer or lease of all or substantially all of its property, assets, and business as an entirety) shall be proposed and action by the Company with respect thereto has been approved by the Company&#146;s Board of
Directors (each, a &#147;<B>Material Action</B>&#148;), the Company shall give notice in writing of such Material Action to the Holder at its last address as it shall appear on the Company&#146;s records at least twenty (20)&nbsp;days&#146; prior to
the date fixed as a record date or the date of closing the transfer books for the determination of the shareholders entitled to such dividends, distribution, or subscription rights, or for the determination of shareholders entitled to vote on the
Material Action. Such notice shall specify such record date or the date of closing the transfer books, as the case may be. Failure to publish, mail or receive such notice or any defect therein or in the publication or mailing thereof shall not
affect the validity of the Material Action. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RESTRICTED SECURITIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holder acknowledges that the Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions upon resale
imposed by state and federal securities laws. In order to enable the Company to comply with the Securities Act and applicable state laws, the Company may require the Holder as a condition of the transfer or exercise of this Warrant, to give written
assurance satisfactory to the Company that the Warrant, or in the case of an exercise hereof the Shares subject to this Warrant, are being acquired for his or her own account, for investment only, with no view to the distribution of the same, and
that any disposition of all or any portion of this Warrant or the Shares issuable upon the due exercise of this Warrant shall not be made, unless made in compliance with the requirements of the Securities Act and applicable securities laws of any
State or other jurisdiction. Holder acknowledges that this Warrant is, and each of the Shares issuable upon the due exercise hereof will be, a restricted security, and that the certificates evidencing securities issued to the Holder upon exercise of
this Warrant will bear a legend substantially similar to the legend set forth on the front page of this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>Title to Warrant</U>. During the Exercise Period, and subject to compliance with applicable laws and Section&nbsp;2.4 above, this
Warrant and all rights hereunder are transferable, in whole or in part, at the office of the Company by the Holder, upon surrender of this Warrant together with the appropriate Assignment form attached hereto properly endorsed. To the extent
Section&nbsp;2.4 above is applicable, the transferee shall sign an investment letter in form and substance reasonably satisfactory to the Company, if required by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Loss Theft Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of
such cancellation, in lieu of such Warrant or stock certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Saturdays, Sundays, Holidays, Etc</U>. If the last or appointed
day for the taking of any action or the expiration of any right required or granted herein shall be a Saturday, Sunday or a legal holiday, then such action may be taken or such right may be exercised on the next succeeding day not a Saturday, Sunday
or legal holiday. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4 <U><FONT STYLE="white-space:nowrap">Non-Waiver</FONT> and Expenses</U>. No course of dealing or any delay or
failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice Holder&#146;s rights, powers or remedies, notwithstanding the fact that all rights hereunder terminate upon expiration of
the Exercise Period. If the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts as shall be sufficient to cover any
costs and expenses including, but not limited to, reasonable attorneys&#146; fees, including those of appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise; enforcing any of its rights, powers or
remedies hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 <U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by Holder to
exercise this Warrant or purchase Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase price of any Common Stock or as a shareholder of the Company, whether such
liability is asserted by the Company or by creditors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6 <U>Remedies</U>. Holder, in addition to being entitled to exercise all rights granted by
law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the
provisions of this Warrant and hereby agrees to waive the defense in any action for specific performance that a remedy at law would be adequate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7 <U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and
shall be enforceable by any such Holder or holder of Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8 <U>Amendment</U>. This Warrant may be modified or amended or the
provisions hereof waived with the written consent of the Company and the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9 <U>Severability</U>. Wherever possible, each
provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.10 <U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a
part of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.11 <U>Notices</U>. All notices, requests, demands and other communications under this Warrant shall be in writing
and shall be deemed to have been duly given on the date of service if served personally on the party to whom notice is to be given, or on the date of mailing if mailed to the party to whom notice is to be given, by first class mail, registered or
certified, postage prepaid, and properly addressed as follows: if to the Holder, at his address as shown in the Company records; and if to the Company, at 9 Village Circle, Suite 527, Westlake, Texas 76262, Attention: Chief Executive Officer. Any
party may change its address for purposes of this Section by giving the other party written notice of the new address in the manner set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.12 <U>Governing Law</U>. This Warrant and any dispute, disagreement or issue of construction of interpretation arising hereunder whether
relating to its execution, its validity, the obligations provided herein or performance shall be governed or interpreted according to the internal laws of the State of Texas without regard to conflicts of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>EXECUTED</B> as of the date first set forth above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HEART TEST LABORATORIES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mark Hilz,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 4.7 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEITHER THIS WARRANT NOR THE SHARES (AS DEFINED BELOW) OF THE COMPANY ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER EITHER THE UNITED STATES
SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION AND MAY NOT BE SOLD, ASSIGNED, PLEDGED, HYPOTHECATED OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT RELATED THERETO, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT TO
PURCHASE SHARES OF COMMON STOCK </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>HEART TEST LABORATORIES, INC. </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Void after </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant No.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Issue Date:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS CERTIFIES THAT</B>, for value received, &nbsp;&nbsp;&nbsp;&nbsp;, or their registered successors or
assigns (hereinafter, the &#147;<B>Holder</B>&#148;), is entitled to purchase, subject to the conditions set forth below, at any time or from time to time during the Exercise Period (as defined in subsection 1.1 below), (&nbsp;&nbsp;&nbsp;&nbsp;)
fully-paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares (the &#147;<B>Shares</B>&#148;) of the common stock, par value $0.001 per share (the &#147;<B>Common Stock</B>&#148;), of Heart Test Laboratories, Inc., a Texas corporation
(the &#147;<B>Company</B>&#148;), at an exercise price of $0.25 per share, subject to adjustment as provided in Section&nbsp;3 below (the &#147;<B>Exercise Price</B>&#148;). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXERCISE OF WARRANT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms and conditions upon which this Warrant may be exercised, and the Shares covered hereby may be purchased, are as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Exercise Period and Vesting</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) This Warrant is fully-vested as of the date of this Warrant. The exercise period of this Warrant is the period beginning on
the date of this Warrant and ending at 5:00 p.m., Dallas, Texas time, on &nbsp;&nbsp;&nbsp;&nbsp; (the &#147;<B>Exercise Period</B>&#148;). Exercise of the purchase rights represented by this Warrant may be made at any time or times on or during the
Exercise Period by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of such Holder appearing on the books of the Company) of a duly executed
facsimile copy of the Notice of Exercise in the form attached to this Warrant (the &#147;<B>Notice of Exercise</B>&#148;); provided, however, within three (3)&nbsp;Business Days after the date said Notice of Exercise is delivered to the Company, the
Holder shall have surrendered this Warrant to the Company, and, if the Holder has not elected to make a cashless exercise as provided below, the Company shall have received payment of the aggregate Exercise Price of the shares thereby purchased by
wire transfer or cashier&#146;s check drawn on a United States bank. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that Holder elects to make a cashless exercise as provided
above, the Company shall issue to Holder the number of shares of Common Stock equal to the result obtained by (i)&nbsp;subtracting B from A; (ii)&nbsp;multiplying the difference by C; and (iii)&nbsp;dividing the product by A, as set forth in the
following equation: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">X = <U>(A&#151;B) x C</U> where: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">A </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">X = the
number of Shares issuable upon a cashless exercise of the Warrant pursuant to the provisions of this Section&nbsp;1.1. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">A = the Fair Market
Value (as defined below) of one share of Common Stock on the date of the Notice of Exercise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">B = the Exercise Price for one Share under
this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">C = the number of Shares as to which this Warrant is being exercised. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If the foregoing calculation results in a negative number, then no Shares shall be issued upon a cashless exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) For the purpose of the above calculations, the &#147;<B>Fair Market Value</B>&#148; per share of Common Stock shall be,
(i)&nbsp;if the cashless exercise of the Warrant is in connection with a public offering of Common Stock, the public offering price (before deducting commission, discounts or expenses) at which the Common Stock is sold in such offering; (ii)&nbsp;if
a public market for the Common Stock exists at the time of such exercise, the average of the closing bid and asked prices of the Common Stock quoted in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Over-The-Counter</FONT></FONT> Market Summary or the last reported sale price of the Common Stock or closing price quoted on the NASDAQ National Market or on any exchange on which the
Common Stock is listed, whichever is applicable, as published in <I>The Wall Street Journal</I> for the five (5)&nbsp;trading days prior to the date of determination of fair market value; or (iii)&nbsp;if there is no public market for the Common
Stock, determined by the Company&#146;s Board of Directors in good faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 <U>Issuance Of Shares and New Warrant</U>. Certificates for
Shares purchased hereunder shall be delivered by the Company to Holder as soon as possible after delivery by Holder to the Company of the items described in Section&nbsp;1.1 above; provided, however, if the Company has appointed a transfer agent for
the Common Stock, then certificates for Shares shall be transmitted by the transfer agent of the Company to the Holder by crediting the account of the Holder&#146;s prime broker with the Depository Trust Company through its Deposit Withdrawal Agent
Commission (&#147;<B>DWAC</B>&#148;) system if the Company is a participant in such system, and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise within 3 trading days from the delivery to the Company of
the Notice of Exercise form, surrender of this Warrant and payment of the aggregate Exercise Price as set forth above (&#147;<B>Share Delivery Date</B>&#146;). This Warrant shall be deemed to have been exercised on the date the Exercise Price is
received by the Company. The Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such Shares for all purposes, as of the date the Warrant
has been exercised by payment to the Company of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section&nbsp;1.5 below prior to the issuance of such Shares, have been paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised
in part, the Company shall, at the time of delivery of the certificate or certificates representing Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Shares called for by this Warrant, which new
Warrant shall in all other respects be identical with this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 <U>No Fractional Shares or Scrip</U>. No fractional shares or
scrip representing fractional Shares shall be issued upon the exercise of this Warrant. As to any fraction of a Share which Holder would otherwise be entitled to purchase upon such exercise, the Company shall pay a cash adjustment in respect of such
final fraction in an amount equal to such fraction multiplied by the Exercise Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 <U>Charges. Taxes and Expenses</U>. Issuance of
certificates for Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such
certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event certificates for Shares are to be issued in a name other than the name of the Holder, this Warrant
when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder; and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax
incidental thereto. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSFERS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Sections 2.4, 5 and 6.1
below, this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company, together with the appropriate form of Assignment, as attached hereto, duly executed by the
Holder and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or
assignees and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. A
Warrant, if properly assigned, may be exercised by a new holder for the purchase of Shares without having a new Warrant issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be
issued, signed by the Holder or its agent or attorney. Subject to compliance with Section&nbsp;2.1, as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange
for the Warrant or Warrants to be divided or combined in accordance with such notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Warrant Register</U>. The Company shall register this Warrant, upon records to be
maintained by the Company for that purpose (the &#147;<B>Warrant Register</B>&#148;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for
the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the
transfer of this Warrant shall not be registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws, the Company may require, as a condition of allowing such transfer
(i)&nbsp;that the Holder or transferee of this Warrant, as the case may be, furnish to the Company a written opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the
effect that such transfer may be made without registration under the Securities Act and under applicable state securities or blue sky laws, (ii)&nbsp;that the Holder or transferee execute and deliver to the Company an investment letter in form and
substance acceptable to the Company, and (iii)&nbsp;that the transferee be an &#147;accredited investor&#148; as defined in Rule 501(a) of Regulation D promulgated under the Securities Act or a qualified institutional buyer as defined in Rule
144A(a) under the Securities Act. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ANTIDILUTION PROVISIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of this Section&nbsp;3 shall apply in the event that any of the events described in this Section&nbsp;3 shall occur with respect
to the Shares at any time on or after the original issuance date of this Warrant: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Splits and Combinations</U>. If the Company
shall at any time subdivide or combine its outstanding shares of Common Stock, this Warrant shall, after that subdivision or combination, evidence the right to purchase the number of shares that would have been issuable as a result of that change
with respect to the Shares which were purchasable under this Warrant immediately before that subdivision or combination. If the Company shall at any time subdivide the outstanding shares of Common Stock, the Exercise Price then in effect immediately
before that subdivision shall be proportionately decreased, and, if the Company shall at any time combine the outstanding shares, the Exercise Price then in effect immediately before that combination shall be proportionately increased. Any
adjustment under this Section shall become effective at the time that such subdivision or combination becomes effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2
<U>Reclassification, Exchange and Substitution</U>. If the Shares issuable upon exercise of this Warrant shall be changed into the same or a different number of securities of any other class or classes of stock, whether by capital reorganization,
reclassification, or otherwise (other than a subdivision or combination of shares provided for above), the Holder of this Warrant shall, on its exercise, be entitled to purchase for the same aggregate consideration, in lieu of the Shares which the
Holder would have become entitled to purchase but for such change, the number of securities of such other class or classes of stock equivalent to the number of Shares that would have been subject to purchase by the Holder on exercise of this Warrant
immediately before that change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Reorganizations, Mergers, Consolidations Or Sale Of Assets</U>. If at any time there
shall be a capital reorganization of the shares of Common Stock (other than a combination, reclassification, exchange, or subdivision of shares provided for elsewhere above) then, as a part of such reorganization, lawful provision shall be made so
that the Holder of this Warrant shall thereafter be entitled to receive upon exercise of this Warrant, during the period specified in this Warrant and upon payment of the Exercise Price then in effect, the number of shares or other securities or
property of the Company to which a holder of the Shares deliverable upon exercise of this Warrant would have been entitled in such capital reorganization if this Warrant had been exercised immediately before that capital reorganization. In any such
case, appropriate adjustment (as determined in good faith by the Company&#146;s Board of Directors) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder of this Warrant after the
reorganization to the end that the provisions of this Warrant (including adjustment of the Exercise Price then in effect and number of Shares purchasable upon exercise of this Warrant) shall be applicable after that event, as near as reasonably may
be, in relation to any shares or other property deliverable after that event upon exercise of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 <U>Distributions</U>. In
the event the Company should at any time prior to the expiration of this Warrant fix a record date for the determination of the holders of shares entitled to receive a distribution payable in additional shares of Common Stock or other securities or
rights convertible into or entitling the holder thereof to receive, directly or indirectly, additional shares of Common Stock (hereinafter referred to as the &#147;<B>Share Equivalents</B>&#148;) without payment of any consideration by such holder
for the additional shares (including the additional shares issuable upon conversion or exercise thereof), then, as of such record date (or the date of such distribution, split or subdivision if no record date is fixed), the Exercise Price shall be
appropriately decreased and the number of Shares issuable upon exercise of the Warrant shall be appropriately increased in proportion to such increase of outstanding shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5 <U>Adjustments of Other Distributions</U>. In the event the Company shall declare a distribution payable in securities of other persons,
evidences of indebtedness issued by the Company or other persons, assets (excluding cash dividends) or options or rights not referred to in Section&nbsp;3.4 above, then, in each such case for the purpose of this Section&nbsp;3.5, upon exercise of
this Warrant the Holder hereof shall be entitled to a proportionate share of any such distribution as though such Holder was the holder of the number of Shares into which this Warrant may be exercised as of the record date fixed for the
determination of the holders of shares entitled to receive such distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6 <U>Certificate as to Adjustments</U>. In the case of
each adjustment or readjustment of the Exercise Price pursuant to this Section&nbsp;3, the Company will promptly compute such adjustment or readjustment in accordance with the terms hereof and cause a certificate setting forth such adjustment or
readjustment and showing in detail the facts upon which such adjustment or readjustment is based, to be delivered to the Holder of this Warrant. The Company will, upon the written request at any time of the Holder of this Warrant, furnish or cause
to be furnished to such Holder a certificate setting forth: (a)&nbsp;such adjustments and readjustments; (b)&nbsp;the Exercise Price at the time in effect; and (c)&nbsp;the number of Shares issuable upon exercise of the Warrant and the amount, if
any, of other property at the time receivable upon the exercise of the Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7 <U>Reservation of Shares Issuable Upon Exercise</U>. The Company shall at all times
reserve and keep available out of its authorized but unissued shares of Common Stock solely for the purpose of effecting the exercise of this Warrant such number of shares of Common Stock as shall from time to time be sufficient to effect the
exercise of this Warrant and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the exercise of this Warrant, in addition to such other remedies as shall be available to the Holder of this
Warrant, the Company will use its best efforts to take such action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RIGHTS PRIOR TO EXERCISE OF WARRANT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Warrant does not entitle the Holder to any of the rights of a shareholder of the Company. If, however, at any time prior to the expiration
of this Warrant and prior to its exercise, any of the following events shall occur: (a)&nbsp;the Company shall make any distribution (other than a cash distribution) to the holders of shares of Common Stock; (b)&nbsp;the Company shall offer to all
of the holders of shares of Common Stock any additional shares or Share Equivalents or any right to subscribe for or purchase any thereof; or (c)&nbsp;a dissolution, liquidation or winding up of the Company (other than in connection with a
consolidation, merger, sale, transfer or lease of all or substantially all of its property, assets, and business as an entirety) shall be proposed and action by the Company with respect thereto has been approved by the Company&#146;s Board of
Directors (each, a &#147;<B>Material Action</B>&#148;), the Company shall give notice in writing of such Material Action to the Holder at its last address as it shall appear on the Company&#146;s records at least twenty (20)&nbsp;days&#146; prior to
the date fixed as a record date or the date of closing the transfer books for the determination of the shareholders entitled to such dividends, distribution, or subscription rights, or for the determination of shareholders entitled to vote on the
Material Action. Such notice shall specify such record date or the date of closing the transfer books, as the case may be. Failure to publish, mail or receive such notice or any defect therein or in the publication or mailing thereof shall not
affect the validity of the Material Action. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RESTRICTED SECURITIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Holder acknowledges that the Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions upon resale
imposed by state and federal securities laws. In order to enable the Company to comply with the Securities Act and applicable state laws, the Company may require the Holder as a condition of the transfer or exercise of this Warrant, to give written
assurance satisfactory to the Company that the Warrant, or in the case of an exercise hereof the Shares subject to this Warrant, are being acquired for his or her own account, for investment only, with no view to the distribution of the same, and
that any disposition of all or any portion of this Warrant or the Shares issuable upon the due exercise of this Warrant shall not be made, unless made in compliance with the requirements of the Securities Act and applicable securities laws of any
State or other jurisdiction. Holder acknowledges that this Warrant is, and each of the Shares issuable upon the due exercise hereof will be, a restricted security, and that the certificates evidencing securities issued to the Holder upon exercise of
this Warrant will bear a legend substantially similar to the legend set forth on the front page of this Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>Title to Warrant</U>. During the Exercise Period, and subject to compliance with applicable laws and Section&nbsp;2.4 above, this
Warrant and all rights hereunder are transferable, in whole or in part, at the office of the Company by the Holder, upon surrender of this Warrant together with the appropriate Assignment form attached hereto properly endorsed. To the extent
Section&nbsp;2.4 above is applicable, the transferee shall sign an investment letter in form and substance reasonably satisfactory to the Company, if required by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Loss Theft Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of
such cancellation, in lieu of such Warrant or stock certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Saturdays, Sundays, Holidays, Etc</U>. If the last or appointed
day for the taking of any action or the expiration of any right required or granted herein shall be a Saturday, Sunday or a legal holiday, then such action may be taken or such right may be exercised on the next succeeding day not a Saturday, Sunday
or legal holiday. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4 <U><FONT STYLE="white-space:nowrap">Non-Waiver</FONT> and Expenses</U>. No course of dealing or any delay or
failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice Holder&#146;s rights, powers or remedies, notwithstanding the fact that all rights hereunder terminate upon expiration of
the Exercise Period. If the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts as shall be sufficient to cover any
costs and expenses including, but not limited to, reasonable attorneys&#146; fees, including those of appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise; enforcing any of its rights, powers or
remedies hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 <U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by Holder to
exercise this Warrant or purchase Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase price of any Common Stock or as a shareholder of the Company, whether such
liability is asserted by the Company or by creditors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6 <U>Remedies</U>. Holder, in addition to being entitled to
exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason
of a breach by it of the provisions of this Warrant and hereby agrees to waive the defense in any action for specific performance that a remedy at law would be adequate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7 <U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and
the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of all
Holders from time to time of this Warrant and shall be enforceable by any such Holder or holder of Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8 <U>Amendment</U>. This
Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable
law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.10 <U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a
part of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.11 <U>Notices</U>. All notices, requests, demands and other communications under this Warrant shall be in writing
and shall be deemed to have been duly given on the date of service if served personally on the party to whom notice is to be given, or on the date of mailing if mailed to the party to whom notice is to be given, by first class mail, registered or
certified, postage prepaid, and properly addressed as follows: if to the Holder, at his address as shown in the Company records; and if to the Company, at 9 Village Circle, Suite 527, Westlake, Texas 76262, Attention: Chief Executive Officer. Any
party may change its address for purposes of this Section by giving the other party written notice of the new address in the manner set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.12 <U>Governing Law</U>. This Warrant and any dispute, disagreement or issue of construction of interpretation arising hereunder whether
relating to its execution, its validity, the obligations provided herein or performance shall be governed or interpreted according to the internal laws of the State of Texas without regard to conflicts of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>EXECUTED</B> as of the date first set forth above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HEART TEST LABORATORIES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Mark Hilz,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">TO:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">HEART TEST LABORATORIES, INC. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) The undersigned hereby elects to purchase __________ Shares (the &#147;<B>Exercised Shares</B>&#148;) pursuant to the terms of the
attached Warrant, and tenders herewith payment of the aggregate Exercise Price for the Exercised Shares, together with all applicable transfer taxes, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) Please issue a certificate or certificates representing the Exercised Shares in the name of the undersigned or in such other name as is
specified below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Exercised Shares shall be delivered to the
following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) All terms used herein but
not otherwise defined shall have the meanings ascribed thereto in the attached Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Date:________________________. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>If an individual:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>If a legal entity:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">(type in name)</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Title:</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ASSIGNMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED ___________________________ hereby sells, assigns and transfers unto _______________________ the within Warrant and all
rights evidenced thereby and does irrevocably constitute and appoint __________________________, attorney, to transfer the said Warrant on the books of the within named Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dated:________________________. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>If an individual:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>If a legal entity:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">(type in name)</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Title:</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PARTIAL ASSIGNMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED ______________________________ hereby sells, assigns and transfers unto _______________________________ that portion of the
within Warrant and the rights evidenced thereby which will an the date hereof entitle the holder to purchase __________ shares of Common Stock of Heart Test Laboratories, Inc., and does hereby irrevocably constitute and appoint
__________________________ and ______________________, or either of them, attorney, to transfer that part of the said Warrant on the books of the within named Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dated:_________________________. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>If an individual:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>If a legal entity:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">(type in name)</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt">Title:</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.1 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>2013 TECHNOLOGY AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS 2013 TECHNOLOGY AGREEMENT (the <B>&#147;Agreement&#148;) </B>is made and entered into as of the 31<I> </I>day of December, 2013 (the
<B>&#147;Effective Date&#148;) </B>by and between <B>GUANGREN &#147;GARY&#148; CHEN, </B>an individual U.S. citizen <B>(&#147;Chen&#148;) </B>and <B>HEART TEST LABORATORIES, INC., </B>a Texas corporation having its principal place of business at
5712 Colleyville Blvd., Suite 229, Colleyville, Texas 76034 <B>(&#147;HTL&#148;)</B>.<B> </B>Chen and HTL are sometimes referred to herein individually as a &#147;Party&#148; and, collectively, as the &#147;Parties.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Chen
conceived and developed certain heart scanning devices and technologies related to products trademarked as the MyoVista as defined herein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Chen and HTL previously entered into a series of license agreements and amendments thereto (the &#147;Prior Agreements&#148;)
regarding rights to the previously described heart scanning devices and technologies developed by Chen as defined herein relating to commercialization of MyoVista; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties wish to enter into a new agreement, superseding all prior, enforceable agreements between them concerning their
respective rights in and to the technology conceived and developed by Chen including the MyoVista technology and related proprietary and intellectual property rights; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Chen wishes to transfer and HTL wishes to receive (i)&nbsp;an exclusive license to the technology, proprietary and intellectual
property rights as defined herein relating to MyoVista and (ii)&nbsp;all rights, title, and interest in and to such technology relating to MyoVista over time and upon the occurrence of certain events and achievement of certain milestones in the
furtherance of HTL&#146;s business objectives; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Chen wishes to retain certain rights and interests, with the possible return
of title in and to the MyoVista technology and related proprietary and intellectual property rights, until HTL demonstrates the continuing viability of its business through the occurrence of certain events. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for and in consideration of the mutual promises, covenants and agreements herein contained, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged by the Parties, the Parties, intending to be legally bound, hereby agree as follows: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Definitions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.1</B> <B>Defined Terms.
</B>For purposes of this Agreement, any term defined in a provision of this Agreement shall have the meaning given such term therein and the following terms shall have the respective meaning set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> <B>&#147;Affiliate&#148; </B>means any Person as defined below who, directly or indirectly, controls, is controlled by, or is under
common control with, another person; for purposes of this definition, &#147;control&#148; means the possession by such a person or entity, directly or indirectly (including through or with one or more other persons pursuant to agreement or binding
obligation among them), of the power to direct or cause the direction of the management and policies of another person or entity, or to vote or dispose of the controlling voting equity of an entity, whether through ownership of securities, or by
agreement. Notwithstanding the effect of any provision or provisions herein, for purposes of this Agreement and the rights and obligations of the Parties hereunder, Chen is not an Affiliate of HTL, and HTL is not an Affiliate of Chen, and there is
no Affiliate relationship between or among any party to that certain Voting Agreement Among Shareholders of Heart Test Laboratories, Inc., dated May&nbsp;2, 2013, and each such party is not an Affiliate of HTL or of any other shareholder of HTL.
Neither Jiali Medical nor Med Care is an Affiliate of Chen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> <B>&#147;Agreement&#148; </B>means this 2013 Technology Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> <B>&#147;Applicable Law&#148; </B>means, with respect to any person or entity, any federal, state or local law (statutory,
common or otherwise), constitution, treaty, convention, ordinance, code, rule, regulation, order, injunction, judgment, decree, ruling or other similar requirement enacted, adopted, promulgated or applied by a Governmental Authority that is binding
upon or applicable to such Person, as amended unless expressly specified otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> <B>&#147;Assignment Event&#148; </B>has
the meaning given such term in Section&nbsp;2.7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)</B> <B>&#147;Chen&#148; </B>has the meaning given the term in the Preamble of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B> <B>&#147;Confidential Information&#148; </B>means technical or business information disclosed by a Party to
the other Party pursuant to this Agreement that is identified in writing at the time of disclosure or within thirty (30)&nbsp;days thereafter as being confidential and proprietary to the disclosing Party. No information will be regarded as
Confidential Information if the receiving Party can show by competent proof that such information (i)&nbsp;was, at the time of disclosure to the receiving Party, already known to the receiving Party, as shown by written records in the possession of
the receiving Party, or (ii)&nbsp;was at the time of disclosure, or subsequently became, through no fault of the receiving Party, known to the general public through publication or otherwise, or (iii)&nbsp;was, subsequent to disclosure to the
receiving Party, lawfully and independently received by the receiving Party from a Third Party who had the right to disclose it without restriction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g)</B> <B>&#148;Consultant&#148; </B>means a Person that is under contract with HTL or
any of its Affiliates to assist HTL or its Affiliates with the manufacture, production, maintenance, repair, sale, distribution, support or development of HTL&#146;s or its Affiliate&#146;s products and services for sale by or on behalf of HTL or
its Affiliate and who agrees to be bound by confidentiality agreement pursuant to section 6.1.13 of this Agreement. For the avoidance of doubt, any rights under a sublicense granted hereunder to a Person in its capacity as a Consultant are for the
Consultant to perform his duties and only to the extent necessary for such Person in its capacity as a Consultant for HTL or its Affiliate to perform his duties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h)</B> <B>&#147;Copyright&#148; </B>means and includes all rights to works of authorship under the prevailing laws of the United States or
any other applicable jurisdiction, whether or not registered, including all registrations and applications therefore and all moral rights related thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B>&#147;Covered Technology&#148; </B>means MyoVista Hardware, MyoVista Software, and Technical Information, including MyoVista
Updates and related Documentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j)</B> <B>&#147;Customer&#148; </B>means any lessee,
<FONT STYLE="white-space:nowrap">end-user</FONT> purchaser or customer of any product or service of HTL or any of its Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k)</B> <B>&#147;Documentation&#148; </B>means all manuals, user guides, instructions, specifications, and drawings and similar information
or materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)</B> <B>&#147;Effective Date&#148; </B>means the date of closing of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m)</B> <B>&#147;Exclusive License&#148; </B>means the license granted to&middot;HTL by Chen as provided in section 2.1 of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)</B> <B>&#147;Final Transfer Event&#148; </B>has the meaning given such term in Section&nbsp;2.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o)</B> <B>&#147;Governmental Authority&#148; </B>means any transnational, domestic or foreign federal, state or local, governmental
authority, department, court, agency or official, including any political subdivision thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p)</B> <B>&#147;Gross Sale Price&#148;
</B>means the actual gross amount received by HTL for Sale of a MyoVista Device to an end user Customer purchasing the MyoVista Device for use, deducting therefrom only direct costs of packing materials for shipment, costs of insurance and
transportation to ship, and any and all import, export, excise, sales and value added taxes and customer duties levied or imposed directly upon the Sale of the MyoVista Device that HTL remits to the government body levying or imposing such taxes or
duties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q)</B> <B>&#147;HTL&#148; </B>has the meaning given the term in the Preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r)</B> <B>&#147;Intellectual Property Rights&#148; </B>means any and all rights under any and all of the following that directly relate to
the Covered Technology: (i)&nbsp;inventions, discoveries and ideas, whether patentable or not in any jurisdiction, computer software (including software, data, and related Documentation); (ii) copyrighted writings or other copyrightable works ,
whether or not registered in any jurisdiction, registrations or applications for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration of copyrights in any jurisdiction, and any renewals or extensions thereof; (iii)&nbsp;trademarks, service marks, brand names certification marks, trade dress, assumed names, trade
names and other indications of origin, and registrations and applications for the foregoing, together with the goodwill associated therewith; (iv)&nbsp;trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> (including research and
development, formulas, compositions, manufacturing and production processes and techniques, technical data, designs, drawings and specifications) and rights in any jurisdiction to limit the use or disclosure thereof; (v)&nbsp;all renewals and
extensions of the foregoing; and (vi)&nbsp;the Intellectual Property Rights include all rights under the Patents and Patent Applications, the Trademark Rights, the Copyrights, and the Trade Secrets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s)</B> <B>&#147;MyoVista Device&#148; </B>means the unitary system developed by Dr.&nbsp;Chen as of the Effective Date, fully operational
as a unit, for <FONT STYLE="white-space:nowrap">non-invasively</FONT> diagnosing abnormalities of the ventricular myocardium by measurement and analysis of electrical heart signals using a <FONT STYLE="white-space:nowrap">non-linear</FONT> 2D
waveform presented using color image elements including Icon and Index to identify abnormalities and for measuring the ratio between the strength (energy) of the left ventricle as compared to the strength (energy) of the right ventricle. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t)</B> <B>&#147;MyoVista Hardware&#148; </B>means systems, devices, system interfaces, components, used in the MyoVista Device, in whole
and part, for <FONT STYLE="white-space:nowrap">non-invasively</FONT> diagnosing abnormalities of the myocardium using measurement and analysis of electrical signals, including the MyoVista Device itself. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u)</B> <B>&#147;MyoVista Software&#148; </B>means any software product or code (object, source, machine and other), formulas, algorithms,
specifications, software interfaces, user interfaces, software methods and processes for diagnosing abnormalities of the myocardium using measurement and analysis of electrical signals for use with the MyoVista Hardware, in whole or part, including
2D color elements and Icon and Index, including such product, codes, formulas, algorithms, specifications, interfaces, methods and processes for operating, testing or using any MyoVista Device. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v)</B> <B>&#147;Pass-Through Rights&#148; </B>means, with respect to the Intellectual Property Rights (including patents and other
proprietary rights and interests) granted under this Agreement, the right or ability for a licensee to pass on to a customer in each jurisdiction those explicit license, implied license, and patent (or other proprietary rights and interests, as
applicable) exhaustion rights which the customer would receive as a matter of law in such jurisdiction under a licensor&#146;s licensed patents (and other proprietary rights and interests) as to a licensed product purchased from the licensee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)</B> <B>&#147;Patent&#148; </B>or <B>&#147;Patents&#148; </B>means any and all U.S. or any other country patents, patents to be issued
pursuant to any Patent Application, and all divisions, continuations, <FONT STYLE="white-space:nowrap">continuations-in-part,</FONT> reissues, substitutes, and extensions thereof, for any Covered Technology, including those Patents as of the
Effective Date for the MyoVista Device listed in attached Exhibit <FONT STYLE="white-space:nowrap">A-1.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x)</B> <B>&#147;Patent Application&#148; </B>or <B>&#147;Patent Applications&#148;
</B>mean(s) any and all applications for patent filed in the U.S. or any other country for any Covered Technology, including those Patent Applications as of the Effective Date for the MyoVista Device listed in Exhibit
<FONT STYLE="white-space:nowrap">A-1.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y)</B> <B>&#147;Person&#148; </B>means an individual, corporation, partnership, limited
liability company, association, trust or other entity or organization, including a Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z)</B>
<B>&#147;Representative Parties&#148; </B>means, with respect to any Party, each of the Party&#146;s Affiliates and Consultants, and each of the officers, employees, agents and representatives of the Party and its Affiliates and Consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa) &#147;Sold,&#148; &#147;Sale,&#148; &#147;Sell&#148; </B>means sold, leased, licensed or otherwise transferred to a Customer or Third
Party for profit or use in return for monetary remuneration or other valuable consideration, and a Sale shall be deemed to have occurred only upon actual receipt of payment from the Customer or other Third Party; provided, any use, shipment,
transfer, or other disposition for developmental, research, testing, lab, inventory, scientific or for which HTL, and its Affiliates, do not charge remuneration or charge only nominal consideration from a Customer or Third Party are excluded from
and deemed not within the definition; further provided, any use, shipment, transfer, or other disposition to or by HTL, its Affiliates, or its or their Consultants which are not a Customer, is excluded from and deemed not within the definition
unless HTL actually receives payment from a Customer or other Third Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb) &#147;Technical Information&#148; </B>means any and
all unpublished research and development information, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, works of authorship, software (whether in source or object code form), designs, conceptions, inventions, instructions, techniques,
formulae, systems interfaces, user interfaces, specifications, data, schematics, research or development documentation, and technical data reduced to and fixed in some tangible medium or other transferrable form that (i)&nbsp;describes, directly
relates to or was used in developing any Covered Technology; or (ii)&nbsp;is used for or to direct or instruct the production, manufacture, operation, maintenance, repair, sale, or use of the Covered Technology, or to train to use, operate, maintain
or repair the MyoVista Device, including that Technical Information as of the Effective Date for the MyoVista Device listed on Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT> attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc) &#147;Third Party&#148; </B>means any person other than Chen or HTL, or any Affiliate of Chen or HTL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(<B>dd) &#147;Trade Secret&#148; </B>means any and all information directly related to the Covered Technology or Technical Information,
whether or not in tangible form, which derives economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use and
which is the subject of efforts that are reasonable under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
circumstances to maintain its secrecy. Without limiting the generality of the foregoing, Trade Secrets will include but are not limited to studies, results, reports, marketing strategies,
technical or nontechnical data, formulae, techniques, drawings, designs, source codes, algorithms, processes, financial data, financial plans, product plans, marketing plans, advertising plans, lists of actual or potential customers or suppliers,
and related items, and include those Trade Secrets as of the Effective Date for the MyoVista Device listed on Exhibits <FONT STYLE="white-space:nowrap">A-1</FONT> and <FONT STYLE="white-space:nowrap">A-2</FONT> attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee) &#147;Trademark Rights&#148; </B>means any and all trade dress, trade names, logos, domain names, trademarks, and service marks,
whether or not registered, together with all translations, adaptations, derivations, and combinations thereof, together with all rights, title and interest thereto, and including all goodwill associated therewith, and all applications,
registrations, reservations, and renewals in connection therewith for the MyoVista Device including the MyoVista<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> mark and registrations of such mark, if any, together with the goodwill of
the business associated with the mark. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff) &#147;MyoVista Updates&#148; </B>means upgrades, modifications, improvements,
enhancements, new versions, new releases, new firmware, corrections and/or derivative works (including any error corrections, patches and bug fixes) with respect to the Covered Technology. For the avoidance of doubt, Chen shall not be required under
this Agreement to develop MyoVista Updates; however, developments of Chen, if any, that would qualify as MyoVista Updates under the definition shall be included in the meaning. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.2 Interpretation. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2.1 Whenever in this Agreement the
terms &#147;include,&#148; &#147;includes,&#148; &#147;including,&#148; and derivative or similar words are used, they will be construed to be followed by the phrase &#147;without limitation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2.2 Wherever in this Agreement a statute or other legislation is referenced, such reference will be deemed to include any and all amendments thereto, as
well as any successor legislation which may be adopted subsequent to the Effective Date, covering the same subject matter of the referenced statute or legislation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2.3 Whenever in this Agreement the term &#147;party to&#148; is used in regard to an agreement, it will be construed as meaning &#147;party signatory to or
bound by&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2.4 Wherever in this Agreement reference is made to an exhibit (or Exhibit) &#147;hereof&#146;, or &#147;attached hereto,&#148; the
contents of such exhibit will be deemed to be incorporated into this Agreement by reference, as an integral and material part of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2.5
The headings of the Articles and Sections of this Agreement are inserted for convenience of reference only and will not constitute a part hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2.6 Each reference in this Agreement to an Article, Section or Exhibit, unless otherwise indicated, will
mean an Article or Section of this Agreement or an Exhibit attached to this Agreement, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2.7 Whenever in this Agreement the terms
&#147;hereof,&#148; &#147;herein,&#148; &#147;hereby&#148;, or derivative or similar words are used, such terms refer to this entire Agreement, including each Exhibit attached hereto, as the same may be amended or modified from time to time during
the Term hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2.8 All references herein to &#147;days&#148; in this Agreement are to consecutive calendar days unless business days are specified.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2.9 Whenever in this Agreement the singular is used, it will include the plural if the context so requires, and whenever the masculine gender is used
in this Agreement, it will be construed as if the masculine, feminine or neuter gender, respectively, has been used where the context so dictates, with the rest of the sentence being construed as if the grammatical and terminological changes thereby
rendered necessary have been made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2.10 The language in all parts of this Agreement will in all cases be construed as a whole according to its fair
meaning, strictly neither for nor against any Party hereto, and without implying a presumption that the terms thereof will be more strictly construed against one Party by reason of the rule of construction that a document is to be construed more
strictly against the person who prepared the same, it being agreed that representatives of both Parties have equally participated in the preparation and negotiation hereof. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Covered
Technology Transfers </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B>Grant of Exclusive License to HTL. </B>Subject to the terms and conditions of this Agreement, Chen hereby grants
to HTL and its Affiliates an exclusive, worldwide right and license under the Intellectual Property Rights, to make, have made, use, sell, offer to sell, have sold, import and commercialize, exploit, legally dispose of, and otherwise provide
products and services that incorporate, utilize, integrate, or embody the Covered Technology, and to use, copy, reproduce, perform, display, distribute, modify and make derivative works of the Covered Technology. HTL and its Affiliates may
sublicense the rights granted in the preceding sentence to any Consultant for the purpose of furthering HTL&#146;s efforts to commercialize the Covered Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.1.1 Chen&#146;s grant to HTL and its Affiliates includes (i)&nbsp;all rights to sue or make any claims for any past, present or future infringement,
misappropriation or unauthorized use of any of the Covered Technology and Intellectual Property Rights therein; and (ii)&nbsp;subject to Chen&#146;s secured right to receive Royalties under this Agreement, all rights to all income, royalties,
damages, and other payments from Third Parties that are now or may hereafter, while HTL is licensed: become due or payable with respect to the Covered Technology and Intellectual Property Rights therein, including damages and other amounts for past,
present or future infringement, misappropriation or unauthorized use thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.1.2 Chen&#146;s grant to HTL does not include a right to use Chen&#146;s name (including &#147;Gary
Chen&#148; or &#147;Guangren Chen&#148;) except as may be separately agreed to in writing signed by the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.1.3. Nothing in this Agreement shall
prohibit Chen from performing or undertaking research and development of any medical devices or products independently and outside of this Agreement and the Covered Technology. Furthermore, Chen is &middot;permitted to develop any technology or
device that does not compete with the MyoVista Device licensed hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.1.4 The licenses set forth in Section&nbsp;2.1 are intended to be sufficient
to and include the right for HTL, its Affiliates, and its and their Consultants, to convey Pass-Through Rights during the term of the Exclusive License, to their respective customers (including, without limitation, to such customers who are
HTL&#146;s distributors, original equipment manufacturers (OEMs), resellers, joint venturers, and associated persons and entities) of MyoVista Devices or Covered Technology to the extent of patent or other proprietary right exhaustion under U.S.
law; provided, however, that (i)&nbsp;exhaustion will be deemed to occur regardless of the country or jurisdiction in which such MyoVista Devices or Covered Technology are Sold, and (ii)&nbsp;if the law of the country or jurisdiction in which such
MyoVista Devices or Covered Technology are imported, Sold, or otherwise disposed of provides broader Pass-Through Rights than patent exhaustion under U.S. law, then such broader Pass-Through Rights shall apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B>Assignment Event. </B>The first to occur of any of the following shall be an &#147;Assignment Event&#148; under this Agreement, upon which, as
provided in Section&nbsp;3.5, the Assignment (as defined in Section&nbsp;3.2.5) shall be released and delivered to HTL from the Escrow (as defined in Section&nbsp;3.5), provided that HTL is not in Default under this Agreement or any exhibits: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The receipt by HTL within twenty four (24)&nbsp;months after the Effective Date of not less than two million dollars ($2,000,000)
earmarked for regular business operations and not used to retire existing convertible notes; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Execution of an agreement by all
necessary parties for the sale by HTL and purchase by a Third Party of substantially all of the assets of HTL where such Third Party (or its ultimate parent undertaking) has a fair market value or assets exceeding liabilities of at least ten million
dollars ($10,000,000) certified under U.S. GAAP, and assumes all of HTL&#146;s obligations hereunder; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The closing of an
acquisition of substantially all of the outstanding shares of HTL stock by a Third Party (or its ultimate parent undertaking) having a current fair market value or assets exceeding liabilities of at least ten million dollars ($10,000,000) certified
under U.S. GAAP, and assuming all of HTL&#146;s obligations hereunder; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Chen&#146;s receipt under this Agreement of aggregate Royalty payments of at least three
million dollars ($3,000,000), exclusive of the 448K Secured Promissory Note (as defined in Section&nbsp;3.1.1); provided, notwithstanding anything to the contrary, HTL has the right, in its sole discretion and from time to time, to make prepayment
of any such aggregate Royalty amount; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) HTL being publicly listed and the value of twelve (12)&nbsp;million common shares in HTL
(being the approximate number that Chen and Cheryl Yang own on the Effective Date of this Agreement), adjusted for any share split or consolidation (&#147;Initial Shares&#148;), is at least twenty five million dollars ($25,000,000) (such value to be
calculated by reference to the quoted closing share price); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Chen and/or Cheryl Yang (either in combination or individually) sell
or transfer, in any one or more transaction, any common stock in HTL for aggregate value of at least twenty five million dollars ($25,000,000); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) HTL&#146;s receipt of a bona fide offer (or offers, whether in a single or more than one transaction) to acquire common stock in HTL from
Chen and/or Cheryl Yang (in combination or individually) for aggregate value of at least twenty five million dollars ($25,000,000); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) In the event that Chen and/or Cheryl Yang have sold or transferred any common stock in HTL such that they no longer own all of the Initial
Shares, HTL&#146;s receipt of a bona fide offer to acquire at least a number of shares of common stock in HTL that equals or exceeds Chen and Cheryl Yang&#146;s then-current level of ownership calculated as a percentage of total shares outstanding
which, if Chen then remained owner of all the Initial Shares, would have valued the Initial Shares, in aggregate, at a value of at least twenty five million dollars ($25,000,000); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>Final Transfer Event. </B>The first to occur of any of the following shall be a &#147;Final Transfer Event&#148; under this Agreement, upon
which, as provided in Section&nbsp;3<I>.5, </I>the Security Interest Release (as defined in Section&nbsp;3.1.3), and if then remaining in the Escrow, also the Assignment, shall be released and delivered to HTL from the Escrow, provided an Event of
Default of this Agreement or any exhibits thereto or notes by HTL has not occurred: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Chen&#146;s receipt under this Agreement of
aggregate Royalty payments of at least three million dollars ($3,000,000) and payment of the 448K Secured Promissory Note; provided, notwithstanding anything to the contrary, HTL has the right, in its sole discretion and from time to time, to make
prepayment of any such amounts; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) HTL being publicly listed and the value of shares totaling the number of the Initial
Shares, is at least twenty five million dollars ($25,000,000) (such value to be calculated by reference to the quoted closing share price); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Chen transfers, in any one or more transaction, any common stock in HTL for aggregate value of at least twenty five million dollars
($25,000,000); or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) HTL&#146;s receipt of a bona fide offer (or offers, whether in a single or more than one transaction) to acquire
common stock in HTL from Chen and/or Cheryl Yang (in combination or individually) for aggregate value of at least twenty five million dollars ($25,000,000); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) In the event that Chen and/or Cheryl Yang have sold or transferred any common stock in HTL such that they no longer own all of the Initial
Shares, HTL&#146;s receipt of a bona fide offer to acquire at least a number of shares of common stock in HTL that equals or exceeds Chen and Cheryl Yang&#146;s then-current level of ownership calculated as a percentage of total shares outstanding
which, if Chen and Cheryl Yang then remained owners of all the Initial Shares, would have valued the Initial Shares, in aggregate, at a value of at least twenty five million dollars ($25,000,000). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.3.1 For the avoidance of doubt, a Final Transfer Event also constitutes an Assignment Event. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Payments
and Deliveries </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.1 Deliveries by HTL. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.1.1
<U>Secured Promissory Notes</U>. On the Effective Date, HTL shall provide to Chen executed promissory notes in the form of Exhibit <FONT STYLE="white-space:nowrap">B-1</FONT> (&#147;448K Secured Promissory Note&#148;) and an executed promissory note
in the form of Exhibit <FONT STYLE="white-space:nowrap">B-3</FONT> (&#147;700K Secured Convertible Promissory Note&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.1.2 <U>Additional Convertible
Notes</U>. On the Effective Date, HTL shall provide to Chen a convertible promissory note in form attached hereto as Exhibit <FONT STYLE="white-space:nowrap">B-2</FONT> (&#147;300K Convertible Note&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.1.3 <U>Security Interest</U>. As of the Effective Date, HTL shall execute and deliver the Security Agreement and Pledge attached hereto as Exhibit <FONT
STYLE="white-space:nowrap">A-3</FONT> (&#147;Security Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.1.4 <U>Secured Royalty to Chen</U>. In addition to the notes pursuant to
Sections 3.1.1 and 3.1.2, HTL shall pay Chen a royalty for each MyoVista Device Sold (the &#147;Royalty&#148;) according to the following schedule: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">$500 on each of the first 2400 MyoVista Devices </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">$200 on each MyoVista Device thereafter until total Royalties under this schedule total $3,500,000.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HTL shall make Royalty payments, on a calendar quarterly basis, in arrears for each immediately preceding calendar quarter, and shall
deliver to Chen, within thirty (30)&nbsp;days of the last day of each such preceding calendar quarter, a report of the number of MyoVista Devices that were Sold (including by Affiliates) during such preceding calendar quarter and the Gross Sale
Price of each MyoVista Device so Sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon reasonable notice at least three (3)&nbsp;business days in advance, Chen (at his cost and expense) shall have
the right, during normal business hours of HTL and no more than twice each calendar year, to audit HTL&#146;s books and records regarding the Royalty payable under this paragraph, which books and records HTL shall keep in accordance with U.S. GAAP,
so that Chen can verify the Royalty paid under this Section&nbsp;3.1.4. Any underpayment of Royalty bears interest from the date due until the date paid at a 5% annual rate. If the audit reveals an underpayment of $5,000 or more, Chen is entitled to
recover reimbursement of costs incurred for the audit. If the audit reveals an overpayment, Chen shall immediately refund the overpaid amount to HTL. Any successor to HTL, including a buyer of HTL&#146;s assets or stock, or any Third Party acquiring
the business or Covered Technology of HTL shall be bound by this Section and shall assume all Royalty obligations hereunder. Such assumption shall survive any bankruptcy proceeding, and obligate any successor, or subsequent owner of the Intellectual
Property Rights and Covered Technology conveyed to HTL, to HTL&#146;s Royalty payment obligations. In the event of any recovery from litigation arising from unauthorized use of the Intellectual Property Rights or Covered Technology or any other
transferred technology under this Agreement, HTL shall pay to Chen a 2.5% royalty on all net proceeds or the cash equivalent of any <FONT STYLE="white-space:nowrap">non-cash</FONT> proceeds, assets, or things of value received through settlement of
litigation or negotiation. The payment obligations of HTL under Sections 3.1.1, 3.1.2 and 3.1.4 shall continue regardless of whether any Patent is determined to be invalid or unenforceable of any Intellectual Property Right is determined to be
unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.1.5 <U>Agreement Securing Royalty Obligation</U>. The Security Agreement (Exhibit <FONT STYLE="white-space:nowrap">A-3)</FONT> shall
provide and the Parties expressly agree that without regard to whether any MyoVista Device is Sold, the Royalty obligation hereunder constitutes a secured right to receive aggregate payments in the amount of $3,000,000.00, payment of which is a
material inducement to Chen conveying the Intellectual Property Rights and Covered Technology to HTL. Chen&#146;s right to receive such payments is a secured obligation of HTL in the amount of $3,000,000 with the remaining $500,000 obligation being
unsecured, and a lien shall remain on all secured property unless and until the amount is paid in full or a Final Transfer Event has occurred. In the event of bankruptcy, all Royalty obligations and the obligation to pay Chen an aggregate amount of
$3,500,000 accelerates and becomes a debt obligation of HTL secured by Chen&#146;s lien and due immediately. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.1.6 <U>Stock Capitalization Table</U>. HTL shall provide and attach to this Agreement as Exhibit <FONT
STYLE="white-space:nowrap">B-</FONT> 4 a stock capitalization table for HTL (as in effect upon execution of this Agreement, and including convertible notes, warrants and options). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.1.7 <U>Escrow Agreement</U>. As of the Effective Date, HTL shall execute and deliver the Intellectual Property Escrow Agreement attached as Exhibit <FONT
STYLE="white-space:nowrap">A-5</FONT> <B>{&#147;IP Escrow Agreement&#148;) </B>to Chen and the escrow agent <B>(&#147;Escrow Agent&#148;) </B>named in the IP Escrow Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.1.8 <U>Expense Reimbursement</U>. HTL shall make a one time payment at closing of ten thousand dollars ($10,000.00) to Chen for reimbursement of travel and
other expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.2 Deliveries by Chen. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.2.1
<U>Technology Deliverables</U>. Within <I>15 </I>days of the Effective Date, Chen shall deliver to HTL (to the extent such items are available to him using his best efforts) the items of the Covered Technology described in Exhibit <FONT
STYLE="white-space:nowrap">A-2.</FONT> Within thirty (30)&nbsp;days of the Effective Date, Chen shall deliver all other Covered Technology to HTL. All tangible documents, software and other items of the Covered Technology or containing, embodying or
evidencing the Covered Technology, shall be delivered as follows: (i)&nbsp;the Covered Technology described in Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT> shall be delivered via hand delivery to HTL on the Effective Date; and (ii)&nbsp;all
other Covered Technology shall be delivered in the manner as provided where practical in Section&nbsp;11.10 for notice, to HTL at its address first given above. If HTL believes any deliverable to be deficient or missing, HTL shall notify Chen of any
deficiency, providing in writing detail of the nature and substance of the alleged deficiency, and Chen shall promptly correct or otherwise rectify any deficient or missing deliverable to the extent under Chen&#146;s control or which Chen can, using
his best efforts, correct or rectify, or obtain correction or rectification, from or through others. Chen shall have thirty (30)&nbsp;days to rectify any noticed deficiency or otherwise inform HTL of the reasons he is unable to provide the requested
thing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.2.2 <U>Cancellation of Notes and Debts</U>. On the Effective Date, Chen shall deliver to HTL any and all notes and other evidences of
indebtedness of HTL to Chen, if any, in Chen&#146;s possession, custody or control, and all notes and other indebtedness of HTL to Chen (whether or not delivered to HTL) are and are hereby deemed canceled, void, and of no effect, and shall be marked
as such, as of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.2.3 <U>Escrow Agreement</U>. As of the Effective Date, Chen shall execute and deliver the IP Escrow Agreement to HTL
and the Escrow Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.2.4 <U>Release of Security Interest</U>. As of the Effective Date, Chen shall execute and deliver into escrow under the IP Escrow
Agreement a Release of Security Interest in the form attached hereto as Exhibit <FONT STYLE="white-space:nowrap">A-6</FONT> <B>(&#147;Security Interest Release&#148;).</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.2.5 <U>Assignment</U>. As of the Effective Date, Chen shall execute and deliver into escrow under the IP
Escrow Agreement an Assignment and Bill of Sale in the form attached hereto as Exhibit <FONT STYLE="white-space:nowrap">A-5</FONT> <B>(&#147;Assignment&#148;).</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B>Taxes. </B>Any and all taxes payable by the Parties hereto as a result of any transaction described herein will be the sole responsibility of
the Party against which such tax is assessed. All payments provided for herein are to be calculated and paid on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis as to taxes on the income and revenue of the paying Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B>No Other Accounting. </B>Except for the payments expressly required and the respective obligations of the Parties hereunder, neither Party shall
have duty or be required to account to the other Party for any amounts received or receivable in connection with the Covered Technology or Intellectual Property Rights, or for the exercise of any rights granted under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.4</B> <B>No Other Notes or Debts. </B>The notes in Sections 3.1.1 and 3.1.2 supersede and replace any and all prior notes and debt obligations of HTL to
Chen. Any and all such prior notes and debts obligations are hereby canceled, void and of no further effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.5</B> <B>Escrow. </B>Pursuant to this
Agreement, the Parties establish an escrow <B>(&#147;Escrow&#148;) </B>under the terms and conditions of the IP Escrow Agreement (Exhibit <FONT STYLE="white-space:nowrap">A-4)</FONT> with the Escrow Agent named in the IP Escrow Agreement, as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Release of Assignment from Escrow</U>. The Assignment shall be delivered to HTL from the Escrow only upon the first to
occur of the Assignment Event under Section&nbsp;2.2 or the Final Transfer Event under Section&nbsp;2.3. HTL shall refrain from exercising any rights conferred by the Assignment until the first of these occurrences and delivery to HTL of the
Assignment from the Escrow. The Assignment shall be delivered to Chen from the Escrow only upon the occurrence of an Event of Default by HTL under Section&nbsp;9.1(b), (c), (d) or (e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Delivery of Security Interest Release from Escrow</U>. The Security Interest Release shall be delivered to HTL from the Escrow only
upon the Final Transfer Event under Section&nbsp;2.3. The Security Interest Release shall be delivered to Chen from the Escrow only upon the occurrence of an Event of Default by HTL under Section&nbsp;9.1(b), (c), (d) or (e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Notice to Escrow Agent</U>. Only upon the occurrence of the Assignment Event under Section&nbsp;2.2 or the Final Transfer Event under
Section&nbsp;2.3, shall HTL be entitled to notify Escrow Agent to release and deliver the Assignment from Escrow. Only upon the occurrence of a Final Transfer Event under Section&nbsp;2.6, shall HTL be entitled to notify Escrow Agent to release and
deliver to HTL the Security Interest Release (and, if then remaining in the Escrow, the Assignment). Only upon the occurrence of an Event of Default by HTL under Section&nbsp;9.1(b), (c), (d) or (e), shall Chen be entitled to notify Escrow Agent to
release and deliver to Chen the Assignment and Security Interest Release from Escrow and nullify their effectiveness. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Security Interest in Covered Technology and Intellectual Property for Payments to Chen </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B>Security Interest Granted to Chen by HTL. </B>HTL grants to Chen, as of the Effective Date of this Agreement and pursuant to and to the extent
permitted by the Texas Uniform Commercial Code, a security interest and lien in all of HTL&#146;s interest in the Covered Technology and Intellectual Property Rights existing on the Effective Date and as further described in the Security Interest
Agreement (Exhibit <FONT STYLE="white-space:nowrap">A-3)</FONT> and transferred by Chen to HTL under this Agreement to secure HTL&#146;s performance of its payment obligations in Sections 3.1.1 and 3.1.4. The security interest shall continue in
effect until the Final Transfer Event in Section&nbsp;2.3. HTL agrees to cooperate, at Chen&#146;s expense, to the full extent necessary for Chen to perfect the security interest granted under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.1.1 With respect to the security interest granted by HTL to Chen under this Agreement, Chen is authorized by HTL to file a financing statement and a notice
of security interest in the U.S. Patent&nbsp;&amp; Trademark Office, each in form and substance mutually agreed by the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.1.2 In the event HTL
fails to perform its payment obligations under the 448 Secured Promissory Note or under the 700K Secured Convertible Promissory Note, Chen shall provide notice to HTL specifying the failure and allow thirty (30)&nbsp;days after such notice for HTL
to cure such failure prior to taking any action to enforce the security interest. If by the thirtieth (30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day following such notice the failure has not been cured, Chen shall have rights and
remedies pursuant to and to the extent permitted in the Texas Uniform Commercial Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.1.3 The security interest granted by HTL to Chen under this
Agreement shall remain in effect until the Final Transfer Event. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Assistance </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.1</B> <B>Chen&#146;s
Cooperation. </B>During the twelve (12)&nbsp;month period commencing on the Effective Date, Chen agrees to use his best efforts (i)&nbsp;to assist HTL, its Affiliates and Consultants, and its and their personnel and representatives, by training and
instructing their personnel and representatives to use, manufacture, configure, test, operate, and to otherwise reasonably provide technical assistance related to MyoVista Devices, (ii)&nbsp;to assist HTL and its attorneys in filing, prosecuting,
enforcing, and exploiting patents and other proprietary rights directly related to MyoVista Devices or the Covered Technology, and (iii)&nbsp;to assist HTL in advertising, marketing, promoting, commercializing, sales, and developing the MyoVista
Devices and Covered Technology. Nothing in this provision permits the use of Chen&#146;s name in connection with such activities. Chen shall not be required or expected to provide any assistance as a medical doctor. Chen will make no diagnoses nor
recommend treatment to any individual. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.1.1 Chen will use his best efforts to obtain cooperation from previous consultants and contractors who
have performed any research or development of the Covered Technology or Intellectual Property Rights, including those who have developed software for MyoVista Devices including those under contract between HTL and Med Care Medical Devices Company,
to assist in explaining the code and operation of the software. Chen&#146;s best efforts shall include making telephone calls, arranging meetings, writing letters, making introductions, and meeting with HTL. Notwithstanding Chen&#146;s obligations
under this section, he shall not be required to devote more than twenty (20)&nbsp;hours per month until HTL closes a funding transaction of at least two million dollars ($2,000,000) at which time, Chen shall be required to devote no more than fifty
(50)&nbsp;hours per month for up to six (6)&nbsp;months. All Parties acknowledge Chen has employment in Shanghai, China, and such assistance shall occur at Chen&#146;s usual place of business in Shanghai, China during normal business hours China
Standard Time or on weekends as necessary to accommodate Chen&#146;s schedule except as otherwise agreed. The Parties shall act reasonably to accommodate Chen&#146;s employment obligations under this clause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.1.2 Chen shall be permitted to approve, including by administering a competency test and interview, a team of no more than five to be employed or contracted
by HTL, to assist in providing technical information under this paragraph. HTL shall pay for the services of such approved personnel. Chen&#146;s obligations under this section V are conditioned on HTL&#146;s payment for expenses incurred in
connection with Chen carrying out his obligations under this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.1.3 Chen shall not be responsible for the completion of the device in working
order as long as he complies with this Article V. Chen&#146;s obligations under this Article V shall expire twelve (12)&nbsp;months from the Effective Date. Chen shall be reimbursed for out of pocket costs that may be incurred by Chen to provide the
assistance, including but not limited to any required travel and lodging consistent with policies of HTL then in effect, which policies HTL will provide to Chen; provided Chen must obtain approval of HTL prior to incurring any such costs. Chen shall
be compensated at the rate of $200/hour actually devoted to providing these services. Chen shall not be required under this paragraph to perform, create, develop or make any new developments or undertake research under this Agreement related to new
developments of the MyoVista Devices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.1.4 On a monthly basis, HTL shall deliver to Chen a scope of work describing activities HTL wishes Chen and his
team to perform and the deliverables HTL wishes to receive under this Article V. Such scope of work statements shall not modify the terms of this Agreement in any way nor shall they constitute contractual obligations of Chen or HTL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.2</B> <B>Liquidated Damages for Violation of Duty to Cooperate. </B>In the event a final judgment is entered in a court of competent jurisdiction finding
that Chen intentionally failed or refused to comply with this Article V, HTL&#146;s sole and exclusive remedy shall be (i)&nbsp;automatic cancellation and nullification of the 300K Convertible Note and the 700K Convertible Note; and (ii)&nbsp;such
finding shall constitute a Final Transfer Event. HTL shall remain obligated to pay Royalties under Section&nbsp;3.1.4 as provided therein. Nothing in this paragraph shall limit Chen&#146;s rights in the event of default by HTL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.3</B> <B>Litigation. </B>The sole right (but not obligation) to institute a suit for infringement of
the Intellectual Property Rights in the Covered Technology rests with HTL. If and as may be reasonably requested by HTL, Chen agrees to cooperate with HTL in all respects, including but not limited to joining in any suit, to testifying when
requested, and to make available any records, papers, information, specimens and the like. Any recovery received pursuant to such suit shall be retained by HTL after payment of 2.5% of the net recovery (i.e., net of attorney fees, court costs, and
expenses of the litigation) to Chen; and such 2.5% of the net recovery is deemed payment by HTL of Royalty under this Agreement. HTL shall reimburse or pay any reasonable expenses incurred by Chen in providing such assistance; provided, any expense
in excess of $200 must be approved by HTL prior to Chen incurring the expense. If Chen notifies HTL of any Third Party infringement of Intellectual Property Rights under this Agreement, HTL, to the extent commercially reasonable and economically
feasible to HTL, shall conduct a reasonable investigation and provide the results of the investigation to Chen. Such investigation shall be commenced within sixty (60)&nbsp;days of notice. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Covenants of
the Parties </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.1 Covenants of HTL. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1.1 HTL
will use commercially reasonable efforts to manufacture, seek and obtain government, regulatory and other certifications or approvals, if any are required (such as, for example, CMDCAS, FDA, SFDA or CE certification), for commercializing and
marketing the MyoVista Devices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1.2 HTL shall maintain performance and finish quality of the MyoVista Devices no less than comparable to that MyoVista
Device demonstrated to the Parties on December&nbsp;30, 2013, and provide customary customer service and warranty service for Customers of MyoVista Devices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1.3 HTL shall use a manufacturer for the MyoVista Devices having applicable certifications that are required (such as, for example, <FONT
STYLE="white-space:nowrap">ISO-9001</FONT> or <FONT STYLE="white-space:nowrap">ISO-13485),</FONT> or else HTL shall obtain such certifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1.4 HTL
shall pay all patent maintenance and application fees, all prosecuting attorney fees, and all other expenses and costs relating to protecting and developing the Covered Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1.5 Until the first to occur of the Assignment or the Final Transfer Event, whichever first occurs, HTL shall assist Chen to continue to prosecute and
obtain patents from the Patent Applications and to consult with Chen concerning the conduct of the prosecution, provided, Chen keeps HTL fully informed. Chen shall provide notice to HTL of any intent not to pay for maintenance or other fees required
to maintain enforceability of an issued patent, trademark, or other registered Intellectual Property Right transferred under this Agreement, and HTL shall pay such maintenance or other fees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1.6 Upon HTL&#146;s actual knowledge of any potential infringement of the Intellectual Property Rights,
HTL shall use good faith, commercially reasonable efforts to apprise Chen of the potential infringement. To the extent commercially reasonable and economically feasible to HTL, HTL shall reasonably investigate potential infringements identified by
Chen during the term of this Agreement and enforce the Patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1.7 HTL will deliver to Chen, within fifteen (15)&nbsp;days of receipt by HTL, a copy
of any notice or correspondence received or obtained by HTL and relating in any way to any Third Party claim that any Party or its Affiliate infringes or otherwise violates any proprietary right of any Third Party. If at any time HTL learns of any
actual or threatened infringement or violation of any proprietary right of any Third Party, HTL will promptly notify Chen thereof within fifteen (15)&nbsp;days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1.8 HTL shall employ commercially reasonable efforts to comply with the marking requirement of 35 U.S.C. &#167; 287 to satisfy legally and factually the
marking statute of the U.S.. laws, including by marking conspicuously on each MyoVista Device or its container with notice of each Patent in effect at the time of marking that includes at least one valid claim that covers the MyoVista Device. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1.9 HTL shall employ commercially reasonable efforts to obtain all necessary and appropriate regulatory approvals and permits and obey all laws governing
the sale, distribution, and offering for sale of MyoVista Devices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1.10 Following execution of this Agreement and prior to the first commercial Sale or
distribution of any kind of any MyoVista Device to any Customer (other than HTL, its Affiliates or Consultants), HTL shall obtain and maintain from an insurance carrier having a rating of at least A by the A.M. Best&nbsp;&amp; Co., Commercial
General Liability insurance, including product, advertising and contractual liability insurance, with coverage limits no less than one million dollars per occurrence and five million dollars in aggregate. If obtainable, HTL shall obtain an
endorsement naming Chen as an additional insured party. HTL shall not cancel or materially change the terms of such policy without at least thirty (30)&nbsp;days prior written notice to Chen; provided, HTL may change carriers without notice so long
as substantially same level and quality of the insurance is maintained. HTL shall request its insurer furnish Chen a certificate of such insurance and additional insured endorsement each year or upon a policy change. Notwithstanding the foregoing of
this section, the Parties recognize that the aforesaid insurance and/or amounts may be inappropriate or unavailable with regard to specific classes of goods or HTL, and it is contemplated that the foregoing insurance and amounts may require
adjustment. Chen&#146;s consent, not to be unreasonably withheld, is required for any adjustment. If HTL is unable to obtain coverage, Chen may purchase coverage and HTL shall reimburse him within ten (10)&nbsp;days for all costs and expenses
associated with obtaining insurance. &middot; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1.11 On the Effective Date, HTL shall maintain Directors and Officers Liability Insurance in the coverage
amount of no less than two million dollars ($2,000,000.00) and shall provide coverage for Chen under HTL&#146;s current D&amp;O policy. HTL shall maintain such insurance of the foregoing sentence in effect until occurrence of the event in
Section&nbsp;2.2(a); thereafter, HTL shall obtain and maintain Directors and Officers Liability Insurance in the coverage amount of no less than five million dollars ($5,000,000.00) or such amount HTL is able to obtain on commercially reasonable
terms and Chen shall be named insured under a claims made policy. Notwithstanding the foregoing of this section, the Parties recognize that the aforesaid insurance and/or amounts may be inappropriate or unavailable with regard to specific classes of
goods or HTL, and it is contemplated that the foregoing insurance and amounts may require adjustment. Chen&#146;s consent, not to be unreasonably withheld, is required for any adjustment. If HTL is unable to obtain coverage, Chen may purchase
coverage and HTL shall reimburse him for all costs and expenses associated with obtaining insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1.12 HTL will comply with Applicable Laws related
to this Agreement and HTL&#146;s obligations hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1.13 HTL will employ commercially reasonable efforts to obtain confidentiality agreements of all
of HTL&#146;s officers, directors, employees and Consultants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1.14 HTL shall not treat Chen, in his capacity as a holder of common stock of HTL,
differently than the other holders of common stock of HTL, taken as a whole, with respect to any opportunity to participate in any future investment offering, financing, stock issuance, stock purchase plan, or other transaction that is offered to
all other holders of the common stock of HTL, and Chen&#146;s participation shall be made available on at least as favorable terms as offered to all other holders of the common stock of HTL. In addition, HTL acknowledges the Voting Agreement Among
Shareholders of HTL, dated May&nbsp;2, 2013, as amended by the First Amendment to Voting Agreement Among Shareholders of Heart Test Labs, Inc., (attached hereto as Exhibit <FONT STYLE="white-space:nowrap">A-7).</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.2.1 Covenants of Chen. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.2.1 Chen will deliver to HTL,
within five (15)&nbsp;days of receipt by Chen, a copy of any notice or correspondence received or obtained by Chen and relating in any way to any Third Party claim that any Party or its Affiliate infringes or otherwise violates any proprietary right
of any Third Party. If at any .time Chen learns of any actual or threatened infringement or violation by HTL of any proprietary right of any Third Party, Chen will promptly notify HTL thereof within fifteen (15)&nbsp;days. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 18 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.2.2 During the period in which the Exclusive License is in effect and, if and as applicable, upon and
after the Assignment is released to HTL from the Escrow, Chen will not sell, offer or solicit to sell, manufacture, or transfer or convey any right, title or license, of or for any MyoVista Device or Covered Technology, or any Intellectual Property
Rights therein, anywhere in the world. Chen agrees not to and shall not Sell, offer or solicit to Sell, manufacture, or transfer or convey title or license, of or for any MyoVista Device, to any Third Party, anywhere in the world, at any time prior
to expiration of the Intellectual Property Rights and during the period in which HTL is licensed or owns the Intellectual Property Rights under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.2.3 Upon reasonable request of HTL, and at HTL&#146;s sole expense including reimbursement for all reasonable attorney&#146;s fees and costs incurred, Chen
will execute and deliver to HTL any short form instrument or memorandum reasonably requested by HTL or to evidence and/or confirm the rights herein granted to HTL, including but not limited to any statement or affidavit required of Chen in
connection with any governmental or regulatory certification or approval process described in 6.1(a) or any prosecution of patents in the U.S. Patent&nbsp;&amp; Trademark Office, any short form document of transfer or assignment for filing in the
U.S. Patent&nbsp;&amp; Trademark Office, and any other instruments or documents required by HTL for any of these purposes or purpose of any other governmental office or governing authority. Notwithstanding any of the preceding, Chen shall not be
responsible in any way for regulatory approval of any product, process, or treatment sought by HTL or for submission to any regulatory body of any information on behalf of or related to approval sought by HTL; provided, Chen shall cooperate to make
available to HTL all information available to Chen that HTL reasonably requires for seeking and obtaining such regulatory approval or submission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.2.4
Chen will comply with Applicable Laws related to this Agreement and Chen&#146;s obligations hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.2.5 Until the first to occur of the Assignment
Event or the Final Transfer Event, Chen shall continue to prosecute and obtain patents from the Patent Applications, shall keep HTL fully and timely apprised, and shall consult with and abide by directions from HTL in every respect concerning the
conduct of the prosecution, including Chen shall engage attorneys for prosecution acceptable to HTL in its reasonable discretion; and HTL shall pay or reimburse to Chen amounts for the prosecution and maintenance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.2.6 Chen shall use best efforts to obtain ownership or rights sufficient for HTL to allow HTL to fully exercise all rights, title and interest to the
Covered Technology and the Intellectual Property Rights and to make, have made, use, sell, offer to sell, have sold, import and commercialize, exploit, legally dispose, and otherwise provide products and services that incorporate or otherwise
utilize or integrate with the Covered Technology and Intellectual Property Rights, and to use, copy, reproduce, perform, display, distribute, modify and make derivative works of the Covered Technology and Intellectual Property Rights; and Chen
hereby licenses all such ownership or rights under and in accordance with the Exclusive License and, pursuant to the Assignment, assigns such ownership or rights upon the first to occur of the Assignment Event or the Final Transfer Event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 19 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.3 Mutual Covenants. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.3.1 Chen and HTL each covenant not to take or permit any person under their respective control or direction to take any actions (i)&nbsp;to defame the other
(Chen or HTL as the case may be) or any business of HTL or Chen, or to knowingly induce, aid or abet others to do so, or (ii)&nbsp;to impair in any way the Intellectual Property Rights or Covered Technology; provided, nothing in (ii)&nbsp;of this
sentence shall preclude Chen from exercising his rights pursuant to Section&nbsp;2.2 and as otherwise provided under this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Representations and Warranties </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1</B>
<B>Mutual Representations and Warranties. </B>Each Party hereby represents and warrants to the other Party that, as of the Effective Date: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.1.1
<B>Binding Agreement. </B>This Agreement, and each document or instrument executed in connection with or required under this Agreement, is the legal and valid obligation of the Party, binding upon and enforceable against such Party in accordance
with the respective terms hereof and thereof. The execution, delivery and performance by such Party of this Agreement, and each such document or instrument executed in connection with or required under this Agreement, does not and will not conflict
with any agreement, oral or written, to which such Party is a party or by which such Party may be or become bound, nor does this Agreement, any such document or instrument, or the obligations of such Party hereunder or thereunder, violate any law or
regulation of any court, governmental body or administrative or other agency having authority over such Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.1.2 <B>Accuracy of Information. </B>To
the best of the Party&#146;s knowledge, information and belief, the statements and representations made by the Party contained in this Agreement, in any exhibit hereto, or in any document or instrument executed in connection with or required or
permitted under this Agreement, are true and do not omit to state any material fact. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.1.3 <B>Due Diligence. </B>The Parties acknowledge that they have
conducted their own due diligence prior to entering this Agreement and that they are satisfied with the information discovered or obtained. The Parties acknowledge that Chen may not own certain technology that is generally commercially available to
HTL from others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.2</B> <B>HTL&#146;s Representations and Warranties. </B>HTL represents and warrants to Chen and his Affiliates all of the
following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.2.1 As of the Effective Date, (i)&nbsp;HTL is duly organized and validly existing under the laws of the State of Texas and has full
corporate power and authority to enter into this Agreement and to perform its obligations hereunder, (ii)&nbsp;the person signing on behalf of HTL is duly authorized to execute this Agreement for HTL, and (iii)&nbsp;HTL is in compliance with all
Applicable Laws to make and enter into this Agreement and perform HTL&#146;s obligations hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 20 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.2.2 HTL is not bound by any agreements, obligations or restrictions and shall not assume any obligation or
restriction or enter into any other agreement that would interfere with its obligations under this Agreement. As of the Effective Date, HTL has entered into no licenses with any Third Party relating to the Covered Technology and/or Intellectual
Property Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.2.3 Chen will receive and have first lien on all Covered Technology, Intellectual Property Rights, and MyoVista Updates under the
security interest granted in Section&nbsp;4.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.2.4 HTL represents and warrants that the stock capitalization table to be delivered to Chen herewith
pursuant to section 3.1 will be accurate and complete as of the Effective Date (as in effect upon execution of this Agreement, and including convertible notes, warrants and options). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.2.5 HTL&#146;s present D&amp;O Liability Insurance policy includes Chen as an insured or additional insured. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.3</B> <B>Chen&#146;s Representations and Warranties. </B>Chen represents and warrants to HTL all of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.3.1 As of the Effective Date, Chen is a U.S. citizen presently living in Shanghai China, and Chen has full capacity and authority to enter into this
Agreement and to perform his obligations hereunder, and to execute and deliver this Agreement, and Chen is in compliance with all Applicable Laws to make and enter into this Agreement and perform Chen&#146;s obligations hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.3.2 Chen is able to and does transfer the Covered Technology and Intellectual Property Rights free and clear of any and all mortgage, pledge, lien, security
interest, charge, claim, encumbrance, restriction on transfer, conditional sale or other title retention device or arrangement, transfer for the purpose of subjection to the payment of any indebtedness, or restriction on the creation of any of the
foregoing, whether relating to any property or right or the income or profits therefrom, no Third Party has any claim on any aspect of the Covered Technology, or any component thereof, or any Intellectual Property Rights therein, by, through or from
Chen, and the MyoVista Devices and Covered Technology existing on and before the Effective Date do not infringe upon the rights of any Third Party to the best knowledge of Chen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.3.3 Chen is aware of no fact or circumstance, act or omission pertaining to the Covered Technology or Intellectual Property Rights, which would impair,
limit, restrict, invalidate, or preclude HTL from exercising its rights under the Exclusive License or as owner of the Covered Technology and Intellectual Property Rights conveyed under this Agreement. Except as set forth in this Section&nbsp;7.3.3,
Chen makes no representation or warranty as to validity, enforceability, or value of the Covered Technology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 21 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.3.4 Chen is not bound by any agreements, obligations or restrictions and shall not assume any obligation
or restriction or enter into any other agreement, that would interfere with his obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.3.5 There is no litigation pending or
threatened against Chen or any of his Affiliates which could impact Chen&#146;s ability to perform his obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.3.6 To
Chen&#146;s knowledge and belief, the Covered Technology (and the use thereof as contemplated by this Agreement) does not infringe, misappropriate, violate or interfere with any proprietary or intellectual property rights or interests, contractual
rights or any other similar rights of any Third Party. The Covered Technology and the Intellectual Property Rights conveyed to HTL by Chen pursuant to this Agreement include all of the rights, title and interest for HTL to make, use, sell, exploit
and commercialize the MyoVista Device. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.3.7 The Patents, the Patent Applications, the Copyrights, the Trademark Rights, the Trade Secrets, and the
Technical Information include all of Chen&#146;s Intellectual Property Rights in and to the MyoVista Device and in and to the Covered Technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.3.8
None of the software included in the Covered Technology contains any software code that is licensed under any terms or conditions that require that any software be (i)&nbsp;made available or distributed in source code form; (ii)&nbsp;licensed for
the purpose of making derivative works; (iii)&nbsp;licensed under terms that allow reverse engineering, reverse assembly or disassembly of any kind; or (iv)&nbsp;redistributable at no charge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.3.9 Chen is not in default under any of his existing financing arrangements (including its outstanding convertible preferred note(s)), and Chen shall not
default under any such existing financing arrangements or under any financing arrangements Chen may enter into in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.3.10 The conveyances by
Chen to HTL include all of Chen&#146;s rights, title and interest that exists in and to the Covered Technology and the Intellectual Property Rights owned by Chen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.3.11 As of the Effective Date, except for the Covered Technology and Intellectual Property Rights, Chen does not own and has no rights to any patents,
copyrights, trademarks, trade secrets or proprietary information or materials related to the MyoVista Device, in whole or part. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE
VIII </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Indemnification; Releases </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.1 Indemnification of Chen by HTL. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.1.1 HTL will, to
the fullest extent allowed by Texas law, indemnify, defend and hold harmless Chen, from and against any and all Losses, resulting or arising from acts of omission or commission committed by Chen in his capacity as an officer or director of HTL prior
to the Effective Date (referred to herein as <B>&#147;Indemnified Events&#148;</B>).<B> </B>For purposes of this Section&nbsp;8.1, the term <B>&#147;Loss&#148; </B>or <B>&#147;Losses&#148; </B>means and includes any and every liability, demand,
claim, suit, expense, attorneys fees, or other damage, loss or cost suffered or incurred by Chen. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 22 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.1.2 Chen will promptly (and in no case more than ten (10)&nbsp;calendar days after first discovering the
fact of the Loss) give written notice to HTL of any third-party notice, demand or allegation of or relating to any Loss of any type, including an invitation to HTL to participate in the defense. Failure to give such written notice will not relieve
HTL from any liability that HTL may have hereunder. Subject to the proviso that follows, Chen will have the ability to select counsel of its own choosing and will have control over the complete defense, but will not settle without HTL&#146;s
consent, which consent will not be unreasonably withheld; provided, however, that if HTL elects to participate in the defense, if HTL and HTL&#146;s insurer agree to fully indemnify and to pay for all costs of defense and any damages, then Chen may
employ separate counsel at the expense of Chen to assist Chen with respect to any liabilities, claims or suits. Notwithstanding anything else to the contrary, before settling, compromising or otherwise extinguishing any claim by a third-party
(whether or not suit or any other type of dispute resolution procedure has been commenced) made against Chen (a <B>&#147;Settlement&#148;), </B>HTL must first obtain the written consent of Chen, and Chen will have discretion to withhold such consent
if the Settlement (a)&nbsp;is for or involves non-monetary consideration or <FONT STYLE="white-space:nowrap">non-monetary</FONT> judicial relief, including, but not limited to, promises by Chen to do or forbear from doing any act or the granting of
equitable remedies, (b)&nbsp;involves, requires or implies admissions of wrongful acts (whether civil or criminal) by Chen, (c)&nbsp;would or could impair, invalidate, or result in loss of value of any Intellectual Property or &middot;rights
thereto, and/or (c)&nbsp;would likely have a detrimental effect on Chen&#146;s reputation or goodwill. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.2</B> <B>No Limitation on Newly Acquired
Shares. </B>With respect to any shares of HTL newly acquired by Chen after the Effective Date, the Voting Agreement Among Shareholders of Heart Test Laboratories, Inc., dated May&nbsp;2, 2013, shall have no effect and shall not govern Chen&#146;s
rights in regard to such shares; provided, the voting agreement shall continue in effect as to shares owned by Chen and/or Cheryl Yang on the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.3</B> <B>Right to Designate a Member of the HTL Board of Directors. </B>Until the occurrence of the Final Transfer Event, Chen shall designate a person
of his sole choosing, excluding Robert Eddy, to a seat on the HTL Board of Directors with all the duties, rights, and obligations of the other members. Chen shall provide written notice to HTL, at least ten (10)&nbsp;days prior to such designation,
of Chen&#146;s desired designee for the seat on the HTL Board of Directors. Chen&#146;s designee to the HTL Board of Directors may refer information of Board proceedings and actions to Chen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.4</B> The Parties have entered into Mutual Releases. See Exhibit <FONT STYLE="white-space:nowrap">A-8.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.5</B> Chen will indemnify, defend, and hold harmless HTL from any claims of ownership of any Covered Technology by Med Care Medical Devices Company.
&middot; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 23 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Default; Term; and Termination </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.1
Default. Subject to the notice and opportunity to cure rights provided hereunder, the occurrence of any of the following shall constitute a default under this Agreement by a Party (each an &#147;Event of Default&#148;): </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Party breaches any material term or condition of this Agreement, or is in material breach of any representation or warranty, and such
breach is not cured within thirty (30)&nbsp;days after the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party gives the breaching Party written notice of such breach; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the Party fails to make any payment hereunder or any report hereunder, within the time required; provided, it shall not be an Event of
Default under this Section if the Party makes a good faith error in any report or in the amount of any payment and upon learning of and verifying the error, takes reasonably prompt action to correct the error; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the Party makes an assignment for the benefit of creditors, or becomes subject to direct control of a trustee, receiver or similar
authority, or becomes subject to any bankruptcy or insolvency proceeding under federal, state or foreign statutes which is not rescinded or dismissed within ninety (90)&nbsp;days; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) breach by HTL of Section&nbsp;8.3; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) by the <FONT STYLE="white-space:nowrap">two-year</FONT> anniversary of the Effective Date, HTL fails to obtain funding pursuant to
Section&nbsp;2.2(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of any event in (a)&nbsp;through (e) above, the other Party shall first give thirty (30)&nbsp;days&#146; notice and
opportunity to cure, and if cure is effected within thirty (30)&nbsp;days from the date of notice (in the reasonable discretion of the Party giving such notice) there shall not be an Event of Default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.2</B> <B>Consequences of Default. </B>In the event of any Event of Default, except as provided in Section&nbsp;5.2, the Parties may exercise all rights
and seek all remedies provided under this Agreement or available at law or in equity. Upon termination of this Agreement because of an Event of Default by HTL during the term of the Exclusive License, the Exclusive License shall terminate concurrent
with termination of the Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 24 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE X </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Confidentiality </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each
Party (a <B>&#147;Disclosing Party&#148;), </B>at its discretion, may on or after the Effective Date disclose to the other Party (a <B>&#147;Receiving Party&#148;) </B>certain of the Disclosing Party&#146;s Confidential Information. In consideration
of each and every disclosure of Confidential Information by the Disclosing Party to the Receiving Party, the Receiving Party agrees (i) to treat as confidential and to preserve the confidentiality of all Confidential Information disclosed by the
Disclosing Party to the Receiving Party, (ii)&nbsp;to use any and all Confidential Information solely for purpose of this Agreement and for no other purpose, (iii)&nbsp;to make no disclosure of any Confidential Information to any Third Party,
(iv)&nbsp;to limit access to Confidential Information to those officers and employees of the Receiving Party having a need to know such information for purposes of this Agreement and who are bound by a written obligation to maintain confidential and
not use or disclose such Confidential Information, which written obligation is at least as restrictive as the terms of this Article X, and (v)&nbsp;to maintain in confidence any information regarding the nature or scope of any transaction or
relationship between the Disclosing Party and the Receiving Party, except to the extent such information must be disclosed pursuant to law or is disclosed to the Party&#146;s attorneys or accountants, and then only after notifying the Disclosing
Party of such requirement. Any obligation imposed by this Article X may be waived only in writing signed by authorized representatives of the Disclosing Party and the Receiving Party, and only as to the particular Confidential Information and to a
particular use or disclosure stated in the writing. Any such waiver will have a <FONT STYLE="white-space:nowrap">one-time</FONT> effect and will not apply to any subsequent situation regardless of its similarity. All Confidential Information will
remain the property of the Disclosing Party. Upon request of the Disclosing Party or termination of this Agreement, the Receiving Party will promptly return to the Disclosing Party all Confidential Information of the Disclosing Party, and each and
every part, reproduction and copy of any thereof and each and every narrative, synopsis, summary, note, writing and media containing, embodying, evidencing or describing any part. This Article X and the obligations hereunder, shall survive
termination of the Agreement to the later of: (a)&nbsp;ten (10) years from the date of termination of the Agreement, or (b)&nbsp;the date on which any trade secret embodied or knowable from the Confidential Information shall no longer remain a trade
secret. For purposes of this Article X, the Technical Information is deemed Confidential Information of the owner of the Technical Information. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE XI </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Miscellaneous </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.1 Costs. Except as
otherwise expressly provided herein, each Party will bear all of its own costs relating to this Agreement, including, by way of example and not by way of limitation, the cost of negotiating and entering into this Agreement and the cost of fulfilling
all of its obligations under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.2 Injunction; Specific Performance; Remedies. Each Party hereby agrees that, in the event of any breach
by the Party of any of Article II or X, or Sections 6.2.2, 6.2.3, or 6.3.1 or any other breach where such breach may cause irreparable harm to the other Party or where monetary damages may not be sufficient or may not be adequately quantified or
effected, such other Party is entitled to obtain temporary and permanent injunctive relief, without posting bond. Each Party shall have remedy of specific performance to enforce this Agreement, in addition to such other remedies that the Party may
have at law or in equity. Except as otherwise provided in this Agreement, all remedies are cumulative and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> of any other remedy a Party may have at law or in equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 25 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.3 Severability. If any provision of this Agreement is found&middot; by a court of competent jurisdiction
to be invalid, illegal, unenforceable or in conflict with any controlling law: (a)&nbsp;such provision will be separated from this Agreement; (b)&nbsp;such invalidity, illegality, unenforceability or conflict will not affect any other provision
hereof; and (c)&nbsp;this Agreement will be interpreted and construed as if such provision, to the extent the same will have been held invalid, illegal, unenforceable or in conflict had never been contained herein. In the event the legality of any
provision of this Agreement is brought into question because of a decision by a court or other tribunal of competent jurisdiction of any country in which this Agreement applies, the Parties may agree to revise the provision in question or may delete
it entirely so as to comply with the decision of the court or other tribunal and so as to most closely comply with the intent of this Agreement prior to the revision or deletion of the provision in question. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.4 Waiver. No waiver hereunder may be effective unless specifically made in a writing signed by the waiving Party and specifically describing the waived
breach or term or provision. A waiver of any breach or term or provision of this Agreement by either Party shall not be or constitute a waiver of any other or subsequent breach, term or provision, nor shall any such waiver affect the rights of the
waiving Party to demand strict compliance with the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.5 Amendment. Any modification or amendment of this Agreement will be effective only
if made in writing and signed by both Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.6 Relationship of the Parties. Each Party is an independent contractor of the other Party. Under no
circumstances will any employees of one Party be deemed the employees of the other Party for any purpose. This Agreement does not create a partnership, joint venture or agency relationship between the Parties of any kind or nature. This Agreement
does not create any fiduciary or other obligation between the Parties, except for those obligations expressly and specifically set forth herein. Neither Party will have any right, power, or authority under this Agreement to act as a legal
representative of the other Party, and neither Party will have any power to obligate or bind the other Party or to make any representations, express or implied, on behalf of or in the name of the other Party in any manner or for any purpose
whatsoever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.7 Governing Law; Venue for Suit; Jurisdiction of Court. This Agreement and the rights and obligations of the Parties hereunder will be
governed by and construed and interpreted in accordance with the laws of the State of Texas, without regard to choice or conflict of laws principles, applicable to agreements made and to be performed entirely within such state. Each Party
irrevocably submits and unconditionally waives any objection to the jurisdiction and venue of the federal or state courts in the State of Texas for purpose of any suit, action or other proceeding arising out of this Agreement or any transaction
contemplated hereby, and each Party hereby further waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. Each Party agrees to provide
counsel for the other Party notice, in the manner provided in Section&nbsp;11.10, of any lawsuit filed under or in connection with this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 26 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.8 No Third Party Beneficiaries. Nothing in this Agreement, express or implied, is intended or will be
construed to confer upon any person, other than the Parties and their respective successors and assigns permitted hereby, any right, remedy or claim under or by reason of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.9 Merger and Integration. This Agreement, along with the executed versions of the agreements and instruments attached in the exhibits hereto and
specifically referenced herein, constitute the entire understanding between the Parties concerning the subject matter of this Agreement, and supersede any and all prior understandings, agreements, representations, and warranties, express or implied,
written or oral, between the Parties concerning the subject matter of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.10 Notices. All notices given by a Party to the other Party will
be in writing and by personal delivery or by first class mail, registered or certified, postage prepaid with return receipt requested, addressed to the other party as indicated below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to Chen: &nbsp;&nbsp;&nbsp;&nbsp;Guangren (Gary) Chen </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with copy to </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Donald R. Taylor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Taylor Dunham,
LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">301 Congress Avenue, Suite 1050 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Austin, Texas 78701 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Robert M. Eddy </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2716 Ocean Park
Blvd., Suite 2028 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Santa Monica, CA 90405 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
to HTL: &nbsp;&nbsp;&nbsp;&nbsp;Heart Test Laboratories, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Mark Hilz, President and CEO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5712 Colleyville Boulevard, Suite 229 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Colleyville, Texas 76034 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">with a
copy to </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">H. Dale Langley, Jr. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Law Firm of H. Dale Langley, Jr., PC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1803 West Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Austin, Texas
78701 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 27 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as a Party may hereafter designate to the other in writing pursuant to this
Section&nbsp;11.11. A notice under this Agreement will be effective on the date of personal delivery or three (3)&nbsp;days after deposit in the U.S. mail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.11</B> <B>Construction. </B>All of the terms and conditions of this Agreement are the result of arms-length negotiation among the Parties, each of which
has had opportunity and has obtained the advice of legal counsel. Any principle of contract interpretation construing a contract or provision against the drafter will not apply to this Agreement or any provision, it being agreed that the Parties
have equally participated in the preparation and negotiation hereof and of all provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.12</B> <B>Assignment; Successors and Assigns. </B>Except
as provided in this Section&nbsp;11.12, or as otherwise provided in this Agreement (which assignment shall require the assumption of all of HTL&#146;s obligations hereunder), a Party shall not assign this Agreement or any right or interest under
this Agreement, nor delegate any work or obligation to be performed under this Agreement (an &#147;assignment&#148;), without the other Party&#146;s prior written consent, which consent shall not be unreasonably withheld; provided, (i)&nbsp;HTL and
its Affiliates may at any time assign this Agreement in its entirety (but not otherwise) to any person who succeeds to a controlling equity interest of HTL by sale, merger, or reorganization or who purchases
<FONT STYLE="white-space:nowrap">substantially-all</FONT> of the assets of HTL which are subject of this Agreement, but only if such successor or purchaser is a publicly traded company having a market capitalization of at least $50,000,000.00, or
tangible assets exceeding liabilities of at least $10,000,000.00 and assumes the obligations of its assignor hereunder; (ii)&nbsp;subject to Chen&#146;s first lien rights, which shall be affirmatively disclosed to any financial institution, and such
first lien rights shall be maintained, HTL and its Affiliates may pledge or collaterally assign any or all of its rights under this Agreement to any financial institution; (iii)&nbsp;HTL and its Affiliates may at any time transfer rights to use the
Covered Technology to Customers or to Consultants to HTL involved in research, development, testing or marketing of MyoVista; and (iv)&nbsp;a Party may assign or otherwise transfer any right or obligation of this Agreement to an Affiliate of the
Party, provided the Party shall remain liable for all its responsibilities and obligations under this Agreement and shall be and remain liable for the conduct and performance of each such assignee or transferee and such Affiliate assumes the
obligations of the assigning Party under this Agreement (each a <B>&#147;Permitted Assign&#148;). </B>Subject to the foregoing of this Section&nbsp;11.12 and the other terms of this Agreement, this Agreement will be binding upon and inure to the
benefit of the Parties and their respective heirs, successors and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.13</B> <B>Force Majeure. </B>Neither Party will be liable for any
failure or delay in performing its obligations hereunder due to any external cause beyond its reasonable control, including, by way of example and not by way of limitation, fire, accident, acts of the public enemy, war, riot, rebellion, labor
dispute, strike, <FONT STYLE="white-space:nowrap">lock-out,</FONT> labor shortage, labor unrest, insurrection, sabotage, epidemic, transportation delay, shortage of raw materials, supplies, energy, components or machinery, an act of God or
government or the judiciary, or any other cause beyond the reasonable control of the <FONT STYLE="white-space:nowrap">non-performing</FONT> or late-performing Party. Notwithstanding the foregoing, nothing in this section excuses a failure or delay
to perform payment or other monetary obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 28 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.14</B> <B>Further Acts. </B>Each Party will, at any time and from time to time during and after the
Term of this Agreement upon the request of the other Party, take all such further actions and execute and deliver all such further instruments, papers or documents, as may be necessary or appropriate to consummate and implement fully the
transactions contemplated herein, and otherwise to effectuate the stated purposes and intents of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.15</B> <B>Counterparts; Facsimiles
and Scans. </B>This Agreement and exhibits thereto may be executed in one or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. Facsimiles and electronic scans
containing original signatures will be deemed for all purposes to be originally-signed copies of the documents which are the subject of such facsimiles or scans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.16</B> <B>Attorneys&#146; Fees. </B>In any action or proceeding between the Parties hereunder, the prevailing Party will be entitled to recover all
fees, costs and other expenses (including, without limitation, the reasonable expenses of its attorneys) incurred in addition to any other relief to which it may be entitled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(The remainder of this page intentionally left blank.) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature page(s) follow.) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 29 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties by their duly authorized representatives have entered into
this Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CHEN:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Guangren Chen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Guangren &#147;Gary&#148; Chen</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HTL:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Heart Test Laboratories, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Hilz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Hilz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 30 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">HTL-CHEN TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>8
<FILENAME>filename8.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FIRST AMENDMENT OF 2013 TECHNOLOGY AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS FIRST AMENDMENT OF 2013 TECHNOLOGY AGREEMENT (this <B>&#147;Amendment&#148;) </B>is made and entered into as of the 13 day of March, 2017
(the <B>&#147;Effective Date&#148;) </B>by and between <B>GUANGREN &#147;GARY&#148; </B>CHEN, an individual U.S. citizen residing at Shanghai China <B>(&#147;Chen&#148;) </B>and <B>HEART TEST LABORATORIES, INC., </B>a Texas corporation having its
principal place of business at 1301 Solana Boulevard, Suite 1527, Westlake, Texas 76262 <B>(&#147;HTL&#148;). </B>Chen and HTL are sometimes referred to herein individually as a &#147;Party&#148; and, collectively, as the &#147;Parties.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Chen
and HTL are parties to that certain 2013 Technology Agreement, dated as of December&nbsp;31, 2013 (the <B>&#147;Technology Agreement&#148;);</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, HTL requires Chen&#146;s signature to documents for patent applications and patents heretofore or presently filed, or to be filed in
the future, by HTL, naming Chen as an inventor, and Chen acknowledges his obligation as provided in Section&nbsp;3 of that certain Master Assignment dated January&nbsp;1, 2014, between the Parties, to cooperate with HTL by executing, delivering and
recording such instruments, documents, and evidence, and taking any and all such other action as HTL may reasonably request; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
Chen desires to sign documents, including declaration and assignment documents, for patent applications and patents filed by HTL naming Chen as an inventor; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Chen desires to be indemnified for his inventive activities and for being named as an inventor on the patent applications and
patents; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subject to Chen&#146;s execution of patent documents, HTL desires to extend the indemnity of Chen in the Technology
Agreement to include indemnity for Chen&#146;s inventive activities and being so named as an inventor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for and in
consideration of the mutual promises, covenants and agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the Parties, the Parties, intending to be legally bound,
hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>Defined Terms. </B>Capitalized terms used herein and defined in the Technology Agreement shall have the meanings
given those terms in the Technology Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>Amendment to ARTICLE VIII, Indemnification; Releases. </B>Section&nbsp;8.1.1 of the Technology
Agreement is hereby superseded and amended to read as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.1.1 HTL will, to the fullest extent allowed by Texas law, indemnify, defend and hold
harmless Chen, from and against any and all Losses, resulting or arising (i)&nbsp;from acts of omission or commission committed by Chen in his capacity as an officer or director of HTL prior to the Effective Date; (ii)&nbsp;Chen&#146;s inventive
activities undertaken to conceive, reduce to practice, develop, or commercialize the Covered Technology for HTL; or (iii)&nbsp;from or relating to Chen&#146;s execution </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of patent documents requested by HTL as a result of Chen being named as an inventor on any existing or future patent applications or patents for the Covered Technology, provided Chen shall comply
with the requirements imposed upon inventors by the United States Patent and Trademark Office in his declarations and attestation to documents presented him by HTL (referred to herein as <B>&#147;Indemnified Events&#148;). </B>For purposes of this
Section&nbsp;8.1, the <B>&#147;Loss&#148; </B>or <B>&#147;Losses&#148; </B>means and includes any and every liability, demand, claim, suit, expense, attorneys&#146; fees, or other damage, loss or cost suffered or incurred by Chen. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>No Other Amendment. </B>Except for the amendment expressly set forth herein, the Technology Agreement shall not be amended or modified in any
manner. The terms of the Technology Agreement not otherwise affected by this amendment shall continue to apply and shall equally apply to and are incorporated in this Amendment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>Counterparts; Facsimiles and Scans. </B>This Amendment may be executed in one or more counterparts, each of which will be deemed an original, but
all of which together will constitute one and the same instrument. Facsimiles and electronic scans containing original signatures will be deemed for all purposes to be originally-signed copies of the documents which are the subject of such
facsimiles or scans. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>Perfection of Dr.</B><B></B><B>&nbsp;Chen&#146;s Security Interest. </B>HTL acknowledges Dr.&nbsp;Chen&#146;s security
interest in the subject patents and patent applications and agrees to execute <FONT STYLE="white-space:nowrap">UCC-1</FONT> financing statements as needed to particularly identify such assets and assist Dr.&nbsp;Chen in perfecting his security
interest in them. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>Mutual Agreement. </B>Each party agrees that, except for the declaration and assignment documents presently requested to be
signed by Chen, which documents shall be signed as a condition to this Amendment, the party will sign such documents as the other party reasonably requests as provided in the Technology Agreement and related documents and return the executed
documents within 21 days of the request. For the avoidance of doubt, the return of documents within such period shall include all security related documents, as well as declaration and assignment and other documents related to patent applications
and patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FIRST AMENDMENT TO 2013 TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties by their duly authorized representatives have entered into
this Amendment as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CHEN:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Guangren Chen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Guangren &#147;Gary&#148; Chen</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HTL:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Heart Test Labor</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Hilz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Hilz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FIRST AMENDMENT TO 2013 TECHNOLOGY AGREEMENT</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">HIGHLY CONFIDENTIAL</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>9
<FILENAME>filename9.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.3 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Master Assignment </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Assignment (&#147;<B>Assignment</B>&#148;)<I> </I>dated January&nbsp;1, 2014, (&#147;<B>Effective Date</B>&#148;),<I> </I>is by
<B>GUANGREN &#147;GARY&#148; CHEN, </B>an individual U.S. citizen, <B>(&#147;Grantor&#148;) </B>and <B>HEART TEST LABORATORIES, INC., </B>a Texas corporation having its principal place of business at 5712 Colleyville Blvd., Suite 229, Colleyville,
Texas 76034 <B>(&#147;Grantee&#148;).</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Assignment is given and made pursuant to that certain 2013 Technology Agreement, dated
December&nbsp;31, 2013, between Grantor and Grantee. Pursuant to the 2013 Technology Agreement, Grantor and Grantee enter into a certain Security Agreement and Pledge dated January __, 2014, covering the Assigned Assets (defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and agreed by Grantor, Grantor agrees as
follows &#151; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. Capitalized terms used in this Assignment and not otherwise defined in this Assignment shall have the respective
meanings given such terms in the Technology Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Grantor hereby assigns, transfers, conveys, and sets over to Grantee the
following rights and assets, consistent with the 2013 Technology Agreement (collectively, the &#147;<B>Assigned Assets</B>&#148;)<I>, </I>subject to the lien, security interest, pledge, and terms of the 2013 Technology Agreement and Security
Agreement and Pledge: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Covered Technology, defined in the 2013 Technology Agreement as the MyoVista Device,
MyoVista Hardware, MyoVista Software, and Technical Information, including MyoVista Updates and related Documentation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
the Intellectual Property Rights, as defined in the 2013 Technology Agreement and described on Exhibit <FONT STYLE="white-space:nowrap">A-1</FONT> (Patents and Patent Applications) and Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT> <FONT
STYLE="white-space:nowrap">(Non-Patent</FONT> IP Inventory) and the marks listed on Schedule A hereto; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) all rights
to sue or make any claims for any past, present or future infringement, misappropriation or unauthorized use of any of the Covered Technology and Intellectual Property Rights therein; and all rights to all income, royalties, damages, and other
payments from Third Parties that are now or may hereafter, become due or payable with respect to the Covered Technology and Intellectual Property Rights therein, including damages and other amounts for past, present or future infringement,
misappropriation or unauthorized use thereof and subject to the terms of the 2013 Technology Agreement and exhibits thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. Grantor
agrees to cooperate with Grantee by executing, delivering and recording such instruments, documents, and evidence, and taking any and all such other and further actions, as Grantee may reasonably request, to more effectively evidence or confirm this
assignment to Grantee under this assignment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. In furtherance of the transactions contemplated under this Assignment, and as further
evidence thereof, Grantor shall execute each attached exhibit hereto and incorporated herein, as follows: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. Patent Assignment (<U><B>Exhibit A</B></U>); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. Assignment of Marks (<B><U>Exhibit C</U></B>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the execution and delivery of the foregoing documents of the exhibits, the assignments via this agreement are, and shall be construed and
interpreted, as fully and completely consummated and effected for all purposes upon the execution and delivery of this instrument subject to the terms of the Technology Agreement. Grantee or its designee may file or record subject to Chen&#146;s
lien rights any of the exhibits hereto as evidence of the transactions hereunder, in all applicable jurisdictions and records of those jurisdictions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. In the event that any provision or portion of this Assignment is determined to be invalid or unenforceable in any jurisdiction, the
remaining provisions or portions thereof will remain in full force and effect in such jurisdiction and will be liberally construed so as to effectuate the purpose and intent of the parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. The governing law provisions of section 11.7 of the 2013 Technology Agreement control this Assignment and are incorporated by reference as
if set forth here. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Witness Whereof, Grantor and Grantee execute this Assignment as of Effective Date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>GRANTOR:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Guangren &#147;Gary&#148; Chen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Witnessed by:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>/s/ </B>Robert Eddy for Guangren Chen</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">as attorney in fact 3/14/14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Guangren &#147;Gary&#148; Chen</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>GRANTEE:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Heart Test Laboratories, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Witnessed by:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/_Mark Hilz</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:<B> </B><U>Mark T.
Hilz</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:&nbsp;<U>CEO</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>10
<FILENAME>filename10.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.4 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SECURITY AGREEMENT AND PLEDGE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS SECURITY AGREEMENT AND PLEDGE (this <B><I>&#147;Security Agreemenf1 </I></B>dated as of March&nbsp;14, 2014, is entered into by and
between <B>HEART TEST LABORATORIES, INC., </B>a Texas corporation <B><I>(&#147;HTL&#148;), </I></B>having its principal place of business at 5712 Colleyville Blvd., Suite 229, Colleyville, Texas 76034, and <B>GUANGREN &#147;GARY&#148; CHEN, </B>an
individual U.S. citizen <B><I>(&#147;Chen&#148;).</I></B> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RECITALS: </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. HTL is exclusive licensee (or owner upon occurrence of certain events) of certain property or rights, as more particularly described in the
2013 Technology Agreement attached hereto and incorporated herein (collectively, the <B><I>&#147;Property Rights&#148;). </I></B>HTL is obligated to Chen under two Promissory Notes in the amounts of $448,000.00 and $700,000.00 and to pay
$3,000,000.00 in Royalties to Chen pursuant to the 2013 Technology Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Secured Obligation: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the 448K Note (Ex. <FONT STYLE="white-space:nowrap">B-1);</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the 700K Note (Ex. <FONT STYLE="white-space:nowrap">B-3);</FONT> and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">right to receive 3MM aggregate Royalty Payments under paragraph 3.1.4 of the 2013 Technology Agreement.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, HTL hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Defined Terms and Related Matters.</U></B><B>
</B>Unless otherwise defined herein or in the 2013 Technology Agreement, the terms defined in Articles 8 and 9 of the Uniform Commercial Code as currently in effect in the State of Texas are used herein as therein defined. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><U>Pledge and Security Interest.</U></B><B> </B>HTL grants to Chen a security interest in the Property Rights and other
collateral of HTL listed in Exhibit A attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. <U>Security for Obligations.</U> This Security Agreement secures the full
performance of the following </B><B><I>&#147;Obligations&#148;:</I></B><B> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payment of the 448K Note; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payment of the 700K Note; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payment of the 3MM aggregate Royalty Payments described in Paragraph 3.1.4 of the 2013 Technology Agreement.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U>Designation of Chen as Lienholder on Title Documents.</U></B><B> </B>Upon Chen&#146;s request, HTL
shall add Chen&#146;s name as a lienholder on any title documents or loan documents which refer to any part of the Property Rights and shall execute UCC 1 for filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Further Assurances</U></B><B>. </B>Upon Chen&#146;s reasonable request, HTL agrees that, from time to time, HTL will promptly
execute and deliver further instruments and documents, and take further action, that may be reasonably required by Chen in order to perfect and evidence the Security Interest or to enable Chen to exercise and enforce his rights and remedies
hereunder with respect to any Property Rights. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6. <U>Events of Defaul</U><U>t</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Subject to the notice and opportunity to cure rights of HTL hereunder, the occurrence, and only during the pendency, of any
of the following default or breach events shall constitute an event of default <B><I>(&#147;Event of Default&#146;) </I></B>hereunder: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">failure to pay the 448K note or the 700K note or the 3MM aggregate Royalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if HTL defaults in the performance of or compliance with any other obligation or term of this Security
Agreement following the notice and opportunity to cure provisions provided herein; or </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) if HTL makes
an assignment for the benefit of creditors, or becomes subject to direct control of a trustee, receiver or similar authority, or becomes subject to any bankruptcy or insolvency proceeding under federal, state or foreign statutes which is not
rescinded or dismissed within ninety (90)&nbsp;days. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding any provision in this Security Agreement to the
contrary, on the occurrence of any default or breach pursuant to any of Section&nbsp;6(a)(i)-(iii) hereunder, Chen shall, prior to and without taking any remedial action as set forth herein, deliver written notice specifically stating the default or
breach claimed <B><I>(&#147;Default Notice&#148;) </I></B>and HTL shall have thirty (30)&nbsp;days thereafter to cure the default or breach specified in the Default Notice. If the default or breach is cured within such thirty (30)&nbsp;day cure
period, there shall be no Event of Default under this Security Agreement. In the event HTL fail to cure any breach, default or conditions specified in the notice, or fails to cure the breach or default within such thirty (30)&nbsp;day period after
the Default Notice, then Chen shall have the right to declare an Event of Default under this Security Agreement and exercise its remedies set forth herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B><U>Remedies upon Default</U></B><B>. </B>If any Event of Default shall have occurred: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Chen may, without notice to HTL, except as required by law and at any time or from time to time, charge, <FONT
STYLE="white-space:nowrap">set-off</FONT> and otherwise apply all or any part of the Property Rights and other collateral against the Obligations. Chen may also exercise in respect of the Property Rights, in addition to other rights and remedies
provided for herein or otherwise available to it, all the rights and remedies of a secured party on default under the Uniform Commercial Code in effect in the State of Texas at that time (the <B><I>&#147;Code&#148;), </I></B>and Chen may also,
without notice except as specified below, sell the Property Rights or any part thereof in one or more parcels at public or private sale, at any exchange, broker&#146;s board or at any of Chen&#146;s offices or elsewhere, for cash, on credit or for
future delivery, and upon such other terms as Chen may deem commercially reasonable. HTL agree that, to the extent notice of sale shall be required by law, at least ten (10)&nbsp;days&#146; notice to HTL of the time and place of any public sale or
the time after which any private sale is to be made shall constitute reasonable notification. Chen shall not be obligated to make any sale of Property Rights regardless of notice of sale having been given. Chen may adjourn any public or private sale
from time to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Chen may exercise any and all rights of conversion, exchange,
subscription or any other rights, privileges or options pertaining to any of the Property Rights including, but not limited to, or upon the exercise by Pledgor or Chen of any right, privilege or option pertaining to any of the Property Rights in
connection therewith, to deposit and deliver such Property Rights with any committee, depository, transfer agent, registrar or other agency upon such terms as Chen may determine, all without liability except to account for property actually received
by it. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Chen may exercise in respect of the Property Rights, in addition to other rights and remedies provided for
herein or otherwise available to it, all the rights and remedies of a secured party on default under the Code in effect in the State of Texas at that time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B><U>Amendments, Etc</U></B><B>. </B>No amendment or waiver of any provision of this Security Agreement nor consent to any
departure by HTL herefrom, shall in any event be effective unless the same shall be in writing, and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B><U>Addresses for Notices</U></B><B>. </B>All notices and other communications provided for hereunder shall be in writing
(including email or telegraphic communication) and mailed via registered or certified mail or faxed or emailed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to HTL:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Heart Test Laboratories, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5712 Colleyville Blvd., Suite 229</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Colleyville, Texas 76034</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">With a Copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">H. Dale Langley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Law Firm of H. Dale Langley, Jr., PC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1803 West Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Austin, Texas 78701</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Chen:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gary Chen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">c/o Donald R. Taylor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Taylor Dunham, LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">301 Congress Ave., Suite 1050</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Austin, Texas 78701</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">With a Copy to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Robert M. Eddy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2716 Ocean Park Blvd Suite 2028</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Santa Monica, CA 90405</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or as to either party at such other address as shall be designated by such party in a written notice to the
other party complying as to delivery with the terms of this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B><U>Consent to
<FONT STYLE="white-space:nowrap">UCC-1</FONT> Filing</U></B><B>. </B>HTL consents to Chen filing a Form <FONT STYLE="white-space:nowrap">UCC-1</FONT> Financing Statement identifying the assets listed on <U>Exhibit A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B><U>Release of Security Interest</U></B><B>. </B>The Security Interest, and all filings made by Chen to perfect the Security
Interest, shall be released and terminated upon satisfaction of all the obligations in section A. Chen agrees to promptly and diligently execute and deliver to HTL any and all such instruments and documents, and take such further action, to release
and terminate the Security Interest as provided in this Security Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B><U>Severability</U></B><B>. </B>Should any
clause, sentence, paragraph, subsection or section of this Security Agreement be judicially declared to be invalid, unenforceable or void, such decision will not have the effect of invalidating or voiding the remainder of this Security Agreement,
and the parties hereto agree that the part or parts of this Security Agreement so held to be invalid, unenforceable or void will be deemed to have been replaced with a revised provision as similar thereto as to render such provision valid and
enforceable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B><U>Captions</U></B><B>. </B>The Captions in this Security Agreement have been inserted for convenience only and
shall be given no substantive meaning or significance whatever in construing the terms and provisions of this Security Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B><U>No Waiver; Remedies</U></B><B>. </B>No failure on the part of Chen to exercise, and no delay in exercising any right
hereunder, shall operate as a waiver thereof; nor shall any single or partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise of any other right. The remedies herein provided are cumulative and not
exclusive of any remedies provided by law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B><U>Execution in Counterparts</U></B><B>. </B>This Security Agreement may be
executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B><U>Governing Law; Venue</U></B><B>. </B>This Security Agreement shall be governed by and construed in accordance with the
internal laws, and not the law of conflicts, of the State of Texas. HTL and Chen each irrevocably submits and unconditionally waives any objection to the exclusive jurisdiction, including personal jurisdiction, and venue of the District Courts of
Travis County, Texas, and of the United States District Court for the Western District of Texas [Austin Division] for purpose of any suit, action or other proceeding arising out of this Security Agreement or any subject matter hereof, and each
hereby further waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, HTL has caused this Security Agreement to be executed and delivered as
of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>HTL</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HEART TEST LABORATORIES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Hilz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Mark Hilz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CEO</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U><B>CHEN</B></U>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Gary Chen</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ Robert Eddy <B></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">for Guangren Chen as attorney in fact</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="right">3/14/14</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Gary Chen</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>11
<FILENAME>filename11.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.5 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EVALUATION, OPTION AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">between </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE UNIVERSITY COURT
OF THE UNIVERSITY OF GLASGOW </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308g0224031743645.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ref: UOF00l.02173 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EVALUATION, OPTION AND LICENCE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">between </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE UNIVERSITY COURT OF THE UNIVERSITY OF
GLASGOW</B>, incorporated under the Universities (Scotland) Act 1889 and having its principal office at University Avenue, Glasgow, G12 8QQ, a registered Scottish charity in terms of Section&nbsp;13 (2) of the Charities and Trustee Investment
(Scotland) Act 2005 (Charity Number SC004401 Charity Name &#147;University of Glasgow Court&#148;) (the <B>University</B>); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HEART TEST
LABORATORIES</B>, incorporated under the laws of Texas, United States with registration number 800859060 and having its registered office at 9 Village Circle, Suite 527, Westlake, TX 76262, USA (the <B>Company</B>). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The University has developed the Technology. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company wishes to evaluate the Technology and thereafter, if the evaluation is successful, to be granted a
licence to commercially exploit the Technology and the University has agreed to consider the granting of such a licence to the Company on the terms and conditions set out in this Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE PARTIES AGREE as follows: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS AND INTERPRETATION</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this Agreement (including the recitals) unless the context otherwise requires the following words and
expressions shall have the following meanings: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Agreement </B>means this agreement and any amendments to it; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Commencement Date </B>means the date of execution of this Agreement by the University; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Evaluation Fee </B>means the <FONT STYLE="white-space:nowrap">non-refundable</FONT> sum of Fifteen Thousand US Dollars ($15,000 USD); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Evaluation Period </B>means the period commencing on the Commencement Date and expiring on the earlier of the six (6)&nbsp;month anniversary
of the Commencement Date and the Option Exercise Date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Evaluation Rights </B>means the rights granted by the University to the Company
under Clause 3; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Initial Licence Period </B>means the period of five (5) years commencing on the Option Exercise Date; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property Rights </B>means any and all patents, copyright, registered
designs, design rights, registered and unregistered trade marks, database rights, know how and any other intellectual property rights anywhere in the world relating to the Program including any and all applications for such rights and the right to
make such applications; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Know How </B>means all information and data relating to the use of the Program which the University is free to
disclose and is in the University&#146;s possession including technical knowledge and documentation relating to the use and development of the Program but excluding the source code; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Option </B>has the meaning given to it in Clause 4.1; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Option Exercise Date </B>means the date upon which the University acknowledges in writing the Company&#146;s written notice exercising the
Option pursuant to Clause 4.2.1; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Product </B>means any product in which the Program is incorporated which is capable of displaying,
analysing, interpreting and/or transmitting electrocardiograms whether the product was designed for that purpose or otherwise but excluding products which are intended to be used as a centralised facility at a single location for receiving and
processing electrocardiogram data from one or more electrocardiogram signal collecting devices; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Program </B>means a collection of
software modules developed by the University, to be supplied to the Company as a library for an Android platform running on a BCM AR6MXQ processor, for analysis of resting twelve (12)&nbsp;lead electrocardiograms, including software for
(i)&nbsp;signal processing including calculation of average/median beats and 12 -lead ECG measurements; (ii)&nbsp;diagnostic interpretation of electrocardiograms from individuals of all ages; and (iii)&nbsp;analysis of cardiac rhythm; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Schedule </B>means the schedule in three (3)&nbsp;parts annexed to and which is deemed to form part of this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Sub-Licensed</FONT> Products </B>means Products manufactured, assembled, marketed, distributed, sold or
otherwise disposed of by a <FONT STYLE="white-space:nowrap">Sub-Licensee;</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Sub-Licensee</FONT>
</B>means a person, company or organisation to whom the Company has granted a sub-licence of rights licensed to it in accordance with this Agreement and <B><FONT STYLE="white-space:nowrap">Sub-Licensees</FONT> </B>shall be construed accordingly;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Technology </B>means the Program and the Know How as well as all and any Intellectual Property Rights in or related to any of the
foregoing; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Territory </B>means the world. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this Agreement, unless the context otherwise requires: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.2.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">references to Clauses are references to the relevant clauses of this Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.2.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Schedule shall form part of this Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.2.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">references in this Agreement to the word <B>include </B>or <B>including </B>are to be construed without
limitation to the generality of the preceding words; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.2.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the masculine gender shall be deemed to include the feminine and neuter and vice versa and the singular shall
be deemed to include references in the plural and vice versa; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">1.2.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Clause headings are for convenience of reference only and shall not affect the construction or
interpretation of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMMENCEMENT AND DURATION OF THE AGREEMENT</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">2.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement will commence on the Commencement Date and subject to earlier termination under Clause 16
(Termination) or Clause 18 (Force Majeure), will continue in full force and effect until expiry of the Evaluation Period. If the Company exercises the Option in accordance with Clause 4, this Agreement shall continue in full force and effect for the
Initial Licence Period and thereafter shall automatically renew for additional five (5)&nbsp;year terms unless and until (i)&nbsp;termination under Clause 16 (Termination) or Clause 18 (Force Majeure); or (ii)&nbsp;either the University or the
Company gives the other written notice of <FONT STYLE="white-space:nowrap">non-renewal</FONT> no later than nine (9)&nbsp;months prior to expiration of the Initial Licence Period or any renewal term of this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GRANT OF EVALUATION RIGHTS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following receipt of the Evaluation Fee in cleared funds, and subject to Clause 3.2, the University will supply
a copy of the Program to the Company. During the Evaluation Period, the Company may use the Program to carry out an assessment of its suitability, functionality and interoperability. This assessment is solely to enable the Company to determine
whether the Program can be incorporated into a product or products to be manufactured and marketed by the Company that are capable of displaying, analysing, interpreting and/or transmitting electrocardiograms (the <B>Purpose</B>).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">3.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company will not use the Program during the Evaluation Period for any purpose other than the Purpose and,
in particular, will not, during the Evaluation Period, sell, supply, deliver or make available to any third party, market, or use to supply services, the Program or any products which include or utilise the Program, other than for testing (excluding
any testing on patients), evaluation and/or regulatory purposes. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OPTION TO OBTAIN A FULL LICENCE</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">4.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall have the option exercisable in accordance with and subject to Clause 4.2 to receive a full
licence for the Technology (on the terms set out in Clause 5) (the <B>Option).</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">4.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Option may be exercised by the Company by serving written notice on the University in the form set out in
Part 3 of the Schedule at any time during the Evaluation Period following successful compatibility testing with the Program delivered to it under Clause 3.1. Following receipt of such written notice, the University will either:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">4.2.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sign and return such written notice to the Company, in which case the Option shall be deemed to have been
exercised; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">4.2.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the sale of a Product by the Company would, in the reasonable opinion of the University, cause the
University to be in breach of relevant regulatory requirements, notify the Company in writing that the Option is no longer effective, in which case this Agreement will terminate on the date of such notice from the University to the Company.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company shall have no rights in or to the Technology, save as set out in Clause 3, unless and until its exercise of
the Option has been accepted by the University in accordance with Clause 4.2.1. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">4.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Company elects in written notice served on the University not to exercise the Option (a <B>Notice of <FONT
STYLE="white-space:nowrap">Non-Election</FONT></B>)<B> </B>or fails to exercise the Option in accordance with Clause 4.2 prior to the date six (6)&nbsp;months following the Commencement Date, then the Option shall lapse and Agreement will terminate
on such date or the date of the University&#146;s receipt of the Notice of <FONT STYLE="white-space:nowrap">Non-Election,</FONT> whichever is the earlier. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">4.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On termination of this Agreement pursuant to Clause 4.2.2 or 4.3, the Company will ensure that the copy of the
Program delivered to it pursuant to Clause 3 and all copies thereof are destroyed and shall certify to the University in writing that this has been done, all within seven (7)&nbsp;days following the date of termination </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GRANT OF FULL RIGHTS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">5.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With effect only following exercise of the Option by the Company and acceptance by the University in accordance
with Clause 4.2.1, the University hereby grants to the Company, subject to the terms and conditions of this Agreement, a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> royalty-bearing licence in the Territory under the Technology to
manufacture, assemble, market, distribute, sell, offer to sell, import or otherwise dispose of Products. The licence granted by the University to the Company under this Clause does not extend to a grant of any rights to the Company to develop, adapt
or make improvements to the Technology. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">5.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Clause 6, the Company shall have the right to grant to any third party (save for a third party which
is or becomes involved in the manufacture, supply or which otherwise promotes the use of any form of tobacco product or which is or becomes affiliated to any other company or organisation that does so), a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> and <FONT STYLE="white-space:nowrap">non-transferable</FONT> sub-licence in the Territory of the rights licensed to the Company pursuant to Clause 5.1 whether to enable the <FONT
STYLE="white-space:nowrap">Sub-Licensee</FONT> to manufacture, assemble, market, distribute, sell or otherwise dispose of Products in the Territory on its own behalf or on behalf of the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">5.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company will, and will ensure that each <FONT STYLE="white-space:nowrap">Sub-Licensee</FONT> will, take all
reasonable steps and technological measures to prevent unauthorised use or copying of the Program whether by customers or otherwise and to ensure that each copy of the Program issued by or on behalf of the Company or its <FONT
STYLE="white-space:nowrap">Sub-Licensees</FONT> may only be used by or in conjunction with the Product for which it has been licensed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">SUB-LICENSING</FONT> OF RIGHTS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">6.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The granting by the Company of any sub-licences pursuant to Clause 5.2 shall be upon terms that specifically
protect the University&#146;s proprietary and other rights in the Technology. The Company shall ensure that the scope of any licence granted to a <FONT STYLE="white-space:nowrap">Sub-Licensee</FONT> does not exceed the scope of the licence granted
to the Company under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">6.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any sub-licences granted by the Company pursuant to Clause 5.2 shall be recorded in writing and shall include
the additional terms and conditions referred to in Part One of the Schedule. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">6.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall send to the University a certified copy of all agreements entered into by the Company from
time to time with <FONT STYLE="white-space:nowrap">Sub-Licensees</FONT> and all amendments or variations thereto in each case within fourteen (14)&nbsp;days of the date of execution of such agreements, amendments or variations by the Company.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">6.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The University shall treat as secret and confidential all certified copies received pursuant to Clause 6.3 and
shall not<B> </B>disclose any such agreements, amendments or variations, or any information contained therein to any third party without the prior written consent of the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">6.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall promptly inform the University of any persistent or material breach by any <FONT
STYLE="white-space:nowrap">Sub-Licensee</FONT> of the terms of any sub-licence agreement with the Company and agrees to enforce the terms of all such sub-licence agreements for the benefit of the University. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">6.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall make available to any <FONT STYLE="white-space:nowrap">Sub-Licensee</FONT> all necessary
information, data, knowledge and documentation in respect of the Technology in its possession which the <FONT STYLE="white-space:nowrap">Sub-Licensee</FONT> reasonably requires for the purpose of incorporating the Program into products in accordance
with the terms of the licence granted to the Company hereunder. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">6.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall indemnify the University and keep the University indemnified against any and all costs,
losses, charges or expenses of whatever kind or description suffered or incurred by the University as a consequence of any proceedings commenced by any <FONT STYLE="white-space:nowrap">Sub-Licensee</FONT> against the University.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMPANY&#146;S OBLIGATIONS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">7.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company acknowledges that it shall be responsible for obtaining and maintaining at its expense all
necessary government and other regulatory approvals that may be required anywhere in the world in relation to the Company&#146;s use of the Technology and the University hereby delegates to the Company (and the Company hereby accepts) all
responsibility for compliance with any applicable legislation in respect of its use of the Technology. The Company further undertakes that no sales or disposals of Products including any <FONT STYLE="white-space:nowrap">Sub-Licensees&#146;</FONT>
Products shall take place unless all necessary government and other regulatory approvals have been obtained and remain in full force and effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONSIDERATION AND ROYALTIES</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In consideration of the grant of the Evaluation Rights and the Option by the University, the Company shall pay
to the University the Evaluation Fee on or promptly following the Commencement Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In consideration of the grant of the licence under Clause 5, the Company shall pay to the University, subject
to Clauses 8.5 to 8.8 (inclusive), a licence fee for each Product sold or otherwise supplied or disposed of for consideration by the Company and its <FONT STYLE="white-space:nowrap">Sub-Licensees</FONT> in each year (being the twelve (12)&nbsp;month
period commencing on the Option Exercise Date and each anniversary thereof) as follows: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="37%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number of Products sold per year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Payable&nbsp;per&nbsp;Product&nbsp;sold&nbsp;(USD&nbsp;$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1 &#150; 250</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">251 &#150; 500</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">501 &#150; 750</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">751 &#150; 1,000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1,001 &#150; 1,500</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1,501 &#150; 2,000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="38%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number of Products sold per year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Payable&nbsp;per&nbsp;Product&nbsp;sold&nbsp;(USD&nbsp;$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2,00l &#150; 3,000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3,001 &#150; 4,000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4,001 &#150; 5,000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5,001 &#150; 7,500</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&gt; 7,501</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">So, by way of example only, if in one year the total number of Products sold by the Company or its <FONT
STYLE="white-space:nowrap">Sub-Licensees</FONT> is 1,000, the royalty due under this Clause 8.2 shall be $110,000 for that year (i.e. 250 x $125 + 250 x $115 + 250 x $105 + 250 x $95). </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties agree that the Company and its Sub-Licencees may loan or otherwise make the Product available free
of charge on a short-term basis to potential customers strictly for the purposes of promoting a sale (i e. by allowing customers the opportunity to evaluate whether the Product is fit for their required purposes). In those circumstances only, the
licence fees set out in Clause 8.2 shall not be payable. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding Clause 8.2, the parties agree that the Company will pay to the University minimum twelve
(12)&nbsp;monthly licence fees in advance as follows: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="33%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date Payable</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Minimum&nbsp;royalty&nbsp;payable&nbsp;(USD&nbsp;$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year l</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On or promptly following the Option Exercise Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">25,000&nbsp;(less&nbsp;the&nbsp;Evaluation&nbsp;Fee)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date six (6)&nbsp;months following the Option Exercise Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year 2</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First anniversary of the Option Exercise Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date six (6) months following the first anniversary of the Option Exercise Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year 3</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second anniversary of the Option Exercise Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date six (6)&nbsp;months following the second anniversary of the Option Exercise Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year 4</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third anniversary of the Option Exercise Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date six (6)&nbsp;months following the third anniversary of the Option Exercise Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year 5 and each subsequent year of this Agreement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth anniversary of the Option Exercise Date (and every year thereafter during the term of this
Agreement)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date six (6)&nbsp;months following the fourth anniversary of the Option Exercise Date (and every
year thereafter during the term of this Agreement)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If , at the end of any twelve (12)&nbsp;month period following the Option Exercise Date , the amount payable by
the Company under Clause 8.2 in respect of that twelve (12)&nbsp;month period is greater than the amount actually paid to the University by the Company under Clause 8.4 in respect of that twelve (12)&nbsp;month period (which in the case of the first
twelve (12)&nbsp;month period shall be deemed to include payment by the Company of the Evaluation Fee) , the Company shall pay to the University the difference between the amount due under Clause 8.2 and the amount paid under Clause 8.4. Such
payment, if due, will be made by the Company within thirty (30)&nbsp;days following the end of the relevant twelve (12)&nbsp;month period and shall be accompanied by a written statement showing the total quantity of Products (together with details
of the relevant batch codes, serial numbers and dates of despatch) sold, supplied or disposed of by the Company and any <FONT STYLE="white-space:nowrap">Sub-Licensees</FONT> during the relevant twelve (12)&nbsp;month period. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The royalty rate set out in Clause 8.2 and each minimum twelve (12) monthly licence fee set out in the table in
Clause 8.4 shall be increased on the fifth (5th) anniversary of the Option Exercise Date and each anniversary thereafter by an amount equal to three per cent (3%) of the then current royalty rates or relevant minimum twelve (12) monthly licence fee
(as the case may be) (providing that any such changes shall not have retrospective effect). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without prejudice to any other rights accruing to the University, if any amounts payable by the Company to the
University under this Agreement remain unpaid on the due date for payment, interest at the rate of four per cent (4%) per annum above the base rate from time to time of the Clydesdale Bank plc shall be payable by the Company on such amounts from the
due date for payment until the date of actual payment in full of such amounts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All amounts payable by the Company under this Agreement: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.8.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">are exclusive of any VAT or other applicable taxes or duties which shall be paid (if applicable) by the Company
at the appropriate rate, subject to receipt of an appropriate VAT invoice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.8.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shall be paid in full without any <FONT STYLE="white-space:nowrap">set-off,</FONT> deduction or withholding
other than such amount (if any) as the Company is required by law to deduct or withhold, and if the Company is required by law to make any such deduction or withholding, the Company shall, when making the payment to which the withholding or
deduction relates, pay to the University such additional amount as will ensure that the University receives the same total amount that it would have received if no such withholding or deduction had been required; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">8.8.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shall be invoiced by the University, and paid in cleared funds by the Company, in US Dollars to the credit of
the University bank account designated in Part Two of the Schedule annexed hereto (or such other account as the University may notify to the Company for this purpose). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMPANY&#146;S FURTHER OBLIGATIONS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall provide the University with a written copy of the Company&#146;s calculation of the annual
reconciliation to be calculated in accordance with Clause 8.5 within thirty (30)&nbsp;days following the end of each twelve (12)&nbsp;month period whether payment is due or not. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall, and (where applicable) shall procure that all Sub-Licensees shall, during the period of this
Agreement and for a period of six (6) years following termination or expiry of this Agreement, keep and maintain true and accurate accounts and records of all sales and other disposals of Products by the Company or any Sub-Licensees (as the case may
be). The Company shall, and shall procure that all Sub-Licensees shall, retain copies of all relevant invoices for the sale or supply of Products for a period of six (6) years from the last day of the Quarter in which the invoice was issued.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall, with effect from the date falling twelve (12)&nbsp;months following the Option Exercise
Date, provide the University with a written report on an annual basis setting out details of (i)&nbsp;all sales and other disposals of Products by the Company or any <FONT STYLE="white-space:nowrap">Sub-Licensees,</FONT> and (ii)&nbsp;each reseller,
distributor or other third party (other than end users of Products) to whom the Company has sold, supplied or disposed of Products, during the relevant twelve (12)&nbsp;month period. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The accounts and records referred to in Clause 9.2 shall show in sufficient detail all facts necessary for the
accurate calculation of any amounts payable by the Company under this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of verifying that the amounts paid to the University have been correctly calculated in
accordance with Clause 8, the Company shall permit and shall procure that any <FONT STYLE="white-space:nowrap">Sub-Licensees</FONT> shall permit the University and its accountants or other professional persons appointed by the University upon
reasonable notice to inspect any relevant accounts, records and invoices referred to in Clause 9.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If it is established as a result of any inspection undertaken pursuant to Clause 9.5 that any amount paid to
the University in respect of any twelve (12)&nbsp;month period is less than the amount which was properly payable under this Agreement in respect of that twelve (12)&nbsp;month period, the Company shall within seven (7)&nbsp;days of the date upon
which the shortfall is notified to it, pay the shortfall to the University. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The costs of any inspection under Clause 9.5 shall be borne by the University unless such inspection reveals an
error in the amount paid to the University in respect of any twelve (12)&nbsp;month period of more than five per cent (5%) of the actual amounts paid by the Company in respect of that twelve (12)&nbsp;month period, in which event the reasonable
costs of the inspection shall be borne by the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">9.8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of this Clause 9 shall survive termination or expiry of this Agreement for a period of six
(6)&nbsp;years or, if earlier, until all outstanding claims for amounts due to the University under this Agreement have been settled to the satisfaction of the Company and the University. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OBLIGATIONS OF THE UNIVERSITY</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">10.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The University shall, at the Company&#146;s cost, provide such reasonable assistance as the Company may require
for a period of three (3)&nbsp;months following the Option Exercise Date in order to fulfil its obligations pursuant to Clause 7. I of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTELLECTUAL PROPERTY RIGHTS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">11.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company acknowledges that the Technology belongs to the University and that the Company shall not, by
virtue of this Agreement or otherwise, acquire any right, title or interest in or to the Technology other than as expressly provided in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">11.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Company becomes aware of any actual, threatened, suspected or alleged infringement or any unauthorised
use of the Technology by any third party, the Company shall as soon as reasonably practicable provide details of any such actual, threatened, suspected or alleged infringement or unauthorised use of the Technology to the University. The Company
shall, at the request and expense of the University, give the University all reasonable assistance to prevent such infringement and/or unauthorised use, and/or to commence infringement or other proceedings in relation thereto. </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">11.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company will not, and will ensure that each <FONT STYLE="white-space:nowrap">Sub-Licensee</FONT> does not,
copy, decompile, disassemble, modify, reverse engineer or make any improvements to the Technology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SALES AND QUALITY</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following exercise of the Option by the Company and acceptance by the University pursuant to Clause 4.2.1, the
Company shall use its reasonable endeavours to exploit the Technology through marketing, distribution and sales or other disposals of Products and shall procure that all <FONT STYLE="white-space:nowrap">Sub-Licensees</FONT> shall use their
respective reasonable endeavours to exploit the Technology through marketing, distribution and sales or other disposals of Products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall ensure that all Products manufactured, assembled, marketed, sold or otherwise disposed of by
the Company and/or by <FONT STYLE="white-space:nowrap">Sub-Licensees</FONT> shall be of good quality and manufactured and assembled to appropriate standards using appropriate materials reasonably available for the purpose and comply with the
requirements of any necessary governmental or other approvals. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">12.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company undertakes to the University that it shall take all reasonable steps and shall procure that all <FONT
STYLE="white-space:nowrap">Sub-Licensees</FONT> take all reasonable steps to ensure that no fault, failure or defect exists in any Products manufactured, distributed and sold or otherwise disposed of by the Company and/or any <FONT
STYLE="white-space:nowrap">Sub-Licensee</FONT> pursuant to this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LIABILITY AND INDEMNITY</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provisions of this Agreement expressly or impliedly to the contrary, the Company and
any Sub-Licensee shall, by incorporating the Program into products and by using the Technology and the Intellectual Property Rights in the Technology be deemed to have satisfied itself in every respect as to the suitability and fitness of the
Program and the Technology for the use(s) for which they are intended and used. Accordingly no warranty, condition, representation or similar term is given or shall be deemed to be given by or on behalf of the University in respect of the
incorporation of the Program and/or the use of the Technology or any Intellectual Property Rights in the Technology in or in relation to the manufacture, use, evaluation, distribution or sale or disposal of any Products pursuant to this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The University hereby excludes all terms, conditions and warranties which, by virtue of statute, common law or
otherwise, may, in the absence of this Clause, be implied into this Agreement in respect of the licensing of the Technology and the Intellectual Property Rights in the Technology to the Company and/or the use of the Technology or the Intellectual
Property Rights in the Technology in or in relation to the manufacture, use, distribution or sale or disposal of any Products pursuant to this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without in any way excluding or limiting any liability that may not by law be excluded or limited (including
any liability for death or personal injury caused by its negligence and liability for fraudulent misrepresentation), the University shall not be liable to the Company for any loss, damage or injury to any person or property howsoever caused arising
from the incorporation of the Program and/or the use of the Technology or the Intellectual Property Rights in the Technology in or in relation to the manufacture, use, distribution, sale , or disposal of any Products. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding Clauses 13.1, 13.2 or 13.3, the University hereby expressly excludes any and all liability for
any indirect, consequential or special damages or losses, or any loss of profits, loss of revenue, loss of data, loss of contracts or opportunity, whether direct or indirect, which may arise from the incorporation of the Program and/or the use of
the Technology or the Intellectual Property Rights in the Technology in or in relation to the manufacture, use, distribution or sale or disposal of any Products pursuant to this Agreement, even if the Company has advised the University of the
possibility of those losses , or if they were within the University&#146;s contemplation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall indemnify the University and keep the University indemnified against any and all liabilities
, loss, damages and expenses to which the University may become liable as a result of any breach of this Agreement by the Company, or any claim by a <FONT STYLE="white-space:nowrap">Sub-Licensee</FONT> or a third party arising from the incorporation
of the Program and/or the use of the Technology or the Intellectual Property Rights in the Technology in or in relation to the manufacture, use, distribution or sale or disposal of any Products pursuant to this Agreement provided that the University
shall, without undue delay, notify the Company in writing of any third party claims of which they (or any one of them) receives notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company warrants and undertakes to the University that during such time as it is using. selling, or
otherwise making available Products it will effect and shall maintain for the period of this Agreement and thereafter at all times during which it is selling, or otherwise making available Products, insurance at a minimum amount equivalent to Five
Million US Dollars (USD $5,000,000) in respect of any one occurrence to cover the loss, liability and damage incurred under this<B> </B>Agreement in respect of each incident or series of connected incidents. The Company shall at any time upon demand
produce to the University proof that this insurance has been effected and is in force. If the University becomes aware that the Company has failed to effect and/or maintain the insurance required under this Clause the University may effect and
maintain this insurance and the Company shall be bound to reimburse the University for the cost of effecting and maintaining this insurance on demand. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">13.7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Clauses 13.1, 13.2, 13.3, and 13.4 and insofar as any liability may not be limited or excluded by
law, the total liability of the University in respect of any claim or series of related claims, whether in contract, delict or otherwise, arising from the incorporation of the Program and/or the use of the Technology or the Intellectual Property
Rights in the Technology in or in relation to the manufacture, use, distribution or sale or disposal of any Products pursuant to this Agreement shall be an amount equal to the sum of money paid by the Company to the University under this Agreement
in the twelve (12)&nbsp;month period immediately preceding the event that gives rise to the claim (or, where there is a series of related claims, the date of the first such claim). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONFIDENTIALITY</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall, and shall procure that each <FONT STYLE="white-space:nowrap">Sub-Licensee</FONT> shall, at
all times during the period of this Agreement and thereafter: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">maintain as secret and confidential all Technology and any information relating thereto; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">use the Technology exclusively for the purposes of this Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.1.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclose the Technology only to its employees, agents or
<FONT STYLE="white-space:nowrap">sub-contractors</FONT> to whom, and then only to the extent to which, disclosure is reasonably necessary for the purposes of this Agreement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.1.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ensure that information is treated as confidential by its employees, agents and
<FONT STYLE="white-space:nowrap">sub-contractors.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may pass on to its customers and may allow any <FONT STYLE="white-space:nowrap">Sub-Licensee</FONT>
to pass on to its customers all information reasonably required in connection with the sale and maintenance of Products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The obligations of confidentiality contained in Clause 14.1 shall not apply to any information which a party
can show: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.3.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the Commencement Date is in, or at any time thereafter comes into, the public domain other than by breach of
the obligation of confidentiality in Clause 14; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.3.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">was known to that party prior to entering into this Agreement and which is not covered by any obligation of
confidentiality or <FONT STYLE="white-space:nowrap">non-use</FONT> owed by it to the other party to this Agreement or to a third party from whom the information was obtained; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.3.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is made available to that party during the period of this Agreement or thereafter by a third party without
breach of any obligation of confidence: or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">14.3.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is required to be disclosed by (i)&nbsp;law (including any information which requires to be disclosed under the
Freedom of Information (Scotland) Act 2002 and the Environmental Information (Scotland) Regulations 2004), (ii) any regulatory authority, or (iii)&nbsp;any court of competent jurisdiction. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ANNOUNCEMENTS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Clause 15.2, neither party shall make or issue at any time any announcement, press release or other
publicity relating to this Agreement or any matter referred to in this Agreement without the prior written approval of the other party as to the form and content of such announcement, press release or other publicity. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clause 15.1 shall not apply to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.2.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any announcement which either party may be required to issue by law or by the rules or regulations of any
regulatory or government body provided that, prior to issuing the announcement, that party shall, so far as reasonably practicable, consult with the other party as regards the form and content of the announcement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">15.2.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any statement placed by the University on its website or in any other of its marketing materials to the effect
that the Company has obtained a licence of the Program. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMINATION</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement may be terminated forthwith by notice in writing from the University to the Company if:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any amounts payable under this Agreement by the Company are not paid on or before the due date for payment and
remain unpaid thirty (30)&nbsp;days after further notice from the University that the due date for payment has passed; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company is in material breach of or fails to perform or observe any of its obligations under this Agreement
and such breach or failure continues for thirty (30)days after notice from the University requiring the Company to rectify such breach or failure; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.1.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company has a receiver, administrative receiver or similar officer appointed in respect of the whole or any
substantial part of its assets in any part of the world, or an order is made or a resolution is passed for the winding up of the Company or a petition is presented for the appointment of an administrator or similar officer to the Company; or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.1.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company enters into any form of insolvency proceedings in any part of the world or is unable to pay its
debts or certifies that it is unable to pay its debts or the Company makes or enters into any arrangement or compromise with any of its creditors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement may be terminated by the Company forthwith by notice in writing to the University if the
University is in material breach of its obligations under this Agreement and such breach or failure continues for thirty (30)&nbsp;days after notice from the Company requiring the University to rectify such breach or failure. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of a change of control of the Company or sale by the Company of the whole or any part of its
business or assets, the University may terminate this Agreement on giving to the Company not less than three (3)&nbsp;months&#146; notice in writing if such change of control results in the Company becoming involved in or otherwise affiliated with
the manufacture, supply or promotion of any form of tobacco product or if the University has reasonable grounds to believe that such change of control has adversely impacted or is likely to adversely impact the name, reputation or business of the
University. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of Clause 16.3, a change of control of the Company shall be deemed to have occurred if at any
time during the period of this Agreement a company or individual has control of the Company who did not have control of the Company on the date of execution of this Agreement by the Company, and subsections (2)&nbsp;and (4) to (6)&nbsp;of
Section&nbsp;416 of the Income and Corporation Taxes Act 1988 shall apply for the purpose of determining whether a company or individual has or had control of the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">16.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No compensation or damages shall be payable to the Company if this Agreement is terminated by the University
pursuant to the terms of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EFFECTS OF TERMINATION</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">17.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On termination for whatever reason or expiry of this Agreement: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">17.1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the rights licensed to the Company pursuant to this Agreement, and the rights granted to any Sub-Licensee,
shall, unless otherwise agreed by the University in writing, terminate on the date of termination or expiry of this Agreement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">17.1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company shall, and shall procure that all <FONT STYLE="white-space:nowrap">Sub-Licensees</FONT> shall,
within seven (7)&nbsp;days of the date of termination or expiry of this Agreement, deliver up to the University or, if the University so directs, irretrievably delete or destroy all copies of the Technology and all and any materials, documents,
designs and drawings of whatever nature in respect of the Technology, disclosed or provided to the Company or the relevant <FONT STYLE="white-space:nowrap">Sub-Licensee</FONT> by or on behalf of the University during the period of this Agreement and
any copies of such materials documents, designs and drawings which are in the possession or control of the Company or the relevant <FONT STYLE="white-space:nowrap">Sub-Licensee.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">17.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The terms of Clauses 4.4, 6.7, 8 (in respect of sums outstanding and/or to the extent required to give effect
to Clauses 17.4), 11, 13, 14, 15, and 17 to 26 (inclusive) will survive the termination of this Agreement </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">17.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The termination or expiry of this Agreement shall not prejudice or affect any accrued rights or liabilities of
any of the parties and the exercise by any of the parties of any rights or remedies under the terms of this Agreement shall be without prejudice to any other rights or remedies to which such party may be entitled. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">17.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On termination or expiry of this Agreement, the Company shall continue to pay the amounts specified in Clause 8
for any Products ordered from the Company or any <FONT STYLE="white-space:nowrap">Sub-Licensee</FONT> prior to the date of termination or expiry of this Agreement and supplied by the Company or any
<FONT STYLE="white-space:nowrap">Sub-Licensee</FONT> following the date of termination or expiry of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">17.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding the termination or expiry of this Agreement and provided that the termination is not related to
a safety or regulatory issue with respect to any Product, the Company and any <FONT STYLE="white-space:nowrap">Sub-Licensee</FONT> shall be entitled to sell or otherwise supply any Products in its possession at the date of termination or expiry
provided that the Company shall continue to pay the amounts specified in Clause 8 in respect of any such Products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FORCE MAJEURE</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">18.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any delays in or failure of performance by either party under this Agreement (other than an obligation to pay
money) will not be considered a breach of this Agreement if and to the extent that such delay or failure is caused by occurrences beyond the reasonable control of that party including acts of God; acts, regulations and laws of any government;
strikes or other concerted acts of workers; fire; floods; explosions; riots; wars; rebellion; and sabotage; and any time for performance hereunder will be extended by the actual time of delay caused by any such occurrence. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">18.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If either party is prevented from carrying out its obligations under this Agreement for a continuous period of
six (6)&nbsp;months the other party may terminate this Agreement on giving thirty (30)&nbsp;days prior written notice provided always that at the date upon which termination becomes effective the party which was prevented from carrying out its
obligations under this Agreement remains so prevented. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSMISSION OF RIGHTS</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The benefit of the rights licensed to the Company pursuant to this Agreement shall be personal to the Company and the Company shall not,
without the prior consent in writing of the University, mortgage or charge such rights to any third party or assign such rights or part with any of its rights or obligations under this Agreement provided however that nothing in this Clause 19 shall
prevent the Company from granting a licence to a <FONT STYLE="white-space:nowrap">Sub-Licensee</FONT> on the terms set out in this Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WAIVER</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The failure of any party at any time to enforce any provision of this Agreement shall not imply the waiver or abandonment of its rights to
enforce such provision and shall in no way affect its rights thereafter to require complete performance by any other party of any provision of this Agreement nor shall a waiver of any breach of any provision of this Agreement be taken or held to be
a waiver of any subsequent breach of any such provision or be a waiver of the provision itself. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ENTIRE AGREEMENT</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">This Agreement constitutes the entire agreement between the parties in relation to its subject matter and supersedes all previous proposals,
representations, agreements and arrangements whether oral, written or implied between the parties in relation to its subject matter. Each party acknowledges that in entering into this agreement it does not rely on, and shall have no remedies in
respect of, any representation or warranty (whether made innocently or negligently) that is not set out in this Agreement. No party shall have any claim for innocent or negligent misrepresentation based upon any statement in this Agreement. Nothing
in this Clause shall limit or exclude any liability for fraud. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICES</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">22.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All notices to be given and other documentation to be sent under the terms of this Agreement may be delivered
personally, or sent by signed for international post, and addressed as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">22.1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the University: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Research Strategy and Innovation Office </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">The University of Glasgow </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">11<B> </B>The Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Glasgow
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">G22 8QQ </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">For the attention
of: Vice Principal (Research&nbsp;&amp; Enterprise) </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">22.1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of the Company: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Heart Test Laboratories, Inc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">9 Village Circle, Suite 527, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">Westlake, TX 76262, USA </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">For
the attention of: Chief Executive Officer. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">22.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any notice or other documentation shall be deemed to have been served, if delivered personally, on the day of
delivery, and, if posted, on the day on which it is signed for. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">22.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In proving the posting of any notice or other documentation, it shall be sufficient to produce a copy of the
notice or other documentation properly addressed with the relevant post office receipt for its despatch by signed for international post or the foreign equivalent. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">23.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ILLEGALITY</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If any one or more of the provisions contained in this Agreement is, in whole or in part, invalid, illegal or unenforceable in any respect, the
validity, legality or enforceability of the remaining provisions shall not in any way be affected or impaired thereby and the provision in question shall to the extent it is invalid, illegal or unenforceable be deemed not to form part of this
Agreement and shall be replaced with another provision which achieves the result of the invalid, illegal or unenforceable provision to the greatest extent permitted by law. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">24.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>VARIATION OF AGREEMENT</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">No amendment, modification, alteration or variation to the terms of this Agreement shall be validly made unless in writing and signed by or on
behalf of the parties. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">25.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NO PARTNERSHIP OR AGENCY</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Nothing in this Agreement shall constitute or be deemed to constitute a partnership or joint venture between the parties or the relationship
between any of the parties of principal and agent. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">26.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>APPLICABLE LAW</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The construction, validity and performance of this Agreement and all matters relating to this Agreement or the subject matter of this Agreement
(including, without limitation, <FONT STYLE="white-space:nowrap">non-contractual</FONT> claims and disputes) shall be governed in all respects in accordance with the law of Scotland and the parties hereby submit to the exclusive jurisdiction of the
Scottish courts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF </B>these presents consisting of this and the preceding eighteen (18)&nbsp;pages together with the Schedule were
executed by the parties as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SIGNED for and on behalf of <B>THE </B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>UNIVERSITY COURT OF THE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>UNIVERSITY OF GLASGOW </B>by</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>David Newall&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Newall</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">at Glasgow on 2 June____ 2015</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">in the presence of:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Authorised Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Witness <U>/s/ Lee McClure&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Full Name <U>Amanda Lee McClure&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address <U>University of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:3.00em; font-size:10pt; font-family:Times New Roman"><U>Glasgow, G12
8QQ&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">SIGNED for and on behalf of <B>HEART </B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>TEST LABORATORIES </B>by</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Andrew Simpson (Chairman)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Simpson</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">at __9:30 am_______ on _May 22,__ 2015 in the presence of:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Authorised Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Witness <U>/s/ Aaron Peterson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Full Name <U>Aaron Peterson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address <U>9 Village Circle, Suite
527&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman"><U>Westlake, TX
76262&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>12
<FILENAME>filename12.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.6 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g271308dsp152.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heart Test Laboratories, Inc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9 Village Circle, Suite 527 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westlake </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TX 76262 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">USA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">23&nbsp;December 2015 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sirs </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Heart Test Laboratories </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The University Court of the University of Glasgow </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ECG
Licensing Arrangements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We refer to the licence agreement between <B>THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW, </B>a charity registered in
Scotland under charity registration number SC004401 with its principal offices at University Avenue, Glasgow G12 8QQ (the <B>University) </B>and <B>HEART TEST LABORATORIES </B>a company incorporated under the laws of Texas, United States with
registration number 800859060 and having its registered office at 9 Village Circle, Suite 527, Westlake, TX 76262, USA (the <B>Company) </B>(together the <B>Parties) </B>dated 22 May 2015 and 2 June 2015, under which the University granted to the
Company: i) a licence to evaluate the Program; and ii) an option to be granted a licence to commercially exploit the Program if the evaluation is successful (the <B>Agreement) </B><B>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Evaluation Period was due to expire on 1&nbsp;December 2015. Notwithstanding, the Company wishes to obtain
a full licence for the Technology (including the Program) and the University has agreed to grant such licence on the terms set out herein. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Company has developed an innovative ECG device which provides standard 12 -lead ECG trace and
automatic interpretive analysis as well as additional proprietary informatics (the <B>MyoVista Model).</B> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has developed a sales and marketing strategy for the MyoVista Model, which will make it difficult
for the Company to fulfill its obligation to pay the per Product licence fees to the University set out in Clause 8.2 of the Agreement. Therefore, the Company has requested that the University reduces the rate of per Product licence fees payable.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:4%">


<IMG SRC="g271308dsp152a.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties have now agreed that certain amendments should be made to the Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THEREFORE IT IS AGREED: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding that the Evaluation Period was due to expire on 1&nbsp;December 2015, the University
acknowledges and agrees that with effect from the date of execution of this letter on behalf of the Company, the Option shall be deemed to have been exercised by the Company, with retrospective effect, on 1&nbsp;December 2015 and that such date
shall be the Option Exercise Date. For clarity, the Agreement shall apply to the entirety of the Initial Licence Period notwithstanding any lapse in time between expiry of the Evaluation Period and signature of this letter by the Parties.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Following execution of this letter, the Company shall promptly pay to the University $10,000 USD in Year 1
minimum licence fee in accordance with Clause 8 of the Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With effect from and following the last date of signature of this letter by the Parties, the Agreement shall be
amended as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following definition shall be added to Clause 1.1: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;MyoVista Model&#148; </B>means the electrocardiogram product developed by the Company, which is expected to be submitted to the FDA
for regulatory approval in or around February 2016, and all subsequent updates or upgrades thereto to the extent that the same contain the Program (irrespective of whether those subsequent updates or upgrades require further FDA approval); </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The definition of &#147;Product&#148; in Clause 1.1 shall be removed and replaced with the following:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Product </B>means any product, including each MyoVista Model, in which the Program is incorporated which is
capable of displaying, analysing, interpreting and/or transmitting electrocardiograms whether the product was designed for that purpose or otherwise but excluding products which are intended to be used as a centralised facility at a single location
for receiving and processing electrocardiogram data from one or more electrocardiogram signal collecting devices.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A new Clause 5.4 shall be added to the Agreement as follows: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;The Company will, and will ensure that each <FONT STYLE="white-space:nowrap">Sub-Licensee</FONT> will, incorporate the Program into each
MyoVista Model sold or otherwise supplied or disposed of by the Company and/ or its Sub-Licensees during the Initial Licence Period.&#148; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clause 8.2 of the Agreement shall be deleted and replaced with the following: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;In consideration of the grant of the licence under Clause 5, the Company shall pay to the University, subject to Clauses 8.5 to 8.8
(inclusive), a licence fee for each Product sold or otherwise supplied or disposed of for consideration by the Company and its <FONT STYLE="white-space:nowrap">Sub-Licensees</FONT> in each year (being the twelve (12)&nbsp;month period commencing on
the Option Exercise Date and each anniversary thereof) as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="38%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number of Products sold per year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;payable&nbsp;per&nbsp;Product&nbsp;sold&nbsp;(USD&nbsp;$)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1 <FONT STYLE="white-space:nowrap">-2,000</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2,001 - 5,000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&gt; 5,001</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Company&#146;s obligation to pay to the University the licence fees set out
in the foregoing table for each MyoVista Model (and not for other Products) sold or otherwise supplied or disposed of for consideration by the Company and its Sub-Licensees in each year shall not commence until the second anniversary of the Option
Exercise Date and shall be payable on each anniversary thereof. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Save as expressly provided in this letter, the provisions of the Agreement shall continue in full force and
effect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Words and expressions defined in the Agreement shall, except where the context otherwise requires, bear the
same meaning where used in this letter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This letter and any dispute or claim arising out of or in connection with it, the Agreement or their subject
matter or formation (including <FONT STYLE="white-space:nowrap">non-contractual</FONT> disputes or claims) shall be governed by and construed in accordance with the laws of Scotland and the Parties irrevocably agree that the courts of Scotland shall
have exclusive jurisdiction. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please confirm your acceptance of the terms contained in this letter by signing (where indicated below),
and thereafter returning, the enclosed copy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Yours sincerely</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Newall</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">David Newall</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For and on behalf of The University Court of the University of Glasgow </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby confirm our acceptance of the terms contained in the above letter and agree to be legally bound by its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Hilz</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">12/23/15 </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Mark Hilz, Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">For and on behalf of Heart Test Laboratories, Inc</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>13
<FILENAME>filename13.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.7 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), OR ANY STATE SECURITIES LAW AND MAY NOT BE
SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR PAYOR SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND
UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UNSECURED DRAWDOWN CONVERTIBLE PROMISSORY NOTE
</U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>UP TO $130,000</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Issuance Date: August&nbsp;12, 2019</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FOR VALUE RECEIVED</B>, the undersigned, Heart Test Laboratories, Inc. D/B/A HeartSciences, a Texas
corporation (the &#147;<B>Company</B>&#148; or &#147;<B>Payor</B>&#148;), hereby promises to pay to the order of Front Range Ventures LLC, a Wyoming limited liability company, or its assigns (&#147;<B>Holder</B>&#148;), the outstanding principal
balance of the borrowings set forth on the last entry on the Schedule attached hereto (the &#147;<B>Loan Amount</B>&#148;) at such place as the Holder may designate in writing to Payor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Borrowings</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
Borrowings under this Note shall be used to pay the monthly retainer fee and expenses of David Kasnic (&#147;<B>Kasnic</B>&#148;) incurred with respect to the Company. Borrowings shall occur, as necessary, the intent being that the Company will pay
Kasnic&#146;s monthly retainer in advance of each month and Kasnic&#146;s expenses upon submission. Borrowings under this Note may not be used for any other purpose than payment of retainer and expenses of Kasnic (including those incurred by the
Company prior to the date of this Note in the amount of $45,571.63). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Holder will enter on the Schedule the amount of each borrowing by
Payor, the date on which each such borrowing occurred, and the outstanding Loan Amount as a result of each such borrowing. Payor hereby authorizes Holder to make such entries and agrees that those entries and the outstanding Loan Amount as shown on
the Schedule will constitute conclusive evidence of all borrowings, the dates thereof, and of the outstanding Loan Amount due under this Note. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Maturity</U><U></U><U>&nbsp;&amp; Interest</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Loan Amount shall be due and payable 20 days after the Company&#146;s MyoVista device is cleared or approved by the U.S. Food and Drug
Administration (the &#147;FDA&#148;) (&#147;<B>Maturity</B>&#148;). Payor may repay the Loan Amount at any time, provided Payor has first provided Holder written notice at least 20 days before payment and such repayment is for the entire Loan
Amount. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Loan Amount shall not accrue interest. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Conversion</U>. Either the Payor or Holder may elect to have the Loan Amount converted into the Company&#146;s Series C Convertible
Preferred Stock upon written notice to the other. Conversion shall otherwise occur upon Maturity. The conversion price shall be the lowest price per share paid for the Company&#146;s Series C Convertible Preferred Stock. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Parties in Interest, Transferability</U>. This Note shall be binding upon Payor and
its successors and assigns and the terms hereof shall inure to the benefit of Holder and its successors and permitted assigns. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.
<U>Expenses</U>. Payor shall pay, on demand, all expenses of collecting and enforcing this Note, including, without limitation, reasonable attorney fees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Amendments</U>. This Note may not be modified or amended in any manner except in writing executed by Payor and Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Notices</U>. Any notice, demand, request, waiver or other communication required or permitted to be given hereunder shall be in writing
and shall be effective (a)&nbsp;upon hand delivery by telecopy or facsimile at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), by email transmission at the
address specified below, or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b)&nbsp;on the second business day following the date of
mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="94%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address of Holder:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Front Range Ventures LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">P.O. Box 1678</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Laramie, WY 82073</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">With copy to:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bohemian Asset Management</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">262 E. Mountain Ave.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fort Collins, CO 80524</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address of the Payor:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Heart Test Laboratories, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">550 Reserve Street, Suite 360</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Southlake, Texas 76072</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Attn: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Governing Law</U>. This Note shall be governed by and construed in accordance with the laws of the
State of Colorado, without giving effect to the choice of law provisions. This Note shall not be interpreted or construed with any presumption against the party causing this Note to be drafted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Headings</U>. Article and section headings in this Note are included herein for purposes of convenience of reference only and shall not
constitute a part of this Note for any other purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief</U>.
The remedies provided in this Note shall be cumulative and in addition to all other remedies available under this Note, at law or in equity (including, without limitation, a decree of specific performance and/or other injunctive relief), no remedy
contained herein shall be deemed a waiver of compliance with the provisions giving rise to such remedy and nothing herein shall limit a Holder&#146;s right to pursue actual damages for any failure by Payor to comply with the terms of this Note.
Amounts set forth or provided for herein with respect to payments and the like (and the computation thereof) shall be the amounts to be received by Holder and shall not, except as expressly provided herein, be subject to any other obligation of
Payor (or the performance thereof). Payor acknowledges that a breach by it of its obligations hereunder will cause irreparable and material harm to Holder and that the remedy at law for any such breach may be inadequate. Therefore Payor agrees that,
in the event of any such breach or threatened breach, Holder shall be entitled, in addition to all other available rights and remedies, at law or in equity, to seek and obtain such equitable relief, including but not limited to an injunction
restraining any such breach or threatened breach, without the necessity of showing economic loss and without any bond or other security being required. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Failure or Indulgence Not Waiver</U>. No failure or delay on the part of Holder in the exercise of any power, right or privilege
hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Binding Effect</U>. The obligations of Payor and Holder set forth herein shall be binding upon the successors and assigns of each such
party, whether or not such successors or assigns are permitted by the terms hereof. Holder may assign any or all if its rights, titles and interests in, to or under this Note to any person or entity upon written notice to Payor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Severability</U>. The provisions of this Note are severable, and if any provision shall be held invalid or unenforceable in whole or in
part in any jurisdiction, then such invalidity or unenforceability shall not in any manner affect such provision in any other jurisdiction or any other provision of this Note in any jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Payor </U>Waivers. Except as otherwise specifically provided herein, Payor and all others that may become liable for all or any part of
the obligations evidenced by this Note, hereby waive presentment, demand, notice of nonpayment, protest and all other demands and notices in connection with the delivery, acceptance, performance and enforcement of this Note, and do hereby consent to
any number of renewals of extensions of the time or payment hereof and agree that any such renewals or extensions may be made without notice to any such persons and without affecting their liability herein and do further consent to the release of
any person liable hereon, all without affecting the liability of the other persons, firms or Payor liable for the payment of this Note. No delay or omission on the part of Holder in exercising its rights under this Note, or course of conduct
relating hereto, shall operate as a waiver of such rights or any other right of the Holder, nor shall any waiver by Holder of any such right or rights on any one occasion be deemed a waiver of the same right or rights on any future occasion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Payor and Holder have executed and delivered this Note
as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HEART TEST LABORATORIES, INC.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>(Payor)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Simpson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Andrew Simpson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chairman</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FRONT RANGE VENTURES LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>(Holder).</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Loren J. Richards</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Loren J. Richards</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">FWTB Trust Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>14
<FILENAME>filename14.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.8 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HEART TEST LABORATORIES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LOAN AND SECURITY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This LOAN AND SECURITY AGREEMENT (&#147;<B><I>Agreement</I></B>&#148;) is made as of April<U> __ </U>, 2020 (the &#147;<B><I>Effective
Date</I></B>&#148;) by and between <B>Heart Test Laboratories, Inc. d/b/a Heart Sciences</B>, a Texas corporation (the &#147;<B><I>Company</I></B>&#148;), <B>Front Range Ventures LLC</B>, a Wyoming limited liability company, or its assigns
(&#147;<B><I>FRV</I></B>&#148;), and <B>John Q. Adams, </B>a Texas resident, or his assigns (&#147;<B><I>JQA</I></B>&#148;) (FRV and JQA each a &#147;<B><I>Lender</I></B>&#148; and together the &#147;<B><I>Lenders</I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITAL: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To provide the
Company with additional resources to conduct its business, each Lender is willing to lend the Company the principal amount of Five Hundred Thousand Dollars ($500,000) (together, the &#147;<B><I>Principal Amount</I></B>&#148; and individually, as to
each Lender&#146;s respective contribution, the &#147;<B><I>Lender Amount</I></B>&#148;), subject to the terms and conditions specified herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, in consideration of the foregoing, and the representations, warranties, covenants and conditions set forth below, the Company and Lenders, intending to be legally bound, hereby agree as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>AMOUNT AND DISBURSEMENTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1.</B> <B>Amount</B>. Subject to the terms and conditions of this Agreement, the Company shall borrow from each Lender such Lender&#146;s
Lender Amount, against the issuance and delivery by the Company of a secured promissory note to such Lender in the amount of the Lender Amount, in the form attached hereto as <B>Exhibit A </B>and incorporated herein (the
&#147;<B><I>Notes</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2.</B> <B>Disbursements</B>. The Notes shall provide for a series of loans to be made by the
Lenders to the Company. The Principal Amount will be disbursed in three installments: (a) $300,000 will be disbursed upon execution of this Agreement and the Notes; (2) $350,000 will be disbursed on or about July&nbsp;2, 2020; and (3) $350,000 will
be disbursed on or about September&nbsp;4, 2020. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTEREST AND FEES. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interest. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Interest will accrue on the outstanding Principal Amount at the rate of twelve percent (12%) per annum, compounded annually
(&#147;<B><I>Accrued Interest</I></B>&#148;). The Company shall pay all Accrued Interest on the &#147;Maturity Date&#148; (as defined in Section&nbsp;3.1). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company will also pay interest at the rate of 18% per annum, compounded annually, on any amount owing under this Agreement or the Notes
(collectively, the &#147;<B><I>Transaction Agreements</I></B>&#148;) that is not paid when due from the due date thereof until the amount is paid (&#147;<B><I>Default Interest</I></B>&#148;). Default Interest will be payable on demand. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Interest, in item (b)&nbsp;above, will accrue from day to day and will be calculated on
the basis of the actual number of days elapsed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2.</B> <B>Maximum Rate. </B>Notwithstanding any other provision of this Agreement,
interest shall not exceed the maximum rate permitted by law; and if any amount is paid as interest in excess of such maximum rate, then the amount so paid will not constitute interest but will constitute a payment on account of the outstanding
Principal Amount of the Notes, and which will be allocated in proportion to the outstanding Lender Amounts. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MATURITY DATE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1.</B> <B>Maturity Date. </B>The outstanding Principal Amount, together with all Accrued Interest thereon, shall be due and payable on
September&nbsp;30, 2021 (the &#147;<B><I>Maturity Date</I></B>&#148;). All payments and other charges due under the Transaction Agreements shall be made in lawful currency of the United States of America. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>THE CLOSING </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1.</B> <B>Closing Date. </B>The closing of the Loan (the &#147;<B><I>Closing</I></B>&#148;) shall be held as of the date hereof (the
&#147;<B><I>Closing Date</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2.</B> <B>Delivery. </B>At the Closing (i)&nbsp;the Company shall execute and deliver to
each Lender an executed counterpart of this Agreement and the Notes and (ii)&nbsp;each Lender shall execute and deliver to the Company an executed counterpart of this Agreement. The executed Transaction Agreements shall be delivered to the Lenders
at the addresses for each respective Lender indicated on the signature pages of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.
&nbsp;&nbsp;&nbsp;&nbsp;REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the Effective Date, the Company hereby
represents and warrants to each Lender as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1.</B> <B>Organization, Good Standing and Qualification</B>. The Company is a
corporation duly organized, validly existing and in good standing under the laws of the State of Texas. The Company has the requisite corporate power to own, lease and operate its properties and assets and to carry on its business as now conducted
and as proposed to be conducted. The Company is duly qualified and is authorized to do business and is in good standing as a foreign corporation in all jurisdictions in which the nature of its activities and of its properties (both owned and leased)
makes such qualification necessary, except for those jurisdictions in which failure to do so would not have a material adverse effect on the Company or its business. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2.</B> <B>Power</B>. The Company has and will have at the Closing all requisite power to execute and deliver the Transaction Agreements,
and to carry out and perform its obligations under the terms of this Agreement and under the terms of the other Transaction Agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3.</B> <B>Authorization. </B>All corporate action on the part of the Company, its
directors and its shareholders necessary for the authorization, execution, delivery by the Company of the Transaction Agreements and the performance of the Company&#146;s obligations hereunder and thereunder, including the issuance and delivery of
the Note, has been taken or will be taken. This Agreement and the other Transaction Agreements, when executed and delivered by the Company, shall constitute valid and binding obligations of the Company enforceable in accordance with their terms,
(a)&nbsp;subject to laws of general application relating to bankruptcy, insolvency, the relief of debtors, (b)&nbsp;with respect to rights to indemnity, subject to federal and state securities laws, and (c)&nbsp;subject to general principles of
equity that restrict the availability of equitable remedies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4.</B> <B>Title to Properties and Assets; Liens, Etc</B>. The Company
has good and marketable title to, valid leasehold interests in, or personal property rights to the Company&#146;s properties and assets, including the properties and assets currently used in its business, in each case subject to no Lien other than
(i)&nbsp;the Lien of current taxes not yet due and payable, (b)&nbsp;Liens created in connection with the transactions contemplated hereby (c)&nbsp;Liens and encumbrances which do not materially detract from the value subject thereto or materially
adversely affect the Company or its business as conducted and proposed to be conducted, and (d)&nbsp;the existing security interest granted in the Company assets to Guangren &#147;Gary&#148; Chen pursuant to that certain Security Agreement and
Pledge between Chen and Debtor dated as of March&nbsp;14, 2014. For the purposes hereof, the term &#147;<B><I>Lien</I></B>&#148; shall mean, with respect to any property, any security interest, mortgage, pledge, lien, claim, charge or other
encumbrance in, of, or on such property or the income therefrom, including, without limitation, the interest of a vendor or lessor under a conditional sale agreement, capital lease or other title retention agreement, or any agreement to provide any
of the foregoing, and the filing of any financing statement or similar instrument under the Uniform Commercial Code or comparable law of any jurisdiction. All facilities, machinery, equipment, fixtures, vehicles and other properties owned, leased or
used by the Company are in good operating condition and repair and are reasonably fit and usable for the purposes for which they are being used. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5.</B> <B>Intellectual Property</B>. The Company owns or possesses sufficient legal rights to all patents, trademarks, service marks,
trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes, and any applications for such that are in the process of being prepared, necessary for its business as now conducted and as presently proposed
to be conducted (the &#147;<B><I>Company Intellectual Property</I></B>&#148;), and, to the Company&#146;s knowledge, without any infringement of the rights of others. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6.</B> <B>Compliance with Laws; Permits</B>. The Company is not in violation of any applicable statute, rule, regulation, order or
restriction of any domestic or foreign government or any instrumentality or agency thereof in respect of the conduct of its business or the ownership or operation of its properties, the violation of which would materially and adversely affect the
business, assets, liabilities, financial condition, operations or prospects of the Company. The Company has all franchises, permits, licenses and any similar authority necessary for the conduct of its business as now being conducted by it, the lack
of which could materially and adversely affect the business, properties or financial condition of the Company and believes it can obtain, without undue burden or expense, any similar authority for the conduct of its business as presently proposed to
be conducted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7.</B> <B>Compliance with Other Instruments</B>. The Company is not in violation or
default of any term of, and the execution and delivery by the Company of the Transaction Agreements will not result in any violation or default with respect to, its articles of incorporation or bylaws, or of any provision of any mortgage, indenture
or contract to which it is a party and by which it is bound or of any judgment, decree, order or writ, other than such violation(s) that would not have a material adverse effect on the Company. The execution, delivery and performance of this
Agreement and the other Transaction Agreements, and the consummation of the transactions contemplated hereby or thereby will not result in any such violation or be in conflict with, give rise to any acceleration or right to accelerate, or
constitute, with or without the passage of time and giving of notice, either a default under any such provision, instrument, judgment, decree, order or writ or an event that results in the creation of any Lien upon any assets of the Company or the
suspension, revocation, impairment, forfeiture, or nonrenewal of any material permit, license, authorization or approval applicable to the Company, its business or operations or any of its assets or properties. Without limiting the foregoing, the
Company has obtained all waivers reasonably necessary with respect to any preemptive rights, rights of first refusal or similar rights, including any notice or offering periods provided for as part of any such rights, in order for the Company to
consummate the transactions contemplated hereunder without any third party obtaining any rights to cause the Company to offer or issue any securities of the Company as a result of the consummation of the transactions contemplated hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8.</B> <B>Litigation</B>. There is no action, suit, proceeding or investigation pending or, to the Company&#146;s knowledge. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.9.</B> <B>Offering. </B>The offer, issue, and sale of the Notes is and will be exempt from the registration and prospectus delivery
requirements of the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;), and has been registered or qualified (or is exempt from registration and qualification) under the registration, permit, or qualification requirements of all
applicable state securities laws and regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.10.</B> <B>Covenants</B>. Until the repayment in full of all amounts due under the
Transaction Agreements, the Company covenants and agrees as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall not undertake any disposition of material
assets without the prior written consent of the Lenders; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall not pledge, encumber or grant any additional security
interest in any assets of the Company or any of its subsidiaries to any third party without the consent of the Lenders, excluding the pledge of assets pursuant to this Agreement and the Note. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SECURITY AGREEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1.</B> As collateral security for the full, prompt, complete and final payment and performance when due (whether at stated maturity, by
acceleration or otherwise) of all of the Company&#146;s obligations under the Transaction Agreements and in order to induce the Lenders to make the loans contemplated hereunder, the Company hereby assigns, conveys, mortgages, pledges, hypothecates
and transfers to the Lenders a security interest in all of the Company&#146;s right, title and interest in, to and under all of the following property and assets, wherever located, whether now owned or hereafter acquired or arising, and all
proceeds, products, accessions, additions, substitutions, rents, profits and replacements thereof, including, without limitation, all Inventory, Equipment, Fixtures, Goods, Accounts, account receivables, contract rights, Commercial Tort
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Claims, chattel paper (tangible and electronic), Deposit Accounts, Documents, General Intangibles, payment intangibles, Software, Instruments, Promissory Notes, Investment Property, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Letter-of-Credit</FONT></FONT> Rights and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">letters-of-credit,</FONT></FONT> and Supporting obligations, intellectual
property (including, and without limitation, patents, patent applications, copyrights, trademarks and trade secrets), license rights, distribution rights, and rights to sue for infringement of General Intangible or intellectual property rights (all
of which being collectively referred to herein as the &#147;Collateral&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2.</B> The Company, on behalf of the Lenders, will
file any financing statement or continuation statement (including &#147;in lieu&#148; continuation statements) necessary to perfect Lenders&#146; security interest in the Collateral. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3.</B> At any time and from time to time, upon the written request of the Lenders, and at the sole expense of the Company, the Company
shall promptly and duly execute and deliver any and all such further instruments and documents and take such further action as the Lenders may reasonably deem necessary or desirable to perfect and continue perfected or better perfect the
Lenders&#146; liens in the Collateral. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4.</B> The Lenders acknowledge that a security interest in the Collateral described in this
Section&nbsp;6 has been granted to Guangren &#147;Gary&#148; Chen pursuant to that certain Security Agreement and Pledge between Chen and Debtor dated as of March&nbsp;14, 2014 (the &#147;Chen Agreement&#148;). The Company represents and warrants
that, except for the security interest granted hereunder and the security interest granted under the Chen Agreement, the Company is the sole legal and equitable owner of each item of the Collateral in which it purports to grant a security interest
hereunder. No other security agreement, financing statement, equivalent security or lien instrument or continuation statement covering all or any part of the Collateral exists, except such as shall be filed in favor of the Lenders pursuant to the
Transaction Agreements or has been filed pursuant to the Chen Agreement. The foregoing representations and warranties are true and accurate as of the date hereof and shall be true and accurate for so long as any amount payable under the Transaction
Agreements remains outstanding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5.</B> The Company has not received any written, or to its knowledge, oral communications alleging
that the Company has violated or, by conducting its business as proposed, would violate any of the trademarks, service marks, trade names, patents, copyrights or trade secrets or other proprietary rights of any other person or entity. The foregoing
representations and warranties are true and accurate as of the date hereof and shall be true and accurate for so long as any amount payable under the Transaction Agreements remains outstanding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.6.</B> Lenders may exercise, in addition to and not in lieu of all other rights and remedies granted to it hereunder and under the Notes,
all rights and remedies of a secured party under the law, including the Uniform Commercial Code in effect in any and all jurisdictions where <FONT STYLE="white-space:nowrap">UCC-1s</FONT> are filed to perfect the Lenders&#146; security interest (the
&#147;<B>UCC</B>&#148;). The Lenders shall not have any obligation or liability hereunder with respect to the Collateral. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.7.</B> For
so long as payment obligations under the Transaction Agreements remain outstanding, the Company (i)&nbsp;shall not sell, lease, transfer, hypothecate, or otherwise dispose of or encumber any of the Collateral; (ii)&nbsp;shall not change the
Company&#146;s jurisdiction of organization without at least seven (7)&nbsp;days prior written notice to the Lenders; and (iii)&nbsp;shall not, directly or indirectly, create, permit or suffer to exist, and shall defend the Collateral against and
take such other action as is necessary to remove, any lien on the Collateral except the lien granted to the Lenders under the Transaction Agreements and the lien granted under Chen Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1.</B> <B>Binding Agreement</B>. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the
respective successors and assigns of the parties. Nothing in this Agreement, expressed or implied, is intended to confer upon any third party any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly
provided in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2.</B> <B>Successors and Assigns</B>. The rights and obligations of the Company and the Lenders shall be
binding upon and benefit the successors, assigns, heirs, administrators and transferees of the parties. All obligations of the Company hereunder shall survive the Closing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3.</B> <B>Assignment by the Company</B>. The rights, interests or obligations hereunder may not be assigned, by operation of law or
otherwise, in whole or in part, by the Company without the prior written consent of the Requisite Lenders, which may be withheld in such Lenders&#146; sole and absolute discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4.</B> <B>Severability of this Agreement</B>. If any provision of this Agreement shall be judicially determined to be invalid, illegal or
unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5.</B> <B>Governing Law. </B>This Agreement shall be governed by and construed under the laws of the State of Texas as applied to
agreements among Texas residents, made and to be performed entirely within the State of Texas, without giving effect to conflicts of laws principles. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6.</B> <B>Counterparts. </B>This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. Facsimile signatures shall be binding as original signatures. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.7.</B>
<B>Titles and Subtitles</B>. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.8.</B> <B>Notices. </B>All notices required or permitted hereunder shall be in writing and shall be deemed effectively given:
(a)&nbsp;upon personal delivery to the party to be notified, (b)&nbsp;five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, within the United States, (c)&nbsp;one (1) day after deposit with
a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt, within the United States, or (d)&nbsp;upon actual delivery if mailed or otherwise delivered in hard copy outside the Unites States. All
communications shall be sent to the Company and to Lenders at the address(es) set forth on the signature page hereto or at such other address(es) as the Company or Lenders may designate by ten (10)&nbsp;days&#146; advance written notice to the other
parties hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.9.</B> <B>Further Assurances</B>. The Company agrees at any time and from time to time at its expense, upon request
of a Lender, to promptly execute, deliver, or obtain or cause to be executed, delivered or obtained any and all further instruments and documents and to take or cause to be taken all such other action as a Lender may deem reasonably desirable in
obtaining the full benefits of, or in preserving the liens and/or security interests of, the Transaction Agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.10.</B> <B>Survival</B>. All representations, warranties, covenants and agreements made
by the Company in connection herewith shall survive the disbursement of the loans, the execution and delivery of this Agreement and the Notes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.11.</B> <B>Modification; Waiver</B>. No modification or waiver of any provision of this Agreement or consent to departure therefrom shall
be effective unless agreed to in writing by the Company and each Lender. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.12.</B> <B>Delays or Omissions. </B>It is agreed that no
delay or omission to exercise any right, power or remedy accruing to Lenders, upon any breach or default of the Company under this Agreement or any other Transaction Agreement, shall impair any such right, power or remedy, nor shall it be construed
to be a waiver of any such breach or default, or any acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default
theretofore or thereafter occurring. It is further agreed that any waiver, permit, consent or approval of any kind or character by Lenders of any breach or default under this Agreement, or any waiver by Lenders of any provisions or conditions of
this Agreement must be in writing and shall be effective only to the extent specifically set forth in writing and that all remedies, either under this Agreement, or by law or otherwise afforded to the Lenders, shall be cumulative and not
alternative. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.13.</B> <B>Entire Agreement</B>. This Agreement together with the other Transaction Agreements constitute and contain
the entire agreement among the Company and Lenders and supersede any and all prior agreements, negotiations, correspondence, understandings and communications among the parties, whether written or oral, respecting the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>In Witness Whereof, </B>the parties have executed this <B>Loan and Security Agreement
</B>as of the date first written above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>COMPANY: </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Heart Test Laboratories, Inc. d/b/a Heart Sciences</B>, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a
Texas corporation </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Simpson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Andrew Simpson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chairman</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Company Address: </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">550
Reserve Street, Suite 360 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Southlake, TX 76092 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>LENDERS: </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Front Range Ventures, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a Wyoming limited liability company </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By: L. Lee
Stryker Irrevocable Trust U/A/D 09/10/74 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Its: Sole Member </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">By: First Western Trust Its: Trustee </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ Loren J. Richards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Loren J. Richards, Trust Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Mailing Address: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">PO Box 1628 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Laramie, WY 82073
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/ John Q. Adams Sr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>John Q. Adams Sr.</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mailing Address: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2350 Airport
Freeway, Suite 1600 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bedford, TX 76022 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Loan&nbsp;&amp; Security
Agreement &#150; Signature Pages </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>15
<FILENAME>filename15.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.9 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 1 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LOAN AND SECURITY AGREEMENT EXTENSION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT (this &#147;<B>Amendment</B>&#148;) is made and entered into as of September&nbsp;30,
2021, by and among Heart Test Laboratories, Inc., a Texas corporation, (the &#147;<B>Company</B>&#148;), Front Range Ventures LLC, a Wyoming limited liability company, or its assigns (&#147;<B>FRV</B>&#148;), and John Q. Adams, a Texas resident, or
his assigns, (&#147;<B>JQA</B>&#148;) (FRV and JQA each a &#147;<B>Lender</B>&#148; and together the &#147;<B>Lenders</B>&#148;) as defined in the Original Agreement (as defined below). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WITNESSETH: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Company, the Lenders (collectively, the &#147;<B>Parties</B>&#148;) have previously entered into a Loan and Security Escrow Agreement dated on or around April&nbsp;24, 2020 (the &#147;<B>Original Agreement</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties desire to extend the Maturity Date of the Original Agreement and the Original Agreement shall be repayable upon demand as
set forth in this Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, in consideration of the issuance of warrants to acquire 500,000 shares of common stock of the
Company on terms set out in a separate warrant agreement and the mutual covenants and agreements set forth herein and for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by each party hereto, the Parties
hereby agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <U>Capitalized Terms</U>. Capitalized terms used in this Amendment shall have the meaning set
forth in the Original Agreement except as otherwise defined in this Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <U>Amendment</U>. The Original Agreement
is hereby amended, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Paragraph 3.1 of the Original Agreement is hereby amended to read, in its entirety, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;The outstanding Principal Amount together with all Accrued Interest thereon shall be due and payable upon demand by the Lenders
(&#147;<B>Maturity Date</B>&#148;). All payments and other charges due and payable un the Transaction Agreements shall be made in the lawful currency of the United States of America&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Release or Claims Against Lenders</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">THE COMPANY, BY SIGNING THIS AMENDMENT, HEREBY ABSOLUTELY AND UNCONDITIONALLY RELEASES AND<I> </I>FOREVER DISCHARGES LENDERS AND ANY AND ALL
OF THEIR PARENT COMPANIES, SUBSIDIARY COMPANIES, AFFILIATED COMPANIES, INSURERS, INDEMNITORS, SUCCESSORS AND ASSIGNS TOGETHER </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
WITH ALL OF THEIR RESPECTIVE PRESENT AND FORMER MANAGERS, DIRECTORS, OFFICERS, AGENTS AND EMPLOYEES FROM ANY AND ALL CLAIMS, DEMANDS OR CAUSES OF ACTION OF ANY KIND, NATURE OR DESCRIPTION,
WHETHER ARISING IN LAW OR EQUITY OR UPON CONTRACT OR TORT OR UNDER ANY STATE OR FEDERAL LAW OR OTHERWISE, WHICH THE COMPANY HAS HAD, NOW HAS, OR HAS MADE CLAIM TO HAVE AGAINST ANY SUCH PARTY FOR OR BY REASON OF ANY ACT, OMISSION, MATTER, CAUSE OR
THING WHATSOEVER ARISING FROM THE BEGINNING OF TIME TO AND INCLUDING THE DATE OF THIS AMENDMENT, WHETHER SUCH CLAIMS, DEMANDS AND CAUSES OF ACTION ARE MATURED OR UNMATURED OR KNOWN OR UNKNOWN. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Execution in Several Counterparts</U>. This Amendment may be executed in several counterparts or by separate instruments
and by facsimile transmission and all of such counterparts and instruments shall constitute one agreement, binding on all of the Parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Headings</U>. The headings in this Amendment are for convenience of reference only and shall not limit or otherwise affect
the meaning hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <U>Governing Law</U>. The laws of the State of Texas shall govern this Amendment without regard to
principles of conflict of laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <U>Original Agreement</U>. Except as expressly amended by this Amendment, the Original
Agreement shall remain in full force and effect and all of the terms of the Original Agreement are hereby incorporated into this Amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of this page deliberately left blank] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned have executed this Amendment as of the day and
year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HEART TEST LABORATORIES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Hilz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Mark T. Hilz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CEO</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">FRONT RANGE VENTURES, LLC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Loren J. Richards</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Loren J. Richards</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">FWTB Trust Offier</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">JOHN Q. ADAMS</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Q. Adams Sr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>16
<FILENAME>filename16.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.10 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 2 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LOAN AND SECURITY AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS AMENDMENT NO. 2 TO LOAN AND SECURITY AGREEMENT (this &#147;<B>No.2 Amendment</B>&#148;) is made and entered into as of November&nbsp;3,
2021, by and among Heart Test Laboratories, Inc., a Texas corporation, (the &#147;<B>Company</B>&#148;), Front Range Ventures LLC, a Wyoming limited liability company, or its assigns (&#147;<B>FRV</B>&#148;), and John Q. Adams, a Texas resident, or
his assigns, (&#147;<B>JQA</B>&#148;) (FRV and JQA each a &#147;<B>Lender</B>&#148; and together the &#147;<B>Lenders</B>&#148;) as defined in the Original Agreement (as defined below). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WITNESSETH: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Company, the Lenders (collectively, the &#147;<B>Parties</B>&#148;) have previously entered into that certain Loan and Security Agreement dated on or around April&nbsp;24, 2020 (the &#147;<B>Original Agreement</B>&#148;) and Amendment No.&nbsp;1 to
the Loan and Security Agreement dated September 30, 2021 (&#147;<B>No.1 Amendment</B>&#148;) (together the &#147;<B>Loan Agreement</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to further extend the Maturity Date as provided in the Loan Agreement to September&nbsp;30, 2022; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in consideration for Lender&#146;s agreement to further extend the Maturity Date, the Company shall issue to each Lender a warrant as
specifically provided in those certain Warrant Agreements between the Company and each Lender and dated as of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW,
THEREFORE, in consideration of the foregoing, and the representations, warranties, covenants and conditions set forth herein, the Loan Agreement, and the other Transaction Agreements, the Company and the Lenders, intending to be legally bound,
hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <U>Capitalized Terms</U>. Except as otherwise provided herein, capitalized terms used in this
No.2 Amendment shall have the meaning set forth in the Loan Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <U>Amendment</U>. The Section&nbsp;3.1 of the Loan
Agreement is hereby amended to read, in its entirety, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;3.1 Maturity Date. </B>The outstanding Principal Amount,
together with all Accrued Interest thereon, shall be due and payable on September&nbsp;30, 2022 (the &#147;<I>Maturity Date</I>&#148;). All payments and other charges due under the Transaction Agreements shall be made in lawful currency of the
United States of America.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Release of Claims Against Lenders</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THE COMPANY, BY SIGNING THIS No.2 AMENDMENT, HEREBY ABSOLUTELY AND UNCONDITIONALLY RELEASES AND FOREVER DISCHARGES LENDERS AND ANY AND ALL OF
THEIR PARENT COMPANIES, SUBSIDIARY COMPANIES, AFFILIATED COMPANIES, INSURERS, INDEMNITORS, SUCCESSORS AND ASSIGNS TOGETHER WITH ALL OF THEIR RESPECTIVE PRESENT AND FORMER MANAGERS, DIRECTORS, OFFICERS, AGENTS AND EMPLOYEES FROM ANY AND ALL CLAIMS,
DEMANDS OR CAUSES OF ACTION OF ANY KIND, NATURE OR DESCRIPTION, WHETHER ARISING IN LAW OR EQUITY OR UPON CONTRACT OR TORT OR UNDER ANY STATE OR FEDERAL LAW OR OTHERWISE, WHICH THE COMPANY HAS HAD, NOW HAS, OR HAS MADE CLAIM TO HAVE AGAINST ANY SUCH
PARTY FOR OR BY REASON OF ANY ACT, OMISSION, MATTER, CAUSE OR THING WHATSOEVER ARISING FROM THE BEGINNING OF TIME TO AND INCLUDING THE DATE OF THIS AMENDMENT, WHETHER SUCH CLAIMS, DEMANDS AND CAUSES OF ACTION ARE MATURED OR UNMATURED OR KNOWN OR
UNKNOWN. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Execution in Several Counterparts</U>. This No.2 Amendment may be executed in several counterparts or by
separate instruments and by facsimile transmission and all of such counterparts and instruments shall constitute one agreement, binding on all of the Parties hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Headings</U>. The headings in this No.2 Amendment are for convenience of reference only and shall not limit or otherwise
affect the meaning hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <U>Governing Law</U>. The laws of the State of Texas shall govern this No.2 Amendment without
regard to principles of conflict of laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <U>Original Agreements</U>. Except as expressly amended by this No.2 Amendment,
the Transaction Agreements shall remain in full force and effect and all of the terms of the Transaction Agreements are hereby incorporated into this No.2 Amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of this page deliberately left blank] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>the undersigned have executed this No.2 Amendment as of the day
and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HEART TEST LABORATORIES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Simpson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Andrew Simpson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chairman</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">FRONT RANGE VENTURES, LLC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Loren J. Richards</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Loren J. Richards</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">First Western Trust Bank, Trust Offier</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LENDER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">JOHN Q. ADAMS</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Q. Adams Sr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">John Q. Adams Sr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>17
<FILENAME>filename17.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.11 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), OR ANY STATE SECURITIES LAW AND MAY NOT BE
SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR BORROWER SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT
AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SECURED CONVERTIBLE PROMISSORY NOTE </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>$______________</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Issuance Date: ________________</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FOR VALUE RECEIVED</B>, the undersigned, Heart Test Laboratories, Inc. d/b/a HeartSciences, a Texas
corporation (&#147;<B>Borrower</B>&#148; or &#147;<B>Company</B>&#148;), hereby promises to pay to the order of __________________, or any future permitted holder of this promissory note (collectively, the &#147;<B>Holder</B>&#148;), at
_____________________________, or at such other place as the Holder may designate in writing to the Borrower, the principal sum of _______________Thousand and No/100 Dollars ($________________), and such other amount as may be outstanding hereunder,
together with all accrued but unpaid interest, in United States dollars, as provided in this Secured Convertible Promissory Note (the &#147;<B>Note</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THE PARTIES INTEND THIS INSTRUMENT TO BE EQUITY FOR TAX PURPOSES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Note is one of a series (the &#147;<B>Series</B>&#148;) of secured convertible promissory notes (collectively, the &#147;<B>Series
Notes</B>&#148;) issued by the Company on the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Principal and Interest Payments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The principal of this Note shall be due and payable on July&nbsp;31, 2022 (the &#147;<B>Maturity Date</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The parties intend this instrument to be equity for tax for purposes and it is expected that the Note shall be converted for equity in the
Borrower on or prior to the Maturity Date in which event no interest shall accrue and interest shall not be due or payable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In the
event the Note is not converted on or prior to the Maturity Date then interest shall accrue on the outstanding principal balance of this Note commencing on the date of this Note, at a simple interest a rate of twelve percent (12%) per annum.
Interest shall only be payable upon a repayment of the Note in cash by Borrower or upon an Event of Default. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Borrower shall only make
interest and principal payments under this Note on a pro rata basis to the Series Notes based on the respective principal amounts of each Note. Each holder of a Note shall hold any amounts received in excess of its pro rata share in trust for the
benefit of the other holders of Series Notes. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Borrower shall be entitled to repay the principal and all accrued but unpaid interest on
this Note in cash upon giving ten (10)&nbsp;days written notice to the Holder at any time upon or after any of the following events of the Borrower (&#147;<B>Borrower Repayment</B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) 30 days following FDA clearance of the Borrower&#146;s MyoVista product; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the closing of further funding of $5&nbsp;million or more which values entire share capital of the Borrower at
$50&nbsp;million or more; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) a public offering of Common Stock which values entire share capital of the Borrower at
$50&nbsp;million or more; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) the sale or merger of a majority of the voting stock of the Borrower. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Conversion</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
Conversion of this Note shall be into shares of Common Stock of Borrower (the &#147;<B>Common Stock</B>&#148;) at a conversion price of Five Cents ($0.05 US Dollars) per share of Common Stock (&#147;<B>Conversion</B>&#148;) (as adjusted for any
splits, recapitalizations, combinations or other similar transactions affecting the Company&#146;s Common Stock). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Borrower may elect
for conversion of the principal balance of, and accrued but unpaid interest on, this Note at any time upon or after any of the following events of the Borrower (&#147;<B>Borrower Conversion</B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) 30 days following FDA clearance of the Borrower&#146;s MyoVista product; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the closing of further funding of $5&nbsp;million or more which values entire share capital of the Borrower at
$50&nbsp;million or more; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) a public offering of Common Stock which values entire share capital of the Borrower at
$50&nbsp;million or more. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Holder shall be entitled to elect for voluntarily Conversion at any time upon written notice to the Company
(&#147;<B>Holder Conversion</B>&#148;). Such election shall be irrevocable and upon receipt of such written notice from the Holder Conversion shall be deemed to have automatically occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As soon as practicable following a Borrower Conversion, Borrower shall send written notice to Holder that such conversion has taken place and that the
principal balance of, and accrued but unpaid interest (if applicable under <U>section 1(c)</U>) on, this Note has been converted into shares of Common Stock. Upon Borrower Conversion or Holder Conversion the Borrower shall send written notice to the
Holder of the number of shares of Common Stock that Holder is entitled to receive upon such conversion (the &#147;<B>Conversion Shares</B>&#148;). Upon receipt by Borrower from Holder of the original copy of this Note, marked &#147;Canceled&#148;,
the Borrower will deliver to Holder a stock certificate evidencing the Conversion Shares. Notwithstanding anything in this Note to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contrary, effective as of the date that a Borrower Conversion or Holder Conversion, this Note shall be deemed to be canceled in its entirety and the only right of Holder thereafter is to receive
from Borrower a stock certificate evidencing the Conversion Shares (which stock certificate shall only be delivered to Holder upon Holder delivering to Borrower the original copy of this Note, marked &#147;Canceled&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U><FONT STYLE="white-space:nowrap">Non-Business</FONT> Days</U>. Whenever any payment to be made shall be due on a Saturday, Sunday or a
public holiday under the laws of the State of Texas, such payment may be due on the next succeeding business day and such next succeeding day shall be included in the calculation of the amount of accrued interest payable on such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Events of Default</U>. The occurrence of any of the following events shall be an &#147;<B>Event of Default</B>&#148; under this Note:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Borrower fails to make any payment on this Note as and when the same becomes due and payable in accordance with the terms hereof, if
the same has continued for five (5)&nbsp;days after written notice specifying such default has been delivered to the Borrower by Holder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Borrower fails to perform any other covenant contained herein, if the same has continued for thirty (30)&nbsp;days after written notice
specifying such default has been delivered to the Borrower by Holder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Borrower shall (i)&nbsp;apply for or consent to the appointment
of, or the taking of possession by, a receiver, custodian, trustee or liquidator of itself or of all or a substantial part of its property or assets, (ii)&nbsp;make a general assignment for the benefit of its creditors, (iii)&nbsp;commence a
voluntary case under the Bankruptcy Code or under the comparable laws of any jurisdiction (foreign or domestic), (iv) file a petition seeking to take advantage of any bankruptcy, insolvency, moratorium, reorganization or other similar law affecting
the enforcement of creditors&#146; rights generally, (v)&nbsp;acquiesce in writing to any petition filed against it in an involuntary case under the Bankruptcy Code or under the comparable laws of any jurisdiction (foreign or domestic), or
(vi)&nbsp;take any action under the laws of any jurisdiction (foreign or domestic) analogous to any of the foregoing; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) a proceeding
or case shall be commenced in respect of Borrower without its application or consent, in any court of competent jurisdiction, seeking (i)&nbsp;the liquidation, reorganization, moratorium, dissolution, winding up, or composition or readjustment of
its debts, (ii)&nbsp;the appointment of a trustee, receiver, custodian, liquidator or the like of it or of all or any substantial part of its assets or (iii)&nbsp;similar relief in respect of it under any law providing for the relief of debtors, and
such proceeding or case described in clause (i), (ii) or (iii)&nbsp;shall continue undismissed, or unstayed and in effect, for a period of thirty (30)&nbsp;consecutive days or any order for relief shall be entered in an involuntary case under the
Bankruptcy Code or under the comparable laws of any jurisdiction (foreign or domestic) against Borrower or any of its subsidiaries or action under the laws of any jurisdiction (foreign or domestic) analogous to any of the foregoing shall be taken
with respect to Borrower or any of its subsidiaries and shall continue undismissed, or unstayed and in effect for a period of thirty (30)&nbsp;consecutive days. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Remedies Upon </U><U>An</U><U> Event of Default</U>. If an Event of Default shall have
occurred and shall be continuing, Holder may at any time at its option, (a)&nbsp;declare the entire unpaid principal balance of this Note, together with all interest accrued hereon, due and payable, and thereupon, the same shall be accelerated and
so due and payable; provided, however, that upon the occurrence of an Event of Default described in (i)<U>&nbsp;Sections </U><U>4(c)</U> or <U>(d)</U>&nbsp;above, without presentment, demand, protest, or notice, all of which are hereby expressly
unconditionally and irrevocably waived by Borrower, the outstanding principal balance and accrued interest hereunder shall be automatically due and payable, and (ii)<U>&nbsp;Sections </U><U>4(a)</U> or <U>(b)</U>&nbsp;above, Holder may exercise or
otherwise enforce any one or more of Holder&#146;s rights, powers, privileges, remedies and interests under this Note or applicable law. No course of delay on the part of Holder shall operate as a waiver thereof or otherwise prejudice the right of
Holder. No remedy conferred hereby shall be exclusive of any other remedy referred to herein or now or hereafter available at law, in equity, by statute or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Security Agreement</U>. As collateral security for the full, prompt, complete and final payment and performance when due (whether at
stated maturity, by acceleration or otherwise) of all of the Borrower obligations under this Note and in order to induce the Holder to enter into the Note, the Borrower hereby assigns, conveys, mortgages, pledges, hypothecates and transfers to the
Series Note holders a security interest in all of the Borrower&#146;s right, title and interest in, to and under all of the following property and assets, wherever located, whether now owned or hereafter acquired or arising, and all proceeds,
products, accessions, additions, substitutions, rents, profits and replacements thereof, including, without limitation, all Inventory, Equipment, Fixtures, Goods, Accounts, account receivables, contract rights, Commercial Tort Claims, chattel paper
(tangible and electronic), Deposit Accounts, Documents, General Intangibles, payment intangibles, Software, Instruments, Promissory Notes, Investment Property,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Letter-of-Credit</FONT></FONT> Rights and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">letters-of-credit,</FONT></FONT> and Supporting obligations, intellectual
property (including, and without limitation, patents, patent applications, copyrights, trademarks and trade secrets), license rights, distribution rights, and rights to sue for infringement of General Intangible or intellectual property rights (all
of which being collectively referred to herein as the &#147;<B><I>Collateral</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At any time and from time to time, upon
the written request of the Holder, the Company shall promptly and duly execute and deliver any and all such further instruments and documents and take such further action as the Holder may reasonably deem necessary or desirable to perfect and
continue perfected or better perfect the Holder&#146;s liens in the Collateral. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Holder acknowledges that prior, senior security
interests in the Collateral described in this <U>Section</U><U></U><U>&nbsp;6</U> have been granted as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) to
Guangren &#147;Gary&#148; Chen pursuant to that certain Security Agreement and Pledge between Chen and Debtor dated as of March&nbsp;14, 2014 (the &#147;<B>Chen Agreement</B>&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) to Front Range Ventures, LLC and John Q. Adams pursuant to a Loan and Security Agreement dated as of April&nbsp;24, 2020
(the &#147;<B>FRV/Adams Agreement</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company represents and warrants that, except for the security interest granted hereunder and the prior
security interests granted under the Chen Agreement and FRV/Adams Agreement, the Company is the sole legal and equitable owner of each item of the Collateral in which it purports to grant a security interest hereunder. No other security agreement,
financing statement, equivalent security or lien instrument or continuation statement covering all or any part of the Collateral exists, except such as shall be filed in favor of the Series Note holders pursuant to the Series Notes or has been filed
pursuant to the Chen Agreement or FRV/Adams Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Holder may exercise, in addition to and not in lieu of all other rights and
remedies granted to it hereunder and under the Notes, all rights and remedies of a secured party under the law, including the Uniform Commercial Code in effect in any and all jurisdictions where <FONT STYLE="white-space:nowrap">UCC-1s</FONT> are
filed to perfect the Holders&#146; security interest (the &#147;<B><I>UCC</I></B>&#148;). The Holder shall not have any obligation or liability hereunder with respect to the Collateral. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. Miscellaneous. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 <U>Successors and Assigns</U>. Except as otherwise provided herein, the terms and conditions of this Note will inure to the
benefit of, and be binding upon, the respective successors and assigns of the parties; provided, however, that the Company may not assign its obligations under this Note without the written consent of the holders of a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the aggregate principal amount of the Series Notes (the &#147;<B>Requisite Noteholders</B>&#148;). This Note is for the sole benefit of the
parties hereto and their respective successors and permitted assigns, and nothing herein, express or implied, is intended to or will confer upon any other person or entity any legal or equitable right, benefit or remedy of any nature whatsoever
under or by reason of this Note. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <U>Choice of Law</U>. This Note, and all matters arising out of or relating to this
Note, whether sounding in contract, tort, or statute will be governed by and construed in accordance with the internal laws of the State of Texas, without giving effect to the conflict of laws provisions thereof to the extent such principles or
rules would require or permit the application of the laws of any jurisdiction other than those of the State of Texas. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3
<U>Counterparts</U>. This Note may be executed in counterparts, each of which will be deemed an original, but all of which together will be deemed to be one and the same agreement. Counterparts may be delivered via facsimile, electronic mail
(including PDF or any electronic signature complying with the U.S. federal ESIGN Act of 2000, <I>e.g.</I>, www.docusign.com) or other transmission method, and any counterpart so delivered will be deemed to have been duly and validly delivered and be
valid and effective for all purposes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4 <U>Titles and Subtitles</U>. The titles and subtitles used in this Note are
included for convenience only and are not to be considered in construing or interpreting this Note. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5 <U>Notices</U>.
All notices and other communications given or made pursuant hereto will be in writing and will be deemed effectively given: (a)&nbsp;upon personal delivery to the party to be notified; (b)&nbsp;when sent by email; (c)&nbsp;three (3) days after
having been sent by registered or certified mail, return receipt requested, postage prepaid; or (d)&nbsp;one (1) day </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications will be sent to the respective parties at the
addresses shown on the signature pages hereto (or to such email address or other address as subsequently modified by written notice given in accordance with this <U>Section</U><U></U><U>&nbsp;5.5</U>). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.6 <U>Expenses</U>. Each party will pay all costs and expenses that it incurs with respect to the negotiation, execution,
delivery and performance of this Note. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.7 <U>Attorneys</U><U>&#146;</U><U> Fees</U>. If any action at law or in equity is
necessary to enforce or interpret the terms of this Note, the prevailing party will be entitled to reasonable attorneys&#146; fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.8 <U>Entire Agreement; Amendments and Waivers</U>. This Note constitutes the full and entire understanding and agreement
between the parties with regard to the subject hereof. The Borrower&#146;s agreements with each of the holders of the Series Notes are separate agreements, and the sales of the Notes to each of the holders thereof are separate sales. Notwithstanding
the foregoing, any term of this Note and the other Series Notes may be amended and the observance of any term may be waived (either generally or in a particular instance and either retroactively or prospectively) with the written consent of the
Borrower and the Requisite Noteholders. Any waiver or amendment effected in accordance with this <U>Section</U><U></U><U>&nbsp;6.8</U> will be binding upon each holder of a Note in the Series and each future holder(s) of the Note and such Series
Notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.9 <U>Delivery of Financial Statements</U>. If requested by the Holder, the Company will deliver to the Holder a
copy of the Company&#146;s annual financial statements as such time as such financial statements are available to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.10 <U>Severability</U>. If one or more provisions of this Note are held to be unenforceable under applicable law, such
provisions will be excluded from this Note and the balance of the Note will be interpreted as if such provisions were so excluded and this Note will be enforceable in accordance with its terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.11 <U>Acknowledgment</U>. For the avoidance of doubt, it is acknowledged that the Holder will be entitled to the benefit of
all adjustments in the number of shares of the Company s capital stock as a result of any splits, recapitalizations, combinations or other similar transactions affecting the Company&#146;s capital stock underlying the Conversion Shares that occur
prior to the conversion of this Note. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.12 <U>Further Assurances</U>. From time to time, the parties will execute and
deliver such additional documents and will provide such additional information as may reasonably be required to carry out the terms of this Note and any agreements executed in connection herewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.13 <U>Limitation on Interest</U>. In no event will any interest charged, collected or reserved under this Note exceed the
maximum rate then permitted by applicable law, and if any payment made by the Company under this Note exceeds such maximum rate, then such excess sum will be credited by the Holder as a payment of principal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.14 <U>Officers and Directors not Liable</U>. In no event will any officer
or director of the Company be liable for any amounts due and payable pursuant to this Note. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.15 <U>Waiver of Jury
Trial</U>. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS NOTE, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE <FONT
STYLE="white-space:nowrap">ALL-ENCOMPASSING</FONT> OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE),
BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER REPRESENTS AND
WARRANTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.16 <U>Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief</U>. The remedies provided in this Note
shall be cumulative and in addition to all other remedies available under this Note, at law or in equity (including, without limitation, a decree of specific performance and/or other injunctive relief), no remedy contained herein shall be deemed a
waiver of compliance with the provisions giving rise to such remedy and nothing herein shall limit a Holder&#146;s right to pursue actual damages for any failure by Borrower to comply with the terms of this Note. Amounts set forth or provided for
herein with respect to payments and the like (and the computation thereof) shall be the amounts to be received by Holder and shall not, except as expressly provided herein, be subject to any other obligation of Borrower (or the performance thereof).
Borrower acknowledges that a breach by it of its obligations hereunder will cause irreparable and material harm to Holder and that the remedy at law for any such breach may be inadequate. Therefore, Borrower agrees that, in the event of any such
breach or threatened breach, Holder shall be entitled, in addition to all other available rights and remedies, at law or in equity, to seek and obtain such equitable relief, including but not limited to an injunction restraining any such breach or
threatened breach, without the necessity of showing economic loss and without any bond or other security being required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS
WHEREOF</B>, Borrower has executed and delivered this Note as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HEART TEST LABORATORIES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>18
<FILENAME>filename18.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.12 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO.1 TO SECURED CONVERTIBLE PROMISSORY NOTES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment to Secured Convertible Promissory Notes (this &#147;<B>Amendment</B>&#148;), dated as of November&nbsp;2, 2021 (the
&#147;<B>Effective Date</B>&#148;), is by and among Heart Test Laboratories, Inc., a Texas corporation (the &#147;<B>Company</B>&#148;), and the Requisite Noteholders. Capitalized terms used herein but not defined herein shall have the respective
meanings ascribed to them in the Notes (as defined below). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WI T N E S S E T H: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>the Company undertook an offering of $1,500,000 of Secured Subordinated Convertible Promissory Notes (each a
&#147;<B>Note</B>&#148; and collectively the &#147;<B>Series Notes</B>&#148;) in or around January 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, pursuant to
Section&nbsp;7.8 of each of the Notes, the Company and the Requisite Noteholders may amend the terms of the Notes; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
the Parties desire to extend the Maturity Date of the Notes as set forth in this Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE, </B>in consideration for
the issuance of warrants to the entire Series Notes to acquire 150,000 shares of common stock of the Company (to be issued <FONT STYLE="white-space:nowrap">pro-rata</FONT> to each Note Holder&#146;s Note principal amount) on terms set out in a
separate warrant agreement and the mutual covenants and agreements set forth herein and for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by each party hereto, the Parties hereby agree as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>A G R E E M E N T: </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Amendments to the Notes</U>. Each of the Notes is hereby amended as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Paragraph 1 (a) of the Note is hereby amended to read, in its entirety, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The principal of this Note shall be due and payable on October&nbsp;31, 2022 (the &#147;<B>Maturity Date</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Attachment to Notes</U>. The Company shall deliver a copy of this Amendment to each Holder of a Note, and instruct each such Holder to
attach such copy of this Amendment to such Holder&#146;s Note. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Except as specifically provided herein, the Notes shall remain in full force and effect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) This Amendment may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The laws of
the State of Texas shall govern this Amendment without regard to principles of conflict of laws </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Company
and Requisite Noteholders have executed this Amendment as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>THE COMPANY: </B><B></B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HEART TEST LABORATORIES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-bottom:1pt; margin-top:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Hilz, President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>REQUISITE NOTEHOLDERS:</B> <I></I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><I>[Note: Only the Holders of at least $750,001 principal amount of the Notes are required to sign]</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[NAME OF ENTITY, IF AN ENTITY]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Principal Amount of Notes:
$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[FOR INDIVIDUALS:]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signed:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Printed
Name:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Principal Amount of Notes:
$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>19
<FILENAME>filename19.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.13</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.13 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>SECURITIES PURCHASE AGREEMENT</B> (the &#147;<B>Agreement</B>&#148;), dated as of December&nbsp;22, 2021, is by and among Heart Test
Laboratories, Inc. (d/b/a HeartSciences), a Texas corporation with offices located at 550 Reserve Street, Suite 360, Southlake, TX 76092 USA (the &#147;<B>Company</B>&#148;), and each of the investors listed on the Schedule of Buyers attached hereto
(individually, a &#147;<B>Buyer</B>&#148; and collectively, the &#147;<B>Buyers</B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RECITALS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. The Company and each Buyer is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
by Section&nbsp;4(a)(2) of the Securities Act of 1933, as amended (the &#147;<B>1933 Act</B>&#148;), and Rule 506(b) of Regulation D (&#147;<B>Regulation</B><B></B><B>&nbsp;D</B>&#148;) as promulgated by the United States Securities and Exchange
Commission (the &#147;<B>SEC</B>&#148;) under the 1933 Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. The Company has authorized a new series of senior subordinated convertible
notes of the Company, substantially in the form attached hereto as <B><U>Exhibit A</U></B> (the &#147;<B>Notes</B>&#148;), which Notes shall be convertible into shares of Common Stock (as defined below) (the shares of Common Stock issuable pursuant
to the terms of the Notes, including, without limitation, upon conversion or otherwise, collectively, the &#147;<B>Conversion Shares</B>&#148;), in accordance with the terms of the Notes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, (i)&nbsp;a Note in
the aggregate original principal amount set forth opposite such Buyer&#146;s name in column (3)&nbsp;on the Schedule of Buyers and (ii)&nbsp;a warrant to initially acquire up to that aggregate number of additional shares of Common Stock set forth
opposite such Buyer&#146;s name in column (4)&nbsp;on the Schedule of Buyers, substantially in the form attached hereto as <B><U>Exhibit B</U></B> (together with any Additional Warrants (as defined below) and
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in substantially the form of <B><U>Exhibit <FONT STYLE="white-space:nowrap">B-1</FONT></U></B> attached hereto (the &#147;<B><U><FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrants</U></B>&#148;), the &#147;<B>Warrants</B>&#148;) (as exercised, collectively, the &#147;<B>Warrant Shares</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. At the
Closing, the parties hereto shall execute and deliver a Registration Rights Agreement, in the form attached hereto as <B><U>Exhibit </U></B><B><U>C</U></B> (the &#147;<B>Registrat</B><B>ion Rights Agreement</B>&#148;), pursuant to which the Company
has agreed to provide certain registration rights with respect to the Registrable Securities (as defined in the Registration Rights Agreement), under the 1933 Act and the rules and regulations promulgated thereunder, and applicable state securities
laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E. The Notes, the Conversion Shares, the Warrants and the Warrant Shares are collectively referred to herein as the
&#147;<B>Securities</B>.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Company and each Buyer hereby agree as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. PURCHASE AND SALE OF NOTES AND WARRANTS. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Purchase of Notes and Warrants</U>. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6 and 7 below, the
Company shall issue and sell to each Buyer, and each Buyer severally, but not jointly, agrees to purchase from the Company on the Closing Date (as defined below) a Note in the original principal amount as is set forth opposite such Buyer&#146;s name
in column (3)&nbsp;on the Schedule of Buyers along with Warrants to initially acquire up to that aggregate number of Warrant Shares as is set forth opposite such Buyer&#146;s name in column (4)&nbsp;on the Schedule of Buyers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Closing</U>. The closing (the &#147;<B>Closing</B>&#148;) of the purchase of the Notes and the Warrants by the Buyers shall occur at the
offices of Kelley Drye&nbsp;&amp; Warren LLP, 3 World Trade Center, 175 Greenwich Street, New York, NY 10007. The date and time of the Closing (the &#147;<B>Closing Date</B>&#148;) shall be 10:00 a.m., New York time, on the first (1st) Business Day
on which the conditions to the Closing set forth in Sections 6 and 7 below are satisfied or waived (or such other date as is mutually agreed to by the Company and each Buyer). As used herein &#147;<B>Business Day</B>&#148; means any day other than
Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed;<U> </U><U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized or
required by law to remain closed due to &#147;stay at home&#148;, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;shelter-in-place&#148;,</FONT></FONT> <FONT STYLE="white-space:nowrap">&#147;non-essential</FONT>
employee&#148;&nbsp;or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of
commercial banks in The City of New York generally are open for use by customers on such day. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Purchase Price</U>. The aggregate
purchase price for the Notes and the Warrants to be purchased by each Buyer (the &#147;<B>Purchase Price</B>&#148;) shall be the amount set forth opposite such Buyer&#146;s name in column (5)&nbsp;on the Schedule of Buyers (or by the surrender for
exchange of such securities of the Company as set forth on Schedule 1(c), if applicable). Each Buyer shall pay $1,000.00 for each $1,111.11 of principal amount of Notes and related Warrants to be purchased by such Buyer at the Closing. Each Buyer
and the Company agree that the Notes and the Warrants constitute an &#147;investment unit&#148; for purposes of Section&nbsp;1273(c)(2) of the Internal Revenue Code of 1986, as amended (the &#147;<B>Code</B>&#148;). The Buyers and the Company
mutually agree that the allocation of the issue price of such investment unit between the Notes and the Warrants in accordance with Section&nbsp;1273(c)(2) of the Code and Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.1273-2(h)</FONT> shall be an aggregate amount equal to one percent (1%) of the Purchase Price allocated to the Warrants and the balance of the Purchase Price allocated to the Notes, and neither the
Buyers nor the Company shall take any position inconsistent with such allocation in any tax return or in any judicial or administrative proceeding in respect of taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Form of Payment</U>. On the Closing Date, (i)&nbsp;each Buyer shall pay its respective Purchase Price (less, in the case of any Buyer,
the amounts withheld pursuant to Section&nbsp;4(g)) to the Company for the Notes and the Warrants to be issued and sold to such Buyer at the Closing, by wire transfer of immediately available funds in accordance with the Flow of Funds Letter (as
defined below) (or by the surrender for exchange of such securities of the Company as set forth on Schedule 1(c), if applicable) and (ii)&nbsp;the Company shall deliver to each Buyer (A)&nbsp;a Note in the aggregate original principal amount as is
set forth opposite such Buyer&#146;s name in column (3)&nbsp;of the Schedule of Buyers and (B)&nbsp;a Warrant pursuant to which such Buyer shall have the right to initially acquire up to such aggregate number of Warrant Shares as is set forth
opposite such Buyer&#146;s name in column (4)&nbsp;of the Schedule of Buyers, in each case, duly executed on behalf of the Company and registered in the name of such Buyer or its designee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Additional Closings; Exchange. </U>The parties hereto acknowledge and agree that the
Company may sell additional Notes (the &#147;<B>Additional Notes</B>&#148;), in an aggregate principal amount not to exceed $5,555,555.56 (inclusive of the principal amount of the Notes sold at the Closing, including up to $712,222.22 of principal
amount of Notes sold pursuant to the surrender for exchange of Exchange Securities (as defined below)).), and related Warrants (the &#147;<B>Additional Warrants</B>&#148;) on the terms set forth herein and in the other Transaction Documents (each,
an &#147;<B>Additional Closing</B>&#148;), provided, that (i)&nbsp;the form of documentation of each such Additional Closing shall be satisfactory to the Required Holders, (ii)&nbsp;all Additional Closings are consummated on or prior to
January&nbsp;31, 2022, and (iii)&nbsp;the purchase price of each Additional Closing shall be a cash amount proportional to the Purchase Price of the Notes and Warrants hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. BUYER&#146;S REPRESENTATIONS AND WARRANTIES. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Buyer, severally and not jointly, represents and warrants to the Company with respect to only itself that, as of the date hereof and as of
the Closing Date: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Organization; Authority</U>. If (a)&nbsp;Buyer is an entity, it is duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization with the requisite power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents (as defined below) to which it is a party and otherwise
to carry out its obligations hereunder and thereunder.<U> </U>If Buyer is a natural person, he or she has the capacity to enter into and to consummate the transactions contemplated by the Transaction Documents to which he or she is a party and
otherwise to carry out his or her obligations hereunder and thereunder </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>No Public Sale or Distribution</U>. Such Buyer (i)&nbsp;is
acquiring its Note and Warrants, (ii)&nbsp;upon conversion of its Note will acquire the Conversion Shares issuable upon conversion thereof, and (iii)&nbsp;upon exercise of its Warrants (other than pursuant to a Cashless Exercise (as defined in the
Warrants)) will acquire the Warrant Shares issuable upon exercise thereof, in each case, for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof in violation of applicable securities
laws, except pursuant to sales registered or exempted under the 1933 Act; provided, however, by making the representations herein, such Buyer does not agree, or make any representation or warranty, to hold any of the Securities for any minimum or
other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement or an exemption from registration under the 1933 Act. Such Buyer does not presently have any agreement or
understanding, directly or indirectly, with any Person to distribute any of the Securities in violation of applicable securities laws. For purposes of this Agreement, &#147;<B>Person</B>&#148; means an individual, a limited liability company, a
partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and any Governmental Entity or any department or agency thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Accredited Investor Status</U>. Such Buyer is an &#147;accredited investor&#148; as that term is defined in Rule 501(a) of Regulation D.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Reliance on Exemptions</U>. Such Buyer understands that the Securities are being
offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and such Buyer&#146;s compliance
with, the representations, warranties, agreements, acknowledgments and understandings of such Buyer set forth herein and in the other Transaction Documents in order to determine the availability of such exemptions and the eligibility of such Buyer
to acquire the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Information</U>. Such Buyer and its advisors, if any, have been furnished with all materials relating to
the business, finances and operations of the Company and materials relating to the offer and sale of the Securities that have been requested by such Buyer. Such Buyer and its advisors, if any, have been afforded the opportunity to ask questions of
the Company and have received answers thereto. Neither such inquiries nor any other due diligence investigations conducted by such Buyer or its advisors, if any, or its representatives shall modify, amend or affect such Buyer&#146;s right to rely on
the Company&#146;s representations and warranties contained herein. Such Buyer understands that its investment in the Securities involves a high degree of risk. Such Buyer has sought such accounting, legal and tax advice as it has considered
necessary to make an informed investment decision with respect to its acquisition of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>No Governmental Review</U>.
Such Buyer understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the
Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Transfer or Resale</U>.
Such Buyer understands that except as provided in the Registration Rights Agreement and Section&nbsp;4(h) hereof: (i)&nbsp;the Securities have not been and are not being registered under the 1933 Act or any state securities laws, and may not be
offered for sale, sold, assigned or transferred unless (A)&nbsp;subsequently registered thereunder, (B)&nbsp;such Buyer shall have delivered to the Company (if requested by the Company) an opinion of counsel, in a form reasonably acceptable to the
Company, to the effect that such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (C)&nbsp;such Buyer provides the Company with reasonable assurance that such
Securities can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the 1933 Act (or a successor rule thereto) (collectively, &#147;<B>Rule 144</B>&#148;); (ii) any sale of the Securities made in reliance on Rule 144
may be made only in accordance with the terms of Rule 144, and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an
underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC promulgated thereunder; and (iii)&nbsp;neither the Company nor any other Person is
under any obligation to register the Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder. Notwithstanding the foregoing, the Securities may be pledged in connection with a
bona fide margin account or other loan or financing arrangement secured by the Securities and such pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no Buyer effecting a pledge of
Securities shall be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or any other Transaction Document (as defined in Section&nbsp;3(b)), including, without limitation,
this Section&nbsp;2(g). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Validity; Enforcement</U>. This Agreement and the Registration Rights Agreement have
been duly and validly authorized, executed and delivered on behalf of such Buyer and shall constitute the legal, valid and binding obligations of such Buyer enforceable against such Buyer in accordance with their respective terms, except as such
enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors&#146;
rights and remedies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>No Conflicts</U>. The execution, delivery and performance by such Buyer of this Agreement and the Registration
Rights Agreement and the consummation by such Buyer of the transactions contemplated hereby and thereby will not (i)&nbsp;result in a violation of the organizational documents of such Buyer, or (ii)&nbsp;conflict with, or constitute a default (or an
event which with notice or lapse of time or both would become a default) under, or give to any other Person (as defined below) any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which
such Buyer is a party, or (iii)&nbsp;result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Buyer, except in the case of clauses (ii)&nbsp;and (iii) above, for
such conflicts, defaults, rights or violations which could not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Buyer to perform its obligations hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Consent to Surrender and Exchange</U>. Each Buyer, to the extent that such Buyer is set forth on <U>Schedule 1(c)</U> and is a holder of
any other security of the Company (each, an &#147;<B>Exchange Security</B>&#148;) that is being surrendered, exchanged, converted, and/or cancelled in consideration of the issuance hereunder of Notes and Warrants to such Buyer, hereby agrees that
such Exchange Securities are being tendered to the Company in full in exchange for the applicable Notes and Warrants set forth on <U>Exhibit A</U> (including, if applicable, any principal amount and any accrued interest on such Exchange Securities).
Effective upon the Company&#146;s and such Buyer&#146;s execution and delivery of this Agreement, without any further action required by the Company or such Buyer, such Exchange Securities and all obligations in connection therewith shall be
immediately deemed satisfied in full and terminated in their entirety (including, if applicable, any security interest effected therein). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.
REPRESENTATIONS AND WARRANTIES OF THE COMPANY. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company represents and warrants to each of the Buyers that, as of the date hereof
and as of the Closing Date: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Organization and Qualification</U>. Each of the Company and each of its Subsidiaries are entities duly
organized and validly existing and in good standing under the laws of the jurisdiction in which they are formed, and have the requisite power and authority to own their properties and to carry on their business as now being conducted and as
presently proposed to be conducted. Each of the Company and each of its Subsidiaries is duly qualified as a foreign entity to do business and is in good standing in every jurisdiction in which its ownership of property or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to
have a Material Adverse Effect (as defined below). As used in this Agreement, &#147;<B>Material Adverse Effect</B>&#148; means any material adverse effect on (i)&nbsp;the business, properties, assets, liabilities, operations (including results
thereof), condition (financial or otherwise) or prospects of the Company or any Subsidiary, individually or taken as a whole, (ii)&nbsp;the transactions contemplated hereby or in any of the other Transaction Documents or any other agreements or
instruments to be entered into in connection herewith or therewith or (iii)&nbsp;the authority or ability of the Company or any of its Subsidiaries to perform any of their respective obligations under any of the Transaction Documents (as defined
below). As of the date hereof and the Closing Date, the Company has no Subsidiaries. &#147;<B>Subsidiaries</B>&#148; means any Person in which the Company, directly or indirectly, (I)&nbsp;owns any of the outstanding capital stock or holds any
equity or similar interest of such Person or (II)&nbsp;controls or operates all or any part of the business, operations or administration of such Person, and each of the foregoing, is individually referred to herein as a
&#147;<B>Subsidiary</B>.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorization; Enforcement; Validity</U>. The Company has the requisite power and authority to enter
into and perform its obligations under this Agreement and the other Transaction Documents and to issue the Securities in accordance with the terms hereof and thereof. The execution and delivery of this Agreement and the other Transaction Documents
by the Company, and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Notes and the reservation for issuance and issuance of the Conversion Shares issuable upon
conversion of the Notes and the issuance of the Warrants and the reservation for issuance and issuance of the Warrant Shares issuable upon exercise of the Warrants) have been duly authorized by the Company&#146;s board of directors or other
governing body, as applicable, and (other than the filing with the SEC of one or more registration statements in accordance with the requirements of the Registration Rights Agreement, a Form D with the SEC and any filing(s) required by applicable
state &#147;blue sky&#148; securities laws, rules and regulations (together the &#147;<B>Securities Filings</B>&#148;)) no further filing, consent or authorization is required by the Company, its Subsidiaries, their respective boards of directors or
their stockholders or other governing body. This Agreement has been, and the other Transaction Documents to which it is a party will be prior to the Closing, duly executed and delivered by the Company, and each constitutes the legal, valid and
binding obligations of the Company, enforceable against the Company in accordance with its respective terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors&#146; rights and remedies and except as rights to indemnification and to contribution may be limited by federal or state securities
law. &#147;<B>Transaction Documents</B>&#148; means, collectively, this Agreement, the Notes, the Warrants, the Registration Rights Agreement, the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement (as defined below) and each of the other
agreements and instruments entered into or delivered by any of the parties hereto in connection with the transactions contemplated hereby and thereby, as may be amended from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Issuance of Securities</U>. The issuance of the Notes and the Warrants are duly authorized and upon issuance in accordance with the
terms of the Transaction Documents shall be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and free from all preemptive or similar rights, mortgages, defects, claims, liens, pledges, charges, taxes, rights of
first refusal, encumbrances, security interests and other encumbrances (collectively, &#147;<B>Liens</B>&#148;) with respect to the issuance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereof. As of the Closing, the Company shall have reserved from its duly authorized capital stock not less than 60,000,000 shares of Common Stock for the issuance of the Conversion Shares upon
conversion of the Notes and the Warrant Shares initially issuable upon exercise of the Warrants. From and after January&nbsp;31, 2022, the Company shall reserve from its duly authorized capital stock not less than 200% of the sum of (i)&nbsp;the
maximum number of Conversion Shares issuable upon conversion of the Notes (assuming for purposes hereof that (x)&nbsp;the Notes are convertible at the Alternate Conversion Price (as defined in the Notes) assuming an Alternate Conversion Date (as
defined in the Note) as of the date hereof, (y)&nbsp;interest on the Notes shall accrue through the third anniversary of the Closing Date and will be converted into shares of Common Stock at a conversion price equal to the Alternate Conversion Price
assuming an Alternate Conversion Date as of the date hereof and (z)&nbsp;any such conversion shall not take into account any limitations on the conversion of the Notes set forth in the Notes, and (ii)&nbsp;the maximum number of Warrant Shares
initially issuable upon exercise of the Warrants (without taking into account any limitations on the exercise of the Warrants set forth therein). Upon issuance or conversion in accordance with the Notes or exercise in accordance with the Warrants
(as the case may be), the Conversion Shares and the Warrant Shares, respectively, when issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights or Liens with respect to the issue thereof, with the
holders being entitled to all rights accorded to a holder of Common Stock. Subject to the accuracy of the representations and warranties of the Buyers in this Agreement, the offer and issuance by the Company of the Securities is exempt from
registration under the 1933 Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>No Conflicts</U>. The execution, delivery and performance of the Transaction Documents by the
Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Notes, the Warrants, the Conversion Shares and the Warrant Shares and the reservation for issuance of
the Conversion Shares and the Warrant Shares) will not (i)&nbsp;result in a violation of the Certificate of Incorporation (as defined below) (including, without limitation, any certificate of designation contained therein), Bylaws (as defined
below), certificate of formation, memorandum of association, articles of association, bylaws or other organizational documents of the Company or any of its Subsidiaries, or any capital stock or other securities of the Company or any of its
Subsidiaries, (ii)&nbsp;conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) in any respect under, or give to others any rights of termination, amendment, acceleration or cancellation
of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, or (iii)&nbsp;result in a violation of any law, rule, regulation, order, judgment or decree (including, without limitation, foreign, federal and
state securities laws and regulations) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected, except in the case of clauses (ii)&nbsp;and (iii) above,
for such conflicts, defaults, rights or violations which could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Consents</U>. Neither the Company nor any Subsidiary is required to obtain any consent from, authorization or order of, or make any
filing or registration with (other than the Securities Filings and any filings necessary to comply with Section&nbsp;3(c) above), any Governmental Entity (as defined below) or any regulatory or self-regulatory agency or any other Person in order for
it to execute, deliver or perform any of its respective obligations under or contemplated by the Transaction Documents, in each case, in accordance with the terms hereof or thereof. Except as contemplated by Section&nbsp;3(c), all consents,
authorizations, orders, filings and registrations which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company or any Subsidiary is required to obtain pursuant to the preceding sentence have been or will be obtained or effected on or prior to the Closing Date, and neither the Company nor any
of its Subsidiaries has actual knowledge of any facts or circumstances which could reasonably prevent the Company or any of its Subsidiaries from obtaining or effecting any of the registration, application or filings contemplated by the Transaction
Documents. &#147;<B>Governmental Entity</B>&#148; means any nation, state, county, city, town, village, district, or other political jurisdiction of any nature, federal, state, local, municipal, foreign, or other government, governmental or
quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal), multi-national organization or body; or body exercising, or entitled to exercise, any
administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise owned or controlled by a government or a public
international organization or any of the foregoing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Acknowledgment Regarding Buyer</U><U>&#146;</U><U>s Purchase of Securities</U>.
The Company acknowledges and agrees that each Buyer is acting solely in the capacity of an arm&#146;s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby and that no Buyer is (i)&nbsp;an
officer or director of the Company or any of its Subsidiaries, (ii)&nbsp;an &#147;affiliate&#148; (as defined in Rule 144) of the Company or any of its Subsidiaries or (iii)&nbsp;to its knowledge, a &#147;beneficial owner&#148; of more than 10% of
the shares of Common Stock (as defined for purposes of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Securities Exchange Act of 1934, as amended (the &#147;<B>1934 Act</B>&#148;)). The Company further acknowledges that no Buyer is acting
as a financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby and thereby, and any advice given by a Buyer or any of its
representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to such Buyer&#146;s purchase of the Securities. The Company further represents to each Buyer that the
Company&#146;s and each Subsidiary&#146;s decision to enter into the Transaction Documents to which it is a party has been based solely on the independent evaluation by the Company, each Subsidiary and their respective representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>No General Solicitation; Placement Agent</U><U>&#146;</U><U>s Fees</U>. Neither the Company, nor any of its Subsidiaries or affiliates,
nor any Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Securities. The Company shall be responsible for
the payment of any placement agent&#146;s fees, financial advisory fees, or brokers&#146; commissions (other than for Persons engaged by any Buyer or its investment advisor) relating to or arising out of the transactions contemplated hereby,
including, without limitation, placement agent fees payable to Benchmark, as placement agent (the &#147;<B>Placement </B><B>Agent</B>&#148;) in connection with the sale of the Securities. The fees and expenses of the Placement Agent to be paid by
the Company or any of its Subsidiaries are as set forth on Schedule 3(g) attached hereto. The Company shall pay, and hold each Buyer harmless against, any liability, loss or expense (including, without limitation, attorney&#146;s fees and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses) arising in connection with any such claim. The Company acknowledges that it has engaged the Placement Agent in connection with the sale of the
Securities. Other than the Placement Agent, neither the Company nor any of its Subsidiaries has engaged any placement agent or other agent in connection with the offer or sale of the Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>No Integrated Offering</U>. None of the Company, its Subsidiaries or any of their
affiliates, nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the issuance of any of the
Securities under the 1933 Act, whether through integration with prior offerings or otherwise, or cause this offering of the Securities to require approval of stockholders of the Company for purposes of the 1933 Act or under any applicable
stockholder approval provisions, including, without limitation, under the rules and regulations of any exchange or automated quotation system on which any of the securities of the Company are listed or designated for quotation. None of the Company,
its Subsidiaries, their affiliates nor any Person acting on their behalf will take any action or steps that would require registration of the issuance of any of the Securities under the 1933 Act or cause the offering of any of the Securities to be
integrated with other offerings of securities of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Dilutive Effect</U>. The Company understands and acknowledges that
the number of Conversion Shares and Warrant Shares will increase in certain circumstances. The Company further acknowledges that its obligation to issue the Conversion Shares pursuant to the terms of the Notes in accordance with this Agreement and
the Notes and the Warrant Shares upon exercise of the Warrants in accordance with this Agreement, the Notes and the Warrants is, in each case, absolute and unconditional regardless of the dilutive effect that such issuance may have on the ownership
interests of other stockholders of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Application of Takeover Protections; Rights Agreement</U>. The Company and its
board of directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, interested stockholder, business combination, poison pill (including, without limitation, any distribution under a rights
agreement), stockholder rights plan or other similar anti-takeover provision under the Certificate of Incorporation, Bylaws or other organizational documents or the laws of the jurisdiction of its incorporation or otherwise which is or could become
applicable to any Buyer as a result of the transactions contemplated by this Agreement, including, without limitation, the Company&#146;s issuance of the Securities and any Buyer&#146;s ownership of the Securities. The Company and its board of
directors have taken all necessary action, if any, in order to render inapplicable any stockholder rights plan or similar arrangement relating to accumulations of beneficial ownership of shares of Common Stock or a change in control of the Company
or any of its Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Material Liabilities; Financial Information; Forecasts</U>. Except as set forth on Schedule 3(k)(i),
the Company has no liabilities or obligations, absolute or contingent (individually or in the aggregate), except obligations under contracts or other obligations made in the ordinary course of business that as of the date of this Agreement would not
be required to be reflected in financial statements prepared in accordance with generally accepted accounting principles as applied in the United States, consistently applied for the periods covered thereby (&#147;<B>GAAP</B>&#148;). The historical
financial information of the Company delivered to the Buyers on or prior to the date hereof, including the unaudited balance sheet, income statement and statement of cash flows of the Company for the fiscal years ended April&nbsp;30, 2020 and 2021,
and the five (5)&nbsp;month period ended September&nbsp;30, 2021, and attached hereto as Schedule 3(k)(ii) (collectively, the &#147;<B>Financial Statements</B>&#148;), fairly present in all material respects the financial position of the Company and
its Subsidiaries, on a consolidated basis, at the respective dates thereof, subject to adjustments which are not reasonably expected to have a Material Adverse Effect on the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and its Subsidiaries, taken as a whole. No other written information provided by or on behalf of the Company to any of the Buyers contains any untrue statement of a material fact or omits to
state any material fact necessary in order to make the statements therein not misleading, in the light of the circumstance under which they are or were made. The Company is not currently contemplating to amend or restate any of the Financial
Statements, nor does the Company have actual knowledge of facts or circumstances which would require the Company to amend or restate any of the Financial Statements, in each case, in order for any of the Financials Statements to be in compliance
with GAAP (except for the absence of footnotes in the September&nbsp;30, 2021 financial statements). The Company has not been informed by its independent accountants that they recommend that the Company amend or restate any of the Financial
Statements or that there is any need for the Company to amend or restate any of the Financial Statements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Absence of Certain
Changes</U>. Since January&nbsp;1, 2021, there has been no Material Adverse Effect on the Company and its Subsidiaries, taken as a whole. Specifically, except as set forth on Schedule 3(l), since January&nbsp;1, 2021, neither the Company nor its
Subsidiaries have:(i) declared, set aside or paid any dividend or other distribution with respect to any shares of capital stock of the Company or any of its Subsidiaries or any direct or indirect redemption, purchase or other acquisition of any
such shares; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) sold, assigned, pledged, encumbered, transferred or otherwise disposed of any tangible asset of the
Company or any of its Subsidiaries (other than sales or the licensing of its products to customers in the ordinary course of business consistent with past practice), or sold, assigned, pledged, encumbered, transferred or otherwise disposed of any
Intellectual Property (as defined in Section&nbsp;3(w)) (other than licensing of products of the Company or its Subsidiaries in the ordinary course of business and on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) entered into any licensing or other agreement with regard to the acquisition or disposition of any Intellectual Property
other than licenses in the ordinary course of business consistent with past practice or any amendment or consent with respect to any licensing agreement filed or required to be filed with respect to any Governmental Entity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) capital expenditures, individually or in the aggregate, in excess of $50,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) any obligation or liability (whether absolute, accrued, contingent or otherwise, and whether due or to become due) incurred
by the Company or any of its Subsidiaries, in excess of $150,000 individually, other than obligations under customer contracts, current obligations and liabilities, in each case incurred in the ordinary course of business and consistent with past
practice; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) any Lien on any property of the Company or any of its Subsidiaries except for Liens in existence on the
date of this Agreement that are described on <U>Schedules 3(l) (vi)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) any payment, discharge, satisfaction or
settlement of any suit, action, claim, arbitration, proceeding or obligation of the Company or any of its Subsidiaries, except in the ordinary course of business and consistent with past practice; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) any split, combination or reclassification of any equity securities;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) any material loss, destruction or damage to any property of the Company or any Subsidiary, whether or not insured;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) any acceleration or prepayment of any Indebtedness (as defined below) for borrowed money or the refunding of any such
Indebtedness; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) any labor trouble involving the Company or any Subsidiary or any material change in their personnel or
the terms and conditions of employment; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) any waiver of any valuable right, whether by contract or otherwise; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) except as disclosed in <U>Schedule 3(l) (xiii)</U>, any loan or extension of credit to any officer or employee of the
Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) any change in the independent public accountants of the Company or its Subsidiaries or any material change
in the accounting methods or accounting practices followed by the Company or its Subsidiaries, as applicable, or any material change in depreciation or amortization policies or rates; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) any resignation or termination of any officer, key employee or group of employees of the Company or any of its
Subsidiaries; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi) any change in any compensation arrangement or agreement with any employee, officer, director or
stockholder that would result in the aggregate compensation to such Person in such year to exceed $100,000; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii) any
material increase in the compensation of employees of the Company or its Subsidiaries (including any increase pursuant to any written bonus, pension, profit sharing or other benefit or compensation plan, policy or arrangement or commitment), or any
increase in any such compensation or bonus payable to any officer, stockholder, director, consultant or agent of the Company or any of its Subsidiaries having an annual salary or remuneration in excess of $200,000, except as may be provided in
projections contained in <U>Schedule 3(l) (xvii)</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xviii) any revaluation of any of their respective assets,
including, without limitation, writing down the value of capitalized inventory or writing off notes or accounts receivable or any sale of assets other than in the ordinary course of business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xix) any acquisition or disposition of any material assets (or any contract or arrangement therefor), or any other material
transaction by the Company or any Subsidiary otherwise than for fair value in the ordinary course of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx)
written-down the value of any asset of the Company or its Subsidiaries or <FONT STYLE="white-space:nowrap">written-off</FONT> as uncollectible of any accounts or notes receivable or any portion thereof except in the ordinary course of business and
in a magnitude consistent with historical practice; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxi) cancelled any debts or claims or any material amendment, termination
or waiver of any rights of the Company or its Subsidiaries; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxii) any agreement, whether in writing or otherwise, to
take any of the actions specified in the foregoing items (i)&nbsp;through (xxi). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Company nor any of its Subsidiaries has
taken any steps to seek protection pursuant to any law or statute relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding up, nor does the Company or any Subsidiary have any actual knowledge or reason to believe that
any of their respective creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead a creditor to do so. The Company and its Subsidiaries, individually and on a consolidated basis,
are not as of the date hereof, and after giving effect to the transactions contemplated hereby to occur at the Closing, will not be Insolvent (as defined below). For purposes of this Section&nbsp;3(l), &#147;<B>Insolvent</B>&#148; means,
(i)&nbsp;with respect to the Company and its Subsidiaries, on a consolidated basis, (A)&nbsp;the present fair saleable value of the Company&#146;s and its Subsidiaries&#146; assets is less than the amount required to pay the Company&#146;s and its
Subsidiaries&#146; total Indebtedness (as defined below), (B) the Company and its Subsidiaries are unable to pay their debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured or
(C)&nbsp;the Company and its Subsidiaries intend to incur or believe that they will incur debts that would be beyond their ability to pay as such debts mature; and (ii)&nbsp;with respect to the Company and each Subsidiary, individually, (A)&nbsp;the
present fair saleable value of the Company&#146;s or such Subsidiary&#146;s (as the case may be) assets is less than the amount required to pay its respective total Indebtedness, (B)&nbsp;the Company or such Subsidiary (as the case may be) is unable
to pay its respective debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured or (C)&nbsp;the Company or such Subsidiary (as the case may be) intends to incur or believes that it will
incur debts that would be beyond its respective ability to pay as such debts mature. Neither the Company nor any of its Subsidiaries has engaged in any business or in any transaction, and is not currently planning to engage in any business or in any
transaction, for which the Company&#146;s or such Subsidiary&#146;s remaining assets constitute unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>No Undisclosed Events, Liabilities, Developments or Circumstances</U>. No event, liability, development or circumstance has
occurred or exists, or is reasonably expected to exist or occur with respect to the Company, any of its Subsidiaries or any of their respective businesses, properties, liabilities, prospects, operations (including results thereof) or condition
(financial or otherwise), that (i)&nbsp;could reasonably be expected to have a material adverse effect on any Buyer&#146;s investment hereunder or (ii)&nbsp;could reasonably be expected to have a Material Adverse Effect. The reserves, if any,
established by the Company or the lack of reserves, if applicable, are reasonable based upon facts and circumstances known by the Company on the date hereof and there are no loss contingencies that are required to be accrued by the Statement of
Financial Accounting Standard No.&nbsp;5 of the Financial Accounting Standards Board which are not provided for by the Company in its financial statements or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Conduct of Business; Regulatory Permits</U>. Neither the Company nor any of its
Subsidiaries is in violation of any term of or in default under its Certificate of Incorporation, any certificate of designation, preferences or rights of any other outstanding series of preferred stock of the Company or any of its Subsidiaries or
Bylaws or their organizational charter, certificate of formation, memorandum of association, articles of association, Certificate of Incorporation or certificate of incorporation or bylaws, respectively. Neither the Company nor any of its
Subsidiaries is in violation of any judgment, decree or order or any statute, ordinance, rule or regulation applicable to the Company or any of its Subsidiaries, and neither the Company nor any of its Subsidiaries will conduct its business in
violation of any of the foregoing, except in all cases for possible violations which could not, individually or in the aggregate, have a Material Adverse Effect. Except as otherwise disclosed in <U>Schedule 3(n)</U>, the Company and each of its
Subsidiaries possess all certificates, authorizations and permits issued by the appropriate regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such certificates, authorizations or permits
would not have, individually or in the aggregate, a Material Adverse Effect, and neither the Company nor any such Subsidiary has received any written notice of proceedings relating to the revocation or modification of any such certificate,
authorization or permit. There is no agreement, commitment, judgment, injunction, order or decree binding upon the Company or any of its Subsidiaries or to which the Company or any of its Subsidiaries is a party which has or would reasonably be
expected to have the effect of prohibiting or materially impairing any business practice of the Company or any of its Subsidiaries, any acquisition of property by the Company or any of its Subsidiaries or the conduct of business by the Company or
any of its Subsidiaries as currently conducted other than such effects, individually or in the aggregate, which have not had and would not reasonably be expected to have a Material Adverse Effect on the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Foreign Corrupt Practices</U>. Neither the Company, the Company&#146;s subsidiary or any director, officer, agent, employee, nor any
other Person acting for or on behalf of the foregoing (individually and collectively, a &#147;<B>Company Affiliate</B>&#148;) have violated the U.S. Foreign Corrupt Practices Act (the &#147;<B>FCPA</B>&#148;) or any other applicable anti-bribery or
anti-corruption laws, nor has any Company Affiliate offered, paid, promised to pay, or authorized the payment of any money, or offered, given, promised to give, or authorized the giving of anything of value, to any officer, employee or any other
person acting in an official capacity for any Governmental Entity to any political party or official thereof or to any candidate for political office (individually and collectively, a &#147;<B>Government Official</B>&#148;) or to any person under
circumstances where such Company Affiliate knew or was aware of a high probability that all or a portion of such money or thing of value would be offered, given or promised, directly or indirectly, to any Government Official, for the purpose of:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) (A) influencing any act or decision of such Government Official in his/her official capacity, (B)&nbsp;inducing such
Government Official to do or omit to do any act in violation of his/her lawful duty, (C)&nbsp;securing any improper advantage, or (D)&nbsp;inducing such Government Official to influence or affect any act or decision of any Governmental Entity, or
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) assisting the Company or its Subsidiaries in obtaining or retaining business for or with, or directing business to,
the Company or its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Transactions With Affiliates</U>. Except as set forth in <U>Schedule 3(p)</U>, no
current or former employee, partner, director, officer or stockholder (direct or indirect) of the Company or its Subsidiaries, or any associate, or, to the actual knowledge of the Company, any affiliate of any thereof, or any relative with a
relationship no more remote than first cousin of any of the foregoing, is presently, or since June&nbsp;30, 2013 has been: (i)&nbsp;a party to any transaction with the Company or its Subsidiaries (including any contract, agreement or other
arrangement providing for the furnishing of services by, or rental of real or personal property from, or otherwise requiring payments to, any such director, officer or stockholder or such associate or affiliate or relative Subsidiaries (other than
for ordinary course services as employees, officers or directors of the Company or any of its Subsidiaries)) or (ii)&nbsp;the direct or indirect owner of an interest in any corporation, firm, association or business organization which is a
competitor, supplier or customer of the Company or its Subsidiaries (except for a passive investment (direct or indirect) in less than 5% of the common stock of a company whose securities are traded on or quoted through an Eligible Market (as
defined in the Notes)), nor does any such Person receive income from any source other than the Company or its Subsidiaries which relates to the business of the Company or its Subsidiaries or should properly accrue to the Company or its Subsidiaries.
No employee, officer, stockholder or director of the Company or any of its Subsidiaries or member of his or her immediate family is indebted to the Company or its Subsidiaries, as the case may be, nor is the Company or any of its Subsidiaries
indebted (or committed to make loans or extend or guarantee credit) to any of them, other than (i)&nbsp;for payment of salary for services rendered, (ii)&nbsp;reimbursement for reasonable expenses incurred on behalf of the Company, and
(iii)&nbsp;for other standard employee benefits made generally available to all employees or executives (including stock option agreements outstanding under any stock option plan approved by the Board of Directors of the Company). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Equity Capitalization</U><U>. </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Definitions</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) &#147;<B>Common Stock</B>&#148; means (x)&nbsp;the Company&#146;s shares of common stock, $0.001 par value per share, and
(y)&nbsp;any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) &#147;<B>Preferred Stock</B>&#148; means (x)&nbsp;the Company&#146;s blank check preferred stock, $0.001 par value per
share, the terms of which may be designated by the board of directors of the Company in a certificate of designations and (y)&nbsp;any capital stock into which such preferred stock shall have been changed or any share capital resulting from a
reclassification of such preferred stock (other than a conversion of such preferred stock into Common Stock in accordance with the terms of such certificate of designations). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Authorized and Outstanding Capital Stock</U>. As of the date hereof, the authorized capital stock of the Company
consists of (A) 300,000,000 shares of Common Stock, of which 109,690,081 are issued and outstanding and 146,807,686 shares are reserved for issuance pursuant to Convertible Securities (as defined below) (other than the Notes and the Warrants)
exercisable or exchangeable for, or convertible into, shares of Common Stock and (B) 20,000,000 shares of Preferred Stock, 503,265 of which are issued and outstanding. No shares of Common Stock are held in the treasury of the Company.
&#147;<B>Convertible Securities</B>&#148; means any capital stock or other security of the Company or any of its Subsidiaries that is at any time and under any circumstances directly or indirectly convertible into, exercisable or exchangeable for,
or which otherwise entitles the holder thereof to acquire, any capital stock or other security of the Company (including, without limitation, Common Stock) or any of its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Valid Issuance; Available Shares; Affiliates</U>. All of such
outstanding shares are duly authorized and have been, or upon issuance will be, validly issued and are fully paid and nonassessable. <U>Schedule 3(q)(iii)</U> sets forth the number of shares of Common Stock that are (A)&nbsp;reserved for issuance
pursuant to Convertible Securities (other than the Notes and the Warrants) and (B)&nbsp;that are, as of the date hereof, owned by Persons who are &#147;affiliates&#148; (as defined in Rule 405 of the 1933 Act and calculated based on the assumption
that only officers, directors and holders of at least 10% of the Company&#146;s issued and outstanding Common Stock are &#147;affiliates&#148; without conceding that any such Persons are &#147;affiliates&#148; for purposes of federal securities
laws) of the Company or any of its Subsidiaries. To the Company&#146;s knowledge, no Person owns 10% or more of the Company&#146;s issued and outstanding shares of Common Stock (calculated based on the assumption that all Convertible Securities (as
defined below), whether or not presently exercisable or convertible, have been fully exercised&nbsp;or converted&nbsp;(as the case may be) taking account of any limitations on exercise or conversion (including &#147;blockers&#148;) contained therein
without conceding that such identified Person is a 10% stockholder for purposes of federal securities laws). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)
<U>Existing Securities; Obligations</U>. Except as disclosed on Schedule 3(q)(iv): (A) none of the Company&#146;s or any Subsidiary&#146;s shares, interests or capital stock is subject to preemptive rights or any other similar rights or Liens
suffered or permitted by the Company or any Subsidiary; (B)&nbsp;there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, or
exercisable or exchangeable for, any shares, interests or capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to
issue additional shares, interests or capital stock of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible
into, or exercisable or exchangeable for, any shares, interests or capital stock of the Company or any of its Subsidiaries; (C)&nbsp;there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register
the sale of any of their securities under the 1933 Act (except pursuant to the Registration Rights Agreement and the registration rights agreements set forth on Schedule 3(q)(iv)); (D) there are no outstanding securities or instruments of the
Company or any of its Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a
security of the Company or any of its Subsidiaries; (E)&nbsp;there are no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities; and (F)&nbsp;neither the Company nor any
Subsidiary has any stock appreciation rights or &#147;phantom stock&#148; plans or agreements or any similar plan or agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Organizational Documents</U>. The Company has furnished to the Buyers
true, correct and complete copies of the Company&#146;s Certificate of Incorporation, as amended and as in effect on the date hereof (the &#147;<B>Certificate</B> <B>of Incorporation</B>&#148;), and the Company&#146;s bylaws, as amended and as in
effect on the date hereof (the &#147;<B>Bylaws</B>&#148;), and the terms of all Convertible Securities and the material rights of the holders thereof in respect thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Indebtedness and Other Contracts</U>. Neither the Company nor any of its Subsidiaries, (i)&nbsp;except as disclosed on
<U>Schedule</U><U></U><U>&nbsp;3(r)</U>, has any outstanding debt securities, notes, credit agreements, credit facilities or other agreements, documents or instruments evidencing Indebtedness of the Company or any of its Subsidiaries or by which the
Company or any of its Subsidiaries is or may become bound, (ii)&nbsp;is a party to any contract, agreement or instrument, the violation of which, or default under which, by the other party(ies) to such contract, agreement or instrument could
reasonably be expected to result in a Material Adverse Effect, (iii)&nbsp;except as set forth on <U>Schedule 3(r)</U>, has any financing statements securing obligations in any amounts filed in connection with the Company or any of its Subsidiaries;
(iv)&nbsp;is in violation of any term of, or in default under, any contract, agreement or instrument relating to any Indebtedness, except where such violations and defaults would not result, individually or in the aggregate, in a Material Adverse
Effect, or (v)&nbsp;is a party to any contract, agreement or instrument relating to any Indebtedness, the performance of which, in the judgment of the Company&#146;s officers, has or is expected to have a Material Adverse Effect. For purposes of
this Agreement: (x) &#147;<B>Indebtedness</B>&#148; of any Person means, without duplication (A)&nbsp;all indebtedness for borrowed money, (B)&nbsp;all obligations issued, undertaken or assumed as the deferred purchase price of property or services
(including, without limitation, &#147;capital leases&#148; in accordance with GAAP) (other than trade payables entered into in the ordinary course of business consistent with past practice), (C) all reimbursement or payment obligations with respect
to letters of credit, surety bonds and other similar instruments, (D)&nbsp;all obligations evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the acquisition of property,
assets or businesses, (E)&nbsp;all indebtedness created or arising under any conditional sale or other title retention agreement, or incurred as financing, in either case with respect to any property or assets acquired with the proceeds of such
indebtedness (even though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property), (F) all monetary obligations under any leasing or similar arrangement which,
in connection with GAAP, consistently applied for the periods covered thereby, is classified as a capital lease, (G)&nbsp;all indebtedness referred to in clauses (A)&nbsp;through (F) above secured by (or for which the holder of such Indebtedness has
an existing right, contingent or otherwise, to be secured by) any Lien upon or in any property or assets (including accounts and contract rights) owned by any Person, even though the Person which owns such assets or property has not assumed or
become liable for the payment of such indebtedness, and (H)&nbsp;all Contingent Obligations in respect of indebtedness or obligations of others of the kinds referred to in clauses (A)&nbsp;through (G) above; and (y) &#147;<B>Contingent
Obligation</B>&#148; means, as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to any Indebtedness, lease, dividend or other obligation of another Person if the primary purpose or intent of the
Person incurring such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability will be paid or discharged, or that any agreements relating thereto will be complied with, or that the
holders of such liability will be protected (in whole or in part) against loss with respect thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U>Litigation</U>. There is no action, suit, arbitration, proceeding, inquiry or
investigation before or by any court, public board, other Governmental Entity, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its Subsidiaries, the Common Stock
or any of the Company&#146;s or its Subsidiaries&#146; officers or directors , whether of a civil or criminal nature or otherwise, in their capacities as such, except as set forth in <U>Schedule 3(s)</U>. No director, officer or employee of the
Company or any of its subsidiaries has willfully violated 18 U.S.C. &#167;1519 or engaged in spoliation in reasonable anticipation of litigation. The Company is not subject to any order, writ, judgment, injunction, decree, determination or award of
any Governmental Entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Insurance</U>. The Company and each of its Subsidiaries are insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary
has been refused any insurance coverage sought or applied for, and neither the Company nor any such Subsidiary has any reason to believe that it will be unable to renew its existing insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Employee Matters; Benefit Plans</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Except as set forth on <U>Schedule 3(u)(i)</U>, the employment of each officer and employee of the Company is terminable at
the will of the Company. The Company and its Subsidiaries have complied in all material respects with all applicable laws relating to wages, hours, equal opportunity, collective bargaining, workers&#146; compensation insurance and the payment of
social security and other taxes. The Company is not aware that any officer, key employee or group of employees intends to terminate his, her or their employment with the Company or its Subsidiaries, as the case may be, nor does the Company have a
present intention, or know of a present intention of its Subsidiaries, to terminate the employment of any officer, key employee or group of employees. There are no pending or, to the knowledge of the Company, threatened employment discrimination
charges or complaints against or involving the Company or its Subsidiaries before any federal, state, or local board, department, commission or agency, or unfair labor practice charges or complaints, disputes or grievances affecting the Company or
its Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Since the Company&#146;s inception, neither the Company nor its Subsidiaries has experienced any
labor disputes, union organization attempts or work stoppage due to labor disagreements. There are no unfair labor practice charges or complaints against the Company or its Subsidiaries pending, or to the knowledge of the Company, threatened before
the National Labor Relations Board or any comparable state agency or authority. There are no written or oral contracts, commitments, agreements, understandings or other arrangements with any labor organization, nor work rules or practices agreed to
with any labor organization or employee association, applicable to employees of the Company or any of its Subsidiaries, nor is the Company or its Subsidiaries a party to, or bound by, any collective bargaining or similar agreement; there is not, and
since the Company&#146;s inception there has not been, any representation of the employees of the Company or its Subsidiaries by any labor organization and, to the knowledge of the Company, there are no union organizing activities among the
employees of the Company or its Subsidiaries, and to the knowledge of the Company, no question concerning representation has been raised or is threatened respecting the employees of the Company or its Subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Schedule 3(u)(iii)</U> contains a true, correct and complete list
of each pension, retirement, savings, deferred compensation and profit-sharing plan and each stock option, stock appreciation, stock purchase, performance share, bonus or other incentive plan, severance plan, health, group insurance or other welfare
plan, or other similar plan (whether written or otherwise) and any &#147;employee benefit plan&#148; within the meaning of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#147;<B>ERISA</B>&#148;), under which
the Company has any current or future obligation or liability (including any potential, contingent or secondary liability under Title IV of ERISA) or under which any employee or former employee (or beneficiary of any employee or former employee) of
the Company has or may have any current or future right to benefits (the term &#147;plan&#148; shall include any contract, agreement (including an employment or independent contractor agreement), policy or understanding, each such plan being
hereinafter referred to in this Agreement individually as a &#147;<B>Benefit Plan</B>&#148;). The Company has delivered to each Buyer true, correct and complete copies of (i)&nbsp;each material Benefit Plan, including any amendments thereto,
(ii)&nbsp;the summary plan description, if any, for each Benefit Plan, including any summaries of material modifications made since the most recent summary plan description, (iii)&nbsp;the latest annual report which has been filed with the Internal
Revenue Service (the &#147;<B>IRS</B>&#148;) for each Benefit Plan required to file an annual report, and (iv)&nbsp;the most recent IRS determination letter for each Benefit Plan that is a pension plan (as defined in ERISA) intended to be qualified
under Section&nbsp;401(a) of the Code. Each Benefit Plan intended to be tax qualified under Sections 401(a) and 501(a) of the Code is and has been determined by the IRS to be tax qualified under Sections 401(a) and 501(a) of the Code and, since such
determination, no amendment to or failure to amend any such Benefit Plan and no other event or circumstance has occurred that could reasonably be expected to adversely affect its tax qualified status. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) There are no actions, claims, audits, lawsuits or arbitrations pending, or, to the knowledge of the Company, threatened,
with respect to any Benefit Plan or the assets of any Benefit Plan. Except as set forth in <U>Schedule 3(u)(iv)</U>, each Benefit Plan has been administered in all material respects in accordance with its terms and with all applicable Legal
Requirements (as defined below) (including, without limitation, the Code and ERISA). &#147;<B>Legal Requirement</B>&#148; means any federal, state, local, municipal, foreign, international, multinational, or other administrative order, constitution,
law, ordinance, principle of common law, regulation, statute, or treaty. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Except as set forth in <U>Schedule
3(u)(v)</U>, the consummation of the transactions contemplated by this Agreement will not (1)&nbsp;entitle any employee or independent contractor of the Company or its Subsidiaries to severance pay or termination benefits, (2)&nbsp;accelerate the
time of payment or vesting, or increase the amount of compensation due to any current or former employee or independent contractor of the Company or its Subsidiaries, (3)&nbsp;obligate the Company or any of its affiliates to pay or otherwise be
liable for any compensation, vacation days, pension contribution or other benefits to any current or former employee, consultant, agent or independent contractor of the Company or its Subsidiaries for periods before the applicable Closing Date,
(4)&nbsp;require assets to be set aside or other forms of security to be provided with respect to any liability under a Benefit Plan, or (5)&nbsp;result in any &#147;parachute payment&#148; (within the meaning of Section&nbsp;280G of the Code) under
any Benefit Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) No Benefit Plan is subject to the provisions of Section&nbsp;412 of the
Code or Part 3 of Subtitle B of Title I of ERISA. No Benefit Plan is subject to Title IV of ERISA and no Benefit Plan is a &#147;multiemployer plan&#148; (within the meaning of Section&nbsp;3(37) of ERISA). Since inception, neither the Company, its
Subsidiaries, nor any business or entity treated as a single employer with the Company or its Subsidiaries for purposes of Title IV of ERISA contributed to or was obliged to contribute to a pension plan that was at any time subject to Title IV of
ERISA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) No Benefit Plan has provided, been required to provide, provides or is required to provide, at any time in
the past, present, or future, health, medical, dental, accident, disability, death or survivor benefits to or in respect of any Person beyond one year following termination of employment, except to the extent required under any state insurance law
or under Part 6 of Subtitle B of Title I of ERISA and under Section&nbsp;4980B of the Code. No Benefit Plan covers any individual that is not an employee or advisor of the Company or its Subsidiaries, other than spouses and dependents of employees
under health and child care policies listed in <U>Schedule</U><U></U><U>&nbsp;3(u)(vii)</U>, true and complete copies of which have been made available to each Buyer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) Except as otherwise permitted pursuant to employment agreements with the Company disclosed to the Buyers, each officer
of the Company is currently devoting all of such officer&#146;s business time to the conduct of the business of the Company. Except as otherwise permitted pursuant to employment agreements with the Company disclosed to the Buyers, the Company is not
aware of any officer or key employee of the Company or any of its Subsidiaries planning to work less than full time at the Company or its Subsidiaries in the future. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Assets; Title.</U><U> </U>(b) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Except as set forth on <U>Schedule 3(v)(i)</U>, each of the Company and its Subsidiaries has good and valid title to, or a
valid leasehold interest in, as applicable, all of its material properties and assets, free and clear of all Liens except (i)&nbsp;any Lien for taxes not yet due or delinquent or being contested in good faith by appropriate proceedings for which
adequate reserves have been established in accordance with GAAP, (ii)&nbsp;any statutory Lien arising in the ordinary course of business by operation of law with respect to a liability that is not yet due or delinquent, (iii)&nbsp;any Lien created
by operation of law, such as materialmen&#146;s liens, mechanics&#146; liens and other similar liens, arising in the ordinary course of business with respect to a liability that is not yet due or delinquent or that are being contested in good faith
by appropriate proceedings, and (iv)&nbsp;such as have been disposed of in the ordinary course of business. All tangible personal property owned by the Company and its Subsidiaries has been maintained in good operating condition and repair, except
(x)&nbsp;for ordinary wear and tear, and (y)&nbsp;where such failure would not have a Material Adverse Effect. All assets leased by the Company or any of its Subsidiaries are in the condition </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
required by the terms of the lease applicable thereto during the term of such lease and upon the expiration thereof. The Company and its Subsidiaries have good and marketable title in fee simple
to all real property, if any, and good and marketable title to all personal property owned by them which is material to the business of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects except such
Liens set forth in <U>Schedule</U><U></U><U>&nbsp;3(v)(i)</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <U>Schedule</U><U></U><U>&nbsp;3(v)(ii)</U> sets forth
a complete list of all real property and interests in real property leased by the Company as of the date hereof (the &#147;<B>Real Property</B>&#148;). The Company has good and valid leasehold interest in all real property and interests in real
property shown on <U>Schedule</U><U></U><U>&nbsp;3(v)(ii)</U> to be leased by it free and clear of all Liens except where such Liens would not have a Material Adverse Effect. Except as set forth on <U>Schedule</U><U></U><U>&nbsp;3(v)(ii)</U>, there
exists no default, or any event which upon notice or the passage of time, or both, would give rise to any default, in the performance of the Company or by any lessor under any such lease, nor, to the knowledge of the Company, is the landlord of any
such lease in default except where any such default would not have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <U>Intellectual Property</U><U>.</U><U>
</U>(c) </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Except as set forth on <U>Schedule 3(w)(i)</U>, the Company and its Subsidiaries own all right, title and
interest in and to, or have a valid and enforceable (except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to, or affecting generally,
the enforcement of applicable creditors&#146; rights and remedies.) license to use all the Intellectual Property used by them in connection with the their respective businesses, which represents all intellectual property rights necessary to the
conduct of the their business as now conducted. The Company and its Subsidiaries are in compliance with all contractual obligations relating to the protection of such of the Intellectual Property as they use pursuant to license or other agreement
except where any <FONT STYLE="white-space:nowrap">non-compliance</FONT> could not reasonably be expected to result in a Material Adverse Effect. The conduct of the business of the Company and its Subsidiaries, to the knowledge of the Company, as
currently conducted, or as reasonably be expected to be conducted, does not, and is not reasonably expected to, conflict with or infringe any proprietary right or Intellectual Property of any third party, including, without limitation, the
transmission, reproduction, use, display or modification of any content or material (including framing, and linking web site content) on a web site, bulletin board or other like medium hosted by or on behalf of the Company or any of its
Subsidiaries, except for such infringements and conflicts which would not reasonably be expected to have a Material Adverse Effect. There is no claim, suit, action or proceeding pending or, to the knowledge of the Company, threatened against the
Company or any Subsidiary: (i)&nbsp;alleging any such conflict or infringement with any third party&#146;s proprietary rights; or (ii)&nbsp;challenging the Company&#146;s or any Subsidiary&#146;s ownership or use of, or the validity or
enforceability of any Intellectual Property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Schedule 3(w)(ii)</U> sets forth a complete and current list of
registered trademarks or copyrights, issued patents, applications therefor, or other forms of Intellectual Property registration anywhere in the world that is owned by the Company or a Subsidiary (&#147;<B>Listed Intellectual Property</B>&#148;) and
the owner of record, date of application or issuance and relevant jurisdiction as to each. Except as set forth on <U>Schedule 3(w)(ii)</U>, all Listed Intellectual Property is owned by the Company or a Subsidiary, free and clear of security
interests, liens, encumbrances or claims of any nature. All Listed Intellectual Property is valid, subsisting, unexpired, in proper form and enforceable and all renewal fees and other maintenance fees that have fallen due on or prior to the
effective date of this Agreement have been paid. No Listed Intellectual Property is the subject of any proceeding before any governmental, registration or other authority in any jurisdiction, including any office action or other form of preliminary
or final refusal of registration, except as noted on <U>Schedule 3(w)(ii)</U>. The consummation of the transactions contemplated hereby will not alter or impair any Intellectual Property that is owned or licensed by the Company or a Subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Schedule 3(w)(iii) </U>sets forth a complete list of all agreements relating to Intellectual Property to which the
Company or a Subsidiary is a party, subject or bound (the &#147;<B>Intellectual Property Contracts</B>&#148;) (other than agreements involving (A)&nbsp;the license of the Company of standard, generally commercially available <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;off-the-shelf&#148;</FONT></FONT> third party products that are not and will not to any extent be part of any product, service or intellectual property offering of the Company or <FONT
STYLE="white-space:nowrap">(B)&nbsp;non-disclosure</FONT> or <FONT STYLE="white-space:nowrap">non-use</FONT> of information). Each Intellectual Property Contract: (i)&nbsp;is valid and binding on the Company or a Subsidiary, as the case may be, and,
to the Company&#146;s knowledge, the counterparties thereto, and is in full force and effect and (ii)&nbsp;upon consummation of the transactions contemplated hereby shall continue in full force and effect without penalty or other adverse
consequence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The Company and its Subsidiaries are not under any obligation to pay royalties or other payments in
connection with any agreement, nor restricted from assigning their rights respecting Intellectual Property nor will the Company or any Subsidiary otherwise be, as a result of the execution and delivery of this Agreement or the performance of the
Company&#146;s obligations under this Agreement, in breach of any agreement relating to the Intellectual Property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)
Except as set forth on <U>Schedule 3(w)(v)</U>, no present or former employee, officer or director of the Company or any Subsidiary, or agent or outside contractor of the Company or any Subsidiary, holds any right, title or interest, directly or
indirectly, in whole or in part, in or to any Intellectual Property that is owned or licensed by the Company or any Subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) To the Company&#146;s knowledge: (i)&nbsp;none of the Listed Intellectual Property has been used, disclosed or
appropriated to the detriment of the Company or any Subsidiary for the benefit of any Person other than the Company; and (ii)&nbsp;no employee, independent contractor or agent of the Company or any Subsidiary has misappropriated any trade secrets or
other confidential information of any other Person in the course of the performance of his or her duties as an employee, independent contractor or agent of the Company or any Subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) Any programs, modifications, enhancements or other inventions,
improvements, discoveries, methods or works of authorship (&#147;<B>Works</B>&#148;) that were created by employees of the Company or any Subsidiary were made in the regular course of such employees&#146; employment or service relationships with the
Company or its Subsidiary using the Company&#146;s or the Subsidiary&#146;s facilities and resources and, as such, constitute either works made for hire or all rights and title to and in such Works have been fully assigned to the Company or a
Subsidiary. Each such employee who has created Works or any employee who in the regular course of his employment may create Works and all consultants have signed an assignment or similar agreement with the Company or the Subsidiary confirming the
Company&#146;s or the Subsidiary&#146;s ownership or, in the alternate, transferring and assigning to the Company or the Subsidiary all right, title and interest in and to such programs, modifications, enhancements or other inventions including
copyright and other intellectual property rights therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) For the purpose of this Agreement, &#147;<B>Intellectual
Property</B>&#148; or &#147;<B>Intellectual Property Rights</B>&#148; shall mean all of the following: (A)&nbsp;trademarks and service marks, trade dress, product configurations, trade names and other indications of origin, applications or
registrations in any jurisdiction pertaining to the foregoing and all goodwill associated therewith; (B)&nbsp;inventions, discoveries, improvements, ideas, <FONT STYLE="white-space:nowrap">know-how,</FONT> formula methodology, processes, technology,
software (including password unprotected interpretive code or source code, object code, development documentation, programming tools, drawings, specifications and data) and applications and patents in any jurisdiction pertaining to the foregoing,
including <FONT STYLE="white-space:nowrap">re-issues,</FONT> continuations, divisions, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> renewals or extensions; (C)&nbsp;trade secrets, including
confidential information and the right in any jurisdiction to limit the use or disclosure thereof; (D)&nbsp;copyrights in writings, designs software, mask works or other works, applications or registrations in any jurisdiction for the foregoing and
all moral rights related thereto; (E)&nbsp;database rights; (F)&nbsp;internet websites, domain names and applications and registrations pertaining thereto and all intellectual property used in connection with or contained in all versions of the
Company&#146;s Web sites; (G)&nbsp;rights under all agreements relating to the foregoing; (H)&nbsp;books and records pertaining to the foregoing; and (I)&nbsp;claims or causes of action arising out of or related to past, present or future
infringement or misappropriation of the foregoing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>Environmental Laws</U>(i) . (i) The Company and its Subsidiaries (A)&nbsp;are in
compliance with any and all Environmental Laws (as defined below), (B) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (C)&nbsp;are in compliance
with all terms and conditions of any such permit, license or approval where, in each of the foregoing clauses (A), (B) and (C), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse
Effect. The term &#147;<B>Environmental Laws</B>&#148; means all federal, state, local or foreign laws relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater,
land surface or subsurface strata), including, without limitation, laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively,
&#147;<B>Hazardous Materials</B>&#148;) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes,
decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <U>No Hazardous Materials</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) have been disposed of or otherwise released from any Real Property of the Company or any of its Subsidiaries in violation
of any Environmental Laws; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) to the knowledge of the Company, are present on, over, beneath, in or upon Real Property
or any portion thereof in quantities that would constitute a violation of any Environmental Laws. No prior use by the Company or any of its Subsidiaries of any Real Property has occurred that violates any Environmental Laws, which violation would
have a material adverse effect on the business of the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Neither the Company nor
any of its Subsidiaries knows of any other person who or entity which has stored, treated, recycled, disposed of or otherwise located on any Real Property any Hazardous Materials, including, without limitation, such substances as asbestos and
polychlorinated biphenyls. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) None of the Real Properties are on any federal or state &#147;Superfund&#148; list or
Liability Information System (&#147;<B>CERCLIS</B>&#148;) list or any state environmental agency list of sites under consideration for CERCLIS, nor subject to any environmental related Liens. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <U>Subsidiary Rights</U>. The Company or one of its Subsidiaries has the unrestricted right to vote, and (subject to limitations imposed by
applicable law) to receive dividends and distributions on, all capital securities of its Subsidiaries as owned by the Company or such Subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <U>Tax Status</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Each of the Company and the Subsidiaries has filed or caused to be filed in a timely manner (within any applicable
extension periods) and in the appropriate jurisdictions all material returns, reports, information statements and other documentation (including any additional or supporting materials) filed or maintained, or required to be filed or maintained, in
connection with the calculation, determination, assessment or collection of any and all federal, state, local, foreign and other taxes, levies, fees, imposts, duties, governmental fees and charges of whatever kind (including any interest, penalties
or additions to the tax imposed in connection therewith or with respect thereto), including, without limitation, taxes imposed on, or measured by, income, franchise, profits, gross income or gross receipts, and also <U>ad</U> <U>valorem</U>, value
added, sales, use, service, real or personal property, capital stock, stock transfer, license, payroll, withholding, employment, social security, workers&#146; compensation, unemployment compensation, utility, severance, production, excise, stamp,
occupation, premium, windfall profits, environmental, transfer and gains taxes and customs duties (each a &#147;<B>Tax</B>&#148;) including amended returns required as a result of examination adjustments made by the IRS or other Governmental Entity
responsible for the imposition of any Tax (collectively, the &#147;<B>Returns</B>&#148;) and such Returns are true, correct and complete in all material respects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Each of the Company and the Subsidiaries has paid all material Taxes
and other assessments due from and payable by the Company and the Subsidiaries on or prior to the date hereof on a timely basis except as to those set forth in <U>Schedule 3(z)(ii)</U>. The charges, accruals, and reserves for Taxes with respect to
the Company and the Subsidiaries are adequate to cover Tax liabilities of the Company and the Subsidiaries accruing throughout the date thereof. Except as set forth in <U>Schedule 3(z)(ii)</U>, each of the Company and the Subsidiaries has complied
in all material respects with all applicable Legal Requirements relating to the payment and withholding of Taxes (including withholding and reporting requirements under Sections 1441 through 1464, 3401 through 3406, and 6041 and 6049 of the Code and
similar provisions under any other applicable Legal Requirements) and, within the time and in the manner prescribed by law, has withheld from wages, fees and other payments and paid over to the proper governmental or regulatory authorities all
amounts required. Except as set forth in <U>Schedule 3(z)(ii)</U>, neither the Company nor any of the Subsidiaries has received notice of assessment or proposed assessment of any Taxes claimed to be owed by it or any other Person on its behalf.
Except as set forth in <U>Schedule 3(z)(ii)</U>, no Returns filed by or on behalf of the Company or any of the Subsidiaries with respect to Taxes are currently being audited or examined. Except as set forth in <U>Schedule 3(z)(ii)</U>, neither the
Company nor any of the Subsidiaries has received notice of any such audit or examination. Except as set forth in <U>Schedule 3(z)(ii)</U>, no issue has been raised by any taxing authority with respect to the Company or any of the Subsidiaries in any
audit or examination which, by application of similar principles, could reasonably be expected to result in a proposed material adjustment to the liability for Taxes for any period not so examined. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Except as set forth in <U>Schedule 3(z)(iii)</U>, no known Liens have been filed and no claims are being asserted by or
against the Company or any of the Subsidiaries with respect to any Taxes (other than Liens for Taxes not yet due and payable). Neither the Company nor any of the Subsidiaries has elected pursuant to the Code to be treated as an S corporation or any
comparable provision of local, state or foreign law, or has made any other elections pursuant to the Code (other than elections that relate solely to entity classification, methods of accounting, depreciation, or amortization) that would reasonably
be expected to have a material effect on the business, properties, prospects, or financial condition of the Company and the Subsidiaries, individually or in the aggregate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) No claim has ever been made, or, to the knowledge of the Company, is threatened or pending, by any authority in a
jurisdiction where the Company or any of the Subsidiaries, respectively, does not file Returns that the Company or any of the Subsidiaries is or may be subject to taxation by that jurisdiction, and neither the Company nor any of the Subsidiaries has
received any notice or request for information from any such authority. Neither the Company nor any of the Subsidiaries has been a member of an affiliated group (as defined in Section&nbsp;1504(a) of the Code) or filed or been included in a
combined, consolidated or unitary income tax return other than the affiliated group of which the Company is currently the common parent. Neither the Company nor any of the Subsidiaries is required to include in income any adjustment pursuant to
Section&nbsp;481(a) of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Code by reason of a voluntary change in accounting methods initiated by the Company or any of the Subsidiaries, and no Governmental Entity has proposed an adjustment or change in accounting
method. All transactions or methods of accounting that could give rise to a substantial understatement of federal income tax as described in Section&nbsp;6662(d)(2)(B)(i) of the Code have been adequately disclosed on the Company&#146;s and the
Subsidiaries&#146; federal income tax returns in accordance with Section&nbsp;6662(d)(2)(B) of the Code. Neither the Company nor any of the Subsidiaries is a party to any Tax sharing or Tax indemnity agreement or any other agreement of a similar
nature that remains in effect. Neither the Company nor any of the Subsidiaries has consented to any waiver of the statute of limitations for the assessment of any Taxes or has requested any extension of time for the payment of any Taxes. Neither the
Company nor any of the Subsidiaries has ever held a material beneficial interest in any other Person, other than those listed in <U>Schedule 3(z)(iv)</U>. Neither the Company nor any of the Subsidiaries is obligated to make, nor as a result of any
event connected with the transactions contemplated by this Agreement will become obligated to make, any payment that would not be deductible under Section&nbsp;280G of the Code. Neither the Company nor any Subsidiary is a &#147;passive foreign
investment company&#148; within the meaning of Section&nbsp;1296 of the Code (a &#147;<B>PFIC</B>&#148;), and the Company does not anticipate that the Company or any additional foreign Subsidiary will become a PFIC in the foreseeable future. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Other than as listed in <U>Schedule 3(z)(v)</U>, the net operating loss carryforwards (&#147;<B>NOLs</B>&#148;) for United
States federal income tax purposes of the consolidated group of which the Company is the common parent, if any, shall not, to the Company&#146;s knowledge, be adversely effected by the transactions contemplated hereby. The transactions contemplated
hereby do not constitute an &#147;ownership change&#148; within the meaning of Section&nbsp;382 of the Code, thereby preserving the Company&#146;s ability to utilize such NOLs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <U>Internal Accounting and Disclosure Controls</U>. The Company and each of its Subsidiaries maintain a system of internal accounting
controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations, (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial
statements that accurately reflect the current status of the business of the Company and its Subsidiaries and to maintain asset and liability accountability, (iii)&nbsp;access to assets or incurrence of liabilities is permitted only in accordance
with management&#146;s general or specific authorization and (iv)&nbsp;the recorded accountability for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals and appropriate action is taken with respect
to any difference. Neither the Company nor any of its Subsidiaries has received any notice or correspondence from any accountant, Governmental Entity or other Person relating to any potential material weakness or significant deficiency in any part
of the internal controls over financial reporting of the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <U>Off Balance Sheet Arrangements</U>.
There is no transaction, arrangement, or other relationship between the Company or any of its Subsidiaries and an unconsolidated or other off balance sheet entity that would be required to be disclosed by the Company in its 1934 Act filings and is
not so disclosed or that otherwise could be reasonably likely to have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <U>Investment Company Status</U>. The Company is not, and upon consummation of the sale
of the Securities will not be, an &#147;investment company,&#148; an affiliate of an &#147;investment company,&#148; a company controlled by an &#147;investment company&#148; or an &#147;affiliated person&#148; of, or &#147;promoter&#148; or
&#147;principal underwriter&#148; for, an &#147;investment company&#148; as such terms are defined in the Investment Company Act of 1940, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <U>U.S. Real Property Holding Corporation</U>. Neither the Company nor any of its Subsidiaries is, or has ever been, and so long as any of
the Securities are held by any of the Buyers, shall become, a U.S. real property holding corporation within the meaning of Section&nbsp;897 of the Code, and the Company and each Subsidiary shall so certify upon any Buyer&#146;s request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <U>Transfer Taxes</U>. On the Closing Date, all stock transfer or other taxes (other than income or similar taxes) which are required to
be paid in connection with the issuance, sale and transfer of the Securities to be sold to each Buyer hereunder will be, or will have been, fully paid or provided for by the Company, and all laws imposing such taxes will be or will have been
complied with. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries is subject to the Bank Holding
Company Act of 1956, as amended (the &#147;<B>BHCA</B>&#148;) and to regulation by the Board of Governors of the Federal Reserve System (the &#147;<B>Federal Reserve</B>&#148;). Neither the Company nor any of its Subsidiaries or affiliates owns or
controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by
the Federal Reserve. Neither the Company nor any of its Subsidiaries or affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <U>Illegal or Unauthorized Payments; Political Contributions</U>. Neither the Company nor any of its Subsidiaries nor, to the best of the
Company&#146;s knowledge (after reasonable inquiry of its officers and directors), any of the officers, directors, employees, agents or other representatives of the Company or any of its Subsidiaries or any other business entity or enterprise with
which the Company or any Subsidiary is or has been affiliated or associated, has, directly or indirectly, made or authorized any payment, contribution or gift of money, property, or services, whether or not in contravention of applicable law,
(i)&nbsp;as a kickback or bribe to any Person or (ii)&nbsp;to any political organization, or the holder of or any aspirant to any elective or appointive public office except for personal political contributions not involving the direct or indirect
use of funds of the Company or any of its Subsidiaries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <U>Money Laundering</U>. The Company and its Subsidiaries are in compliance
with, and have not previously violated, the USA Patriot Act of 2001 and all other applicable U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> anti-money laundering laws and regulations, including, without limitation, the laws, regulations
and Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets Control, including, but not limited, to (i)&nbsp;Executive Order 13224 of September&nbsp;23, 2001 entitled, &#147;Blocking Property and Prohibiting
Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism&#148; (66 Fed. Reg. 49079 (2001)); and (ii)&nbsp;any regulations contained in 31 CFR, Subtitle B, Chapter V. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Books and Records</U>. The books of account, ledgers, order books, records and
documents of the Company and its Subsidiaries accurately and completely reflect all information relating to the respective businesses of the Company and its Subsidiaries, the nature, acquisition, maintenance, location and collection of each of their
respective assets, and the nature of all transactions giving rise to material obligations or accounts receivable of the Company or its Subsidiaries, as the case may be, except where the failure to so reflect such information would not have a
Material Adverse Effect. The minute books of the Company and its Subsidiaries contain accurate records of all meetings and accurately reflect all other actions taken by the stockholders, boards of directors and all committees of the boards of
directors, and other governing Persons of the Company and its Subsidiaries, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <U>Acknowledgement Regarding Buyers&#146;
Trading Activity</U>. It is understood and acknowledged by the Company (a)&nbsp;(i) that none of the Buyers have been asked by the Company or its Subsidiaries to agree, nor has any Buyer agreed with the Company or its Subsidiaries, to desist from
purchasing or selling, long and/or short, securities of the Company, or &#147;derivative&#148; securities based on securities issued by the Company or to hold the Securities for any specified term; (ii)&nbsp;that each Buyer shall not be deemed to
have any affiliation with or control over any arm&#146;s length counter party in any &#147;derivative&#148; transaction and (iii)&nbsp;each Buyer may rely on the Company&#146;s obligation to timely deliver shares of Common Stock upon conversion,
exercise or exchange, as applicable, of the Securities as and when required pursuant to the Transaction Documents for purposes of effecting trading in the Common Stock of the Company The Company further understands and acknowledges that following
the public disclosure of the transactions contemplated by the Transaction Documents pursuant to the Press Release (as defined below) one or more Buyers may engage in hedging and/or trading activities at various times during the period that the
Securities are outstanding, including, without limitation, during the periods that the value and/or number of the Conversion Shares deliverable with respect to the Notes are being determined and such hedging and/or trading activities, if any, can
reduce the value of the existing stockholders&#146; equity interest in the Company both at and after the time the hedging and/or trading activities are being conducted. The Company acknowledges that such aforementioned hedging and/or trading
activities do not constitute a breach of this Agreement, the Notes or any other Transaction Document or any of the documents executed in connection herewith or therewith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <U>Management</U>. Except as set forth in <U>Schedule</U><U></U><U>&nbsp;3(kk)</U> hereto, during the past five year period, no current
or, to the Knowledge of the Company, former officer or director or, to the knowledge of the Company, no current ten percent (10%) or greater stockholder of the Company or any of its Subsidiaries has been the subject of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a petition under bankruptcy laws or any other insolvency or moratorium law or the appointment by a court of a receiver,
fiscal agent or similar officer for such Person, or any partnership in which such person was a general partner at or within two years before the filing of such petition or such appointment, or any corporation or business association of which such
person was an executive officer at or within two years before the time of the filing of such petition or such appointment; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a conviction in a criminal proceeding or a named subject of a pending criminal proceeding (excluding traffic violations
that do not relate to driving while intoxicated or driving under the influence); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) any order, judgment or decree, not subsequently reversed, suspended or
vacated, of any court of competent jurisdiction, permanently or temporarily enjoining any such person from, or otherwise limiting, the following activities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor
broker, leverage transaction merchant, any other person regulated by the United States Commodity Futures Trading Commission or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or
as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) Engaging in any particular type of business practice; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(3) Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any
violation of securities laws or commodities laws; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) any order, judgment or decree, not subsequently reversed, suspended
or vacated, of any authority barring, suspending or otherwise limiting for more than sixty (60)&nbsp;days the right of any such person to engage in any activity described in the preceding sub paragraph, or to be associated with persons engaged in
any such activity; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) a finding by a court of competent jurisdiction in a civil action or by the SEC or other authority
to have violated any securities law, regulation or decree and the judgment in such civil action or finding by the SEC or any other authority has not been subsequently reversed, suspended or vacated; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) a finding by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have
violated any federal commodities law, and the judgment in such civil action or finding has not been subsequently reversed, suspended or vacated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <U>Stock Option Plans</U>(d) . Each stock option granted by the Company was granted (i)&nbsp;in accordance with the terms of the
applicable stock option plan of the Company and (ii)&nbsp;with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option
granted under the Company&#146;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company to knowingly grant, stock options prior to, or otherwise knowingly
coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <U>No Disagreements with Accountants and Lawyers</U>(e) . There are no material disagreements of any kind presently existing, or
reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company and the Company is current with respect to any fees owed to its accountants and lawyers
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which could affect the Company&#146;s ability to perform any of its obligations under any of the Transaction Documents. In addition, on or prior to the date hereof, the Company had discussions
with its accountants about its financial statements. Based on those discussions, the Company has no reason to believe that it will need to restate any such financial statements or any part thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <U>No Disqualification Events</U>(f) . With respect to Securities to be offered and sold hereunder in reliance on Rule 506(b) under the
1933 Act (&#147;<B>Regulation D Securities</B>&#148;), none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the offering contemplated hereby, any
beneficial owner of 20% or more of the Company&#146;s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the 1933 Act) connected with the Company in any capacity
at the time of sale (each, an &#147;<B>Issuer Covered Person</B>&#148; and, together, &#147;<B>Issuer Covered Persons</B>&#148;) is subject to any of the &#147;Bad Actor&#148; disqualifications described in Rule 506(d)(1)(i) to (viii)&nbsp;under the
1933 Act (a &#147;<B>Disqualification Event</B>&#148;), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a
Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Buyers a copy of any disclosures provided thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <U>Other Covered Persons</U>(g) . Other than as disclosed on <U>Schedule 3(oo)</U>, the Company is not aware of any Person (other than the
Placement Agent) that has been or will be paid (directly or indirectly) remuneration for solicitation of Buyers or potential purchasers in connection with the sale of any Regulation D Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <U>No Additional Agreements</U>. The Company does not have any agreement or understanding with any Buyer with respect to the transactions
contemplated by the Transaction Documents other than as specified in the Transaction Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <U>Public Utility Holding Act</U>.
None of the Company nor any of its Subsidiaries is a &#147;holding company,&#148; or an &#147;affiliate&#148; of a &#147;holding company,&#148; as such terms are defined in the Public Utility Holding Act of 2005. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <U>Federal Power Act</U>. None of the Company nor any of its Subsidiaries is subject to regulation as a &#147;public utility&#148; under
the Federal Power Act, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <U>Potential Products; FDA; EMEA.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Except as otherwise disclosed in <U>Schedule 3(ss)(i)</U>, the Company possesses all certificates, authorizations and
permits issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct its business as currently conducted, including without limitation all such certificates, authorizations and permits required by the United States
Food and Drug Administration (the &#147;<B>FDA</B>&#148;) or any other federal, state or foreign agencies or bodies engaged in the regulation of pharmaceuticals or biohazardous materials, except where the failure to so possess such certificates,
authorizations and permits, individually or in the aggregate, would not result in a Material Adverse Effect. The Company has not received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or
permit which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Except as otherwise disclosed in <U>Schedule 3(ss)(ii)</U>, the Company
has not received any written notices or statements from the FDA, the European Medicines Agency (the &#147;<B>EMEA</B>&#148;) or any other governmental agency, and otherwise has no knowledge or reason to believe, that (i)&nbsp;any medical device or
other product of the Company (each a &#147;<B>Potential Product</B>&#148;) may or will be rejected or determined to be <FONT STYLE="white-space:nowrap">non-approvable;</FONT> (ii)&nbsp;a delay in time for review and/or approval of a marketing
authorization application or marketing approval application in any jurisdiction for any Potential Product is or may be required, requested or being implemented; (iii)&nbsp;one or more clinical studies for any Potential Product shall or may be
requested or required in addition to the clinical studies submitted to the FDA prior to the date hereof as a precondition to or condition of issuance or maintenance of a marketing approval for any Potential Product; (iv)&nbsp;any license, approval,
permit or authorization to conduct any clinical trial of or market any product or Potential Product of the Company has been, will be or may be suspended, revoked, modified or limited, except in the cases of clauses (i), (ii), (iii) and
(iv)&nbsp;where such rejections, determinations, delays, requests, suspensions, revocations, modifications or limitations might not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) To the Company&#146;s knowledge, the preclinical and clinical testing, application for marketing approval of,
manufacture, distribution, promotion and sale of the products and Potential Products of the Company is in compliance, in all material respects, with all laws, rules and regulations applicable to such activities, including without limitation
applicable good laboratory practices, good clinical practices and good manufacturing practices, except for such <FONT STYLE="white-space:nowrap">non-compliance</FONT> as would not, individually or in the aggregate, have a Material Adverse Effect.
The Company is not aware of any studies, tests or trial the results of which reasonably call into question the results of the tests and trials conducted by or on behalf of the Company. The Company has not received notice of adverse finding, warning
letter or clinical hold notice from the FDA or any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart of any of the foregoing, or any untitled letter or other correspondence or notice from the FDA or any other governmental authority or
agency or any institutional or ethical review board alleging or asserting noncompliance with any law, rule or regulation applicable in any jurisdiction, except notices, letters, and correspondences and
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterparts thereof alleging or asserting such noncompliance as would not, individually or in the aggregate, have a Material Adverse Effect. The Company has not, either voluntarily or involuntarily,
initiated, conducted or issued, or caused to be initiated, conducted or issued, any recall, field correction, market withdrawal or replacement, safety alert, warning, &#147;dear doctor&#148; letter, investigator notice, or other notice or action
relating to an alleged or potential lack of safety or efficacy of any product or Potential Product of the Company, any alleged product defect of any product or Potential Product of the Company, or any violation of any material applicable law, rule,
regulation or any clinical trial or marketing license, approval, permit or authorization for any product or potential product of the Company, and the Company is not aware of any facts or information that would cause it to initiate any such notice or
action and has no knowledge or reason to believe that the FDA, the EMEA or any other governmental agency or authority or any institutional or ethical review board or other <FONT STYLE="white-space:nowrap">non-governmental</FONT> authority intends to
impose, require, request or suggest such notice or action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <U>Cybersecurity</U>. The Company and its Subsidiaries&#146; information technology
assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are adequate for, and operate and perform in all material respects as required in connection
with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants that would reasonably be expected to have a
Material Adverse Effect on the Company&#146;s business. The Company and its Subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and
protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including &#147;Personal Data,&#148; used in connection with their businesses. &#147;<B>Personal
Data</B>&#148; means (i)&nbsp;a natural person&#146;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number,
passport number, credit card number, bank information, or customer or account number; (ii)&nbsp;any information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii)
&#147;personal data&#148; as defined by the European Union General Data Protection Regulation (&#147;<B>GDPR</B>&#148;) (EU 2016/679); (iv) any information which would qualify as &#147;protected health information&#148; under the Health Insurance
Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#147;<B>HIPAA</B>&#148;); and (v)&nbsp;any other piece of information that allows the identification of
such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#146;s health or sexual orientation. To the Company&#146;s knowledge, there have been no breaches, violations, outages or
unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same except in
each case, where such would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. The Company and its Subsidiaries are presently in compliance with all applicable laws or statutes and all
judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of
such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification except in each case, where such would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <U>Compliance with Data Privacy Laws</U>. The Company and its Subsidiaries are, and at all prior times were, in compliance with all
applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its Subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May&nbsp;25, 2018,
have been and currently are in compliance with, the GDPR (EU 2016/679) (collectively, the &#147;<B>Privacy Laws</B>&#148;) except in each case, where such would not, either individually or in the aggregate, reasonably be expected to result in a
Material Adverse Effect. To ensure compliance with the Privacy Laws, the Company and its Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and
procedures relating to data privacy and security and the collection, storage, use, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosure, handling, and analysis of Personal Data (the &#147;<B>Policies</B>&#148;). The Company and its Subsidiaries have at all times made all disclosures to users or customers required by
applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in
any material respect. The Company further certifies that neither it nor any Subsidiary: (i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no
knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any
Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <U>Ranking of Notes</U>. Except as set forth on <U>Schedule 3(vv)</U>, no Indebtedness of the Company, at the Closing, will be senior to,
or <I>pari passu</I> with, the Notes in right of payment, whether with respect to payment or redemptions, interest, damages, upon liquidation or dissolution or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) <U>Disclosure</U>. No written statement made by the Company in this Agreement, any other Transaction Document or the exhibits and
schedules attached hereto or in any certificate or schedule furnished or to be furnished by or on behalf of the Company to the Investors or any of their representatives in connection with the transactions contemplated hereby contains any untrue
statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein or therein not misleading. The written due diligence materials previously provided by or on behalf of the Company to each Buyer
(the &#147;<B>Due Diligence Materials</B>&#148;), have been prepared in a good faith effort by the Company to describe the Company&#146;s present and proposed products, and projected growth of the Company and do not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements therein not misleading, except that with respect to assumptions, projections and expressions of opinion or predictions contained in the Due Diligence Materials, the
Company represents only that such assumptions, projections, expressions of opinion and predictions were made in good faith and that the Company believes there is a reasonable basis therefor. The Company acknowledges and agrees that no Buyer makes or
has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section&nbsp;2. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. COVENANTS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Best Efforts</U>.
Each Buyer shall use its best efforts to timely satisfy each of the covenants hereunder and conditions to be satisfied by it as provided in Section&nbsp;6 of this Agreement. The Company shall use its best efforts to timely satisfy each of the
covenants hereunder and conditions to be satisfied by it as provided in Section&nbsp;7 of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Form D and Blue Sky</U>.
The Company shall file an amended Form D with respect to the Securities as required under Regulation D and to provide a copy thereof to each Buyer promptly after such filing. The Company shall, on or before the Closing Date, take such action as the
Company shall reasonably determine is necessary in order to obtain an exemption for, or to, qualify the Securities for sale to the Buyers at the Closing pursuant to this Agreement under applicable securities or &#147;Blue Sky&#148; laws of the
states of the United States (or to obtain an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exemption from such qualification), and shall provide evidence of any such action so taken to the Buyers on or prior to the Closing Date. Without limiting any other obligation of the Company
under this Agreement, the Company shall timely make all filings and reports relating to the offer and sale of the Securities required under all applicable securities laws (including, without limitation, all applicable federal securities laws and all
applicable &#147;Blue Sky&#148; laws), and the Company shall comply with all applicable foreign, federal, state and local laws, statutes, rules, regulations and the like relating to the offering and sale of the Securities to the Buyers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Reporting Status</U>. Immediately following the date the Common Stock of the Company is initially registered (or is exchanged into a
class of securities registered) under the 1934 Act (whether by registration, merger or otherwise) (the &#147;<B>Public Company Date</B>&#148;) and until the date on which a Buyer or any transferee or assignee thereof to which a Buyer assigns its
rights as a holder of Securities under this Agreement (each an &#147;<B>Investor</B>&#148;, and collectively, the &#147;<B>Investors</B>&#148;) shall have sold all of the Conversion Shares (the &#147;<B>Reporting Period</B>&#148;), the Company shall
timely file all reports required to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder
would no longer require or otherwise permit such termination, and the Company shall use its reasonable best efforts to maintain its eligibility to register the Conversion Shares for resale by the Investors on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> once Form <FONT STYLE="white-space:nowrap">S-3</FONT> is available to the Company for such use. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Use of Proceeds</U>. The Company will use the proceeds from the sale of the Securities for general corporate purposes, but not, directly
or indirectly, for (i)&nbsp;except as set forth on Schedule 4(d), the satisfaction of any indebtedness of the Company or any of its Subsidiaries, (ii)&nbsp;the redemption or repurchase of any securities of the Company or any of its Subsidiaries, or
(iii)&nbsp;the settlement of any outstanding litigation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Financial Information</U>. From and after the Public Company Date, the
Company agrees to send the following to each Investor during the Reporting Period (i)&nbsp;unless the following are filed with the SEC through EDGAR and are available to the public through the EDGAR system, within one (1)&nbsp;Business Day after the
filing thereof with the SEC, a copy of its Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> any interim reports or any consolidated balance sheets, income
statements, stockholders&#146; equity statements and/or cash flow statements for any period other than annual, any Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and any registration statements (other than on Form <FONT
STYLE="white-space:nowrap">S-8)</FONT> or amendments filed pursuant to the 1933 Act, (ii)&nbsp;unless the following are either filed with the SEC through EDGAR or are otherwise widely disseminated via a recognized news release service (such as PR
Newswire), on the same day as the release thereof, <FONT STYLE="white-space:nowrap">e-mail</FONT> copies of all press releases issued by the Company or any of its Subsidiaries and (iii)&nbsp;unless the following are filed with the SEC through EDGAR,
copies of any notices and other information made available or given to the stockholders of the Company generally, contemporaneously with the making available or giving thereof to the stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Listing</U>. Immediately following the Public Company Date, the Company shall promptly secure the listing or designation for quotation
(as the case may be) of all of the Underlying Securities (as defined below) upon each national securities exchange and automated quotation system, if any, upon which the Common Stock is then listed or designated for quotation (as the case may be)
(subject to official notice of issuance) and shall maintain such listing or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
designation for quotation (as the case may be) of all Underlying Securities from time to time issuable under the terms of the Transaction Documents on such national securities exchange or
automated quotation system; provided, that in connection with any Public Company Date, the Company shall be required to secure the listing of the Common Stock and the Conversion Shares on either The New York Stock Exchange, the NYSE MKT, the Nasdaq
Capital Market, the Nasdaq Global Market or the Nasdaq Global Select Market (each, an &#147;<B>Eligible Market</B>&#148;, and the later of (x)&nbsp;the Public Company Date and (y)&nbsp;the date the Common Stock is listed on an Eligible Market, the
&#147;<B>Qualified Public Company Date</B>&#148;). From and after such listing of the Common Stock on an Eligible Market, neither the Company nor any of its Subsidiaries shall take any action which could be reasonably expected to result in the
delisting or suspension of the Common Stock on an Eligible Market. The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section&nbsp;4(f). &#147;<B>Underlying Securities</B>&#148; means the
(i)&nbsp;the Conversion Shares, (ii)&nbsp;the Warrant Shares and (iii)&nbsp;any capital stock of the Company issued or issuable with respect to the Notes, the Conversion Shares, the Warrant Shares, or the Warrants, respectively, including, without
limitation, (1)&nbsp;as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise and (2)&nbsp;shares of capital stock of the Company into which the shares of Common Stock are converted or exchanged and
shares of capital stock of a Successor Entity (as defined in the Warrants) into which the shares of Common Stock are converted or exchanged, in each case, without regard to any limitations on conversion of the Notes or exercise of the Warrants,
respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Fees</U>. The Company shall reimburse the Lead Investor (as defined below) for all costs and expenses incurred by it
or its affiliates in connection with the structuring, documentation, negotiation and closing of the transactions contemplated by the Transaction Documents (including, without limitation, as applicable, all reasonable legal fees of outside counsel
and disbursements of Kelley Drye&nbsp;&amp; Warren LLP, counsel to the Lead Investor, any other reasonable fees and expenses in connection with the structuring, documentation, negotiation and closing of the transactions contemplated by the
Transaction Documents and due diligence and regulatory filings in connection therewith) (the &#147;<B>Transaction Expenses</B>&#148;) and shall be withheld by the Lead Investor from its Purchase Price at the Closing, less $20,000 previously paid by
the Company to Kelley Drye&nbsp;&amp; Warren LLP; provided, that the Company shall promptly reimburse Kelley Drye&nbsp;&amp; Warren LLP on demand for all Transaction Expenses not so reimbursed through such withholding at the Closing. The Company
shall be responsible for the payment of any placement agent&#146;s fees, financial advisory fees, transfer agent fees, depository trust company fees or broker&#146;s commissions (other than for Persons engaged by any Buyer) relating to or arising
out of the transactions contemplated hereby (including, without limitation, any fees or commissions payable to the Placement Agent, who is the Company&#146;s sole placement agent in connection with the transactions contemplated by this Agreement).
The Company shall pay, and hold each Buyer harmless against, any liability, loss or expense (including, without limitation, reasonable attorneys&#146; fees and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses) arising in connection with any claim relating to any such payment. Except as otherwise set forth in the Transaction Documents, each party to this
Agreement shall bear its own expenses in connection with the sale of the Securities to the Buyers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Pledge of Securities</U>.
Notwithstanding anything to the contrary contained in this Agreement, the Company acknowledges and agrees that the Securities may be pledged by an Investor in connection with a bona fide margin agreement or other loan or financing arrangement that
is secured by the Securities. The pledge of Securities shall not be deemed to be a transfer, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sale or assignment of the Securities hereunder, and no Investor effecting a pledge of Securities shall be required to provide the Company with any notice thereof or otherwise make any delivery to
the Company pursuant to this Agreement or any other Transaction Document, including, without limitation, Section&nbsp;2(g) hereof; <U>provided</U> that an Investor and its pledgee shall be required to comply with the provisions of Section&nbsp;2(g)
hereof in order to effect a sale, transfer or assignment of Securities to such pledgee. The Company hereby agrees to execute and deliver such documentation as a pledgee of the Securities may reasonably request in connection with a pledge of the
Securities to such pledgee by a Buyer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Disclosure of Transactions and Other Material Information</U>. On or before 9:30 a.m., New
York City time, on each of the following dates: (i)&nbsp;the date that the Company files a Form 10 registering the Company&#146;s Common Stock under the 1934 Act, (ii)&nbsp;the date that the Company files a registration statement under the 1933 Act
for a public offering of Common Stock of the Company, and (iii)&nbsp;if the Public Company Date occurs by virtue of a merger, the effective time of such merger, the Company shall issue a press release (each, a &#147;<B>Press Release</B>&#148;)
reasonably acceptable to the Lead Investor describing the terms of the transactions contemplated by the Transaction Documents if not already publicly disclosed and disclosing any other material <FONT STYLE="white-space:nowrap">non-public</FONT>
information provided to any Buyer on or prior to the public disclosure of the Press Release and attach to the Press Release a hypertext link to the material Transaction Documents (including, without limitation, this Agreement (and all schedules and
exhibits to this Agreement)) and the form of the Notes as well as any other material documents related to any such other material nonpublic information, if not already publicly available, which documents must be available to the public either on the
Company&#146;s website (or the website of a successor, subsidiary or parent company of the Company pursuant to such merger) or on the SEC&#146;s EDGAR website. From and after the public disclosure of the applicable Press Release, no Buyer shall be
in possession of any material, nonpublic information received from the Company, any of its Subsidiaries or any of their respective officers, directors, employees or agents, that is not disclosed in such Press Release. In addition, effective upon the
public disclosure of the first Press Release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their
respective officers, directors, affiliates, employees or agents, on the one hand, and any of the Buyers or any of their affiliates, on the other hand, shall terminate. The Company shall not, and shall cause each of its Subsidiaries and its and each
of their respective officers, directors, affiliates, employees and agents, not to, provide any Buyer with any material, nonpublic information regarding the Company or any of its Subsidiaries from and after the date that any such Buyer shall instruct
the Company in writing without the express prior written consent of such Buyer. If a Buyer has, or believes it has, received or is otherwise in possession of any material, nonpublic information regarding the Company or any of its Subsidiaries from
the Company, any of its Subsidiaries or any of their respective officers, directors, affiliates, employees or agents after the earlier of (i)&nbsp;the date that the Company publicly discloses the first Press Release and (ii)&nbsp;the date that the
Company is required to publicly disclose the first Press Release, at any time and from time to time, it may provide the Company with written notice thereof. If requested by the Lead Investor, the Company shall, within one (1)&nbsp;Trading Day (as
defined in the Notes) of receipt of such notice, make public disclosure of such material, nonpublic information. In the event of a breach of the foregoing covenant by the Company, any of its Subsidiaries, or any of its or their respective officers,
directors, affiliates, employees and agents (as determined in the reasonable good faith judgment of such Buyer), in addition to any other remedy provided herein or in the Transaction </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Documents, such Buyer shall have the right to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such breach or such material, <FONT
STYLE="white-space:nowrap">non-public</FONT> information, as applicable, without the prior approval by the Company, any of its Subsidiaries, or any of its or their respective officers, directors, affiliates employees or agents. No Buyer shall have
any liability to the Company, its Subsidiaries, or any of its or their respective officers, directors, affiliates, employees, stockholders or agents for any such disclosure. To the extent that the Company delivers any material, <FONT
STYLE="white-space:nowrap">non-public</FONT> information to a Buyer without such Buyer&#146;s consent or the Company fails to publicly disclose any confidential information on or prior to the dates and time periods specified in this
Section&nbsp;4(i), the Company hereby covenants and agrees that such Buyer shall not have any duty of confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents with
respect to, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates or agents not to trade on the basis of, such material, <FONT STYLE="white-space:nowrap">non-public</FONT>
information. Subject to the foregoing, neither the Company, its Subsidiaries nor any Buyer shall issue any press releases or any other public statements with respect to the transactions contemplated hereby; provided, however, that the Company shall
be entitled, without the prior approval of any Buyer, to make any press release or other public disclosure with respect to such transactions (i)&nbsp;in substantial conformity with the Press Releases and contemporaneously therewith and (ii)&nbsp;as
is required by applicable law and regulations (provided that in the case of clause (i)&nbsp;each Buyer shall be consulted by the Company in connection with any such press release or other public disclosure prior to its release). Without the prior
written consent of the applicable Buyer (which may be granted or withheld in such Buyer&#146;s sole discretion), the Company shall not (and shall cause each of its Subsidiaries and affiliates to not) disclose the name of such Buyer in any filing,
announcement, release or otherwise. Notwithstanding anything contained in this Agreement to the contrary and without implication that the contrary would otherwise be true, the Company expressly acknowledges and agrees that no Buyer shall have
(unless expressly agreed to by a particular Buyer after the date hereof in a written definitive and binding agreement executed by the Company and such particular Buyer (it being understood and agreed that no Buyer may bind any other Buyer with
respect thereto)), any duty of confidentiality with respect to, or a duty not to trade on the basis of, any material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Reservation of Shares</U>. As of the Closing, the Company shall have reserved from its duly authorized capital stock not less than
60,000,000 shares of Common Stock for issuance upon conversion of the Notes and the Warrant Shares initially issuable upon exercise of the Warrants. From and after January&nbsp;31, 2022, so long as any of the Notes or Warrants remain outstanding,
the Company shall take all action necessary to at all times have authorized, and reserved for the purpose of issuance, no less than 200% of (i)&nbsp;the maximum number of shares of Common Stock issuable upon conversion of all the Notes then
outstanding (assuming for purposes hereof that (x)&nbsp;the Notes are convertible at the Alternate Conversion Price then in effect assuming an Alternate Conversion Date as of the applicable date of determination, (y)&nbsp;interest on the Notes shall
accrue through the third anniversary of the Closing Date and will be converted in shares of Common Stock at a conversion price equal to the Alternate Conversion Price assuming an Alternate Conversion Date as of the applicable date of determination
and (z)&nbsp;any such conversion shall not take into account any limitations on the conversion of the Notes set forth in the Notes), and (ii)&nbsp;the maximum number of Warrant Shares issuable upon exercise of all the Warrants then outstanding
(without regard to any limitations on the exercise of the Warrants set forth therein) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(collectively, the &#147;<B>Required Reserve Amount</B>&#148;); provided that at no time shall the number of shares of Common Stock reserved pursuant to this Section&nbsp;4(j) be reduced other
than proportionally in connection with any conversion, exercise and/or redemption, as applicable of Notes and Warrants. If at any time after January&nbsp;31, 2022, the number of shares of Common Stock authorized and reserved for issuance is not
sufficient to meet the Required Reserve Amount, the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares, including, without limitation, calling a special meeting of stockholders to
authorize additional shares to meet the Company&#146;s obligations pursuant to the Transaction Documents, in the case of an insufficient number of authorized shares, obtain stockholder approval of an increase in such authorized number of shares, and
voting the management shares of the Company in favor of an increase in the authorized shares of the Company to ensure that the number of authorized shares is sufficient to meet the Required Reserve Amount. On or prior to January&nbsp;31, 2022 (the
&#147;<B>Consent Deadline</B>&#148;), holders of a majority of the issued and outstanding shares of Common Stock and the Preferred Stock shall have voted by written consent (the <B>&#147;Stockholder Resolutions&#148;</B>) approving an amendment to
the Certificate of Incorporation to, among other items, approve a reverse stock split and, on an advisory basis, approve the transactions contemplated by this Agreement (the &#147;<B>Stockholder Approval</B>&#148;, and the date the Stockholder
Approval is obtained, the &#147;<B>Stockholder Approval Date</B>&#148;), Thereafter, the Company shall provide each stockholder entitled to vote at a meeting of stockholders of the Company notice of the Consent Action (the &#147;<B>Consent
Notice</B>&#148;). The Stockholder Resolutions and the Consent Notice shall be in a form reasonably acceptable to the Buyers and Kelley Drye&nbsp;&amp; Warren LLP, at the expense of the Company, with the Company obligated to reimburse the expenses
of Kelley Drye&nbsp;&amp; Warren LLP incurred in connection therewith in an amount not exceed $3,000, The Company shall be obligated to seek to obtain the Stockholder Approval by the Consent Deadline.&nbsp;If, despite the Company&#146;s reasonable
best efforts the Stockholder Approval is not obtained on or prior to the Consent Deadline, the Company shall cause either an additional consent action or a stockholder meeting to be held on or prior to March&nbsp;31, 2021.&nbsp;If, despite the
Company&#146;s reasonable best efforts the Stockholder Approval is not obtained after such subsequent consent action or stockholder meeting, the Company shall cause an additional consent action or stockholder meeting to be held semi-annually
thereafter until such Stockholder Approval is obtained. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Conduct of Business</U>. The business of the Company and its Subsidiaries
shall not be conducted in violation of any law, ordinance or regulation of any Governmental Entity, except where such violations would not reasonably be expected to result, either individually or in the aggregate, in a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Other Notes; Variable Securities</U>. So long as any Notes remain outstanding, the Company and each Subsidiary shall be prohibited from
effecting or entering into an agreement to effect any Subsequent Placement involving a Variable Rate Transaction. &#147;<B>Variable Rate Transaction</B>&#148; means a transaction in which the Company or any Subsidiary (i)&nbsp;issues or sells any
Convertible Securities either (A)&nbsp;at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such
Convertible Securities, or (B)&nbsp;with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such Convertible Securities or upon the occurrence of specified or contingent events
directly or indirectly related to the business of the Company or the market for the Common Stock, other than pursuant to a customary &#147;weighted average&#148; anti-dilution provision or (ii)&nbsp;enters into any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement (including, without limitation, an equity line of credit or an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> offering)
whereby the Company or any Subsidiary may sell securities at a future determined price (other than standard and customary &#147;preemptive&#148; or &#147;participation&#148; rights). Each Buyer shall be entitled to obtain injunctive relief against
the Company and its Subsidiaries to preclude any such issuance, which remedy shall be in addition to any right to collect damages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)
<U>Passive Foreign Investment Company</U>. The Company shall conduct its business, and shall cause any Subsidiaries to conduct their respective businesses, in such a manner as will ensure that the Company will not be deemed to constitute a passive
foreign investment company within the meaning of Section&nbsp;1297 of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Restriction on Redemption and Cash Dividends</U>.
So long as any Notes are outstanding, the Company shall not, directly or indirectly, redeem, or declare or pay any cash dividend or distribution on, any securities of the Company without the prior express written consent of the Buyers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Corporate Existence</U>. So long as any Buyer beneficially owns any Notes, the Company shall not be party to any Fundamental Transaction
(as defined in the Notes) unless the Company is in compliance with the applicable provisions governing Fundamental Transactions set forth in the Notes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Regulation M</U>. The Company will not take any action prohibited by Regulation M under the 1934 Act, in connection with the
distribution of the Securities contemplated hereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>General Solicitation</U>(h) . None of the Company, any of its affiliates (as
defined in Rule 501(b) under the 1933 Act) or any person acting on behalf of the Company or such affiliate will solicit any offer to buy or offer or sell the Securities by means of any form of general solicitation or general advertising within the
meaning of Regulation&nbsp;D, including: (i)&nbsp;any advertisement, article, notice or other communication published in any newspaper, magazine or similar medium or broadcast over television or radio; and (ii)&nbsp;any seminar or meeting whose
attendees have been invited by any general solicitation or general advertising. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Integration</U>(i) . None of the Company, any of
its affiliates (as defined in Rule 501(b) under the 1933 Act), or any person acting on behalf of the Company or such affiliate will sell, offer for sale, or solicit offers to buy or otherwise negotiate in respect of any security (as defined in the
1933 Act) which will be integrated with the sale of the Securities in a manner which would require the registration of the Securities under the 1933 Act and the Company will take all action that is appropriate or necessary to assure that its
offerings of other securities will not be integrated for purposes of the 1933 Act with the issuance of Securities contemplated hereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)
<U>Notice of Disqualification Events</U>(j) . The Company will notify the Buyers in writing, prior to the Closing Date of (i)&nbsp;any Disqualification Event relating to any Issuer Covered Person and (ii)&nbsp;any event that would, with the passage
of time, become a Disqualification Event relating to any Issuer Covered Person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Books and Records</U>(k) . The Company will keep
proper books of record and account, in which full and correct entries shall be made of all financial transactions and the assets and business of the Company and any Subsidiaries in accordance with GAAP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Confidentiality, <FONT STYLE="white-space:nowrap">Non-Compete,</FONT> <FONT
STYLE="white-space:nowrap">Non-Solicit</FONT> and Assignment of Inventions Agreements</U>(l) . The Company shall cause every employee and consultant to be hired by the Company after the date hereof to enter into a Confidentiality, <FONT
STYLE="white-space:nowrap">Non-Compete,</FONT> <FONT STYLE="white-space:nowrap">Non-Solicit</FONT> and Assignment of Inventions Agreement prior to being hired. The Company shall not amend, waive or terminate any material provision of any
Confidentiality, <FONT STYLE="white-space:nowrap">Non-Compete,</FONT> <FONT STYLE="white-space:nowrap">Non-Solicit</FONT> and Assignment of Inventions Agreement and shall enforce the provisions of each the Confidentiality, <FONT
STYLE="white-space:nowrap">Non-Compete,</FONT> <FONT STYLE="white-space:nowrap">Non-Solicit</FONT> and Assignment of Inventions Agreements in accordance with its terms. If any party to a Confidentiality,
<FONT STYLE="white-space:nowrap">Non-Compete,</FONT> <FONT STYLE="white-space:nowrap">Non-Solicit</FONT> and Assignment of Inventions Agreement breaches any material provision of a Confidentiality,
<FONT STYLE="white-space:nowrap">Non-Compete,</FONT> <FONT STYLE="white-space:nowrap">Non-Solicit</FONT> and Assignment of Inventions Agreement, the Company shall promptly use its best efforts to specific performance of the terms of such
Confidentiality, <FONT STYLE="white-space:nowrap">Non-Compete,</FONT> <FONT STYLE="white-space:nowrap">Non-Solicit</FONT> and Assignment of Inventions Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Financial Statements and Inspection</U>(m) . </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall deliver to each Buyer (unless any such Buyer has elected by written notice to the Company that it does
not want to receive any or all of the following): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) as soon as practicable following the end of each fiscal quarter
(other than the fourth fiscal quarter of each fiscal year), but in no event later than forty-five (45)&nbsp;days after the end of such fiscal quarter, the Company&#146;s consolidated unaudited balance sheet, income statement, a statement of
stockholder&#146;s equity and a statement of cash flows for such quarter, such <FONT STYLE="white-space:nowrap">quarter-end</FONT> financial reports to be in reasonable detail, prepared in accordance with GAAP (except that such financial statements
may (A)&nbsp;be subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments and (B)&nbsp;not contain all notes thereto that may be required in accordance with GAAP); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) as soon as practicable following the end of each fiscal year, but in no event later than ninety (90)&nbsp;days following
the end of such fiscal year, the Company&#146;s audited consolidated balance sheet, income statement, a statement of stockholder&#146;s equity and a statement of cash flows for such year and, if applicable, the immediately preceding fiscal year,
such <FONT STYLE="white-space:nowrap">year-end</FONT> financial reports to be in reasonable detail, prepared in accordance with GAAP, and audited by independent public accountants registered and in good standing with the Public Company Accounting
Oversight Board and selected by the Company and reasonably acceptable to the Required Holders; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) as soon as practicable,
all material communications with stockholders or the financial community, including press releases, but in no event later than three (3)&nbsp;days after the date of each such communication unless such communications are available via EDGAR; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) as soon as practicable, (x)&nbsp;all material reports prepared for the Company by outside consultants, and (y)&nbsp;all
reports prepared for the Company by outside legal counsel and auditors, but in no event later than three (3)&nbsp;days after receipt thereof by the Company, provided that the Company shall have no obligation to deliver to any Investor any report
prepared by outside legal counsel to the extent such report is privileged communication and is subject to the attorney/client privilege, in the reasonable opinion of such legal counsel; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5) as soon as practicable (but in no event later than two (2)&nbsp;Business
Days after any such communication), all material communications with and from United States federal or state or foreign regulatory agencies or other governmental or quasi-governmental authorities of any kind; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(6) as soon as practicable, notice of any material events, including any pending or threatened litigation and/or events that is
reasonably likely to materially delay the advancement of the business objectives of the Company or any of its Subsidiaries, but in no event later than five (5)&nbsp;Business Days after the occurrence thereof; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(7) notice of any Material Adverse Effect as soon as practicable after upon the occurrence thereof, but in no event later than
five (5)&nbsp;Business Days thereafter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company shall notify the Buyers in writing of (i)&nbsp;any default under
any of the Company&#146;s agreements governing its Indebtedness and (ii)&nbsp;the receipt by the Company of any default notices in connection therewith, in each case promptly and in no event later than five (5)&nbsp;Business Days after the
occurrence of any such default or the receipt of any such default notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Company shall permit each Buyer to
visit and inspect the Company&#146;s properties, to examine its books of account, records, contracts and agreements and to discuss the Company&#146;s affairs, finances and accounts with its Chief Executive Officer or Chief Financial Officer, all at
such times as may be reasonably requested by the Investor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The covenants set forth in this Section&nbsp;4(v) shall
terminate as to Buyers and be of no further force or effect upon the earlier of the Public Company Date and the time when no Notes are outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <U>Additional Issuance of Securities</U>. So long as any Buyer beneficially owns any Securities, the Company will not, without the prior
written consent of the Required Holders, issue any Notes (other than to the Buyers as contemplated hereby) and the Company shall not issue any other securities that would cause a breach or default under the Notes or the Warrants. The Company agrees
that for the period commencing on the Public Company Date and ending on the date immediately following the 90<U><SUP STYLE="font-size:85%; vertical-align:top">th</SUP></U> Trading Day after the later of (x)&nbsp;the Qualified Public Company Date
(or, if any of the Underlying Securities are subject to a lockup in connection with the Public Company Date, the date of termination (or expiration, as applicable) of such lockup) and (y)&nbsp;the earlier to occur of (x)&nbsp;the effective date of a
registration statement registering the resale by the Investors of the Underlying Securities and (y)&nbsp;the date the Securities are initially eligible to be resold by the Investors pursuant to Rule 144 (provided that such period shall be extended
by the number of calendar days during such period and any extension thereof contemplated by this proviso on which any registration statement registering the resale of any Underlying Securities is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not effective or any prospectus contained therein is not available for use or any Current Public Information Failure (as defined in the Registration Rights Agreement) exists) (the
&#147;<B>Restricted</B> <B>Period</B>&#148;), neither the Company nor any of its Subsidiaries shall directly or indirectly issue, offer, sell, grant any option or right to purchase, or otherwise dispose of (or announce any issuance, offer, sale,
grant of any option or right to purchase or other disposition of) any equity security or any equity-linked or related security (including, without limitation, any &#147;equity security&#148; (as that term is defined under Rule 405 promulgated under
the 1933 Act), any Convertible Securities (as defined below), any debt, any preferred stock or any purchase rights) (any such issuance, offer, sale, grant, disposition or announcement (whether occurring during the Restricted Period or at any time
thereafter) is referred to as a &#147;<B>Subsequent Placement</B>&#148;). Notwithstanding the foregoing, this Section&nbsp;4(w) shall not apply in respect of the issuance of (i)&nbsp;shares of Common Stock or standard equity awards to purchase
Common Stock to directors, officers or employees of the Company in their capacity as such pursuant to an Approved Stock Plan (as defined below), provided that (1)&nbsp;all such issuances (taking into account the shares of Common Stock issuable upon
exercise of such options) after the date hereof pursuant to this clause (i)&nbsp;do not, in the aggregate, exceed more than 5% of the Common Stock issued and outstanding immediately prior to the date hereof and (2)&nbsp;the exercise price of any
such options is not lowered, none of such options are amended to increase the number of shares issuable thereunder and none of the terms or conditions of any such options are otherwise materially changed in any manner that adversely affects any of
the Buyers; (ii)&nbsp;shares of Common Stock issued upon the conversion or exercise of Convertible Securities (other than standard options to purchase Common Stock issued pursuant to an Approved Stock Plan that are covered by clause (i)&nbsp;above)
issued prior to the date hereof, provided that the conversion, exercise or other method of issuance (as the case may be) of any such Convertible Security is made solely pursuant to the conversion, exercise or other method of issuance (as the case
may be) provisions of such Convertible Security that were in effect on the date immediately prior to the date of this Agreement, the conversion, exercise or issuance price of any such Convertible Securities (other than standard options to purchase
Common Stock issued pursuant to an Approved Stock Plan that are covered by clause (i)&nbsp;above) is not lowered, none of such Convertible Securities (other than standard options to purchase Common Stock issued pursuant to an Approved Stock Plan
that are covered by clause (i)&nbsp;above) are amended to increase the number of shares issuable thereunder and none of the terms or conditions of any such Convertible Securities (other than standard options to purchase Common Stock issued pursuant
to an Approved Stock Plan that are covered by clause (i)&nbsp;above) are otherwise materially changed in any manner that adversely affects any of the Buyers; (iii)&nbsp;the Conversion Shares, (iv)&nbsp;the Warrant Shares and (v)&nbsp;any shares of
Common Stock issued or issuable in connection with any bona fide strategic or commercial alliances, acquisitions, mergers, licensing arrangements, and strategic partnerships, provided, that (x)&nbsp;the primary purpose of such issuance is not to
raise capital as reasonably determined, and (y)&nbsp;the purchaser or acquirer or recipient of the securities in such issuance solely consists of either (I)&nbsp;the actual participants in such strategic or commercial alliance, strategic or
commercial licensing arrangement or strategic or commercial partnership, (II)&nbsp;the actual owners of such assets or securities acquired in such acquisition or merger or (III)&nbsp;the stockholders, partners, employees, consultants, officers,
directors or members of the foregoing Persons, in each case, which is, itself or through its subsidiaries, an operating company or an owner of an asset, in a business synergistic with the business of the Company and shall provide to the Company
additional benefits in addition to the investment of funds, and (z)&nbsp;the number or amount of securities issued to such Persons by the Company shall not be disproportionate to each such Person&#146;s actual participation in (or fair market value
of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contribution to) such strategic or commercial alliance or strategic or commercial partnership or ownership of such assets or securities to be acquired by the Company, as applicable (each of the
foregoing in clauses (i)&nbsp;through (v), collectively the &#147;<B>Excluded Securities</B>&#148;). For purposes of this Agreement, &#147;<B>Approved Stock Plan</B>&#148; means any employee benefit plan which has been approved by the board of
directors of the Company subsequent to the date hereof pursuant to which shares of Common Stock and standard options to purchase Common Stock may be issued to any employee, officer or director for services provided to the Company in their capacity
as such. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>Conversion and Exercise Procedures</U>. Each of the form of Exercise Notice (as defined in the Warrants) included in the
Warrants and the form of Conversion Notice (as defined in the Notes) included in the Notes set forth the totality of the procedures required of the Buyers in order to exercise the Warrants or convert the Notes. Except as provided in
Section&nbsp;5(d), no additional legal opinion, other information or instructions shall be required of the Buyers to exercise their Warrants or convert their Notes. The Company shall honor exercises of the Warrants and conversions of the Notes and
shall deliver the Conversion Shares and Warrant Shares in accordance with the terms, conditions and time periods set forth in the Notes and Warrants. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <U>Collateral Agent</U>. Subject to the terms of the Security Agreement (as defined below), each Buyer hereby (i)&nbsp;appoints the Lead
Investor, as the collateral agent hereunder and the Security Documents (as defined in the Security Agreement) (in such capacity, the &#147;<B>Collateral Agent</B>&#148;), and (ii)&nbsp;authorizes the Collateral Agent (and its officers, directors,
employees and agents) to take such action on such Buyer&#146;s behalf in accordance with the terms hereof and thereof. The Collateral Agent shall not have, by reason hereof or any of the Security Documents, a fiduciary relationship in respect of any
Buyer. Neither the Collateral Agent nor any of its officers, directors, employees or agents shall have any liability to any Buyer for any action taken or omitted to be taken in connection hereof or any Security Document except to the extent caused
by its own gross negligence or willful misconduct, and each Buyer agrees to defend, protect, indemnify and hold harmless the Collateral Agent and all of its officers, directors, employees and agents (collectively, the &#147;<B>Collateral Agent
Indemnitees</B>&#148;) from and against any losses, damages, liabilities, obligations, penalties, actions, judgments, suits, fees, costs and expenses (including, without limitation, reasonable attorneys&#146; fees, costs and expenses) incurred by
such Collateral Agent Indemnitee, whether direct, indirect or consequential, arising from or in connection with the performance by such Collateral Agent Indemnitee of the duties and obligations of Collateral Agent pursuant hereto or any of the
Security Documents. The Collateral Agent shall not be required to exercise any discretion or take any action, but shall be required to act or to refrain from acting (and shall be fully protected in so acting or refraining from acting) upon the
instructions of the Required Holders, and such instructions shall be binding upon all holders of Notes; provided, however, that the Collateral Agent shall not be required to take any action which, in the reasonable opinion of the Collateral Agent,
exposes the Collateral Agent to liability or which is contrary to this Agreement or any other Transaction Document or applicable law. The Collateral Agent shall be entitled to rely upon any written notices, statements, certificates, orders or other
documents or any telephone message believed by it in good faith to be genuine and correct and to have been signed, sent or made by the proper Person, and with respect to all matters pertaining to this Agreement or any of the other Transaction
Documents and its duties hereunder or thereunder, upon advice of counsel selected by it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <U>Successor Collateral Agent</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Collateral Agent may resign from the performance of all its functions and duties hereunder and under the other Transaction Documents
at any time by giving at least ten (10)&nbsp;Business Days&#146; prior written notice to the Company and each holder of Notes. Such resignation shall take effect upon the acceptance by a successor Collateral Agent of appointment pursuant to clauses
(ii)&nbsp;and (iii) below or as otherwise provided below. If at any time the Collateral Agent (together with its affiliates) beneficially owns less than $100,000 in aggregate principal amount of Notes, the Required Holders may, by written consent,
remove the Collateral Agent from all its functions and duties hereunder and under the other Transaction Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Upon any such
notice of resignation or removal, the Required Holders shall appoint a successor collateral agent. Upon the acceptance of any appointment as Collateral Agent hereunder by a successor agent, such successor collateral agent shall thereupon succeed to
and become vested with all the rights, powers, privileges and duties of the collateral agent, and the Collateral Agent shall be discharged from its duties and obligations under this Agreement and the other Transaction Documents. After the Collateral
Agent&#146;s resignation or removal hereunder as the collateral agent, the provisions of this Section&nbsp;4(z) shall inure to its benefit as to any actions taken or omitted to be taken by it while it was the Collateral Agent under this Agreement
and the other Transaction Documents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) If a successor collateral agent shall not have been so appointed within ten (10)&nbsp;Business
Days of receipt of a written notice of resignation or removal, the Collateral Agent shall then appoint a successor collateral agent who shall serve as the Collateral Agent until such time, if any, as the Required Holders appoint a successor
collateral agent as provided above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) In the event that a successor Collateral Agent is appointed pursuant to the provisions of this
Section&nbsp;4(z) that is not a Buyer or an affiliate of any Buyer (or the Required Holders or the Collateral Agent (or its successor), as applicable, notify the Company that they or it wants to appoint such a successor Collateral Agent pursuant to
the terms of this Section&nbsp;4(z)), the Company and each Subsidiary thereof covenants and agrees to promptly take all actions reasonably requested by the Required Holders or the Collateral Agent (or its successor), as applicable, from time to
time, to secure a successor Collateral Agent satisfactory to the requesting part(y)(ies), in their sole discretion, including, without limitation, by paying all reasonable and customary fees and expenses of such successor Collateral Agent, by having
the Company and each Subsidiary thereof agree to indemnify any successor Collateral Agent pursuant to reasonable and customary terms and by each of the Company and each Subsidiary thereof executing a collateral agency agreement or similar agreement
and/or any amendment to the Security Documents reasonably requested or required by the successor Collateral Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <U>Closing
Documents</U>. On or prior to fourteen (14)&nbsp;calendar days after the Closing Date, the Company agrees to deliver, or cause to be delivered, to each Buyer and Kelley Drye&nbsp;&amp; Warren LLP a complete closing set of the executed Transaction
Documents, Securities and any other document required to be delivered to any party pursuant to Section&nbsp;7 hereof or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. REGISTER; TRANSFER AGENT INSTRUCTIONS; LEGEND. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Register</U>. The Company shall maintain at its principal executive offices (or such other office or agency of the Company as it may
designate by notice to each holder of Securities), a register for the Notes and the Warrants in which the Company shall record the name and address of the Person in whose name the Notes and<B> </B>the Warrants have been issued (including the name
and address of each transferee), the principal amount of the Notes held by such Person, the number of Conversion Shares issuable pursuant to the terms of the Notes and the number of Warrant Shares issuable upon exercise of the Warrants held by such
Person. The Company shall keep the register open and available at all times during business hours for inspection of any Buyer or its legal representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Transfer Agent Instructions</U>. On or prior to the Public Company Date, the Company shall issue irrevocable instructions to its
transfer agent and any subsequent transfer agent (as applicable, the &#147;<B>Transfer Agent</B>&#148;) in a form acceptable to each of the Buyers (the &#147;<B>Irrevocable Transfer Agent Instructions</B>&#148;) to issue certificates or credit
shares to the applicable balance accounts at The Depository Trust Company (&#147;<B>DTC</B>&#148;), registered in the name of each Buyer or its respective nominee(s), for the Conversion Shares and the Warrant Shares in such amounts as specified from
time to time by each Buyer to the Company upon conversion of the Notes or the exercise of the Warrants (as the case may be). The Company represents and warrants that no instruction other than the Irrevocable Transfer Agent Instructions referred to
in this Section&nbsp;5(b), and stop transfer instructions to give effect to Section&nbsp;2(g) hereof, will be given by the Company to its transfer agent with respect to the Securities, and that the Securities shall otherwise be freely transferable
on the books and records of the Company, as applicable, to the extent provided in this Agreement and the other Transaction Documents. If a Buyer effects a sale, assignment or transfer of the Securities in accordance with Section&nbsp;2(g), the
Company shall permit the transfer and shall promptly instruct its transfer agent to issue one or more certificates or credit shares to the applicable balance accounts at DTC in such name and in such denominations as specified by such Buyer to effect
such sale, transfer or assignment. In the event that such sale, assignment or transfer involves Conversion Shares or Warrant Shares sold, assigned or transferred pursuant to an effective registration statement or in compliance with Rule 144, the
transfer agent shall issue such shares to such Buyer, the assignee or transferee (as the case may be) without any restrictive legend in accordance with Section&nbsp;5(d) below. The Company acknowledges that a breach by it of its obligations
hereunder will cause irreparable harm to a Buyer. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section&nbsp;5(b) will be inadequate and agrees, in the event of a breach or threatened breach
by the Company of the provisions of this Section&nbsp;5(b), that a Buyer shall be entitled, in addition to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without the
necessity of showing economic loss and without any bond or other security being required. The Company shall cause its counsel to issue the legal opinion referred to in the Irrevocable Transfer Agent Instructions to the Company&#146;s transfer agent
on each Effective Date (as defined in the Registration Rights Agreement). Any fees (with respect to the transfer agent, counsel to the Company or otherwise) associated with the issuance of such opinion or the removal of any legends on any of the
Securities shall be borne by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Legends</U>. Each Buyer understands that the Securities have been issued (or will be
issued in the case of the Conversion Shares and the Warrant Shares) pursuant to an exemption from registration or qualification under the 1933 Act and applicable state securities laws, and except as set forth below, the Securities shall bear any
legend as required by the &#147;blue sky&#148; laws of any state and a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of such stock certificates): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE
[CONVERTIBLE] [EXERCISABLE] HAVE BEEN][THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD,
TRANSFERRED OR ASSIGNED (I)&nbsp;IN THE ABSENCE OF (A)&nbsp;AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B)&nbsp;AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM
REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II)&nbsp;UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN
CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Removal of
Legends</U>. Certificates evidencing Securities shall not be required to contain the legend set forth in Section&nbsp;5(c) above or any other legend (i)&nbsp;while a registration statement covering the resale of such Securities is effective under
the 1933 Act, (ii)&nbsp;following any sale of such Securities pursuant to Rule 144 (assuming the transferor is not an affiliate of the Company), (iii) if such Securities are eligible to be sold, assigned or transferred under Rule 144 (provided that
a Buyer provides the Company with reasonable assurances that such Securities are eligible for sale, assignment or transfer under Rule 144 which shall not include an opinion of Buyer&#146;s counsel), (iv) in connection with a sale, assignment or
other transfer (other than under Rule 144), provided that such Buyer provides the Company with an opinion of counsel to such Buyer, in a generally acceptable form, to the effect that such sale, assignment or transfer of the Securities may be made
without registration under the applicable requirements of the 1933 Act or (v)&nbsp;if such legend is not required under applicable requirements of the 1933 Act (including, without limitation, controlling judicial interpretations and pronouncements
issued by the SEC). If a legend is not required pursuant to the foregoing, the Company shall no later than two (2)&nbsp;Trading Days (or such earlier date as required pursuant to the 1934 Act or other applicable law, rule or regulation for the
settlement of a trade initiated on the date such Buyer delivers such legended certificate representing such Securities to the Company) following the delivery by a Buyer to the Company or the transfer agent (with notice to the Company) of a legended
certificate representing such Securities (endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect the reissuance and/or transfer, if applicable), together with any other deliveries from such Buyer as
may be required above in this Section&nbsp;5(d), as directed by such Buyer, either: (A)&nbsp;provided that the Company&#146;s transfer agent is participating in the DTC Fast Automated Securities Transfer Program (&#147;<B>FAST</B>&#148;) and such
Securities are Conversion Shares or Warrant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares, credit the aggregate number of shares of Common Stock to which such Buyer shall be entitled to such Buyer&#146;s or its designee&#146;s balance account with DTC through its
Deposit/Withdrawal at Custodian system or (B)&nbsp;if the Company&#146;s transfer agent is not participating in FAST, issue and deliver (via reputable overnight courier) to such Buyer, a certificate representing such Securities that is free from all
restrictive and other legends, registered in the name of such Buyer or its designee (the date by which such credit is so required to be made to the balance account of such Buyer&#146;s or such Buyer&#146;s designee with DTC or such certificate is
required to be delivered to such Buyer pursuant to the foregoing is referred to herein as the &#147;<B>Required Delivery Date</B>&#148;, and the date such shares of Common Stock are actually delivered without restrictive legend to such Buyer or such
Buyer&#146;s designee with DTC, as applicable, the &#147;<B>Share Delivery Date</B>&#148;). The Company shall be responsible for any transfer agent fees or DTC fees with respect to any issuance of Securities or the removal of any legends with
respect to any Securities in accordance herewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Failure to Timely Deliver; <FONT STYLE="white-space:nowrap">Buy-In</FONT></U>.
After the Public Company Date, if the Company fails to fail, for any reason or for no reason, to issue and deliver (or cause to be delivered) to a Buyer (or its designee) by the Required Delivery Date, either (I)&nbsp;if the Transfer Agent is not
participating in FAST, a certificate for the number of Conversion Shares or Warrant Shares (as the case may be) to which such Buyer is entitled and register such Conversion Shares or Warrant Shares (as the case may be) on the Company&#146;s share
register or, if the Transfer Agent is participating in FAST, to credit the balance account of such Buyer or such Buyer&#146;s designee with DTC for such number of Conversion Shares or Warrant Shares (as the case may be) submitted for legend removal
by such Buyer pursuant to Section&nbsp;5(d) above or (II)&nbsp;if a registration statement covering the resale of the Conversion Shares or Warrant Shares (as the case may be) submitted for legend removal by such Buyer pursuant to Section&nbsp;5(d)
above (the &#147;<B>Unavailable Shares</B>&#148;) is not available for the resale of such Unavailable Shares and the Company fails to promptly, but in no event later than as required pursuant to the Registration Rights Agreement (x)&nbsp;so notify
such Buyer and (y)&nbsp;deliver the Conversion Shares or Warrant Shares, as applicable, electronically without any restrictive legend by crediting such aggregate number of Conversion Shares or Warrant Shares (as the case may be) submitted for legend
removal by such Buyer pursuant to Section&nbsp;5(d) above to such Buyer&#146;s or its designee&#146;s balance account with DTC through its Deposit/Withdrawal At Custodian system (the event described in the immediately foregoing clause (II)&nbsp;is
hereinafter referred as a &#147;<B>Notice Failure</B>&#148; and together with the event described in clause (I)&nbsp;above, a &#147;<B>Delivery Failure</B>&#148;), then, in addition to all other remedies available to such Buyer, the Company shall
pay in cash to such Buyer on each day after the Share Delivery Date and during such Delivery Failure an amount equal to 2% of the product of (A)&nbsp;the sum of the number of shares of Common Stock not issued to such Buyer on or prior to the
Required Delivery Date and to which such Buyer is entitled, and (B)&nbsp;any trading price of the Common Stock selected by such Buyer in writing as in effect at any time during the period beginning on the date of the delivery by such Buyer to the
Company of the applicable Conversion Shares or Warrant Shares (as the case may be) and ending on the applicable Share Delivery Date. In addition to the foregoing, if on or prior to the Required Delivery Date either (I)&nbsp;if the Transfer Agent is
not participating in FAST, the Company shall fail to issue and deliver a certificate to a Buyer and register such shares of Common Stock on the Company&#146;s share register or, if the Transfer Agent is participating in FAST, credit the balance
account of such Buyer or such Buyer&#146;s designee with DTC for the number of shares of Common Stock to which such Buyer submitted for legend removal by such Buyer pursuant to Section&nbsp;5(d) above (ii)&nbsp;below or (II)&nbsp;a Notice Failure
occurs, and if on or after such Trading Day such Buyer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Buyer of shares of Common Stock submitted for legend removal by such
Buyer pursuant to Section&nbsp;5(d) above that such Buyer anticipated receiving from the Company (a &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT></B>&#148;), then the Company shall, within two (2)&nbsp;Trading Days after such Buyer&#146;s
request and in such Buyer&#146;s discretion, either (i)&nbsp;pay cash to such Buyer in an amount equal to such Buyer&#146;s total purchase price (including brokerage commissions and other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, if any, for the shares of Common Stock so purchased) (the &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT> Price</B>&#148;), at which point the Company&#146;s obligation to so
deliver such certificate or credit such Buyer&#146;s balance account shall terminate and such shares shall be cancelled, or (ii)&nbsp;promptly honor its obligation to so deliver to such Buyer a certificate or certificates or credit the balance
account of such Buyer or such Buyer&#146;s designee with DTC representing such number of shares of Common Stock that would have been so delivered if the Company timely complied with its obligations hereunder and pay cash to such Buyer in an amount
equal to the excess (if any) of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> Price over the product of (A)&nbsp;such number of shares of Conversion Shares or Warrant Shares (as the case may be) that the Company was required to deliver to such
Buyer by the Required Delivery Date multiplied by (B)&nbsp;the lowest Closing Sale Price (as defined in the Warrants) of the Common Stock on any Trading Day during the period commencing on the date of the delivery by such Buyer to the Company of the
applicable Conversion Shares or Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this clause (ii). Nothing shall limit such Buyer&#146;s right to pursue any other remedies available to it hereunder, at
law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver certificates representing shares of Common Stock (or to electronically deliver
such shares of Common Stock) as required pursuant to the terms hereof. Notwithstanding anything herein to the contrary, with respect to any given Notice Failure and/or Delivery Failure, this Section&nbsp;5(e) shall not apply to the applicable Buyer
the extent the Company has already paid such amounts in full to such Buyer with respect to such Notice Failure and/or Delivery Failure, as applicable, pursuant to the analogous sections of the Note or Warrant, as applicable, held by such Buyer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>FAST Compliance</U>. While any Warrants remain outstanding, the Company shall maintain a transfer agent that participates in FAST. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. CONDITIONS TO THE COMPANY&#146;S OBLIGATION TO SELL. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The obligation of the Company hereunder to issue and sell the Notes<B> </B>and the related Warrants to each Buyer at the Closing is subject
to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for the Company&#146;s sole benefit and may be waived by the Company at any time in its sole discretion by providing each
Buyer with prior written notice thereof: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Such Buyer shall have executed each of the other Transaction Documents to
which it is a party and delivered the same to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Such Buyer and each other Buyer shall have delivered to
the Company the Purchase Price (less, in the case of any Buyer, the amounts withheld pursuant to Section&nbsp;4(g)) for the Note and the related Warrants being purchased by such Buyer at the Closing by wire transfer of immediately available funds in
accordance with the Flow of Funds Letter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The representations and warranties of such Buyer shall be true and
correct in all material respects as of the date when made and as of the Closing Date as though originally made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct as of such
specific date), and such Buyer shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by such Buyer at or prior to
the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. CONDITIONS TO EACH BUYER&#146;S OBLIGATION TO PURCHASE. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The obligation of each Buyer hereunder to purchase its Note<B> </B>and its related Warrants at the Closing is subject to the satisfaction,
at or before the Closing Date, of each of the following conditions, provided that these conditions are for each Buyer&#146;s sole benefit and may be waived by such Buyer at any time in its sole discretion by providing the Company with prior written
notice thereof: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have duly executed and delivered to such Buyer each of the Transaction Documents to
which it is a party and the Company shall have duly executed and delivered to such Buyer (A)&nbsp;a Note in such original principal amount as is set forth across from such Buyer&#146;s name in column (3)&nbsp;of the Schedule of Buyers and (B)&nbsp;a
Warrant initially exercisable for such aggregate number of Warrant Shares as is set forth across from such Buyer&#146;s name in column (4)&nbsp;of the Schedule of Buyers, in each case, as being purchased by such Buyer at the Closing pursuant to this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Such Buyer shall have received the opinion of Jackson Walker L.L.P., the Company&#146;s counsel, dated as
of the Closing Date, in the form acceptable to such Buyer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Company shall have delivered to such Buyer a
certificate evidencing the formation and good standing of the Company in Texas as of a date within ten (10)&nbsp;days of the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The Company shall have delivered to such Buyer a certificate evidencing the Company&#146;s and each Subsidiary&#146;s
qualification as a foreign corporation and good standing issued by the Secretary of State (or comparable office) of each jurisdiction in which the Company and each Subsidiary conducts business and is required to so qualify, as of a date within ten
(10)&nbsp;days of the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) The Company shall have delivered to such Buyer a certified copy of the Certificate
of Incorporation as certified by the Texas Secretary of State within ten (10)&nbsp;days of the Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) The
Company shall have delivered to such Buyer a certificate, in the form acceptable to such Buyer, executed by the Secretary of the Company and dated as of the Closing Date, as to (i)&nbsp;the resolutions consistent with Section&nbsp;3(b) as adopted by
the Company&#146;s board of directors in a form reasonably acceptable to such Buyer, (ii)&nbsp;the Certificate of Incorporation of the Company and (iii)&nbsp;the Bylaws of the Company, each as in effect at the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) Each and every representation and warranty of the Company shall be
true and correct as of the date when made and as of the Closing Date as though originally made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct as of such specific date) and
the Company shall have performed, satisfied and complied in all respects with the covenants, agreements and conditions required to be performed, satisfied or complied with by the Company at or prior to the Closing Date. Such Buyer shall have
received a certificate, duly executed by the Chief Executive Officer of the Company, dated as of the Closing Date, to the foregoing effect and as to such other matters as may be reasonably requested by such Buyer in the form acceptable to such
Buyer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any,
necessary for the sale of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) No statute, rule, regulation, executive order, decree, ruling or injunction
shall have been enacted, entered, promulgated or endorsed by any court or Governmental Entity of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by the Transaction Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) Since the date of execution of this Agreement, no event or series of events shall have occurred that reasonably would have
or result in a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) Such Buyer shall have received a letter on the letterhead of the Company,
duly executed by the Chief Executive Officer of the Company, setting forth the wire amounts of each Buyer and the wire transfer instructions of the Company (the &#147;<B>Flow of Funds Letter</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) Each of the other Buyers shall have duly executed and delivered to the Company the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement (the &#147;<B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement</B>&#148;) in the form attached hereto as <B><U>Exhibit D</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) The Company shall have delivered to such Buyer a waiver of conversion rights (the &#147;<B>Waiver</B>&#148;), dated on
or about even date herewith, by and among the Company, Andrew Simpson and Mark Hilz, pursuant to which both Andrew Simpson and Mark Hilz agree to waive their respective Conversion Rights (as defined in the Waiver) until such time as the Required
Reserve Amount (as defined in the Waiver) is properly reserved for issuance by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) The Company and its
Subsidiaries shall have delivered to such Buyer such other documents, instruments or certificates relating to the transactions contemplated by this Agreement as such Buyer or its counsel may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) Notes and the Warrants with a minimum Purchase Price of at least $2,000,000 must be sold to Buyers pursuant to this
Agreement, not including any Notes and Warrants that are sold pursuant to the surrender, exchange, conversion, or cancellation of Exchange Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi) The Collateral Agent shall have received the security agreement (the
&#147;<B>Security Agreement</B>&#148;) in the form attached hereto as <B><U>Exhibit E</U></B>, duly executed by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. TERMINATION. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Closing shall not have occurred with respect to a Buyer within five (5)&nbsp;days of the date hereof, then such Buyer
shall have the right to terminate its obligations under this Agreement with respect to itself at any time on or after the close of business on such date without liability of such Buyer to any other party; provided, however, (i)&nbsp;the right to
terminate this Agreement under this Section&nbsp;8 shall not be available to such Buyer if the failure of the transactions contemplated by this Agreement to have been consummated by such date is the result of such Buyer&#146;s breach of this
Agreement and (ii)&nbsp;the abandonment of the sale and purchase of the Notes and the Warrants shall be applicable only to such Buyer providing such written notice, provided further that no such termination shall affect any obligation of the Company
under this Agreement to reimburse such Buyer for the expenses described in Section&nbsp;4(g) above. Nothing contained in this Section&nbsp;8 shall be deemed to release any party from any liability for any breach by such party of the terms and
provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. MISCELLANEOUS. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Governing Law;
Jurisdiction; Jury Trial</U>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of Illinois, without giving effect to any choice of law or
conflict of law provision or rule (whether of the State of Illinois or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Illinois. The Company hereby irrevocably submits to the
exclusive jurisdiction of the state and federal courts sitting in The City of Chicago, County of Cook, for the adjudication of any dispute hereunder or in connection herewith or under any of the other Transaction Documents or with any transaction
contemplated hereby or thereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is
brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by
mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to
limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude any Buyer from bringing suit or taking other legal action against the Company in any other jurisdiction to
collect on the Company&#146;s obligations to such Buyer or to enforce a judgment or other court ruling in favor of such Buyer. <B>EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE
ADJUDICATION OF ANY DISPUTE HEREUNDER OR </B><B>UNDER ANY OTHER TRANSACTION DOCUMENT OR </B><B>IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT</B><B>, ANY OTHER TRANSACTION DOCUMENT</B><B> OR ANY TRANSACTION CONTEMPLATED HEREBY</B><B> OR
THEREBY</B><B>.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Counterparts</U>. This Agreement may be executed in two or more identical
counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. In the event that any signature is delivered by facsimile
transmission or by an <FONT STYLE="white-space:nowrap">e-mail</FONT> which contains a portable document format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on
whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<U>Headings; Gender</U>. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed
to include the masculine, feminine, neuter, singular and plural forms thereof. The terms &#147;including,&#148; &#147;includes,&#148; &#147;include&#148; and words of like import shall be construed broadly as if followed by the words &#147;without
limitation.&#148; The terms &#147;herein,&#148; &#147;hereunder,&#148; &#147;hereof&#148; and words of like import refer to this entire Agreement instead of just the provision in which they are found. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Severability; Maximum Payment Amounts</U>. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid
or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or
unenforceability of such provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change, the original intentions of the parties as to the
subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the
benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as
possible to that of the prohibited, invalid or unenforceable provision(s). Notwithstanding anything to the contrary contained in this Agreement or any other Transaction Document (and without implication that the following is required or applicable),
it is the intention of the parties that in no event shall amounts and value paid by the Company and/or any of its Subsidiaries (as the case may be), or payable to or received by any of the Buyers, under the Transaction Documents (including without
limitation, any amounts that would be characterized as &#147;interest&#148; under applicable law) exceed amounts permitted under any applicable law. Accordingly, if any obligation to pay, payment made to any Buyer, or collection by any Buyer
pursuant the Transaction Documents is finally judicially determined to be contrary to any such applicable law, such obligation to pay, payment or collection shall be deemed to have been made by mutual mistake of such Buyer, the Company and its
Subsidiaries and such amount shall be deemed to have been adjusted with retroactive effect to the maximum amount or rate of interest, as the case may be, as would not be so prohibited by the applicable law. Such adjustment shall be effected, to the
extent necessary, by reducing or refunding, at the option of such Buyer, the amount of interest or any other amounts which would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
constitute unlawful amounts required to be paid or actually paid to such Buyer under the Transaction Documents. For greater certainty, to the extent that any interest, charges, fees, expenses or
other amounts required to be paid to or received by such Buyer under any of the Transaction Documents or related thereto are held to be within the meaning of &#147;interest&#148; or another applicable term to otherwise be violative of applicable
law, such amounts shall be <FONT STYLE="white-space:nowrap">pro-rated</FONT> over the period of time to which they relate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Entire
Agreement; Amendments</U>. This Agreement, the other Transaction Documents and the schedules and exhibits attached hereto and thereto and the instruments referenced herein and therein supersede all other prior oral or written agreements between the
Buyers, the Company, its Subsidiaries, their affiliates and Persons acting on their behalf, including, without limitation, any transactions by any Buyer with respect to Common Stock or the Securities, and the other matters contained herein and
therein, and this Agreement, the other Transaction Documents, the schedules and exhibits attached hereto and thereto and the instruments referenced herein and therein contain the entire understanding of the parties solely with respect to the matters
covered herein and therein; provided, however, nothing contained in this Agreement or any other Transaction Document shall (or shall be deemed to)&nbsp;(i) have any effect on any agreements any Buyer has entered into with, or any instruments any
Buyer has received from, the Company or any of its Subsidiaries prior to the date hereof with respect to any prior investment made by such Buyer in the Company or (ii)&nbsp;waive, alter, modify or amend in any respect any obligations of the Company
or any of its Subsidiaries, or any rights of or benefits to any Buyer or any other Person, in any agreement entered into prior to the date hereof between or among the Company and/or any of its Subsidiaries and any Buyer, or any instruments any Buyer
received from the Company and/or any of its Subsidiaries prior to the date hereof, and all such agreements and instruments shall continue in full force and effect. Except as specifically set forth herein or therein, neither the Company nor any Buyer
makes any representation, warranty, covenant or undertaking with respect to such matters. For clarification purposes, the Recitals are part of this Agreement. No provision of this Agreement may be amended other than by an instrument in writing
signed by the Company and the Required Holders (as defined below), and any amendment to any provision of this Agreement made in conformity with the provisions of this Section&nbsp;9(e) shall be binding on all Buyers and holders of Securities, as
applicable; provided that no such amendment shall be effective to the extent that it (A)&nbsp;applies to less than all of the holders of the Securities then outstanding or (B)&nbsp;imposes any obligation or liability on any Buyer without such
Buyer&#146;s prior written consent (which may be granted or withheld in such Buyer&#146;s sole discretion). No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party, provided that the
Required Holders may waive any provision of this Agreement, and any waiver of any provision of this Agreement made in conformity with the provisions of this Section&nbsp;9(e) shall be binding on all Buyers and holders of Securities, as applicable,
provided that no such waiver shall be effective to the extent that it (1)&nbsp;applies to less than all of the holders of the Securities then outstanding (unless a party gives a waiver as to itself only) or (2)&nbsp;imposes any obligation or
liability on any Buyer without such Buyer&#146;s prior written consent (which may be granted or withheld in such Buyer&#146;s sole discretion). No consideration (other than reimbursement of legal fees) shall be offered or paid to any Person to amend
or consent to a waiver or modification of any provision of any of the Transaction Documents unless the same consideration also is offered to all of the parties to the Transaction Documents, all holders of the Notes or all holders of the Warrants (as
the case may be). From the date hereof and while any Notes or Warrants are outstanding, the Company shall not be permitted to receive any consideration from a Buyer or a holder of Notes or Warrants </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that is not otherwise contemplated by the Transaction Documents in order to, directly or indirectly, induce the Company or any Subsidiary (i)&nbsp;to treat such Buyer or holder of Notes or
Warrants in a manner that is more favorable than to other similarly situated Buyers or holders of Notes or Warrants, as applicable, or (ii)&nbsp;to treat any Buyer(s) or holder(s) of Notes or Warrants in a manner that is less favorable than the
Buyer or holder of Notes or Warrants that is paying such consideration; provided, however, that the determination of whether a Buyer has been treated more or less favorably than another Buyer shall disregard any securities of the Company purchased
or sold by any Buyer. The Company has not, directly or indirectly, made any agreements with any Buyers relating to the terms or conditions of the transactions contemplated by the Transaction Documents except as set forth in the Transaction
Documents. Without limiting the foregoing, the Company confirms that, except as set forth in this Agreement, no Buyer has made any commitment or promise or has any other obligation to provide any financing to the Company, any Subsidiary or
otherwise. As a material inducement for each Buyer to enter into this Agreement, the Company expressly acknowledges and agrees that no due diligence or other investigation or inquiry conducted by a Buyer, any of its advisors or any of its
representatives shall affect such Buyer&#146;s right to rely on, or shall modify or qualify in any manner or be an exception to any of, the Company&#146;s representations and warranties contained in this Agreement or any other Transaction Document.
&#147;<B>Required Holders</B>&#148; means (I)&nbsp;prior to the Closing Date, each Buyer entitled to purchase Notes at the Closing and (II)&nbsp;on or after the Closing Date, (x)&nbsp;Cavalry Investment Fund, LP (the &#147;<B>Lead
Investor</B>&#148;), so long as it holds any Securities or (y)&nbsp;if the Lead Investor holds no Securities, holders of a majority of the Underlying Securities as of such time (excluding any Underlying Securities held by the Company or any of its
Subsidiaries as of such time) issued or issuable hereunder or pursuant to the Notes and/or the Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Notices</U>. Any notices,
consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i)&nbsp;upon receipt, when delivered personally; (ii)&nbsp;upon receipt,
when sent by electronic mail (provided that such sent email is kept on file (whether electronically or otherwise) by the sending party and the sending party does not receive an automatically generated message from the recipient&#146;s email server
that such <FONT STYLE="white-space:nowrap">e-mail</FONT> could not be delivered to such recipient); or (iii)&nbsp;one (1) Business Day after deposit with an overnight courier service with next day delivery specified, in each case, properly addressed
to the party to receive the same. The mailing addresses and <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses for such communications shall be: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heart Test Laboratories, Inc. (d/b/a HeartSciences) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">550 Reserve Street, Suite 360 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Southlake, TX 76092 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Telephone: (469) 844 4414 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Chief Executive Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-Mail:</FONT> mark.hilz@heartsciences.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy (for informational purposes only) to: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jackson Walker, L.L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2323 Ross Ave., Suite 600 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dallas, Texas 75201 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Telephone: (214) <FONT STYLE="white-space:nowrap">953-5896</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Richard A. Dahlson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> rdahlson@jw.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to a Buyer, to its mailing address and <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth on the Schedule of Buyers, with copies to such
Buyer&#146;s representatives as set forth on the Schedule of Buyers, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy (for informational purposes only) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kelley Drye&nbsp;&amp; Warren LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3 World Trade Center </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">175 Greenwich Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10007 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Telephone: (212) <FONT STYLE="white-space:nowrap">808-7540</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Michael A. Adelstein, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> madelstein@kelleydrye.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other mailing address and/or <FONT STYLE="white-space:nowrap">e-mail</FONT> address and/or to the attention of such other Person as the recipient
party has specified by written notice given to each other party five (5)&nbsp;days prior to the effectiveness of such change, provided that Kelley Drye&nbsp;&amp; Warren LLP shall only be provided copies of notices sent to the Lead Investor. Written
confirmation of receipt (A)&nbsp;given by the recipient of such notice, consent, waiver or other communication, (B)&nbsp;mechanically or electronically generated by the sender&#146;s <FONT STYLE="white-space:nowrap">e-mail</FONT> containing the
time, date and recipient&#146;s <FONT STYLE="white-space:nowrap">e-mail</FONT> or (C)&nbsp;provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by <FONT STYLE="white-space:nowrap">e-mail</FONT> or
receipt from an overnight courier service in accordance with clause (i), (ii) or (iii)&nbsp;above, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Successors and
Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns, including any purchasers of any of the Notes and Warrants. The Company shall not assign this Agreement or any
rights or obligations hereunder without the prior written consent of the Required Holders, including, without limitation, by way of a Fundamental Transaction (as defined in the Warrants) (unless the Company is in compliance with the applicable
provisions governing Fundamental Transactions set forth in the Warrants) or a Fundamental Transaction (as defined in the Notes) (unless the Company is in compliance with the applicable provisions governing Fundamental Transactions set forth in the
Notes). A Buyer may assign some or all of its rights hereunder in connection with any transfer of any of its Securities without the consent of the Company, in which event such assignee shall be deemed to be a Buyer hereunder with respect to such
assigned rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>No Third Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their
respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, other than the Indemnitees referred to in Section&nbsp;9(k). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Survival</U>. The representations, warranties, agreements and covenants shall survive
the Closing. Each Buyer shall be responsible only for its own representations, warranties, agreements and covenants hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)
<U>Further Assurances</U>. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may
reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Indemnification</U>. In consideration of each Buyer&#146;s execution and delivery of the Transaction Documents and acquiring the
Securities thereunder and in addition to all of the Company&#146;s other obligations under the Transaction Documents, the Company shall defend, protect, indemnify and hold harmless each Buyer and each holder of any Securities and all of their
stockholders, partners, members, officers, directors, employees and direct or indirect investors and any of the foregoing Persons&#146; agents or other representatives (including, without limitation, those retained in connection with the
transactions contemplated by this Agreement) (collectively, the &#147;<B>Indemnitees</B>&#148;) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in
connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys&#146; fees and disbursements (the &#147;<B>Indemnified
Liabilities</B>&#148;), incurred by any Indemnitee as a result of, or arising out of, or relating to (i)&nbsp;any misrepresentation or breach of any representation or warranty made by the Company or any Subsidiary in any of the Transaction
Documents, (ii)&nbsp;any breach of any covenant, agreement or obligation of the Company or any Subsidiary contained in any of the Transaction Documents or (iii)&nbsp;any cause of action, suit, proceeding or claim brought or made against such
Indemnitee by a third party (including for these purposes a derivative action brought on behalf of the Company or any Subsidiary) or which otherwise involves such Indemnitee that arises out of or results from (A)&nbsp;the execution, delivery,
performance or enforcement of any of the Transaction Documents, (B)&nbsp;any transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the Securities, (C)&nbsp;any disclosure properly
made by such Buyer pursuant to Section&nbsp;4(i), or (D)&nbsp;the status of such Buyer or holder of the Securities either as an investor in the Company pursuant to the transactions contemplated by the Transaction Documents or as a party to this
Agreement (including, without limitation, as a party in interest or otherwise in any action or proceeding for injunctive or other equitable relief). To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the
Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. Except as otherwise set forth herein, the mechanics and procedures with respect to the
rights and obligations under this Section&nbsp;9(k) shall be the same as those set forth in Section&nbsp;6 of the Registration Rights Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Construction</U>. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual
intent, and no rules of strict construction will be applied against any party. No specific representation or warranty shall limit the generality or applicability of a more general representation or warranty. Each and every reference to share prices,
shares of Common Stock and any other numbers in this Agreement that relate to the Common Stock shall be automatically adjusted for any stock splits, stock dividends, stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combinations, recapitalizations or other similar transactions that occur with respect to the Common Stock after the date of this Agreement. Notwithstanding anything in this Agreement to the
contrary, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty against, or a prohibition of, any actions with respect to the borrowing of, arrangement to borrow, identification of the availability of,
and/or securing of, securities of the Company in order for such Buyer (or its broker or other financial representative) to effect short sales or similar transactions in the future. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Remedies</U>. Each Buyer and in the event of assignment by Buyer of its rights and obligations hereunder, each holder of Securities,
shall have all rights and remedies set forth in the Transaction Documents and all rights and remedies which such holders have been granted at any time under any other agreement or contract and all of the rights which such holders have under any law.
Any Person having any rights under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any breach of any provision of this Agreement and to
exercise all other rights granted by law. Furthermore, the Company recognizes that in the event that it or any Subsidiary fails to perform, observe, or discharge any or all of its or such Subsidiary&#146;s (as the case may be) obligations under the
Transaction Documents, any remedy at law would inadequate relief to the Buyers. The Company therefore agrees that the Buyers shall be entitled to specific performance and/or temporary, preliminary and permanent injunctive or other equitable relief
from any court of competent jurisdiction in any such case without the necessity of proving actual damages and without posting a bond or other security. The remedies provided in this Agreement and the other Transaction Documents shall be cumulative
and in addition to all other remedies available under this Agreement and the other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) the
Transaction Documents, whenever any Buyer exercises a right, election, demand or option under a Transaction Document and the Company or any Subsidiary does not timely perform its related obligations within the periods therein provided, then such
Buyer may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company or such Subsidiary (as the case may be), any relevant notice, demand or election in whole or in part without prejudice to its future actions
and rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Payment Set Aside; Currency</U>. To the extent that the Company makes a payment or payments to any Buyer hereunder or
pursuant to any of the other Transaction Documents or any of the Buyers enforce or exercise their rights hereunder or thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently
invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without
limitation, any bankruptcy law, foreign, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in
full force and effect as if such payment had not been made or such enforcement or setoff had not occurred. Unless otherwise expressly indicated, all dollar amounts referred to in this Agreement and the other Transaction Documents are in United
States Dollars (&#147;<B>U.S. </B><B>Dollars</B>&#148;), and all amounts owing under this Agreement and all other Transaction Documents shall be paid in U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Dollars. All amounts denominated in other currencies (if any) shall be converted into the U.S.&nbsp;Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation.
&#147;<B>Exchange Rate</B>&#148;<B> </B>means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Agreement, the U.S.&nbsp;Dollar exchange rate as published in the Wall Street Journal on the relevant date of
calculation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Judgment Currency</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) If for the purpose of obtaining or enforcing judgment against the Company in connection with this Agreement or any other
Transaction Document in any court in any jurisdiction it becomes necessary to convert into any other currency (such other currency being hereinafter in this Section&nbsp;9(p) referred to as the &#147;<B>Judgment Currency</B>&#148;) an amount due in
US Dollars under this Agreement, the conversion shall be made at the Exchange Rate prevailing on the Trading Day immediately preceding: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) the date actual payment of the amount due, in the case of any proceeding in the courts of Illinois or in the courts of any
other jurisdiction that will give effect to such conversion being made on such date: or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) the date on which the foreign
court determines, in the case of any proceeding in the courts of any other jurisdiction (the date as of which such conversion is made pursuant to this Section&nbsp;9(p)(i)(2) being hereinafter referred to as the &#147;<B>Judgment Conversion
Date</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) If in the case of any proceeding in the court of any jurisdiction referred to in
Section&nbsp;9(p)(i)(2) above, there is a change in the Exchange Rate prevailing between the Judgment Conversion Date and the date of actual payment of the amount due, the applicable party shall pay such adjusted amount as may be necessary to ensure
that the amount paid in the Judgment Currency, when converted at the Exchange Rate prevailing on the date of payment, will produce the amount of US Dollars which could have been purchased with the amount of Judgment Currency stipulated in the
judgment or judicial order at the Exchange Rate prevailing on the Judgment Conversion Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Any amount due from the
Company under this provision shall be due as a separate debt and shall not be affected by judgment being obtained for any other amounts due under or in respect of this Agreement or any other Transaction Document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Independent Nature of Buyers&#146; Obligations and Rights</U>. The obligations of each Buyer under the Transaction Documents are
several and not joint with the obligations of any other Buyer, and no Buyer shall be responsible in any way for the performance of the obligations of any other Buyer under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Buyer pursuant hereto or thereto, shall be deemed to constitute the Buyers as, and the Company acknowledges that the Buyers do not so constitute, a partnership, an association, a joint venture or any
other kind of group or entity, or create a presumption that the Buyers are in any way acting in concert or as a group or entity, and the Company shall not assert any such claim with respect to such obligations or the transactions contemplated by the
Transaction Documents or any matters, and the Company acknowledges that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Buyers are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or the transactions contemplated by the Transaction
Documents. The decision of each Buyer to purchase Securities pursuant to the Transaction Documents has been made by such Buyer independently of any other Buyer. Each Buyer acknowledges that no other Buyer has acted as agent for such Buyer in
connection with such Buyer making its investment hereunder and that no other Buyer will be acting as agent of such Buyer in connection with monitoring such Buyer&#146;s investment in the Securities or enforcing its rights under the Transaction
Documents. The Company and each Buyer confirms that each Buyer has independently participated with the Company and its Subsidiaries in the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors. Each Buyer
shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of any other Transaction Documents, and it shall not be necessary for any other Buyer to be joined as
an additional party in any proceeding for such purpose. The use of a single agreement to effectuate the purchase and sale of the Securities contemplated hereby was solely in the control of the Company, not the action or decision of any Buyer, and
was done solely for the convenience of the Company and its Subsidiaries and not because it was required or requested to do so by any Buyer. It is expressly understood and agreed that each provision contained in this Agreement and in each other
Transaction Document is between the Company, each Subsidiary and a Buyer, solely, and not between the Company, its Subsidiaries and the Buyers collectively and not between and among the Buyers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Pages Follow</I>] </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> each Buyer and the Company have caused their respective signature
page to this Agreement to be duly executed as of the date first written above. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COMPANY:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HEART TEST LABORATORIES, INC. (D/B/A HEARTSCIENCES)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> each Buyer and the Company have caused their respective signature
page to this Agreement to be duly executed as of the date first written above. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BUYER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CAVALRY INVESTMENT FUND, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> each Buyer and the Company have caused their respective signature
page to this Agreement to be duly executed as of the date first written above. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BUYERS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Lary Conel Snodgrass</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Albert Paul Knuckley</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Daniel Simpson</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Raymond Pettitt</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>John J. Bussa</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Marilyn L. Bussa</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MATTHEWS HOLDINGS SOUTHWEST, INC</B>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Scott Sullivan</B></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>20
<FILENAME>filename20.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.14</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.14 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SENIOR SUBORDINATED CONVERTIBLE NOTE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I)&nbsp;IN THE ABSENCE OF (A)&nbsp;AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B)&nbsp;AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR
(II)&nbsp;UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED
BY THE SECURITIES. ANY TRANSFEREE OF THIS NOTE SHOULD CAREFULLY REVIEW THE TERMS OF THIS NOTE, INCLUDING SECTIONS 3(c)(iii) AND 20(a) HEREOF. THE PRINCIPAL AMOUNT REPRESENTED BY THIS NOTE AND, ACCORDINGLY, THE SECURITIES ISSUABLE UPON CONVERSION
HEREOF MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 3(c)(iii) OF THIS NOTE. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS NOTE HAS BEEN ISSUED WITH
ORIGINAL ISSUE DISCOUNT (&#147;OID&#148;). PURSUANT TO TREASURY REGULATION <FONT STYLE="white-space:nowrap">&#167;1.1275-3(b)(1),</FONT> MARK HILZ, A REPRESENTATIVE OF THE COMPANY HEREOF WILL, BEGINNING TEN DAYS AFTER THE ISSUANCE DATE OF THIS NOTE,
PROMPTLY MAKE AVAILABLE TO THE HOLDER UPON REQUEST THE INFORMATION DESCRIBED IN TREASURY REGULATION <FONT STYLE="white-space:nowrap">&#167;1.1275-3(b)(1)(i).</FONT> MARK HILZ MAY BE REACHED AT TELEPHONE NUMBER (469)
<FONT STYLE="white-space:nowrap">844-4414.</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>H<SMALL>EART</SMALL> T<SMALL>EST</SMALL> L<SMALL>ABORATORIES</SMALL>,
I<SMALL>NC</SMALL>. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(<SMALL>D</SMALL>/<SMALL>B</SMALL>/<SMALL>A</SMALL> H<SMALL>EART</SMALL>S<SMALL>CIENCES</SMALL>) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>ENIOR</SMALL> S<SMALL>UBORDINATED</SMALL> C<SMALL>ONVERTIBLE</SMALL> N<SMALL>OTE</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Issuance Date: January &#151;, 2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Original Principal Amount: U.S. $_________</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>FOR VALUE RECEIVED,</B> Heart Test Laboratories, Inc. (d/b/a HeartSciences), a Texas corporation (the
&#147;<B>Company</B>&#148;), hereby promises to pay to the order of __________________or its registered assigns (&#147;<B>Holder</B>&#148;) the amount set forth above as the Original Principal Amount (as reduced pursuant to the terms hereof pursuant
to redemption, conversion or otherwise, the &#147;<B>Principal</B>&#148;) when due, whether upon the Maturity Date, or upon acceleration, redemption or otherwise (in each case in accordance with the terms hereof) and to pay interest
(&#147;<B>Interest</B>&#148;) on any outstanding Principal at the applicable Interest Rate (as defined below) from the date set forth above as the Issuance Date (the &#147;<B>Issuance</B> <B>Date</B>&#148;) until the same becomes due and payable,
whether upon the Maturity Date or upon acceleration, conversion, redemption or otherwise (in </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each case in accordance with the terms hereof). This Senior Subordinated Convertible Note (including all Senior Subordinated Convertible Notes issued in exchange, transfer or replacement hereof,
this &#147;<B>Note</B>&#148;) is one of an issue of Senior Subordinated Convertible Notes issued pursuant to the Securities Purchase Agreement, dated as of December&nbsp;22, 2021 (the &#147;<B>Subscription Date</B>&#148;), by and among the Company
and the investors (the &#147;<B>Buyers</B>&#148;) referred to therein, as amended from time to time (collectively, the &#147;<B>Notes</B>&#148;, and such other Senior Subordinated Convertible Notes, the &#147;<B>Other</B> <B>Notes</B>&#148;).
Certain capitalized terms used herein are defined in Section&nbsp;33. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>PAYMENTS OF PRINCIPAL</U>. On the Maturity Date, the Company
shall pay to the Holder an amount in cash representing all outstanding Principal, accrued and unpaid Interest and accrued and unpaid Late Charges (as defined in Section&nbsp;26(c)) on such Principal and Interest. Other than as specifically permitted
by this Note, the Company may not prepay any portion of the outstanding Principal, accrued and unpaid Interest or accrued and unpaid Late Charges on Principal and Interest, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>INTEREST; INTEREST RATE</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Interest on this Note shall commence accruing on the Issuance Date and shall be computed on the basis of a <FONT
STYLE="white-space:nowrap">360-day</FONT> year and twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months and shall compound annually. Interest shall be paid on the Maturity Date in cash. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Prior to the payment of Interest on the Maturity Date, Interest on this Note shall accrue at the Interest Rate and be
payable by way of inclusion of the Interest in the Conversion Amount<B> </B>on each Conversion Date in accordance with Section&nbsp;3(b)(i) or upon any redemption in accordance with Section&nbsp;11 or any required payment upon any Bankruptcy Event
of Default. From and after the occurrence and during the continuance of any Event of Default, the Interest Rate shall automatically be increased to thirteen percent (13.0%) per annum (the &#147;<B>Default Rate</B>&#148;). In the event that such
Event of Default is subsequently cured (and no other Event of Default then exists, including, without limitation, for the Company&#146;s failure to pay such Interest at the Default Rate on the Maturity Date), the adjustment referred to in the
preceding sentence shall cease to be effective as of the calendar day immediately following the date of such cure; provided that the Interest as calculated and unpaid at such increased rate during the continuance of such Event of Default shall
continue to apply to the extent relating to the days after the occurrence of such Event of Default through and including the date of such cure of such Event of Default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>CONVERSION OF NOTES</U>. At any time after the Issuance Date, this Note shall be convertible into validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock (as defined below), on the terms and conditions set forth in this Section&nbsp;3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Conversion Right</U>. Subject to the provisions of Section&nbsp;3(d), at any time or times on or after the Issuance
Date, the Holder shall be entitled to convert any portion of the outstanding and unpaid Conversion Amount (as defined below) into validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock in
accordance with Section&nbsp;3(c), at the Conversion Rate (as defined below). The Company shall not issue any fraction of a share of Common Stock upon any conversion. If the issuance would result in the issuance
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of a fraction of a share of Common Stock, the Company shall round such fraction of a share of Common Stock up to the nearest whole share. The Company shall pay any and all transfer, stamp,
issuance and similar taxes, costs and expenses (including, without limitation, fees and expenses of the Transfer Agent (as defined below)) that may be payable with respect to the issuance and delivery of Common Stock upon conversion of any
Conversion Amount. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Conversion Rate</U>. The number of shares of Common Stock issuable upon conversion of any
Conversion Amount pursuant to Section&nbsp;3(a) shall be determined by dividing (x)&nbsp;such Conversion Amount by (y)&nbsp;the Conversion Price (the &#147;<B>Conversion Rate</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Conversion Amount</B>&#148; means the sum of (x)&nbsp;portion of the Principal to be converted, redeemed or
otherwise with respect to which this determination is being made and (y)&nbsp;all accrued and unpaid Interest with respect to such portion of the Principal amount and accrued and unpaid Late Charges with respect to such portion of such Principal and
such Interest, if any. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) &#147;<B>Conversion Price</B>&#148; means, as of any Conversion Date or other date of
determination, $0.1835, subject to adjustment as provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Optional Conversion</U>. To convert any Conversion Amount into shares of Common Stock on any date (a &#147;<B>Conversion
Date</B>&#148;), the Holder shall deliver (whether via electronic mail or otherwise), for receipt on or prior to 11:59 p.m., New York time, on such date, a copy of an executed notice of conversion in the form attached hereto as <U>Exhibit I</U>
(each, a &#147;<B>Conversion Notice</B>&#148;) to the Company. If required by Section&nbsp;3(c)(iii), within two (2)&nbsp;Trading Days following a conversion of this Note as aforesaid, the Holder shall surrender this Note to a nationally recognized
overnight delivery service for delivery to the Company (or an indemnification undertaking with respect to this Note in the case of its loss, theft or destruction as contemplated by Section&nbsp;20(b)). On or before the first (1st) Trading Day
following the date of receipt of a Conversion Notice, the Company shall transmit by electronic mail an acknowledgment, in the form attached hereto as <U>Exhibit II</U>, of confirmation of receipt of such Conversion Notice and representation as to
whether such shares of Common Stock may then be resold pursuant to Rule 144 or an effective and available registration statement (each, an &#147;<B>Acknowledgement</B>&#148;) to the Holder and, if after the Public Company Date, to the Company&#146;s
transfer agent (the &#147;<B>Transfer Agent</B>&#148;) which confirmation shall constitute an instruction to the Company and, if after the Public Company Date, to the Transfer Agent to process such Conversion Notice in accordance with the terms
herein. On or before the second (2nd) Trading Day following the date on which the Company has received a Conversion Notice (or such earlier date as required pursuant to the 1934 Act or other applicable law, rule or regulation for the settlement of a
trade initiated on the applicable Conversion Date of such shares of Common Stock issuable pursuant to such Conversion Notice) (the &#147;<B>Share Delivery Deadline</B>&#148;), the Company shall (1)&nbsp;if on or after the Public Company Date,
provided </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
that the Transfer Agent is participating in The Depository Trust Company&#146;s (&#147;<B>DTC</B>&#148;) Fast Automated Securities Transfer Program (&#147;<B>FAST</B>&#148;), credit such
aggregate number of shares of Common Stock to which the Holder shall be entitled pursuant to such conversion to the Holder&#146;s or its designee&#146;s balance account with DTC through its Deposit/Withdrawal at Custodian system or (2)&nbsp;if
either (x)&nbsp;prior to the Public Company Date or (y)&nbsp;on or after the Public Company Date if the Transfer Agent is not participating in FAST, upon the request of the Holder, issue and deliver (via reputable overnight courier) to the address
as specified in the Conversion Notice, a certificate, registered in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder shall be entitled pursuant to such conversion. If this Note is physically
surrendered for conversion pursuant to Section&nbsp;3(c)(iii) and the outstanding Principal of this Note is greater than the Principal portion of the Conversion Amount being converted, then the Company shall as soon as practicable and in no event
later than two (2)&nbsp;Business Days after receipt of this Note and at its own expense, issue and deliver to the Holder (or its designee) a new Note (in accordance with Section&nbsp;20(d)) representing the outstanding Principal not converted. The
Person or Persons entitled to receive the shares of Common Stock issuable upon a conversion of this Note shall be treated for all purposes as the record holder or holders of such shares of Common Stock on the Conversion Date. Notwithstanding
anything to the contrary contained in this Note or the Registration Rights Agreement, after the effective date of the Registration Statement (as defined in the Registration Rights Agreement) and prior to the Holder&#146;s receipt of the notice of a
Grace Period (as defined in the Registration Rights Agreement), the Company shall cause the Transfer Agent to deliver unlegended shares of Common Stock to the Holder (or its designee) in connection with any sale of Registrable Securities (as defined
in the Registration Rights Agreement) with respect to which the Holder has entered into a contract for sale, and delivered a copy of the prospectus included as part of the particular Registration Statement to the extent applicable, and for which the
Holder has not yet settled. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Company</U><U>&#146;</U><U>s Failure to Timely Convert</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) <U>General</U>. The Company shall in all cases use its reasonable best efforts to comply with the delivery requirements set
forth herein and shall do all things and take all actions reasonably requested by the Holder in furtherance thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2)
<U>Conversion Failures On or After the Public Company Date</U>. If on or after the Public Company Date the Company shall fail, for any reason or for no reason, on or prior to the applicable Share Delivery Deadline, either (I)&nbsp;if the Transfer
Agent is not participating in FAST, to issue and deliver to the Holder (or its designee) a certificate for the number of shares of Common Stock to which the Holder is entitled and register such shares of Common Stock on the Company&#146;s share
register or, if the Transfer Agent is participating in FAST, to credit the balance account of the Holder or the Holder&#146;s designee with DTC for such number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s
conversion of this Note (as the case may be) or (II)&nbsp;if the Registration Statement covering the resale of the shares of Common Stock that are the subject of the Conversion Notice (the &#147;<B>Unavailable Conversion Shares</B>&#148;) is not
available for the resale of such Unavailable Conversion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Shares and the Company fails to promptly, but in no event later than as required pursuant to the Registration Rights Agreement (x)&nbsp;so notify the Holder and (y)&nbsp;deliver the shares of
Common Stock electronically without any restrictive legend by crediting such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such conversion to the Holder&#146;s or its designee&#146;s balance account with DTC
through its Deposit/Withdrawal At Custodian system (the event described in the immediately foregoing clause (II)&nbsp;is hereinafter referred as a &#147;<B>Notice Failure</B>&#148; and together with the event described in clause (I)&nbsp;above, a
&#147;<B>Conversion Failure</B>&#148;), then, in addition to all other remedies available to the Holder, (1)&nbsp;the Company shall pay in cash to the Holder on each day after such Share Delivery Deadline that the issuance of such shares of Common
Stock is not timely effected an amount equal to 2% of the product of (A)&nbsp;the sum of the number of shares of Common Stock not issued to the Holder on or prior to the Share Delivery Deadline and to which the Holder is entitled, multiplied by
(B)&nbsp;any trading price of the Common Stock selected by the Holder in writing as in effect at any time during the period beginning on the applicable Conversion Date and ending on the applicable Share Delivery Deadline and (2)&nbsp;the Holder,
upon written notice to the Company, may void its Conversion Notice with respect to, and retain or have returned (as the case may be) any portion of this Note that has not been converted pursuant to such Conversion Notice, provided that the voiding
of a Conversion Notice shall not affect the Company&#146;s obligations to make any payments which have accrued prior to the date of such notice pursuant to this Section&nbsp;3(c)(ii) or otherwise. In addition to the foregoing, if on or after the
Public Company Date and on or prior to the applicable Share Delivery Deadline either (A)&nbsp;if the Transfer Agent is not participating in FAST, the Company shall fail to issue and deliver to the Holder (or its designee) a certificate and register
such shares of Common Stock on the Company&#146;s share register or, if the Transfer Agent is participating in FAST, the Transfer Agent shall fail to credit the balance account of the Holder or the Holder&#146;s designee with DTC for the number of
shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion hereunder or pursuant to the Company&#146;s obligation pursuant to clause (II)&nbsp;below or (B)&nbsp;a Notice Failure occurs, and if on or after such Share
Delivery Deadline the Holder acquires (in an open market transaction, a stock loan or otherwise) shares of Common Stock corresponding to all or any portion of the number of shares of Common Stock issuable upon such conversion that the Holder is
entitled to receive from the Company and has not received from the Company in connection with such Conversion Failure or Notice Failure, as applicable (a &#147;<B>Buy-In</B>&#148;), then, in addition to all other remedies available to the Holder,
the Company shall, within two (2)&nbsp;Business Days after receipt of the Holder&#146;s request and in the Holder&#146;s discretion, either: (I)&nbsp;pay cash to the Holder in an amount equal to the Holder&#146;s total purchase price (including
brokerage commissions, stock loan costs and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, if any) for the shares of Common Stock so acquired (including, without limitation, by any other
Person in respect, or on behalf, of the Holder) (the &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT> Price</B>&#148;), at which point the Company&#146;s obligation to so issue and deliver such certificate (and to issue such shares of Common
Stock) or credit the balance account of such Holder or such Holder&#146;s designee, as applicable, with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion hereunder (as the case may be)
(and to issue such shares of Common Stock) shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
terminate, or (II)&nbsp;promptly honor its obligation to so issue and deliver to the Holder a certificate or certificates representing such shares of Common Stock or credit the balance account of
such Holder or such Holder&#146;s designee, as applicable, with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder&#146;s conversion hereunder (as the case may be) and pay cash to the Holder in an amount
equal to the excess (if any) of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> Price over the product of (x)&nbsp;such number of shares of Common Stock multiplied by (y)&nbsp;the lowest Closing Sale Price of the Common Stock on any Trading Day
during the period commencing on the date of the applicable Conversion Notice and ending on the date of such issuance and payment under this clause (II) (the &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT> Payment Amount</B>&#148;). Nothing
shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to
timely deliver certificates representing shares of Common Stock (or to electronically deliver such shares of Common Stock) upon the conversion of this Note as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) <U>Registration; Book-Entry</U>. The Company shall maintain a register (the &#147;<B>Register</B>&#148;) for the
recordation of the names and addresses of the holders of each Note and the principal amount of the Notes held by such holders (the &#147;<B>Registered Notes</B>&#148;). The entries in the Register shall be conclusive and binding for all purposes
absent manifest error. The Company and the holders of the Notes shall treat each Person whose name is recorded in the Register as the owner of a Note for all purposes (including, without limitation, the right to receive payments of Principal and
Interest hereunder) notwithstanding notice to the contrary. A Registered Note may be assigned, transferred or sold in whole or in part only by registration of such assignment or sale on the Register. Upon its receipt of a written request to assign,
transfer or sell all or part of any Registered Note by the holder thereof, the Company shall record the information contained therein in the Register and issue one or more new Registered Notes in the same aggregate principal amount as the principal
amount of the surrendered Registered Note to the designated assignee or transferee pursuant to Section&nbsp;20, provided that if the Company does not so record an assignment, transfer or sale (as the case may be) of all or part of any Registered
Note within two (2)&nbsp;Business Days of such a request, then the Register shall be automatically deemed updated to reflect such assignment, transfer or sale (as the case may be). Notwithstanding anything to the contrary in this
Section&nbsp;3(c)(iii), the Holder may assign any Note or any portion thereof to an Affiliate of such Holder or a Related Fund of such Holder without delivering a request to assign or sell such Note to the Company and the recordation of such
assignment or sale in the Register (a &#147;<B>Related Party Assignment</B>&#148;); <U>provided</U>, that (x)&nbsp;the Company may continue to deal solely with such assigning or selling Holder unless and until such Holder has delivered a request to
assign or sell such Note or portion thereof to the Company for recordation in the Register; (y)&nbsp;the failure of such assigning or selling Holder to deliver a request to assign or sell such Note or portion thereof to the Company shall not affect
the legality, validity, or binding effect of such assignment or sale and (z)&nbsp;such assigning or selling Holder shall, acting solely for this purpose as a <FONT STYLE="white-space:nowrap">non-fiduciary</FONT> agent of the Company, maintain a
register (the &#147;<B>Related Party Register</B>&#148;) comparable to the Register on behalf of the Company, and any such assignment or sale shall be effective upon recordation of such assignment or sale in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Related Party Register. Notwithstanding anything to the contrary set forth in this Section&nbsp;3, following conversion of any portion of this Note in accordance with the terms hereof, the Holder
shall not be required to physically surrender this Note to the Company unless (A)&nbsp;the full Conversion Amount represented by this Note is being converted (in which event this Note shall be delivered to the Company following conversion thereof as
contemplated by Section&nbsp;3(c)(i)) or (B)&nbsp;the Holder has provided the Company with prior written notice (which notice may be included in a Conversion Notice) requesting reissuance of this Note upon physical surrender of this Note. The Holder
and the Company shall maintain records showing the Principal, Interest and Late Charges converted and/or paid (as the case may be) and the dates of such conversions and/or payments (as the case may be) or shall use such other method, reasonably
satisfactory to the Holder and the Company, so as not to require physical surrender of this Note upon conversion. If the Company does not update the Register to record such Principal, Interest and Late Charges converted and/or paid (as the case may
be) and the dates of such conversions and/or payments (as the case may be) within two (2)&nbsp;Business Days of such occurrence, then the Register shall be automatically deemed updated to reflect such occurrence. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) <U>Pro Rata Conversion; Disputes</U>. In the event that the Company receives a Conversion Notice from more than one holder
of Notes for the same Conversion Date and the Company can convert some, but not all, of such portions of the Notes submitted for conversion, the Company, subject to Section&nbsp;3(d), shall convert from each holder of Notes electing to have Notes
converted on such date a pro rata amount of such holder&#146;s portion of its Notes submitted for conversion based on the principal amount of Notes submitted for conversion on such date by such holder relative to the aggregate principal amount of
all Notes submitted for conversion on such date. In the event of a dispute as to the number of shares of Common Stock issuable to the Holder in connection with a conversion of this Note, the Company shall issue to the Holder the number of shares of
Common Stock not in dispute and resolve such dispute in accordance with Section&nbsp;25. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Limitations on
Conversions</U>. From and after the Public Company Date, the Company shall not effect the conversion of any portion of this Note, and the Holder shall not have the right to convert any portion of this Note pursuant to the terms and conditions of
this Note and any such conversion shall be null and void and treated as if never made, to the extent that after giving effect to such conversion, the Holder together with the other Attribution Parties collectively would beneficially own in excess of
4.99% (the &#147;<B>Maximum Percentage</B>&#148;) of the shares of Common Stock outstanding immediately after giving effect to such conversion. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned
by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon conversion of this Note with respect to
which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (A)&nbsp;conversion of the remaining, nonconverted portion of this Note beneficially owned by the Holder or any of the
other Attribution Parties and (B)&nbsp;exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
without limitation, any convertible notes or convertible preferred stock or warrants, including, without limitation, the Warrants) beneficially owned by the Holder or any other Attribution Party
subject to a limitation on conversion or exercise analogous to the limitation contained in this Section&nbsp;3(d). For purposes of this Section&nbsp;3(d), beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the 1934
Act. For purposes of determining the number of outstanding shares of Common Stock the Holder may acquire upon the conversion of this Note without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common
Stock as reflected in (x)&nbsp;the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> or other public filing with the SEC, as the case may be, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other written notice by the Company or the Transfer Agent, if any, setting forth
the number of shares of Common Stock outstanding (the &#147;<B>Reported Outstanding Share Number</B>&#148;). From and after the Public Company Date, if the Company receives a Conversion Notice from the Holder at a time when the actual number of
outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Conversion Notice would
otherwise cause the Holder&#146;s beneficial ownership, as determined pursuant to this Section&nbsp;3(d), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of shares of Common Stock to be purchased pursuant to
such Conversion Notice. For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1)&nbsp;Business Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common
Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Note, by the Holder and any other Attribution
Party since the date as of which the Reported Outstanding Share Number was reported. From and after the Public Company Date, in the event that the issuance of shares of Common Stock to the Holder upon conversion of this Note results in the Holder
and the other Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section&nbsp;13(d) of the 1934 Act), the number of shares
so issued by which the Holder&#146;s and the other Attribution Parties&#146; aggregate beneficial ownership exceeds the Maximum Percentage (the &#147;<B>Excess Shares</B>&#148;) shall be deemed null and void and shall be cancelled ab initio, and the
Holder shall not have the power to vote or to transfer the Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase (with such increase not effective until the sixty-first (61<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP>) day after delivery of such notice) or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified in such notice; provided that (i)&nbsp;any such increase in the
Maximum Percentage will not be effective until the sixty-first (61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after such notice is delivered to the Company and (ii)&nbsp;any such increase or decrease will apply only to the Holder
and the other Attribution Parties and not to any other holder of Notes that is not an Attribution Party of the Holder. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Note in excess of the Maximum
Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section&nbsp;13(d) or Rule <FONT STYLE="white-space:nowrap">16a-1(a)(1)</FONT> of the 1934 Act. No prior inability to convert this Note
pursuant to this paragraph shall have any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of convertibility. The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section&nbsp;3(d) to the extent necessary to correct this paragraph (or any portion of this paragraph) which may be defective or inconsistent with the intended beneficial
ownership limitation contained in this Section&nbsp;3(d) or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor
holder of this Note. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Right of Alternate Conversion Upon an Event of Default</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>General</U>. Subject to Section&nbsp;3(d), at any time after the Public Company Date and during an Event of Default
Redemption Right Period (as defined below) with respect to an Event of Default (regardless of whether such Event of Default has been cured or if the Holder has delivered an Event of Default Redemption Notice to the Company), the Holder may, at the
Holder&#146;s option, convert (each, an &#147;<B>Alternate Conversion</B>&#148;, and the date of such Alternate Conversion, each, an &#147;<B>Alternate Conversion Date</B>&#148;) all, or any part of, the Conversion Amount (such portion of the
Conversion Amount subject to such Alternate Conversion, the &#147;<B>Alternate Conversion Amount</B>&#148;) into shares of Common Stock at the Alternate Conversion Price. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Mechanics of Alternate Conversion</U>. On any Alternate Conversion Date, the Holder may voluntarily convert any
Alternate Conversion Amount pursuant to Section&nbsp;3(c) (with &#147;Alternate Conversion Price&#148; replacing &#147;Conversion Price&#148; for all purposes hereunder with respect to such Alternate Conversion and with &#147;Redemption Premium of
the Conversion Amount&#148; replacing &#147;Conversion Amount&#148; in clause (x)&nbsp;of the definition of Conversion Rate above with respect to such Alternate Conversion) by designating in the Conversion Notice delivered pursuant to this
Section&nbsp;3(e) of this Note that the Holder is electing to use the Alternate Conversion Price for such conversion. Notwithstanding anything to the contrary in this Section&nbsp;3(e), but subject to Section&nbsp;3(d), until the Company delivers
shares of Common Stock representing the applicable Alternate Conversion Amount to the Holder, such Alternate Conversion Amount may be converted by the Holder into shares of Common Stock pursuant to Section&nbsp;3(c) without regard to this
Section&nbsp;3(e). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Automatic Conversion</U>. If (x)&nbsp;a Public Company Date occurs, (y)&nbsp;a Qualified
Offering occurs, and (z)&nbsp;no Equity Conditions Failure then exists (collectively, the &#147;<B>Automatic Conversion Conditions</B>&#148;, and the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) Trading Day (or such later date
as mutually agreed to by the Company and the Holder) after all such Automatic Conversion Conditions are met, the &#147;<B>Automatic Conversion Date</B>&#148;), this Note shall convert into shares of Common Stock in accordance with Section&nbsp;3(c)
hereof at the Conversion Rate as of the Automatic Conversion Date (giving effect to any adjustment under Section&nbsp;7(g) hereof) (a &#147;<B>Automatic Conversion</B>&#148;) as if the Holder delivered a Conversion Notice for the entire Conversion
Amount then outstanding on the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) Trading Day immediately prior to the Automatic Conversion Date; provided, that if the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
aggregate number of shares of Common Stock to be received by the Holder in the Automatic Conversion would result in a violation Section&nbsp;3(d), in lieu of the delivery of such Excess Shares,
the Holder shall receive a right (a &#147;<B>Right</B>&#148;) to receive such Excess Shares as <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. At least two (2)&nbsp;Trading Days prior to the Automatic Conversion Date (the
&#147;<B>Automatic Conversion Notice Date</B>&#148;), the Company shall deliver a written notice to the Holder setting forth (i)&nbsp;the Trading Day selected for the Automatic Conversion in accordance with this Section&nbsp;3(f), (ii) the aggregate
Conversion Amount, of the Notes subject to Automatic Conversion from the Holder and all of the holders of the Notes pursuant to this Section&nbsp;3(f) (and analogous provisions under the Other Notes)(the &#147;<B>Automatic Conversion
Amount</B>&#148;), (iii) the number of shares of Common Stock to be issued to the Holder on the Automatic Conversion Date and (iv)&nbsp;a certification that all Automatic Conversion Conditions have been satisfied. Notwithstanding anything herein to
the contrary, if on or prior to the Automatic Conversion Date any of the Automatic Conversion Conditions are not satisfied, (A)&nbsp;the Company shall provide the Holder a subsequent notice to that effect and (B)&nbsp;unless the Holder waives the
applicable failure, the Automatic Conversion shall be cancelled and shall not occur. Notwithstanding the foregoing, any Conversion Amount subject to an Automatic Conversion may be converted by the Holder hereunder prior to the Automatic Conversion
Date and such aggregate Conversion Amount converted hereunder on or after the Automatic Conversion Notice Date and prior to such Automatic Conversion Date shall reduce the Automatic Conversion Amount to be converted on such Automatic Conversion
Date. For the avoidance of doubt, the Company shall have no right to effect a Automatic Conversion if any Event of Default has occurred and continuing, but any Event of Default shall have no effect upon the Holder&#146;s right to convert this Note
in its discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>RIGHTS UPON EVENT OF DEFAULT</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Event of Default</U>. Each of the following events shall constitute an &#147;<B>Event of Default</B>&#148; and each of
the events in clauses (ix), (x) and (xi)&nbsp;shall constitute a &#147;<B>Bankruptcy Event of Default</B>&#148;: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the
failure of the applicable Registration Statement (as defined in the Registration Rights Agreement) to be filed with the SEC on or prior to the date that is five (5)&nbsp;days after the applicable Filing Deadline (as defined in the Registration
Rights Agreement) or the failure of the applicable Registration Statement to be declared effective by the SEC on or prior to the date that is five (5)&nbsp;days after the applicable Effectiveness Deadline (as defined in the Registration Rights
Agreement); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) while the applicable Registration Statement is required to be maintained effective pursuant to the terms
of the Registration Rights Agreement, the effectiveness of the applicable Registration Statement lapses for any reason (including, without limitation, the issuance of a stop order) or such Registration Statement (or the prospectus contained therein)
is unavailable to any holder of Registrable Securities (as defined in the Registration Rights Agreement) for sale of all of such holder&#146;s Registrable Securities in accordance with the terms of the Registration Rights Agreement, and such lapse
or unavailability continues for a period of ten (10)&nbsp;consecutive Trading Days or for more than an aggregate of twenty (20)&nbsp;Trading Days in any <FONT STYLE="white-space:nowrap">365-day</FONT> period (excluding days during an Allowable Grace
Period (as defined in the Registration Rights Agreement)); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) from and after the Public Company Date, the suspension from trading or
the failure of the Common Stock to be trading or listed (as applicable) on an Eligible Market for a period of five (5)&nbsp;consecutive Trading Days; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) (A) from and after the Public Company Date, the Company&#146;s failure to cure a Conversion Failure or a Delivery Failure
(as defined in the Warrants) by delivery of the required number of shares of Common Stock within five (5)&nbsp;Trading Days after the applicable Conversion Date or exercise date (as the case may be) or (B)&nbsp;the Company&#146;s notice, written or
oral, to any holder of the Notes or Warrants, including, without limitation, by way of public announcement or through any of its agents, at any time, of its intention not to comply, as required, with a request for conversion of any Notes into shares
of Common Stock that is requested in accordance with the provisions of the Notes, other than pursuant to Section&nbsp;3(d), or a request for exercise of any Warrants for shares of Common Stock in accordance with the provisions of the Warrants; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) except to the extent the Company is in compliance with Section&nbsp;10(b) below, at any time following the tenth (10<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) consecutive day that the Holder&#146;s Authorized Share Allocation (as defined in Section&nbsp;10(a) below) is less than the sum of (A)&nbsp;the number of shares of Common Stock that the Holder
would be entitled to receive upon a conversion of the full Conversion Amount of this Note (without regard to any limitations on conversion set forth in Section&nbsp;3(d) or otherwise), and (B)&nbsp;the number of shares of Common Stock that the
Holder would be entitled to receive upon exercise in full of the Holder&#146;s Warrants (without regard to any limitations on exercise set forth in the Warrants); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi) the Company&#146;s or any Subsidiary&#146;s failure to pay to the Holder any amount of Principal, Interest, Late Charges
or other amounts when and as due under this Note (including, without limitation, the Company&#146;s or any Subsidiary&#146;s failure to pay any redemption payments or amounts hereunder) or any other Transaction Document (as defined in the Securities
Purchase Agreement) or any other agreement, document, certificate or other instrument delivered in connection with the transactions contemplated hereby and thereby, except, in the case of a failure to pay Interest and Late Charges when and as due,
in which case only if such failure remains uncured for a period of at least five(5) Trading Days; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) from and after the
Public Company Date, the Company fails to remove any restrictive legend on any certificate or any shares of Common Stock issued to the Holder upon conversion or exercise (as the case may be) of any Securities (as defined in the Securities Purchase
Agreement) acquired by the Holder under the Securities Purchase Agreement (including this Note) as and when required by such Securities or the Securities Purchase Agreement, unless otherwise then prohibited by applicable federal securities laws, and
any such failure remains uncured for at least five (5)&nbsp;days; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) the occurrence of any default under, redemption of or acceleration
prior to maturity of at least an aggregate of $250,000 of Indebtedness (as defined in the Securities Purchase Agreement) of the Company or any of its Subsidiaries, other than with respect to any Other Notes; provided, that for Indebtedness of
$1,000,000 or less, the Company shall have ten (10)&nbsp;days to cure any such default, redemption or acceleration thereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for the relief of debtors shall be
instituted by or against the Company or any Subsidiary and, if instituted against the Company or any Subsidiary by a third party, shall not be dismissed within thirty (30)&nbsp;days of their initiation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) the commencement by the Company or any Subsidiary of a voluntary case or proceeding under any applicable federal, state or
foreign bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or insolvent, or the consent by it to the entry of a decree, order, judgment or other similar document in respect of
the Company or any Subsidiary in an involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or to the commencement of any bankruptcy or insolvency case or proceeding
against it, or the filing by it of a petition or answer or consent seeking reorganization or relief under any applicable federal, state or foreign law, or the consent by it to the filing of such petition or to the appointment of or taking possession
by a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or any Subsidiary or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors, or the
execution of a composition of debts, or the occurrence of any other similar federal, state or foreign proceeding, or the admission by it in writing of its inability to pay its debts generally as they become due, the taking of corporate action by the
Company or any Subsidiary in furtherance of any such action or the taking of any action by any Person to commence a Uniform Commercial Code foreclosure sale or any other similar action under federal, state or foreign law; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi) the entry by a court of (i)&nbsp;a decree, order, judgment or other similar document in respect of the Company or any
Subsidiary of a voluntary or involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or (ii)&nbsp;a decree, order, judgment or other similar document adjudging the
Company or any Subsidiary as bankrupt or insolvent, or approving as properly filed a petition seeking liquidation, reorganization, arrangement, adjustment or composition of or in respect of the Company or any Subsidiary under any applicable federal,
state or foreign law or (iii)&nbsp;a decree, order, judgment or other similar document appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or any Subsidiary or of any substantial
part of its property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree, order, judgment or other similar document or any such other decree, order, judgment or other similar document unstayed and in
effect for a period of forty-five (45)&nbsp;consecutive days; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii) a final judgment or judgments for the payment of money aggregating in
excess of $250,000 are rendered against the Company and/or any of its Subsidiaries and which judgments are not, within thirty (30)&nbsp;days after the entry thereof, bonded, discharged, settled or stayed pending appeal, or are not discharged within
thirty (30)&nbsp;days after the expiration of such stay; provided, however, any judgment which is covered by insurance or an indemnity from a credit worthy party shall not be included in calculating the $250,000 amount set forth above so long as the
Company provides the Holder a written statement from such insurer or indemnity provider (which written statement shall be reasonably satisfactory to the Holder) to the effect that such judgment is covered by insurance or an indemnity and the Company
or such Subsidiary (as the case may be) will receive the proceeds of such insurance or indemnity within thirty (30)&nbsp;days of the issuance of such judgment; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii) the Company and/or any Subsidiary, individually or in the aggregate, either (i)&nbsp;fails to pay, when due, or within
any applicable grace period, any payment with respect to any Indebtedness in excess of $250,000 due to any third party (other than, with respect to unsecured Indebtedness only, payments contested by the Company and/or such Subsidiary (as the case
may be) in good faith by proper proceedings and with respect to which adequate reserves have been set aside for the payment thereof in accordance with GAAP) or is otherwise in breach or violation of any agreement for monies owed or owing in an
amount in excess of $250,000, which breach or violation permits the other party thereto to declare a default or otherwise accelerate amounts due thereunder, or (ii)&nbsp;suffer to exist any other circumstance or event that would, with or without the
passage of time or the giving of notice, result in a default or event of default under any agreement binding the Company or any Subsidiary, which default or event of default would or is likely to have a material adverse effect on the business,
assets, operations (including results thereof), liabilities, properties, condition (including financial condition) or prospects of the Company or any of its Subsidiaries, individually or in the aggregate; provided, that with respect to this part
(ii), the Company shall have ten (10)&nbsp;Trading Days to cure any such circumstances or event upon the earlier of (A)&nbsp;receipt of written notice thereof from the Holder, and (B)&nbsp;date on which an officer of the Company has actual knowledge
thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv) other than as specifically set forth in another clause of this Section&nbsp;4(a), the Company or any
Subsidiary breaches any representation or warranty in any material respect (other than the representations or warranties subject to material adverse effect on materiality limitation, which may not be breached in any respect) or any covenant or other
term or condition of any Transaction Document, except, in the case of a breach of a covenant or other term or condition that is curable, only if such breach remains uncured for a period of five (5)&nbsp;consecutive Trading Days; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xv) a false or inaccurate certification (including a false or inaccurate deemed certification) by the Company that either
(A)&nbsp;the Equity Conditions are satisfied, (B)&nbsp;there has been no Equity Conditions Failure, or (C)&nbsp;as to whether any Event of Default has occurred; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvi) any breach or failure in any respect by the Company or any Subsidiary to comply with any provision of Section&nbsp;13 or
14 of this Note; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvii) any Material Adverse Effect (as defined in the Securities Purchase
Agreement) occurs; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xviii) any provision of any Transaction Document (including, without limitation, the Security
Documents) shall at any time for any reason (other than pursuant to the express terms thereof) cease to be valid and binding on or enforceable against the parties thereto, or the validity or enforceability thereof shall be contested by any party
thereto, or a proceeding shall be commenced by the Company or any Subsidiary or any governmental authority having jurisdiction over any of them, seeking to establish the invalidity or unenforceability thereof, or the Company or any Subsidiary shall
deny in writing that it has any liability or obligation purported to be created under any Transaction Document (including, without limitation, the Security Documents); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xix) any Security Document shall for any reason fail or cease to create a separate valid and perfected (other than by action
or inaction of the holder of the Note after written notice by the Company of such failure) for a period exceeding ten (10)&nbsp;days, or any material provision of any Security Document shall at any time for any reason cease to be valid and binding
on or enforceable against the Company or the validity or enforceability thereof shall be contested by any party thereto, or a proceeding shall be commenced by the Company or any governmental authority having jurisdiction over the Company, seeking to
establish the invalidity or unenforceability thereof; any material damage to, or loss, theft or destruction of, any Collateral, whether or not insured, or any strike, lockout, labor dispute, embargo, condemnation, act of God or public enemy, or
other casualty which causes, for more than fifteen (15)&nbsp;consecutive days, the cessation or substantial curtailment of revenue producing activities at any facility of the Company or any Subsidiary, if any such event or circumstance could have a
Material Adverse Effect; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xx) any Event of Default (as defined in the Other Notes) occurs with respect to any Other
Notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Notice of an Event of Default; Redemption Right</U>. Upon the occurrence of an Event of Default with respect
to this Note or any Other Note, the Company shall within one (1)&nbsp;Business Day deliver written notice thereof via electronic mail and overnight courier (with next day delivery specified) (an &#147;<B>Event of Default Notice</B>&#148;) to the
Holder. At any time after the earlier of the Holder&#146;s receipt of an Event of Default Notice and the Holder becoming aware of an Event of Default (such earlier date, the &#147;<B>Event of Default Right Commencement Date</B>&#148;) and ending
(such ending date, the &#147;<B>Event of Default Right Expiration Date</B>&#148;, and each such period, an &#147;<B>Event of Default Redemption Right Period</B>&#148;) on the twentieth (20<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>)
Trading Day after the later of (x)&nbsp;the date such Event of Default is cured and (y)&nbsp;the Holder&#146;s receipt of an Event of Default Notice that includes (I)&nbsp;a reasonable description of the applicable Event of Default, (II)&nbsp;a
certification as to whether, in the opinion of the Company, such Event of Default is capable of being cured and, if applicable, a reasonable description of any existing plans of the Company to cure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
such Event of Default and (III)&nbsp;a certification as to the date the Event of Default occurred and, if cured on or prior to the date of such Event of Default Notice, the applicable Event of
Default Right Expiration Date, the Holder may require the Company to redeem (regardless of whether such Event of Default has been cured on or prior to the Event of Default Right Expiration Date) all or any portion of this Note by delivering written
notice thereof (the &#147;<B>Event of Default Redemption Notice</B>&#148;) to the Company, which Event of Default Redemption Notice shall indicate the portion of this Note the Holder is electing to redeem. Each portion of this Note subject to
redemption by the Company pursuant to this Section&nbsp;4(b) shall be redeemed by the Company at a price equal to the greater of (i)&nbsp;the product of (A)&nbsp;the Conversion Amount to be redeemed multiplied by (B)&nbsp;the Redemption Premium and
(ii)&nbsp;solely if the Public Company Date has occurred, the product of (X)&nbsp;the Conversion Rate with respect to the Conversion Amount in effect at such time as the Holder delivers an Event of Default Redemption Notice multiplied by
(Y)&nbsp;the product of (1)&nbsp;the Redemption Premium multiplied by (2)&nbsp;the greatest Closing Sale Price of the Common Stock on any Trading Day during the period commencing on the date immediately preceding such Event of Default and ending on
the date the Company makes the entire payment required to be made under this Section&nbsp;4(b) (the &#147;<B>Event of Default</B> <B>Redemption Price</B>&#148;). Redemptions required by this Section&nbsp;4(b) shall be made in accordance with the
provisions of Section&nbsp;11. To the extent redemptions required by this Section&nbsp;4(b) are deemed or determined by a court of competent jurisdiction to be prepayments of this Note by the Company, such redemptions shall be deemed to be voluntary
prepayments. Notwithstanding anything to the contrary in this Section&nbsp;3(e)(ii), but subject to Section&nbsp;3(d), until the Event of Default Redemption Price (together with any Late Charges thereon) is paid in full, the Conversion Amount
submitted for redemption under this Section&nbsp;4(b) (together with any Late Charges thereon) may be converted, in whole or in part, by the Holder into Common Stock pursuant to the terms of this Note. In the event of the Company&#146;s redemption
of any portion of this Note under this Section&nbsp;4(b), the Holder&#146;s damages would be uncertain and difficult to estimate because of the parties&#146; inability to predict future interest rates and the uncertainty of the availability of a
suitable substitute investment opportunity for the Holder. Accordingly, any redemption premium due under this Section&nbsp;4(b) is intended by the parties to be, and shall be deemed, a reasonable estimate of the Holder&#146;s actual loss of its
investment opportunity and not as a penalty. Any redemption upon an Event of Default shall not constitute an election of remedies by the Holder, and all other rights and remedies of the Holder shall be preserved. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Mandatory Redemption upon Bankruptcy Event of Default</U>. Notwithstanding anything to the contrary herein, and
notwithstanding any conversion that is then required or in process, upon any Bankruptcy Event of Default, whether occurring prior to or following the Maturity Date, the Company shall immediately pay to the Holder an amount in cash representing
(i)&nbsp;all outstanding Principal, accrued and unpaid Interest and accrued and unpaid Late Charges on such Principal and Interest, multiplied by (ii)&nbsp;the Redemption Premium, in addition to any and all other amounts due hereunder, without the
requirement for any notice or demand or other action by the Holder or any other person or entity, provided that the Holder may, in its sole discretion, waive such right to receive payment upon a Bankruptcy Event of Default, in whole or in part, and
any such waiver shall not affect any other rights of the Holder hereunder, including any other rights in respect of such Bankruptcy Event of Default, any right to conversion, and any right to payment of the Event of Default Redemption Price or any
other Redemption Price, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>RIGHTS UPON FUNDAMENTAL TRANSACTION</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Assumption</U>. The Company shall not enter into or be party to a Fundamental Transaction unless the Successor Entity
assumes in writing all of the obligations of the Company under this Note and the other Transaction Documents in accordance with the provisions of this Section&nbsp;5(a) pursuant to written agreements in form and substance satisfactory to the Holder
and approved by the Holder prior to such Fundamental Transaction, including agreements to deliver to each holder of Notes in exchange for such Notes a security of the Successor Entity evidenced by a written instrument substantially similar in form
and substance to the Notes, including, without limitation, having a principal amount and interest rate equal to the principal amounts then outstanding and the interest rates of the Notes held by such holder, having similar conversion rights as the
Notes and having similar ranking and security to the Notes, and satisfactory to the Holder. Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such
Fundamental Transaction, the provisions of this Note and the other Transaction Documents referring to the &#147;Company&#148; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of
the obligations of the Company under this Note and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of a Fundamental Transaction, the Successor Entity shall
deliver to the Holder confirmation that there shall be issued upon conversion or redemption of this Note at any time after the consummation of such Fundamental Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or
other property (except such items still issuable under Sections 6 and 17, which shall continue to be receivable thereafter)) issuable upon the conversion or redemption of the Notes prior to such Fundamental Transaction, such shares of the common
stock (or their equivalent) of the Successor Entity (including its Parent Entity) which the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Note been converted immediately prior to such
Fundamental Transaction (without regard to any limitations on the conversion of this Note), as adjusted in accordance with the provisions of this Note. Notwithstanding the foregoing, the Holder may elect, at its sole option, by delivery of written
notice to the Company to waive this Section&nbsp;5(a) to permit the Fundamental Transaction without the assumption of this Note. The provisions of this Section&nbsp;5 shall apply similarly and equally to successive Fundamental Transactions and shall
be applied without regard to any limitations on the conversion of this Note. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Notice of a Change of Control;
Redemption Right</U>. No sooner than twenty (20)&nbsp;Trading Days nor later than ten (10)&nbsp;Trading Days prior to the consummation of a Change of Control (the &#147;<B>Change of Control Date</B>&#148;), but not prior to the public announcement
of such Change of Control, the Company shall deliver written notice thereof via facsimile or electronic mail and overnight courier to the Holder (a &#147;<B>Change of Control</B> <B>Notice</B>&#148;). At any time during the period beginning after
the Holder&#146;s receipt of a Change of Control Notice or the Holder becoming aware of a Change of Control if a Change of Control Notice is not delivered to the Holder in accordance with the immediately preceding
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
sentence (as applicable) and ending on twenty (20)&nbsp;Trading Days after the later of (A)&nbsp;the date of consummation of such Change of Control or (B)&nbsp;the date of receipt of such Change
of Control Notice or (C)&nbsp;the date of the announcement of such Change of Control, the Holder may require the Company to redeem all or any portion of this Note by delivering written notice thereof (&#147;<B>Change of Control Redemption
Notice</B>&#148;) to the Company, which Change of Control Redemption Notice shall indicate the Conversion Amount the Holder is electing to redeem. The portion of this Note subject to redemption pursuant to this Section&nbsp;5 shall be redeemed by
the Company in cash at a price equal to the greatest of (i)&nbsp;the product of (w)&nbsp;the Change of Control Redemption Premium multiplied by (y)&nbsp;the Conversion Amount being redeemed, (ii)&nbsp;solely if after the Public Company Date, the
product of (x)&nbsp;the Change of Control Redemption Premium multiplied by (y)&nbsp;the product of (A)&nbsp;the Conversion Amount being redeemed multiplied by (B)&nbsp;the quotient determined by dividing (I)&nbsp;the greatest Closing Sale Price of
the shares of Common Stock during the period beginning on the date immediately preceding the earlier to occur of (1)&nbsp;the consummation of the applicable Change of Control and (2)&nbsp;the public announcement of such Change of Control and ending
on the date the Holder delivers the Change of Control Redemption Notice by (II)&nbsp;the Conversion Price<B> </B>then in effect and (iii)&nbsp;the product of (y)&nbsp;the Change of Control Redemption Premium multiplied by (z)&nbsp;the product of
(A)&nbsp;the Conversion Amount being redeemed multiplied by (B)&nbsp;the quotient of (I)&nbsp;the aggregate cash consideration and the aggregate cash value of any <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration per share of Common
Stock to be paid to the holders of the shares of Common Stock upon consummation of such Change of Control (any such <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration constituting publicly-traded securities shall be valued at the highest
of the Closing Sale Price of such securities as of the Trading Day immediately prior to the consummation of such Change of Control, the Closing Sale Price of such securities on the Trading Day immediately following the public announcement of such
proposed Change of Control and the Closing Sale Price of such securities on the Trading Day immediately prior to the public announcement of such proposed Change of Control) divided by (II)&nbsp;the Conversion Price then in effect (the
&#147;<B>Change of Control Redemption Price</B>&#148;). Redemptions required by this Section&nbsp;5 shall be made in accordance with the provisions of Section&nbsp;11 and shall have priority to payments to stockholders in connection with such Change
of Control. To the extent redemptions required by this Section&nbsp;5(b) are deemed or determined by a court of competent jurisdiction to be prepayments of this Note by the Company, such redemptions shall be deemed to be voluntary prepayments.
Notwithstanding anything to the contrary in this Section&nbsp;5, but subject to Section&nbsp;3(d), until the Change of Control Redemption Price (together with any Late Charges thereon) is paid in full, the Conversion Amount submitted for redemption
under this Section&nbsp;5(b) (together with any Late Charges thereon) may be converted, in whole or in part, by the Holder into Common Stock pursuant to Section&nbsp;3. In the event of the Company&#146;s redemption of any portion of this Note under
this Section&nbsp;5(b), the Holder&#146;s damages would be uncertain and difficult to estimate because of the parties&#146; inability to predict future interest rates and the uncertainty of the availability of a suitable substitute investment
opportunity for the Holder. Accordingly, any redemption premium due under this Section&nbsp;5(b) is intended by the parties to be, and shall be deemed, a reasonable estimate of the Holder&#146;s actual loss of its investment opportunity and not as a
penalty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>RIGHTS UPON ISSUANCE OF PURCHASE RIGHTS AND OTHER CORPORATE EVENTS</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Purchase Rights</U>. In addition to any adjustments pursuant to Section&nbsp;7 below, if at any time the Company grants,
issues or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the &#147;<B>Purchase Rights</B>&#148;),
then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete
conversion of this Note (without taking into account any limitations or restrictions on the convertibility of this Note and assuming for such purpose that the Note was converted at the Alternate Conversion Price as of the applicable record date)
immediately prior to the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant,
issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, after the Public Company Date, to the extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder and the other Attribution
Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Common Stock as a
result of such Purchase Right (and beneficial ownership) to the extent of any such excess) and such Purchase Right to such extent shall be held in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar
provision, such term shall be extended by such number of days held in abeyance, if applicable) for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties
exceeding the Maximum Percentage, at which time or times the Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right held similarly in abeyance (and, if
such Purchase Right has an expiration date, maturity date or other similar provision, such term shall be extended by such number of days held in abeyance, if applicable)) to the same extent as if there had been no such limitation). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Other Corporate Events</U>. In addition to and not in substitution for any other rights hereunder, prior to the
consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a &#147;<B>Corporate Event</B>&#148;), the
Company shall make appropriate provision to ensure that the Holder will thereafter have the right to receive upon a conversion of this Note, at the Holder&#146;s option (i)&nbsp;in addition to the shares of Common Stock receivable upon such
conversion, such securities or other assets to which the Holder would have been entitled with respect to such shares of Common Stock had such shares of Common Stock been held by the Holder upon the consummation of such Corporate Event (without
taking into account any limitations or restrictions on the convertibility of this Note) or (ii)&nbsp;in lieu of the shares of Common Stock otherwise receivable upon such conversion, such securities or other assets received by the holders of shares
of Common Stock in connection with the consummation of such Corporate Event in such amounts as the Holder would have been entitled to receive had this Note initially </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
been issued with conversion rights for the form of such consideration (as opposed to shares of Common Stock) at a conversion rate for such consideration commensurate with the Conversion Rate.
Provision made pursuant to the preceding sentence shall be in a form and substance satisfactory to the Holder. The provisions of this Section&nbsp;6 shall apply similarly and equally to successive Corporate Events and shall be applied without regard
to any limitations on the conversion or redemption of this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>RIGHTS UPON ISSUANCE OF OTHER SECURITIES</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Adjustment of Conversion Price upon Issuance of Common Stock</U>. If and whenever on or after the Subscription Date and
on or prior to the second anniversary of the Issuance Date the Company grants, issues or sells (or enters into any agreement to grant, issue or sell), or in accordance with this Section&nbsp;7(a) is deemed to have granted, issued or sold, any shares
of Common Stock (including the issuance or sale of shares of Common Stock owned or held by or for the account of the Company, but excluding any Excluded Securities granted, issued or sold or deemed to have been granted, issued or sold) for a
consideration per share (the &#147;<B>New Issuance Price</B>&#148;) less than a price equal to the Conversion Price in effect immediately prior to such granting, issuance or sale or deemed granting, issuance or sale (such Conversion Price then in
effect is referred to herein as the &#147;<B>Applicable Price</B>&#148;) (the foregoing a &#147;<B>Dilutive Issuance</B>&#148;), then, immediately after such Dilutive Issuance, the Conversion Price then in effect shall be reduced to an amount equal
to the New Issuance Price. For all purposes of the foregoing (including, without limitation, determining the adjusted Conversion Price and the New Issuance Price under this Section&nbsp;7(a)), the following shall be applicable: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Issuance of Options</U>. If the Company in any manner grants, issues or sells (or enters into any agreement to grant,
issue or sell) any Options and the lowest price per share for which one share of Common Stock is at any time issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Convertible Securities issuable upon exercise
of any such Option or otherwise pursuant to the terms thereof is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the granting, issuance
or sale of such Option for such price per share. For purposes of this Section&nbsp;7(a)(i), the &#147;lowest price per share for which one share of Common Stock is at any time issuable upon the exercise of any such Option or upon conversion,
exercise or exchange of any Convertible Securities issuable upon exercise of any such Option or otherwise pursuant to the terms thereof&#148; shall be equal to (1)&nbsp;the lower of (x)&nbsp;the sum of the lowest amounts of consideration (if any)
received or receivable by the Company with respect to any one share of Common Stock upon the granting, issuance or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Convertible Security issuable upon
exercise of such Option or otherwise pursuant to the terms thereof and (y)&nbsp;the lowest exercise price set forth in such Option for which one share of Common Stock is issuable (or may become issuable assuming all possible market conditions) upon
the exercise of any such Options or upon conversion, exercise or exchange of any Convertible Securities issuable upon exercise of any such Option or otherwise pursuant to the terms thereof, minus (2)&nbsp;the sum of all amounts paid or payable to
the holder of such Option </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
(or any other Person) with respect to any one share of Common Stock upon the granting, issuance or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of
any Convertible Security issuable upon exercise of such Option or otherwise pursuant to the terms thereof plus the value of any other consideration (including, without limitation, consideration consisting of cash, debt forgiveness, assets or any
other property) received or receivable by, or benefit conferred on, the holder of such Option (or any other Person). Except as contemplated below, no further adjustment of the Conversion Price shall be made upon the actual issuance of such share of
Common Stock or of such Convertible Securities upon the exercise of such Options or otherwise pursuant to the terms thereof or upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Convertible
Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <U>Issuance of Convertible Securities</U>. If the Company in any manner issues or sells (or enters into
any agreement to issue or sell) any Convertible Securities and the lowest price per share for which one share of Common Stock is at any time issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof is
less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the issuance or sale (or the time of execution of such agreement to issue or sell, as
applicable) of such Convertible Securities for such price per share. For the purposes of this Section&nbsp;7(a)(ii), the &#147;lowest price per share for which one share of Common Stock is at any time issuable upon the conversion, exercise or
exchange thereof or otherwise pursuant to the terms thereof&#148; shall be equal to (1)&nbsp;the lower of (x)&nbsp;the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to one share of Common
Stock upon the issuance or sale (or pursuant to the agreement to issue or sell, as applicable) of the Convertible Security and upon conversion, exercise or exchange of such Convertible Security or otherwise pursuant to the terms thereof and
(y)&nbsp;the lowest conversion price set forth in such Convertible Security for which one share of Common Stock is issuable (or may become issuable assuming all possible market conditions) upon conversion, exercise or exchange thereof or otherwise
pursuant to the terms thereof minus (2)&nbsp;the sum of all amounts paid or payable to the holder of such Convertible Security (or any other Person) with respect to any one share of Common Stock upon the issuance or sale (or the agreement to issue
or sell, as applicable) of such Convertible Security plus the value of any other consideration received or receivable (including, without limitation, any consideration consisting of cash, debt forgiveness, assets or other property) by, or benefit
conferred on, the holder of such Convertible Security (or any other Person). Except as contemplated below, no further adjustment of the Conversion Price shall be made upon the actual issuance of such shares of Common Stock upon conversion, exercise
or exchange of such Convertible Securities or otherwise pursuant to the terms thereof, and if any such issuance or sale of such Convertible Securities is made upon exercise of any Options for which adjustment of the Conversion Price has been or is
to be made pursuant to other provisions of this Section&nbsp;7(a), except as contemplated below, no further adjustment of the Conversion Price shall be made by reason of such issuance or sale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) <U>Change in Option Price or Rate of Conversion</U>. If the purchase
or exercise price provided for in any Options, the additional consideration, if any, payable upon the issue, conversion, exercise or exchange of any Convertible Securities, or the rate at which any Convertible Securities are convertible into or
exercisable or exchangeable for shares of Common Stock increases or decreases at any time (other than proportional changes in conversion or exercise prices, as applicable, in connection with an event referred to in Section&nbsp;7(b) below), the
Conversion Price in effect at the time of such increase or decrease shall be adjusted to the Conversion Price which would have been in effect at such time had such Options or Convertible Securities provided for such increased or decreased purchase
price, additional consideration or increased or decreased conversion rate (as the case may be) at the time initially granted, issued or sold. For purposes of this Section&nbsp;7(a)(i), if the terms of any Option or Convertible Security (including,
without limitation, any Option or Convertible Security that was outstanding as of the Subscription Date) are increased or decreased in the manner described in the immediately preceding sentence, then such Option or Convertible Security and the
shares of Common Stock deemed issuable upon exercise, conversion or exchange thereof shall be deemed to have been issued as of the date of such increase or decrease. No adjustment pursuant to this Section&nbsp;7(a) shall be made if such adjustment
would result in an increase of the Conversion Price then in effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) <U>Calculation of Consideration Received</U>. If
any Option and/or Convertible Security and/or Adjustment Right is issued in connection with the issuance or sale or deemed issuance or sale of any other securities of the Company (as determined by the Holder, the &#147;<B>Primary Security</B>&#148;,
and such Option and/or Convertible Security and/or Adjustment Right, the &#147;<B>Secondary Securities</B>&#148;), together comprising one integrated transaction (or one or more transactions if such issuances or sales or deemed issuances or sales of
securities of the Company either (A)&nbsp;have at least one investor or purchaser in common, (B)&nbsp;are consummated in reasonable proximity to each other and/or (C)&nbsp;are consummated under the same plan of financing), the aggregate
consideration per share of Common Stock with respect to such Primary Security shall be deemed to be equal to the difference of (x)&nbsp;the lowest price per share for which one share of Common Stock was issued (or was deemed to be issued pursuant to
Section&nbsp;7(a)(i) or 7(a)(ii) above, as applicable) in such integrated transaction solely with respect to such Primary Security, minus (y)&nbsp;with respect to such Secondary Securities, the sum of (I)&nbsp;the Black Scholes Consideration Value
of each such Option, if any, (II)&nbsp;the fair market value (as determined by the Holder in good faith) or the Black Scholes Consideration Value, as applicable, of such Adjustment Right, if any, and (III)&nbsp;the fair market value (as determined
by the Holder) of such Convertible Security, if any, in each case, as determined on a per share basis in accordance with this Section&nbsp;7(a)(iv). If any shares of Common Stock, Options or Convertible Securities are issued or sold or deemed to
have been issued or sold for cash, the consideration received therefor (for the purpose of determining the consideration paid for such Common Stock, Option or Convertible Security, but not for the purpose of the calculation of the Black Scholes
Consideration Value) will be deemed to be the net amount of consideration received by the Company therefor. If any shares of Common Stock, Options or Convertible Securities are issued or sold for a consideration other than cash, the amount of such
consideration received by the Company (for the purpose </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
of determining the consideration paid for such Common Stock, Option or Convertible Security, but not for the purpose of the calculation of the Black Scholes Consideration Value) will be the fair
value of such consideration, except where such consideration consists of publicly traded securities, in which case the amount of consideration received by the Company for such securities will be the arithmetic average of the VWAPs of such security
for each of the five (5)&nbsp;Trading Days immediately preceding the date of receipt. If any shares of Common Stock, Options or Convertible Securities are issued to the owners of the <FONT STYLE="white-space:nowrap">non-surviving</FONT> entity in
connection with any merger in which the Company is the surviving entity, the amount of consideration therefor (for the purpose of determining the consideration paid for such Common Stock, Option or Convertible Security, but not for the purpose of
the calculation of the Black Scholes Consideration Value) will be deemed to be the fair value of such portion of the net assets and business of the <FONT STYLE="white-space:nowrap">non-surviving</FONT> entity as is attributable to such shares of
Common Stock, Options or Convertible Securities (as the case may be). The fair value of any consideration other than cash or publicly traded securities will be determined jointly by the Company and the Holder. If such parties are unable to reach
agreement within ten (10)&nbsp;days after the occurrence of an event requiring valuation (the &#147;<B>Valuation Event</B>&#148;), the fair value of such consideration will be determined within five (5)&nbsp;Trading Days after the tenth (10<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) day following such Valuation Event by an independent, reputable appraiser jointly selected by the Company and the Holder. The determination of such appraiser shall be final and binding upon all
parties absent manifest error and the fees and expenses of such appraiser shall be borne by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) <U>Record
Date</U>. If the Company takes a record of the holders of shares of Common Stock for the purpose of entitling them (A)&nbsp;to receive a dividend or other distribution payable in shares of Common Stock, Options or in Convertible Securities or
(B)&nbsp;to subscribe for or purchase shares of Common Stock, Options or Convertible Securities, then such record date will be deemed to be the date of the issuance or sale of the shares of Common Stock deemed to have been issued or sold upon the
declaration of such dividend or the making of such other distribution or the date of the granting of such right of subscription or purchase (as the case may be). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Adjustment of Conversion Price upon Subdivision or Combination of Common Stock</U>. Without limiting any provision of
Section&nbsp;6, Section&nbsp;17 or Section&nbsp;7(a), if the Company at any time on or after the Subscription Date subdivides (by any stock split, stock dividend, stock combination, recapitalization or other similar transaction) one or more classes
of its outstanding shares of Common Stock into a greater number of shares, the Conversion Price in effect immediately prior to such subdivision will be proportionately reduced. Without limiting any provision of Section&nbsp;6, Section&nbsp;17 or
Section&nbsp;7(a), if the Company at any time on or after the Subscription Date combines (by any stock split, stock dividend, stock combination, recapitalization or other similar transaction) one or more classes of its outstanding shares of Common
Stock into a smaller number of shares, the Conversion Price in effect immediately prior to such combination will be proportionately increased. Any adjustment pursuant to this Section&nbsp;7(b) shall become effective immediately after the effective
date of such subdivision or combination. If any event requiring an adjustment under this Section&nbsp;7(b) occurs during the period that a Conversion Price is calculated hereunder, then the calculation of such Conversion Price shall be adjusted
appropriately to reflect such event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Holder&#146;s Right of Adjusted Conversion Price</U>. In addition to
and not in limitation of the other provisions of this Section&nbsp;7, if the Company in any manner issues or sells or enters into any agreement to issue or sell, any Common Stock, Options or Convertible Securities (any such securities,
&#147;<B>Variable Price Securities</B>&#148;), after the Subscription Date that are issuable pursuant to such agreement or convertible into or exchangeable or exercisable for shares of Common Stock at a price which varies or may vary with the market
price of the shares of Common Stock, including by way of one or more reset(s) to a fixed price, but exclusive of such formulations reflecting customary anti-dilution provisions (such as share splits, share combinations, share dividends and similar
transactions) (each of the formulations for such variable price being herein referred to as, the &#147;<B>Variable Price</B>&#148;), the Company shall provide written notice thereof via electronic mail and overnight courier to the Holder on the date
of such agreement and the issuance of such Common Stock, Convertible Securities or Options. From and after the date the Company enters into such agreement or issues any such Variable Price Securities, the Holder shall have the right, but not the
obligation, in its sole discretion to substitute the Variable Price for the Conversion Price upon conversion of this Note by designating in the Conversion Notice delivered upon any conversion of this Note that solely for purposes of such conversion
the Holder is relying on the Variable Price rather than the Conversion Price then in effect. The Holder&#146;s election to rely on a Variable Price for a particular conversion of this Note shall not obligate the Holder to rely on a Variable Price
for any future conversion of this Note. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Events</U>. In the event that the Company (or any Subsidiary) shall
take any action to which the provisions hereof are not strictly applicable, or, if applicable, would not operate to protect the Holder from dilution or if any event occurs of the type contemplated by the provisions of this Section&nbsp;7 but not
expressly provided for by such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights with equity features), then the Company&#146;s board of directors shall in good faith determine
and implement an appropriate adjustment in the Conversion Price so as to protect the rights of the Holder, provided that no such adjustment pursuant to this Section&nbsp;7(d) will increase the Conversion Price as otherwise determined pursuant to
this Section&nbsp;7, provided further that if the Holder does not accept such adjustments as appropriately protecting its interests hereunder against such dilution, then the Company&#146;s board of directors and the Holder shall agree, in good
faith, upon an independent investment bank of nationally recognized standing to make such appropriate adjustments, whose determination shall be final and binding absent manifest error and whose fees and expenses shall be borne by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Calculations</U>. All calculations under this Section&nbsp;7 shall be made by rounding to the nearest cent or the
nearest 1/100<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of a share, as applicable. The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for the account of the Company, and the
disposition of any such shares shall be considered an issue or sale of Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Voluntary Adjustment by Company</U>. The Company may at any time
during the term of this Note, with the prior written consent of the Required Holders (as defined in the Securities Purchase Agreement), reduce the then current Conversion Price of each of the Notes to any amount and for any period of time deemed
appropriate by the board of directors of the Company; provided, that if after the Public Company Date, ay such reduction shall be subject to the rules and regulations of the Principal Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Adjustment Upon Public Company Date and Qualified Offering</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) If a Public Company Date occurs without the occurrence of a Qualified Offering with respect thereto and, if on the Public
Company Date, the Closing Bid Price of the Common Stock on the Public Company Date is less than the Conversion Price then in effect (the &#147;<B>No QO Measuring Price</B>&#148;), immediately following the Public Company Date the Conversion Price
shall automatically lower to the No QO Measuring Price. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Upon the occurrence of a Qualified Offering, if 70% of the
New Issuance Price of such Qualified Offering is less than the Conversion Price then in effect (the &#147;<B>QO Measuring Price</B>&#148;), immediately following the time of consummation of such Qualified Offering (and prior to any Automatic
Conversion hereunder), the Conversion Price shall automatically lower to the QO Measuring Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. REDEMPTIONS AT THE COMPANY&#146;S
ELECTION. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Company Optional Redemption</U>. At any time after the first anniversary of the Subscription Date, so
long as no Equity Conditions Failure exists, the Company shall have the right to redeem all, but not less than all, of the Conversion Amount then remaining under this Note (the &#147;<B>Company Optional Redemption Amount</B>&#148;) on the Company
Optional Redemption Date (each as defined below) (a &#147;<B>Company Optional Redemption</B>&#148;). The portion of this Note subject to redemption pursuant to this Section&nbsp;8(a) shall be redeemed by the Company in cash at a price (the
&#147;<B>Company Optional Redemption Price</B>&#148;) equal to 115% of the greater of (i)&nbsp;the Conversion Amount being redeemed as of the Company Optional Redemption Date and (ii)&nbsp;solely if after the Public Company Date, the product of
(1)&nbsp;the Conversion Rate with respect to the Conversion Amount being redeemed as of the Company Optional Redemption Date multiplied by (2)&nbsp;the greatest Closing Sale Price of the Common Stock on any Trading Day during the period commencing
on the date immediately preceding such Company Optional Redemption Notice Date and ending on the Trading Day immediately prior to the date the Company makes the entire payment required to be made under this Section&nbsp;8(a). The Company may
exercise its right to require redemption under this Section&nbsp;8(a) by delivering a written notice thereof by electronic mail and overnight courier to all, but not less than all, of the holders of Notes (the &#147;<B>Company Optional Redemption
Notice</B>&#148; and the date all of the holders of Notes received such notice is referred to as the &#147;<B>Company Optional Redemption Notice Date</B>&#148;). The Company may deliver only one Company Optional Redemption Notice hereunder and such
Company Optional Redemption Notice shall be irrevocable. The Company Optional Redemption Notice shall (x)&nbsp;state the date on which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Company Optional Redemption shall occur (the &#147;<B>Company Optional Redemption Date</B>&#148;) which date shall not be less than twenty (20)&nbsp;calendar days nor more than ninety
(90)&nbsp;calendar days following the Company Optional Redemption Notice Date, (y)&nbsp;certify that there has been no Equity Conditions Failure and (z)&nbsp;state the aggregate Conversion Amount of the Notes which is being redeemed in such Company
Optional Redemption from the Holder and all of the other holders of the Notes pursuant to this Section&nbsp;8 (and analogous provisions under the Other Notes) on the Company Optional Redemption Date. Notwithstanding anything herein to the contrary,
(i)&nbsp;if no Equity Conditions Failure has occurred as of the Company Optional Redemption Notice Date but an Equity Conditions Failure occurs at any time prior to the Company Optional Redemption Date, (A)&nbsp;the Company shall provide the Holder
a subsequent notice to that effect and (B)&nbsp;unless the Holder waives the Equity Conditions Failure, the Company Optional Redemption shall be cancelled and the applicable Company Optional Redemption Notice shall be null and void and (ii)&nbsp;at
any time prior to the date the Company Optional Redemption Price is paid, in full, the Company Optional Redemption Amount may be converted, in whole or in part, by the Holder into shares of Common Stock pursuant to Section&nbsp;3. All Conversion
Amounts converted by the Holder after the Company Optional Redemption Notice Date shall reduce the Company Optional Redemption Amount of this Note required to be redeemed on the Company Optional Redemption Date. Redemptions made pursuant to this
Section&nbsp;8 shall be made in accordance with Section&nbsp;11. In the event of the Company&#146;s redemption of any portion of this Note under this Section&nbsp;8, the Holder&#146;s damages would be uncertain and difficult to estimate because of
the parties&#146; inability to predict future interest rates and the uncertainty of the availability of a suitable substitute investment opportunity for the Holder. Accordingly, any redemption premium due under this Section&nbsp;8 is intended by the
parties to be, and shall be deemed, a reasonable estimate of the Holder&#146;s actual loss of its investment opportunity and not as a penalty. For the avoidance of doubt, the Company shall have no right to effect a Company Optional Redemption if any
Event of Default has occurred and continuing, but any Event of Default shall have no effect upon the Holder&#146;s right to convert this Note in its discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata Redemption Requirement</U>. If the Company elects to cause a Company Optional Redemption of this Note pursuant
to Section&nbsp;8, then it must simultaneously take the same action with respect to all of the Other Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>NONCIRCUMVENTION</U>.
The Company hereby covenants and agrees that the Company will not, by amendment of its Certificate of Incorporation (as defined in the Securities Purchase Agreement), Bylaws (as defined in the Securities Purchase Agreement) or through any
reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Note, and
will at all times in good faith carry out all of the provisions of this Note and take all action as may be required to protect the rights of the Holder of this Note. Without limiting the generality of the foregoing or any other provision of this
Note or the other Transaction Documents, the Company (a)&nbsp;shall not increase the par value of any shares of Common Stock receivable upon conversion of this Note above the Conversion Price then in effect, and (b)&nbsp;shall take all such actions
as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the conversion of this Note. Notwithstanding anything herein to the contrary, if after the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sixty (60)&nbsp;calendar day anniversary of the Issuance Date, the Holder is not permitted to convert this Note in full for any reason (other than pursuant to restrictions set forth in
Section&nbsp;3(d) hereof), the Company shall use its best efforts to promptly remedy such failure, including, without limitation, obtaining such consents or approvals as necessary to permit such conversion into shares of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>RESERVATION OF AUTHORIZED SHARES</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Reservation</U>. As of the Closing Date, the Company shall have reserved from its duly authorized capital stock not less
than 60,000,000 shares of Common Stock for issuance upon conversion of the Notes and exercise of the SPA Warrants. From and after January&nbsp;31, 2022, so long as any of the Notes remain outstanding, the Company shall take all action necessary to
at all times have authorized, and reserved for the purpose of issuance, no less than 200% of the sum of (i)&nbsp;the maximum number of shares of Common Stock issuable upon conversion of all the Notes then outstanding (assuming for purposes hereof
that (x)&nbsp;the Notes are convertible at the Alternate Conversion Price then in effect assuming an Alternate Conversion Date as of the applicable date of determination, (y)&nbsp;interest on the Notes shall accrue through the third anniversary of
the Closing Date and will be converted in shares of Common Stock at a conversion price equal to the Alternate Conversion Price assuming an Alternate Conversion Date as of the applicable date of determination and (z)&nbsp;any such conversion shall
not take into account any limitations on the conversion of the Notes set forth in the Notes, and (ii)&nbsp;the maximum number of Warrant Shares issuable upon exercise of all the Warrants then outstanding (without regard to any limitations on the
exercise of the Warrants set forth therein) (collectively, the &#147;<B>Required Reserve Amount</B>&#148;); provided, that at no time shall the number of Shares of Common Stock reserved pursuant to this Section be reduced other than proportionally
in connection with any conversion, exercise and/or redemption, as applicable, of the Notes. The Required Reserve Amount (including, without limitation, each increase in the number of shares so reserved) shall be allocated pro rata among the holders
of the Notes based on the original principal amount of the Notes held by each holder on the Closing Date or increase in the number of reserved shares, as the case may be (the &#147;<B>Authorized Share Allocation</B>&#148;). In the event that a
holder shall sell or otherwise transfer any of such holder&#146;s Notes, each transferee shall be allocated a pro rata portion of such holder&#146;s Authorized Share Allocation. Any shares of Common Stock reserved and allocated to any Person which
ceases to hold any Notes shall be allocated to the remaining holders of Notes, pro rata based on the principal amount of the Notes then held by such holders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Insufficient Authorized Shares</U>. If at any time after January&nbsp;31, 2022, the number of shares of Common Stock
authorized and reserved for issuance is not sufficient to meet the Required Reserve Amount (an &#147;<B>Authorized Share Failure</B>&#148;), the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number
of shares, including, without limitation, calling a special meeting of stockholders to authorize additional shares to meet the Company&#146;s obligations pursuant to the Transaction Documents, in the case of an insufficient number of authorized
shares, obtain stockholder approval of an increase in such authorized number of shares, and voting the management shares of the Company in favor of an increase in the authorized shares of the Company to ensure that the number of authorized shares is
sufficient to meet the Required </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Reserve Amount. On or prior to January&nbsp;31, 2022 (the &#147;<B>Consent Deadline</B>&#148;), holders of a majority of the issued and outstanding shares of Common Stock and the Preferred Stock
shall have voted by written consent (the <B>&#147;Stockholder Resolutions&#148;</B>) approving an amendment to the Certificate of Incorporation to, among other items, approve a reverse stock split and, on an advisory basis, approve the transactions
contemplated by this Agreement (the &#147;<B>Stockholder Approval</B>&#148;, and the date the Stockholder Approval is obtained, the &#147;<B>Stockholder Approval Date</B>&#148;). Thereafter, the Company shall provide each stockholder entitled to
vote at a meeting of stockholders of the Company notice of the Consent Action (the &#147;<B>Consent Notice</B>&#148;). The Stockholder Resolutions and the Consent Notice shall be in a form reasonably acceptable to the Buyers and Kelley
Drye&nbsp;&amp; Warren LLP, at the expense of the Company, with the Company obligated to reimburse the expenses of Kelley Drye&nbsp;&amp; Warren LLP incurred in connection therewith in an amount not exceed $3,000, The Company shall be obligated to
seek to obtain the Stockholder Approval by the Consent Deadline.&nbsp;If, despite the Company&#146;s reasonable best efforts the Stockholder Approval is not obtained on or prior to the Consent Deadline, the Company shall cause either an additional
consent action or a stockholder meeting to be held on or prior to March&nbsp;31, 2021.&nbsp;If, despite the Company&#146;s reasonable best efforts the Stockholder Approval is not obtained after such subsequent consent action or stockholder meeting,
the Company shall cause an additional consent action or stockholder meeting to be held semi-annually thereafter until such Stockholder Approval is obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>REDEMPTIONS</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Mechanics</U>. The Company shall deliver the applicable Event of Default Redemption Price to the Holder in cash within
five (5)&nbsp;Business Days after the Company&#146;s receipt of the Holder&#146;s Event of Default Redemption Notice. If the Holder has submitted a Change of Control Redemption Notice in accordance with Section&nbsp;5(b), the Company shall deliver
the applicable Change of Control Redemption Price to the Holder in cash concurrently with the consummation of such Change of Control if such notice is received prior to the consummation of such Change of Control and within five (5)&nbsp;Business
Days after the Company&#146;s receipt of such notice otherwise. The Company shall deliver the applicable Company Optional Redemption Price to the Holder in cash on the applicable Company Optional Redemption Date. Notwithstanding anything herein to
the contrary, in connection with any redemption hereunder at a time the Holder is entitled to receive a cash payment under any of the other Transaction Documents, at the option of the Holder delivered in writing to the Company, the applicable
Redemption Price hereunder shall be increased by the amount of such cash payment owed to the Holder under such other Transaction Document and, upon payment in full or conversion in accordance herewith, shall satisfy the Company&#146;s payment
obligation under such other Transaction Document. In the event of a redemption of less than all of the Conversion Amount of this Note, the Company shall promptly cause to be issued and delivered to the Holder a new Note (in accordance with
Section&nbsp;20(d)) representing the outstanding Principal which has not been redeemed. In the event that the Company does not pay the applicable Redemption Price to the Holder within the time period required, at any time thereafter and until the
Company pays such unpaid Redemption Price in full, the Holder shall have the option, in lieu of redemption, to require the Company to promptly return to the Holder all or any portion of this Note representing the Conversion Amount that was submitted
for redemption and for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
which the applicable Redemption Price (together with any Late Charges thereon) has not been paid. Upon the Company&#146;s receipt of such notice, (x)&nbsp;the applicable Redemption Notice shall
be null and void with respect to such Conversion Amount, (y)&nbsp;the Company shall immediately return this Note, or issue a new Note (in accordance with Section&nbsp;20(d)), to the Holder, and in each case the&nbsp;principal amount of this Note or
such new Note (as the case may be) shall be increased by an amount equal to the difference between (1)&nbsp;the applicable Redemption Price (as the case may be, and as adjusted pursuant to this Section&nbsp;11, if applicable) minus (2)&nbsp;the
Principal portion of the Conversion Amount submitted for redemption and (z)&nbsp;the Conversion Price of this Note or such new Notes (as the case may be) shall be automatically adjusted with respect to each conversion effected thereafter by the
Holder to the lowest of (A)&nbsp;the Conversion Price as in effect on the date on which the applicable Redemption Notice is voided, (B) 75% of the lowest Closing Bid Price of the Common Stock during the period beginning on and including the date on
which the applicable Redemption Notice is delivered to the Company and ending on and including the date on which the applicable Redemption Notice is voided and (C) 75% of the quotient of (I)&nbsp;the sum of the five (5)&nbsp;lowest VWAPs of the
Common Stock during the twenty (20)&nbsp;consecutive Trading Day period ending and including the applicable Conversion Date divided by (II)&nbsp;five (5) (it being understood and agreed that all such determinations shall be appropriately adjusted
for any stock dividend, stock split, stock combination or other similar transaction during such period). The Holder&#146;s delivery of a notice voiding a Redemption Notice and exercise of its rights following such notice shall not affect the
Company&#146;s obligations to make any payments of Late Charges which have accrued prior to the date of such notice with respect to the Conversion Amount subject to such notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Redemption by Other Holders</U>. Upon the Company&#146;s receipt of notice from any of the holders of the Other Notes
for redemption or repayment as a result of an event or occurrence substantially similar to the events or occurrences described in Section&nbsp;4(b) or Section&nbsp;5(b) (each, an &#147;<B>Other Redemption Notice</B>&#148;), the Company shall
immediately, but no later than one (1)&nbsp;Business Day of its receipt thereof, forward to the Holder by facsimile or electronic mail a copy of such notice. If the Company receives a Redemption Notice and one or more Other Redemption Notices,
during the seven (7)&nbsp;Business Day period beginning on and including the date which is two (2)&nbsp;Business Days prior to the Company&#146;s receipt of the Holder&#146;s applicable Redemption Notice and ending on and including the date which is
two (2)&nbsp;Business Days after the Company&#146;s receipt of the Holder&#146;s applicable Redemption Notice and the Company is unable to redeem all principal, interest and other amounts designated in such Redemption Notice and such Other
Redemption Notices received during such seven (7)&nbsp;Business Day period, then the Company shall redeem a pro rata amount from each holder of the Notes (including the Holder) based on the principal amount of the Notes submitted for redemption
pursuant to such Redemption Notice and such Other Redemption Notices received by the Company during such seven (7)&nbsp;Business Day period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>VOTING RIGHTS</U>. The Holder shall have no voting rights as the holder of this Note, except as required by law (including, without
limitation, the Texas Business Organizations Code) and as expressly provided in this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>NEGATIVE COVENANTS</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Until all of the Notes have been converted, exchanged, redeemed or
otherwise satisfied in accordance with their terms, the Company shall not, and the Company shall not permit any of its Subsidiaries without the prior written consent of the Required Holders to, directly or indirectly: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) incur or guarantee, assume or suffer to exist any Indebtedness, other than Permitted Indebtedness; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) allow or suffer to exist any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any
property or assets (including accounts and contract rights) owned by the Company or any of its Subsidiaries (collectively, &#147;<B>Liens</B>&#148;) other than Permitted Liens; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) redeem, defease, repurchase, repay or make any payments in respect of, by the payment of cash or cash equivalents (in
whole or in part, whether by way of open market purchases, tender offers, private transactions or otherwise), all or any portion of any Indebtedness (other than this Note or the Other Notes) of the Company or any other Person, whether by way of
payment in respect of principal of (or premium, if any) or interest on, such Indebtedness if at the time such payment with respect to such Indebtedness is due or is otherwise made or, after giving effect to such payment, (i)&nbsp;an event
constituting an Event of Default has occurred and is continuing or (ii)&nbsp;an event that with the passage of time and without being cured would constitute an Event of Default has occurred and is continuing; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) make any material change in the nature of its business as described in <U>Schedule 13(a)(iv)</U> attached hereto, or to
modify its corporate structure or purpose; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) encumber or allow any Liens on, any of its own or its licensed copyright
rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, patent applications and like protections, including improvements, divisions,
continuations, renewals, reissues, extensions, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part</FONT></FONT> of the same, trademarks, service marks and, to the extent permitted under applicable law, any
applications therefor, whether registered or not, and the goodwill of the business of the Company and its Subsidiaries connected with and symbolized thereby, <FONT STYLE="white-space:nowrap">know-how,</FONT> operating manuals, trade secret rights,
rights to unpatented inventions, and any claims for damage by way of any past, present, or future infringement of any of the foregoing, other than Permitted Liens; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) redeem or repurchase its Equity Interests other than the repurchase at cost on or prior to the Public Company Date of
restricted stock issued under the Approved Stock Plan; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) declare or pay any cash dividend or distribution on any of
its Equity Interest; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) prior to the Public Company Date, authorize or effect (a)&nbsp;any
Fundamental Transaction pursuant to which the aggregate <FONT STYLE="white-space:nowrap">pre-closing</FONT> valuation of the Company is less than $80,000,000, based on the economic terms in the definitive agreements therefor (not including any <FONT
STYLE="white-space:nowrap">earn-out</FONT> or similar contingent consideration), or (b)&nbsp;a Liquidation Event, or consent to any of the foregoing; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) sell, lease, license, assign, transfer, <FONT STYLE="white-space:nowrap">spin-off,</FONT>
<FONT STYLE="white-space:nowrap">split-off,</FONT> close, convey or otherwise dispose of any assets or rights of the Company or any Subsidiary owned or hereafter acquired whether in a single transaction or a series of related transactions, other
than (i)&nbsp;sales, leases, licenses, assignments, transfers, conveyances and other dispositions of such assets or rights by the Company and its Subsidiaries in the ordinary course of business consistent with its past practice and (ii)&nbsp;sales
of inventory and product in the ordinary course of business </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) enter into, renew, extend or be a party to, any
transaction or series of related transactions (including, without limitation, the purchase, sale, lease, transfer or exchange of property or assets of any kind or the rendering of services of any kind) with any Affiliate, except in the ordinary
course of business in a manner and to an extent consistent with past practice and necessary or desirable for the prudent operation of its business, for fair consideration and on terms no less favorable to it or its Subsidiaries than would be
obtainable in a comparable arm&#146;s length transaction with a Person that is not an Affiliate thereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) prior to the
Public Company Date, amend, repeal, restate, supplement or otherwise modify its or any Subsidiary&#146;s Organizational Documents in a manner adverse to the holders of Notes; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii) engage in any material line of business substantially different from those lines of business conducted by or publicly
contemplated to be conducted by the Company and each of its Subsidiaries on the Subscription Date or any business substantially related or incidental thereto. The Company shall not, and the Company shall cause each of its Subsidiaries to not,
directly or indirectly, modify its or their corporate structure or purpose; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) issue any other securities that would
cause a breach or default under the Notes or the Warrants; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv) issue any debt (other than the Notes and the Other Notes)
that grant the holder thereof the right to vote with holders of Common Stock; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv) issue any preferred equity that
grants the holder thereof voting power to vote with holders of Common Stock on a basis greater than one vote for each share of Common Stock underlying such preferred equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14. <U>AFFIRMATIVE COVENANTS</U>. Until all of the Notes have been converted, exchanged, redeemed or otherwise satisfied in accordance with
their terms, the Company shall, and the Company shall cause each Subsidiary to, directly or indirectly: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) comply with the following corporate governance standards (the
&#147;<B>Corporate Governance Standards</B>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the Company shall at all times have at least two executive
officers; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) all disbursements of cash in amounts greater than $75,000 must be signed by at least two executive officers
of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the board of directors of the Company shall consist of at least three directors, with at least two
independent directors (as determined in accordance with the rules and regulations of the Nasdaq Capital Market); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)
deliver (or otherwise make available on a secured website or publicly available on the SEC&#146;s Electronic Data Gathering, Analysis, and Retrieval system) unaudited balance sheet and income statement to the Holder and each holder of Other Notes
within forty-five (45)&nbsp;days of the end of each calendar quarter, in form and substance satisfactory to the Required Holders; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) maintain and preserve, its existence, rights and privileges, and become or remain, and cause each of its Subsidiaries to
become or remain, duly qualified and in good standing in each jurisdiction in which the character of the properties owned or leased by it or in which the transaction of its business makes such qualification necessary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) take all action necessary or advisable to maintain all of the material Intellectual Property Rights (as defined in the
Securities Purchase Agreement) of the Company and/or any of its Subsidiaries that are necessary or material to the conduct of its business in full force and effect; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) maintain and preserve, and cause each of its Subsidiaries to maintain and preserve, all of its properties which are
necessary or useful in the proper conduct of its business in good working order and condition, ordinary wear and tear excepted, and comply, and cause each of its Subsidiaries to comply, at all times with the provisions of all leases to which it is a
party as lessee or under which it occupies property, so as to prevent any loss or forfeiture thereof or thereunder; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) maintain, and cause each of its Subsidiaries to maintain, insurance with responsible and reputable insurance companies or
associations (including, without limitation, comprehensive general liability, hazard, rent and business interruption insurance) with respect to its properties (including all real properties leased or owned by it) and business, in such amounts and
covering such risks as is required by any governmental authority having jurisdiction with respect thereto or as is carried generally in accordance with sound business practice by companies in similar businesses similarly situated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Additional Covenants.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stay, Extension and Usury Laws</U>. To the extent that it may lawfully do so, the Company (A)&nbsp;agrees that it will
not at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law (wherever or whenever enacted or in force) that may affect the covenants or the performance of this Note; and
(B)&nbsp;expressly waives all benefits or advantages of any such law and agrees that it will not, by resort to any such law, hinder, delay or impede the execution of any power granted to the Holder by this Note, but will suffer and permit the
execution of every such power as though no such law has been enacted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Taxes</U>. The Company and its Subsidiaries
shall pay when due all material taxes, fees or other charges of any nature whatsoever (together with any related interest or penalties) now or hereafter imposed or assessed against the Company and its Subsidiaries or their respective assets or upon
their ownership, possession, use, operation or disposition thereof or upon their rents, receipts or earnings arising therefrom (except where the failure to pay would not, individually or in the aggregate, have a material effect on the Company or any
of its Subsidiaries). The Company and its Subsidiaries shall file on or before the due date therefor all personal property tax returns (except where the failure to file would not, individually or in the aggregate, have a material effect on the
Company or any of its Subsidiaries). Notwithstanding the foregoing, the Company and its Subsidiaries may contest, in good faith and by appropriate proceedings, taxes for which they maintain adequate reserves therefor in accordance with GAAP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Independent Investigation</U>. At the request of the Holder (subject to the last sentence of this
<U>Section</U><U></U><U>&nbsp;15(c)</U>) either (x)&nbsp;at any time when an Event of Default has occurred and is continuing, (y)&nbsp;upon the occurrence of an event that with the passage of time or giving of notice would constitute an Event of
Default or (z)&nbsp;at any time the Holder reasonably believes an Event of Default may have occurred or be continuing, the Company shall hire an independent, reputable investment bank selected by the Company and approved by the Holder to investigate
as to whether any breach of this Note has occurred (the &#147;<B>Independent Investigator</B>&#148;). If the Independent Investigator determines that such breach of this Note has occurred, the Independent Investigator shall notify the Company of
such breach and the Company shall deliver written notice to each holder of a Note of such breach. In connection with such investigation, the Independent Investigator may, during normal business hours, inspect all contracts, books, records,
personnel, offices and other facilities and properties of the Company and its Subsidiaries and, to the extent available to the Company after the Company uses reasonable efforts to obtain them, the records of its legal advisors and accountants
(including the accountants&#146; work papers) and any books of account, records, reports and other papers not contractually required of the Company to be confidential or secret, or subject to attorney-client or other evidentiary privilege, and the
Independent Investigator may make such copies and inspections thereof as the Independent Investigator may reasonably request. The Company shall furnish the Independent Investigator with such financial and operating data and other information with
respect to the business and properties of the Company as the Independent Investigator may reasonably request. The Company shall permit the Independent Investigator to discuss the affairs, finances and accounts of the Company with, and to make
proposals and furnish advice with respect thereto to, the Company&#146;s officers, directors, key employees and independent public accountants or any of them (and by this provision the Company authorizes said accountants to discuss with such
Independent Investigator the finances and affairs of the Company and any Subsidiaries), all at such reasonable times, upon reasonable notice, and as often as may be reasonably requested. Notwithstanding the foregoing, the Holder shall only have
rights under this <U>Section</U><U></U><U>&nbsp;15(c)</U> if the Original Principal Amount of this Note, plus the Original Principal Amount of any Other Notes held by the Holder or its Affiliates, is greater than or equal to $500,000 in the
aggregate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>SECURITY; SUBORDINATION</U>. This Note and the Other Notes are secured to the extent
and in the manner set forth in the Transaction Documents (including, without limitation, the Security Agreement, the other Security Documents), except the Liens created for the benefit of the holders of Notes with respect to the Security Documents
shall be subordinate to the Liens with respect to the Permitted Senior Indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>DISTRIBUTION OF ASSETS</U>. In addition to
any adjustments pursuant to Sections 6 and 7, if the Company shall declare or make any dividend or other distributions of its assets (or rights to acquire its assets) to any or all holders of shares of Common Stock, by way of return of capital or
otherwise (including without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (the
&#147;<B>Distributions</B>&#148;), then the Holder will be entitled to such Distributions as if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Note (without taking into account any limitations or
restrictions on the convertibility of this Note and assuming for such purpose that the Note was converted at the Alternate Conversion Price as of the applicable record date) immediately prior to the date on which a record is taken for such
Distribution or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for such Distributions (provided, however, after the Public Company Date, to the extent that the Holder&#146;s right to
participate in any such Distribution would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to the extent of the Maximum Percentage
(and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and beneficial ownership) to the extent of any such excess) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such Distribution
(and any Distributions declared or made on such initial Distribution or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such limitation). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18. <U>AMENDING THE TERMS OF THIS NOTE</U>. Except for Section&nbsp;3(d), which may not be amended, modified or waived by the parties hereto,
the prior written consent of the Required Holders (as defined in the Securities Purchase Agreement) shall be required for any amendment, modification or waiver to this Note. Any amendment, modification or waiver so approved shall be binding upon all
existing and future holders of this Note and any Other Notes; provided, however, that no such change, waiver or, as applied to any of the Notes held by any particular holder of Notes, shall, without the written consent of that particular holder,
(i)&nbsp;reduce the amount of Principal, reduce the amount of accrued and unpaid Interest, or extend the Maturity Date, of the Notes, (ii)&nbsp;disproportionally and adversely affect any rights under the Notes of any holder of Notes; or
(iii)&nbsp;modify any of the provisions of, or impair the right of any holder of Notes under, this 18. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19. <U>TRANSFER</U>. This Note and
any shares of Common Stock issued upon conversion of this Note may be offered, sold, assigned or transferred by the Holder without the consent of the Company, subject only to the provisions of Section&nbsp;2(g) of the Securities Purchase Agreement.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20. <U>REISSUANCE OF THIS NOTE</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Transfer</U>. If this Note is to be transferred, the Holder shall surrender this Note to the Company, whereupon the
Company will forthwith issue and deliver upon the order of the Holder a new Note (in accordance with Section&nbsp;20(d)), registered as the Holder may request, representing the outstanding Principal being transferred by the Holder and, if less than
the entire outstanding Principal is being transferred, a new Note (in accordance with Section&nbsp;20(d)) to the Holder representing the outstanding Principal not being transferred. The Holder and any assignee, by acceptance of this Note,
acknowledge and agree that, by reason of the provisions of Section&nbsp;3(c)(iii) following conversion or redemption of any portion of this Note, the outstanding Principal represented by this Note may be less than the Principal stated on the face of
this Note. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Lost, Stolen or Mutilated Note</U>. Upon receipt by the Company of evidence reasonably satisfactory to
the Company of the loss, theft, destruction or mutilation of this Note (as to which a written certification and the indemnification contemplated below shall suffice as such evidence), and, in the case of loss, theft or destruction, of any
indemnification undertaking by the Holder to the Company in customary and reasonable form and, in the case of mutilation, upon surrender and cancellation of this Note, the Company shall execute and deliver to the Holder a new Note (in accordance
with Section&nbsp;20(d)) representing the outstanding Principal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Note Exchangeable for Different Denominations</U>.
This Note is exchangeable, upon the surrender hereof by the Holder at the principal office of the Company, for a new Note or Notes (in accordance with Section&nbsp;20(d) and in principal amounts of at least $1,000) representing in the aggregate the
outstanding Principal of this Note, and each such new Note will represent such portion of such outstanding Principal as is designated by the Holder at the time of such surrender. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Issuance of New Notes</U>. Whenever the Company is required to issue a new Note pursuant to the terms of this Note, such
new Note (i)&nbsp;shall be of like tenor with this Note, (ii)&nbsp;shall represent, as indicated on the face of such new Note, the Principal remaining outstanding (or in the case of a new Note being issued pursuant to Section&nbsp;20(a) or
Section&nbsp;20(c), the Principal designated by the Holder which, when added to the principal represented by the other new Notes issued in connection with such issuance, does not exceed the Principal remaining outstanding under this Note immediately
prior to such issuance of new Notes), (iii) shall have an issuance date, as indicated on the face of such new Note, which is the same as the Issuance Date of this Note, (iv)&nbsp;shall have the same rights and conditions as this Note, and
(v)&nbsp;shall represent accrued and unpaid Interest and Late Charges on the Principal and Interest of this Note, from the Issuance Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21. <U>REMEDIES, CHARACTERIZATIONS, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF</U>.
The remedies provided in this Note shall be cumulative and in addition to all other remedies available under this Note and any of the other Transaction Documents at law or in equity (including a decree of specific performance and/or other injunctive
relief), and nothing herein shall limit the Holder&#146;s right to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Note. No failure on the part of the Holder to exercise, and no delay in
exercising, any right, power or remedy hereunder shall operate as a waiver thereof; nor shall any single or partial exercise by the Holder of any right, power or remedy preclude any other or further exercise thereof or the exercise of any other
right, power or remedy. In addition, the exercise of any right or remedy of the Holder at law or equity or under this Note or any of the documents shall not be deemed to be an election of Holder&#146;s rights or remedies under such documents or at
law or equity. The Company covenants to the Holder that there shall be no characterization concerning this instrument other than as expressly provided herein. Amounts set forth or provided for herein with respect to payments, conversion and the like
(and the computation thereof) shall be the amounts to be received by the Holder and shall not, except as expressly provided herein, be subject to any other obligation of the Company (or the performance thereof). The Company acknowledges that a
breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the Holder
shall be entitled, in addition to all other available remedies, to specific performance and/or temporary, preliminary and permanent injunctive or other equitable relief from any court of competent jurisdiction in any such case without the necessity
of proving actual damages and without posting a bond or other security. The Company shall provide all information and documentation to the Holder that is requested by the Holder to enable the Holder to confirm the Company&#146;s compliance with the
terms and conditions of this Note (including, without limitation, compliance with Section&nbsp;7). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22. <U>PAYMENT OF COLLECTION,
ENFORCEMENT AND OTHER COSTS</U>. If (a)&nbsp;this Note is placed in the hands of an attorney for collection or enforcement or is collected or enforced through any legal proceeding or the Holder otherwise takes action to collect amounts due under
this Note or to enforce the provisions of this Note or (b)&nbsp;there occurs any bankruptcy, reorganization, receivership of the Company or other proceedings affecting Company creditors&#146; rights and involving a claim under this Note, then the
Company shall pay the costs incurred by the Holder for such collection, enforcement or action or in connection with such bankruptcy, reorganization, receivership or other proceeding, including, without limitation, attorneys&#146; fees and
disbursements. The Company expressly acknowledges and agrees that no amounts due under this Note shall be affected, or limited, by the fact that the purchase price paid for this Note was less than the original Principal amount hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">23. <U>CONSTRUCTION; HEADINGS</U>. This Note shall be deemed to be jointly drafted by the Company and the initial Holder and shall not be
construed against any such Person as the drafter hereof. The headings of this Note are for convenience of reference and shall not form part of, or affect the interpretation of, this Note. Unless the context clearly indicates otherwise, each pronoun
herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms thereof. The terms &#147;including,&#148; &#147;includes,&#148; &#147;include&#148; and words of like import shall be construed broadly as if followed by
the words &#147;without limitation.&#148; The terms &#147;herein,&#148; &#147;hereunder,&#148; &#147;hereof&#148; and words of like import refer to this entire Note instead of just the provision in which they are found. Unless expressly indicated
otherwise, all section references are to sections of this Note. Terms used in this Note and not otherwise defined herein, but defined in the other Transaction Documents, shall have the meanings ascribed to such terms on the Closing Date in such
other Transaction Documents unless otherwise consented to in writing by the Holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">24. <U>FAILURE OR INDULGENCE NOT WAIVER</U>. No failure or delay on the part of the Holder
in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or
privilege. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party. Notwithstanding the foregoing, nothing contained in this Section&nbsp;24 shall permit any waiver of any provision of
Section&nbsp;3(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">25. <U>DISPUTE RESOLUTION</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Submission to Dispute Resolution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the case of a dispute relating to a Closing Bid Price, a Closing Sale Price, a Conversion Price, an Alternate
Conversion Price, a Black Scholes Consideration Value, a VWAP or a fair market value or the arithmetic calculation of a Conversion Rate, or the applicable Redemption Price (as the case may be) (including, without limitation, a dispute relating to
the determination of any of the foregoing), the Company or the Holder (as the case may be) shall submit the dispute to the other party via facsimile or electronic mail (A)&nbsp;if by the Company, within two (2)&nbsp;Business Days after the
occurrence of the circumstances giving rise to such dispute or (B)&nbsp;if by the Holder at any time after the Holder learned of the circumstances giving rise to such dispute. If the Holder and the Company are unable to promptly resolve such dispute
relating to such Closing Bid Price, such Closing Sale Price, such Conversion Price, such Alternate Conversion Price, such Black Scholes Consideration Value, such VWAP or such fair market value, or the arithmetic calculation of such Conversion Rate
or such applicable Redemption Price (as the case may be), at any time after the second (2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>) Business Day following such initial notice by the Company or the Holder (as the case may be) of such
dispute to the Company or the Holder (as the case may be), then the Holder may, at its sole option, select an independent, reputable investment bank to resolve such dispute. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Holder and the Company shall each deliver to such investment bank (A)&nbsp;a copy of the initial dispute submission
so delivered in accordance with the first sentence of this Section&nbsp;25 and (B)&nbsp;written documentation supporting its position with respect to such dispute, in each case, no later than 5:00 p.m. (New York time) by the fifth (5<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>) Business Day immediately following the date on which the Holder selected such investment bank (the &#147;<B>Dispute Submission Deadline</B>&#148;) (the documents referred to in the immediately
preceding clauses (A)&nbsp;and (B) are collectively referred to herein as the &#147;<B>Required Dispute Documentation</B>&#148;) (it being understood and agreed that if either the Holder or the Company fails to so deliver all of the Required Dispute
Documentation by the Dispute Submission Deadline, then the party who fails to so submit all of the Required Dispute Documentation shall no longer be entitled to (and hereby waives its right to) deliver or submit any written documentation or other
support to such investment bank with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
respect to such dispute and such investment bank shall resolve such dispute based solely on the Required Dispute Documentation that was delivered to such investment bank prior to the Dispute
Submission Deadline). Unless otherwise agreed to in writing by both the Company and the Holder or otherwise requested by such investment bank, neither the Company nor the Holder shall be entitled to deliver or submit any written documentation or
other support to such investment bank in connection with such dispute (other than the Required Dispute Documentation). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The Company and the Holder shall cause such investment bank to determine the resolution of such dispute and notify the
Company and the Holder of such resolution no later than ten (10)&nbsp;Business Days immediately following the Dispute Submission Deadline. The fees and expenses of such investment bank shall be borne solely by the Company, and such investment
bank&#146;s resolution of such dispute shall be final and binding upon all parties absent manifest error. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Miscellaneous</U>. The Company expressly acknowledges and agrees that (i)&nbsp;this Section&nbsp;25 constitutes an agreement to arbitrate between the Company and the Holder (and constitutes an arbitration agreement) under the Illinois Uniform
Arbitration Act, as amended, (ii)&nbsp;a dispute relating to a Conversion Price includes, without limitation, disputes as to (A)&nbsp;whether an issuance or sale or deemed issuance or sale of Common Stock occurred under Section&nbsp;7(a), (B) the
consideration per share at which an issuance or deemed issuance of Common Stock occurred, (C)&nbsp;whether any issuance or sale or deemed issuance or sale of Common Stock was an issuance or sale or deemed issuance or sale of Excluded Securities,
(D)&nbsp;whether an agreement, instrument, security or the like constitutes and Option or Convertible Security and (E)&nbsp;whether a Dilutive Issuance occurred, (iii)&nbsp;the terms of this Note and each other applicable Transaction Document shall
serve as the basis for the selected investment bank&#146;s resolution of the applicable dispute, such investment bank shall be entitled (and is hereby expressly authorized) to make all findings, determinations and the like that such investment bank
determines are required to be made by such investment bank in connection with its resolution of such dispute and in resolving such dispute such investment bank shall apply such findings, determinations and the like to the terms of this Note and any
other applicable Transaction Documents, (iv)&nbsp;the Holder (and only the Holder), in its sole discretion, shall have the right to submit any dispute described in this Section&nbsp;25 to any state or federal court sitting in The City of Chicago,
County of Cook in lieu of utilizing the procedures set forth in this Section&nbsp;25 and (v)&nbsp;nothing in this Section&nbsp;25 shall limit the Holder from obtaining any injunctive relief or other equitable remedies (including, without limitation,
with respect to any matters described in this Section&nbsp;25). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">26. <U>NOTICES; CURRENCY; PAYMENTS</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Notices</U>. Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice
shall be given in accordance with Section&nbsp;9(f) of the Securities Purchase Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Note, including in reasonable detail a description of
such action and the reason therefore. Without limiting the generality of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
foregoing, the Company will give written notice to the Holder (i)&nbsp;immediately upon any adjustment of the Conversion Price, setting forth in reasonable detail, and certifying, the calculation
of such adjustment and (ii)&nbsp;at least fifteen (15)&nbsp;days prior to the date on which the Company closes its books or takes a record (A)&nbsp;with respect to any dividend or distribution upon the Common Stock, (B)&nbsp;with respect to any
grant, issuances, or sales of any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property to holders of shares of Common Stock or (C)&nbsp;for determining rights to vote with respect to any Fundamental
Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Currency</U>. All dollar amounts referred to in this Note are in United States Dollars (&#147;<B>U.S.
Dollars</B>&#148;), and all amounts owing under this Note shall be paid in U.S. Dollars. All amounts denominated in other currencies (if any) shall be converted into the U.S.&nbsp;Dollar equivalent amount in accordance with the Exchange Rate on the
date of calculation. &#147;<B>Exchange Rate</B>&#148;<B> </B>means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Note, the U.S.&nbsp;Dollar exchange rate as published in the Wall Street Journal on the
relevant date of calculation (it being understood and agreed that where an amount is calculated with reference to, or over, a period of time, the date of calculation shall be the final date of such period of time). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Payments</U>. Whenever any payment of cash is to be made by the Company to any Person pursuant to this Note, unless
otherwise expressly set forth herein, such payment shall be made in lawful money of the United States of America by a certified check drawn on the account of the Company and sent via overnight courier service to such Person at such address as
previously provided to the Company in writing (which address, in the case of each of the Buyers, shall initially be as set forth on the Schedule of Buyers attached to the Securities Purchase Agreement), provided that the Holder may elect to receive
a payment of cash via wire transfer of immediately available funds by providing the Company with prior written notice setting out such request and the Holder&#146;s wire transfer instructions. Whenever any amount expressed to be due by the terms of
this Note is due on any day which is not a Business Day, the same shall instead be due on the next succeeding day which is a Business Day. Any amount of Principal or other amounts due under the Transaction Documents which is not paid when due shall
result in a late charge being incurred and payable by the Company in an amount equal to interest on such amount at the rate of eighteen percent (18%) per annum from the date such amount was due until the same is paid in full (&#147;<B>Late
Charge</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">27. <U>CANCELLATION</U>. After all Principal, accrued Interest, Late Charges and other amounts at any time owed on
this Note have been paid in full, this Note shall automatically be deemed canceled, shall be surrendered to the Company for cancellation and shall not be reissued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">28. <U>WAIVER OF NOTICE</U>. To the extent permitted by law, the Company hereby irrevocably waives demand, notice, presentment, protest and
all other demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this Note and the Securities Purchase Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">29. <U>GOVERNING LAW</U>. This Note shall be construed and enforced in accordance with, and
all questions concerning the construction, validity, interpretation and performance of this Note shall be governed by, the internal laws of the State of Illinois, without giving effect to any choice of law or conflict of law provision or rule
(whether of the State of Illinois or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Illinois. Except as otherwise required by Section&nbsp;25 above, the Company hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in The City of Chicago, County of Cook, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient
forum or that the venue of such suit, action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed to limit in any
way any right to serve process in any manner permitted by law. Nothing contained herein (i)&nbsp;shall be deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction to
collect on the Company&#146;s obligations to the Holder, to realize on any collateral or any other security for such obligations, or to enforce a judgment or other court ruling in favor of the Holder or (ii)&nbsp;shall limit, or shall be deemed or
construed to limit, any provision of Section&nbsp;25. <B>THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF
THIS NOTE OR ANY TRANSACTION CONTEMPLATED HEREBY.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">30. <U>JUDGMENT CURRENCY</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If for the purpose of obtaining or enforcing judgment against the Company in any court in any jurisdiction it becomes
necessary to convert into any other currency (such other currency being hereinafter in this Section&nbsp;30 referred to as the &#147;<B>Judgment Currency</B>&#148;) an amount due in U.S. dollars under this Note, the conversion shall be made at the
Exchange Rate prevailing on the Trading Day immediately preceding: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the date actual payment of the amount due, in the
case of any proceeding in the courts of Illinois or in the courts of any other jurisdiction that will give effect to such conversion being made on such date: or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the date on which the foreign court determines, in the case of any proceeding in the courts of any other jurisdiction (the
date as of which such conversion is made pursuant to this Section&nbsp;30(a)(ii) being hereinafter referred to as the &#147;<B>Judgment Conversion Date</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If in the case of any proceeding in the court of any jurisdiction referred to in Section&nbsp;30(a)(ii) above, there is a
change in the Exchange Rate prevailing between the Judgment Conversion Date and the date of actual payment of the amount due, the applicable party shall pay such adjusted amount as may be necessary to ensure that the amount paid in the Judgment
Currency, when converted at the Exchange Rate prevailing on the date of payment, will produce the amount of US dollars which could have been purchased with the amount of Judgment Currency stipulated in the judgment or judicial order at the Exchange
Rate prevailing on the Judgment Conversion Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Any amount due from the Company under this provision shall be due as a
separate debt and shall not be affected by judgment being obtained for any other amounts due under or in respect of this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">31.
<U>SEVERABILITY</U>. If any provision of this Note is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be
deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Note so long as this Note as so
modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair
the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited,
invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">32. <U>MAXIMUM PAYMENTS</U>. Without limiting Section&nbsp;9(d) of the Securities Purchase Agreement, nothing contained herein shall be deemed
to establish or require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges hereunder exceed the maximum permitted by
such law, any payments in excess of such maximum shall be credited against amounts owed by the Company to the Holder and thus refunded to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">33. <U>CERTAIN DEFINITIONS</U>. For purposes of this Note, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>$1.5M Note Series</B>&#148; means the series of Secured Convertible Promissory Notes issued by the Company on or
about the date of January&nbsp;31, 2021, as amended Amendment No.&nbsp;1 to the Secured Convertible Promissory Note, dated November&nbsp;2, 2021, which extends the maturity date of such secured convertible promissory notes to October&nbsp;31, 2022.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>1933 Act</B>&#148; means the Securities Act of 1933, as amended, and the rules and regulations thereunder.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>1934 Act</B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations
thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Adjustment Right</B>&#148; means any right granted with respect to any securities issued in
connection with, or with respect to, any issuance or sale (or deemed issuance or sale in accordance with Section&nbsp;7) of shares of Common Stock (other than rights of the type described in Section&nbsp;6(a) hereof) that could result in a decrease
in the net consideration received by the Company in connection with, or with respect to, such securities (including, without limitation, any cash settlement rights, cash adjustment or other similar rights). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Affiliate</B>&#148; means, with respect to any Person, any
other Person that directly or indirectly controls, is controlled by, or is under common control with, such Person, it being understood for purposes of this definition that &#147;control&#148; of a Person means the power directly or indirectly either
to vote 10% or more of the stock having ordinary voting power for the election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Alternate Conversion Price</B>&#148; means, with respect to any Alternate Conversion that price which shall be the
lower of (i)&nbsp;the applicable Conversion Price as in effect on the applicable Conversion Date of the applicable Alternate Conversion and (ii)&nbsp;solely if after the Public Company Date, the lowest of (x) 80% of the VWAP of the Common Stock as
of the Trading Day immediately preceding the delivery or deemed delivery of the applicable Conversion Notice, (y) 80% of the VWAP of the Common Stock as of the Trading Day of the delivery or deemed delivery of the applicable Conversion Notice and
(z) 80% of the price computed as the quotient of (I)&nbsp;the sum of the VWAP of the Common Stock for each of the three (3)&nbsp;Trading Days with the lowest VWAP of the Common Stock during the fifteen (15)&nbsp;consecutive Trading Day period ending
and including the Trading Day immediately preceding the delivery or deemed delivery of the applicable Conversion Notice, divided by (II)&nbsp;three (3) (such period, the &#147;<B>Alternate Conversion Measuring Period</B>&#148;). All such
determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock during such Alternate Conversion Measuring
Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Approved Stock Plan</B>&#148; means any employee benefit plan which has been approved by the board of
directors of the Company prior to or subsequent to the Subscription Date pursuant to which shares of Common Stock and standard options to purchase Common Stock may be issued to any employee, officer or director for services provided to the Company
in their capacity as such. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Attribution Parties</B>&#148; means, collectively, the following Persons and
entities: (i)&nbsp;any investment vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the Issuance Date, directly or indirectly managed or advised by the Holder&#146;s investment manager or any of
its Affiliates or principals, (ii)&nbsp;any direct or indirect Affiliates of the Holder or any of the foregoing, (iii)&nbsp;any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and
(iv)&nbsp;any other Persons whose beneficial ownership of the Company&#146;s Common Stock would or could be aggregated with the Holder&#146;s and the other Attribution Parties for purposes of Section&nbsp;13(d) of the 1934 Act. For clarity, the
purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Black Scholes Consideration Value</B>&#148; means the value of the applicable Option, Convertible Security or
Adjustment Right (as the case may be) as of the date of issuance thereof calculated using the Black Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg utilizing (i)&nbsp;an underlying price per share equal to the
Closing Sale Price of the Common Stock on the Trading Day immediately preceding the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
public announcement of the execution of definitive documents with respect to the issuance of such Option, Convertible Security or Adjustment Right (as the case may be), (ii) a risk-free interest
rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of such Option, Convertible Security or Adjustment Right (as the case may be) as of the date of issuance of such Option, Convertible Security or Adjustment Right
(as the case may be), (iii) a zero cost of borrow and (iv)&nbsp;an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the &#147;HVT&#148; function on Bloomberg (determined utilizing a 365 day annualization
factor) as of&nbsp;the Trading Day immediately following the date of issuance of such Option, Convertible Security or Adjustment Right (as the case may be). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) &#147;<B>Bloomberg</B>&#148; means Bloomberg, L.P. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) &#147;<B>Business Day</B>&#148; means any day other than Saturday, Sunday or other day on which commercial banks in The
City of New York are authorized or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#147;stay at home&#148;, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;shelter-in-place&#148;,</FONT></FONT> <FONT STYLE="white-space:nowrap">&#147;non-essential</FONT> employee&#148;&nbsp;or any other similar orders or restrictions or the closure of any
physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B>Change of Control</B>&#148; means any Fundamental Transaction other than (i)&nbsp;any merger of the Company
or any of its, direct or indirect, wholly-owned Subsidiaries with or into any of the foregoing Persons, (ii)&nbsp;any reorganization, recapitalization or reclassification of the shares of Common Stock in which holders of the Company&#146;s voting
power immediately prior to such reorganization, recapitalization or reclassification continue after such reorganization, recapitalization or reclassification to hold publicly traded securities and, directly or indirectly, are, in all material
respects, the holders of the voting power of the surviving entity (or entities with the authority or voting power&nbsp;to elect the members of the board of directors (or their equivalent if other than a corporation) of such entity or entities) after
such reorganization, recapitalization or reclassification, or (iii)&nbsp;pursuant to a migratory merger effected solely for the purpose of changing the jurisdiction of incorporation of the Company or any of its Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) &#147;<B>Change of Control Redemption Premium</B>&#148; means 125%. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) &#147;<B>Closing Bid Price</B>&#148; and &#147;<B>Closing Sale Price</B>&#148; means, for any security as of any date, the
last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid
price or the closing trade price (as the case may be) then the last bid price or last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the principal
securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed or traded as reported by
Bloomberg, or if the foregoing do not apply, the last closing bid </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
price or last trade price, respectively, of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin
board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for
such security as reported in The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices). If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on
any of the foregoing bases, the Closing Bid Price or the Closing Sale Price (as the case may be) of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are
unable to agree upon the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;25. All such determinations shall be appropriately adjusted for any stock splits, stock dividends,
stock combinations, recapitalizations or other similar transactions during such period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) &#147;<B>Closing
Date</B>&#148; shall have the meaning set forth in the Securities Purchase Agreement, which date is the date the Company initially issued Notes pursuant to the terms of the Securities Purchase Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) &#147;<B>Common Stock</B>&#148; means (i)&nbsp;the Company&#146;s shares of common stock, $0.001 par value per share, and
(ii)&nbsp;any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) &#147;<B>Convertible Securities</B>&#148; means any stock or other security (other than Options) that is at any time and
under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any shares of Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) &#147;<B>Current Subsidiary</B>&#148; means any Person in which the Company on the Subscription Date, directly or
indirectly, (i)&nbsp;owns any of the outstanding capital stock or holds any equity or similar interest of such Person or (ii)&nbsp;controls or operates all or any part of the business, operations or administration of such Person, and all of the
foregoing, collectively, &#147;<B>Current</B> <B>Subsidiaries</B>&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) &#147;<B>Eligible Market</B>&#148; means The
New York Stock Exchange, the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Select Market, or the Nasdaq Global Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) &#147;<B>Equity Conditions</B>&#148; means, with respect to an given date of determination, (i)&nbsp;any shares of Common
Stock to be issued in connection with the event requiring determination (or issuable upon conversion of the Conversion Amount being redeemed in the event requiring this determination) may be issued in full without violating Section&nbsp;3(d) hereof
(after giving effect to any reduction in shares of Common Stock with respect to any Rights to be delivered to the Holder, if applicable, in accordance with Section&nbsp;3(f)); (ii) on each day during the period beginning thirty calendar days prior
to the applicable date of determination and ending on and including the applicable date of determination (the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
&#147;<B>Equity Conditions Measuring Period</B>&#148;), no public announcement of a pending, proposed or intended Fundamental Transaction shall have occurred which has not been abandoned,
terminated or consummated; (iii)&nbsp;the Holder shall not be in (and no other holder of Notes shall be in) possession of any material, <FONT STYLE="white-space:nowrap">non-public</FONT> information provided to any of them by the Company, any of its
Subsidiaries or any of their respective affiliates, employees, officers, representatives, agents or the like; (iv)&nbsp;on the applicable date of determination (A)&nbsp;no Authorized Share Failure shall exist or be continuing and all shares of
Common Stock to be issued in connection with the event requiring this determination (or issuable upon conversion of the Conversion Amount being redeemed, as applicable, in the event requiring this determination at the Alternate Conversion Price then
in effect (without regard to any limitations on conversion set forth herein)) (each, a &#147;<B>Required Minimum Securities Amount</B>&#148;) are available under the certificate of incorporation of the Company and reserved by the Company to be
issued pursuant to the Notes and (B)&nbsp;all shares of Common Stock to be issued in connection with the event requiring this determination (or issuable upon conversion of the Conversion Amount being redeemed in the event requiring this
determination (without regards to any limitations on conversion set forth herein)) may be issued in full without resulting in an Authorized Share Failure; (v)&nbsp;on each day during the Equity Conditions Measuring Period, there shall not have
occurred and there shall not exist an Event of Default or an event that with the passage of time or giving of notice would constitute an Event of Default under Section&nbsp;4(a)(i)-(xiii); provided, that any Event of Default or event that with the
passage of time or giving of notice would constitute an Event of Default under Section&nbsp;4(a)(vii), (xii) and/or (xiii), respectively, that is outstanding during the Equity Conditions Measuring Period, solely in connection with a determination as
to whether the Equity Conditions have been satisfied with respect to an Automatic Conversion, shall not be deemed to be outstanding during such Equity Conditions Measuring Period if such Event of Default is fully cured prior to the applicable
Automatic Conversion Date from the proceeds of a Subsequent Placement (as defined in the Securities Purchase Agreement) in connection with the uplisting of the Common Stock to an Eligible Market; and (vi)&nbsp;on each day during Equity Measurement
Period, the Company shall have been incompliance with the covenant set forth in Section&nbsp;4(f) of the Securities Purchase Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) &#147;<B>Equity Conditions Failure</B>&#148; means that (i)&nbsp;on any day during the period commencing twenty
(20)&nbsp;Trading Days prior to the applicable Company Optional Redemption Notice Date through the applicable Company Optional Redemption Date or (ii)&nbsp;on any day during the period commencing twenty (20)&nbsp;Trading Days prior to the applicable
Automatic Conversion Notice Date through the applicable Automatic Conversion Date, the Equity Conditions have not been satisfied (or waived in writing by the Holder). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) &#147;<B>Equity Interests</B>&#148; means (i)&nbsp;all shares of capital stock (whether denominated as common capital stock
or preferred capital stock), equity interests, beneficial, partnership or membership interests, joint venture interests, participations or other ownership or profit interests in or equivalents (regardless of how designated) of or in a Person (other
than an individual), whether voting or <FONT STYLE="white-space:nowrap">non-voting</FONT> and (ii)&nbsp;all securities convertible into or exchangeable for any of the foregoing and all warrants, Options or other rights to purchase, subscribe for or
otherwise acquire any of the foregoing, whether or not presently convertible, exchangeable or exercisable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) &#147;<B>Excluded Securities</B>&#148; means (i)&nbsp;shares of Common
Stock or standard options to purchase Common Stock issued to directors, officers or employees of the Company for services rendered to the Company in their capacity as such pursuant to an Approved Stock Plan (as defined above), provided that
(A)&nbsp;all such issuances (taking into account the shares of Common Stock issuable upon exercise of such options) after the Subscription Date pursuant to this clause (i)&nbsp;do not, in the aggregate, exceed more than 5% of the Common Stock issued
and outstanding immediately prior to the Subscription Date and (B)&nbsp;the exercise price of any such options is not lowered, none of such options are amended to increase the number of shares issuable thereunder and none of the terms or conditions
of any such options are otherwise materially changed in any manner that adversely affects any of the Buyers; (ii)&nbsp;shares of Common Stock issued upon the conversion or exercise of Convertible Securities or Options (other than standard options to
purchase Common Stock issued pursuant to an Approved Stock Plan that are covered by clause (i)&nbsp;above) issued prior to the Subscription Date, provided that the conversion price of any such Convertible Securities (other than standard options to
purchase Common Stock issued pursuant to an Approved Stock Plan that are covered by clause (i)&nbsp;above) is not lowered, none of such Convertible Securities or Options (other than standard options to purchase Common Stock issued pursuant to an
Approved Stock Plan that are covered by clause (i)&nbsp;above) are amended to increase the number of shares issuable thereunder and none of the terms or conditions of any such Convertible Securities or Options (other than standard options to
purchase Common Stock issued pursuant to an Approved Stock Plan that are covered by clause (i)&nbsp;above) are otherwise materially changed in any manner that adversely affects any of the Buyers; (iii)&nbsp;the shares of Common Stock issuable upon
conversion of the Notes or otherwise pursuant to the terms of the Notes; provided, that the terms of the Notes are not amended, modified or changed on or after the Subscription Date (other than antidilution adjustments pursuant to the terms thereof
in effect as of the Subscription Date), and (iv)&nbsp;the shares of Common Stock issuable upon exercise of the Warrants; provided, that the terms of the Warrants are not amended, modified or changed on or after the Subscription Date (other than
antidilution adjustments pursuant to the terms thereof in effect as of the Subscription Date). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) &#147;<B>FRV and JQA
Loan</B>&#148; means the Loan and Security Agreement, dated April&nbsp;24, 2020, by and between the Company, Front Range Ventures LLC (or its assigns), and John Q. Adams, together with all ancillary documents thereto, including, but not limited to,
the Secured Promissory Notes, dated April&nbsp;24, 2020 issued for the benefit of Front Range Ventures LLC and the Secured Promissory Note, dated April&nbsp;24, 2020 issued for the benefit of John Q. Adams, and as amended by Amendment No.&nbsp;1 to
the Loan Security Agreement, dated September&nbsp;30, 2021 and Amendment No.&nbsp;2 to the Loan and Security Agreement, dated November&nbsp;3, 2021. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) &#147;<B>Fundamental Transaction</B>&#148; means (A)&nbsp;that the Company shall, directly or indirectly, including through
subsidiaries, Affiliates or otherwise, in one or more related transactions, (i)&nbsp;consolidate or merge with or into (whether or not the Company is the surviving corporation) another Subject Entity, or (ii)&nbsp;sell, assign, transfer, convey or
otherwise dispose of all or substantially all of the properties or assets of the Company or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
any of its &#147;significant subsidiaries&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X)</FONT> to one or more Subject
Entities, or (iii)&nbsp;make, or allow one or more Subject Entities to make, or allow the Company to be subject to or have its Common Stock be subject to or party to one or more Subject Entities making, a purchase, tender or exchange offer that is
accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding shares of Common Stock calculated as if any shares of Common Stock held by all Subject Entities making or party to, or
Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding; or (z)&nbsp;such number of shares of Common Stock such that all Subject Entities making or party to, or Affiliated with any
Subject Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the 1934 Act) of at least 50% of the outstanding shares of
Common Stock, or (iv)&nbsp;consummate a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement)
with one or more Subject Entities whereby all such Subject Entities, individually or in the aggregate, acquire, either (x)&nbsp;at least 50% of the outstanding shares of Common Stock, (y)&nbsp;at least 50% of the outstanding shares of Common Stock
calculated as if any shares of Common Stock held by all the Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such stock purchase agreement or other business combination were not outstanding; or
(z)&nbsp;such number of shares of Common Stock such that the Subject Entities become collectively the beneficial owners (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the 1934 Act) of at least 50% of the outstanding shares
of Common Stock, or (v)&nbsp;reorganize, recapitalize or reclassify its Common Stock, (B)&nbsp;that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any
Subject Entity individually or the Subject Entities in the aggregate to be or become the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the 1934 Act), directly or indirectly, whether through
acquisition, purchase, assignment, conveyance, tender, tender offer, exchange, reduction in outstanding shares of Common Stock, merger, consolidation, business combination, reorganization, recapitalization,
<FONT STYLE="white-space:nowrap">spin-off,</FONT> scheme of arrangement, reorganization, recapitalization or reclassification or otherwise in any manner whatsoever, of either (x)&nbsp;at least 50% of the aggregate ordinary voting power represented
by issued and outstanding Common Stock, (y)&nbsp;at least 50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock not held by all such Subject Entities as of the date of this Note calculated as if any shares of
Common Stock held by all such Subject Entities were not outstanding, or (z)&nbsp;a percentage of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock or other equity securities of the Company sufficient to
allow such Subject Entities to effect a statutory short form merger or other transaction requiring other stockholders of the Company to surrender their shares of Common Stock without approval of the stockholders of the Company or (C)&nbsp;directly
or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, the issuance of or the entering into any other instrument or transaction structured in a manner to circumvent, or that circumvents, the
intent of this definition in which case this definition shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this definition or any portion of this
definition which may be defective or inconsistent with the intended treatment of such instrument or transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) &#147;<B>GAAP</B>&#148; means United States generally accepted
accounting principles, consistently applied. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) &#147;<B>Group</B>&#148; means a &#147;group&#148; as that term is used
in Section&nbsp;13(d) of the 1934 Act and as defined in Rule <FONT STYLE="white-space:nowrap">13d-5</FONT> thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) &#147;<B>Indebtedness</B>&#148; shall have the meaning ascribed to such term in the Securities Purchase Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) &#147;<B>Interest</B> <B>Rate</B>&#148; means eight percent (8%) per annum, as may be adjusted from time to time in
accordance with Section&nbsp;2. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) &#147;<B>Liquidation Event</B>&#148; means the voluntary or involuntary liquidation,
dissolution or winding up of the Company or such Subsidiaries the assets of which constitute all or substantially all of the assets of the business of the Company and its Subsidiaries taken as a whole, in a single transaction or series of
transactions, or adoption of any plan for the same. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) &#147;<B>Maturity</B> <B>Date</B>&#148; shall mean
December&nbsp;21, 2024; provided, however, the Maturity Date may be extended at the option of the Holder (i)&nbsp;in the event that, and for so long as, an Event of Default shall have occurred and be continuing or any event shall have occurred and
be continuing that with the passage of time and the failure to cure would result in an Event of Default or (ii)&nbsp;through the date that is twenty (20)&nbsp;Business Days after the consummation of a Fundamental Transaction in the event that a
Fundamental Transaction is publicly announced or a Change of Control Notice is delivered prior to the Maturity Date, provided further that if a Holder elects to convert some or all of this Note pursuant to Section&nbsp;3 hereof, and the Conversion
Amount would be limited pursuant to Section&nbsp;3(d) hereunder, the Maturity Date shall automatically be extended until such time as such provision shall not limit the conversion of this Note. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) &#147;<B>New Subsidiary</B>&#148; means, as of any date of determination, any Person in which the Company after the
Subscription Date, directly or indirectly, (i)&nbsp;owns or acquires any of the outstanding capital stock or holds any equity or similar interest of such Person or (ii)&nbsp;controls or operates all or any part of the business, operations or
administration of such Person, and all of the foregoing, collectively, &#147;<B>New Subsidiaries</B>&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg)
&#147;<B>Options</B>&#148; means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) &#147;<B>Organizational Documents</B>&#148; means, (a)&nbsp;with respect to any corporation, the certificate or articles
of incorporation and the bylaws (or equivalent or comparable constitutive documents with respect to any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdiction); (b) with respect to any limited liability company, the certificate or articles of
formation or organization and operating agreement; (c)&nbsp;with respect to any partnership, joint venture, trust or other form of business entity, the partnership, joint venture or other applicable agreement of formation or organization and any
agreement, instrument, filing or notice with respect thereto filed in connection with its formation or organization with the applicable governmental authority in the jurisdiction of its formation or organization and, if applicable, any certificate
or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
articles of formation or organization of such entity, and (d)&nbsp;in each case, all shareholder or other equity holder agreements, voting trusts and similar arrangements to which such Person is
a party or which is applicable to its Equity Interests and all other arrangements relating to the control or management of such Person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) &#147;<B>Parent Entity</B>&#148; of a Person means an entity that, directly or indirectly, controls the applicable Person
and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of
consummation of the Fundamental Transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) &#147;<B>Permitted Indebtedness</B>&#148; means (i)&nbsp;Indebtedness
evidenced by this Note and the Other Notes, (ii)&nbsp;Indebtedness set forth on Schedule 3(r) to the Securities Purchase Agreement, as in effect as of the Subscription Date, (iii)&nbsp;Indebtedness secured by Permitted Liens or unsecured but as
described in clauses (iv)&nbsp;and (v) of the definition of Permitted Liens, (iv)&nbsp;Permitted Senior Indebtedness, and (vi)&nbsp;Permitted Subordinated Indebtedness. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) &#147;<B>Permitted Liens</B>&#148; means (i)&nbsp;any Lien for taxes not yet due or delinquent or being contested in good
faith by appropriate proceedings for which adequate reserves have been established in accordance with GAAP, (ii)&nbsp;any statutory Lien arising in the ordinary course of business by operation of law with respect to a liability that is not yet due
or delinquent, (iii)&nbsp;any Lien created by operation of law, such as materialmen&#146;s liens, mechanics&#146; liens and other similar liens, arising in the ordinary course of business with respect to a liability that is not yet due or delinquent
or that are being contested in good faith by appropriate proceedings, (iv)&nbsp;Liens (A) upon or in any equipment acquired or held by the Company or any of its Subsidiaries to secure the purchase price of such equipment or Indebtedness incurred
solely for the purpose of financing the acquisition or lease of such equipment, or (B)&nbsp;existing on such equipment at the time of its acquisition, provided that the Lien is confined solely to the property so acquired and improvements thereon,
and the proceeds of such equipment, in either case, with respect to Indebtedness in an aggregate amount not to exceed $250,000, (v)&nbsp;Liens incurred in connection with the extension, renewal or refinancing of the Indebtedness secured by Liens of
the type described in clause (iv)&nbsp;above, provided that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness being extended, renewed or
refinanced does not increase, (vi)&nbsp;Liens in favor of customs and revenue authorities arising as a matter of law to secure payments of custom duties in connection with the importation of goods, and (vii)&nbsp;Liens arising from judgments,
decrees or attachments in circumstances not constituting an Event of Default under Section&nbsp;4(a)(xii), (viii) Liens with respect to the Permitted Senior Indebtedness, and (ix)&nbsp;Liens with respect to the Permitted Subordinated Indebtedness.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) &#147;<B>Permitted Senior Indebtedness</B>&#148; means the FRV and JQA Loan and the $1.5 Million Note Series, as in
effect as of the Subscription Date, <U>provided</U>, <U>however</U>, that the aggregate outstanding principal amount of such Indebtedness permitted hereunder does not at any time exceed $2.5&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) &#147;<B>Permitted Subordinated Indebtedness</B>&#148; means up to
$250,000 of Indebtedness incurred by the Company that is unsecured or is secured but has <I>ab initio </I>subordination terms and any financing statement perfecting such Indebtedness is filed after the filing of the
<FONT STYLE="white-space:nowrap">UCC-1</FONT> financing statement filed in connection with the Notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) &#147;<B><FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant</B>&#148; has the meaning ascribed to such term in the Securities Purchase Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) &#147;<B>Person</B>&#148; means an individual, a limited liability company, a partnership, a joint venture, a corporation,
a trust, an unincorporated organization, any other entity or a government or any department or agency thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp)
<B></B>&#147;<B>Principal Market</B>&#148; means the Eligible Market that is the principal securities exchange market for the Common Stock after the Public Company Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) &#147;<B>Public Company Date</B>&#148; means the date on which the shares of Common Stock of the Company (or its direct or
indirect successor, subsidiary or parent company, whose securities are issued or issuable to holders of Common Stock), whether as a result of a public offering, merger, recapitalization, reorganization or otherwise, are registered under the 1934
Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) &#147;<B>Qualified Offering</B>&#148; means a public offering in the United States pursuant to a registration
statement declared effective by the Securities and Exchange Commission pursuant to the Securities Act, pursuant to which the Common Stock is listed for trading on an Eligible Market, with (i)&nbsp;minimum gross proceeds of $6,000,000, and
(ii)&nbsp;minimum net proceeds of $5,000,000 after deducting all fees and expenses in connection with such Qualified Offering and any proceeds used to cure an Event of Default as permitted under part (v)&nbsp;of the definition of &#147;Equity
Conditions&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) &#147;<B>Related Fund</B>&#148; means, with respect to any Person, a fund or account managed by
such Person or an Affiliate of such Person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) &#147;<B>Required Holders</B>&#148; means, as of any date of
determination, holders of at least a majority of the aggregate principal amount then outstanding under this Note and the Other Notes; provided that such holders must include the Lead Investor (as such term is defined in the Securities Purchase
Agreement) so long as the Lead Investor holds any Notes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) &#147;<B>Redemption Notices</B>&#148; means, collectively,
the Event of Default Redemption Notices, the Company Optional Redemption Notices and the Change of Control Redemption Notices, and each of the foregoing, individually, a &#147;<B>Redemption Notice</B>.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) &#147;<B>Redemption Premium</B>&#148; means 125%. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) &#147;<B>Redemption Prices</B>&#148; means, collectively, Event of Default Redemption Prices, the Change of Control
Redemption Prices, and the Company Optional Redemption Prices, and each of the foregoing, individually, a &#147;<B>Redemption Price</B>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) &#147;<B>Registration Rights Agreement</B>&#148; means that certain
registration rights agreement, dated as of the Closing Date, by and among the Company and the initial holders of the Notes relating to, among other things, the registration of the resale of the Common Stock issuable upon conversion of the Notes or
otherwise pursuant to the terms of the Notes and exercise of the Warrants, as may be amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy)
&#147;<B>SEC</B>&#148; means the United States Securities and Exchange Commission or the successor thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(zz)
&#147;<B>Securities Purchase Agreement</B>&#148; means that certain securities purchase agreement, dated as of the Subscription Date, by and among the Company and the initial holders of the Notes pursuant to which the Company issued the Notes, as
may be amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aaa) &#147;<B>Security Agreement</B>&#148; shall have the meaning as set forth in the
Securities Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bbb) &#147;<B>Subscription Date</B>&#148; means December&nbsp;21, 2021. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ccc) &#147;<B>Subsidiaries</B>&#148; means, as of any date of determination, collectively, all Current Subsidiaries and all
New Subsidiaries, and each of the foregoing, individually, a &#147;<B>Subsidiary</B>.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ddd) <B>&#147;Subject
Entity</B>&#148; means any Person, Persons or Group or any Affiliate or associate of any such Person, Persons or Group. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(eee) &#147;<B>Successor Entity</B>&#148; means the Person (or, if so elected by the Holder, the Parent Entity) formed by,
resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been entered into. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(fff) &#147;<B>Trading Day</B>&#148; means, as applicable, (A)&nbsp;prior to the Public Company Date, any Business Day and
(B)&nbsp;from and after the Public Company Date, (x)&nbsp;with respect to all price or trading volume determinations relating to the Common Stock, any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is
not the principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded, provided that &#147;Trading Day&#148; shall not include any day on which the Common Stock
is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in
advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time) unless such day is otherwise designated as a Trading Day in writing by the Holder or (y)&nbsp;with respect to all
determinations other than price determinations relating to the Common Stock, any day on which The New York Stock Exchange (or any successor thereto) is open for trading of securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ggg) &#147;<B>Transaction Document</B>&#148; shall have the meaning ascribed to such term in the Securities Purchase
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hhh) &#147;<B>VWAP</B>&#148; means, for any security as of any date, the
dollar volume-weighted average price for such security on the Principal Market (or, if the Principal Market is not the principal trading market for such security, then on the principal securities exchange or securities market on which such security
is then traded), during the period beginning at 9:30 a.m., New York time, and ending at 4:00 p.m., New York time, as reported by Bloomberg through its &#147;VAP&#148; function (set to 09:30 start time and 16:00 end time) or, if the foregoing does
not apply, the dollar volume-weighted average price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security during the period
beginning at 9:30 a.m., New York time, and ending at 4:00 p.m., New York time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid
price and the lowest closing ask price of any of the market makers for such security as reported in The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices). If the VWAP cannot be calculated for such
security on such date on any of the foregoing bases, the VWAP of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market
value of such security, then such dispute shall be resolved in accordance with the procedures in Section&nbsp;25. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination, recapitalization or
other similar transaction during such period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) &#147;<B>Warrants</B>&#148; has the meaning ascribed to such term in
the Securities Purchase Agreement, and shall include all warrants issued in exchange therefor or replacement thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">34.
<U>DISCLOSURE</U>. After the Public Company Date, upon delivery by the Company to the Holder (or receipt by the Company from the Holder) of any notice in accordance with the terms of this Note, unless the Company has in good faith determined that
the matters relating to such notice do not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries, the Company shall on or prior to 9:00 am, New York city time on the
Business Day immediately following such notice delivery date, publicly disclose such material, <FONT STYLE="white-space:nowrap">non-public</FONT> information on a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or otherwise. After
the Public Company Date, in the event that the Company believes that a notice contains material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries, the Company so shall indicate to the
Holder explicitly in writing in such notice (or immediately upon receipt of notice from the Holder, as applicable), and in the absence of any such written indication in such notice (or notification from the Company immediately upon receipt of notice
from the Holder), the Holder shall be entitled to presume that information contained in the notice does not constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information relating to the Company or any of its Subsidiaries.
Nothing contained in this Section&nbsp;34 shall limit any obligations of the Company, or any rights of the Holder, under Section&nbsp;4(i) of the Securities Purchase Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">35. <U>ABSENCE OF TRADING AND DISCLOSURE RESTRICTIONS</U>. The Company acknowledges and
agrees that the Holder is not a fiduciary or agent of the Company and that the Holder shall have no obligation to (a)&nbsp;maintain the confidentiality of any information provided by the Company or (b)&nbsp;refrain from trading any securities while
in possession of such information in the absence of a written <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement signed by an officer of the Holder that explicitly provides for such confidentiality and trading restrictions. In the
absence of such an executed, written <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement, the Company acknowledges that the Holder may freely trade in any securities issued by the Company, may possess and use any information provided by
the Company in connection with such trading activity, and may disclose any such information to any third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page
Follows</I>] </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Note to be duly executed as of the Issuance
Date set out above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HEART TEST LABORATORIES, INC. (D/B/A HEARTSCIENCES)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Mark Hilz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Senior Convertible Note - Signature Page </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>21
<FILENAME>filename21.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.15 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSULTING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This CONSULTING AGREEMENT (this &#147;<I><U>Agreement</U></I>&#148;)<I> </I>is entered into and is effective as of June&nbsp;25, 2013 (the
&#147;<I><U>Effective Date</U></I>&#148;),<I> </I>by and between <B>KYNGSTONE LIMITED, </B>a company registered in England (&#147;<I><U>Consultant</U></I>&#148;),<I> </I>and <B>Heart Test Laboratories Inc, a Texas Corporation
</B>(&#147;<I><U>HTL</U></I>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, HTL desires to retain Consultant to perform certain consulting functions with respect to the business and operations of HTL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the premises and the covenants made herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, HTL and Consultant hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENGAGEMENT OF MANAGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;1.1.</B> <B><I>Engagement of Consultant. </I></B>Subject to the terms and conditions set forth in this
Agreement, HTL hereby engages Consultant to perform the Services, and Consultant accepts such engagement and agrees to perform the Services for HTL in accordance with the terms and conditions hereof. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.1.</B> <B><I>Term. </I></B>The term (the &#147;<I><U>Term</U></I>&#148;) of this Agreement shall
commence on the Effective Date and shall terminate in accordance with Section&nbsp;2.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;2.2.</B>
<B><I>Termination. </I></B>This Agreement may be terminated (a)&nbsp;by either HTL or Consultant upon sixty (60)&nbsp;days written notice to the other party, or (b)&nbsp;by mutual agreement of HTL and Consultant. In the event of termination the
provisions of section 4 shall remain fully in force and effective in relation to any actions or duties prior to the termination date. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DUTIES AND
FEES OF CONSULTANT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.1. </B><B><I>Duties of Consultant. </I></B>From and after the Effective Date the
Consultant shall assist and advise on any and all business, commercial, financial and other matters relating to HTL, as reasonably requested or required by HTL and is duly authorized to represent HTL in connection with the performance of such as
appropriate (the &#147;<I><U>Services</U></I>&#148;).<I> </I>At no time shall any of the Services performed by Kyngstone or its representative(s) (&#147;Representative&#148;) constitute or form statutory duties or responsibilities as an officer
and/or director of HTL and the Services shall be subject to the ultimate authority of the board of HTL. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.2. </B><B><I>Fees of Consultant. </I></B>Fee arrangements
shall be agreed by separate arrangement as appropriate. The Consultant acknowledges that as at the Effective Date, HTL is not in a financial position to pay fees and that fees can only be agreed if and when HTL has adequate financial resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;3.2. </B><B><I>Expenses. </I></B>HTL shall reimburse the Consultant for bona fide expenses incurred in
connection with HTL. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXONERATION; INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.1. </B><B><I>Exoneration. </I></B>The doing of any act or the failure to do any act by Consultant, the effect
of which may cause or result in loss or damage to HTL, shall not subject Consultant to any liability to HTL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.2. </B><B><I>Indemnification. </I></B>HTL shall, to the fullest extent permitted by law, defend, indemnify and
hold harmless Consultant from and against any and all claims, actions, damages, expenses (including reasonable attorneys&#146; fees and expenses incurred before trial or at trial or appellate levels), losses, payments, or liabilities claimed or
asserted against Consultant arising as a result of or in any way connected with HTL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;4.3.
</B><B><I>Separate Responsibilities. </I></B>The Parties acknowledge that if a Representative is also an officer and/or director of HTL he may have separate statutory duties and responsibilities as an officer and/or director of HTL which are
personal to the Representative and do not form part of, or are additional to, the Services (&#147;Personal Director Duties&#148;). To the extent, and only to the extent, that a Representative has Personal Director Duties then the provisions of this
Agreement shall not apply. For the avoidance of doubt, if Services are performed in relation to a business, commercial, financial or other matter relating to HTL (&#147;Business Matter&#148;) and the Representative is also required to undertake
Personal Director Duties in relation to the Business Matter then this Agreement shall apply in connection to the Services performed but not the Personal Director Duties. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.1. </B><B><I>Counterparts; Effective Date. </I></B>This Agreement may be executed in two or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement shall be effective as of the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.2. </B><B><I>Other Business of Consultant. </I></B>It is expressly understood and agreed that nothing herein
contained shall be construed to prevent or prohibit Consultant from providing the same or similar services with respect to projects of any type or in any location. The Consultant, may at any time engage or participate independently or with others in
other business ventures of every nature and description, including business ventures pertaining to any aspect of HTL&#146;s business. Nothing in this Agreement shall be deemed to prohibit dealing, or otherwise engaging in business, with persons
transacting business with HTL or from providing services relating to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business of HTL and receiving compensation therefore. HTL shall not have any right by virtue of this Agreement or agency relationship created hereby in or to such other ventures or activities or
to the income or proceeds derived therefrom, and the pursuit of such ventures, even if competitive with the business of HTL, shall not be deemed in violation of this Agreement or Consultant&#146;s obligations, or otherwise wrongful or improper.
Consultant shall not be obligated to present any particular investment or business opportunity to HTL or any of the members even if such opportunity is of a character which, if presented to HTL to be taken advantage of by HTL and each of them shall
have the right to take for its own account or to recommend to others any such particular investment opportunity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.3. </B><B><I>Waiver. </I></B>The waiver of any breach of any terms or conditions hereof shall not be deemed a
waiver of any other subsequent breach, whether of like or different nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.4. </B><B><I>Severability.
</I></B>If any term or provision of this Agreement or the performance thereof shall to any extent be invalid or unenforceable, such invalidity or unenforceability shall not affect or render invalid or unenforceable any other provision of this
Agreement, and this Agreement shall be valid and enforced to the fullest extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.5.</B>
<B><I>Amendment. </I></B>No modification or amendment of this Agreement shall be valid unless in writing, executed by both parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.6. </B><B><I>Governing Law. </I></B>This Agreement shall be governed by, and construed in accordance with, the
laws of England and Wales in the United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section</B><B></B><B>&nbsp;5.7.</B> <B><I>Entire Agreement. </I></B>This Agreement
and all exhibits and schedules hereto constitutes the entire Agreement between the parties pertaining to the subject matter contained herein and supersedes all prior agreements, arrangements, understandings, representations, warranties, commitments
and communications (oral or written) related to the subject matter hereof. The parties make no representation or warranties except as set forth in this Agreement. By execution of this Agreement, each of the parties represents and warrants that it
has relied on no oral or written statements, promises, inducements, representations or warranties to enter into this Agreement except for those expressly set forth herein, and that inclusion of this provision evidences the intent of the parties that
no parole evidence shall be admissible to alter or vary the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of this page intentionally left blank;
signature page immediately follows.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Effective
Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>CONSULTANT:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>KYNGSTONE LIMITED,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">a company registered in England</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Simpson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Andrew Simpson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B><U>HTL:</U></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HEART TEST LABORATORIES INC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">a Texas Corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Hilz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Mark T. Hilz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CEO</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>22
<FILENAME>filename22.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.16</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.16 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DocuSign Envelope ID: 8AECDBFA-9CBD-4535-BD1A-CAEEA94FB7C8 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308dsp300.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Employment Agreement (&#147;<B><U>Agreement</U></B>&#148;) is made as of March&nbsp;7, 2017 (the &#147;<B><U>Effective Date</U></B>&#148;) by and between
Heart Test Laboratories, Inc., a Texas corporation with principal offices at 1301 Solana Blvd, Suite 1527, Westlake, TX 76262 (&#147;<B><U>HTL</U></B>&#148;, &#147;<B><U>Company</U></B>&#148; or &#147;<B><U>Employer</U></B>&#148;) and Mark Hilz
whose primary residence is 528 East Hickory Ridge Circle, Argyle, Texas 76226 (&#147;<B><U>you</U></B>&#148; or &#147;<B><U>Employee</U></B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employee has been employed by Employer for an extended period and the Parties wish to formalize the terms of such employment. This Agreement shall represent an
employment contract for the purposes of section 3 (b)&nbsp;(i) of the Restricted Stock Agreement for Series B Convertible Preferred Stock between you and the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, for and in consideration of the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties hereto agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Employment. </B>You and Company desire to formalize an employment relationship by means of this Agreement.
Company, hereby employs you subject to the terms hereof, and you hereby accept such employment upon such terms as of the Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidentiality. </B>Employee recognizes that the Company has expended and will continue to expend
substantial time, money and effort in developing formulas, patterns, designs, compilations, programs, devices, methods, techniques, processes, training, intellectual property, and general knowhow that derive independent economic value, actual or
potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use, which is the subject of efforts that are reasonable under the circumstances
to maintain its secrecy. Company possesses valuable information, including information about customers, dealers and suppliers, and among other things, about their technical problems and needs, purchasing habits, and procedures, all resulting in a
great deal of customer goodwill. Company owns financial records, contracts, marketing and strategic plans, intellectual property, and other valuable information. For purposes of this Agreement, all such items and information, as well as the
information defined as &#147;Confidential Information&#148; in the CONFIDENTIALITY, INVENTION ASSIGNMENT, <FONT STYLE="white-space:nowrap">NON-SOLICITATION</FONT> AND <FONT STYLE="white-space:nowrap">NO-HIRE</FONT> AGREEMENT
(&#147;<B><U>Confidentiality Agreement</U></B>&#148;) (required to be executed by you concurrently herewith) are owned by Company and hereafter referred to in this Agreement as &#147;<B><U>Trade Secrets and Confidential Information</U></B>.&#148;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You will, in the course of your employment, be personally entrusted with and exposed to Company&#146;s Trade
Secrets and Confidential Information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Company, during the term of this Agreement and after its termination, will be engaged, throughout the world, in
the highly competitive Healthcare industry, in which many firms, including Company, compete. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Heart Test Laboratories
Employment Agreement</I> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Your</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Company</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> Page
 1
 of 12</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DocuSign Envelope ID: 8AECDBFA-9CBD-4535-BD1A-CAEEA94FB7C8 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308dsp300.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You could, after having access to Company&#146;s Trade Secrets and Confidential Information, become or be
employed by a competitor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Company will suffer great loss and irreparable harm if you were to separate your employment and thereafter
participate, directly or indirectly, as a consultant, employee, manager, officer, director or in any other capacity in any business or venture in competition with Company, or if you at any time (during or after your employment) disclose
Company&#146;s Trade Secrets and Confidential Information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is Company&#146;s policy that you should have no investment in or relationship with an outside organization
that might affect the independence of your judgment in performing your duties or in any way conflict with the best interests of Company. The company shall allow an Employee or any of his affiliates to purchase or hold an aggregate equity interest of
up to 1% in any publicly-traded company which is in competition with Employer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Employee agrees to execute a Heart Test Laboratories, Inc., CONFIDENTIALITY, INVENTION ASSIGNMENT, <FONT
STYLE="white-space:nowrap">NON-SOLICITATION</FONT> AND <FONT STYLE="white-space:nowrap">NO-HIRE</FONT> AGREEMENT &#147;<B><U>Confidentiality Agreement</U></B>&#148; as a condition of employment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Term of Employment. </B>UNLESS EARLIER TERMINATED PURSUANT TO SECTION 4 BELOW, THE TERM OF THIS AGREEMENT
SHALL COMMENCE AS OF THE DATE IN ATTACHMENT &#147;A&#148;, AND SHALL RUN FOR ONE (1)&nbsp;YEAR THEREAFTER; PROVIDED, HOWEVER, THAT THE TERM SHALL AUTOMATICALLY RENEW FOR AN ADDITIONAL <FONT STYLE="white-space:nowrap">ONE-YEAR</FONT> PERIOD AT THE
END OF THE ORIGINAL <FONT STYLE="white-space:nowrap">ONE-YEAR</FONT> TERM AND ANY ADDITIONAL <FONT STYLE="white-space:nowrap">ONE-YEAR</FONT> TERM, UNLESS EITHER PARTY GIVES WRITTEN NOTICE TO THE OTHER PARTY, AT LEAST NINETY (90)&nbsp;DAYS PRIOR TO
THE END OF THE APPLICABLE TERM, OF SUCH PARTY&#146;S TERMINATION OF THIS AGREEMENT AT THE END OF THE APPLICABLE TERM. AS USED HEREIN, &#147;TERM&#148; SHALL MEAN THE ORIGINAL TERM AND ANY ADDITIONAL RENEWAL TERM(S). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination. </B>This Agreement and the employment relationship created hereby shall terminate upon the
occurrence of any of the following events (each, a &#147;<B>Termination Event</B>&#148;): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The expiration of the Term; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The death of Employee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Excessive Absence (as hereinafter defined) of Employee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written notice to Employee from Employer of termination for Just Cause (as hereinafter defined);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written notice to Employee from Employer of termination for any reason other than subparts (b), (c) or
(d)&nbsp;in this Section&nbsp;4 above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written notice to Employer from Employee of termination for any reason other than subpart (g)&nbsp;in this
Section&nbsp;4 below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written notice to Employer from Employee of termination for Constructive Termination (as hereinafter defined)
and Employer does not cure the breach within the time periods required; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">h.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written notice from either party for any reason in the 18 months following a Change of Control (as hereinafter
defined). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Heart Test Laboratories
Employment Agreement</I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Your</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Company</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 2 of 12</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DocuSign Envelope ID: 8AECDBFA-9CBD-4535-BD1A-CAEEA94FB7C8 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308dsp300.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event of the termination of Employee&#146;s employment pursuant to (b), (c), (d)
or (f)&nbsp;in this Section&nbsp;4 above, then Employee shall be entitled to compensation (as provided for in Exhibit A) not yet paid, for the period up to the date of such Termination Event, as follows: (i)&nbsp;base salary; (ii)&nbsp;his pro rata
share of any bonus, calculated and paid at the end of the bonus scheme period, that would otherwise have been earned and be payable had he continued to be employed by the Company; (iii)&nbsp;health insurance; and (iv)&nbsp;other benefits. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event of the termination of Employee&#146;s employment pursuant to (a), (e), (g) or (h)&nbsp;in this Section&nbsp;4 above, then
Employee shall be entitled to compensation (as provided for in Exhibit A) payable for a period of twelve (12)&nbsp;months as if no Termination Event had occurred as follows: (i)&nbsp;base salary; (ii)&nbsp;the greater of: (a)&nbsp;one times base
salary; and (b)&nbsp;his share of any bonus calculated and paid at the end of the bonus scheme period, that would otherwise have been earned and be payable had he continued to be employed by the Company; (iii)&nbsp;health insurance; and
(iv)&nbsp;other benefits. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Employee&#146;s right to compensation under Section&nbsp;4 (ii) above will be waived by the Employee unless
the Employee has signed a general release in favor of the Company in the form set out in Exhibit C within 21 days of the Termination Event. In the event that the Employee does not sign such general release then compensation shall be calculated on
the same basis as Section&nbsp;4 (i) above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;4 the following terms have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#148;<B>Constructive Termination</B>&#148; shall mean: (i)&nbsp;a material reduction in Employee&#146;s duties and responsibilities
without Employee&#146;s consent; (ii)&nbsp;an action by the Employer which undermines or renders unfeasible the Employee&#146;s ability to undertake or fulfil the role in an effective manner; (iii)&nbsp;any breach by Employer of any of the material
terms of, or the failure to perform any material covenant contained in this Agreement, and following written notice thereof from Employee to Employer, Employer does not cure such breach or failure within fifteen (15)&nbsp;days thereafter; provided,
however, that Employer will not be entitled to cure any such breach or failure more than one time in any consecutive three month period; or (iv)&nbsp;a reduction in Employee&#146;s compensation without Employee&#146;s prior written consent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#148;<B>Excessive Absence</B>&#148;<B> </B>of Employee shall mean her inability, for whatever reason, to perform his duties under this
Agreement for a continuous period of 60 days or for 120 days out of a continuous period of 240 days. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#148;<B>Just Cause</B>&#148;<B>
</B>shall mean (i)&nbsp;Employee&#146;s conviction of a felony or commission of any act of fraud, moral turpitude or dishonesty, (ii)&nbsp;an intentional, material violation by Employee of a statutory or fiduciary duty not corrected within ten days
after written notice from Employer, (iii)&nbsp;any material breach by Employee of any of the terms or conditions of, or the failure to perform any material covenant contained in, this Agreement and Employee does not cure such breach or failure
within ten days following notice from Employer; provided, however, that Employee will not be entitled to cure any breach or failure under this <FONT STYLE="white-space:nowrap">sub-clause</FONT> (iii)&nbsp;more than one time in any consecutive three
(3)&nbsp;month period, or (iv)&nbsp;the violation by Employee of reasonable instructions or policies established by Employer with respect to the operation of its business and affairs or Employee&#146;s failure to carry out the reasonable
instructions of the Board of Directors, and following notice thereof from Employer to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Heart Test Laboratories
Employment Agreement</I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Your</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Company</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 3 of 12</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DocuSign Envelope ID: 8AECDBFA-9CBD-4535-BD1A-CAEEA94FB7C8 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308dsp300.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employee, Employee does not cure any such violation or failure within ten days following notice from
Employer; provided, however, that Employee will not be entitled to cure any breach or failure under this <FONT STYLE="white-space:nowrap">sub-clause</FONT> (iv)&nbsp;more than one time in any consecutive three (3)&nbsp;month period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#148;<B>Change of Control</B>&#148; shall mean a change of control of HTL being: (i)&nbsp;the sale of all or substantially all the assets
of the Company; (ii)&nbsp;any merger, consolidation or acquisition of the Company with, by or into another corporation, entity or person; (iii)&nbsp;any change in the ownership of more than fifty percent (50%) of the voting capital stock of HTL in
one or more related transactions; or (iv)&nbsp;the Employee ceasing to be a director for the Company for any reason other than the resignation by the Employee of his director position. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Compensation. </B>In consideration of the services provided by you to Company under the terms of this
Agreement, Company will pay you starting on your actual Start Date the compensation as set forth in <B><U>Exhibit &#147;A&#148;</U>. </B>The Company will undertake an independent benchmarking review of compensation of the Employee prior to an
initial public offering of HTL or by May&nbsp;1, 2018 if earlier. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Duties and Responsibilities. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Duties</U>. Subject to the power of the Board of Directors to hire and/or remove officers and employees,
Employee shall continue to serve as President and CEO of Employer, and shall perform, faithfully and diligently, the services and functions relating to such position or otherwise reasonably incident to such position as may be designated from time to
time by the Board of Directors of the Employer. Employee shall report directly to the Board of Directors. Employee shall be based in the Dallas/Fort Worth Metroplex, but shall travel as required by his duties under this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Full Time and Attention</U>. During your employment, you will devote your best efforts and entire time,
attention and energy to the business of Company. Employee shall not provide services or conduct activities for or related to any other business(es) unless approved by the Board of Directors. The initial approved outside businesses and related
activities will be listed in <U><B>Exhibit &#147;B&#148;.</B></U> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Compliance with Company Rules, Policies and Procedures</U>. During the employment, you will, at all times,
comply with all of Company&#146;s rules, policies and procedures, including but not limited to those regarding employment and confidentiality,. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Legal Obligations Owed to Others</U>. You represent and warrant to Company that this Agreement, the
performance of your obligations under this Agreement or the employment relationship between Company and you under this Agreement does not and will not violate or conflict with (i)&nbsp;any of the following agreements or restrictive covenants:
employment, <FONT STYLE="white-space:nowrap">non-competition</FONT> (as pertaining to being employed by a competitor), <FONT STYLE="white-space:nowrap">non-solicitation</FONT> (as pertaining to customers, employees, or independent contractors), <FONT
STYLE="white-space:nowrap">no-hire</FONT> (as pertaining to employees or independent contractors), <FONT STYLE="white-space:nowrap">non-interference</FONT> (as pertaining to employees, agents or servants) or confidentiality (as pertaining to trade
secrets and other confidential information); and (ii)&nbsp;any judgment, writ, injunction, or order of any court, arbitrator, or governmental agency, or any other obligation to which you are subject. To the extent </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Heart Test Laboratories
Employment Agreement</I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Your</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Company</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 4 of 12</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DocuSign Envelope ID: 8AECDBFA-9CBD-4535-BD1A-CAEEA94FB7C8 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308dsp300.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">you are subject to any of the foregoing restrictions or agreements, you represent and warrant to Company that you have provided such documents to the Company&#146;s Employee Services prior to the offer of employment
being made to you. You also represent and warrant to Company that you will not use or disclose the trade secrets or other confidential information of former employers or other persons or entities in connection with your employment by Company and
that you will not bring onto the premises of Company any unpublished document or proprietary information belonging to any such employer, person, or entity unless consented to in writing by such employer, person, or entity. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Fiduciary Duties. </B>You acknowledge and agree that you owe a fiduciary duty of loyalty, fidelity and
allegiance to act at all times in the best interests of Company. You agree that you will not act or will not fail to act in any manner that would injure the business, interests, or reputation of Company or any of its affiliates. Additionally, you
agree to immediately disclose to the Board of Directors or Chairman of the Board all information and business opportunities pertaining to the business of Company and any of its affiliates learned of by you while employed by Company and not to
appropriate for your benefit or that of any third party such opportunities or information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Dishonesty by Others. </B>If at any time you become aware, or believe, that any other employee, agent or
servant of Company, or any third party, is or appears to be (a)&nbsp;removing, concealing, transferring or using any property or funds of Company for the benefit of anyone other than Company or is otherwise not authorized by Company to do so, or
(b)&nbsp;divulging, providing or otherwise disseminating in any manner not authorized by Company any of Company&#146;s Trade Secrets and Confidential Information to any third person not authorized by Company to possess such Trade Secrets and
Confidential Information, you will immediately communicate your knowledge or belief as to such matters to the Chairman of the Board of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Restrictive Covenants. </B>You agree that the following covenants are reasonable and necessary to protect
Company&#146;s interests, including but not limited to its client and vendor relationships, competitive position, Trade Secrets and Confidential Information, and therefore agree to the following covenants which are agreed to be ancillary to the
Confidentiality Agreement to be executed by you concurrently herewith. You agree as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That certain Confidentiality Agreement entered into by and between Company and you is incorporated herein by
reference for all pertinent purposes and such Confidentiality Agreement and all of its terms and provisions will be deemed a part hereof and will be enforceable hereunder separate and distinct from its enforceability as a separate agreement (e.g.,
it will be enforceable as a separate and distinct agreement as well as being enforceable as a part hereof); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You further agree that you will not, while at any time employed by Company and for a period of twelve
(12)&nbsp;months following the termination of such employment, whether as an individual, or in any capacity, directly or indirectly do the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Solicit or sell or participate in any way concerning the sale or development of products or services, similar
to Company&#146;s products or services, to any customer or client; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Heart Test Laboratories
Employment Agreement</I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Your</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Company</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 5 of 12</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DocuSign Envelope ID: 8AECDBFA-9CBD-4535-BD1A-CAEEA94FB7C8 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308dsp300.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Request, advise, induce or attempt to request, advise, or induce any distributor, vendor, representative, agent
or contractor of Company to terminate, modify, curtail, or alter its business relationship with Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Request, advise, induce or attempt to request, advise, or induce any of Company&#146;s customers or clients to
terminate or in any way modify, curtail, or alter its business relationship with Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Request, advise, solicit, divert or take away, or attempt to request, advise, solicit, divert or take away,
from Company, any individuals or entities, who were with Company as an employee, consultant or independent contractor within twelve (12)&nbsp;months preceding your Termination Date; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">v.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Be employed, advise or participate in any way concerning another ECG manufacturer or company involved in the
sale or development of products or services similar to Company&#146;s products or services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You further agree that enforcement of the above Sections 9(b)(i) through (v), inclusive, is the only practical
means of enforcing Section&nbsp;9(a), above, and of enforcing the Confidentiality Agreement. You agree that enforcement of Sections 9(b)(i) through (v), inclusive, is necessary to protect Company&#146;s goodwill and other business interests. You
further agree that Company will suffer irreparable injury, not readily susceptible of valuation in monetary damages, if you breach any of the obligations under Sections 9(b)(i) through (v), inclusive. Accordingly, you agree that Company will be
entitled to injunctive relief against any breach or prospective breach by you of your obligations under Sections 9(b)(i) through (v)&nbsp;inclusive. Nothing herein will be construed as prohibiting Company from pursuing any other remedies available
to Company for such breach or threatened breach, including the recovery of damages from you. In the event of a violation or attempted violation of Sections 9(b)(i) through (v)&nbsp;inclusive, you agree that an amount of time equal to the time period
during which a violation exists will be added to the duration of the restrictions in Sections 9(b)(i) through (v)&nbsp;inclusive. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sections 9(a) and (b)(i) through (v), inclusive, will be deemed ancillary to the Confidentiality Agreement. You
agree that all of the provisions of this Agreement and the Confidentiality Agreement are valid and enforceable as written and according to their terms. The obligations of Company hereunder will not apply to any of its parents, subsidiaries, or
affiliates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">You agree to notify any prospective employer of the existence and terms of this Section&nbsp;9, prior to
acceptance of employment. Company may inform any person or entity subsequently employing you, or evidencing an intention to employ you, of the existence of this Agreement, the terms hereof, and provide to that person or entity a copy of this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assignment. </B>Company may assign this Agreement at any time without notice (but you cannot). This
Agreement is personal to you and no individual or entity will have any interest in same except you, personally, on the one hand, and Company and its subsidiaries, affiliates, successors, assigns or its associated companies, on the other hand.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Heart Test Laboratories
Employment Agreement</I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Your</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Company</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 6 of 12</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DocuSign Envelope ID: 8AECDBFA-9CBD-4535-BD1A-CAEEA94FB7C8 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308dsp300.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-Waiver.</FONT> </B>The failure of Company at any time to enforce any
provision hereof will never be construed to be a waiver of such provision or of the right of Company to enforce each and every provision hereof at any time. No course of dealing between Company and you will be implied as a waiver by Company of any
provision of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Savings Clause. </B>The provisions of this Agreement are severable. In the event any paragraph, provision or
clause, or any combination of same hereof will be found or held to be unenforceable at law or in equity, or under any ordinance, statute or regulation, such finding or holding will not in any way affect the other paragraphs, provisions and clauses
which will remain in full force and effect. In the event any paragraph, provision or clause , or any combination of same hereof will not be enforceable in accordance with its terms, Company and you agree that such paragraph, provision, or clause
will be reformed to make such paragraph, provision, or clause enforceable in a manner which provides Company the maximum rights permitted at law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Resolution of Disputes. </B>Any controversy or claim arising out of or relating to this Agreement, your
employment or director position with the Company, other than under Section&nbsp;6 or the Confidentiality Agreement, shall be determined by binding arbitration in accordance with the Employment Arbitration Rules of the American Arbitration
Association. The place of arbitration shall be Dallas, Texas. This Agreement shall be exclusively construed, applied and performed, per the internal laws of the state of Texas, U.S.A. Judgment on any award rendered by the arbitrator(s) may be
entered in any court of competent jurisdiction . The arbitration provision in this section 13 shall survive if this Agreement should be adjudged null and void or should be canceled or terminated for any reason. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Governing Law. </B>This Agreement shall be governed by and construed in accordance with the laws of the
State of Texas, without reference to the principles of conflict of laws. All actions and proceedings arising out of or relating to this Agreement shall be heard and determined in any court in a county as determined by the Company and the parties
hereto hereby consent to the jurisdiction of such courts in any such action or proceeding. You hereby consent to the exclusive venue and personal jurisdiction of said court with respect to any litigation arising from this Agreement or your
employment with Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Construction. </B>Each party hereto acknowledges and agrees that it has had the opportunity to consult with
its own legal counsel in connection with the negotiation of this Agreement and that it has bargaining power equal to that of the other party hereto in connection with the negotiation, execution and delivery of the Agreement. Accordingly, the parties
hereto agree that the rule of contract construction that an agreement will be construed against the drafter will have no application in the construction or interpretation of this Agreement. For purposes of this Agreement, whenever the context
requires: (i)&nbsp;the singular number shall include the plural, and vice versa; (ii)&nbsp;the masculine gender shall include the feminine and neuter genders, the feminine gender shall include the masculine and neuter genders, the neuter gender
shall include the masculine and feminine genders; and (iii)&nbsp;the words include and including, and variations thereof, shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words without limitation.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Heart Test Laboratories
Employment Agreement</I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Your</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Company</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 7 of 12</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DocuSign Envelope ID: 8AECDBFA-9CBD-4535-BD1A-CAEEA94FB7C8 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308dsp300.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Legal Fees. </B>The parties hereto agree that the <FONT STYLE="white-space:nowrap">non-prevailing</FONT>
party in any dispute, claim, action or proceeding between the parties hereto arising out of or relating to the terms and conditions of this Agreement or any provision thereof (a &#147;Dispute&#148;), shall reimburse the prevailing party for
reasonable attorney&#146;s fees and expenses incurred by the prevailing party in connection with such Dispute; provided, however, that the Employee shall only be required to reimburse the Company for its fees and expenses incurred in connection with
a Dispute if the Employee&#146;s position in such Dispute was found by the court, arbitrator or other person or entity presiding over such Dispute to be frivolous or advanced not in good faith. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Consideration for This Agreement. </B>In consideration for the covenants and promises made by you in the
recitals to this Agreement and in Sections 2, 9, 18 and 22 herein, the sufficiency of which you hereby acknowledge, Company will employ you as set forth herein. You acknowledge that your execution of this Agreement and your agreement to the
covenants contained in Sections 2, 9, 18 and 22 herein are integral to Company&#146;s agreement to employ you on these terms and, without such agreements, covenants and promises by you, Company would not employ you on these terms.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-Disparagement,</FONT> Defamation and Privacy. </B>Director will
refrain, both during and after termination of the Directorship from publishing, promoting, uttering or otherwise disseminating any oral or written statements about Company or its officers, directors, employees, agents or representatives that are
disparaging, derogatory, slanderous, libelous, or otherwise defamatory; or that disclose private or confidential information about Company or its business affairs, officers, directors, employees, agents, or representatives that you know or should
know is materially injurious to Company; or that place Company or any of its officers, directors, employees, agents or representatives in a false light before the public; or that constitute a misappropriation of the name or likeness of Company or
its officers directors, employees, agents or representatives. A violation or threatened violation of this prohibition may be enjoined by any court of competent jurisdiction. The rights afforded Company under the provision of this Section&nbsp;18 are
in addition to any and all rights and remedies otherwise afforded by law or by this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entire Agreement. </B>This Agreement (including all written amendments and modifications hereto and all
documents ancillary hereto) constitutes the entire agreement and understanding between the parties and it is expressly agreed that no representations, promises, warranties or understandings, express or implied, other than set forth herein or
referred to herein, will be binding on either party. The Confidentiality Agreement is ancillary to this Agreement. None of the provisions hereof will be waived, altered or amended unless in writing signed by the parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Survival. </B>Notwithstanding anything to the contrary in this Agreement, the provisions of Sections 2, 4,
9, 10, 11, 12, 13, 14, 16, and 18 of this Agreement and the Confidentiality Agreement shall survive any termination, for whatever reason, of Employee&#146;s employment under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Counterparts. </B>You and Company agree that this Agreement may be executed in any number of counterparts,
and in that event, each counterpart will be deemed a complete original and all counterparts will constitute a single agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Your Certification. </B>YOU HEREBY CERTIFY THAT: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Heart Test Laboratories
Employment Agreement</I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Your</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Company</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 8 of 12</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DocuSign Envelope ID: 8AECDBFA-9CBD-4535-BD1A-CAEEA94FB7C8 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g271308dsp300.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">YOU RECEIVED A COPY OF THIS AGREEMENT AND THE CONFIDENTIALITY AGREEMENT FOR REVIEW AND STUDY BEFORE YOU WERE
ASKED TO EXECUTE THEM; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">YOU HAVE READ SUCH AGREEMENTS CAREFULLY; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">YOU HAVE BEEN AFFORDED THE OPPORTUNITY TO DISCUSS AND REVIEW THIS AGREEMENT AND THE CONFIDENTIALITY AGREEMENT
WITH AN ATTORNEY OF YOUR CHOICE; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">YOU UNDERSTAND WHAT YOUR RIGHTS ARE UNDER THE AGREEMENTS AS WELL AS YOUR OBLIGATIONS; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">YOU HAVE READ AND UNDERSTAND EACH AND EVERY PROVISION OF THE AGREEMENTS AND DO HEREBY ACCEPT AND AGREE TO THE
SAME; AND </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">YOU ARE EXECUTING THIS AGREEMENT VOLUNTARILY AND WITHOUT ANY DURESS OR UNDUE INFLUENCE BY COMPANY OR ANYONE
ELSE. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, you have, on the date set forth below, affixed your hand and Company has caused this Agreement
to be executed by a duly authorized person, on the date set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><U>Employee:</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: <U>3/7/2017</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Hilz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">IF07Di/FA6684F 1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark<B> </B>Hilz</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Heart Test Laboratories, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: <U>3/7/2017</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Simpson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Andrew Simpson</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Chairman</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I>Heart Test Laboratories
Employment Agreement</I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Your</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Company</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Initials</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Page 9 of 12</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>23
<FILENAME>filename23.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.17</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 10.17 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">April&nbsp;10, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heart Test Laboratories,
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">550 Reserve Street, Suite 360 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Southlake, Texas 76092
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Chairman of the Board </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Re:
<U>Conversion of Notes, Nomination of Director, Board Observation Rights and Approval Rights</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heart Test Laboratories, Inc., a Texas corporation (the &#147;<B>Company</B>&#148;), has undertaken an offering (the
&#147;<B>Offering</B>&#148;) of up to $5,000,000 (subject to increase) of Series C Convertible Preferred Stock, par value $0.001 per share, of the Company (the &#147;<B>Series C Preferred Stock</B>&#148;) as more specifically described in the
Company&#146;s Subscription Agreement for Series C Convertible Preferred Stock (the &#147;<B>Subscription Agreement</B>&#148;). As part of the Offering, the Company and Front Range Ventures LLC (&#147;<B>FRV</B>&#148;) have agreed to the following
terms and provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. FRV hereby agrees to execute a Subscription Agreement in the Offering to purchase $2,000,000 of Series C
Preferred Stock in the Offering; it being agreed and understood that in the Offering FRV is converting the principal balance of, and accrued but unpaid interest on, loans made to the Company since January&nbsp;1, 2019, and the principal so being
converted will be included in calculating such $2,000,000 subscription (but not the interest being converted). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. Effective as of the
initial closing of the Offering (after satisfaction of the conditions precedent to such initial closing as set forth in the Subscription Agreement): (a) the principal balance of, and all accrued but unpaid interest on, (1)&nbsp;that certain Secured
Promissory Note, dated November&nbsp;13, 2018, in the original principal amount of $500,000, and issued by the Company to FRV (the &#147;<B>First FRV Note</B>&#148;); and (2)&nbsp;that certain Secured Promissory Note, dated December&nbsp;21 2018, in
the original principal amount of $1,000,000, and issued by the Company to FRV (the &#147;<B>Second FRV Note</B>&#148;), shall be deemed to have been converted into shares of Series C Preferred Stock at the conversion price of $25.00 per share of
Series C Preferred Stock; and (b)&nbsp;FRV shall have filed a <FONT STYLE="white-space:nowrap">UCC-3</FONT> termination releasing its lien on certain assets of the Company as provided in that certain Security Agreement, dated as of November&nbsp;13,
2018, by and between the Company and FRV. In order to receive a certificate for shares of Series C Preferred Stock upon such automatic conversions, FRV must deliver to the Company the <U>original</U> First FRV Note and the <U>original</U> Second FRV
Note, in each case marked &#147;canceled&#148;; it being agreed and understood that any failure to do so will not affect in any way the above conversions, which shall be automatic, and that FRV shall only retain the right to receive such shares of
Series C Preferred Stock following the delivery of FRV&#146;s original First FRV Note and Second FRV Note as provided above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. For so long as FRV continues to own beneficially at least 71,000 shares of Series C
Preferred Stock (the &#147;<B>Requisite Shares</B>&#148;), which number is subject to appropriate adjustment for any stock splits, stock dividends, combinations, recapitalizations and the like), FRV shall be entitled to nominate one person to the
Board (the &#147;<B>FRV Nominee</B>&#148;). Upon nomination of the FRV Nominee, the Board will use all commercially reasonable efforts to cause the FRV Nominee to be elected to the Board. The Company agrees to reasonably compensate the FRV Nominee
should the FRV Nominee not otherwise be presently employed by FRV. The initial FRV Nominee is to be determined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. For so long as FRV
continues to own beneficially the Requisite Shares, FRV shall be entitled to designate one person to attend all meetings of the Board as an observer (the &#147;<B>FRV Observer</B>&#148;); it being agreed and understood that the FRV Observer shall
not be a member of the Board and shall have no voting rights with respect to any matter being considered by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. Neither FRV nor
any Affiliate of FRV shall have any liability as a result of designating the FRV Nominee for election as a director of the Company for any act or omission by the FRV Nominee in his or her capacity as a director of the Company, nor shall any
shareholder or director of the Company have any liability as a result of voting for any such FRV Nominee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. For purposes of this
Agreement, an individual, firm, corporation, partnership, association, limited liability company, trust or any other entity (collectively, a &#147;<B>Person</B>&#148;) shall be deemed an &#147;<B>Affiliate</B>&#148; of another Person who, directly
or indirectly, controls, is controlled by or is under common control with such Person, including, without limitation, any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund or registered
investment company now or hereafter existing that is controlled by one or more general partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. FRV hereby represents and warrants to the Company that, to FRV&#146;s knowledge, none of the &#147;bad actor&#148; disqualifying events
described in Rule 506(d)(1)(i)-(viii) under the Securities Act of 1933, as amended (each, a &#147;<B>Disqualification Event</B>&#148;), will be applicable to any FRV Nominee except, if applicable, for a Disqualification Event as to which Rule
506(d)(2)(ii) or (iii)&nbsp;or (d)(3) is applicable. Any FRV Nominee to whom any Disqualification Event is applicable, except for a Disqualification Event to which Rule 506(d)(2)(ii) or (iii)&nbsp;or (d)(3) is applicable, is hereinafter referred to
as a &#147;<B>Disqualified Nominee</B>&#148;. FRV hereby covenants and agrees (A)&nbsp;not to nominate or participate in the nomination of any FRV Nominee who, to FRV&#146;s knowledge, is a Disqualified Nominee and (B)&nbsp;that in the event FRV
becomes aware that any individual previously nominated by FRV as a FRV Nominee is or has become a Disqualified Nominee, FRV shall notify the Company in writing of the occurrence of such event, and FRV and the Board shall as promptly as practicable
thereafter take such actions as are necessary to remove such Disqualified Nominee from the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. For so long as FRV continues to own
beneficially the Requisite Shares, the Company will not, at any time, grant any security interest in any of its assets, without the prior written consent of FRV. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. This Letter Agreement shall be enforced, governed and construed in all respects in
accordance with the laws of the State of Texas, United States of America, and shall be binding upon the parties hereto and their respective heirs, estate, legal representatives, successors and assigns. If any provision of this Letter Agreement is
invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed to be modified to conform with such statute or rule of law. Any
provision hereof that may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. In any action, proceeding or counterclaim brought to enforce any of the provisions of this Letter Agreement or to recover damages, costs
and expenses in connection with any breach of the Letter Agreement, the prevailing party shall be entitled to be reimbursed by the opposing party for all of the prevailing party&#146;s attorneys&#146; reasonable fees, costs and other <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with such action, proceeding or counterclaim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. This Letter Agreement may be amended, terminated or waived only with the written consent of each party hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement may be executed through the use of separate signature pages or in any number of counterparts, and each of such
counterparts shall, for all purposes, constitute one (1)&nbsp;and the same agreement binding on all parties, notwithstanding that all parties are not signatories to the same counterpart. The parties may execute this Letter Agreement and exchange
counterparts by means of electronic mail, and the parties agree that the receipt of such executed counterparts shall be binding on such parties and shall be construed as originals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing terms are acceptable to you, please sign two copies of this letter agreement and return one copy to the undersigned. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FRONT RANGE VENTURES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lauren J. Richards</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Lauren J. Richards</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Trust Officer, First Western Trust Bank</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AGREED TO AND ACCEPTED</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as of the date first above written:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HEART TEST LABORATORIES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Simpson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Andrew Simpson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chairman</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g271308dsp152.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271308dsp152.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MH#P99R1+%>7E]=HO\,LY(/U%1S]BN5&[:VD-G;I!;Q+%$@P%48 J&RUH6.E
M!0 4 % !0 4 % !0 G:D+H%-#Z!3!;!2$% "T#"@!*3V&**8@H * $I#%IB"
K@ H * "@ H * "@ H * "@!.] @H&% @I#0M, H * "@ H * "@ H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g271308dsp152a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271308dsp152a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M\"%*V@^I9I#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M:(MPFBV@NK2&SN"@+P0#Y(R><"LY;FD=M2_2&% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %
M6?3+"ZE\VXL;>63IN>)6/YD4[M"LF6(XTB0)&BHB]%48 I#(KBRM+O'VFUAF
MQT\Q V/SIW:$TF2HBQH$10JJ,  8 I#(7L+.2<3R6D+S#I(T8+#\:=V*R)3#
M$5=3&N'^\,?>^OK2&/ P,#B@"-((8W9XXD1V^\54 GZT 24 0W%G:W8 N;:*
M8+T\Q V/SIW:%9,?'%'"FR)%1?11@4AC\#(..10 8&<XYH ,<YH C>"&1U:2
M)'9>A902* )* (Q!")3*(D$AZOM&?SH DH * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H 3(]1Z4 +0 TR(KA"ZACT!/)H =0 4 % !0 4
M% !0 4 % "!@20""1U'I0 R6>&#;YLJ1[C@;F R:!7L24#"@ H * "@ H *
M$R,D C(ZB@!K31(VUI$#>A89H%=(<2!C) SP/>@8M !0 4 % !0 4 -DD2*-
MI)'5$499F. ![F@-AU "*P894@CVH "0,9(&>!0 M "$@=3B@!: $!!S@@XX
M/M0 M !0 4 ,,L8E$1=1(5+!,\D#J<>G(H ?0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '$_$2&.Y/ANVF&Z&;5HHY%
MR1N4@@CBM:6E_0RJ:V0DNE6WA?Q;I+Z27A@NXYXY;0S-Y9VH7#\DXY !/O1=
MRB[A90DK!H_B_4+[4-*AE>PD2^9T=;:-R(2$+#]YG:_0#C'6AP5F$9MLN:5X
MKGU)M'M3#$E]</,+M "1$(LJQ SQEMH&?7O2<+78U.]D4].UJ_EM]$TK28K2
MTEN;>2X9Y%9TC56 VA=V223U)XHLM6Q)O1(7X>M.TWB;[3M\X:M)O"_=!P,X
M]J=3I;L%/K?N9EA>WND>--:U+<&TF2_^S7@8_P"I^1=D@]LL0?;%-I.*74E-
MJ3?0L:=KT^FZ#I=K;,BRWU[=KYSQM*(U61V)"KRW8#GO3E&[^0U*R5BU'XQU
M*W-M]MLU$ U$6<MP87B5T9?DD4-TYX(Y^M2X+H-3?4K:7X\U'56L[>*R@2[N
M+]4V,#Q:LGF"3KUV^_X4."0E4;$B\<7ZW6F.[V<\5[>K:M%;Q.5B#$@,)C\K
MGCD 4^1:ASO0M::?]*@_[&*Z_P#1<U2_T*6_S.WK,T/.;JRDC34X[WP^-:L;
MB:63^T[26-ID&X_+AN04/RC!_AZ=JV36EG8QM:]U<VY-=D\R.UL+MDMXK**;
MSFL9;EWW[L9V8 X7)]<]L&IY>K*;[$MIJ^KZM-900I%I[M:"XN#/$68$L5"J
MI((&03D]L>M#BD--L:NJ:]_;^F:5(MDC/#)-<N$8Y5) HV#=QN!'!Z9[XQ2M
M&UPN[I$,7B._F)NH@TD/VOR1;II\S?NQ+L+>:/ES@%NF.WO3<5L+F>Y!;7]W
MI<&OW)U&U8G4O+47 95B)V#C!)8X(PHQD]^:+7LA)M)C7\4ZM%;ZZD<<4TUB
MMN]O));20[Q(Q!W(QS@8//\ A3Y%H',U<V6U.[TK4;:#5;FW>*>"5Q)'$4PZ
M?-MY8\;-W_?!J;)K0IMIZC]'U6]F\*+J^IP+%,T3W!B4$;4Y*COSMQFDTN:R
M"+?+=E!=8U>STW2M3OWMFCO988Y+>.(J8_,( PVXYP2.W//2JY4VTA7:2;'^
M"8IULM2FN'1YI-0N S"+8Q*R,.>>>G'H.*4WL$.I1\)65MK7]MWVJVT5W=-J
M$T)$ZB3RT0@*@ST&/SJI/ELD*"O=LEMKI[>33?#N@ZBKQ/'.YNYOWK1*CA=B
MC@$@MCG. O>E;>30UV01^(]2CU6#2Y!%*\>I"SGG$9 =##YBMC/RGMWZ>_!R
MJUPYG>Q-?:_J,6HZG:6XMP8+JT@B,B$@"7&XG!&>OM0HJUP<G=V)E34$\:62
MSWT<B_8)2RK"5!P\8/\ $<<G/MT[TM.4=GS%G6[^X@NK>UM[Q;8R(SDI;/<2
MG!7&$4<+R<D^U)+J$G9V,;1O$>KZ]9:.8FM;66\CN6F<Q,V/*=5!5=W!.>A)
MJY14;DJ3DD36^M:K<PQ6"S0+>/?S61NO*X"QJS;]F?O$#'7'\J7*EJ.[V+/A
M]+F/Q-X@6ZECEE'V?YT38"-A[9//XTI;(<=V%GI.FZAK^O27NGVMRZW,:AIH
M5<@>1'QDBAMI*P<J;=SGM$U"2UEMK )'<6T>O36EO),N]HXQ&S?(>Q!RN?3B
MK:OKY&<7;3S-<^(-5@TBPN;MK<3:C.L4"PV[R>6N&8L0"2QVKT&,'UJ>57=N
MA7,[+S)$UK5(;9X)#OE>YAM[:ZEM)(@V_P"\60XY7!Z$ \=*.5,=VM!=5CUZ
M'39X)M0MW420-%<B'#Y,HRK(#C'3D'U&.]"M<'=+<DM]0UG4-0U6VMY[:%--
M*1;W@+&:0QAB<;AM'(]?K2LDD%Y.Z[$>E:]J6NW6G-;&WMK>:PCNYE>,R-DL
M04!R,=#SSTZ4W%1O<%)RM8U-5N;\ZA9:=830P/<))(\TB;RJIM&%7(R27'7L
M#4JUKLIMWLCF?$DM_=Z4;"[FMWDM]6M8F<0_+(K-&RY7=Q][D=\=LU<4D[KL
M9R;M;S.F\1ZN- \/7-\$\R6-0L4:C[\A.%4#ZD5$5=V-)/E5SD= UVS\.6NJ
M6,<4YCM[,7Z>;&\;2,$ E&&']X Y']\^E:2BY-&49*-T:5RNL^=X>GO;R"XB
MGO4=T6'9Y1,;$!3GD=N>:E6UL4[Z7&PZWKD^GZ7J7VJU5;VY^RF#[.2%RS*'
MSNR3\O3@?SIN*3:'>5DR5-7OE-]97I@NY++4[6!96AQN5S&<[<X##=P?8&CE
M6Z[ F]4R3^T]:DAN-0%U;);V]^UN(! 29$$NS+-G@XZ8':E9;!>6Y4EUC5%N
MM6CTZRC'EZFL$LMO;[I!&80Q<KGYV!P._'8XIJ*MJ*[UL5-9U&[O+;0XX=22
M1UUJ.!Y! 48$ D;T.-K<<CH<YXIQ25_03;:6O4WVU2\5];N9;RVM[6P=H8U>
M(_>\M&#,<Y/+8P .M19*R+N]3GK[6M5$NJ:/]LFG1]*FN4GFLC ZLN 0HXR"
M#Z<'UJDEH_,AR>J);_7KG0-2B>X2&[>WT.2X,@A"R.P=<#<,D+Z]N]-14M/,
M&^7[C=M9M5LKS3/MFH)=QWY*,GDA?+;RV?*D=OE(P<]N?6-&F7JK7*=A?:W-
MIFD:O+J$+1W#Q)+;+;A5*N=N<Y)W D'TXZ466J$F[)G6U!H% !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 8GB7PW%XDM[2.2\GM
M&M9Q/') 0&# $#DCCK51ERD2CS%?3O!MG974]Y<7U]J%W+$81-=RAVC0]0N
M *;FWH"@D5[+P1]D;3F;7=1F.G.#;JS*%5 ,%< <Y!QD\XZ8INIY"5.UM33L
M?#5AI_B"^UF$/]IO  P8C:GKM&.,D9/O4N3:L4HI.Y1NO!=O+96$5KJ-Y9W%
MBK)%<PN Y5CDJ>,$=*:G8EP5D6_#?AJW\,V]U%;W5Q<FYF,TCW# L6( /( ]
M*4I<Q48\I-;^'[.'^U5?=-'J<ADGCDP5Y4*0..F!1S/3R!12N9O_  A%C'X?
ML])MKR[MS92-+;7*.!+&Q+9YQ@C#$=*KVCO<7(K6+!\)6<GAJYT2YN;FY2Y)
M:6XE?,K.2#NSC&1@8X[4N=WN'(N6Q-;>&--M=6BU&)")8[,607C;L!X/3K@8
M^E+F;5AJ*3N8L/PVTZ!+>./5-3$-I.)[:(S I P;/RC;_/G]:MU6^A'LDC>M
M] MK>17624E;V2]&2/ONK*1TZ?.:SN7RFK2*.9O/!=M<W4[QZIJ5I;3L7EM+
M:?9$S'[QQC(R>3@^OK5\[ML9N"ON6]1\,P7K0/:WMYIKQ1>1NLY FZ/LIR#T
M['J,GUI*5BG&^PR^\)V=U'9BVN[S3Y;2/R4EM)=C%./E;(.>F>>]-3:$XIEB
MP\.V6G7-K<0M,9+:!X 7?<7#,&9F]6+#.?<TG)L:BD5O^$2M?[6%Y]NOO($W
MG_8O._<>9G.[;C/7G&<9I\[M87(KW(KOP78WDFH.UW>)]LF2XPD@ AE3I(G'
M!X'KTH4V@<$QUKX.LK5[F3[7>RR7< AN'EFW&4@Y#GC[PZ<<8[4.;8<B1%XS
MTFXUR#3M/@LS(C72R2W&\*($7[W?)+ D8'J<T0?+J*:O9'3%5*%"H*D8((XQ
M4&ASMCX-LK"^BF6]OI;6W;=;V4TVZ"$]MHQGC)QDG%6YMD*"3-JRL8;".5(=
MV)9GF;<<_,S$G\,FI;N4E8Q]2\(VU]J#WD&H7^G23#$ZV4PC6;W88//;/6J4
MK*Q+A=W);WPIIUU86=M 9K%[($6T]J^R2/(P<'OGOG.:2DT#@FK"-X4LCHW]
MGK<72R>:)_M@D_?F7^^6QR<<=.G%',[W#D5K#;/PAIUFTT@ENI99IH9Y)99=
MS.\1RI)_G_2GSL%!(T;G2H;G5+34#+-'/;!E'EO@.K8RK#N,@'\*E.RL5;6Y
M5U;P]#JMW!="\N[.>-=C/:R[#(F<[6XZ9_K34K:"<;ZBZ7X;T_1S#]D$H6#S
M1$C.6""1E9@/;*C'U-#DWN"BH[#;GPU97%E<6ZR3P-+<&Z$T4FV2*0]64]N_
MX$BCF8.*:L2:-H%MHCW,D,]S/+<E3+)<R[V8@8!S^-#E<%%(I:AX.M-0U*>^
M.I:I;/.5,B6UVT:$A0O0>P%-3:5K"<$W<O?\(]IJQ:;%%#Y,>G2^; L9Q\VT
MKSZY#'.>_-+F>H^5:>0Z?0[6?1H],+2I%$%\N1&Q)&5Z,&[$4KZW#E5K%6'P
MO9QZ3<6,ES=SO<,'DNI9<S%AC:P;L1@8QTI\SO<2BDK$<'A&RBLKR&2ZO;B>
M["B2[EFS-A3E0&[8/(P*;DPY%:PRZ\&VMQ*LJ:CJ-M*T:Q7#PS[3<A1@>8<<
MG'<8-'.P<$S6MM*M+.[6XMX_+VVZVRHO"*BDD #\:F]RK)$6L:+;ZS#$LDT]
MO-"VZ*>WDV2(>^#Z'N#Q0G83C<JQ>%;"/3DLS)<RXNDNWFDEW222*P(+-W^Z
M!CT%/F=[BY%:QI7=A!>R6KS@G[-,)D7/!8 @9^F[/U I)V*:N,N]*M+Z[MKF
M>/=);[POHRNNUE8=P?3V%";6@-)F59^#;&TNH)VO+^X-M()+9)[@LL'!&U1Z
M<]\GIS5<[M8E02+J>'[&.PLK-/,$5G.)X_FYW D\^V6-+F=[CY5:PYM!LFN+
MJ8B3?<W$5R_S<;X]NW'M\@HYF'*AXT>U%E-:C>(Y9S.WS<[B^\_AFCF=[CMI
M8IW/A/3;H73$SQS7%R+KSHY2KQR!0H*'MP,?B::FT)P3&2>$--ETDV#O<DF<
M7#7/G$3-(.C%^Y'3Z 4N9WN+D5K%^;1;.>VU"W=&\N^??+AL'=M5<@]B-H/U
MI<S*LC/@\':=#>+>23WMQ=>4\#RSW!9I$;JI]AVQBJYW:Q/(A]AX3TZPE@EW
MW%U)#;O:AKF4R;HV;<0<]>F![<4.;8*"0NF>%K'2[Y;M)[N=XU*0+<3F18%/
M4(#TXX]<<4G)M6&HI%^+2K2#3K>QCC*V]N4,:[B2-I!'/?D4KZW#E25B[2*"
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * .=\5Z
MIJ.F?V6=.V$R7)\Y7'WXEC9V ]#A>/>K@D[W(FVK6#Q-KLVFIIZV+1O)-<1&
M3D']P9%5B/J749]Z(QO>X2E:UB[=:_:V<K^=#.+>.0127.S]VCD@ =<GD@9
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M2&3@HP/S#:>O'4C!QFGRV3%S7:L6M1O)KG7(-#M;B2U9H#<S3QA2RH&"JHW
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M>]-NXDK#I+2&:Y@N)$W20;O+)_A)&"?KC(_$^M%QDU( H * "@ H * "@ H
M* "@ QD8- !0 4 % !0 4 % !0 4 % !0 4 % !0 4 06=G#80>1;J5CWLX4
ML3@L23C/;)/%-NXDK;#A;1"[:ZV_OB@CW'LH).!Z<G]!Z4O(=B6@ H * "@
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M % !0 =* "@ H :TB(RJSJK-PH)QGZ4 #2QQLJNZJ6.%!.,_2@!U !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M:1VS6R6L*V[9)B$8"G/7CI1=A9%BD,* "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
/ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g271308dsp300.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271308dsp300.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M[?[$GR\RD=+HOBG2]<4"UGQ)_P \WX:MJ=:,CRJ^"K4'=K0VUP!6NYR7N/H
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M9>?=V-S&UN_FNNP@9Z @'D#KFNI>Y!36]W^2_P SDOS3<'M9?J>_UB;'RO\
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M;4ETM^IZ0O2N\^=%I@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M/X5I7]UODT_KS(I^]O\ U]QKIXDU*+P1X?9;^WN=3U6:.U6[10R*6)RQ X)
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M H ,#TH 8L4<>=D:KDY.!C)H'=C\#TH$% !0 4 % !0 4 % !0 4 % !0 4
9% !0 4 % !0 4 % !0 4 % !0 4 % '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g271308g01a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271308g01a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1X44&AO=&]S:&]P(#,N,  X0DE-! 0
M    '?B^=G(X0DE-! 0      $8< @   @  ' )0  AR<C,Y,#DX-QP"!0 M
M36EC<F]S;V9T(%=O<F0@+2!(96%R=%-C:65N8V5S(&1R869T(%,M,2YD;V-X
M.$))300E       0EZ8 9]LYE$M369@FLZ 6ESA"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^
M-0 "  $#O_XU  (  3A"24T$)@      #@             _@   .$))300-
M       $    6CA"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          3A"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #/0    8              I(   /(    ! !3
M %0 ,0 W     0                         !              /(   "
MD@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MD@    !29VAT;&]N9P   \@    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   I(     4F=H=&QO;F<
M  /(     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M   '.$))300,     !.*     0   *    !M   !X   S&   !-N !@  ?_8
M_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,
M$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !M * # 2(  A$!
M Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !
M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M%[6YE,.:'--K6UBQMW\U^0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6FFVT#"$(0A*4X"0!MQ6>/URB2I%&2222:9)))B22523S/V9?JJEB JI @
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M=8"8JJ8HME"Z)Q3G4K<17MH42/Y66QTM<QMRDA;(73:F0)48J*54L$H#2.9
M!IH&5))R5;Y\TC((45D$I?ILT&!ZJZ!.LD^N*-C8:B-I,A*17&2BJI4G(0D&
MB=@+V43Z^3 _E&HG>(%+FP*@]*GS(52\9*1XF4&$4U+3DEZ6%K6@NQ'W6TJ6
MHJ+:R\=R OIBMEBIIVD,-.L%MI*6VU.M.J<R) 2D*R/(2I0 NH% /\LXI8IJ
MND99I:=VD]7IT-LL][3OJ=2RVD)2A62J0A:D@90L=V" );F24RG*5S*/NZJ
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M&4I:5T.R]*.U5;P"DI'>X3Q^HX<S3ONH*PRCB2VDMO.-(6DK#:'0LH2L3'O
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MQY+/AEAWG*%#F2M((!>'./A/JZ?]'QVK::J*7MA2U-,^TP^U5,\([RG=IZA
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MJBI:AY*4.O,-K=0B<B'2F'4("BI61+F=(S*4;022"<4\W-<9SFXZ[GO:@/\
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MFE3'5M-I0PGE;;0A/>H*:GI:)JFI'77V&DK2VX]5.UKJI4I1SU+[CSKI"E$
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M !(V Q8&2 1WSYF\E:3>22;H.LV A*19( M@YNTKW8< -DUE)<13LAZTUN?
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M,*M,=4,6Y6!%5+4ZICQT<,*D,,\HD*9$3NRZEI:FDJ*2I*"0#C(X,&$QU_:
MVM2IGX$''C(H.%J(&_@LY'7F.Y&!TQP8,*%=H=9:\&;<K"HJ'Y;J(_O!CPZ7
MFF5%;R&3#[I*W$DH2L)YD!1*3N<F#"<=H!D_]5:E]:.G^>Q/]*A2@?YA^@ 0
ML9^,[D\&#!Z^T6X]'BQ7+=K3L:,F2N)&75([C,<N.%3_ '#)@E#9?<3SN%M
MYE?$H$C/") $G[\]!YX"0+D@#F3 ^)M@L:_-%T(^BU1!+K",^.AG=U',"0:>
M0>4 @IR><[D9W#P8$[VBW'X\=#UNUEUJ+%48K3M5C.-QFERN133"%T\AD*6
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MR(5D(_L[9)F\V $1U!$1CS_$TK-8@(4$DTPDD9K=ZLQ%]Q/X:XZ#OXL/M?\
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M=+0ZD *6I+Y+C:94?5P$$C+-\%H%'1);46Z@ZGQ,8+:'<,$D-JP$R"B2$E.
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M/.+[[^> HW!N.1(M:TYM/GM,8QHJE\SX-7ETVFT.Q+DBM5FL4^=(3KA9]!5
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MM(2CG;)75B&L #NWCWQ!4I2HY"0'(GUR/8;I<Q$#-4/%.:9"C%*"H7(*!DD
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MU%(U&*"94"5&DL@N9*'D!1020()X6XX@.-K0MLE4*2Y(.112JW=[*20;C37
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M0D+7KE!#1DQ>;)@:\[6G:I\J#+8<*1*@G,2!I_/SPUM1]LC[3:E2)L&I:?\
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M$[6& *J4I+!2&J'@1V@G--M]1P'AU6N"M:]@=UJ45'XB2HD\!IFR;KJCJ?\
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M7.3D=,\'W]_?CA3T/R_/$Q-TL4"E&I#ZN9ME.#I[+&"WNK9,M602G*?Z0QD
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MK2TH0O5RXUI:1W;:5U&]%!MOF6ONVP:>0A'.XXKE3RIYG%JQS*43+_2NEO\
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M8*Z\RN8G.<;Y!)RD9)((SDCN$03XD8ZX5)L"(U\00!&UI/,[X2*&3DIP4D8
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MG)&3C@E-S.E[&?E/T!OK>,$#^FWP_/"UBARG,?$0""1\6"K/(0<X(&.<#XB
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MO:V/@T_^%&?W8^?]R"B1S \<&\7'E;YC[!MT%_%P:'_0D?>A&_S&$C8_/]G
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M?,P,!/9Y:!VB)R/]4;>9_0QUZ$>GICAYB;@F]]<(WD$>7G'X _UP'^+P@_\
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-"-N4'S&_W$<&#'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g271308g01a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271308g01a02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1RH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '(R^<P@X0DE-! 0      $8< @   @  ' )0  AR<C,Y,#DX-QP"!0 M
M36EC<F]S;V9T(%=O<F0@+2!(96%R=%-C:65N8V5S(&1R869T(%,M,2YD;V-X
M.$))300E       0EZ8 9]LYE$M369@FLZ 6ESA"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^
M-0 "  $#O_XU  (  3A"24T$)@      #@             _@   .$))300-
M       $    6CA"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          3A"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #/0    8              N    0\    ! !3
M %0 -P U     0                         !              0\   "
MX                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MX     !29VAT;&]N9P  !#P    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   N      4F=H=&QO;F<
M  0\     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M?YW>AY/U"ZWD,K#*^F8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M8F5R>(&ALK72L__$ !X! 0 !!0$! 0$            # 0($!08'" D*_\0
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MR)$=$4'BM>U+@?A[-R,#+X6TZRZC"P\Q.QTC2^7(&7EG%%-//6I-M*J^1;S
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M_P "4<AT .=L4S<2$E*<?F+%HF99R[=;,ED4$$B]O$=14]&*4H>T #N/<QA
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M6%UY\.KDW'/R7-SA?.5W4C<>@]#Z1)7HN1;R\9'RS,3"TDV+60:B</"<6[Q
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MX-;P=0((E=V%._55"6L)?<,UK9@E0.QC%"B8JUB$2N5@[EA4P Q)5+9JE.
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M451L%51L !Y@ -I6Y9+HQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)
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MTC2,2VKQ')&[UBY1\JW=)J#VG"O!>9Q2MMF-D54TT.*[W;E)I9@2@8-8A/:
M,4Y5??8C;<$31\0<5\*\)XE>5Q%K PVN%AQL''Q;<O.R>SV#&JI2E:J"R@V6
MVUUJ2 S@D2.61ZR7+274\81.BZ2F(B88VL5RWWIRD41[%2-9;+.5=BN8O< ,
MJE5B%,(=RD#N !Z?A^!_1Z@&U'5LRX@^4F-774/E >Q6/3YCOOTVVG@/$'LC
M\&IK*>'.'[;CL>RR=8RUKYN_9SAX:/RCN(!S"=]]^@EPA^IES4M2J:=>;O)E
M4XA]C*576[93OV^L 1@I(0*/< [B\$>W\/?-H_ /@\PE_P (KRW.W5K]5:L_
M/RU5C;^!/?M/,;?#GX4M1N*X%VB8@)(2K&TDY-G7J!SWY%G,2/0F^WR])MI'
M</.G9LU5;79^,FJ[O-U!R#VH6*^Z[KDQ-UAV*[=UYW7I96$<R$"Z%PU;.!<1
M2C-7R[9%;OY1%,Q=!EZ%X*ZN8-9EUL.FU.HV/MMOO_C*R#MMU\WG^6=#IO'G
MAXR KUU8V2A((-W#O*I&XZ%J>4[=>\$=//TG95;Y2\\8TJ9KAQ=K%@1* "J>
M LTG#/#%  \0D3D8M=#Q=N_8#=@[B'<>P".<[=PUP!D[^)\396"3[T9=:9"#
MY6:NNOU\P'3S;[SO,/PA>%W%"G4N!<74UZ%CA+E85I&PWY5NLO!/>0!63OTV
MVFY(?G?#LD#AM'3NU-=/R(G4*W+$)6Q!X<@&[IL5($RKM4#&#P@HJR12*(AY
M10@9P_$NFZ+H.,^7C\5Z'JZ*W(F+A9539]CD;A%Q4LL8N=CL"PV\Y$]AX$UC
MB?C/.KT[(X XGX>L90]N?JN'91H]%1(!NMU'(JQT6H;D\P1B0/)!W&^D[IU!
M-\R?G!-&\0[/868"(-+!?)Q[&HK%[B!5P@:=7+4Z*F?V"5)Y)L5P]H'3(8!
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M"6:CP?<2.^U^$*:@"SLN1BO8P'\BI%OV-C=R\[(@/5G '6.SB?2@OZJ\V.2
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M>!"@  !0  ]@  =@ /N  ?\ V^Y_!F+-J !T'0>CS?W2D<L47A!2<B8Z1O\
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MS"RL5.6%3.4%8J*AV0N.9%"OLWZP;E]R=YW#TUR'^B;::@$-Y(L#6DC*>$?
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M;(Y455IQZM^QQZR>1 >]F)\JRUOY=SDNQZ;A0%%U-"U<S$FRY]NTN<#F;;N
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9,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g271308g01a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271308g01a03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2+@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (L2^B0 X0DE-! 0      $8< @   @  ' )0  AR<C,Y,#DX-QP"!0 M
M36EC<F]S;V9T(%=O<F0@+2!(96%R=%-C:65N8V5S(&1R869T(%,M,2YD;V-X
M.$))300E       0EZ8 9]LYE$M369@FLZ 6ESA"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!C0           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^
M-0 "  $#O_XU  (  3A"24T$)@      #@             _@   .$))300-
M       $    6CA"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          3A"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #/0    8              >$   *_    ! !3
M %0 -P X     0                         !              *_   !
MX0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
MX0    !29VAT;&]N9P   K\    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   >$     4F=H=&QO;F<
M  *_     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MGN>Q^(YC#8X7&& @$_HKN[X:L_K5 SZJJ\NM^.UCBYI%E(DQ_P )8$V8,HR
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" $L ;8# 1$  A$! Q$!_\0 'P !  (!!0$! 0
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M\1N*QD3/.&,>V5%EB]!B]4KM[R95ZG.E9/"3AS-'HQ4N[[#= 13L=QUM44U
M*)!XJ^=']KM-HK[C!5U\DM+!UK&2NI^K<X/8,.W:<.Q@D^2YIR!ZNP[*=+-Z
MO^T5JL]3;K7!!7U#HI)8&U?6L:V":7+.LJ7LR3& =YKM.SM7[?0#@ !X@ /%
MT?!KR<<!Z%[XM=5$T15/GKVC,T?)/D7\SYC15O$>D>]?RP&O_6S?_P"X1_\
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MVIE>KO/L,45LJC>G-()_*N7#F/RKMI[A#9[?/%=I)+A44U95RM926Z.!KH9
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M^8-T$V", RK[A)Z\D-S]/7IM?*]U:#3Q;5QV;P%U+ &NII6@X=,V%E1O1$
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M]U.[S^5\W5O(=#I$!NENETVM,JS O'% )&5.I!:7D&,VJ:/OLE8-PS>7@).
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M'!XRZT.<YMGMK7.<7%P$A<2X^67//EDO!<'N+MYV<EQ.<G="ML<SJSM!>"P
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MLTK''><UY&"X=IW1QQH2<@]JU:V^WFZ1"EK[E4U=/$[?8R:1SCO: .><Y<[
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M2BX0@IYL@W<JQR^(81PH1%VD5=NH*K&H.6P@JBHF<"@J)PY7 P 80#5#7.(
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MUB'14<?4[W%9-:*)HB:(JGSU[1F:/DGR+^9\QHJWB/2/>I?1OL)I_P!JU?\
MR2TT44IT1>0&XK^ZUM(>#N,KWY+8:ZEMO_>1G_7CWM6RJ>)]+?<[X*KKU=ZA
MC2HV&_W^QQE2I=4CEIBR6697%M%PT8@<I%GCY<"*"B@0YR$,?DCP$Y1X>+R*
MF@DJ9V4\0S*\EK&D9+G;I(:!KDNQ@>=:(^J .6-#PQW'/FYZ$]JY@VBME?5V
M,+-QJCZW,GTC6$$G!%1G8Z.:H/GKZ-,GRR.&S=F[:N3K%-R0271,43%4 =3J
MI0USG1D%AW7@MQ@G49!QNY&HR -..JP,N#@M.FNF>[AKKZNSBN_,7@)0'F$>
M'$. =(CXN/BX_-S?! P$'R@"-W>!<T.\KANM.I)(XC(&N3S=;Q.-!G77'].,
M:XXK4"")A*'2''I#APX"''F$!#CSAP#CQ'Y]:9>S#B7!NZ2"" 2TM)SG!+L9
M''!TQJ1JG6@<1DCU9/+&..HT\_FTAEHR#2:7V86T6B%AE6$2G/.VSQX0KQ&%
M/*M(0)869.6Y,P&7?,XX7)43)=EKD2Y7*-K7BADFR86&2,N#&RXPTR%N^&9.
M@.[J<Z$>?1:@.\ <$9!/'U:GT'.A]&5,BD,8I3!T" "'-S\!#B'$. #XNGQ@
M/A#CHDC#M[R7-:7%N #C.,YX<2,9T/9G.%@Z0-)&ZX^?7&<D:96HD$./'D]
M#XA / (AX./'AT<.CGYP$;OX=NACFY:UP<=6XP,\^WCH#J/,L@ 0#J>><$YY
M:CAZQQU[<0C(X?UF30#SAR6W3\+MN/@\(<1Y_FUSNR#@_:"W.QC$LY'F(C>-
M.0QH!R6,0_A'#L\D$:\2?/KP [M=5[1XQ]K;'OVCU/\ (+#7N*Y1O >@>Y3C
M158\[>UT&M4R8Y<JIH-V^?-P:ZZZIRII(HI95M1U555#"!2)ID*8YSF$"E*
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MQ[6)"?B(IM:X$7:*R#.SUI26K<D=%7M;*NRI'$I",*Q>47QAS_M\_,/$.D.
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M3LA;-[CN*R.WM6#I+$A8*Y4J(QU/A6<!3\A6:7"9@;SC2WV/LB,CI*V&C8J
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M*9;Y1<Y7E6LU?4+6I::'/N&)IB1065935+5J5JK"3YZWJ5@@FZQ$DB$D_$
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MZP6?'>/;)7JQ1:S *4YE.3X/I^.B(R(<78T0Q2NCV?1D;2G8BN3YNX?#AYN
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M\&B+&#,&[#'>%+0A4[5%VMY(KQ;>6(M"1\:Z9@V=*N$4R&5=R[!7KP&;'$Y
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M08P#J--.Y:"?B/$><?C+_P K66Z1@ 'N*S#,# T \SOU5V$5Q"29@/ !,IS
M!@,/#X0 1#P#Q ?!TZ]2Z#P7]+G1\&@_\9[>-3N#ZY)!<[  QQ.0.SF%YGTQ
M@.Z+]M3KAMFG)):X $%I.A ) ';W+]5&,>/>VQ]QYQ[B:KT_!!,/V#X-?L\>
M)])[<^W7/IR5^4[-&-'\D>[AZN79P4YU%DL?MNGV-9&_Q@<__P"=BTZ*GCZF
M^X*_^27^"7Q= ='BZ-%%KP#HX!PYN;@'@Z/F\'BT1. >(/F#1$X!X@^8-$3D
ME_@AS!P#F#F >D/B'1$Y)?X)?F#1$Y)?X(?,'@Z-$3@'B#Y@T1.27^"7IX]
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M)+#_ )=W7^86[]JI_9;7O_)&W_SZH_8K7V#&X+W 2 ?\+U[^:2'5'X$E@/\
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M]Q636BB:(FB*I\]>T9FCY)\B_F?,:*MXCTCWJ7T;[":?]JU?_)+3112G10G
M)Y#*_+/U<H>%K??^?X[#YZ_)AKSSI2'^]6/S7.G/^I,/O7V9^ O_ ,LM2.>Q
MMU'_ -S2?!?G%.'%0W_EF#YS'X_BX?=U\_#1C?.UISRP&CV<?8OUO.CSG4!Q
MR.>#]ZR!VKU*NW[<5ANEVY@A*5JS7^$B)Q@Z6=-VSN-=JBFLW769*).DDCAQ
M$ZJ"I%4P*!B<0$2&YK9FBCK;[0TU2T.@FJ-UV]JUP$;SKW^C4G*\XZ6+U==G
M>C7;&\V:JEHKK06Z2>EJH-QTL(#HFQN8R0%KCJYN"1J,ZG19*4K;;1E*3DAZ
MM<<8W>=)EC"51KSBIR-HF5*HRN.07$'*FDXQ_%UI!\Q>LC(-5TRNEECIMSI(
MN&JHBXUV"@L5"8*YTDUOJ'^'6YD8B+Y7PQR5SF.!U9C##U?;P)/8%Y7M#TH[
M1P7C9J/Z)VGLE#+L?M5<KG3UM+2T/TQ/062CJ(9::H;X2(S'(]TIE<&=4'DE
MCCEJZ2M;5\92\<SA;-E"QP.5+?C[)>5ZE78JCHR=."K4%.YKLXF7GS3Z3]C.
M6<E*DW#/L6-?1\2S.BB_='>F$I-K3[,4<QCCJ*^6.MDIJZO@@CA<Z!T,$TV&
MNE) 8[$8R2-UA.#G!6[NG31?X7UM79MDZ.Z;)VJY[/[-W:[UE\%-=(;O>!;&
M/EBI&0NBDH:&2X-9(YV[+5N$CX0(]5<M[VP8#7RFX;42=F#/*-;=M*E]QNXK
MQVE,4JV5Y"C0,BPK]L//NIMW,)2,X=S,$=1K%H=&153BG/%J4^N9J-GK4;E)
MX)))FFGM!KZ1\3FQ.971Q,#@\X#^LEFWG[H(8<Y."NG[.=,'2)'LI$R^6^"2
MGO-LZ0V;.[5LKM^[QW'9H7:MB?6T#Z>*""F934IBIQ$'N/5QNF'\( ,9K9MM
M9 O;+I#31V>,X6N9(LLG**1YBMX&SU*[NZ8TQL0RKQ0[QX\F).G-V#TZA7"L
M5/I22B9@:G _ U%CA$E=5Q5);014U7,#U?DPSPS&(4F"_)()#&$D$MP[=Y^D
MV'I2J'Q[/;.5U"^IVNKJK9VD; ZHWGW"W72RLNL^T<N(8V,CCI8:^2:%K"UL
MU.Z-L@W@1AX(@(B(<> B(AQ'CT\_-S!P#Q!P ?'Q'B(]1.- "2!D!Q;NEVIU
M+<G![,9/!>ZYS_&QD@!YR1@X[=0"02 >:R#VO^WOCS_TD_\ R+):[5L,,[66
M;_M)/<PG[EX=^$X<=!?2#_\ *(QWUM,%_06QI[7&/_M)JGY"8:^G5^&S/J-_
MS6^X*;:+)8_;<_L;R-_C Y__ ,[%IT5/'U-]P60.BB^/7>G][S<P<P\>GH#^
MUX>+CS\ X]/3HB=>#@(@''_\73X>'1T^( X\>@.(\0 B^A3<KCS<.'P\_P"W
MX_!HBW:(FB+:8W)#\7'B''X./ ?V^+1%LZ[P#B)1#GX=/'\7BYN/Q\W'FXD6
M\IN5S\.'BZ>?X>@/]/C#1$,;DE$>''AX.CCS\-$0IN4''AP^[Q\7AT1;M$31
M$T1;3&Y(<>'']NG[G3\71Q'@ D6H#Q#C^W\VB+71%H8> "/BT1?/KO@X (\!
M$0 >/0'Q<>8>8>;F\''HT1?4.< 'QZ(@] ^'1%\^N!QX!P$1$.' >GQ\.8!'
MA_,/.'#1%O*/$ 'Q_MX0#\6B+71$T1-$6TQ@+XN?CPXCPZ.'-T#T\> ?#P#I
M$ T1: 81X<W3T\_$0^X ?%TB'3S?"1;]$31$T1-$31$T1-$31%C+NZ]IIM\M
M6U_^4UB'14<?4[W%9-:*)HB:(JGSU[1F:/DGR+^9\QHJWB/2/>I?1OL)I_VK
M5_\ )+3112G11W ^@^Y?EFZN7]E3[_S_ !U^;\GKSWI2_P"*L?\ \RI__#,5
M]F?@+?\ +-4>;8ZZ_P#F:0+\XQO_ )4WBY1_'_". #S>+CKY\&L?,X;CN:5^
MM[_KOTSESARXDC30Z\M#JLI<38MS#75,7YKI4MCZK/G\^^=XT?6^]T:#>R4U
M6I%..=J(0]E?-T5TFLDLFU+VQ12:JJ*)B90A!,8O8+70W.,TEQHY::"1TCQ1
M^$U<$9FDC=U3FQ0R$N^N2S&CL[V 6G)\BV\VPV)N4.TNPM\M]_N,%);Z<;0Q
M6JRW.L\&I*Z!E=%,^LH8BTX8 \",N?%&'AP9G"C,59\S8I&]0S1C(0X-;G7I
M"[)J0#=^WCKCCN?<S,05]("U>-F8LIPJRIVZ+H&CTO!)7K[<P:VT53>[?)7P
MLB+)!4Q22O; )8V34TC9@USV!T8W7-\K)T).>!7)U=OV!VO;L]5R5U/5ODL-
M=!L]"+GX'6U-GOU RDK)11R2Q54G74[0T989&2@M+!*,-ROQSN@:57%$/#N\
M;V.0R:\J.1\7U.UV&-IB-,6B\J*6 LA),[C+5=6Y0;>*+9WY@K<'80A3/2*K
M%78-)!^Q6[)0WQU/0 5$%0^KFI:NC@J#30EA?6%Y B?)3NEZH%[P6L?N#R@"
M,A>-[5=%4=TVPN-32[1V^GV:I[ELU>[U9[965C[NT[.P438HJVV05[K=4RSF
MEC8^XU5&ZJC:QL9$DP:\4;(W3<?!O'N1)0Z44[RC7J+=6TD]CH A;9#8MML.
MSICR!CTT5/\ 9F5EJT>/:Y!)JZDV[155TW<1[LAU^,\*VCA=+7.AZM]?3TE1
MF1HWIXZ&6%D6Z"2#NO#=YH&2TZC!!7?Z>Q]$<U/'LS22RSLV6NE^L[V1W"J?
M%15VU%JFJ;G'63EV\(Y:2LE<USY#'#*71;QDC>!\)[.TK,8&3PC 1UG=/;GD
M^2R1DN2?%;.&<I:UC)BPKM091K5!=E%+K-VD[+,EG#A1]*LXX4VJ:$8V.;&H
MKYI;.;;"R1YKKA)/62M:YS>O(WS2QAK3@'25S<\< G.2=W:]A+9:^D-VV%=5
M6F*EV=V2H[!LS ^J!J:2VTS&MGNMTGFJ R>1H<^DBG+6MBII98W/>)',&+DA
M%2,<\59R31W'O43@"[1ZW69NDSG#E<E5NY(BLD8 _?"4Y ,!1 1X<===FBFI
MW.;-$^,@$CK6.C(:TAN@D#2[5PU / \<%>OTM327*,55OJZ:OIY</94TU1#4
M03%Q=O%L\+C"[!:[>:R1Y8 -\@D!7GM=X]_?'OAX2;X/N]I)+^<!UV;8<$;7
M6?(Q_;!P-.UCCV>8A>'_ (3A#N@OI!(.1]$Q?^=I>:_H+XT]KC'_ -I-4_(3
M#7TVOPX9]1O^:WW!3;19+%W$"RS;&.:G#=55!PAF/<LJ@NB<Z:R*J>2;@9-5
M)1,2G353. '3.0P&*< ,40$ '14\1Z&^?L'9VKS,P7G+<)8Z5U(M*Z1EUC82
M^5B76N%XE,M]TI\VF;;%LQ6AJ>^1#.0&;F!D)^-8W0PVQ=^JVGHYG(JJ!--F
M[I(/GY^_MXK+ (><<,8\V7#7U_>NGJ^\K-<)C+;#CK$+3%]"G+7M V899JM3
M=8SR/D6+MDOFNV*0.2*W%2Z>18XF-Z[C>HQ3J;A'M]L$PJ]*\ZZXD7S*NR1'
M!8D<>W'9@YQS.BMW!N7,PX\R-(-#S]5L6/,L]4VW%80D*_(UZ;"TP[/N2R3=
MFL]#VTUN<1[=-E.4=@R;UH:L9FG".GB0/RO 2<IDTQY^WV\/O]G:JBVX[L<T
MXLVV;7\8M(^"L-FSEMOPH3;1/3C&;D#O,I2>18W'6465_6&Q(K62.HL!<:KE
MU1%BYKL@ZJ,9;FHN52Q*\JT)CV8]JO7<VZR59=Z4YC:KQNX*[I*;$7MBK%4P
MWGE]A:#@LEOLKV. B[S/$4S'C",55Y)64;VR29W.48M$2@:&<MT2HG*+ZS>Z
MC<CBJL7]Q9I3&\^_VM2VTW$F3ZR^K\RI;\XW3*E6Q:YOUQI]C:V&(9UPDI,9
M%6CL=0R=%G49F;J,XB[=E3E2-*Z^?G"H&<8XGV*O\[[H<KM:9G:B9U@*0SLS
M2:BY['>)WU&M*]5MN*6VZ.@T*NY$@,W4S*R\7:UXZO6" 7M-7<,*%=*W>))D
M=]7$J^V,WEBN ,'((SKIG'I'?W9'F^*M_P ME?9=5R!8Z_D>*;]5JP_B"D0=
MF@K>U#'\++GPNBQD:Z]9Y&3.BC%L;"$G"P9&R%>&><2LZ^CY!K/KQB!,</\
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MIFAGA-LBDW;X,S\@W03(B@BECA!-)%),H$323(6= I$TR !"$* %(4 *4
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MEZ]T3 YCV_!._P#F\B.X+T=)>O=$P.8]OP3O_F\B.X+T=)>O=$P.8]OP3O\
MYO(CN"]'27KW1,#F/;\$[_YO(CN"]'27KW1,#F/;\$[_ .;R([@O1TEZ]T3
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=)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g271308g01a04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271308g01a04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2= 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )R2^$ (#A"24T$!       1AP"   "   < E  "')R,SDP.3@W' (% "
MU-:6-R;W-O9G0@5V]R9" M($AE87)T4V-I96YC97,@9')A9G0@4RTQ+F1O8W
M@X0DE-!"4      !"7I@!GVSF42U-9F":SH!:7.$))300Z      #E    $
M    $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&
M5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M    MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V
M)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M    $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P
M X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M  0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F
M)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
M !        4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&
M]U8D!OX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4F
MQT                0FQD(%5N=$8C4FQT                4G-L=%5N=$
M8C4'AL0&*@           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M   %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W
M @56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !
M!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M        QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&
M]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      !  E0
M    $  0"5     0 !.$))300F       .             #^    X0DE-!
MT       0   !:.$))3009       $    'CA"24T#\P      "0
M   0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &
MQF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M ! #4    ! "T    &       !.$))30/X      !P  #_______________
M______________ ^@     _____________________________P/H     /
M____________________________\#Z     #_______________________
M______ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M    0     .$))300:      -!    !@             "*    I<    & %
M, 5  W #D 7P!A     0                         !
M*7   "*                      !                         !
M !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M  !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;V
MYG   "*     !29VAT;&]N9P   I<    &<VQI8V5S5FQ,<P    %/8FIC
M   0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7
M!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6
M%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6
M<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F
M<          $QE9G1L;VYG          !"=&]M;&]N9P   B@     4F=H=&
MQO;F<   *7     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M  37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL5&
M5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06
MQI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G
M1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F
M=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&
M)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$
M))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M    0    %.$))300,     !RR     0   *    "%   !X   ^6   !R6 !
M@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0
M@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,#
MP,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1#
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MW "L0=OO)^C[F:>_\ \^?OKA'<_:H93^[$^<(K.LS'6.>SJ 98UIFIS'1NK
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ML:"XEPG8U^UO\ 95;_ )N=-/4*\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)S5&4E9BD[?1TS@Y9')TDI26TN'Q*$=99W.$AJ6GL[2VQ,5E9G=X@J2F_\0
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M=.KZ#JCJ!A6)5.29SE+^.8!!I<SA3I\7*K'(X,:;W-8W&C,/AX-EHLR M2@
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M4A9!8Y5VFK?.\YI\DQ6)B&18M$QZLH],\PT>NW[1*H^'QWK6OEY3(L)*X>H
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MD-ZU?T2,$K[.NS2[AS(\G';ES5!&17&I&"Z9376*FN;@W.(1Y-<(T?._!8]
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MN0W.J."YUE."Z7XOB^,VN.^/T[H9BK^DD)QC3O5'%VLL0B1C-+ ?N)UAG53
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M #BXS_S"Q_\ Y7_ET_\ 0@\E7_M=Q']C /\ S:/LZ?:T_ _H/RZA_P"@\/\
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M@A):Y6?9/-S#CH7"V-W6/6#EY=6B;-:'U,I;27(4@!*BK\8 >8'21II7Q?\
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MA2C[.GZ([\/#0O\ ?JS_ )JX4H^SI^B._#PT+_?JS_FKA2C[.GZ([\/#0O\
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MR(T*4DQT2T*84M2QLX"!N.O'A?)<#\VXE'Z^/^Y1]>F@Y]VD_6_^4 6D\?\
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MQ'S6Y^G8]J_[E/G!G\U?L'WT#T??:8/GAL4?1D= ?_W)/$G"W.3['K*Q_P"
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M65"8Y)9EB3'<4CCPGDM4#A^)I]*4WC!5)T!+22=B)E2".FGA/UO\OY"T\?\
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M91D+;5--?M<+MG!"CMV[<:4PIS!ZU@L6K%@CNY]J\V&Y4OOT.R,3(WCG[1(
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MIO+@I&M'8/\ %/6;FA%[D4J1=+<5&MVGZIE%(_DK"I++Z,>S&O;]8,XFSX:
M]#\,RQ9/.NJ9! ?<M!B_U_'Z#8 G;3?D!RV'JJ^7K. 0RHDQ,S&VI21'@>A^
MN?IWJCV:I&H6D$G3#2=K#LKJLEG7N63KR?-D4LY@5=L[)HH\.QMK%@4$AQZ
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MG]M/]VCU]0?WVJ?WSB?Z3P[-?YCG[L_?3,/ST_MI_NTBL;ZA\!-VMZG<PY0
M%E$)5NRL= )"NH!) V /Q\MZDMKS)]!SZ0,E)  !U)G?U5!6D RL&00 % SI
MT '2M5VA6>:48#?YM.U5PJ7G5?D6,VF(5U9&\"CU1\H75,664,29J7%LW-'"
M27:'PR&EJG/ETRXR6B'?5/M/.(:#2TH4@H62K<Y84$@]#S&\SJ:TS+C3:W Z
MDN!25( 3$ G0*\>A$Z[BG"ZA97V/(>.0Z/3O!&9FH=Q7X$[!RNODY!#JL9F,
M9;83+".]'L+NQ9E7AQ@U$&]E NU4J6)+L5F$ZPH*Q&T7L*+BU=F$O9DJC,9
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MHS*3 G\D)2DDZ2(@G>.?+7.:>MTMA#K*EQ!D2),G001.G7GU&E7KE>H/8<1
M88I-)9ALI&//N.OP&\B<B0W[3'J%R/3AZ?FS#KU_39&FZ*LD\"B"("DUIJ)P
M#,ANRAJ^,E3V6# !C73Z4&?1/+^,FZIRQV[.= =]"53IO(*2-=QK)T,5LS]#
M/;X/K/Z1^@H]$*&-HX;#LM=I#"X<BH@RXDBGNK9O,U8WD:Y1NK&QLK&MH+C&
MP_-<G,S!+K7&6W.1AA]6LQQMUO"G>U45*5<L$*ZC4[<MM>LZ<IR\+6A5\@(
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M;3SL%UHR'WFDQFUH?0T0LA1(M%F^4\MSMFD96DMI4EM?9J!6%*)96XM/:I@
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M9]EQV&NPU.$1B4RIIVJ*W)5M#L>\W?O@DI3$AQ QR@*)*RZ%<_LJ0$]>5^5
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MB)B!L#I/CI6K6#Y^P4Q/G%N!FF-2-X@QIRUK3&!5]=S8D[G?9,8;>[;],'N
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MKIO,P(A=Y5GO96_(CKW#('ZM>WV'B/O>A)Z ;[D]?.>[NTT'4GQ&I)[Y[Z3
M.T'E[1$C<Z0-YWT@T]KLF=SZSU6#2W%>W3\_>-I1L._R';EY7%[^9W!('D..
M0^5/? =/RL0CGKEM>6Q]\QRK](_\GOH?*\3I_)>$-3&__K3WZ> Y==)9A>B&
M)LC=Z3TGV9/VAO;I.=W_ +(&X&Q.^P.PW(XZK:?T2V_V=D?_ *-/QZJ_/3B#
M7',:&DC%+_QTNWH^H@".NM2EHA^LIX+DDG:S!^YVMQ]SO[[CQ'NZ;?/OT)XR
M*U$B9TVF#T(.G."29@;CIK*5287A(_VR2 ),G^L->?=Q0?.2#Y[#YC]'"AU
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ME!/VAD;_ '?(\ONGX]"1[Q[APJ--N_;U\Y ^R!WDTF:3"+,W[9)_2$=?#M=
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MH3#,9$E#Y+#<Z(E"TE(1N"-MDA)V )YCN=K:D@+$$GF3$:ZF.6\5422-8&A
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M+XCS&P'&LL<+L\)L4V%JIPMA]]YKM'5.N-JN[AVY<U69[)*W5)0G1*$A*1H
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MD5#)<2Q0L-2KIY2&9*E);JXSS4B<X0$QV%I=<*4=>(2X%3E7,220K0 ;DF8
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M=$\MM_"E#';"@O2H44:786GQ:F$)5\FZDA'?K#8)ZC<@G<CW@ [CW21,:J!
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MDJ(U&H((@ ]Q[HYLQA0RI 2 D) !2$@R  02.9W@Z$C2HAVQH 7'3]:[# 9
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MEC<&';6>0+HH2:!B1&L^Y@1(5<N?)>BJ>ENRGD=U'2Q(MBY>42DH<2H*.Y,
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M"^IZ-9J9#)#I< RJM=]@-E7. V@NJ4G=(:"EDA*2>%54PK6ZTFP<PKFXUH_
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MXZ$C8\3GN.;"3$&$NI@Z:@9D@P>\B.HWJ\'[K*,UD J-2+ELD&>4A*9!/Y0
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M^ZBN*(\%<<1VV[)E)FI4IU?<;I2#;(NYD%C+,P<Y/A.G@.E5@M1JE85!_*$
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MJ)!U"T;DU#MNR[=V+U18UMQ'I?!\C\.N:C4TN*[+\8LOLREED\K#:%H+;KJ
MAZ1Z2(YR#U^Z@*(,I5/+4:>R=ZNBQQ7M1N65^N)EN-> >NLBD8_W5TY"4Q3.
M9"_,I(D^.]A=ES/.8TIBD5X=]KU9/;-H'YZBIMROTB=P/5OWZS[_ &52G^L#
MOU\>A\-(CI%.4Q=F\CXSC\?)WHTC)&*:L:OY$-U3T1^X;AM)LG8SRXL)3T=<
ML.J:=5#B*<00LQV2HMIJY#[?B/9O5(S3J-(Y=>_U=/\ "N\*JHX4HX4I%9?[
M73__  *5_P#<.<*E.X\1[Z^?#Z37_LO<]/\ \4FE'_,?B'%U'^B'?_Z<Y_W2
M*U;W^E6_]KM_>*9!I#CT"579MD\R+&L7Z6%44U7#D54:W8@6N4V'A(V3VD>:
M[X1JDHFX;[<UY^%.0J18PHZ6XSK[<V/SU1^C_9$?'QRZ5ZKF? >)F=)D>JG"
MP;JGMLAM\?N,5S#(ZG3K)L8K;C'I\#'+=G(JWUU!PR54X7CWR>B-87<649U$
MFL@U,Z2)L>,YWTA4QM$]"4CIJ-3!D;F -=-8TWUD&:0-OX2>I.FO?UUILK^.
M-XEK5#QMF6U.:J<^IXS4AEDQTJ0;:"ZEI<=4F8J,_&#GAI,94N4J-(9=95(>
M*"ZL1$_V0?\ XAWGWF@G6>OU?'6*^Q!BGZUL:_Q!3_R=&XQ5;GQ/OK(3L/ >
MZN(;ZKY_9([%?[B]7OY;PKB*I7L/'[#7&OPJU3[^S)/B5./5MI,BNS&:_(Y$
MT1V)28CCKL9V,\RE3ZX\H);+K: L!HDIW 4DGF"KR/HCU^\UGV-D$4S\FE3*
M]UYG)&)C2F8\Q,9<1R39QK-M8>=B/AX,N1TM*06FN]"BH+;\RJJF-ZZJ?3FE
M>&Y+3:34Q.CBD)4294D\W*I(.RAU ]P/0;\*I5M,3![N\<P>M8=*Y7?V8,R.
M#R2/ZZV/[)3YGE^/^3\L\QS[OLJB-"1RTF)_)'+72)&Y&HY &I"URO",;S(_
MZ;)W/>->7)'^;^/^+B*:'NUU&O? T'CI![B"3*@KE"=,^[&![,W^NMC]H[OT
M"3YGW]/FZ<.OQ&H_P]=1KJ9'CSV,:Z'6.1GJ-Z3ER48>WC8_+XD[#O4?W.-O
MVOET]_\ T\*JE0&FADCEKK!\ )C3V14]2Y?CE#QK'1ASIWR#Y05=0>7?R.WG
ML .A\^'=UWTW[O#NVJ=9)!/=$CT@8!TU,>'70")D)<E>#<'C&.LM@'[<CI]K
MD_\ %^'3^/;KOPJDZ3N) Z]#TTU(T@Q'=(JI0%R3<UY,M@GEC;;.-]?N5/OV
M\QYGA0[QM]$:SII[-B=SR/6J:RY*\'*^[&![<;KWJ#M^G[[]-MSY#Y^%(C4$
M$\@/X:GGN?7K%+H2I(M*7[L8.[U?T[QOR[]/S= ?,#A3,9YQWB?5J-==#[)Y
MTB2N643]YK!'(-_MB#MM*:/O2![_ "Z^>_0^;H?N^NIF!I!.D'70&!,;<SIJ
M1(@1H)O>S2NLYYS2N1IM"07D=$":]LCR.R1OORC9)W]P._" )@ %1W &I, 3
MXP 8B!ZZC4 @" K,J$C+*E#52HT48  S$F -!%/VT9Q&L3IMEGK27$6[D[]P
MY:K#R%F!7J1(9@I?4E6S?(P53P'$I*1("^7R5QWO@3";0<)WW:J9'SDA[SR5
M(66F%H6FW[0 'L\B4./*&I"%)(.T_+7E2X@Q(<?82+-E^,"7:>8)+:DINKL.
MM.W";>8#H6O);9T@I6ME0$B13$KN'.J9;E:[.BN+@RI\53B'FEI=2S)4A+J%
M!)0I#R0%H4E1!00I*B/+A=TQYM</VY4%]BZMH+1]!>0Z*3OZ*D^D-=B*^G;.
MY%Y:6]VA*T"Z9:>[-U)2ZCM$2I*@=2I"I0J- 08$5+4Y+%C/^[& >6RZ=XWL
M3X>1T^]\OCMU]K;SV/%BLCF=>1UB#.NIG323S'M$4D<7*,..#,8/W1)_KC9V
M^U1>FVWGTZ_1Y^8X4D@2"0=]1,[<X\.0&P&H-*$JE"</NQC<,)WV=1N=X1^;
MW'I^+??AR(,$'<'U_88^!$YB-E$'7T@1&A@>CJ.AV.G+4TEYY7@B?',DJE$G
M=Y&^_=^>_(-R0?/\?GYM8CE]V@]0F!4[0#'4&.@ T&@$0#Z, @:"E8<E>.A;
M3&-^2"?TY'EW+70>R3O] ^/S\*A,SW"!,=_V]1U!/<E2Y+\'(/C8_25#W^W-
M]?M4W?;=&QWZGYO(#AT\-O9TVC[?"@D9^OJ[]?9KWTH*Y7>UGW8QN6X_FZCH
M3(=&_E_F_P"CA5(D"1/,Z1L/$=^XGPD5*YI);F@3(X"EM'].1TW=7_Q>I\_G
MZ\*JD\Y,$Z0(,1O&T'Q&N\5&A<OFK1XY@ \@(#K9WVF.;;CE\D@#;;?;?<;=
M-AY=T\A[]_B*9C((!/K)TUT)B2%:B)TC<<H0N4&9H\:P=Y4??=U Z[RNOWIW
MX3/NJ#,'0F22#)\8Y: 3'U<ZGMN2>]J/NQ@>RC;[:@\OW?(._P![]!_C\^%(
M.ATD$3UWB/5MH0"-.5)6ER@W-(F,?I*-SWC9\I3 )WVZCS(W&W3YCPI&ITB"
M>9UD]/"!I)UV,B(BN5W</[L8^_=_KC?3[>GYO<?>/C[^%1RVZ:Z[0>Z=M=3T
MT@165M&UR#J&0Y):=3X.X]A#B5$^QMN$I"3L".O57PV^ ^S7O^.[7ZZK;W4=
M]Q]1UV[^GLKIO^IXO"_+#MR^.>,>%ZAT_$Q]* X68IL-1O$.A"D.)<+;/.L-
MEM05M[0(Z'I;1(L;*-^R;(\0@1[Z\DV8N;X_](O7_M.F_C]7.MLZ--M!]*9Z
M<<5VH<WI\DO%TKC$>L#;<7&85VEZVKC*I:R"J%3UMM'L(*4RKA)<#C4%3\H%
M2@K' 2E64NJF"8S)&G*-#H.4:5L2M:IAN0-#H?J/?H=/"J^]@O9X7C=)0V?:
MEM<ALJ&'D=GCMPYE2G)['R@8M'D3FG:E:I+AK6)O,F2W(,M#;".=:$.-L\"E
MLB"M15M.< D [F-R#W=Q.E1G6/R"#OM Y#GZM-MN=6YC&A?9WQ.PDW=EVELP
M?OLTK\9RBUB3LC?KK&\3:X7.,66[%=6FT<9L5RI^8,1'%ERL=8Y.5N)&6C@V
MA*53VBLRDA4*<T2"=X(TU$ F=>LU)4M03"! Z@@G70:2.Z.^(!BMD6G#]$_@
MN+'&<B7EM$Q3Q(5;DKLCQ;URQ 1X+QK\G8=\^XMA8><V',ZE1XN[ZS,U2-N7
MJVJ]>%31PI1PI1PI1PI1PI1PI1PI1PI1PI1PI22Q255U@!N5&%*"0!N22PX
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M8<FXW((Z<*0(B/L^O>I*>SYBHC/(]:9 0M^.OO4J@\B.[1)'*?N( K6E94@
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M-4IF5#D(C[O9%*>%54<*4<*4<*4<*4<*4<*5P6>FH&WI(>T.   ,7P38 #8
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MJ*P.1VY F-#5>B5=RQ95\B10S&(VT,=^]73FF05QD=WNXXE*!WA(Y-U>WON
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M[]ZKW\VP'F>I]QZ\1T_A'=SY_554&"G+N1$2=-U$S^:!)CEO!JMT%0]=659
M4PB*519CR'%17EA3\42GV(Y'>)V,E]MN.%?M.]*N7=/*;%RZ6&RL(6HYVT!(
M$*.=Q*"H 9B0D',8&P.U85]=^86Z'R@+';VS*A)"4I?>;;6I1('T&UETI'TL
MD RJ:HVTD1YOYW[ 28_-]H?Z=90Z]1MN1L"1U.VW0[<7IF(2HR)^B=IWZQSV
MYUEG*9(*(D[.)C8:#TMIUZGNBJHS5W;B:>2C'YJXW(%^(36SE,J0BPD\ZPXE
M"DJ0C8\R@2E.VRCMN1:\YMPOLR\WVFQ0'&RH'D%)*PL ]<OJK'-[9!WL3=V@
M=2I*2R;AGM051HML+*DJ@C*"!GW&FE4EE,GNIN\#R90!M'>_NICK]_Y#RZ?$
M>[B[N) 4= =!(/@=C]4^_(T!,QST4H ^)!@QL0=)D$$[UZ1)[N$#  )6X-C'
M?Z_;A[@3Y ;GX#W=.*NAA8TDDH("8C<SIW&.1I$D_1B"3Z0,1TC3QDCQWC+&
MC:'T:C%+L/N.6'<[E3+C:DGE\BI2MAOY<I'GT\^G%,@@$%.L;*!YSRZCVU6V
M08(](+2I0('HY1(!!.A'.4DCI,373Q]3M0X]CG/;;K)2U(CV55IU =Y%AMPM
M2[+41A[NE$'9P-+44D \NQ)!VZ=,:_H-G V9:,]/1TGU_&U>3;,75[_UJ]/^
MTUWGEW5T 6_8VTQR*X?O\CO<_O+E<?'8T:;.R%D)JQC$2/!K':>OC5L>KJY
MC164R)$&$P^^L+><<4ZZZM5DH!.:3,0"#$ ](T]=;"2 <L:QN)&GM^KW4E9[
M%FF34AR2]E>JMBM5-,I66[;.)5FQ&:E*EJ9E-L3(KK3TRM1,4Q7.2T24,,,M
M-J;<270Y!:03)S$Q ])0@=T$13,>80->0Y=#-56=V1=/YUQ$MUY5J5&$#'\7
MQN)4PLJ1%I&J_$\>>QJN4:UJM#*Y+L*0_*DO+YOSS4W.CICNQ8?AY"(,YE;
M1F) B?O^^:!1 C0C,221KJ( GN^OWYXT_P )K=.L/I,+J)UO95M#&<BQ)E[-
M%A:NM.27I($N8&F>_4VI\M-K+:5!I#:5%2@5&H"!$D^)DU%7CQ-*]'F/I'S>
M_P"/3A3QU[NM:*?2O=J"XT\U8T$PC#+(,V&G=M"U?O&&'?TRS3+=@8_ EA"@
M0A5>Q<.+97RE4>R;64D*0>.@<'X2BZL\1?N$#)=!=B@G<(R%2W$SL4N=E!TF
M"-9TX-Y5>*+C#,4X?L;)XI>PY]&*7(!/I.YUM,M+W*DY$NZ :"#^4*W68-EU
M3J!AF+9Q0OB339905E_6O)(6%1;*&U+;2I224]XT'.Z=&_LN)(W)WX\+<,KM
MGW;=P%+C*U(4D[@@[^!&HKMMC>LW]G:7MN<[%W;M/LJ'Y2%H2K:-,H(F>>\5
M=/%FLRCA2CA2CA2CA2CA2CA2CA2N CT[/_9]]J/]PV%?\SV+\9%Q_HJ^_P!C
M?_X16I/^E&/]H9]XKF6XY?7MJ.%*NS OU]87^ZS'/Y8A\*5]S##?UH8K^YNC
M_DN+PI7$7]5\_LD=BO\ <7J]_+>%<*H7L/'[#7&OPJU3_.RC&D2X.-L18[\E
MXYFRX&H[+CSA;;G5ZW%\C:5*Y&T)4M:MN5"4E2B -^%7D?1'K]YIQR(TF9;:
MG,Q([TIWPUJL-1V5ON<C665:G%=VVE:N1M.ZG%<O*D J41MOPJJF#ZW6UK!R
M^"S#O;"M95515KC1YDYAIQ9E2-UJ;CD-J40$]5;D[#BTMAEPRXTVLQE)4A))
M'0DBL2XL;*Y6';BSM7W0,B77K=EQQ*=LN=:"K+'*8.V]8:EV=C.D3C-OYDON
M!(+'B9=@]W)$E&W<]X%AO;8$<G+MRCYAP2PP@$(993(@Y6D D="0F8ZB8/.K
M;-C8VH6+:UM64N)*5I9MV6PL$[+"$I"A!.AT//32AR_O#$:WRBR42_(YBJ=9
MJ*MD,;;DDD^_8D]>OS;T>:6N_FS$]>R1/3?+5KYIPN-+&R C;S9@;?1  0(C
MZN0I5\H+M,V6!DT_9(FJ3]U3SRE*'"#N4D]#\=P?HX&TM3O;,'_LD?=3YIPS
M]2LO5;LB/8GZM)ZZ5"G);I,$H5=(=49)*)$J*)4E@%I)6(TB1%=?C<VP4I3"
MT*)"2"% @P;.W,G(1E'T$J6E)Y;)4!IR$:>O0,*L2MM260SED$,N.-,K4 <O
M:,MJ2AS:)6E0',$15=F9 $QJYZ!<&%>NKG&X=KT2X+CJ(L%(KGW5QVVD*=>2
M^]WBD$J<<CH=> 64GBPFU!?>2ZTEVV&1;0> <@GZ2$A95(20#XD]*Q$8<AR\
MNT75LV]9MMLFR\Z+=PVA;\^<-M(.=00CLVS"P$I"U!!,J!M_Y0WYC+4<KM2I
M,F-RJ-A:%6R$R"D [[I*2=P1U! VV.W%_P SM!M;,#_LD?=65\TX5"A\VV.5
M0@I\S8RP1/T<F4I,3!&PG0Q*BLM;)O((LIN_F"2^B,)#IDSBX^!'0L!]2TGO
MDA24*Y7 L;I2=B4@\5JMV%(#:F6R@&0G(D)!F=  (UUTJ^JPL2VEHVUJ&D:H
M;##65L\U-@) 23J90$DS-2F,EO4PY(&1/$)7'"0XEUU*.;OBHI2Y'4$J)&Y*
M-E;]=]]SQ3YK;\FDC^S*?:4D>PU1\VV$SV#04=RD92><$I()YP2=#RUJHP\G
MNC:U"C=,J+CD!"U*KV%J6E3Z H%2H)4>O78G<JZC91),>9VY_P!6?WCG]_ZJ
M?-MD8]$C41E=>$<M ET==A2)O*;<-3M[2&XZ4;&0_519$I3:I+6[*WWX#BU,
M)*E%+7,4 J5R@[) CS.W)U#N7;('7@ H00KT5IGGJ9B-Y,U97A%BLQ#B$Z*[
M)JYN&60H$PL):=1Z>Q)5,Z<MZQ:WACM8PBDNC \56,2K1JN5(C(38N64Q+Z0
M&64>'W6VI]++7=H;;E]VD=V DV&;9+BKCSAO/D6IMI3J2O.VE""GZ4Y@HKRR
M<Q):DDF:Q+7#VWW;Q5];A[L;A;%HN[2'%+MTMI6EQ!.<.((6&RIW52V05DN)
MFG8Z+3)DG3/4YV19/RG6;#(4-2''9*UL)35%26T+>]L!L[J ;&P)W21QW3R?
M-MHX0XF2EM"4E&(2E"4I28L%ZE( !.@&HG;H*X3Y4;6V8X_X.0Q;LLH6;$K2
MTA"$KG% "5!( 5(TU!TVBF1MV5A#B1T1;Z5'0Z77'4LR9S:75AQ20MQ"4A"U
M@$@+4%$ D;[;CCB[C##A!<9:61,%2$J(\%$$QM F*^B7;.S=4DO6EJZ6T%IM
M3C#:BAN9" 2@D(!$Y1H3!.H$5)5[<^L9GZ);#9*;  >-L?9"67]MAOT (W ]
MV_Q&_%'FEK^KL_ND;Z;Z:Z"K/S7ALG^066I)GS9K?KHV.?=N.FZ=607:8C)&
M2302_)!(D3CO]KC;;GE/4>25;<P/7<;[\!9VNL6[23!U2A*2!N=0!XQMW55\
MW8>=#9VA&T*9!2=M#Z!@<YC0CI%5B+D<N1;1&+&R@NUSICIL655S*1(:<B(1
M+?><1!#JI2VRMQ4KG#Q= 6%\P XMKM6D-N*;2YVN4J:(4Y)4D2$E.;+!("=H
MCPJR[AC"&GEVW:HN0TKS=0N7U%MQ,J:0@9P@-Z! 3DRA!B)%2;>]G1WI;%5D
MS[==&L%LP_!OS6FE,MQVV MOND(YDK2TE7,/9625IVW/$,VS:VD*?8;+BT)+
M@4G, 1.A"I ()/0GOWJBTPZT?MF'KZQMUW3C:2]VS2%+2LC.4J*DDR"2DDDG
M0 S2,7UUXV*@9/9!+C4)M:4SK(!:%LM<R%%(',@[D*2K<'<D^?%T6EJ#/F[$
MC42T@P>H!20#ZJR1A6%R";&Q,$$!=JPH CF I! />!(.Q.]28E[<1:Y]EJ_>
M[I,B(AM#I??2RD(FJY6A(9<[H%1W(;Y 3L2#L.)-LP23V24DZG(,F;32<F68
M&TS F-S5:K"R4XMPVK*5+4"I3;:6U.$:!2RV$YS W5F.F44N&47J7ZP>O]]D
ML$ER.'=_MZP=PY$4%>0^^!V\@.*3:6YU*#KK_..?8O\ Q]=1\W61F6 D&(*5
M.)4"2(A:5!0Y;'4 D]*EC)[H-34FWC+;*VCW*ZV.N.5!\K0M44P RMQ"QSMJ
M4@E"AN/,[QYE;DR$J!'/M'=HUUS[Z0.\Z[ZT*PJQ7'XIQ*D9@'$W+Z74A0A:
M0YVI<2A0 "LBAMIR-5>!?MN0EO3K&,U=1H\84<J+7F(^%NVG+,0%P8;*#RL;
M.H4^-VRA?=KW7R&RY;?C&D-HS,.%1N$N%3@2 E100'%*/TH!$]-- :Q',.[*
MXLFK=M;EB\ZOYR0_<.W(RH;465@O7#A"E.!+9"$JS(,J"?I51#D5Z6; G*+
MJ=E,$D2IX!]J0KV4\FR1S)!V2$@^7ETXR/,[00/-V?1$#\6D["!!(GE\;5E#
M"L, $8?9B -[9I6I@&5%))5KK)/>3K4DVED[-I);N0S7)33:$-2')=BIYM'C
MI"0EMU6ZT(Y>A0A024^R1L2.*DV["$E"6&4I)D@-H )[X3KZZNIL;%#:VDV=
MFEEU04XV+=H-N*29&='9Y5$3NI)$;1K0W?79;F$Y-8'[0@ ^,L2.DE@;]>@)
MZ;GS)ZG<D\4^:6OZNS^[1]U6OFO#"?Z!9C<B+=KT=>Y $#EI !B1RB&0WB8\
M5L9-."'%K"]Y,Y2B$OC;E44E:1Y[\BD\P)"MQTXCS.TD'S9G20!V:8$QRB#M
M&H.D]:DX1AA(4;*SE,@?B&H(.AE,95:#0*!CE&]97TDO+.QU!;9FVZIC:85K
MS-%+@7(4E 2'I+A9094A*0$^(D.+>Y $A9!V-2+=IJ2A"4224A,Y4S) "0<H
M&NB0D '2-A5VUP^SM59K=E"")"0!Z+:3^0RDREI"1LAL!(&@ !KJ'^IS(M<<
MI[8TL*"K3QVG32FU;'DAHFYTMIU.X/*5.K>1S;@\HZ#KQU)&EC9@?H&)\>S]
M(]VH)CPVK0-1YQ=GGVKFA_MF,PZDGNVC:NI$^9]_7BBL[7GJ>?C7G"E'"E'"
ME'"E>CH0?@>%/9Z]O7W5S<>F'PC&J#6W2N[KJY*+3-ZJQL<GG/..R9%F]&M:
MVKALK4ZM240H4!E$>)#:2AAE!=4A'.^XI73N"7G'+*]03Z#2FDH3L 5 %1.F
MZM">Z)Y ?-OEDLK9C&,&?;0>UO4N&X6HG,X4.V[* KN2V2A$#8J)E4D]"^ 8
M3C6G6(5&'8A %3CE0T_ZJJDNO/1ZUB;)?G+APR^M;C4-E^2[X6/SJ;C,J;8:
M"6VD@<XN7W+EY;SQSNK,K7L5D'Z2HTGJ  .[E7T'A]G;V-HQ;6C9:9:$-MR<
MK:%;H;!)]$&8DDQL>57?Q8K/HX4HX4HX4HX4HX4HX4HX4K@(].S_ -GWVH_W
M#85_S/8OQD7'^BK[_8W_ /A%:D_Z48_VAGWBN9;CE]>VHX4J[,"_7UA?[K,<
M_EB'PI7W,,-_6ABO[FZ/^2XO"E<1?U7S^R1V*_W%ZO?RWA7"J%[#Q^PUQK\*
MM4]KL_NN,X/WC3BVEBWL %-J4A74,)/M)(/5*B/HZ'<=.%7D?1'K]YK-3;SK
M2BIMUQ"E A2D+4@J"OO@HI(Y@K8;@[^70C?HJJFDZY5\^5F%<[&IYDULU45
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M=CTDL?V#:;#8R3YD;CS]_7W?'A4P8(@:Z\]^AUTGN,"*G(I[@.4_Z&['JE!
M\#9]4^/E#<=-R//J/+8@\/CX^.=4@$:%,[G?_&=MM9'UIFJBW[J;^ARP!#3?
M7P-GTVEL$;]/=Y=?,GKPJ8.JHT(,CGX>O?W=\1I[CNH(^3MA[2W.O@;3K]O'
M^3S/S$$\*F)/T.O.(Y=.FWU5E/1ZNL(NH9>DTTN$V(5P"^]&G--I)  25O\
MVO=2ARI"NIWZ [<0=AXCWCWZ#_"I;!!5(C0Z>H_?73Y]3D\WUQ>V?UZ&-IB/
M+?J;C4'W>?N&^WS;=>.EMF;*S,;LMG_X=I]?NKR3?])O?^M7_P!Y75,?,_\
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M^_@MMM^NVPZ=-^FW"E5=.6Q!3&H\ @\SJG#.-19&:$EQMP)#O<!'LJ;#86$
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M(M7AV729"MO]ZA5,RG<_.X-^'FKWYOUU!N6A_K#/4@^PZG0"3MIZZL0^G?\
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MB )X>;.=4>M4>\5(NFSH%GZZ/L\/H\?^&V>CZ=.+W?\ )MO_ )_@#Q/FCW(
M^!^/;MH=:CSMK](?KKW[/!Z/+_AKGO\ !Q><1YL[_5]O\*>=M?I#]='V>#T>
M7_#7/?X.+SAYL[_5]O\ "GG;7Z0_77H]._Z/(_[M<]'TZ<7G_1P\V=_JG_>'
MVQ3SMK](?KKDL]*MK]IUVG>U)V@=:-*)T^QP3*L+I&:>9:5LBHG.KHM-Z*BL
M [ DGOVN2PKY+:.;HML<X'(I)%5TE2,,O4JB?,[G8[#)!/@8 /*:Q4*"\0ME
M@D@W#!$\]QS[]/#;G//]QRVO<T<*5=F!?KZPO]UF.?RQ#X4K[F&&_K0Q7]S=
M'_)<7A2N+'ZK*L<=J]9>Q#-RFE>R"G;P;6=+]8Q)\*MY;EKAB&3WWF@(4>8G
MXA)3S$%)Q;QNY=86BTN!;/&(=("@ #)T,ZQ.VM:K&[?$[K#G+?"+Y&'7ZU M
M7;C N$(RE!(+9WS)"A.G*#(KD.LM0<3EX]*IXF!5T23(<9?18%3"GVG0J%(E
M)#K;#,E+#\A$U+:&WT>%C/ML-*0&P>-<UAMVB[;N%8DZI*$%OL@"F0,Z0H2H
MA2DIA1"@05)4HBO/VW#V+-7[%X_Q%<O(;+J5,E#@;6TI+[;(2A3CK1>9;5;R
MHMJ[5YLKRYEE)<MI//I[/'9T['Z1..4[]U,5"I43I-DF$A#,-IQ!G3"9,CO'
MDN/\SA'*5A*0$H3QL[5M]JW:;N;@W3Z00X^6TM=H<Q(_%I]%(2DA B20D*))
M)KTV&,7EM8V[%_>G$;MM*@_>FW:M2^HN+4%>;L@-MY4%* $S(2%%2E$J.3>,
MBL^FP:R91E%-E<&+37,NOAKJXSKC#$IMI"G52'TK<*%+!)4E*02 .@ ZD#A4
M'4::?'QX[5BU6>9YWT\?*>QY6TOE \:WLDI?2D%([S?H"0.%4>GTGU_<1/Q-
M259]GWA65#*++F4[(!5XYL;@)CE*3[?N))'PW/3A\=_M]5(7'?X_7O UZ>[2
MIZL\SWQ<M R>R"$"84I\>V.4H2X4D K_ &IZC^+B??X"/X>RD+/='?W^N?74
MGY?9Z(I7\I[(*[\IW$YL;I[H'EV"]^7<GR]QV\^(I)[YU"M=-X)'0Z]1&\0:
MGG/,]\64_*>QY TL\IG-;<PB%6^Q7Y\WM'RZ@<*B%1IRV@[\N9]FGLI.,^S[
MPJU?*BR*O$,IYO'-;A*FWR0/;\O923N#UVZ[;#A23'/?0<]B#.QU.GJG?>HP
MLZSM=K";7DL]3:TL<[9FM%*BN.E74!?4E77S WW\^%5'-)C;EKW>.OKGNJG(
MSW/C&D*.46)4ER.$GQS9*>8.\VWM]-RD;D_#\7"HA?P1]A^-QK2V)G6>+L:M
MM>3V*FW78(=29K1#@6\D+"O;V(4-P=_=MY\* +G[=-/5MK V[M=Z2(SW/N2:
M?E/8GE;3RGQS0Y=Y3*3L.?X$C?W;G?8<*>GSTZ00-=NNHUVZQ49SS/>:O!R>
MQ(<0@K G->WO,>3NH<YW/*.4^\  #RWX<IH9@[Q!Z&(!!B-=-!H.M/ T<N[R
MPTYU)EV-B_+EPK"^:@OO/(<7'0S6%;(0M*N5(:6 M 41L0#U!Z]GX )_!'B0
M#8(O^G+#U@3IJ>1Y>JOG+RK#_P"D'@SG/F$Z<QBN_P 3&L:TSMS/L_$>(H91
M8A2@Z5$3V_:(=V!.R]MP-P/AY#H=^.,G<\]3KUKZ-,Z@3OIKRTY\N4"9@ZCJ
MH5GF>"?,0,GL>1";'E3XUL!/(P^4;#F/WI2"/G2"#OMQ%(7[/ ^O7[:3*S[/
MQ&95\J+(*+TD$B<WN4I;CJ2.BM]@5$CYRH^9X4],=\Q[3)/U[_=(I0,[SP3
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MO\CO&IQ/^93_ -<Y_P 2JZ\C^9;_ +3?_=IK*6%_K1QDD@?G!4^9_P"XFO\
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MII/523W::CXU\=-12)OO^2=TA@=VGW0CT\4SOY[^8._^HX;Q\>V-_KZ<ZI!
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MX4N=^IEO2'L^JW6L,I):HZ0)#3.H>F:5-J1),KJN1E+#92I$@M H4X>]8>W
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M\G"E>[#RV&WP_B_R=.%*-A\!PI1L.O3S\_G^GA2O-A\!^3A2O=AUZ#KY_/\
M3PI7FP'D!^0<*4;#X#\@X0.E*-A\!^0<*4;#X#\@X4HV'P'Y!PI1LD>X?D'"
ME0<S>^W3?;?;;KM]&W_LX4H4IO8^7D?,;>[YQ_KY>?"H.QC>#%<LWU1 4'4#
MLED;;>J]0-SMTV]=XAYGRV\_X^.T>250\UQR"!^,M3,QH4/JW[TZ]^V^E?-W
MEX_TAPOINU?#;0DOVB0)VG6.L'I74#CJD?)ZBWV_VFK-^GO\$QOUV^/'&W@4
MNN@Z$.+![B%$'NKZ,MC-O;D:RRT1ZT)BJRDH5OR[';YNG7Y]MC^+BW5ZHMA\
M!^0<*4;#X#\@X4HV'P'Y!PI1L/@/R#A2C8? ?D'"E&P^ _(.%*-A\!^0<*4<
MJ?/8;_'8?Z^X<*4;#X#\G"E&P^ _(.%*.5/P'Y![_/\ +PI7O"E'"E'"E'"E
M'"E'"E'"E'"E'"E'"E'"E'"E'"E'"1UI1PI1PI6J3TA78B[1O:NR[3Z[T1[1
M\G0VLQ/'[6JNZUBRS*"+Z=-LTS(\]:<8G167#&828X,M"W!OLV0CH?:\*<28
M3@;-XUB6#C$UW#K:V7%)MU=BE"8( >2J<QUT B?9S/CO@W'N)KK#W\&X@5@J
M+5AUI]"7;QOMUN.!:7(M5I22D )],'<G2M6F2>@<[6&8W5=DF6]L/&\FR&G$
M=-3>7S6H-M;UB8LDRXR8%C.F/RXJ6)2C(92RZ@-/$N-\JCOQ[9GRG8);M*99
MX?=::7.=MOS-#:\P 5F0A 2HJ @J()C2N:W'D3XGNW6W[GBRWN'V@$MOW'GS
MSK:4J"DAM;F8MY3,98WUDZTY70GT5?;9TQUGTLU$S'MO3<TQ/"<\QC)\CQ)R
M]U,>1DE-36T6=84RF;*T=KW!81F7(Q1,;7'5WFSJ2C<<:?%...';W#KVT8X;
M%N]<VSK++X:LAV+BTD(<EMH+] ZZ&>^O0X+Y,N,<.Q?#<0NN,EW5M9WUO<W%
MJ7L06+AEIP+<9RNK[/\ &)!3Z0@ [5T&,@I1L3OU/\8!(Z_ [CW]/>>.6?'+
M[/CU17=:F\*4<*4<*4<*4<*4<*4<*4<*4<*4<*4<*4<*4<*4<*4<*4<*4<*5
MX?(_0>%*T/\ :M]&9VQ=<]?M0M4]-^V3,TTPO+)U?*I,):N]18S=$Q$IJZN?
M82S26;%8COY<61+(BLH1O(W5NLJXZ7@7&> 89A5I97?#R;NY90I+MQV=HKM3
MVBU)5^-2L_16 >X#OGBO%'DYXKQK'K[$\/XM7A]G<J26;--QB* RE+32"DH9
M6&9SH692D'6).L-KF>AI[?K_ ";]OR7(Y23L[E&KS 1T\TENS=*B?+J!L/?Q
MN4^4+A;GPN->89P_0=WXL3UV]1C7SR_))QLJ/_7A:B"#K<XKUZ!8T.^O21I6
M/<J] SVN<[>@/9QVN<4S%VL#J:Y_*)6I.0OUR'UMK?$!=L92XW>J;:4XAE;2
M75--E6Y3S#*:\I^ VR5BUP*X8"P,X;39M!4 I!6$)0%0DP)G*)B"23K[CR(\
M47I;5>\56UVIK,&U71OWR@*(4<@=+@224@DB)($SI&<\(]$1VZ\8R[$;VS[>
M,ZTI\>R*AM9],+[50HL*VJLHDJ36!MZV5'*)49A<7D=26=G.5:2WN.-;<<?<
M-/,/M(X92E;K3J$N=G8@I6M"DI7(;SRE1"I"ITT-;NR\E?&=M=6CZ^-7%LV]
MPPZID/XE"VV7$+4T$E240I*2@ @)@ZZ5T?,C8'Z!OL203UZ[GX_^WCD=?0%3
MN%*.%*.%*.%*.%*.%*.%*.%*.%*.%*.%*.%*.%*;/VH-7\KTIQC J_3ZLI+'
M4+5K5+%M)L*<RCQBL8J+C(X]K8/WM^U7O1Y\J!4U-+92A!B2([LV4B/%\0RE
MU3B=Q@U@Q?/72[I:T6MA9/7]R&H[9QMDH2&FLWHA;BW$)E1 2"5<J\[Q)BMU
MAEM9(L&F';[%,2M<+M/.BH6S;MSVBR\_D4EPH:::<6$H.9:PE 'I2,=,ZXZF
MZ',9#$[2T:CS#OK[$J72>WT6QNQ5DVIMIDT6<[-QIC3.5>W=G#NZ%VM??7,1
M;&IF4Y5/<<B*B24#(&&6>)K95@ZG;=(;N'+].(N!+-BADIAUR[#:$J;6%I"0
M&PM*R04ZA2L(8QB>"IN$<0H:O9>M6L+?P>V6;K$EW(<*K88;VSSB'F"RI16'
M TMHDR"VHTDF^D(T-9CTBZJBU;RJPN,3SG,)./XMIU86N1XU7Z:9'$Q7/(66
M4XEL2J"UQBYF(CV4:8 R@(6&I+KBX[;]U/"N)2YVCM@PA#]K;I<>NTH:>5>L
M+N+1;*PE0<;?;0<BA!S%(*1)(MKX[P4!GLF<4NENVM]=*9ML/<=>MT8;<)M;
MYNY:S)4R[;.JAU*AE2$GTR2D*K\?MW=G^56S;5BTR%<:+;Z6U<=LT@;DVT;5
M^CC9'B.05,=V:A<K'$TKLZ?=6:^Y]4-45^)+//5O)-D\-8H%H04,RI%\LGMD
MD-JP]U3-RTX0#E=2X$)2@3F+K6HSZ7T\:8&II3J7+A24NX<A(#/I.MXHTEZU
MN6AG]*W[(K<=<,%M++WH')!L^'Z27LSSL<RG*(T[-78&,4E-E#<9.*.+M,GQ
M:^R*)BU=D6*5R)RI%K7+N9T2.XVZF'8M(DQW50.1]@N9"N$<82[;LJ1;A5PX
MZS)? 0R\RRNX<9?44@-K#2"K3,CD5#6,-'E"X<<MKFZ0[=K:M[=F[&6V)7<V
MMP^FW;N+5 65/-EQ:.25E*DJ""%";?RCTA6(P[73BLQ/2C5[)9^7:SW6C>68
MT]A[]5F>'75+ADC-2EW'Y$OFES+"M576-=%,IEN31+LK'Q"%UYBO5M<)OK;N
MW+B_PYA+&'M8C;O&Z2IBX;<N0QHXE)("%!25^CJO*D:$D6KCCRT2YAZ+;#,5
MN576+OX1<V_FI;O+-]FR-X NV4N2MULMN-MJ*5%@K=(!1E-0QWMU8914EL[F
MQR7-<@.H&M,"OH-+M-;N;=4>"Z39*JEO+[):<W%D\W78TER+%MLB;D,Q[26L
M*K:P+6(PASAJX<=;3;!FW:%IARUO7MZSV;MQ?,!UI#+@;1*G]2TUE4I(/I+@
M%55,<:V;++JKPW%V^;[&$M6^'6#JWV+'"KCLKAZX:[51[.VE*77Y3G4?1:!]
M&KOR/M_:!XYD$2F4,]NZR1C.EV93,WQO#Y-O@M)BNL4]ZLP2]O<A9E(16P+.
MP:3%<4['+K*WV5=TXWWRVK#7"^)NM*<FU;<#]Y;)M7KE+=VZ_8I"[AII@B5J
M2G4 '4 [:3E7''.!V[X9 OKAKS;#;Q=[:VBGK%FUQ9:F[&X>N L!#3JTE)5E
M(22)TDBW]8NW+@V*UNJV.8M$R:%J'C."ZL6^!VF68?8PL$R_*-+L8F7UY5TU
MD[)C.W'JA,</RTAN%'F1F92ZZ;(2PXM-S#^&KFX79NO+9-H[<63=TAAY*[JV
M9O'@RAQUD"4APD(3"E',1($S5K%>,[*V;Q*WM4W";^WL\4=LG;FT<397-SAM
MNMYYMETE)=+665$)"" 848-4#M+=IG/M,=!.S7J!19#B.'6VL&H6E.)Y;E.0
MXC;9?28]4YMA5_D%S90\9J;>NLY3D:=61_#,M3EJ0PIUM0<*N=-W!L&M;[%,
M9M'&;FY;P^UO7[=EEY%NZZNVNV64(6ZMMU 3V:U?F@*"96 (./Q'Q'?X9@?#
ME\T_:6;V+XAA5I=7%Q:KN6F&KVR??>6W;MNM+6L+:3E 4K0D%)W%#Q_7_7'/
M\FTXT?TOU)THRW)\FP_-=3\FUBM-+\LHL;KL2QW(Z[%*JAHM.Y661[:9>S;R
M9(9GV$^^CPXT*(9345UQ]E"KCV%8;:,WM_?6=];M,7%I9L8<W>L/.J?=:=>>
M<>NTLJ0&DM(!0A#>8N$ DB35JWQO&;ZXP["<.Q'"[JYN;2\Q*ZQ9W#+MEANW
MM;AJT2RQ8*N&UN/*N%E*UN/(0EKTDYCES3;7M"]H]5_0:/V9T;TGU#H=.LUU
M2U?U)R3UCDNG%5A^,Y0YC./V&/U;&1TLJ*WE19=M[/U]?)5BT*+)CR/%O+97
MQ2C"L&0T]?@W][:KNV+/#[-OL[>[<=>9#JP\OLW$@-3E1D0>V/=FB7<?XA#]
MMA3OS1AM^QA]WB6+XC<!VXP]FVM;HVS*V&T/M%/G,=HX'K@&V2"E04H@'-&G
M6HVJ^M_9W@Y?AN<Z/4VH:+&ZKIN7XFE&KNF5F<6MK"MFRZ5JIRBK=93=L1&)
MB8$J\<G8^](77STOR&%DZZZL['#<77;7%M?/6A0TKL'CYE>H+S;:X<)96D]F
M5J AI*7  M,@R=Q8W^)XS@+=W9WF$,WW:/(-U:E&*8<ZFW=<05LI;?2I/;(2
M%95/*6P24F5)U;SV:^VIE#^'Z*2^T!:NY=F?:'T^>U*P^CTFTANX];AN.8[,
M;@Y9)RFT&59"MV'"5.@2_'N1*YMF*U(2E$B0ZRVO<8QPZRE_$4X4V+>WPFZ3
M97"[[$&U.7+[S8<8%N@L,#,HH=2$ J).6<H!-:#AWB^Y59X.K'G57=[CU@<1
MM6L+PIY+5K;L.%NY-PI-Q<*RH+C*BX4H $@9B0!GJ%V]="I--E%G+CZATL_&
M4X8XSB=W@]C S+*V=1)TNKP5W#\<+KDVZ.464"9!K8I$6<W)C/-SXL,MJ(UJ
MN&,3#C"$&U>2_P"<2^S<H<MV/-$I7<FX= AH,)6DK404@'0F1.Z1QO@JVKIQ
M2;]EVV\S(LWK)Q%[=#$%%NR-I;25O^<N)4AL#*K,A69*0DD2<B[?FA&*4&.V
M^0QM1*FWR*7E\5."6.%RJ[/*9.!.1V\NF7U!82XH@0*@3(KGBT2Y#=BB0R*C
MU@ZL-\&>&,2N'76V56;C;08/G*;E"K9WSD++"67 "5J=R$)3D!!("@G4BFYX
MXP2T8MGKA-^T[<N7;:;%RS6U?-^8J0FZ6];NJ04--=HA1<"E)4E0*,VH%WX[
MVR-&LPU%H--\27EN3S\AIL6NV,BH\9DS\2KXF:T2\EQ<7%LT]XBN]:TR#*1+
M=@*K(RU-19L^-+>:878>X?Q&VM'KRX##"67;AI3+KZ$7"E6KO8O]FA4)7D<A
M,!84J04)4 8R[?BS";N_M\/M#<W*[EFV?1<,6Y<M4(NV?.+?M70K,CM&97F+
M9;1!2XM*H!=2E04-P"/I\_\ /QI*]-47"E'"E'"E'"E'"E'"E'"E'"E'"E'"
ME'"E'"E'"E'"E'"E'"E'"E>*\C]!_P G"E:T]7NU#JK2Y1K398?E.@VGVGNA
M.1XUA$A.L\Y^F=U2SNVQNMS"UH(66/Y'1T^&,1J6TBQ*B8_$NW9EFF4])CLP
MF=N/6V.#6"F,.3=,XE=7>*,NW*/F\!0LK=#SENATL=DXY<J+B)6E)0 B0F5D
M%//<6XCQ1BYQA=I=8'866#.VUG&,*6U\Y7[K'G;K";CSAAJV 86@-&%J6X96
M,@FKBQOMMU5'6:J7VH]7<VE9C.L^:8=C+>F^,R<E=C8-B6(8QE4V_OY42>Y7
MF-5P[B5(E6C<IIN<SX=JKA2Y'*ARR[PVMQ=DS9NLI6[86UP^;M]+0-P_</LA
MIE)&;.HM ]D$DHF%'0FLBWXR::1BC]^TZXU;8Q>V5L,/ME7"DV5K9VUXNXN%
MI46\K:'7"5AS\9Z(:0I2@FLG+[<&@R<IM\;18Y*_"Q_#8F<WV9QL;ER,)IJ6
MPPY&?P4V=RTXI^))F8FXU:1E.P! >+K4%$XV*Q$XQ?P<Q/L6W2EA*W7UV[=L
MNX;3=*6W<FT64M$^DE+X*3E42 "HIR@FMC^&."^<NL!RX+;%DW?O7@MU&S:8
M=M!?-]HZ#G0I=L0XG,V$D^@%EST:M:N]('HO/;R1AS%-:*K(L?.G;<;";C3*
MR@9IE4G54Y"K"(N'T"Y:G[QZVB8Q;6*EH6Q&AU[0D2WV2B2B/>7PQ?H+!\XP
MY;3PNRJX;O4+8MTV19%PJX="8;"%/MI &=2B3 U3FQ6^.L'<%RGS;%V[BW^;
M@+-W#G$7=RO%3<>8HM6"O,^IY%LXZ<I"4-P5J2<R4QS/2&=G&NK8]I96.6UK
M+\'&YBHUCC#L*PBOY!GEKIO)J)L"3+:DQ;G%,JI+*+F,%UL*HXT<S%K?84E1
MD<*XLI2DH0PY!=&9MW.E0;M$WJ5I4E)!0^PM*F%?EDP<L$B5<=X AM+CCETV
M%(MU%+ELI#B%/WSF'+96A2@4O6MTTM%VWNT!F!6#5P:F=J6I;[.^<ZL:7(,N
MWCY79:68$,E@F/6W6I SH:9U;J6&YJ')^.JRM2WO$LR8ZY=5#DR$]PD<R;5I
M@CAQ:VL+T94*81?7?9*)4S:>;^=KS&)0\&=(@A+A2)(B;^(\2MHP&]Q3#4E;
MR+EW#;%-PC*A_$!>G#FH 5+EL;J25)4"IE*U>C$C'-!V]L*QS2K3*_U,I,OM
M\ZR3%,[L<NJ]+\1E91#IK71ZR9Q[564ZPS.\174U-:!^='<D+>)J0A:G5R%-
M-OY3G##[M[?-63K"+5A^V1;KO+@-+=1B""[9(!*3F=6B$F8!7SU,8#/&]E;X
M9AUQB+5T[>/VU^N[:PVT<N4,N8.\+;$W"D+*VV&W/QB2K,0T=3(@WWEO;3TN
MASGL6HDY0N]N<3L;?"<HGXI.:T^N<@&G=AJ-44#60.O1T2K*101/'KC,->'4
M$KA>.1-!:3C,\.WJD]LZ&PVS<-MW3"'4F[::\[3:..EH @(2Z<DE0))$)(,U
MFW'&&&)=-LP;A3SEJX]:W*K97F#K_P W.XBU;A\J"5NJMV^TR)!3)2@K"S%6
MEIGV[]-9VFN)6NH;UO SERKT]8R^NK,==$<6V9:3.:M/W]-#3.D27L.B8U77
M<R19)4XN*NKF0N[>D,[*O7?#-XB[?;M0A=MFNEL.*<_U;%]Y@EIQ12 +E;RD
M)2UK.8&0"*Q<.XTP]S#[1V^+Z+U36'INFV[=1 >N\*^<UO,I2I15:(8;=6MQ
M,E!24E,@U3)/;MP.V;TRR^G>R+$M/KFWS%62KS?3RV38WN-4.DU_J;#ML3L8
M%NNN;B+K*9RP,LIMG70@T[\"OGO)**OP8NVS>,.]B_<H:8+/F]VC(VZY?-69
M2^A;>8$+7E*,J(D+"R 15"N-K%T8?=,^<VUDZ_="X5>8>_G>M[?"W\22Y;.(
M<* %M-9DK/:$D%I3:5J2:=9HIK7BVN6((S#%*O*ZFM,Q4-$?+J-5'/>!CL3(
M\V*@29D2=7S(<J/(C3(,R2T0M3+I9E,OQVM-B.'/X6^+:X6PM>4*EAWM$B5*
M3E4"$K0M*DD%*T)ZIS)()]+A&,6V-6IN[9JZ:1FRE%TR67"5(2XE21F4A:5(
M6E04A:A)*50L*2,Q<8%;6CA2CA2CA2CA2CA2CA2L1ZTZ.8GK?A[6(Y6[<P/
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MIC"9;$I$C=PW$8Z4&Y;3AF'BRNNR4[8$7*V.V9D)?;6Y<.7#:R"9AV#,$!(
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M75(R"H@VB8$AXI;?7&$MEWNA(0RTF0A/VM]+:$O)6E*0%*0N:0:7.WEWD[F
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=H%2@Q^6&GQK#4TI: !F($L@R!WO"E9/\N%*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g271308g01a05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271308g01a05.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2OJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *\Z^$2%#A"24T$!       3AP!6@ #&R5'' (   (  !P"4  (<G(S.3
M Y.#<< @4 +4UI8W)O<V]F="!7;W)D("T@2&5A<G138VEE;F-E<R!D<F%F="
M!3+3$N9&]C>#A"24T$)0      $+Q^N!G$0Y[4QV 5T##\C]HX0DE-!#H
M   .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O;
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MUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M    !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8V
MMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M   $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F
M1456YT1B-2;'0               !";&0@56YT1B-2;'0
M!2<VQT56YT1B-0>&Q 8J            IV96-T;W)$871A8F]O; $     4&
M=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M       %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
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M09       $    'CA"24T#\P      "0           0 X0DE-)Q
MH  0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@
M ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M     !.$))30/X      !P  #_____________________________ ^@
M  _____________________________P/H     /____________________
M________\#Z     #_____________________________ ^@  #A"24T$"
M      $     $   )    "0      X0DE-!!X       0     .$))300:
M    ,U    !@              WP   3D          0
M         !              $Y    WP                     !
M                   !     !        ;G5L;     (    &8F]U;F1S3V
M)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&
MQO;F<          $)T;VUL;VYG    WP    !29VAT;&]N9P   3D    &<V
MQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94
ME$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F
M-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&
M]M;&]N9P   -\     4F=H=&QO;F<   $Y     W5R;%1%6%0    !
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M4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#
MP,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@
MX.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,#
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M:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!
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M42(),CU<7ZW8^,S(HMI8&Y.0RSU@P %^TL;18YK?\ "^J]U;'KJ&BP-:+=;
MUHL/\ *@>I_P!-9'3^E9;\P]5ZR6NS"0:<9NK*MO\ -[OI-_0S^@J_P;_T]E
MEN1_-:>1DTXU%F1D6-JHI:7VVO,!K1RYR?.5B,=^$;^:R$:,CMQ'9#U+/;@T
M;P ZQ\^FUQVL&T;K+;G_F44M^G_P!MUK'KZ7F]:#<G.R'BDZL#AM!!X=1A_1
MHK<WZ'K?IE@]:^M3^IVG[)C^GB,:UHLR)+W@.]7<<=H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M02?.0M(!@&0D[BP)(X@XE7MG8!90TS[4V8 @ZF1 KL0QV01BM98'',DV&02
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M6ZHAEEY;@M_@H4K>^R1OO)[$3 @G:C/,M0I2ZFH0V"2$I<.D  ".=/S;GRS
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M%!* T@(U;,LXZ/1RD XC!E<S;XP5^W5SY%2!V\I*29$FWUQ#>R.HIX2I"NX
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M85X;3@-[ITC4!*3%A$" 3._. !VG[>KG<%K7@&C&(@8?[X][<B."02L% J3
MX%='&4B1X)S?Z1-5'N<>!"EQ8XE>1JHGNCVT5%8Y7OC_  Z=>O2L>52DDD$)
M4 -2B+1<FQWG#HZXK7,ORH98V8>J4!*5H.E006P )2-K[?MF3$'&RW0_9%H7
MHS"C3IV,P=1]0U:,MIG>9@'9N6:\;$.S'\?D?4T>/UHR]U8S(L0E@T;^#SI#
MN%1E9EU9G5>4M"K?IJ5M(;;IJ<EML(23I*E(4"208(LD0/+A(Y?TKEC(6ZZP
MT\\ZM3BG7AJ65*"=0N#,&;D F;D'%_99I3I?GM)+Q[--.\*R&GFA< T27C=6
M-XA*WI1L.=&C L(94:G4,\.1'D!<U"!,(C&O; I<VS.D=0ZS75C*P9!2^X25
M3<J2I12;[R"#,$$6.5;T[E;[:P*5DD1$H0(22 8*0#VM,"W(&,\O[-GVX[WH
M6(:<6,XT7$-8L6H\:[LL\ZQ3'LJ)1)(QF?,E..>R6/6V\RLDDEE<8P(P32G$
MDA61Z>N8U']?^'R:VM2DOEF5K4E(U*:4I)6G: JR@4\_086.2)7E?5;U"U)9
MA>E"5'2"5#@GY@# )$B5 ;WTK*BJY[>I5X5>%\?\*^5^5_1%7E>5Y_EZYVX(
MG>_/)%MQ$"0.!>-\.]"=0;(3$IDCTBUN<?&4>/#CFE2CACQ(H"R9<F0488\:
M,$;B&D&,1>@8@C:YY'O7AK4<Y?">MB$EQ02E,E1"4I"25$D@  "Y,\^OKC%Q
M264>(I0$2K>+#<\".."..257ZX;TL\R:W;B&@!&XI1S#R:VMSV17,M<QSZ4#
MK;(?@F+'A330:)C1.^FOY<-Q):(R0(T".].XR\BZ+HVFDUV?.>)*4N?I$JT-
ML)L0'W00"Y!&I"38$C2HB2!9SU-4.J--EH45!2DAP:E**IB$B+C@'@WD8I2F
M]OS7;6 1<CU2U -7%GO>9#Y796N279&D7EI#1#G(D5'(U.(HW1FLY5B(UC6M
M]$3W7'3V2J\#+,N8="!'^"TVE(($&Y0 ;!)) -Y,W) T.GNH\T\M54O,^(2H
M:EJ .Y /F$$&1,0?2,$MH5L!IMO>H]-JE+UOD68JFLMZVSQNSQ''(..W-1;Q
M4!80YYIL^28 &D#',$K0J]'!5'\JKN OJ#JQ?4C"J7^EI2%+2I*F=1<2L A)
M 2@3(492"+&T@3@IR+I]_(7"M=?)"2%%UPP!J2J05*(_;>(]+",>NLVGOM>Y
MI-E"U.H]#8=]*1\8MSC%D7";_P#WSB.[EGIU84YB$0PT5ZR^\CWM3GK1./0L
MCH_-J@%;>3UBD+!43X1FX&Q6 K@Q"AL<&K/5#=.XC1G#+;K:@I(\0*0E0V,&
M002 3(F3; K_ /DU-O6?1XZ;5-Y>8XC^&/,^DQ63ET#4REKB291ITH,.,>VI
M,IJ0S+.0^3+8*6=[S(YXW(15ZZ?,.FJZA_\ DTE93 :K+0ZA$ C]Q!387D*&
M^P%\$N7==U+K@!?I*\*TA1TLE2HM$02>U[VW@8&77;V_]_M0XAY$''=S&.5U
MF^ZCMJ<R8+)$D)"#%-*6AS/\!G_B#QA<@TK;^7(:%W981S$5ZC[V5N*\S+KF
MK>"201?8[&8$GOV,8+:'K3+F7IJ:1A"2""=* 021L0D\SM8VM:< >'/=8]M.
M3@+;P]8=#KV(8C7Q,K@W:4AQE<[KCI7YC7V6,6T0B$[*C=*EQRL<CD>K7-<M
M8K^HTI&L*$$S!D$3(B)$QR((,W&"YK-.FLT;6/$;\58)!4;@&PDD#3$V@CVL
M,%OA'N.ZMPI;+[OZ39+DD>FATT7+,AP!M7<'J(0#A@U3VXE+BT*-C1S/'&F)
M4LEL [L(0@V-:N\9VMM(2ZA:;FTJN;$F1S,$@&)DP3!&I72665:/$2X5ZE$A
M+2P+V-Q()!,D6C<#!:X=[O&1U]7$K\LTGEWTX &M.;#L[HFCL!KW%:4@,GK)
M-K#._JX*. 4!$8QC?O5C5;FC/F5.)3 "C,IDVM)'[)]!&^(+O0R"99"D[W6F
M8'MJB;P)F\<XLBM]X[2FO&UV7:0ZTXR5PNN,"/\ AV0UTECD7H4,J>V&=6+Q
MRA1$*)%7EO"*B^IZ<[8 &K1%KD0KO,HW@B0-)G:3&*9WHE[40E<^HDB>38D;
M#_<<8J+/?>O#8Q+")I1I)E]5-;'*R+<Y6&-/<T[B(@S1*R Z/":X8T:5WXO-
M0#7(B-:5.I/6*L_HM)!43,\*2([&=1!F]N($0!.MCH>K#DZ0DFY(N29YU$ "
M_K?[X1'KAK/J[KUFEGEVK5Y!MITTSWA:6NJI=R&.T'T[(C[_ .E58D1@FL[-
M;3BCQAN^YQ"$8YQAW-\Z14I#;:0$(D @G3$@3'W&Q]Q>"S+^D54ZFUJ("Y&J
MV\3N>\02/H8V-%O$5%:C6JB-\J-R];45%X1&N5$9QT\(KEZ55>>I$5>?0QKU
M%0X4)L-CL8[<;"(/)P>IHU(:2$+T^$V" #!4>_UMQMO@U]H.@N7:Q!W29#C5
MC05<O2K;5DE\^3=S94*5$B9 "SC79J.-7!.>?+D8_6'JBD*\400[IPR$9UKR
MRN@Z^BRQBO<J&/U#KM+54S9A*BE3S1"%$J'E 4 1N20(@1A.?%MC,*I&7-TC
MJFF?$8<?2)TJ#:RI05I$24@C4=IB<;3=G?\ 9&VL\?\ PXZ(?Y98QZBIV'L/
MQA6JNI1_YC^<)?VI;"] -8=0-S.N6IN+R\TR"5O'W*TPJBZMYA\7!&I-2;$,
M=P,=C-C@(]SE0DITT\H)2(BJ!$16J<9%GK]%E@I6"&U)>>EQ"87"U C4K5?<
M1"9BP.*ROR9-<^*A:EP6V_*%@)\@BP*5&#>;P>Q.'08OBF/872P\=Q*BI<:H
MZ]B#AU5'6Q:NOCL:B-1HX<(0 ,7A$ZU[?4]>%>KE3QIJ:FHJ%J<><6HK)/F4
M5'>=R21[<<8G4='1TR8;80%I&A2M(DF-Y$7]>=R).._(G*-3G\U55^554X3S
MSS^?E>>>5^?/GU'*BJ)X[<^_]_QB4@>&5%,RKDF2D2+)VBPC'K(2..),+-D1
MXL(<&66;+D%0(8L)L8RR)!B/5&L &/W"%>Y6-&QBO<Y$1?6QM01!Y!$ "9((
M@"-C8@<GL;8CO(<>A(DZB4_<:8(DC<[W]#:,8$MS&>Q-5=R.9Y9!O8N08)A5
M37X5A%Y#<UU.6GH!R36!X724['NL;(LRREF%P0JE&QH6/$-KQ[KK/$YA74M(
MA1/AJ;!3<B1IW@W@ QM[D@DL+H/)3EU)4UCJ-"U)69-@ =418$<'?GWQHN]H
M+9=K5H>VNUKU.Q>FQB'J;@<ZZ9!GW "9?#'D):XV&1'T$4,AE8P.,A619"FV
M@I@+"WE(L155[4OVE9>UEC3%*A27BILNJ2B$R "L%<";DQI"MKJYP)9K7U=?
MFSIJBEQ#*W&V@9TZ0I24D@J)ND1, Q$<X>RKTY55X3GXY7A6^>?'GY^43Y_1
M.>/.D24I\P2('F^_]G[B(Q'")*H1J)43I0;"1P)-IX-\4;N"W!8)MTP*7F&7
MS &M9+) ,-P\1Q-N\QNPC5[(D*.0B.!5PE5)%];'[<"IKAR),J0-R"$6XR7*
M*K-JYIAK4&DP7ZA5VV6C *E6NJ"?#3,DD6T@D4&<YBQ24ZP3#QLAM-U:]Y,<
M2(N ?6<+CV0;=\TU%U%F;N-983XXK2YM,MQ"+8#(&3E66V[>S^U$:#+%]1"P
M_'H7<B8J60C)-M+5+ ?37@C%G'_6'4E*UES/2^4J46*5*&WU@BP2(+:=)2E1
M)'G!28E1D&0 SIG(GUYH]G-6%%Q>J)(T^94W24DD;D$$[BYPX1\D3%<Y5Y5?
MGQX\_*_EQY7E?[_A./2ITGS2;&"(/W'I[=L-. I"0!&D1MN3WC>.XGG? 0;\
M-:,+TNTA@Q<WS''L,ILRR$=99GR"ZB5#K*CKX4NSGUD$9C!E67XB:-%@R 0@
MRD>$Q(YVJ(I'(3=+"F3F27ZE20EA"E)*@"GQ%'2DD$[I$D<S<<8H>H&*AZD4
MVQ^\08F0D"#>8$]R(M'?"EMJWN";-]-+G(<WU-R+,[G4&_L;&2V1BFEV49-%
MQ_%8LML>@Q*BLSQHL2/ ='&2UL%KE*.40PP(<C1/8^^ZQSU%2!2Y>\%4Z AM
M*5NZ I:DDK<*4)\Q$ (!V@DDF#BFZ8Z>+2_'J_*M1U2;J4)O?;>=KD?63]O_
M '@MEZ87=W.)9[:&S 01Q\9P[.,.RK""V5I+D#C@4]I:5[:0,**-Y)\OFR[Q
M0!<(;5>5%$%Y51JK:UAE];++*W$AYWQ4^5/,!0U%2K)'E($ZIM!+\X5^EH7G
M*8:W&VU%(B1(B!((/)($F38  SA9&2ZK[@-VFI=9AN-DL,SO\C,0]?C]38-A
MXM7U;'HDBYG2W%?!KZ*L 9OUMQ,<<0T<.-#"4CD&_HUIGICI3*4UJO"4 $I*
MDA*GEK() !*-1*@+)%RJ+DV//[U3U'GU6JD0A]/AJ\PA:$@&!)_Q#.Y@  !)
M)B(!.7!_:CJ'UH)6K6N%H6]D#:4]7IG5U$6D@E>U$<$=SE4*SGVZC3EKC_AE
M6,CN2#C(->KT"UGQ7K"ZM-!1--L-J5H+P)<"0 !K2TH)$V.YG;>V">D^'#SK
M(<?>6%GYP7"9N9W2)(,Q VCZP/5_VN\OPNKDYEH#J/)S:VHQ/MDQ3)(\/'\O
M.&O:AR,Q+*L;? @K<<LYA0;*OA"EE16-LX;W-59=%\1J/-76J7/<N92RLZ"\
MTA1 *O*"M+@U)3&ZAJTF";#$6JZ.SK)4+JLOJE>25:=1E0 F8M)])OL"=L6I
M[>.\S)L^NA:":LSIEOD*Q+.9@.56S2,R*7^#(KK;#,M=()URKJK&"7(AS2#;
M,(T)HLQ3/ (Y!_KGI)O*0G-LN"D4CP0IQ$@MH#GR*;"4@I!E.H2I)$J!L22S
MI3J'^K-G+Z[PR^T2C4FSBEIB2K5,R0;@"X.T'#9;NEI\D@2*B]J:V^JI ^W(
MJ[J!$M:\[%;TO86%/"8#V?;_ %7,5/A%YX3TLW$H<2"M()5)B!-YG>?MWGZ'
M:9IY"5%)$HD?Y0;<;P??;Z@AJQ[8VSG5E9,O^CI^E]]*8Y'7ND%@W"937KW.
M@A*AD6;C$E$<]"*(U*B%>QB$>B(Y'0G\NIG4W;"AYI-K3!@6$&8$QM! WQ94
MF=YI1_\  J7YD0%+40(G@$$B_?TGNK_5_P!E_6W%PFG:!:L8GJA"@N/)!CNJ
M$*;@^8R(S6G(2,'**45MAUG.0:A!%=90\8C%?UL<6/\ Q'>J"IZ90\5.4X4V
MHF0++N2+0 E< ;@)-M[1@MRSX@UU(4HKWVEI)\P456!L2H:Q<'>Y@@V PGK,
MLBR;33,;C2S4FHS3 ,VQQ4C6&&9.P$1XPF&X@)55*C6-G3V]+-:]30;6DFSX
M,MBJ]"L(AA,'\SR2NRM"7J@GP5V2O0I-Y(B)]P3 &_OADY-U/E&<N>'3U#/C
M0=7F !('RP9).\2;V(VQ74[*ISPE.!PFQ5ZA,D-E]XZ*_GJ8)6&:K2,14[G\
M+I:U6HG4J\-H=*^0#V!DP=N.P![BWUP5(<0I0(5Y3O$;F-S!GWCDX@Y"'DO:
M<1GDZCN8T+7]TB.&SN/*YG4I&L=ST(YR<(].?/CC2H7VB#L#'Y[[=H)Q*5I.
MG25$&XDB=K3">3-_^\\KO3%>YLA&#&&._H5K51RG1>MKGJ[PKU=PQR_U?G[4
MY7UX6F^_XX'][XT>=)5%PH:2)D1)VVN/>^+>TGU@SK19,YR[![@$&?>Z8YKA
M=U56C5?091C&0XU95]I1W8(TAAG"&LM+2FE X-"NH4&8X+V,*$UYDM1^E6IM
M2E0Y(@G]RB ".P]@3QS@;ZCRQG-,OJ45!2@T].ZZVM-E$M)4X #-U6B(B"01
M!ON\V=IQM'VLHG/";<M$$\^%\:9XQ\I^OHK3L/8?C',ROF5[G\XS[:;4^^(^
M4;FI^@,S/G8,N\/<P*)#QRUQN+7#LF:D6:63VQ[UX&J]Y'->5_=<U7MX1JK]
MBNCHM/1IZ;3_ %<,_P!2-3525H)4$:AX4D)) ($#L/3 %U#7]1,9XEG+@HT7
M@4T0"02I,N; VD'T/)W!=UMOL=5;31;#%UKHKG']3H<>569,._)6OL;,T"68
M,2Z(ZG,6 C;:%V)*,"YBL>KVO$-WA1',T4J:U\42T+I2K4UH"H2FX(,@F9$F
M8W X@&M"^XNF9-2E2'RA.N1,DC<1Q?:-YB<7BK'-5J*WX5R>4\?JGZ_*>4^?
M5=*9 *AZQ^-IGZ8G:DQ.H>@O_M ^N%+^\=NR9MXVR?T<XV52:G;BYDS J2$*
M1(C2:W"0QD/GN2N?#5DL8F0R0J *B,!2'NEZ3,1CW+'JGTTZ%N&X;0M0(N2O
M2K1,P(3!)@[Z9%\6F4T;M94(0VG40I"C-@ %"Y])]2;'W" _;5VH1]S&X_#L
M(M(GU6G6$2$U1U3>..UD9:2IG,F0\;<QB-8T647S8=&T+'*OX8ZP*G6,#F(
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M*"RXM/(O*W*<T2Y<:91,G!BSJ^-.(21',H9I(I7P1H,PF#81KWL[B_*AC/\
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MA"@?(@P0!.UR;;Q%@)DX=SZK^[?K^JK_ .Q?5!53GY_\R;KX3X7_ +O^Q=5
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MZ>459-3*S6O $9A6-Z$,JB%%M!0E0!B1I2FX&I9TV'E9=U!G86*BH%&PY_\
M0F02@\'4I5QSP.R<'/HSH?IGH%B@\2TTQR-4Q'L'^*W<D8I&29))'U*V7D%T
MH62[$K5>Y(X'JR'"'TAB18[&HQHGFF;UN<U#E36/+==*CI$G0VF  EM )2D
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MVN:Y.Y8YY+WH]U;6,& (HPVC:B>L<^J<Q6^JK655#BBM1)$)"@ AL:=DH2(
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M+Y&\VKE!TTJM6A$*@&!YI)]"?]QA[=!9;3O9&Q5Z$!];]0E2RD24I4 D:K;
M>L6]L'W[3&Y/3O;WKW8GU*6OK\7SZB!C!<JL8B'7"K@$Y#TU\INT0L&O(Z39
M4]I- U'1HMK',=Z1Q/:^PR+-$MI4P%E#2BE2DJ64ZB!&D@$%4[W( (2;7(V=
M:].#,Z=+C#2EU#"5%(2  I)@J@D?-,1MR( .-?,&57W-?&MJNQ@VU9/"V57V
M=9-C3ZZ9&)]K#Q9L0A02&.7A.H9'(CN45$<JM]&+;C:@/#/E)$@3)/!'O?\
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M.?Y!FF279["I'<R(.2:E6\<-I>Y3:1'*DJBT\JI SU>*XCC[VMA.D(TSR"0
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MLO0QE5*1 9HTZ"$0;:R57(@2D)/(XQ7M])-*=2YF-0Y6+$D@DEO43L9,$ V
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M174Y2G*1HA#1^%W2-5Q7_8SJ56HG*HCE<U.>5X7XX%+:<2D%2BVY"0)/RF0
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M.5EA,E&&9H&QQ]1#GHOIQROKF<TK!X&6TBP\E3LH_4%!U)2@JLM(NI2Q*?+
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CH'\/!+@S8YXLD+T1PC">QR<M7TG!L/88/E1J5&TF/:<?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g271308g01a06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271308g01a06.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1OL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &]"^<2 X0DE-! 0      $X< 5H  QLE1QP"   "   < E  "')R,SDP
M.3@W' (% "U-:6-R;W-O9G0@5V]R9" M($AE87)T4V-I96YC97,@9')A9G0@
M4RTQ+F1O8W@X0DE-!"4      !"\?K@9Q$.>U,=@%= P_(_:.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             !P@
M G8          0                         !              )V   !
MP@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
MP@    !29VAT;&]N9P   G8    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   <(     4F=H=&QO;F<
M  )V     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8U
MPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P"IUGJW6&]:ZBQG4<QC&9=[
M&,9D6M:UK;'-8QC&/VM:UH5/]K]<_P#+/-_]B;?_ $HI]:_Y;ZG_ .'<C_SZ
M]4E"2;.IW;\(1X(^D;#HVOVQUO\ \M,W_P!B;?\ THE^V.M_^6F=_P"Q-O\
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MNP\JH38PL;,;W
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MD@IHUN1'L(@$)N1)9SA'9\3;Q$3(3SF<?"9$ YN;WGVBW=L5OY?XGK5I?[E
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MSI(D2 0^VVK;-BA(4:=4*#*-.H2?ZSH,G5X(.]]G^FYR>_T2.5K_ (<^"/\
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M8@S;KNV^+9W^G7^K!R]N[Z_C@V/]5[:;.-&\M;F,5*4**MAL@@D3/3W&\S[
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M^7.)O$3AZRYHHVUT[5&'5!:E!UEE:%$DF8/<F#$==\9+C5&GD,]6IT:*4TP
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M.SL#T_K=#I@.BK>:4$M%PJ* LH9W*!)2-1) F?F5$&9/3!DG2;Z.VMGO]=,
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MQ7V>TUO4G4M^WTZU$*DP5**B8/63O.-SER10IGE!)2DNP< @/>]M9.LVXI6
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M3LTP)),2>^4$@<IG*\"F3^CMP4G<C?\ N:Y9QV\6'<,?-57WE?XC\<0%_$I
M/B#\YNW_ ,0V?NP._P 73_+;:.^\8P/'@_$JM_N4G,@"-]!N8]V/3OHP2_8_
M)^TSYS/G4?[0UQ$L;B/BB*#J!$1N#]Q_\/WCVG%*F"1):Q/4:%M#Y1;&\6"
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MCE4?99WB[]T3XM?&]X/GN*FFD5\[F*U,?=0NLM26%X4;1W=\8[7,=,3ES,Z
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M.YZXL</>$F7W\QY\S?9<F6FG:4367:O:I5.PDE3=+3D_$U3RP"$-TS;BU="
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MW-.MK;6-:'T)"*QET$ZDNL5*5I4@^I(Z]1A">8'V@#W3$O!Z : !R<6^445
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MI@B% $L&?;=H/3;PFOPY4H@'U)U$)U#H9,?3O]W3!@@!Y:'<&';=_P +3J3
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M"2[$X/P9MRN3 S!9^L?]X4W7V_SF.5?D+C7_ &3Q'_X/,?\ ]>/9?Y_]AO\
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MFAPTF -(\<9AX=G/JE86.3/F#41ZAIX?5*?5.TS4]0.X_L!_D+B)!_1HN_\
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MTYB$[DC_  !JIU;^K:K G?J1.%?F]Q/2E3'=5'3QTW;8 S@'TJ]B)_7<[_\
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>U=!74S]+4(2I00\TM(40)/0<>8U%U*-W42_CC__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g271308g01a07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271308g01a07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1X&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '>J^=E@X0DE-! 0      $8< @   @  ' )0  AR<C,Y,#DX-QP"!0 M
M36EC<F]S;V9T(%=O<F0@+2!(96%R=%-C:65N8V5S(&1R869T(%,M,2YD;V-X
M.$))300E       0EZ8 9]LYE$M369@FLZ 6ESA"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^
M-0 "  $#O_XU  (  3A"24T$)@      #@             _@   .$))300-
M       $    6CA"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          3A"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #/0    8              P0   1[    ! !3
M %0 -P W     0                         !              1[   #
M!                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
M!     !29VAT;&]N9P  !'L    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   P0     4F=H=&QO;F<
M  1[     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MLKOO6%O"6[XI*=W_ )Z_6H_]Z5W^<F_YZ?6K_P LK_\ .*PP\<"4^\)*=O\
MYY_6G_RSO_SRB8_UN^L=UI9;UI^(T,>_UKGOV2QN\5_HM]F^WZ#/3KL6!O\
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M9EXKWAC;)>20
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,S1#4V)RDE2"DZ*RTM,E1&.#PC5%9'.CP^()592SA)6D_]H # ,!  (1 Q$
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MN)8J,"MH=9<*5C"W6I*$;$DM*.X+90.93:02",US:XM;EK'?A7O;\_CCJ/\
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M[^^<8Z/W8,#V\$I..#@$ #)XQDCL.3D'/H1ST8, !3P24Y3P,?<,X]/@?3'
M'/1@P(D8'V3GUS\LGG^.<XYQVQT8,*V20 .1V(!)[?'/W'Y=\=&#"U/*<9.,
M=L>Z<DC )XV@]OA]_<P82KQDY!]<>O?&,?'OQZ\9^?1@PG=&0/=221P0K!/'
M)^0R3GC(Y ''!@P6#A..!@' QA)..<JX!_?QP>YP3!@T. I!)"@!R <$9'/X
M\#GT&">>>F.9 (&HTY<B#]<\&**<0K"4$\>\K!! R. >Y')SGL3D8Y.6I0(
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M"0< <*.8$^VD09RJ((CL&_U,8-O$<NWZ^AC@_P!;6D)@U/W<':X0.-N<D
MC/8]@< D>G4\&->+C)??>&Y#24HD/N..DH::8C-./O.+4D*60VRVXO:VE3CF
MT-M-N.J2@G=]<_?@Q955"&<):=>6D$X665)'?'JK?M/<$C..X!R \IM;7POK
M;LC?!A.J1%.25GY>ZLYR1G!"3S@'.X@?B1EA))&D;P1([?C^6#!B9\5((*U
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M(J" 7SM)) \J0,' !!(:Q\S@'G)'< $$_O'./B<&$_UC'=!(D#:"<C8^#QD
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M6M$X/U[2^3R [)R?3/\ 11C'PS_K(0"2<PY[SML ? 3//G@Q7ZSHJB,5^DI
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M&QZ[H[P^AK65JJJ=+JDU(1*EN@Y2ALY80L @&;1N3.//\9K*JE4.H=R L+5
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MG<W'*-D8)PZGKYIZ+.E]-TWZ/\5XW1U1K*9OI;TEX2RZ5E:4_HBN]1<9;5)
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MMD%R3<'0$B^/45/%FTM+#4A]3G5M :03'6'G;8Z&)VQM=\/GAJM.VJ74[N7
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M-ML4E2Q34]6$L-'A[]>\5&K>9= <9:0E+()4# QWZ3T2=+*7AW1&B%?P%Y7
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MZ\NST"Z,,"&J2J -QFXKQ1>AFQ76*.O;V:0,<9CHQP>F #--4(, PKB/%G+
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MO;-4EZIJ>&52JEYESA-8JMID4_5M,.O*I7Z-2*UCJU-UE/U%2^!3N@MAQ8=
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M$;2_",4RR,)0ZD8;M3 2H+"]OZXG9@J\SD\;L%)P08,+89TI8;D!^W[#G>?
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M!*4[4N-[2"D[E%()2K]6%#WAD\JZU5'M)@"VVB1!$>T!K<&]HD]N,S"@@G2
M3-RHR";=FLF-Q>3IU?4-Y+L>.ZGE+J L>GNK!4%8^X@D#XX'PZXRMN[YGZC;
M3&U,W\/.)/Q%]^9QG,8_#G* <_=C_7U'$\&KQN!/]5"C_=_?T8,:QOI:Z_\
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M]>5-P-*<J)=<6Q+2774!Q]+8WD(:D+;4^P"IL':PXV""H8*5K!0HZ5,96$)
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M,0J<[7;WA&4P_0J72W;9F+4RVS3JQ(AU%$)Y^M*DR*5D#]6Z;*-JA0*3( (
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M8IR?:X].:?0_$J2FP:?&B@+2@PVM))DI#JE?L@645W$I R\S.74E;_:%K E
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MVUB'$5(FK"8XIK1244BFB-+J6X @V $A2@;"!<*FPL+V%L*5B05),[$ S>;
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MC_?U1BW"M\^XX3Q[XQ\]J2#CX]O]?1@QRM?E&%R(,[P]6J'#F/;^H%?<1E6
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M3,,5&>-M:DIL-3-SH ,>7]4!Z:50MV:@-A36&TE*]\C:I0,984D'&Y(+>02
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M>R4^Z3OV_+X=NN34)A2OR@$&-!/;RMMIC:VH6O?>W,38SSC;73>=C$,Y:'S
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MX'S/>4. .Y]WG@P84Q)^GT:4R^];]KS$-R5OJC/BTPV\XI."26:DVX'$J*'
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M1YU1==>2[4Z;E3AB3'Y$ER2XXX\XD>6HK4M&UM"&D(:;0EMMM"6VVT"$-MH
M2A"0-$H2 E(V  QVF&&:9EFFIVFV*>G:;889:2$-,LLH2VTTV@60VVA*4(0+
M)2 D  ##(^)FGL0'J30GYC3@@7%7H@D^6XVB2J IF$74,I\Q;8<W%80I1\L*
MVE2B.4M2T@9&RX=P%)3';*B >4"^^@PW%+2 4-%V3! 6A&7M]LC-R@7&N(MB
M'3UN-GVUCWZ@X0DH?]Y68Y"<^7A()41DY R3C@]5]:__ **H_P#FLCXJ \R.
M_%76U$B*14;_ *Y@1YK /GA;3:)!FI;\JH,KE,/>U;$-/",(QD4UJ2^_*?+#
MS0B(?4\XAJ&\%)CND.% 2M5#]8XQU:G*5:6UK4U*G6BZ7>K=6VA#:"M)+BFL
MB2IU$EQ%ID#)4U[U*6U.T2DLK4MO,:AHOJ>#3[C33;#?6(47E,A"%+J6[NHE
M 5F0$;4:AI88"GZCYH8EK1MAT_RR,O@%956DN)R$ J 02DC&3@=6E5;(AFDR
MVD&J?S;3I1%,@S%X-K@21I*N(9K,4.2TDUKX5I[0 _1\2"3'M!*@)D;4,:BH
M,9)DS5H$!U6]N%"23O7,*AL<K"<*2I6T>]M41D<'HSUA!BGI@>2JMT\MTT1U
MU[-X,@(+KRDGU:D2J3"55SI3$V.9- 3)%XRVT)F<#=CV^&P6Y%5WII[?#L&F
M)1[SJ59)37%*_KY.$DDY(R#T@JNF[-'$WRU3\@=QH1)[O#2,(+XEF]NFH,L_
ML5U1FB-@KAJ4S/\ >B+S-L*D4FD28\Q<>3+4N%$A.RW7F(C3+<!,<.*=::34
M7G79+BFF6FFG5QFRX\$*<PKS45.552TXTEQA@=?+;*$/K6LOE302E2RRA*4!
M*EJ6I*'82A13I"J7*RK9=90]34P%0"TPA%4ZMQ527&DI2XX:5#;;02XZM:T)
M>5D:S >P4K32HUO[70U)J@4$PT$N0::$!(;2"?<KJU'"$Y2G:,JPG*0=PM"J
MX1F9I"+R$U3\G[L310 =Y-IG;%P7Q(?;IJ B]D5]1FF^7[?#4I )B3F,"X!P
M7,BT</3$IE/O 2TC>F)'2A1 ?!"?,JB'-G<!3B$+5C)0G..I!RK(!]693(G*
MJJ45"= <M*4S&H2I0!&ID8F'*P@$TK")OE56**D\@<E(I.8B) 44@R I6H&(
MM'6Z[NF.M.&I$MAR*UY*EAU1"%.,5!YU .3A28SH"@ I(!*DHN58(FE:4G?J
MZJ5CM"7&&T*C<%Q)UB2(P%RL!$4C2D2,Q162X =2EMRF:0LC=)>1(F#,2LBT
M6GOM1YD>8'&HM2;^L7'&$-MQ4.>1Y2HP,IQZ87'LL(#C4(%105EM!6I%)K'4
M/)9<I@EQX*-,D/!9=4@G.'#D2AD(1"U*2MX0"!F)3.95=4-U 8<HTI4\E1HT
MIJ@M3RT*5UB7R&0W3I0V$N%25U!C,$I60D*1L0:&4L>54E[PM\H$J AAI7ZI
MLJRY&J$YU! !/]'621C '/5H=K!==&@C?JJM*E@039+K+"53I&<>.+NOX@",
M_#VLNY9KVW'!8Z(=IJ9"O%],3OBL>G4-+3"GJKM68\X%,>"N0@99D9_62)4%
M1 3R?U2<\ C//07:N?9HDQ;[=6VA5XU2AMX6WA2AVV.(FHK\R@CAR"D$%*GJ
MYILD6U0TQ4P1>1G4#SM@9@4(MM>74SGV-[(?IY:3L\^2%%"H\^8HK!/NH6A"
M%#)+J. 3K:S]JC1V9*M"B3M(6VUE3K*I)&H2K3 '^( @*X<V1<2UQ!I9FY!4
M':>F 3L5)4M8ME;7-A*I5.]@34//=$-+ B.+\F/YYE^V(6AMA@5 -EM40^>I
M;TEO:MMQK!W-E5?K3_7&FZAKU@HZU*0^OJPP!"EK<+.;-UOL!*6S(4E6RXCZ
MW4]>JE]69-04!Y %2YU(I\F4K==-+F"_6060A#*AD4APK$+ 3NQ*$M3B439;
M8,2)N<DPHFT>Y%*>(M7DK)5@#'E\'@\94+ Y6BZJ>G4)B&ZIPJUU_64K8CQY
MV-IMZSB"4E2J2E<5-D,UZ\Q$Q<O4+*08@P5"TP20 2)$6E_M(#\@CRXF3[-%
M!/ZIH$X^L\9XXYYSP3CJ6>KWIV#/*J7\Z6>Z0/#%F>JM_)V-Y_E:[<O^Y7G"
MIR#1UKFDU!;)$MM2@_#3@I*G\^68\V3N= 4=J' RA1&"\@$GI=;5B?Y(V=8R
M58,'8*#C#)RDZJ3FRB^4V!K4]6I(BA0L$&[=:BRHD!0=89A!-BM)6I.H;58$
M^32*>TPF<F4LQ)$QKRU*89#YEIDU)I]@-":6T-,HBI=\PR2M0D,)#&5K+=2*
MMU3RZ?U=/7MDE:0^>J2T6VEMJZPLYBI9=*0GJ0/U:SFL :6ZU];[M*:5 J&E
M*4H"I/4A@M,.-+ZTTX6IQ:GRC(EDI!9=)6,J0IU;'1&1IKJ"B,MQ:15:2M?F
M--M$'S&4IQY<J2%#W>Y4D@XPD\D>BZ/J</%:?K&VT'];E"'5.@RRZ/:*F68D
MP  %3)N ,1XB754#_6MH;@M0$.EV?UB29EIHB( %B#),B(.T:RZ5!K54LZE3
M?U,*K3[:ITQYE3##K42H/P8LAQI]]B0RPXAEY:VWGH[[32PE;K+K:5(5]S60
MFG*PE)*6RL BTI:*P#!22"H7 -P8-B<>32)<"=B (F-5 2.T3/A?&W__ ($&
MA]KZ<>)*O,3ZQ6JG:7ALU#OJVG+AKEGUU%/N6V*_8Z*:["^J;9HSD*7(CU6=
M'+@<=D/-E3#!;2I[S?,'B]6NHX>V4,H2[Q!AISJFW$%2'$.R""XH$2A)@$@Q
M)[.GZJTE#R@2HI8<4G,I*O:247LVF" 3$01YG&@C7YE TXFN!M \FK4=X$(2
M"#[4&N./4.'(&,@GTSUZ#B20*8F/ZQ&PWS3?E!]T;XYELQ2+Q$=LC8=DQJ<2
M?TLM"DW[J'I]9M7K$6V:5=MV6W0*E<+\9B0S18%7J<2'*J*F'Y,%A\Q6'EN-
MLO38C+BPA#DAE"E.)N?=+-*X\AOK%ML+<2@>SG6A.8))"5905?:5E,"3!TP-
MHZQY*"K*DJ2"=8!U($@2!,20"8DC7&Q;6#17PW5:SM?&;0O:+(O[2Z9==YT6
MCTO2'3RP9%H4BEUA,*7IY?TNT]4JRQ5X[*6$VU1ZQ^;4BKHOF93F5S#!J;L5
M?!I:JO0]0EU@!BI#+*UKJGZCKEJ3(?8#U*@H4J>L6GK$I+ 62D%!5CHNM,%+
MX2X"MLJ<2 TE&1,@=6HAPR-D^R3F(VG&D?7UEM-BL2 TWF+<M$?!"$C'ZQ]"
ML\=B%X(]<XQUU^(@=0DA('ZUI1( T.<7-HU_?;',!))DDPH@=P!\8_+MP_U$
M;@FLT9<V,S(A?6M,7,8<;!;D0Q,8,EAP)PKRWF-[:PE0.U1 4._6Q:9;7E$*
M*"4D) *599&H.X&L[ C$@86B8RZD&.=_AOM/+'1S]+QX'="M*O#_ !]:-,O#
MU1="ZE;>HMK6C'?M.NP)E"O:W+H:N-3DNHT*(EPPI\5^%1WHTN06930DR8!7
M)82E8^?=%N,5E37&DJ:TUJ7*=QU27FU!;*VBW[*5J D$%8,2FV803CO<2I&F
MF0XVP&2'4HE*@0L+F2I//,E,:3/ACD_\0C"$673):&FPJ'==(>W!"00E3%00
M03CE))&0>#QZXZ]KQ%(#*2 +/-Z"]P9E5XM^ N<>?221)F\B8@3&Q'N[=</Y
M%3"3)BNRHS;\428[DED'R?/C!U"GV@ZA.]GS6=Z Z@;F]V](RD=;"$E)@)!5
M]DY08)2"+0=3L3OOA@^W&T"W._/73D#YXW-?2!>%70+2?1M^N:8:>O6O<>GN
MH5"L"=5PFJH9KU'?9JL*;.FKG7+6452:Y58$)TU*?%%2*YSR$3410S"1Y+@7
M$:VIJDHJ7TN-OL*?"80<JI;.5,-I*4PM0RI,2)(WQUJZF9:94IM&53:@B?:]
MH0;F5J!)@&2+S:Q@<\_B&CMILB!+2VVE4.YZ6]N"$A02IB>V0" " 2I.>0#@
M9^7H>)#*PA8%T/(580;9B+C32)QQISI4D@?9*=O:)!VMY<L0&D:8:<6RQHY3
M3HW4-:]1_$!5=0JE%1(U!JUF4N@.475N\-.:;:U.@T5F,A3J8]K?G+6;BK=9
M]C;CUQB.(E,C4B34*A\"X[5TG"5\6K*YY--1T+M8[4/*2HI;::<620A 4M2B
M!"&T)4M:BE"$J40#[AE]M%"S4.+R-IIFG%J()A/5I)L 22=@D%1, "2!C)*Y
MIIH)2+[TFLVM:,4ARRM9*I;% A:JZ6ZV75<!M>IW&:"U4X08N&#4:&]==CBY
MJ14:U;=197'FPI,-#4^*W4F:A&X/!./T_&O7&TTU905="^MM^BKV>HJ"QU[[
M%/7-())715BJ9\4[T)S*9=;4E*VR,%+5HJNM2$.-.-+4E;;J2A>7.M"'4B?:
M:<R$H6+&%1IB,E8H<BW6Z=0)2@J9;XKUNS5 ;4JF6_>%QTQ\A)RI.0R@A*U*
M4$J3S@CKT"3"3/;STM;LUMWG37&R(^.%%.(%.Y)RW+D#';@M1"GOV^TX1SCD
M9P2,V V2"(U@=N_F!@ N2)O]&W=KV>..@3Z%2NI;O^3 =D--ESS&TM.KPLDH
M:);2"=A2ZE;@(*<*]_>I2N$=*D(+:Q),!(O?EIV3K!&]KXPU1.9%S]HR#]F(
M!@P).A(!G?'6/X!*E]3^*#4:@[\-U2%-=:;W'.U<9B:W[A.&SM92I+:5.I0E
M:4%U6Q2E550, Q(WN)L0! \9UM).ILV"%";#LD$V)),@$0 8BY%NX[[J>LE&
M,>@^[@?Z^W![XZY>-@T$<L7*;@J"3[H]Q.>,C&U)()^6>.?ET8>/FD^."\?S
MJUKUJN9;J%-W)JGJ#66CW"FZC==7EM*2M6-P\IX$'&5#N!C BC[(CO\ ,SX:
MS',\\-1DD\X^&-*>L$TO2]N=P+AQC'!00.><8W9['G.!U+EVVC]W[N6%ACJL
M 8M":(X]AER<C.2IZJ36"3\/=A( []@,\=,Q CMF^]OR^A.#$D]'FO8]#];:
MD0?VV=;-(0LXVJ#4&M*>03G.0:I&( &#ORH]7 13N*UEQM(CN428VB!),:C$
M)_6!(%\BU3XI&Q',ZZWC?#+'@'[CU1B>-H%JR8L"Q:'2"S(5)(MJ9(*O+3'$
M:E4:3&1'1@J=+SRZB\IQ2D!#:6T!/F%:MA@Q'OQ-3H]3N6@/1QEB?4J[4T(J
M"PW(;$ZH07"E8CO!M2D*4I)4E2@H)2K@E20:8,1?92G?#):@',IQ9_7R?0L9
M(Q)_[)YY[>O'1@PMILQ4 E3<>F*,NEU2&K>_*_5HE(=;6ZT!*'ZQ"6LHW93G
MND\8H?ITU :"R0&GV7P!H5,J*DA6^4DW@@C8B<9JJE15"G"UK0*>KIZL9,OM
MFG45AI>9*OU:S9>7*O+(2H2<(MJ (Y\NG\0I)(\^3ZKF#@F7]V1G!^\C-^-.
M/*2C" &Z<<0<']I?XWN*(']+R ?-[_VXZ,&*K2@>9AJFX3"BC^DR!@*$57_E
M@)R3GUS\SV,&%+<MV(S5F&FZ9LJ%/@0I 7(D9\MIZGS1L/MH 7YL1"2<$;%+
M&,D*%3C*''&'%3FIW%.(B/M*:<:(,@F(<*A!!S)29@$',_2MU#U&\LK"J)]=
M0T$E(2I:Z6HI2ER4J)0$5"U )*3UB4*S0""EE(0%3!Y5-R'6D#,F1C"4.CTF
M=^..?49[\6XTX,?0A3TG]53#_*!'])D'LI\#/[6?C@8XP3V'1@Q5"4%Y!\JF
MG=4A_P!9D9)*T^OMG?WL>F!CCOT8,+:?-+,-RGICTHMU"?"=<<5,DA2/8%>:
ME* )>%!U3R2O) 'DI(!)XSN4Z7*BGJ"2%TZ7TI %CUZ4)))U]D(M$&2;XRN4
MH<JZ2K*UI-(BJ2&P$Y'#4I:2%*)!4%-!M67*1/6&28Q;HZ$CV;]53#Q*/])D
M'@,8XS,Y/![GX?CHQJQY"$$,Y:I@_99Q(]IDX_FI()!]K).,8QW]1\>CWX,"
MV("&OU5+_H+_ ![3( /Z^1\9F3W_ +_O,&%RYRC1Q2O(I/D(6*EO,J1YA=6(
M\;9CVW'EAM 4D]]RE#.#U1U"/634R<Y8#$6@)#BG)TF25 $3E]D&)OC+ZJGU
MXUV=><TB:/J_9ZO(EY3V?3-G)4$GVLN5*82#)-N<2C#WZJE\1(9 ]JD?Z.*<
M<S!@ ^F..,=N+]_W1^/RQJQYY"3[3^KIF0U#/]*D'@LL]S[8/4@<=^_/1@P.
M2A&^;^KI>?:6N3)D?_7\$>U]^?[N.C!A?*FEV W35,TORH-9ER4.>UR"I1G#
M"FBD20 EI452FSD^](<X QFA#"4U#U2"<[[;+:A B&>L@S$DD+2D@F &T@#&
M5NE2W65-8%J*JEBF94V8R)-.NH5UB3KF<#R4K!M#+9$'-+K:?I2-/M24 1Q^
MTT=0$=QQP$^>0-Y<==*"".,;>W;@8[O S'%:3M4X/-ISZY>[%/%/Z"_V)23_
M )D[;XG=8VONCU,EV\_<U:N5N'3X<=4G\VXD^%7(M0CTXIA2:?/=AN,,/T^J
MIC2_,225HC*;8=:6XW(;^RJK6"P$(6,Q0D0XTLID@!84!J"DJ3'<9C'D$0%!
M2LPM?*1-C(@QS N"/QD;(\9?AUNB"NF:A:M^*^Y::M6]5.GW4_7H)."C/LM=
M#L12L.!_>Y%60Y$0QRU,<<C8@\AM69A'#FU 64*5QM7^9M&;2T3EC8'6XN)5
M9;E2H$R0IS,)T_:G\3S MB#^L6JNGEUV=6Z+;55F2WY$^(Y36)5-FL/F+'J;
M3R#*?7%9BI?3#1EXH*6UO!0;1M*0-%76,O4ZFTJS.2@V0H)D&3!44GLN!8D1
M&*( 42DFY$<[:>//MTMC.8^NFFAA,-O5QY+ABM(=0Y1:LL)<\E*7$+"8:D+
M5N!"5*2H X)!SUH3Q&FR@9U I2 ?U:K$"XGE(O:._"R@'-/*1-C;33;OL</O
M>OBWT-N:BUB%#O/6E3\M^(Y3Z7=5Q5>YK> BS(KGM%30_3&9<N4IAN5(C90I
M,"<ZTE+DE#(D=9&:AIM:59Z8) (*FJ9;;D7@ @*$:2) (W.+UK2I)$NDV@*7
M*01OV]FF(CZMZJ6/=-DS:/1*J[,J3DRFOL,JIE2C)4(TI+CJB]*BLLIVM;R
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MY>)Q>AXZF4D8\*GA3'EE6W&E<,8SPHI(D @'MP.3GCMB\\5UCAW"M;?R)/\
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M$[F+WB1:>R)W '+G@Q14.F#!\RH'DG&R( !WQ_. X'KR/4D^A4D=FP%CR,V
MYB/&^Q,&"/3L A4_U'*(A!Y_[QX],8SR21GLRL0/?/(1/GW7O@M\/KPVP8&Z
M?C^<J'KGW(F<\#D@_P !\,=^GFM*1R$6OL-YT'CX8/KZ]V#4M4K/O.5+'J$H
MAY/&"0<G')Y.,]L8/'0 DDB#S,['>\]O=[L&U_'!I9I6.5U0X2 ,"'PK'(^[
M X)Y)]>W3F#M $Z&WU!B/WK46@_#]V*);I. ":H?CA,+CMSR/7_5DCJ,2!8
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M<&PCO&_=;#>D$Y)R?M9402%$9_<0".XX.02/2L 7]\<]X(B>_G.)7[]K?O\
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M[X&0.EF5!WTUC0VW!D7DV/OP>R#:;_L@S'?'+?: 0,5)<0E:4-$!;8!R$DI
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MR1CB2HG"0.Y_'G=T9FQ<*)DZ%/=?7PVTTN<%^0\_RP:U]&QJXV<_6UO$\_\
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M?G(^ ]/ER>A,$Z@^-O'Z'?A01H><V%_S[=][6QX:&.^D)2?GY9[??D'^W/\
M;AVY'S__ !Q+!HT,4/\ J63C@[%=NV.3W]>?OZ+<CYC\,(@G0QX:^_!HT,5G
M/L*N!QA*N?3GCOGGMV/RST D<O(=V_PY;;X!.L@CZTO;;RYDX]^@M9/,$_?M
M5GGX]L\<?$=_O).IBW8/P^1C!!YGW?AOO[HQ[]!2_2"H>G (!^_@_P!I/W]2
MS"#[(/E/@ !/@,._T/SQ7]!CW'['S_W#C^W(/S.!\NC, 9 .FDV\HU[-N4X4
M7-S!FWER[OJ\U_08Z>/8<Y[Y0>_?C_9C[NW244F\'MC\@?/W8>/#0QP?]1'?
MT2K'W\ Y'QYY^'0"D7B=H)GQ^SA?7+WSR_'%/T%N$C$ 9'_8/(&>.W?Y^O\
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M!8:7/,CY=L=W9A^*#;S41"24ISCW0,=L=^/AQ\^ .W/4M@5C_" 9\9VUCRQ
@DDP#IJ3>.P _NPY4..$(W$>F !VQ_=_CGJ.N):8__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g271308g01a08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271308g01a08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[22F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )(J^DU0X0DE-! 0      $X< 5H  QLE1QP"   "   < E  "')R,SDP
M.3@W' (% "U-:6-R;W-O9G0@5V]R9" M($AE87)T4V-I96YC97,@9')A9G0@
M4RTQ+F1O8W@X0DE-!"4      !"\?K@9Q$.>U,=@%= P_(_:.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE- _(       H  /_______P  .$))300-       $    6CA"24T$
M&0      !    !XX0DE- _,       D           $ .$))32<0       *
M  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8
M 0"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M     3A"24T#^       <   _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H   X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #-0    8              ;X   )V          $
M         0             "=@   ;X                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   ;X     4F=H=&QO;F<   )V    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   &^     %)G:'1L;VYG   "=@    -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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MAE^@/L:?V_J<%QS<F!J8OMCY?I%N=.P>I.H;9E9627O]VUU]WM!^BW^<0\#
MJR,X5!H./BQ9>>Q=_@:O^_KHCJ3/=6,8)%EK<V(QE[<0-/F("_2>FX]@>;S;
M;! &ZZX_^CEIV=+Z4Q@_0NW?\==_Z70.F>UE@[[I^4+08! )&KM?DH)2D)$
MK8QCP@D.:_I..XR*W5-/_"W$_P#G]!NZ?A5M]K;"?$W7S_Y^6K?8 -%EY=L
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MT3(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M(E$5(V%Q%C*!%R0S0I&Q&">A)2A2P>'P-D-65W)VT?'_Q  = 0 !!0$! 0$
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MMC/G&0" #]^I?WF&I*JUL&O8GO384/'<RW24@D4NWTI^FV!$O?4-V$B5$9?
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M6D4)BK5C22-?E-=CK=5+TGK3%RUJ)Z'-:DS+74&*JIYN.V'GVX+=22VD]E*
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M%OY:4#T!^OK>E[P[U@(I#:FI[4IR,R&W9H<;<1(9&.)0ZE2O6<6M1(R2L\L
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M/N@;E4^X:-!K$5!E;A]3)J VB:TX&SPD Y1@@D'))SU;\HS*-(R\)4"-&0H
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M:^'<:)Z1QM++6;;G--F\ZTVU+N"<D)+D;FGFQ1XJE#DW%B!0#J0K\Y_FM?8
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M)))/[DG/WZTF!_N8+_\ *A_^@8\.YB#_ !">J1_KDU2G_/7VPKV[$J.INN1
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MU>$894=35VK7>G<87WO(WKKW-1:=I7I?;E9I.GD*KLU>HSJMQ;N&\ZE"2XF
MTJFQ?6_#Z5%=6'TLN+5(E.A"G$MI''K1^D^CT=,:\SS2;@JG##4E,$*U(ETF
MX"R64I1 <D!A87?.NJ^IXF<Z)21@1%PS$"1$0@AW(#@6#.2 Y\U2< ]NFU%O
M';#MF<V\T:7)HNM&[MZ+6KNB-I#%5L30"C)7";;J".1>A5:]ZGZJ(S"PVX:7
MZKG;ECK+/M2ZEE(\98A1$K$-*X<-25)TF(:1"DBA"!Y21_,5C^5SJWV7=,31
MAPB4*TI*5G6Y-3J +UJ2>6"0&>@^/PJ=HC6MNMU"DUZDEW2311NFWE>#;K2C
M!K5?8<2;5M$''!U4R8VBHSF2KZ(44E2>*TDX!D>7Q)^?5&B#4A$0E*C47!O9
M@:GEJUQO/4>8#*LM3)(641XJ #I+$@IJ"&9J<OP7%.@G6.,)6H%VO<!E=0C\
M@D?EI)A,<6VP>R4(1Q2E(PE"4A*>V!UJZH28<"& VC3;;W8O=Z4>N,@B1 YB
M :2HG4U235W9VK<&Y#WQ3+T (4HI!';  '8X.5?I]O(R>_?!Z9*;Z2U!V)^M
M/G7?#:8K !QZ TO>@N1O3T? -[ZI[UHZ&W!6X"U1YDZ?3:,N0U]"FF*BXM+X
M/'CDN(RC/D@]OUCK&DE2A<LWJ.UO6M#LV$3,4:$C=0+"UG ?O\W'<4Y>]6]5
M*C;CX9I\QR-Z;:WD*;64^J4#NES'+*"1R(&22._DGIB*OPP%:6"J!S3W+\LW
M-,1Y2&1$>]:4^0V:EZ^F.FK0W3F+96@VDM7I,-<J+=5C6[<<ZXTQ^3M5JE6A
M-SIJI<H!1;4S(=6TW&4I(::0G"0"2.(*U,=/EIWV[N;_ #8<G!=<)8<M=K=]
M_0G\ZXLP5)T* 7ZCB@,865$#_<'L/;VQC'@.$$%B&(V_>_\ D,-$"Q'Z_P!O
M3UOCV3)+BE%*""#E6 H >",#QG[=^Y^W77/%J]A:S6KP:[X^QF-*>=*2GU5?
MH4@=C^A&#Y_7!^W7P;=F&S5;Y,3Z^]'QV_MM7]TOC/$9]> 00#V.?M_KG/\
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M"0]W^\FIQKBJ-JV]QF75%C(#CSH#E&MEJ4SZD<H8_EGU,H6A99*0TV2 ZK)
MZM,MD8BRYB1"& U!Q4-:@]JTXYP!FLVAPHWAI\Q)! WON]JCDT'.)G;&G$2O
M:<TZK72RF57JS929M7F/L(:D?.2:4X\N00@)++BRMM:>& VGLG'N,EX$.!-Z
M$$+"5"@J/,2_[9SN.)BHA7+F(0$D@E]Z!VVXJQVQH-C\N9'=O>VY\IQBUZ31
MJK>,VHU%WC#HT2VU\:_.??6/3:83#+;KA*@5NI3Y4H$S,YA)$L(J4!&@$G2
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MT_1+])TAQ+/JA*BGL!X-BE$E$-)4*AR0S-7G>K>];X'F84D%(4[<[U]!;?\
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MPTK5X>M0=3"CL3=G('-3I7V;]&P\O^\9C,0OQ(TQXA7IU*,-(!"7=P"SL*6
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MCRF8Q2]5ZG$4<NQ8R$925A01T*M<EF</,U041X4NL#PXGPJ91)V--+@$?S$
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MLU<(8WSZXVSN6N.V3IN)=<MBSW)5!H$UN$LSKHJ51?8=F3:5""3+,-Y;3,2
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:3?$I1^)0N2;5;T?%SUM06%!3_P#T/R&/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g271308g0224031743645.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271308g0224031743645.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !@ /L# 2(  A$! Q$!_\0
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MCA-I>LWVGC0DD%M.\(<W)&[:<9QMJX0E/X2)U(P^(]CHKQ#_ (7]/_T+R?\
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M&.J+J1&?-B"+"&]!'M^[^.:YK0O%FLWVM7?@CQ!>&PUN(_Z/J%JB_O@!G[K
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J#3[&#3=/M[&V7;!;QK%&/0 8%6,4M2WI8I+6X4444AA1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g271308g69l36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271308g69l36.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[12"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %&:^4B(X0DE-! 0      #P< @   @  ' )0  AR<C,Y,C8T,1P"!0 C
M36EC<F]S;V9T(%=O<F0@+2!(5$P@1FEN86YC:6%L<R!V-3$X0DE-!"4
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M;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&+
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (  0.__C4
M @ !.$))300F       .             #^    X0DE-! T       0   !:
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      -!    !@              6P   :\    & &< -@ Y &P ,P V
M     0                         !              &O    6P
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    6P    !2
M9VAT;&]N9P   :\    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   %L     4F=H=&QO;F<   &O
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
M   /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E
M;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T
M;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E
M=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M     C_P        .$))3001       ! 0 X0DE-!!0       0    %.$))
M300,      G^     0   *     B   !X   /\    GB !@  ?_8_^T #$%D
M;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5
M#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  B * # 2(  A$! Q$!_]T
M!  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$!
M 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2
M,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D23
M5&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&
MUN;V-T=7
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! ?_  !$( #H!% ,!$0 "$0$#$0'_Q  ?  $  @$$ P$
M            " D* @,$!P4&"P'_Q  \$  !! (! P,# @0#! L    $ 0(#
M!08'"  )$1(3(105,0I!%B(C41<R81HD<:$E4E56@9&5F+'3UO_$ !T! 0 "
M P$! 0$            ! @,'" 8)!03_Q  Z$0 ! @0#!@0% P,$ P$    !
M A$  P0A!1(Q!@=!46%Q$R*!\ B1H;'!%#+1(U+A%3-"@D.R\=+_V@ , P$
M A$#$0 _ ,^LHF,=DLLDJ1LAC>^1RN1&,:UBN5SE7X1&M17*J_Y417+X3YZ@
M.HF6CS3%,$I_Y9CIE[ZQ51"!XJU99:+J)T8.23<#YVLQ,48=PGO9ZEXKBVN$
M:297;JW$*V<<E1#DFU]B1;?Y',R"\KWRNM;,9Z.22@I?5-'*U833@WHZ-?98
M'L=65P\:N)II*6(2K,F;-2=<J2 S,[J((>P ,?DG%45<Y,J@F25C-E7,4H>$
MF[?O3G2=>UG<L1$!.R?W<N7G*+D_L74O) ;,=EX3FC9+3#<[Q?6D(N%:ARBL
M!(,=A-_>8U30ATF/Y-3B3D4DN3GEV7WH1D'U3X;-)>OZ=IL H*20J=0J3(5)
M"<TI2U!:PI>4L^;,M(4%,I0)3F'_ !2#[2MH*&31HG2)ZDSTI"YJ9B_$1-=@
M42E)=(()"P[$@*#Z$Y9JSQHWU.D:WRB>/6_TJGQZE_/^G_E_K^_@2I+9<X!;
M5[\WZVOQL[Z&/PPF86(02.+ FQT)Y=;\?EKB)@E5K8Y6/<K?*(U?*K\>5_Y?
M/60:#C#Z1O\ 2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#
MI"'2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"*@.\+RF)T=Q^FU?AT\[MG;W:
M7B%5#7O*;95F)30.@RB]@<#-$3%(D$T5.'+&]%:79),J+$/,G7OMWFSR\8QA
M-3,DYJ2B6)DQ3 A4Q*0I(+B[$!P+W&C@G6F\[:F5@>"JHI<Y":VOES$I!4I)
MER7*5KS)T) 7ES65E4.8%07;F[3.&\@I!=K<A #K;$Q+%Y(>-(7(,%;O'>U6
MC6CH5;,?$LKG.L6)*K%<V&)9)OZLDFQ-MMI:+9^C5)IY4J;B4UTRDJ0K)1RT
M@CQDA) 4N85'RJS)&0*(O&NMVAQ_:B9,2B:NFV:IB#/K4K*:O$*DZR$YK2Y,
ME"<PF2R%*5-*=4 )LIY/=P[C3V_7VFB>.>H\+FSFJB@DNZ;$*VJPG!\8MBAV
MO&CRHBGKT+N,@<)) 6X080@E()8?KK$9\S6OY2VLVVJ*.J5(5+JL3K5RP0<Y
M5+DA3'^HM1*4@<4)*6=+@"\?3?<G\,&,[Q\,IMH<<Q$;.;(H6E-)-J%F;B&(
MIY4\@J7-EI(!4)TV4H+#94D+"Q3!LGN0\O\ >+R0I-C9#C4%O9/]-5@#G8T.
M-#,QD05.'+4*S)#B4E\HZ.(Z*6=[_1.][E</UH;%MK-H*R;.I45LQ-1-F%Z6
MBF*1D0H@H0E<OS!01YEA,R_F22SB/HCL7\.&Y[9&EIL2.S-!6R\/IU*J<9VF
M7+KJ92TA17/FT5=-F4A91 0#2H0@A+ *#1XR+1_/W' DV3_#/)*NA5&D-OPQ
M<U@M(D1BR1F/B",CR.)D36J_ZI\<;(T5CUE9Y8J_RC9S:JG1*Q%5#BJ% E:)
MTF?.="F<3%H14B:!9KI"GN+AH_=E;Q?ATQ.L7LFK:3=[6K*E2#AM1@N%C#PI
M9R*DB;-PY.'K!)8I$XI+M$\N#O=<V?@.75.L>3V36&5X&79?98\YO463*<*+
M8]HOJO2WPO-O:@6:&6.U2R=)=U?]4OZ@QD4XX_M=CMXU3*K%89M'.)2")4N=
M-M-DEF3XJRV=((=2IA,P9E*6LA);G7?U\(. 8M@U3M?NJI*:CQ26B;73,'P^
M8DX7C$H9IJI6&R4+5(IJE9*A*ER/#D*RHE(0@G,,C/<F]]4<>=2Y)N_<>9!8
M;J[#PPS\CR\D6SM P!+"Q$J@IU%HP;*R*:2><(/&T,(AWJF:Y42-'/3?#@!R
M0VK@N&.C$._>/EL4+2HRU(6B8DE*D3$E"TJ2[I4E0!20Q<$!HCUQ;[DW"?FE
MF&08#QEWI3[2R[%L:?F%]2U^-YO23@8Y':5U*^T=-E&,T8L\3+.VKA'1#3S$
M(\J-RP^VCGM!0.A^\"E20Y%M+$'[$Q.7J8K%8]MWD>VQ1[<L=$VO)['A-K5.
MPRM4V&)/P_93YQL_#R)^)DX\ZRBPQ],^:+((WUWUD=B^N>]/>88X94F6N8.W
M'DQ]WX1?(IG8,S_N3HSZ.^D6<=6BD.D(=(0Z0ATA#I"'2$.D(?C\](15=O;O
M7=LOCEGMAK+9G*#'&9M2V<E/?TV'8UF^PVX]90/?$2%=V6#XW?U->4',Q\)H
MTIWU(<S5B*BB>GIZ@D#4B+!"B':UM6&NFI#CKI$SN.?*WCIRWPZ;/>.&WL.V
MUC 9$8EF9B]@Z0RE,F;(^ ._I3(A+NA+GCAED@&MZ\*:>*-\L+'QM5R3$$%)
M8@@]8D'TB(=(1ZU29GA^2V60T^.97C606^(GQU65U5)>U=K98Q:31>_%6Y""
M 4052GRP?UHP[*(8A\7]1L:L_FZ08\H]EZ0ATA#I"'2$.D(=(0Z0ATA#I"'2
M$.D(Q7^YA+;V?._9)Y,I!0V(:3U_C>+-G:T@6D-S6SEA+*K_ 'E5@)LK2"Y'
MRP,261J^?<8K&O;T=NS3^EV6J:E"$E*TU*YTQ@%)F!2D)";$EDI2YXNVB6CC
MS?;/FUFVM!A*YF22O].24J+B5E<AM/.HJ&71W)!>+]N)F-UF+ZGI*:H9&P"E
M'%H861^E7(E.$,/.YZ_O*1.LDSW+Y54>W_JIUI3:NJG56*3YM2Q7F<)<*&3,
MH)+WN &Z )XEXZ#W;4DBBV9IY%( B2B:M!8!U3$(EF856U4M:EA[C,UVC /V
M+;V%WO#9C; DTPTS9^PE,?8SD$%?4"Y-:Q1.F<2KI?6U[8(W-G5TC(8XHV^&
MHWKFS:T3J:GQ&M1-F2YDJ8M(0 @I4"J8HE2EH,P*S!)#+2&#,=1]]MVLR14X
M7LO0TR)1IIV'TA$I(9$KPZ64$F5+04RAYBG]R5,D,&>^3'V8^(6*F8[8<E<P
MIQ[.TCM[#%=:,-A^I@JX*SV4OLFC'(:Z/[H983$5@I2I+[ X\\D+XY2/$=MU
M&S]-44B]H:N2)M1/7,\!<P$Y A825#,=59LJ5!B$R['S*?F;XX-[F(X?BM'N
MDV>K)N'T--0TM;M',I)JD3:I59(_4TM',6DVD^$I$ZHEY1XBIDO4!HR'F"12
MQ+&]SWL=ZT6)51%]#W*WQX1$7PB(U4=\N7QX5?3Y:N[,S@A@R73D"4Y2&+ A
MGT/ @DNY,?. @%BRDJ(<J"UYC>RB2LD+MQ+6("1>,8KO-\;</UCG>$;KPJDC
MI6[0L+>IS(4)B15A6550D%@+;,@8QL8QUL#*0TYS'(TN0%Q#H_??-+)SYO>P
M&DP]>&X[14XDS:J<N57&6X0I8(5*)#LE4QU!1!\S6N'CZL_ GO/QC:7"MI-W
M^/5PKY>SJ:*LP']253*Q-'4"9+J)"IJUJ\213+E2?!2$ R_&*"HI*4IW>66>
MV^<_IU]YP9$089D." !:\MS3B'E3E.Q_=.+3U+O?E:V9[8,=LJ8-/=3U^H9W
MA59Z579^P>(3Z_9F1^JF3)U11U%3139\U04J=X<[Q)2G 39,B=*E7 /]-V8B
M.,_BCV;P_9O?1M ,)E4]-A..4>%8_AU-3(3+E4\JMP]%/4RPE+(!5B-'63?+
M8B8ER5.349^DY,$#YL\AY#"AQ(W<6;)C7DSQ0,<__%K5[O0UTKF-5WI:J^E%
M5?"*OCPB]>Q1J>WY$<]+_9_V3]E1GS_?:3_MFJ_]1$_^[K+&&/E7[A>R3O$[
M(DC>U\;^X_D[V/8Y',>QW)0M6N:YJJUS7(J*CD545%147QUB-UVYC\1G'[?^
MBO\ U,?3YWUR0T1Q>P>;9'(/:V%ZDPJ(AH4=WF5Q!6LL+!['R1UE,#_4L[VU
MDBCDEBJJ8(^PDCCDD8,YC'N;E<#4M&$ G0/$#M5=[WM@;AS47 <6Y5X969#8
MF-KZE<W O\#I;<V1[F0C!9%E=55439B7M1@D9E@(\N:2$<9)29HH7U"@;/[]
M^]8L4* >Q[$$_3\.(L*V[O'3F@L,+V)NW:&"ZJP<)$2;*,\R:IQJH?,YBOB$
M$)LRATL+ E/#0ZX!"3S97,A$'FED8QUB6N8J 3I%9P_?M[4)&1S8XG+''85B
M\HEX1B&P8<<F=\>$AM78JK7>57PCW1,C3PKE>C$5W5<Z>?WBV13/;LX?C_'V
MBS0#=FH[?496^Z38V(Y#I<3$;O/9=FXW=!Y%AS\/QL,\^]R 6YI)#Q3@*H6K
ML7F/"<1)%($2.L:D1/B2SV?AK%6+LUS9N\1"UYW8NW-M43/#\%Y;:KMJ_6.'
M$; SRP+*NL? QK$!K:JHI+DX[)*>H%?&ZYO*BK'%%F(/+.L11Q19I96MZC,.
M8YQ.17+\^^\>O:([P';MY(9'FF)ZKY'XQ8WF"8WE.:70]]6W^(CRX;A-=+;Y
M5E=989-5U8!U+1U4$UE83M)9-!7Q3&O'04<B6* H'C^(%"@UG?D0>C6XW]>$
M8SG%7OL2;1[O^=;;WKR-RO3O!>3%MB8YKW7>0W^4-UN('4 #5N!75UA5&RQK
MILTR.2$F^-L9*PD@,ZP<"TY1@1G)4*\Q<VX<O\6BY2,H %P!?F7OZ<!VYQD%
M\E.?6G>3?;VYY9CP)W76[6SK4VA\J>;8:_@R,6YQ$[(L<R!]<<*MC3UIC;%:
MBER.PJY@&3213U+W^N&1C'+=Q>^ES%0EE)S"Q/V9]'YB*T.P+Q<[6_(/A'0'
MEZDTUN7D:CKL;D5!M*HILUS^KO"+:917#UF1*>53X:;5.K)*2PIQ10CIG%N(
M)EMTL$: '(?RVAZ\W^IUB\TJ"SP!T:P(MKS+ZO\ 9HO,XC=N[C5P;SG>.6<;
M,8+U_2;YDP<W)-?#'3F8C0VN$1Y/%";BD)SB+"I'M8\FF4RI^MFK!9!(75@X
M4<DL*@ - T8U**@'U''F+,_9H]KY)\^N&_$(@.OY&\A];ZOO+ -+"OQ:ZNVE
M9>< KGL:<-B=1'89#(%))')'$7]M0:62.1D<KG,<B"0-2!WB DG0'\?./,\:
M.;/%+F)76MCQJWI@6VEH(12,AJL;M?&18] :]\8<U[C1\8=_4P%21R1CSG5T
M,,TC'QQR.>US4G6!21J"(J@[2W&3@IIWEMSAS_BWS NN16R<PNBX-F:^+%G#
M'U,)99]>6\H-H8\(>/+;A,F$L*L7(5= HX810\8?DT@J>B0 3=S] .7+WI:+
MK*F ( XZCER!M\K\S%J_)/G)Q(X@05S^26_==:G,N!I3*:BR.[C7)[@2%_MR
ME56+U[#<@/%9(BQN*'KGCI(BQ^[ZT]/5XJ$J5H">T>1XW<SN+'+VJL;?C;O/
M7VVXJ5(G7@&+W<4M]1-G1BPON\<+06^JHIED8R*8ZN@AED58XY'2->UL @Z1
M!!&H(]\XWLHYD\6,)W&1Q\S#?6M<7W0)BY.;&:\OLD$JK\+$0J0W)#,C-C-6
M$42H%H:XZV(-))BAA!%FGD<UK%ZF#%G )',"W;OTZCG'3&INZ;V]MY[09IK5
M/++4.8;&)*^@J<>"R!1OXD.^4^AQ2SL8 ZC*3?**C1* ZP(D\*L4;T152'#M
MQ]GUB2A0#E) [1/8DD8(8@PPB$006&4DHHF5D XP\#'233SS2N;'##%&UTDL
MLCFLC8USG.1J*O4Q6*SLJ[S'; PS,W8%>\S=.MOHCI:XN6KMS;['Z\R"1T4T
M-CE5'7V&-!>U(QS)))[5D37)X5Z=1F',>^?+UBV17]I^7#GVZZ187C.>X1F>
M&5>Q<2R[&\EP&[IFY%49I275?98O8T+X7$)<!W@I$M;/6I Q\KC&$+ QC'N>
M]J,=XF*L=&ORBOVS[QW;"J,Z=KH[FGI)F1QER 330Y&\K&AS8B/I7C$9F*)-
MB4,C9_Y'*^Z2-/"O5Z,:KD1?(O\ M.C^D6)#91C1F.19B)D%(3B4]0E_#DX]
MH#-C\M$HOUR7,=S'.ZO?5*$BE_7M(47Z9%G]WVT]72*178'WC^V$=G<VN8.:
M>DFY%"4T'Z@C(WBXM*:Z=HR##9L2+%AY$B3.1JK#=OC1$<]7^VQSDAQS$6R*
M_M.C^G;6+)PS!+$06PKRAS@#AH# C1)HR!3!"HFSC%#$0N?%..1"]DL,T3W1
MRQO:]CG-<BK,5C'B[D.NB&\A=IY C8E/RK5NN;*B1KE=+(W$RLA5S'0HJ>I[
MK$!8XWIX?XD]/G^9OCH_=/.35;,XG0_\D*J0UB?-+21J?V^;ULUP8XTW_(71
M;<8+77"5T-,IVL *F>@N6U(207)LUCH+/."&:IEVI"R5>US(;F(EK_#VR/\
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MP#D@!P+OJ7Y \HLW_P!GC[R?_<.D_P#<5@?_ .KZG(KE]1_,1F3_ '#Y*_\
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MJ-+O?G=B/D[1=0( 2E24AF(S-W^][OZ/$FCA68?W/N'W)KMY\".9'&G%;3)
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M:4A5'7$J-1+8!.19!*%I(-RI)42D/QCQTG91&&X__K.#SS2R:UT8AAK)_33
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@'2$.D(=(0Z0ATA#I"'2$.D(=(0Z0ATA#I"'2$.D(_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
